Intermittent O
fasting-dietary O
restriction O
( O
IF-DR O
) O
is O
an O
increasingly O
popular O
intervention O
to O
promote O
healthy O
aging O
and O
delay O
age O
associated O
decline O
in O
brain O
functions O
. O

Also O
, O
the O
use O
of O
herbal O
interventions O
is O
gaining O
attention O
due O
to O
their O
non-pharmacological O
approach O
to O
treat O
several O
abnormalities O
and O
promote O
general O
health O
with O
least O
side O
effects O
. O

The O
present O
study O
was O
aimed O
to O
investigate O
the O
synergistic O
effects O
of O
IF-DR O
regimen O
with O
herbal O
supplementation O
on O
anxiety-like B-Symptom_TestedFor
behavior O
and O
neuroinflammation B-Symptom_TestedFor
in O
middle O
aged O
female O
rats O
. O

We O
used O
dried O
leaf O
powder O
of O
Withania B-Medicinal food
somnifera I-Medicinal food
and O
dried O
stem O
powder O
of O
Tinospora B-Medicinal food
cordifolia I-Medicinal food
for O
our O
study O
. O

The O
rats O
were O
divided O
into O
three O
groups O
: O
( O
1 O
) O
Control O
group O
fed O
ad O
libitum O
( O
AL O
) O
; O
( O
2 O
) O
rats O
deprived O
of O
food O
for O
full O
day O
and O
fed O
ad O
libitum O
on O
every O
alternate O
day O
( O
IF-DR O
) O
; O
and O
( O
3 O
) O
IF-DR O
and O
herbal O
extract O
( O
DRH O
) O
group O
in O
which O
rats O
were O
fed O
ad O
libitum O
with O
herbal O
extract O
supplemented O
diet O
, O
every O
alternate O
day O
. O

Post O
regimen O
, O
the O
rats O
were O
tested O
for O
anxiety-like O
behavior O
and O
further O
used O
for O
study O
of O
key O
inflammatory O
molecules O
( O
NFκB O
, O
Iba1 O
, O
TNFα O
, O
IL O
- O
1β O
, O
IL O
- O
6 O
) O
and O
glial O
marker O
( O
GFAP O
) O
in O
hippocampus O
and O
piriform O
cortex O
regions O
of O
brain O
. O

The O
study O
was O
further O
extended O
to O
explore O
the O
effect O
of O
DRH O
regimen O
on O
stress O
response O
protein O
( O
HSP70 O
) O
and O
calcium O
dependent O
regulators O
of O
synaptic O
plasticity O
( O
CaMKIIα O
, O
Calcineurin O
) O
. O

Our O
data O
demonstrated O
that O
DRH O
regimen O
reduced O
anxiety-like B-Symptom_WorkedFor
behavior O
in O
middle O
age O
female O
rats O
and O
associated O
neuroinflammation O
by O
ameliorating O
key O
inflammatory O
cytokines O
and O
modulated O
stress B-Symptom_WorkedFor
response O
. O

The O
present O
data O
may O
provide O
scientific O
validation O
for O
anxiolytic O
and O
anti-inflammatory O
potential O
of O
herbal O
intervention O
combined O
with O
short O
term O
IF-DR O
regimen O
. O

The O
present O
study O
was O
undertaken O
to O
explore O
the O
protective O
effects O
of O
tuberous O
root O
extract O
of O
Pueraria B-Medicinal food
tuberosa I-Medicinal food
on O
chronic O
foot O
shock O
stress B-Symptom_TestedFor
( O
CS O
) O
induced O
physiological O
, O
neurobehavioral O
and O
neuropathological O
alterations O
. O

Male O
Wistar O
rats O
( O
120 O
- O
150 O
g O
) O
were O
divided O
into O
seven O
groups O
, O
consisting O
of O
ten O
animals O
in O
each O
. O

Group O
I O
served O
as O
normal O
, O
group O
II O
as O
positive O
control O
, O
while O
group O
III-VII O
as O
test O
drug O
treated O
. O

P B-Medicinal food
tuberosa I-Medicinal food
tuber I-Medicinal food
extract I-Medicinal food
( O
PTE O
) O
was O
given O
to O
rats O
of O
groups O
III-VI O
at O
the O
doses O
of O
50 O
, O
100 O
, O
200 O
and O
400 O
mg O
/ O
kg O
respectively O
, O
while O
group O
VII O
treated O
with O
Withania B-Other_ingredients
somnifera I-Other_ingredients
rhizome I-Other_ingredients
extract I-Other_ingredients
( O
WSE O
) O
( O
100 O
mg O
/ O
kg O
) O
as O
reference O
drug O
. O

Group O
II O
( O
stress O
control O
) O
received O
only O
equivalent O
volume O
of O
distilled O
water O
( O
0.5 O
ml O
/ O
100 O
g O
) O
orally O
. O

All O
the O
drugs O
were O
given O
orally O
once O
/ O
day O
for O
14 O
consecutive O
days O
. O

The O
last O
dose O
was O
given O
1 O
h O
before O
study O
. O

Simultaneously O
, O
all O
the O
animals O
( O
except O
group O
I O
) O
were O
subjected O
to O
1 O
h O
of O
foot-shock O
( O
2 O
mA O
) O
through O
a O
grid O
floor O
for O
those O
14 O
days O
in O
a O
standard O
conditioning O
chamber O
with O
the O
escape O
route O
closed O
[ O
Chronic O
stress O
( O
CS O
) O
] O
. O

Thereafter O
, O
the O
rats O
were O
placed O
on O
open-field O
and O
plus O
maze O
apparatus O
for O
studying O
the O
behavioral O
patterns O
of O
them O
, O
and O
the O
anxiolytic O
effects O
of O
the O
putative O
drug O
. O

Sexual O
activities O
of O
the O
animals O
were O
also O
studied O
. O

Finally O
, O
the O
animals O
were O
sacrificed O
and O
their O
ulcer O
formation O
in O
gastric O
mucosa O
was O
noted O
. O

Weights O
of O
adrenals O
and O
spleen O
were O
also O
taken O
. O

Further O
, O
plasma O
corticosterone O
levels O
were O
estimated O
spectroflurometrically O
. O

Results O
indicated O
that O
, O
CS O
significantly O
altered O
the O
behavioral O
patterns O
, O
decreased O
the O
sexual O
urge O
and O
activities O
, O
damaged O
the O
gastric O
mucosal O
layers O
, O
enhanced O
plasma O
corticosterone O
levels O
and O
increased O
adrenal O
glands O
and O
spleen O
weights O
. O

PTE O
and O
WSE O
showed O
significant O
anxiolytic O
activity O
, O
protected O
the O
gastric O
mucosa O
, O
lowered O
plasma O
corticosterone O
level O
( O
indicating O
HPA O
axis O
inhibition O
) O
and O
negated O
the O
hypertrophy O
of O
adrenals O
and O
spleen O
. O

PTE O
also O
enhanced O
the O
sexual O
urge O
and O
activities O
in O
animals O
exposed O
to O
chronic O
stress O
. O

The O
findings O
suggest O
significant O
anxiolytic O
and O
anti-stress O
properties O
of O
PTE O
, O
confirming O
the O
clinical O
efficacy O
of O
the O
plant O
mentioned O
in O
Ayurveda O
( O
Indian O
system O
of O
traditional O
medicine O
) O
. O

Nonrestorative B-Symptom_TestedFor
sleep I-Symptom_TestedFor
( O
NRS O
) O
is O
one O
of O
the O
cardinal O
symptoms O
of O
insomnia B-Symptom_TestedFor
and O
can O
occur O
independent O
of O
other O
components O
of O
insomnia B-Symptom_TestedFor
. O

Among O
the O
sleep O
disturbances O
, O
NRS O
has O
been O
little O
studied O
in O
the O
general O
population O
, O
even O
though O
this O
symptom O
plays O
an O
important O
role O
in O
several O
medical O
conditions O
associated O
with O
chronic O
inflammation O
such O
as O
heart O
disease O
, O
fibromyalgia O
, O
and O
chronic O
fatigue O
syndrome O
, O
as O
well O
as O
various O
sleep O
disorders O
. O

There O
is O
paucity O
in O
the O
literature O
about O
effective O
treatments O
for O
NRS O
. O

Ashwagandha B-Medicinal food
( O
Withania B-Drug/Scientific name
somnifera I-Drug/Scientific name
) O
has O
been O
demonstrated O
to O
reduce O
anxiety B-Symptom_WorkedFor
and O
stress B-Symptom_WorkedFor
, O
allowing O
the O
body O
to O
settle O
down O
and O
prepare O
for O
sleep O
. O

This O
study O
will O
be O
a O
double-blind O
, O
randomized O
, O
placebo-controlled O
interventional O
study O
in O
NRS O
population.The O
NRS O
participants O
are O
identified O
using O
Restorative O
Sleep O
Questionnaire-weekly O
version O
( O
RSQ-W O
) O
questionnaire O
. O

Actigraphy O
and O
polysomnography O
are O
used O
for O
the O
objective O
assessment O
of O
sleep O
. O

The O
other O
assessments O
used O
are O
Hamilton B-Metric
Anxiety I-Metric
Depression I-Metric
Scale I-Metric
( O
HADS O
) O
, O
World B-Metric
Health I-Metric
Organization I-Metric
Quality I-Metric
of I-Metric
Life I-Metric
( O
WHOQOL O
) O
scales O
, O
and O
C-reactive O
protein O
. O

Routine O
blood O
and O
urine O
analyses O
will O
be O
conducted O
to O
assess O
the O
safety O
of O
treatment O
. O

Duration O
of O
study O
for O
each O
participant O
will O
be O
50 B-Duration
days I-Duration
with O
" O
day O
one O
" O
for O
screening O
followed O
by O
randomization O
for O
the O
treatment O
. O

The O
duration O
for O
medicine O
/ O
placebo O
intake O
shall O
be O
42 O
days.Primary O
outcome O
will O
be O
to O
evaluate O
effect O
of O
daily O
supplement O
of O
ashwagandha B-Medicinal food
extract O
compared O
with O
placebo O
in O
subjects O
with O
NRS O
at O
6 O
weeks O
from O
baseline O
, O
as O
assessed O
by O
the O
total O
score O
of O
RSQ-W O
. O

Ctri O
registration O
number O
: O
CTRI O
/ O
2017 O
/ O
02 O
/ O
007801 O
. O

Objective O
: O
To O
assess O
existing O
reported O
human O
trials O
of O
Withania B-Drug/Scientific name
somnifera I-Drug/Scientific name
( O
WS O
; O
common O
name O
, O
ashwagandha B-Medicinal food
) O
for O
the O
treatment O
of O
anxiety B-Symptom_WorkedFor
. O

Design O
: O
Systematic O
review O
of O
the O
literature O
, O
with O
searches O
conducted O
in O
PubMed O
, O
SCOPUS O
, O
CINAHL O
, O
and O
Google O
Scholar O
by O
a O
medical O
librarian O
. O

Additionally O
, O
the O
reference O
lists O
of O
studies O
identified O
in O
these O
databases O
were O
searched O
by O
a O
research O
assistant O
, O
and O
queries O
were O
conducted O
in O
the O
AYUSH O
Research O
Portal O
. O

Search O
terms O
included O
" O
ashwagandha B-Medicinal food
, O
" O
" O
Withania B-Drug/Scientific name
somnifera I-Drug/Scientific name
, O
" O
and O
terms O
related O
to O
anxiety B-Symptom_WorkedFor
and O
stress B-Symptom_WorkedFor
. O

Inclusion O
criteria O
were O
human O
randomized O
controlled O
trials O
with O
a O
treatment O
arm O
that O
included O
WS O
as O
a O
remedy O
for O
anxiety B-Symptom_WorkedFor
or O
stress B-Symptom_WorkedFor
. O

The O
study O
team O
members O
applied O
inclusion O
criteria O
while O
screening O
the O
records O
by O
abstract O
review O
. O

Intervention O
: O
Treatment O
with O
any O
regimen O
of O
WS O
. O

Outcome O
measures O
: O
Number O
and O
results O
of O
studies O
identified O
in O
the O
review O
. O

Results O
: O
Sixty-two O
abstracts O
were O
screened O
; O
five O
human O
trials O
met O
inclusion O
criteria O
. O

Three O
studies O
compared O
several O
dosage O
levels O
of O
WS O
extract O
with O
placebos O
using O
versions O
of O
the O
Hamilton B-Metric
Anxiety I-Metric
Scale I-Metric
, O
with O
two O
demonstrating O
significant O
benefit O
of O
WS O
versus O
placebo O
, O
and O
the O
third O
demonstrating O
beneficial O
effects O
that O
approached O
but O
did O
not O
achieve O
significance O
( O
p O
= O
0.05 O
) O
. O

A O
fourth O
study O
compared O
naturopathic O
care O
with O
WS O
versus O
psychotherapy O
by O
using O
Beck B-Metric
Anxiety I-Metric
Inventory I-Metric
( O
BAI O
) O
scores O
as O
an O
outcome O
; O
BAI O
scores O
decreased O
by O
56.5% O
in O
the O
WS O
group O
and O
decreased O
30.5% O
for O
psychotherapy O
( O
p O
< O
0.0001 O
) O
. O

A O
fifth O
study O
measured O
changes O
in O
Perceived B-Metric
Stress I-Metric
Scale I-Metric
( O
PSS O
) O
scores O
in O
WS O
group O
versus O
placebo O
; O
there O
was O
a O
44.0% O
reduction O
in O
PSS O
scores O
in O
the O
WS O
group O
and O
a O
5.5% O
reduction O
in O
the O
placebo O
group O
( O
p O
< O
0.0001 O
) O
. O

All O
studies O
exhibited O
unclear O
or O
high O
risk O
of O
bias O
, O
and O
heterogenous O
design O
and O
reporting O
prevented O
the O
possibility O
of O
meta-analysis O
. O

Conclusions O
: O
All O
five O
studies O
concluded O
that O
WS O
intervention O
resulted O
in O
greater O
score O
improvements O
( O
significantly O
in O
most O
cases O
) O
than O
placebo O
in O
outcomes O
on O
anxiety B-Symptom_WorkedFor
or O
stress B-Symptom_WorkedFor
scales O
. O

Current O
evidence O
should O
be O
received O
with O
caution O
because O
of O
an O
assortment O
of O
study O
methods O
and O
cases O
of O
potential O
bias O
. O

Ethnopharmacological O
relevance O
: O
Withania B-Drug/Scientific name
somnifera I-Drug/Scientific name
( O
WS O
) O
has O
been O
traditionally O
used O
in O
Ayurvedic O
medicine O
as O
a O
remedy O
for O
debility B-Symptom_WorkedFor
, O
stress B-Symptom_WorkedFor
, O
nervous B-Symptom_WorkedFor
exhaustion I-Symptom_WorkedFor
, O
insomnia B-Symptom_WorkedFor
, O
loss B-Symptom_WorkedFor
of I-Symptom_WorkedFor
memory I-Symptom_WorkedFor
, O
and O
to O
enhance O
cognitive B-Symptom_WorkedFor
function I-Symptom_WorkedFor
. O

This O
study O
provides O
an O
empirical O
evidence O
to O
support O
the O
traditional O
use O
of O
WS O
to O
aid O
in O
mental O
process O
engaging O
GABAergic O
signaling O
. O

Aim O
of O
the O
study O
: O
We O
evaluated O
the O
effect O
of O
aqueous O
WS O
root O
extract O
( O
aqWS O
) O
, O
and O
its O
two O
main O
components O
, O
withaferin B-Drug/Scientific name
A I-Drug/Scientific name
and O
withanolide B-Drug/Scientific name
A I-Drug/Scientific name
, O
on O
the O
main O
inhibitory O
receptors O
in O
the O
central O
nervous O
system O
: O
ionotropic O
GABAA O
receptors O
. O

Materials O
and O
methods O
: O
The O
pharmacological O
activity O
of O
aqWS O
, O
withaferin B-Drug/Scientific name
A I-Drug/Scientific name
and O
withanolide B-Drug/Scientific name
A I-Drug/Scientific name
, O
was O
tested O
on O
native O
rat O
brain O
GABAA O
channels O
microtransplanted O
into O
Xenopus O
oocytes O
and O
GABAρ1 O
receptors O
heterologously O
expressed O
in O
oocytes O
. O

The O
GABAergic O
activity O
of O
aqWS O
compounds O
was O
evaluated O
by O
the O
two-electrode O
voltage-clamp O
method O
and O
the O
fingerprint O
of O
the O
extract O
was O
done O
by O
LC-MS O
. O

Results O
: O
Concentration-dependent O
inward O
ion O
currents O
were O
elicited O
by O
aqWS O
in O
microtransplanted O
oocytes O
with O
an O
EC50 O
equivalent O
to O
4.7 O
mg O
/ O
mL O
and O
a O
Hill O
coefficient O
( O
nH O
) O
of O
1.6 O
. O

The O
GABAA O
receptor O
antagonist O
bicuculline O
blocked O
these O
currents O
. O

Our O
results O
show O
that O
aqWS O
activated O
inotropic O
GABAA O
channels O
but O
with O
lower O
efficacy O
compared O
to O
the O
endogenous O
agonist O
GABA O
. O

We O
also O
demonstrate O
for O
first O
time O
that O
aqWS O
is O
a O
potent O
agonist O
of O
GABAρ1 O
receptors O
. O

GABAρ1 O
receptors O
were O
27 O
fold O
more O
sensitive O
to O
aqWS O
than O
GABAA O
receptors O
. O

Furthermore O
, O
aqWS O
activated O
GABAρ1 O
receptors O
eliciting O
maximum O
currents O
that O
were O
no O
significantly O
different O
to O
those O
produced O
by O
GABA O
( O
paired O
t-test O
; O
p O
= O
0.533 O
) O
. O

The O
differential O
activity O
on O
GABAA O
and O
GABA O
ρ1 O
receptors O
and O
the O
reported O
lack O
of O
significant O
GABA O
presence O
in O
WS O
root O
extract O
indicates O
that O
the O
GABAergic O
activity O
of O
aqWS O
is O
not O
mediated O
by O
GABA O
. O

WS O
main O
active O
components O
, O
witaferin O
A O
and O
withanolide O
A O
, O
were O
tested O
to O
determine O
if O
they O
were O
responsible O
for O
the O
activation O
of O
the O
GABA O
receptors O
. O

Neither O
compound O
activated O
GABAA O
nor O
GABAρ1 O
receptors O
, O
suggesting O
that O
other O
constituent O
/ O
s O
in O
WS O
are O
responsible O
for O
GABAA O
receptor O
mediated O
responses O
. O

Conclusions O
: O
Our O
results O
provide O
evidence O
indicating O
that O
key O
constituents O
in O
WS O
may O
have O
an O
important O
role O
in O
the O
development O
of O
pharmacological O
treatments O
for O
neurological O
disorders O
associated O
with O
GABAergic O
signaling O
dysfunction O
such O
as O
general O
anxiety B-Symptom_WorkedFor
disorders O
, O
sleep B-Symptom_WorkedFor
disturbances I-Symptom_WorkedFor
, O
muscle B-Symptom_WorkedFor
spasms I-Symptom_WorkedFor
, O
and O
seizures B-Symptom_WorkedFor
. O

In O
addition O
, O
the O
differential O
activation O
of O
GABA O
receptor O
subtypes O
elucidates O
a O
potential O
mechanism O
by O
which O
WS O
accomplishes O
its O
reported O
adaptogenic O
properties O
. O

Ethnopharmacological O
relevance O
: O
Withania B-Drug/Scientific name
somnifera I-Drug/Scientific name
( O
L O
. O
) O

Dunal O
, O
commonly O
known O
as O
Ashwagandha B-Medicinal food
, O
is O
an O
important O
medicinal O
plant O
that O
has O
been O
used O
in O
Ayurvedic O
and O
indigenous O
medicine O
for O
more O
than O
3000 O
years O
. O

According O
to O
Charaka O
Samhita O
, O
Susruta O
Samhita O
and O
other O
ancient O
texts O
, O
Ashwagandha B-Medicinal food
is O
known O
as O
Balya O
( O
increases O
strength O
) O
, O
Brusya O
( O
sexual O
performance O
enhancer O
) O
, O
vajikari O
( O
spermatogenic O
) O
, O
Kamarupini O
( O
libido-enhancing O
) O
, O
Pustida O
( O
nourishing O
) O
. O

Aim O
of O
the O
review O
: O
This O
review O
article O
documented O
and O
critically O
assessed O
W B-Drug/Scientific name
. I-Drug/Scientific name
somnifera I-Drug/Scientific name
regarding O
its O
ethnopharmacology O
, O
traditional O
use O
, O
botanical O
description O
, O
phytochemicals O
present O
, O
pharmacological O
activities O
, O
clinical O
trials O
, O
and O
marketed O
formulations O
. O

Materials O
and O
methods O
: O
The O
sources O
of O
information O
used O
in O
the O
study O
are O
traditional O
Ayurvedic O
books O
like O
Charaka O
Samhita O
, O
Susruta O
Samhita O
, O
Astanga O
Hridaya O
etc O
, O
government O
reports O
, O
dissertations O
, O
books O
, O
research O
articles O
and O
databases O
like O
Science-Direct O
, O
SciFinder O
, O
Web O
of O
Science O
, O
PubMed O
, O
Wiley O
Online O
Library O
, O
and O
ACS O
Publications O
on O
Ashwagandha B-Medicinal food
and O
Withania B-Drug/Scientific name
somnifera I-Drug/Scientific name
( I-Drug/Scientific name
L I-Drug/Scientific name
. O
) O

Dunal O
. O

Results O
: O
Traditional O
uses O
of O
Ashwagandha B-Medicinal food
in O
Ayurveda O
are O
very O
prominent O
in O
several O
texts O
where O
formulations O
with O
various O
dosage O
forms O
have O
been O
mentioned O
in O
Charaka O
Samhita O
, O
Susruta O
Samhita O
, O
Astanga O
Hridaya O
, O
different O
nighantus O
etc O
. O

The O
drugs O
were O
identified O
based O
on O
their O
composition O
containing O
Ashwagandha B-Medicinal food
as O
one O
of O
the O
major O
ingredients O
and O
their O
medicinal O
uses O
. O

Phytochemical O
studies O
on O
W B-Drug/Scientific name
. I-Drug/Scientific name
somnifera I-Drug/Scientific name
revealed O
the O
presence O
of O
important O
chemical O
constituents O
such O
as O
flavonoids O
, O
phenolic O
acids O
, O
alkaloids O
, O
saponins O
, O
tannins O
, O
and O
withanolides O
. O

The O
phytochemicals O
showed O
various O
pharmacological O
activities O
like O
anti-cancer O
, O
immunomodulatory O
, O
cardioprotective O
, O
neuroprotective O
, O
anti-aging O
, O
anti-stress O
/ O
adaptogenic O
and O
anti-diabetic O
. O

Various O
clinical O
trials O
show O
that O
the O
plant O
extract O
and O
its O
bioactive O
compounds O
are O
used O
in O
the O
prevention O
and O
treatment O
of O
many O
diseases O
, O
such O
as O
arthritis B-Symptom_WorkedFor
, O
impotence B-Symptom_WorkedFor
, O
amnesia B-Symptom_WorkedFor
, O
anxiety B-Symptom_WorkedFor
, O
cancer B-Symptom_WorkedFor
, O
neurodegenerative B-Symptom_WorkedFor
and I-Symptom_WorkedFor
cardiovascular I-Symptom_WorkedFor
diseases I-Symptom_WorkedFor
, O
and O
others O
. O

Conclusions O
: O
Pharmacological O
data O
reviewed O
here O
revealed O
that O
W B-Drug/Scientific name
. I-Drug/Scientific name
somnifera I-Drug/Scientific name
is O
a O
potential O
source O
for O
the O
treatment O
of O
a O
wide O
range O
of O
diseases O
especially O
anxiety B-Symptom_WorkedFor
and O
other O
CNS O
disorders O
. O

From O
its O
ancient O
use O
to O
its O
modern O
application O
it O
has O
been O
proven O
to O
be O
non-toxic O
and O
effective O
clinically O
for O
human O
health O
and O
wellness O
. O

W B-Drug/Scientific name
. I-Drug/Scientific name
somnifera I-Drug/Scientific name
based O
herbal O
formulation O
has O
been O
marketed O
in O
the O
form O
of O
supplement O
, O
extract O
, O
capsule O
, O
powder O
etc O
. O

This O
review O
will O
be O
helpful O
to O
correlate O
the O
mechanism O
of O
action O
with O
the O
phytochemical O
profile O
of O
this O
well-known O
plant O
from O
Ayurveda O
. O

This O
study O
investigated O
the O
effect O
of O
Withania B-Drug/Scientific name
somnifera I-Drug/Scientific name
Dunal I-Drug/Scientific name
( O
WS O
) O
root O
extract O
and O
diazepam B-Other_ingredients
in O
social O
isolation O
induced O
behavior O
such O
as O
anxiety B-Symptom_WorkedFor
and O
depression B-Symptom_WorkedFor
in O
rats O
. O

Rats O
were O
isolated O
for O
6 O
weeks O
and O
the O
assessment O
of O
changed O
behavior O
were O
done O
on O
elevated O
plus O
maze O
( O
EPM O
) O
and O
forced O
swim O
test O
( O
FST O
) O
. O

Isolation O
reared O
rats O
spent O
less O
time O
into O
the O
open O
arms O
on O
EPM O
and O
significantly O
increased O
immobility O
time O
in O
FST O
compared O
to O
group O
housed O
rats O
. O

WS B-Medicinal food
( O
100 O
, O
200 O
or O
500 O
mg O
/ O
kg O
, O
oral O
) O
and O
diazepam B-Other_ingredients
( O
1 O
or O
2 O
mg O
/ O
kg O
, O
ip O
) O
dose O
dependently O
increased O
the O
time O
spent O
and O
entries O
into O
the O
open O
arms O
on O
EPM O
test O
and O
showed O
the O
anxiolytic O
activity O
. O

Subeffective O
dose O
of O
WS B-Medicinal food
( O
50 O
mg O
/ O
kg O
, O
oral O
) O
potentiated O
the O
anxiolytic O
action O
of O
diazepam B-Other_ingredients
( O
0.5 O
, O
1 O
or O
2 O
mg O
/ O
kg O
, O
ip O
) O
. O

WS O
( O
100 O
, O
200 O
or O
500 O
mg O
/ O
kg O
, O
oral O
) O
also O
reduced O
the O
immobility O
time O
in O
FST O
, O
thus O
showed O
antidepressant O
effect O
in O
both O
group O
housed O
and O
social O
isolates O
. O

The O
investigations O
support O
the O
use O
of O
WS O
as O
a O
mood O
stabilizer O
in O
socially O
isolation O
behavior O
in O
Ayurveda O
. O

Perment B-Medicinal food
, O
a O
polyherbal O
Ayurvedic O
formulation O
that O
contains O
equal O
parts O
of O
Clitoria B-Medicinal food
ternatea I-Medicinal food
Linn I-Medicinal food
. O
, O
Withania B-Medicinal food
somnifera I-Medicinal food
Dun I-Medicinal food
. O
, O
Asparagus B-Medicinal food
racemosus I-Medicinal food
Linn I-Medicinal food
. I-Medicinal food
, O
Bacopa B-Medicinal food
monniera I-Medicinal food
Linn I-Medicinal food
. I-Medicinal food
, O
is O
used O
clinically O
as O
mood O
elevators O
. O

The O
aim O
of O
the O
present O
study O
was O
to O
explore O
the O
behavioural O
effects O
and O
to O
understand O
possible O
mode O
of O
action O
of O
Perment B-Medicinal food
in O
stress O
induced O
depressive B-Symptom_WorkedFor
model O
. O

Chronic O
unpredictable O
mild O
stress O
( O
CUMS O
) O
was O
used O
to O
induce O
depression O
in O
rats O
. O

Open O
field O
exploratory O
behaviour O
, O
elevated O
plus O
maze O
, O
social O
interaction O
and O
behavioural O
despair O
tests O
were O
used O
to O
assess O
behaviour O
. O

Using O
standard O
protocols O
plasma O
noradrenaline O
, O
serotonin O
, O
corticosterone O
and O
brain O
/ O
adrenal O
corticosterone O
levels O
were O
measured O
to O
support O
the O
behavioural O
effects O
of O
Perment B-Medicinal food
. O

Exposure O
to O
CUMS O
for O
21 O
days O
caused O
anxiety O
and O
depression O
in O
rats O
, O
as O
indicated O
by O
significant O
decrease O
in O
locomotor O
activity O
in O
the O
open O
field O
exploratory O
behaviour O
test O
and O
increased O
immobility O
period O
in O
the O
behavioural O
despair O
test O
. O

Perment B-Medicinal food
predominantly O
exhibited O
antidepressant B-Symptom_WorkedFor
action O
than O
anxiolytic B-Symptom_TestedFor
activity O
. O

Further O
Perment B-Medicinal food
increased O
the O
plasma O
noradrenaline O
and O
serotonin O
levels O
in O
stressed O
rats O
. O

No O
significant O
alteration O
in O
the O
brain O
corticosterone O
level O
in O
stressed O
rats O
was O
observed O
with O
Perment B-Medicinal food
treatment O
. O

However O
the O
adrenal O
corticosterone O
level O
is O
decreased O
with O
Perment B-Medicinal food
. O

It O
can O
be O
concluded O
that O
the O
Perment O
formulation O
exhibited O
synergistic O
activity O
, O
has O
a O
significant O
antidepressant B-Symptom_WorkedFor
and O
anxiolytic B-Symptom_TestedFor
activity O
, O
which O
may O
be O
mediated O
through O
adrenergic O
and O
serotonergic O
system O
activation O
. O

Currently O
the O
formulation O
is O
clinically O
used O
as O
anxiolytic B-Symptom_TestedFor
but O
the O
present O
results O
suggest O
that O
the O
formulation O
can O
also O
be O
indicated O
in O
patients O
affected O
with O
depression B-Symptom_WorkedFor
. O

Background O
Stress O
, O
anxiety O
and O
impeded O
sleep O
are O
a O
frequent O
feature O
of O
life O
in O
modern O
societies O
. O

Across O
socio-economic O
strata O
, O
stress O
, O
anxiety O
and O
ineffective O
sleep O
detract O
from O
healthful O
living O
and O
serve O
as O
precursors O
of O
various O
ailments O
. O

The O
use O
of O
herbs O
to O
offset O
these O
antecedents O
and O
outcomes O
has O
greatly O
increased O
in O
recent O
years O
. O

Ashwagandha B-Medicinal food
, O
an O
adaptogenic O
Ayurvedic O
herb O
, O
has O
been O
often O
used O
to O
combat O
and O
reduce O
stress O
and O
thereby O
enhance O
general O
wellbeing O
. O

While O
there O
have O
been O
other O
studies O
documenting O
the O
use O
of O
Ashwagandha B-Medicinal food
for O
stress B-Symptom_WorkedFor
resistance O
, O
this O
is O
the O
first O
study O
to O
use O
a O
high-concentration O
root O
extract O
while O
also O
varying O
the O
dosage O
substantially O
. O

Therefore O
, O
this O
is O
the O
first O
study O
to O
offer O
insight O
into O
dose-response O
of O
a O
high O
concentration O
root O
extract O
. O

Material O
and O
methods O
In O
this O
eight-week B-Duration
, O
prospective O
, O
randomized O
, O
double-blind O
, O
placebo-controlled O
study O
, O
the O
stress-relieving O
effect O
of O
Ashwagandha O
root O
extract O
was O
investigated O
in O
stressed O
healthy O
adults O
. O

Sixty B-#Participants
male O
and O
female O
participants O
with O
a O
baseline O
perceived B-Metric
stress I-Metric
scale I-Metric
( O
PSS O
) O
score O
> O
20 O
were O
randomized O
to O
receive O
capsules O
of O
Ashwagandha B-Medicinal food
extract O
125 B-Dosage
mg I-Dosage
, O
Ashwagandha B-Medicinal food
extract O
300 B-Dosage
mg I-Dosage
or O
identical O
placebo O
twice O
daily O
for O
eight O
weeks O
in O
a O
1 O
: O
1 O
: O
1 O
ratio O
. O

Stress B-Symptom_WorkedFor
was O
assessed O
using O
PSS B-Metric
at O
baseline O
, O
four O
weeks O
and O
eight O
weeks O
. O

Anxiety B-Symptom_WorkedFor
was O
assessed O
using O
the O
Hamilton-Anxiety B-Metric
( O
HAM-A O
) O
scale O
and O
serum O
cortisol O
was O
measured O
at O
baseline O
and O
at O
eight O
weeks O
. O

Sleep B-Symptom_WorkedFor
quality I-Symptom_WorkedFor
was O
assessed O
using O
a O
seven-point B-Metric
sleep I-Metric
scale I-Metric
. O

A O
repeat O
measures O
ANOVA O
( O
general O
linear O
model O
) O
was O
used O
for O
assessment O
of O
treatment O
effect O
at O
different O
time O
periods O
. O

Post-hoc O
Dunnett's O
test O
was O
used O
for O
comparison O
of O
two O
treatments O
with O
placebo O
. O

Results O
Two O
participants O
( O
one O
each O
in O
250 B-Dosage
mg I-Dosage
/ I-Dosage
day I-Dosage
Ashwagandha B-Medicinal food
and O
placebo O
) O
were O
lost O
to O
follow-up O
and O
58 O
participants O
completed O
the O
study O
. O

A O
significant O
reduction O
in O
PSS O
scores O
was O
observed O
with O
Ashwagandha B-Medicinal food
250 B-Dosage
mg I-Dosage
/ I-Dosage
day I-Dosage
( O
P O
< O
0.05 O
) O
and O
600 B-Dosage
mg I-Dosage
/ I-Dosage
day I-Dosage
( O
P O
< O
0.001 O
) O
. O

Serum O
cortisol O
levels O
reduced O
with O
both O
Ashwagandha B-Medicinal food
250 B-Dosage
mg I-Dosage
/ I-Dosage
day I-Dosage
( O
P O
< O
0.05 O
) O
and O
Ashwagandha B-Medicinal food
600 B-Dosage
mg I-Dosage
/ I-Dosage
day I-Dosage
( O
P O
< O
0.0001 O
) O
. O

Compared O
to O
the O
placebo O
group O
participants O
, O
the O
participants O
receiving O
Ashwagandha B-Medicinal food
had O
significant O
improvement O
in O
sleep B-Symptom_WorkedFor
quality I-Symptom_WorkedFor
. O

Conclusion O
Ashwagandha O
root O
aqueous O
extract O
was O
beneficial O
in O
reducing O
stress B-Symptom_WorkedFor
and O
anxiety B-Symptom_WorkedFor
. O

Sleep B-Symptom_WorkedFor
is O
a O
profound O
regulator O
of O
cellular O
immunity O
, O
and O
the O
curtailment O
of O
sleep B-Symptom_WorkedFor
in O
present O
day O
lifestyle O
leads O
to O
disruption O
of O
neuro-immune-endocrine O
interactions O
. O

No O
therapeutic O
remedy O
is O
yet O
known O
for O
the O
amelioration O
of O
detrimental O
effects O
caused O
by O
sleep B-Symptom_WorkedFor
deprivation I-Symptom_WorkedFor
( O
SD O
) O
. O

The O
current O
study O
was O
aimed O
to O
elucidate O
the O
effects O
of O
acute O
SD O
on O
immune O
function O
and O
its O
modulation O
by O
water O
extract O
from O
leaves O
of O
Withania B-Medicinal food
somnifera I-Medicinal food
( O
ASH-WEX O
) O
. O

Three O
groups O
of O
animals O
, O
i.e O
. O

Vehicle-Undisturbed O
sleep O
( O
VUD O
) O
, O
Vehicle-Sleep O
deprived O
( O
VSD O
) O
and O
ASH-WEX O
fed O
sleep O
deprived O
( O
WSD O
) O
rats O
were O
tested O
for O
their O
anxiety-like B-Symptom_WorkedFor
behaviour O
and O
further O
used O
for O
the O
study O
of O
inflammatory O
and O
apoptotic O
markers O
expression O
in O
piriform O
cortex O
and O
hippocampus O
regions O
of O
the O
brain O
. O

VSD O
animals O
showed O
high O
level O
of O
anxiety B-Symptom_WorkedFor
in O
elevated O
plus O
maze O
test O
, O
which O
was O
ameliorated O
in O
WSD O
group O
. O

The O
stress O
induced O
expression O
of O
inflammatory O
and O
immune O
response O
markers O
GFAP O
, O
TNFα O
, O
IL O
- O
6 O
, O
OX O
- O
18 O
and O
OX O
- O
42 O
in O
VSD O
animals O
was O
found O
to O
be O
modulated O
by O
ASH-WEX O
. O

Further O
, O
the O
stress O
induced O
apoptosis O
was O
suppressed O
in O
WSD O
group O
as O
indicated O
by O
expression O
of O
NF-κB O
, O
AP O
- O
1 O
, O
Bcl-xL O
and O
Cytochrome O
c O
. O

This O
study O
provides O
scientific O
validation O
to O
the O
anxiolytic O
, O
anti-inflammatory O
and O
anti-apoptotic O
properties O
of O
ASH-WEX O
, O
which O
may O
serve O
as O
an O
effective O
dietary O
supplement O
for O
management O
of O
SD O
induced O
stress B-Symptom_WorkedFor
and O
associated O
functional O
impairments O
. O

Context O
: O
Stress B-Symptom_WorkedFor
is O
a O
state O
of O
mental O
or O
emotional O
strain O
or O
tension O
, O
which O
can O
lead O
to O
underperformance O
and O
adverse O
clinical O
conditions O
. O

Adaptogens O
are O
herbs O
that O
help O
in O
combating O
stress B-Symptom_WorkedFor
. O

Ayurvedic O
classical O
texts O
, O
animal O
studies O
and O
clinical O
studies O
describe O
Ashwagandha B-Medicinal food
as O
a O
safe O
and O
effective O
adaptogen O
. O

Aims O
: O
The O
aim O
of O
the O
study O
was O
to O
evaluate O
the O
safety O
and O
efficacy O
of O
a O
high-concentration O
full-spectrum O
extract O
of O
Ashwagandha B-Medicinal food
roots O
in O
reducing O
stress B-Symptom_WorkedFor
and O
anxiety B-Symptom_WorkedFor
and O
in O
improving O
the O
general O
well-being O
of O
adults O
who O
were O
under O
stress O
. O

Settings O
and O
design O
: O
Single O
center O
, O
prospective O
, O
double-blind O
, O
randomized O
, O
placebo-controlled O
trial O
. O

Materials O
and O
methods O
: O
A O
total O
of O
64 B-#Participants
subjects O
with O
a O
history O
of O
chronic B-participant_health
stress I-participant_health
were O
enrolled O
into O
the O
study O
after O
performing O
relevant O
clinical O
examinations O
and O
laboratory O
tests O
. O

These O
included O
a O
measurement O
of O
serum O
cortisol O
, O
and O
assessing O
their O
scores O
on O
standard O
stress-assessment O
questionnaires O
. O

They O
were O
randomized O
to O
either O
the O
placebo O
control O
group O
or O
the O
study O
drug O
treatment O
group O
, O
and O
were O
asked O
to O
take O
one O
capsule O
twice O
a O
day O
for O
a O
period O
of O
60 B-Duration
days I-Duration
. O

In O
the O
study O
drug O
treatment O
group O
, O
each O
capsule O
contained O
300 B-Dosage
mg I-Dosage
of O
high-concentration O
full-spectrum O
extract O
from O
the O
root O
of O
the O
Ashwagandha B-Medicinal food
plant O
. O

During O
the O
treatment O
period O
( O
on O
Day O
15 O
, O
Day O
30 O
and O
Day O
45 O
) O
, O
a O
follow-up O
telephone O
call O
was O
made O
to O
all O
subjects O
to O
check O
for O
treatment O
compliance O
and O
to O
note O
any O
adverse O
reactions O
. O

Final O
safety O
and O
efficacy O
assessments O
were O
done O
on O
Day O
60 O
. O

Statistical O
analysis O
: O
t-test B-Metric
, O
Mann-Whitney B-Metric
test I-Metric
. O

Results O
: O
The O
treatment O
group O
that O
was O
given O
the O
high-concentration O
full-spectrum O
Ashwagandha B-Medicinal food
root O
extract O
exhibited O
a O
significant O
reduction O
( O
P O
< O
0.0001 O
) O
in O
scores O
on O
all O
the O
stress-assessment B-Metric
scales I-Metric
on O
Day O
60 O
, O
relative O
to O
the O
placebo O
group O
. O

The O
serum O
cortisol O
levels O
were O
substantially O
reduced O
( O
P O
= O
0.0006 O
) O
in O
the O
Ashwagandha B-Medicinal food
group O
, O
relative O
to O
the O
placebo O
group O
. O

The O
adverse O
effects O
were O
mild O
in O
nature O
and O
were O
comparable O
in O
both O
the O
groups O
. O

No O
serious O
adverse O
events O
were O
reported O
. O

Conclusion O
: O
The O
findings O
of O
this O
study O
suggest O
that O
a O
high-concentration O
full-spectrum O
Ashwagandha B-Medicinal food
root O
extract O
safely O
and O
effectively O
improves O
an O
individual's O
resistance O
towards O
stress B-Symptom_WorkedFor
and O
thereby O
improves O
self-assessed O
quality O
of O
life O
. O

Anxiety B-Symptom_WorkedFor
disorders O
are O
chronic O
and O
functionally O
disabling O
conditions O
with O
high O
psychological O
stress B-Symptom_WorkedFor
, O
characterised O
by O
cognitive O
symptoms O
of O
excessive O
worry B-Symptom_WorkedFor
and O
focus B-Symptom_WorkedFor
difficulties I-Symptom_WorkedFor
and O
physiological O
symptoms O
such O
as O
muscle B-Symptom_WorkedFor
tension I-Symptom_WorkedFor
and O
insomnia B-Symptom_WorkedFor
. O

Gamma-aminobutyric O
acid O
( O
GABA O
) O
is O
an O
inhibitory O
neurotransmitter O
within O
the O
central O
nervous O
system O
and O
is O
a O
key O
target O
of O
pharmacotherapies O
in O
the O
treatment O
of O
anxiety O
. O

Although O
current O
pharmaceutical O
treatments O
are O
often O
efficacious O
, O
they O
may O
cause O
undesirable O
side O
effects O
including O
cognitive O
decrements O
and O
withdrawal O
symptoms O
. O

Plant-based O
" O
phytomedicines O
" O
may O
provide O
novel O
treatment O
options O
, O
to O
act O
as O
an O
adjunctive O
or O
alternative O
to O
existing O
anxiolytic O
medications O
. O

As O
such O
, O
we O
conducted O
a O
systematic O
review O
to O
assess O
the O
current O
body O
of O
literature O
on O
anxiolytic O
phytomedicines O
and O
/ O
or O
phytoconstituents O
. O

An O
open-ended O
search O
to O
5 O
July O
2017 O
was O
conducted O
using O
MEDLINE O
( O
PubMed O
) O
, O
Scopus O
, O
and O
Cochrane O
library O
online O
databases O
and O
performed O
in O
a O
stepped O
format O
from O
preclinical O
to O
clinical O
investigations O
. O

Eligible O
studies O
must O
have O
had O
( O
a O
) O
in O
vitro O
evidence O
of O
GABA-modulating O
activity O
, O
( O
b O
) O
animal O
studies O
using O
anxiety B-Symptom_WorkedFor
models O
to O
test O
an O
anxiolytic O
effect O
, O
and O
( O
c O
) O
human O
clinical O
trials O
. O

Ten O
phytomedicines O
were O
identified O
as O
having O
preclinical O
investigations O
showing O
interaction O
with O
the O
GABA O
system O
, O
in O
addition O
to O
human O
clinical O
trials O
: O
kava B-Medicinal food
, O
valerian B-Medicinal food
, O
pennywort B-Medicinal food
, O
hops B-Medicinal food
, O
chamomile B-Medicinal food
, O
Ginkgo B-Medicinal food
biloba I-Medicinal food
, O
passionflower B-Medicinal food
, O
ashwagandha B-Medicinal food
, O
skullcap B-Medicinal food
, O
and O
lemon B-Medicinal food
balm I-Medicinal food
. O

Collectively O
, O
the O
literature O
reveals O
preclinical O
and O
clinical O
evidence O
for O
various O
phytomedicines O
modulating O
GABA-pathways O
, O
with O
comparative O
anxiolytic O
effect O
to O
the O
current O
array O
of O
pharmaceuticals O
, O
along O
with O
good O
safety O
and O
tolerability O
profiles O
. O

Chronic O
stress O
has O
been O
associated O
with O
a O
number O
of O
illnesses O
, O
including O
obesity O
. O

Ashwagandha B-Medicinal food
is O
a O
well-known O
adaptogen O
and O
known O
for O
reducing O
stress B-Symptom_WorkedFor
and O
anxiety B-Symptom_WorkedFor
in O
humans O
. O

The O
objective O
of O
this O
study O
was O
to O
evaluate O
the O
safety O
and O
efficacy O
of O
a O
standardized O
root O
extract O
of O
Ashwagandha B-Medicinal food
through O
a O
double-blind O
, O
randomized O
, O
placebo-controlled O
trial O
. O

A O
total O
of O
52 B-#Participants
subjects O
under O
chronic B-participant_health
stress I-participant_health
received O
either O
Ashwagandha B-Medicinal food
( O
300 B-Dosage
mg I-Dosage
) O
or O
placebo O
twice B-Dosage
daily I-Dosage
. O

Primary O
efficacy O
measures O
were O
Perceived B-Metric
Stress I-Metric
Scale I-Metric
and O
Food B-Metric
Cravings I-Metric
Questionnaire I-Metric
. O

Secondary O
efficacy O
measures O
were O
Oxford B-Metric
Happiness I-Metric
Questionnaire I-Metric
, O
Three-Factor B-Metric
Eating I-Metric
Questionnaire I-Metric
, O
serum O
cortisol O
, O
body O
weight O
, O
and O
body O
mass O
index O
. O

Each O
subject O
was O
assessed O
at O
the O
start O
and O
at O
4 O
and O
8 O
weeks O
. O

The O
treatment O
with O
Ashwagandha O
resulted O
in O
significant O
improvements O
in O
primary O
and O
secondary O
measures O
. O

Also O
, O
the O
extract O
was O
found O
to O
be O
safe O
and O
tolerable O
. O

The O
outcome O
of O
this O
study O
suggests O
that O
Ashwagandha O
root O
extract O
can O
be O
used O
for O
body B-Symptom_WorkedFor
weight I-Symptom_WorkedFor
management I-Symptom_WorkedFor
in O
adults O
under O
chronic O
stress O
. O

Ethnopharmacological O
relevance O
: O
Withania B-Drug/Scientific name
somnifera I-Drug/Scientific name
( O
L O
. O
) O

Dunal O
also O
known O
as O
' O
Ashwaghanda B-Medicinal food
' O
in O
Sanskrit O
and O
as O
' O
Indian B-Medicinal food
Winter I-Medicinal food
Cherry I-Medicinal food
' O
in O
english O
. O
is O
an O
important O
medicinal O
herb O
in O
India O
. O

It O
is O
widely O
used O
in O
Indian O
systems O
of O
medicine O
as O
an O
adaptogen O
, O
nerve O
tonic O
, O
anti-stress O
, O
memory O
enhancer O
and O
against O
cognitive O
deficits O
, O
insomnia B-Symptom_WorkedFor
, O
anxiety B-Symptom_WorkedFor
, O
infectious B-Symptom_WorkedFor
diseases I-Symptom_WorkedFor
, O
infertility B-Medicinal food
, O
rheumatoid B-Medicinal food
arthritis I-Medicinal food
and O
gout B-Medicinal food
over O
thousands O
of O
years O
. O

Its O
formulations O
are O
mainly O
used O
in O
Unani O
and O
Ayurvedic O
system O
of O
medicine O
. O

It O
is O
a O
remarkable O
centuries O
old O
herbal O
Rasayana O
used O
to O
treat O
neuronal O
ailments O
and O
is O
known O
as O
' O
' O
Sattvic O
Kapha O
Rasayana O
. O

Aim O
of O
the O
study O
: O
To O
review O
neuroprotective O
properties O
of O
Withania B-Drug/Scientific name
somnifera I-Drug/Scientific name
( I-Drug/Scientific name
L I-Drug/Scientific name
. I-Drug/Scientific name
) O
extract O
as O
well O
as O
its O
active O
constituents O
in O
neurodegenerative B-Symptom_WorkedFor
diseases I-Symptom_WorkedFor
and O
other O
neurological O
ailments O
. O

Materials O
and O
methods O
: O
The O
sources O
of O
information O
used O
in O
present O
article O
include O
Indian O
system O
of O
Medicine O
reports O
on O
the O
use O
of O
natural O
products O
, O
Medicinal O
books O
, O
research O
articles O
and O
scientific O
databases O
like O
PubMed O
, O
Google O
Scholar O
, O
Web O
of O
Science O
, O
Science-Direct O
, O
SciFinder O
, O
ACS O
Publications O
and O
Wiley O
Online O
Library O
. O

Results O
: O
Research O
reports O
based O
largely O
on O
preclinical O
studies O
as O
well O
as O
few O
clinical O
trials O
have O
highlighted O
the O
neuroprotective O
role O
of O
Ashwagandha B-Medicinal food
against O
many O
neurodegenerative O
diseases O
including O
Alzheimer's B-Symptom_WorkedFor
, O
Huntington's B-Symptom_WorkedFor
and O
Parkinson's B-Symptom_WorkedFor
disease I-Symptom_WorkedFor
. O

The O
protective O
effects O
of O
Ashwagandha B-Medicinal food
were O
accomplished O
by O
restoring O
mitochondrial O
and O
endothelial O
function O
, O
mitigation O
of O
apoptosis O
, O
inflammation O
and O
oxidative O
stress O
mechanisms O
. O

Conclusion O
: O
In O
this O
review O
, O
we O
recapitulated O
neuroprotective O
properties O
of O
Ashwagandha B-Medicinal food
extracts O
and O
/ O
or O
its O
major O
constituents O
and O
discussed O
their O
mechanisms O
of O
action O
and O
potential O
therapeutic O
applications O
. O

The O
pre-clinical O
as O
well O
as O
clinical O
studies O
suggest O
the O
use O
of O
Withania B-Medicinal food
somnifera I-Medicinal food
( I-Medicinal food
L I-Medicinal food
. I-Medicinal food
) I-Medicinal food
against O
neurodegenerative B-Symptom_WorkedFor
disease I-Symptom_WorkedFor
. O

However O
, O
extensive O
studies O
are O
warranted O
to O
validate O
the O
use O
of O
extract O
or O
its O
single O
constituents O
for O
its O
clinical O
use O
. O

Ethnopharmacological O
relevance O
: O
Withania B-Drug/Scientific name
somnifera I-Drug/Scientific name
popularly O
known O
as O
Aswagandha B-Medicinal food
or O
Indian B-Medicinal food
Ginseng I-Medicinal food
/ O
Poison B-Medicinal food
Gooseberry I-Medicinal food
have O
thousands O
years O
of O
history O
of O
use O
in O
Indian O
traditional O
medicine O
. O

Besides O
, O
finding O
place O
root O
of O
the O
plant O
as O
Indian B-Medicinal food
Ginseng I-Medicinal food
, O
Ayurveda O
also O
uses O
root O
of O
this O
plant O
as O
general O
health O
tonic O
, O
adaptogenic O
, O
nootropic O
, O
immunomodulatory O
etc O
. O

With O
its O
widespread O
and O
growing O
use O
, O
it O
becomes O
prudent O
to O
scientifically O
evaluate O
and O
document O
both O
the O
efficacy O
and O
safety O
of O
this O
plant O
in O
humans O
. O

Aim O
of O
the O
study O
: O
Aswagnadha B-Medicinal food
root O
is O
rapidly O
gaining O
popularity O
abroad O
for O
use O
as O
medicine O
. O

Current O
article O
attempts O
to O
primarily O
review O
the O
human O
efficacy O
and O
safety O
of O
Aswagandha B-Medicinal food
generated O
through O
clinical O
trials O
. O

Methods O
: O
A O
systematic O
search O
both O
for O
indexed O
and O
non-indexed O
literature O
was O
made O
for O
W B-Drug/Scientific name
. I-Drug/Scientific name
somnifera I-Drug/Scientific name
using O
various O
search O
engines O
and O
databases O
and O
the O
details O
of O
research O
articles O
pertaining O
to O
all O
clinical O
trials O
/ O
human O
studies O
, O
animal O
studies O
addressing O
safety O
issues O
of O
CNS O
, O
CVS O
, O
general O
toxicity O
, O
mutagenicity O
, O
genotoxicity O
, O
reproductive O
safety O
and O
herb-drug O
interactions O
were O
reviewed O
and O
compiled O
comprehensively O
from O
full O
texts O
. O

Results O
: O
A O
total O
of O
69 O
( O
39 O
pre-clinical O
and O
30 O
clinical O
) O
studies O
documenting O
efficacy O
and O
safety O
aspects O
were O
identified O
and O
the O
desired O
information O
of O
these O
studies O
is O
comprehensively O
presented O
in O
this O
review O
. O

Retrieved O
thirty O
( O
30 O
) O
human O
studies O
demonstrated O
reasonable O
efficacy O
of O
root O
preparations O
in O
subclinical O
hypothyroidism O
( O
1 O
) O
, O
schizophrenia O
( O
3 O
) O
, O
chronic O
stress O
( O
2 O
) O
, O
insomnia O
( O
2 O
) O
, O
anxiety O
( O
1 O
) O
, O
memory O
and O
cognitive O
improvement O
( O
2 O
) O
, O
obsessive-compulsive O
disorder O
( O
1 O
) O
, O
rheumatoid O
arthritis O
( O
2 O
) O
, O
type O
- O
2 O
diabetes O
( O
2 O
) O
, O
male O
infertility O
( O
6 O
) O
, O
fertility O
promotion O
activity O
in O
females O
( O
1 O
) O
, O
adaptogenic O
( O
3 O
) O
, O
growth O
promoter O
in O
children O
( O
3 O
) O
and O
chemotherapy O
adjuvant O
( O
1 O
) O
. O

Reasonable O
safety O
of O
root O
preparations O
of O
Aswagandha B-Medicinal food
has O
been O
established O
by O
these O
retrieved O
30 O
human O
trials O
. O

No O
serious O
adverse O
events O
or O
any O
changes O
in O
haematological O
, O
biochemical O
or O
vital O
parameters O
were O
reported O
in O
these O
human O
studies O
. O

Only O
mild O
and O
mainly O
transient O
type O
adverse O
events O
of O
somnolence O
, O
epigastric O
pain O
/ O
discomfort O
and O
loose O
stools O
were O
reported O
as O
most O
common O
( O
> O
5% O
) O
; O
and O
giddiness O
, O
drowsiness O
, O
hallucinogenic O
, O
vertigo O
, O
nasal O
congestion O
( O
rhinitis O
) O
, O
cough O
, O
cold O
, O
decreased O
appetite O
, O
nausea O
, O
constipation O
, O
dry O
mouth O
, O
hyperactivity O
, O
nocturnal O
cramps O
, O
blurring O
of O
vision O
, O
hyperacidity O
, O
skin O
rash O
and O
weight O
gain O
were O
reported O
as O
less O
common O
adverse O
events O
. O

Pre-clinical O
chronic O
toxicity O
studies O
conducted O
up O
to O
8 O
months O
also O
found O
root O
extracts O
to O
be O
safe O
. O

No O
mutagenicity O
or O
genotoxicity O
was O
reported O
for O
the O
root O
; O
only O
mild O
CNS O
depression O
and O
increase O
in O
thyroxine O
( O
T4 O
) O
levels O
were O
reported O
with O
rootby O
some O
studies O
. O

Further O
, O
there O
was O
no O
in O
vitro O
and O
in O
vivo O
inhibition O
seen O
for O
CYP3A4 O
and O
CYP2D6 O
, O
the O
two O
major O
hepatic O
drug O
metabolizing O
enzymes O
. O

Conclusion O
: O
Root O
of O
the O
Ayurvedic O
drug O
W B-Drug/Scientific name
. I-Drug/Scientific name
somnifera I-Drug/Scientific name
( O
Aswagandha B-Medicinal food
) O
appears O
a O
promising O
safe O
and O
effective O
traditional O
medicine O
for O
management O
of O
schizophrenia B-Symptom_WorkedFor
, O
chronic B-Symptom_WorkedFor
stress I-Symptom_WorkedFor
, O
insomnia B-Symptom_WorkedFor
, O
anxiety B-Symptom_WorkedFor
, O
memory B-Symptom_WorkedFor
/ I-Symptom_WorkedFor
cognitive I-Symptom_WorkedFor
enhancement I-Symptom_WorkedFor
, O
obsessive-compulsive B-Symptom_WorkedFor
disorder I-Symptom_WorkedFor
, O
rheumatoid B-Symptom_WorkedFor
arthritis I-Symptom_WorkedFor
, O
type B-Symptom_WorkedFor
- I-Symptom_WorkedFor
2 I-Symptom_WorkedFor
diabetes I-Symptom_WorkedFor
and O
male O
infertility B-Symptom_WorkedFor
, O
and O
bears O
fertility O
promotion O
activity O
in O
females O
adaptogenic O
, O
growth O
promoter O
activity O
in O
children O
and O
as O
adjuvant O
for O
reduction O
of O
fatigue O
and O
improvement O
in O
quality O
of O
life O
among O
cancer O
patients O
undergoing O
chemotherapy O
. O

Properly O
designed O
, O
randomized-controlled O
, O
large-size O
, O
prospective O
trials O
with O
standardized O
preparations O
are O
needed O
to O
ascertain O
efficacy O
of O
Aswagandha B-Medicinal food
root O
in O
previously O
studied O
and O
other O
new O
indications O
. O

The O
aquatic O
environment O
provides O
a O
sink O
for O
the O
environmental O
pollutants O
that O
have O
potential O
to O
induce O
oxidative O
stress O
by O
altering O
neurobehavioral O
response O
of O
aquatic O
animals O
. O

Benzo B-Other_ingredients
[ I-Other_ingredients
a I-Other_ingredients
] I-Other_ingredients
pyrene I-Other_ingredients
( O
B B-Other_ingredients
[ I-Other_ingredients
a I-Other_ingredients
] I-Other_ingredients
P I-Other_ingredients
) O
, O
a O
polycyclic O
aromatic O
hydrocarbon O
is O
known O
to O
induce O
oxidative O
stress O
in O
the O
brain O
. O

Withania B-Drug/Scientific name
somnifera I-Drug/Scientific name
has O
been O
used O
traditionally O
for O
its O
neuroprotective B-Symptom_WorkedFor
effect O
in O
experimental O
models O
of O
neurological O
disorders O
. O

The O
present O
study O
is O
aimed O
to O
evaluate O
the O
neuroprotective B-Symptom_WorkedFor
potential O
of O
Withania B-Drug/Scientific name
somnifera I-Drug/Scientific name
leaf O
extract O
( O
WSLE B-Drug/Scientific name
) O
following O
exposure O
to O
waterborne O
B B-Other_ingredients
[ I-Other_ingredients
a I-Other_ingredients
] I-Other_ingredients
P I-Other_ingredients
. O

Wild-type O
zebrafish O
( O
Danio O
rerio O
) O
were O
designated O
as O
naive O
, O
control O
( O
dimethyl O
sulfoxide O
) O
, O
WSLE B-Drug/Scientific name
, O
B B-Other_ingredients
[ I-Other_ingredients
a I-Other_ingredients
] I-Other_ingredients
P I-Other_ingredients
, O
and O
B B-Other_ingredients
[ I-Other_ingredients
a I-Other_ingredients
] I-Other_ingredients
P I-Other_ingredients
+ O
WSLE B-Drug/Scientific name
groups O
. O

Behavioral O
studies O
showed O
reversal O
in O
scototaxis O
( O
anxiety-like B-Symptom_WorkedFor
) O
behavior O
in O
B B-Other_ingredients
[ I-Other_ingredients
a I-Other_ingredients
] I-Other_ingredients
P I-Other_ingredients
group O
and O
was O
restored O
by O
WSLE B-Drug/Scientific name
cosupplementation O
in O
B B-Other_ingredients
[ I-Other_ingredients
a I-Other_ingredients
] I-Other_ingredients
P I-Other_ingredients
+ O
WSLE B-Drug/Scientific name
group O
. O

B B-Other_ingredients
[ I-Other_ingredients
a I-Other_ingredients
] I-Other_ingredients
P-induced I-Other_ingredients
altered O
antioxidant O
status O
was O
ameliorated O
by O
WSLE B-Drug/Scientific name
in O
the O
B B-Other_ingredients
[ I-Other_ingredients
a I-Other_ingredients
] I-Other_ingredients
P I-Other_ingredients
+ O
WSLE B-Drug/Scientific name
group O
. O

Previous O
studies O
showed O
that O
the O
periventricular O
gray O
zone O
( O
PGZ O
) O
of O
the O
optic O
tectum O
in O
zebrafish O
brain O
regulates O
scototaxis O
( O
anxiety-like B-Symptom_WorkedFor
) O
behavior O
. O

Our O
histopathological O
observation O
showed O
a O
significant O
increase O
in O
the O
pyknotic O
neuronal O
counts O
in O
PGZ O
of O
the O
B B-Other_ingredients
[ I-Other_ingredients
a I-Other_ingredients
] I-Other_ingredients
P I-Other_ingredients
group O
and O
was O
ameliorated O
by O
WSLE B-Drug/Scientific name
cosupplementation O
. O

The O
study O
showed O
that O
the O
reversal O
in O
scototaxis O
behavior O
following O
exposure O
to O
waterborne O
B B-Other_ingredients
[ I-Other_ingredients
a I-Other_ingredients
] I-Other_ingredients
P I-Other_ingredients
might O
be O
associated O
with O
neuromorphological O
alterations O
in O
PGZ O
, O
whereas O
a O
pioneer O
ethnopharmacological O
approach O
of O
WSLE B-Drug/Scientific name
cosupplementation O
showed O
its O
neuroprotective O
role O
to O
restore O
normal O
scototaxis O
of O
zebrafish O
. O

Future O
research O
directing O
toward O
understanding O
the O
role O
of O
visual O
circuit O
involved O
with O
impaired O
scototaxis O
behavior O
in O
zebrafish O
might O
provide O
new O
pathological O
outcomes O
following O
exposure O
to O
B B-Other_ingredients
[ I-Other_ingredients
a I-Other_ingredients
] I-Other_ingredients
P I-Other_ingredients
. O

The O
roots O
of O
Withania B-Drug/Scientific name
somnifera I-Drug/Scientific name
( O
WS B-Drug/Scientific name
) O
are O
used O
extensively O
in O
Ayurveda O
, O
the O
classical O
Indian O
system O
of O
medicine O
, O
and O
WS B-Medicinal food
is O
categorized O
as O
a O
rasayana O
, O
which O
are O
used O
to O
promote O
physical O
and O
mental O
health O
, O
to O
provide O
defence O
against O
disease O
and O
adverse O
environmental O
factors O
and O
to O
arrest O
the O
aging O
process O
. O

WS B-Drug/Scientific name
has O
been O
used O
to O
stabilize O
mood O
in O
patients O
with O
behavioural O
disturbances O
. O

The O
present O
study O
investigated O
the O
anxiolytic O
and O
antidepressant O
actions O
of O
the O
bioactive B-Other_ingredients
glycowithanolides I-Other_ingredients
( O
WSG B-Drug/Scientific name
) O
, O
isolated O
from O
WS B-Drug/Scientific name
roots O
, O
in O
rats O
. O

WSG B-Drug/Scientific name
( O
20 O
and O
50 O
mg O
/ O
kg O
) O
was O
administered O
orally O
once O
daily O
for O
5 O
days O
and O
the O
results O
were O
compared O
by O
those O
elicited O
by O
the O
benzodiazepine B-Other_ingredients
lorazepam I-Other_ingredients
( O
0.5 O
mg O
/ O
kg O
, O
i.p O
. O
) O
for O
anxiolytic O
studies O
, O
and O
by O
the O
tricyclic O
anti-depressant O
, O
imipramine O
( O
10 O
mg O
/ O
kg O
, O
i.p O
. O
) O
, O
for O
the O
antidepressant O
investigations O
. O

Both O
these O
standard O
drugs O
were O
administered O
once O
, O
30 O
min O
prior O
to O
the O
tests O
. O

WSG B-Drug/Scientific name
induced O
an O
anxiolytic O
effect O
, O
comparable O
to O
that O
produced O
by O
lorazepam B-Other_ingredients
, O
in O
the O
elevated O
plus-maze O
, O
social O
interaction O
and O
feeding O
latency O
in O
an O
unfamiliar O
environment O
, O
tests O
. O

Further O
, O
both O
WSG B-Drug/Scientific name
and O
lorazepam B-Other_ingredients
, O
reduced O
rat O
brain O
levels O
of O
tribulin O
, O
an O
endocoid O
marker O
of O
clinical O
anxiety B-Symptom_WorkedFor
, O
when O
the O
levels O
were O
increased O
following O
administration O
of O
the O
anxiogenic O
agent O
, O
pentylenetetrazole O
. O

WSG B-Drug/Scientific name
also O
exhibited O
an O
antidepressant O
effect O
, O
comparable O
with O
that O
induced O
by O
imipramine O
, O
in O
the O
forced O
swim-induced O
' O
behavioural O
despair O
' O
and O
' O
learned O
helplessness O
' O
tests O
. O

The O
investigations O
support O
the O
use O
of O
WS B-Drug/Scientific name
as O
a O
mood O
stabilizer O
in O
clinical O
conditions O
of O
anxiety B-Symptom_WorkedFor
and O
depression B-Symptom_WorkedFor
in O
Ayurveda O
. O

Sleep B-Symptom_WorkedFor
disruption I-Symptom_WorkedFor
involves O
extensive O
changes O
in O
physiological O
function O
, O
including O
EEG O
, O
motor O
, O
metabolic O
, O
autonomic O
processes O
physiological O
homeostasis O
and O
psychological O
balance O
that O
are O
necessary O
for O
physical O
health O
. O

Benzodiazepines B-Other_ingredients
are O
the O
most O
widely O
used O
drugs O
for O
the O
sleep O
related O
problems O
in O
spite O
of O
their O
limitations O
and O
side O
effects O
. O

Objective O
of O
the O
study O
was O
to O
investigate O
the O
protective O
effect O
of O
W B-Drug/Scientific name
. I-Drug/Scientific name
somnifera I-Drug/Scientific name
on O
the O
behavioral O
and O
biochemical O
alterations O
in O
sleep O
disturbed O
mice O
. O

Pretreatment O
with O
W B-Drug/Scientific name
. I-Drug/Scientific name
somnifera I-Drug/Scientific name
root O
extract O
( O
100 O
. O
200 O
mg O
/ O
kg O
) O
and O
diazepam B-Other_ingredients
( O
0.5 O
mg O
/ O
kg O
) O
significantly O
protected O
reduction O
in O
body O
weight O
, O
improved O
the O
reduced O
locomotor O
activity O
and O
anxiety O
levels O
in O
animals O
. O

Biochemical O
studies O
also O
revealed O
that O
W B-Drug/Scientific name
. I-Drug/Scientific name
somnifera I-Drug/Scientific name
( O
100 O
and O
200 O
mg O
/ O
kg O
) O
and O
diazepam B-Other_ingredients
( O
0.5 O
mg O
/ O
kg O
) O
pretreatment O
for O
five O
days O
decreased O
significantly O
lipid O
peroxidation O
, O
nitrites O
levels O
and O
improved O
catalase O
, O
and O
reduced O
glutathione O
levels O
. O

Co-administration O
of O
W B-Drug/Scientific name
. I-Drug/Scientific name
somnifera I-Drug/Scientific name
( O
100 O
mg O
/ O
kg O
) O
with O
diazepam B-Other_ingredients
( O
0.5 O
mg O
/ O
kg O
) O
improved O
significantly O
all O
the O
biochemical O
parameters O
as O
compared O
to O
their O
effect O
per O
se O
. O

Preliminary O
results O
suggest O
that O
Withania B-Drug/Scientific name
root I-Drug/Scientific name
extract O
can O
be O
used O
in O
the O
management O
sleep B-Symptom_WorkedFor
loss I-Symptom_WorkedFor
and O
associated O
oxidative O
stress O
. O

Bacopa B-Medicinal food
monnieri I-Medicinal food
, O
commonly O
known O
as O
Brahmi B-Medicinal food
, O
has O
been O
extensively O
used O
as O
a O
neuromedicine O
for O
various O
disorders O
such O
as O
anxiety B-Symptom_WorkedFor
, O
depression B-Symptom_WorkedFor
and O
memory B-Symptom_WorkedFor
loss I-Symptom_WorkedFor
. O

Chemical O
characterization O
studies O
revealed O
the O
major O
active O
constituents O
of O
the O
herb O
as O
the O
triterpenoid O
saponins O
, O
bacosides O
. O

Bacoside O
A O
, O
the O
vital O
neuroprotective B-Symptom_WorkedFor
constituent O
, O
is O
composed O
of O
four O
constituents O
viz O
. O
, O
bacoside O
A3 O
, O
bacopaside O
II O
, O
jujubogenin O
isomer O
of O
bacopasaponin O
C O
( O
bacopaside O
X O
) O
and O
bacopasaponin O
C O
. O

B B-Medicinal food
. I-Medicinal food
monnieri I-Medicinal food
extracts O
as O
well O
as O
bacosides O
successfully O
establish O
a O
healthy O
antioxidant O
environment O
in O
various O
tissues O
especially O
in O
the O
liver O
and O
brain O
. O

Free O
radical O
scavenging O
, O
suppression O
of O
lipid O
peroxidation O
and O
activation O
of O
antioxidant O
enzymes O
by O
bacosides O
help O
to O
attain O
a O
physiological O
state O
of O
minimized O
oxidative O
stress O
. O

The O
molecular O
basis O
of O
neuroprotective O
activity O
of O
bacosides O
is O
attributed O
to O
the O
regulation O
of O
mRNA O
translation O
and O
surface O
expression O
of O
neuroreceptors O
such O
as O
AMPAR O
, O
NMDAR O
and O
GABAR O
in O
the O
various O
parts O
of O
the O
brain O
. O

Bioavailability O
as O
well O
as O
binding O
of O
neuroprotective O
agents O
( O
such O
as O
bacosides O
) O
to O
these O
receptors O
is O
controlled O
by O
the O
Blood O
Brain O
Barrier O
( O
BBB O
) O
. O

However O
, O
nano O
conversion O
of O
these O
drug O
candidates O
easily O
resolves O
the O
BBB O
restriction O
and O
carries O
a O
promising O
role O
in O
future O
therapies O
. O

This O
review O
summarizes O
the O
neuroprotective B-Symptom_WorkedFor
functions O
of O
B B-Medicinal food
. I-Medicinal food
monnieri I-Medicinal food
extracts O
as O
well O
as O
its O
active O
compounds O
( O
bacoside O
A O
, O
bacopaside O
I O
) O
and O
the O
molecular O
mechanisms O
responsible O
for O
these O
pharmacological O
activities O
. O

Research O
in O
the O
area O
of O
herbal O
psychopharmacology O
has O
revealed O
a O
variety O
of O
promising O
medicines O
that O
may O
provide O
benefit O
in O
the O
treatment O
of O
general O
anxiety B-Symptom_WorkedFor
and O
specific O
anxiety B-Symptom_WorkedFor
disorders O
. O

However O
, O
a O
comprehensive O
review O
of O
plant-based O
anxiolytics O
has O
been O
absent O
to O
date O
. O

Thus O
, O
our O
aim O
was O
to O
provide O
a O
comprehensive O
narrative O
review O
of O
plant-based O
medicines O
that O
have O
clinical O
and O
/ O
or O
preclinical O
evidence O
of O
anxiolytic O
activity O
. O

We O
present O
the O
article O
in O
two O
parts O
. O

In O
part O
one O
, O
we O
reviewed O
herbal O
medicines O
for O
which O
only O
preclinical O
investigations O
for O
anxiolytic B-Symptom_WorkedFor
activity O
have O
been O
performed O
. O

In O
this O
current O
article O
( O
part O
two O
) O
, O
we O
review O
herbal O
medicines O
for O
which O
there O
have O
been O
both O
preclinical O
and O
clinical O
investigations O
of O
anxiolytic B-Symptom_WorkedFor
activity O
. O

A O
search O
of O
MEDLINE O
( O
PubMed O
) O
, O
CINAHL O
, O
Scopus O
and O
the O
Cochrane O
Library O
databases O
was O
conducted O
( O
up O
to O
28 O
October O
2012 O
) O
for O
English O
language O
papers O
using O
the O
search O
terms O
' O
anxiety O
' O
OR O
' O
anxiety O
disorder O
' O
OR O
' O
generalized O
anxiety O
disorder O
' O
OR O
' O
social O
phobia O
' O
OR O
' O
post-traumatic O
stress O
disorder O
' O
OR O
' O
panic O
disorder O
' O
OR O
' O
agoraphobia O
' O
OR O
' O
obsessive O
compulsive O
disorder O
' O
in O
combination O
with O
the O
search O
terms O
' O
Herb O
* O
' O
OR O
' O
Medicinal O
Plants O
' O
OR O
' O
Botanical O
Medicine O
' O
OR O
' O
Chinese O
herb O
* O
' O
, O
in O
addition O
to O
individual O
herbal O
medicines O
. O

This O
search O
of O
the O
literature O
revealed O
1,525 O
papers O
, O
of O
which O
53 O
plants O
were O
included O
in O
the O
review O
( O
having O
at O
least O
one O
study O
using O
the O
whole O
plant O
extract O
) O
. O

Of O
these O
plants O
, O
21 O
had O
human O
clinical O
trial O
evidence O
( O
reviewed O
here O
in O
part O
two O
) O
, O
with O
the O
other O
32 O
having O
solely O
preclinical O
evidence O
( O
reviewed O
in O
part O
one O
) O
. O

Support O
for O
efficacy O
was O
found O
for O
chronic O
use O
( O
i.e O
. O
greater O
than O
one O
day O
) O
of O
the O
following O
herbs O
in O
treating O
a O
range O
of O
anxiety B-Symptom_WorkedFor
disorders O
in O
human O
clinical O
trials O
: O
Piper B-Medicinal food
methysticum I-Medicinal food
, O
Matricaria B-Medicinal food
recutita I-Medicinal food
, O
Ginkgo B-Medicinal food
biloba I-Medicinal food
, O
Scutellaria B-Medicinal food
lateriflora I-Medicinal food
, O
Silybum B-Medicinal food
marianum I-Medicinal food
, O
Passiflora B-Medicinal food
incarnata I-Medicinal food
, O
Withania B-Medicinal food
somniferum I-Medicinal food
, O
Galphimia B-Medicinal food
glauca I-Medicinal food
, O
Centella B-Medicinal food
asiatica I-Medicinal food
, O
Rhodiola B-Medicinal food
rosea I-Medicinal food
, O
Echinacea B-Medicinal food
spp I-Medicinal food
. I-Medicinal food
, O
Melissa B-Medicinal food
officinalis I-Medicinal food
and O
Echium B-Medicinal food
amoenum I-Medicinal food
. O

For O
several O
of O
the O
plants O
studied O
, O
conclusions O
need O
to O
be O
tempered O
due O
to O
methodological O
issues O
such O
as O
small O
sample O
sizes O
, O
brief O
intervention O
durations O
and O
non-replication O
. O

Current O
evidence O
does O
not O
support O
Hypericum B-Medicinal food
perforatum I-Medicinal food
or O
Valeriana B-Medicinal food
spp I-Medicinal food
. I-Medicinal food
for O
any O
anxiety B-Symptom_WorkedFor
disorder O
. O

Acute O
anxiolytic B-Symptom_WorkedFor
activity O
was O
found O
for O
Centella B-Medicinal food
asiatica I-Medicinal food
, O
Salvia B-Medicinal food
spp I-Medicinal food
. I-Medicinal food
, O
Melissa B-Medicinal food
officinalis I-Medicinal food
, O
Passiflora B-Medicinal food
incarnata I-Medicinal food
and O
Citrus B-Medicinal food
aurantium I-Medicinal food
. O

Bacopa B-Medicinal food
monnieri I-Medicinal food
has O
shown O
anxiolytic B-Symptom_WorkedFor
effects O
in O
people O
with O
cognitive O
decline O
. O

The O
therapeutic O
application O
of O
psychotropic O
plant-based O
treatments O
for O
anxiety B-Symptom_WorkedFor
disorders O
is O
also O
discussed O
, O
specifically O
Psychotria B-Medicinal food
viridis I-Medicinal food
and O
Banisteriopsis B-Drug/Scientific name
caarti I-Drug/Scientific name
( O
ayahuasca B-Medicinal food
) O
, O
Psilocybe B-Medicinal food
spp I-Medicinal food
. I-Medicinal food
and O
cannabidiol-enriched O
( O
low O
tetrahydrocannabinol O
( O
Δ O
( O
9 O
) O
- O
THC O
) O
) O
Cannabis O
spp O
. O

Alzheimer B-Symptom_WorkedFor
disease I-Symptom_WorkedFor
( O
AD B-Symptom_WorkedFor
) O
is O
characterized O
by O
dementia B-Symptom_WorkedFor
that O
begins O
as O
mild O
short O
term O
memory O
deficit O
and O
culminates O
in O
total O
loss O
of O
cognitive O
and O
executive O
functions O
. O

The O
present O
study O
was O
conducted O
to O
evaluate O
the O
neuroprotective O
potential O
of O
Bacopa B-Medicinal food
monnieri I-Medicinal food
( O
BM B-Medicinal food
) O
, O
an O
Indian O
traditional O
medicinal O
plant O
effective O
against O
cognitive O
impairment O
, O
in O
colchicine-induced O
dementia B-Symptom_WorkedFor
. O

Intracerebroventricular O
administration O
of O
colchicine O
( O
15 O
μg O
/ O
5 O
μl O
) O
induced O
cognitive O
impairment O
in O
rats O
as O
assessed O
by O
elevated O
plus O
maze O
. O

This O
was O
accompanied O
by O
a O
significant O
increase O
in O
oxidative O
stress O
in O
term O
of O
enhanced O
levels O
of O
lipid O
peroxidation O
and O
protein O
carbonyls O
. O

Concomitantly O
, O
decrease O
in O
activity O
of O
antioxidant O
enzymes O
was O
observed O
in O
colchicine O
treated O
animals O
. O

BM B-Medicinal food
( O
50 O
mg O
/ O
kg O
body O
weight O
) O
supplementation O
reversed O
memory O
impairment O
observed O
in O
the O
colchicine O
treated O
rats O
. O

BM B-Medicinal food
administration O
attenuated O
oxidative O
damage O
, O
as O
evident O
by O
decreased O
LPO O
and O
protein O
carbonyl O
levels O
and O
restoration O
in O
activities O
of O
the O
antioxidant O
enzymes O
. O

The O
activity O
of O
membrane O
bound O
enzymes O
( O
Na O
( O
+ O
) O
K O
( O
+ O
) O
ATPase O
and O
AChE O
) O
was O
altered O
in O
colchicine O
treated O
brain O
regions O
and O
BM B-Medicinal food
supplementation O
was O
able O
to O
restore O
the O
activity O
of O
enzymes O
to O
comparable O
values O
observed O
in O
controls O
. O

The O
results O
suggest O
therapeutic O
potential O
of O
BM B-Medicinal food
in O
the O
treatment O
of O
AD B-Symptom_WorkedFor
associated O
cognitive O
decline O
. O

Bacopa B-Medicinal food
monnieri I-Medicinal food
is O
effective O
in O
stress B-Symptom_WorkedFor
management O
, O
brain O
function O
and O
a O
balanced O
mood O
. O
5 O
- O
HT2C O
receptors O
have O
been O
implicated O
in O
stress B-Symptom_WorkedFor
whereas O
NMDA O
receptors O
and O
mGlu5 O
play O
crucial O
role O
in O
memory O
and O
cognition O
. O

In O
the O
present O
study O
, O
we O
investigated O
the O
role O
of O
B B-Medicinal food
. I-Medicinal food
monnieri I-Medicinal food
extract O
in O
ameliorating O
pilocarpine O
induced O
temporal O
lobe O
epilepsy O
through O
regulation O
of O
5 O
- O
HT2C O
and O
NMDA O
receptors O
in O
cerebral O
cortex O
. O

Our O
studies O
confirmed O
an O
increased O
5 O
- O
HT2C O
receptor O
function O
during O
epilepsy O
thereby O
facilitating O
IP3 O
release O
. O

We O
also O
observed O
an O
decreased O
NMDA O
receptor O
function O
with O
an O
elevated O
mGlu5 O
and O
GLAST O
gene O
expression O
in O
epileptic O
condition O
indicating O
the O
possibility O
for O
glutamate O
mediated O
excitotoxicity O
. O

These O
alterations O
lead O
to O
impaired O
behavioural O
functions O
as O
indicated O
by O
the O
Elevated O
Plus O
maze O
test O
. O

Carbamazepine B-Other_ingredients
and O
B B-Medicinal food
. I-Medicinal food
monnieri I-Medicinal food
treatments O
to O
epileptic O
rats O
reversed O
the O
alterations O
in O
5 O
- O
HT2C O
, O
NMDA O
receptor O
functions O
and O
IP3 O
content O
thereby O
effectively O
managing O
the O
neurotransmitter O
balance O
in O
the O
cerebral O
cortex O
. O

Little O
research O
exists O
in O
humans O
concerning O
the O
anxiolytic O
, O
antidepressant O
, O
sedative O
, O
and O
adaptogenic O
actions O
the O
traditional O
Ayurvedic O
medicine O
Bacopa B-Medicinal food
monnieri I-Medicinal food
( O
BM B-Medicinal food
) O
possesses O
in O
addition O
to O
its O
documented O
cognitive-enhancing B-Symptom_WorkedFor
effects O
. O

Preclinical O
work O
has O
identified O
a O
number O
of O
acute O
anxiolytic O
, O
nootropic O
, O
and O
adaptogenic O
effects O
of O
BM O
that O
may O
also O
co-occur O
in O
humans O
. O

The O
current O
double-blind O
, O
placebo-controlled O
cross-over O
study O
assessed O
the O
acute O
effects O
of O
a O
specific O
extract O
of O
BM B-Medicinal food
( O
KeenMind B-Drug/Scientific name
® I-Drug/Scientific name
- I-Drug/Scientific name
CDRI I-Drug/Scientific name
08 I-Drug/Scientific name
) O
in O
normal O
healthy O
participants O
during O
completion O
of O
a O
multitasking O
framework O
( O
MTF O
) O
. O

Seventeen B-#Participants
healthy O
volunteers O
completed O
the O
MTF O
, O
at O
baseline O
, O
then O
1 O
h O
and O
2 O
h O
after O
consuming O
a O
placebo O
, O
320 B-Dosage
mg I-Dosage
BM B-Medicinal food
and O
640 B-Dosage
mg I-Dosage
of O
BM B-Medicinal food
. O

Treatments O
were O
separated O
by O
a O
7 O
- O
day O
washout O
with O
order O
determined O
by O
Latin O
Square O
. O

Outcome O
measures O
included O
cognitive O
outcomes O
from O
the O
MTF O
, O
with O
mood O
and O
salivary O
cortisol O
measured O
before O
and O
after O
each O
completion O
of O
the O
MTF O
. O

Change O
from O
baseline O
scores O
indicated O
positive O
cognitive O
effects O
, O
notably O
at O
both O
1 O
h O
post O
and O
2 O
h O
post O
BM B-Medicinal food
consumption O
on O
the O
Letter O
Search O
and O
Stroop O
tasks O
, O
suggesting O
an O
earlier O
nootropic O
effect O
of O
BM B-Medicinal food
than O
previously O
investigated O
. O

There O
were O
also O
some O
positive O
mood O
effects O
and O
reduction O
in O
cortisol O
levels O
, O
pointing O
to O
a O
physiological O
mechanism O
for O
stress B-Symptom_WorkedFor
reduction O
associated O
with O
BM B-Medicinal food
consumption O
. O

It O
was O
concluded O
that O
acute O
BM B-Medicinal food
supplementation O
produced O
some O
adaptogenic O
and O
nootropic O
effects O
that O
need O
to O
be O
replicated O
in O
a O
larger O
sample O
and O
in O
isolation O
from O
stressful O
cognitive O
tests O
in O
order O
to O
quantify O
the O
magnitude O
of O
these O
effects O
. O

The O
study O
was O
registered O
with O
the O
Australian O
and O
New O
Zealand O
Clinical O
Trials O
Registry O
( O
ACTRN12612000834853 O
) O
. O

Bacopa B-Medicinal food
monnieri I-Medicinal food
( O
BM B-Medicinal food
) O
an O
herb O
, O
found O
throughout O
the O
Indian O
subcontinent O
in O
wet O
, O
damp O
and O
marshy O
areas O
is O
used O
in O
Ayurvedic O
system O
of O
medicine O
for O
improving B-Symptom_WorkedFor
intellect I-Symptom_WorkedFor
/ I-Symptom_WorkedFor
memory I-Symptom_WorkedFor
, O
treatment O
of O
anxiety B-Symptom_WorkedFor
and O
neuropharmacological B-Symptom_WorkedFor
disorders I-Symptom_WorkedFor
. O

Although O
extensively O
given O
to O
children O
as O
a O
memory O
enhancer O
, O
no O
data O
exists O
on O
its O
ability O
to O
modulate O
neuronal O
oxidative O
stress O
in O
prepubertal O
animal O
models O
. O

Hence O
in O
this O
study O
, O
we O
examined O
if O
dietary O
intake O
of O
BM B-Medicinal food
leaf O
powder O
has O
the O
propensity O
to O
modulate O
endogenous O
markers O
of O
oxidative O
stress O
, O
redox O
status O
( O
reduced O
GSH O
, O
thiol O
status O
) O
, O
response O
of O
antioxidant O
defenses O
( O
enzymic O
) O
, O
protein O
oxidation O
and O
cholinergic O
function O
in O
various O
brain O
regions O
of O
prepubertal O
( O
PP O
) O
mice O
. O

PP O
mice O
maintained O
on O
a O
BM-enriched B-Medicinal food
diet O
( O
0.5 O
and O
1% O
) O
for O
4 O
weeks O
showed O
a O
significant O
diminution O
of O
basal O
oxidative O
markers O
( O
malondialdehyde O
levels O
, O
reactive O
species O
generation O
, O
hydroperoxide O
levels O
and O
protein O
carbonyls O
) O
in O
both O
cytoplasm O
and O
mitochondria O
of O
all O
brain O
regions O
. O

This O
was O
accompanied O
with O
enhanced O
reduced O
glutathione O
, O
thiol O
levels O
and O
elevated O
activities O
of O
antioxidant O
enzymes O
( O
catalase O
, O
glutathione O
peroxidase O
, O
superoxide O
dismutase O
) O
. O

Significant O
reduction O
in O
the O
activity O
of O
acetyl O
cholinesterase O
enzyme O
in O
all O
brain O
regions O
suggested O
the O
potential O
of O
BM B-Medicinal food
leaf O
powder O
to O
modulate O
cholinergic O
function O
. O

Further O
evidence O
that O
dietary O
intake O
of O
BM B-Medicinal food
leaf O
powder O
confers O
the O
prepubertal O
brain O
with O
additional O
capacity O
to O
cope O
up O
with O
neurotoxic O
prooxidants O
was O
obtained O
by O
exposing O
cortical O
/ O
cerebellar O
synaptosomes O
of O
normal O
and O
BM O
fed O
mice O
to O
3 O
- O
nitropropionic O
acid O
( O
3 O
- O
NPA O
) O
. O

While O
synaptosomes O
from O
control O
mice O
exhibited O
a O
concentration O
related O
lipid O
peroxidation O
and O
ROS O
generation O
, O
synaptosomes O
obtained O
from O
BM O
fed O
mice O
showed O
only O
a O
marginal O
induction O
at O
the O
highest O
concentration O
clearly O
suggesting O
their O
increased O
resistance O
to O
3 O
- O
NPA-induced O
oxidative O
stress O
. O

Collectively O
these O
data O
clearly O
indicate O
the O
potential O
of O
Bacopa B-Medicinal food
monnieri I-Medicinal food
to O
modulate O
endogenous O
markers O
of O
oxidative O
stress O
in O
brain O
tissue O
of O
PP O
mice O
. O

Based O
on O
these O
results O
, O
it O
is O
hypothesized O
that O
dietary O
intake O
of O
BM B-Medicinal food
leaf O
powder O
confers O
neuroprotective B-Symptom_WorkedFor
advantage O
and O
is O
likely O
to O
be O
effective O
as O
a O
prophylactic O
/ O
therapeutic O
agent O
for O
neurodegenerative B-Symptom_WorkedFor
disorders O
involving O
oxidative O
stress O
. O

Anxiety O
disorders O
are O
one O
of O
the O
most O
common O
mental O
disorders O
, O
and O
benzodiazepines B-Other_ingredients
( O
BDZs O
) O
, O
acting O
on O
gamma-aminobutyric O
acid O
type O
A O
( O
GABA-A O
) O
receptor O
complex O
, O
represent O
the O
most O
common O
antianxiety O
medications O
in O
the O
world O
. O

However O
, O
chronic O
BDZ O
use O
elicits O
several O
adverse O
reactions O
. O

Reportedly O
, O
aromatherapy O
is O
safer O
for O
the O
management O
of O
anxiety B-Symptom_WorkedFor
. O

Bergamot B-Medicinal food
essential O
oil O
( O
BEO O
) O
extracted O
from O
Citrus B-Drug/Scientific name
bergamia I-Drug/Scientific name
Risso I-Drug/Scientific name
et I-Drug/Scientific name
Poiteau I-Drug/Scientific name
fruit O
, O
like O
other O
essential O
oils O
, O
is O
widely O
used O
in O
aromatherapy O
to O
relieve O
symptoms O
of O
stress-induced B-Symptom_WorkedFor
anxiety I-Symptom_WorkedFor
. O

Interestingly O
, O
preclinical O
data O
indicate O
that O
BEO O
induces O
anxiolytic-like O
/ O
relaxant O
effects O
in O
animal O
behavioural O
tasks O
not O
superimposable O
to O
those O
of O
benzodiazepine B-Other_ingredients
diazepam I-Other_ingredients
. O

To O
better O
elucidate O
the O
involvement O
of O
GABAergic O
transmission O
, O
the O
present O
study O
examines O
the O
effects O
of O
pretreatment O
with O
flumazenil O
( O
FLZ O
) O
, O
a O
benzodiazepine O
site O
antagonist O
, O
on O
BEO O
effects O
using O
open-field O
task O
( O
OFT O
) O
in O
rats O
. O

The O
data O
yielded O
show O
that O
FLZ O
does O
not O
significantly O
affect O
behavioural O
effects O
of O
the O
phytocomplex O
. O

These O
results O
demonstrate O
the O
lack O
of O
overlapping O
between O
BEO O
and O
BDZ O
behavioural O
effects O
, O
contributing O
to O
the O
characterization O
of O
the O
neurobiological O
profile O
of O
the O
essential O
oil O
for O
its O
rational O
use O
in O
aromatherapy O
. O

A O
large O
number O
of O
studies O
showed O
that O
aluminum B-Other_ingredients
( O
Al O
) O
has O
potential O
neurotoxicity O
to O
human O
and O
animal O
bodies O
. O

Al-treated O
animals O
showed O
anxiety-like O
behavior O
, O
oxidative O
stress O
, O
neuroinflammation O
and O
γ-aminobutyric O
acid O
( O
GABA O
) O
changes O
. O

Bergamot B-Medicinal food
essential O
oil O
( O
BEO O
) O
is O
a O
kind O
of O
well-known O
plant O
extract O
from O
the O
fresh O
fruit O
of O
bergamot B-Medicinal food
. O

Previous O
studies O
suggested O
that O
BEO O
improved O
mood O
and O
relieved O
symptoms O
of O
stress-induced B-Symptom_WorkedFor
anxiety I-Symptom_WorkedFor
. O

This O
study O
was O
designed O
to O
study O
the O
effects O
of O
BEO O
on O
anxiety-like B-Symptom_TestedFor
behavior I-Symptom_TestedFor
, O
oxidative B-Symptom_TestedFor
stress I-Symptom_TestedFor
, O
neuroinflammation B-Symptom_TestedFor
and O
GABA B-Symptom_TestedFor
system I-Symptom_TestedFor
in O
aluminum B-Other_ingredients
trichloride I-Other_ingredients
( O
AlCl3 O
) O
treated O
rats O
. O

Results O
showed O
that O
AlCl3 O
exposure O
induced O
anxiety-like O
behavior O
in O
the O
elevated O
plus O
maze O
and O
the O
open O
field O
test O
. O

Moreover O
, O
AlCl3 O
exposure O
decreased O
the O
level O
of O
GABA O
and O
the O
activity O
of O
glutathione O
peroxidase O
( O
GPx O
) O
, O
catalase O
( O
CAT O
) O
and O
superoxide O
dismutase O
( O
SOD O
) O
in O
the O
hippocampus O
( O
HP O
) O
and O
the O
frontal O
cortex O
( O
FC O
) O
. O

In O
addition O
, O
AlCl3 O
exposure O
increased O
the O
levels O
of O
malondialdehyde O
( O
MDA O
) O
and O
8 O
- O
hydroxy O
- O
2 O
' O
- O
deoxyguanosine O
( O
8 O
- O
OHdG O
) O
and O
the O
levels O
of O
interleukin O
- O
1 O
beta O
( O
IL O
- O
1β O
) O
, O
interleukin O
- O
6 O
( O
IL O
- O
6 O
) O
and O
tumor O
necrosis O
factor-alpha O
( O
TNF-α O
) O
in O
the O
HP O
and O
the O
FC O
. O

To O
the O
contrary O
, O
co-administration O
of O
BEO O
and O
AlCl3 O
improved O
the O
anxiety-like O
behavior O
, O
GABA O
system O
, O
oxidative O
stress O
and O
neuroinflammation O
. O

These O
results O
indicated O
that O
BEO O
can O
alleviate O
the O
anxiety-like B-Symptom_WorkedFor
behavior O
of O
AlCl3 O
- O
exposed O
rats O
through O
the O
combined O
action O
of O
antioxidant O
, O
anti-inflammatory O
and O
GABA O
regulation O
. O

The O
essential O
oil O
obtained O
by O
the O
fresh O
fruit O
of O
Citrus B-Drug/Scientific name
bergamia I-Drug/Scientific name
Risso I-Drug/Scientific name
et I-Drug/Scientific name
Poiteau I-Drug/Scientific name
is O
used O
worldwide O
in O
aromatherapy O
to O
reduce O
pain B-Symptom_WorkedFor
, O
facilitate O
sleep O
induction O
, O
and O
/ O
or O
minimize O
the O
effects O
of O
stress-induced B-Symptom_WorkedFor
anxiety I-Symptom_WorkedFor
. O

Preclinical O
pharmacological O
data O
demonstrate O
that O
bergamot B-Medicinal food
essential O
oil O
( O
BEO O
) O
modulates O
specific O
neurotransmissions O
and O
shows O
an O
anxiolytic-relaxant O
effect O
not O
superimposable O
to O
that O
of O
the O
benzodiazepine B-Other_ingredients
diazepam I-Other_ingredients
, O
suggesting O
that O
neurotransmissions O
, O
other O
than O
GABAergic O
, O
could O
be O
involved O
. O

Several O
studies O
on O
essential O
oils O
indicate O
a O
role O
for O
serotonergic O
( O
5 O
- O
HT O
) O
neurotransmission O
in O
anxiety B-Symptom_WorkedFor
. O

Interestingly O
, O
among O
serotonergic O
receptors O
, O
the O
5 O
- O
HT1A O
subtype O
seems O
to O
play O
a O
key O
role O
in O
the O
control O
of O
anxiety B-Symptom_WorkedFor
. O

Here O
, O
we O
report O
that O
modulation O
of O
the O
5 O
- O
HT1A O
receptor O
by O
selective O
agonist O
( O
( O
± O
) O
8 O
- O
OH-DPAT O
) O
or O
antagonist O
( O
WAY O
- O
100635 O
) O
may O
influence O
some O
of O
the O
anxiolytic-relaxant O
effects O
of O
BEO O
in O
Open O
Field O
and O
Elevated O
Plus O
Maze O
tests O
. O

Bergamot B-Medicinal food
essential O
oil O
( O
BEO O
) O
, O
Citrus B-Medicinal food
aurantium I-Medicinal food
subsp I-Medicinal food
. I-Medicinal food
bergamia I-Medicinal food
( O
Risso O
) O
Wright O
& O
Arn O
. O

( O
Rutaceae O
) O
, O
is O
used O
widely O
in O
aromatherapy O
to O
reduce O
stress B-Symptom_WorkedFor
and O
anxiety B-Symptom_WorkedFor
despite O
limited O
scientific O
evidence O
. O

A O
previous O
study O
showed O
that O
BEO O
significantly O
increased O
gamma-aminobutyric O
acid O
levels O
in O
rat O
hippocampus O
, O
suggesting O
potential O
anxiolytic O
properties O
. O

The O
aim O
of O
this O
study O
was O
to O
investigate O
the O
effect O
of O
BEO O
( O
1.0% O
, O
2.5% O
and O
5.0% O
w O
/ O
w O
) O
administered O
to O
rats O
on O
both O
anxiety-related B-Symptom_WorkedFor
behaviours O
( O
the O
elevated O
plus-maze O
( O
EPM O
) O
and O
hole-board O
tests O
) O
and O
stress-induced B-Symptom_WorkedFor
levels O
of O
plasma O
corticosterone O
in O
comparison O
with O
the O
effects O
of O
diazepam B-Other_ingredients
. O

Inhalation O
of O
BEO O
( O
1% O
and O
2.5% O
) O
and O
injection O
of O
diazepam B-Other_ingredients
( O
1 O
mg O
/ O
kg O
, O
i.p O
. O
) O
significantly O
increased O
the O
percentage O
of O
open O
arm O
entries O
on O
the O
EPM O
. O

The O
percentage O
time O
spent O
in O
the O
open O
arms O
was O
also O
significantly O
enhanced O
following O
administration O
of O
either O
BEO O
( O
2.5% O
and O
5% O
) O
or O
diazepam O
. O

Total O
arm O
entries O
were O
significantly O
increased O
with O
the O
highest O
dose O
( O
5% O
) O
, O
suggesting O
an O
increase O
in O
locomotor O
activity O
. O

In O
the O
hole-board O
test O
, O
2.5% O
BEO O
and O
diazepam O
significantly O
increased O
the O
number O
of O
head O
dips O
. O
2.5% O
BEO O
and O
diazepam O
attenuated O
the O
corticosterone O
response O
to O
acute O
stress O
caused O
by O
exposure O
to O
the O
EPM O
. O

In O
conclusion O
, O
both O
BEO O
and O
diazepam O
exhibited O
anxiolytic-like O
behaviours O
and O
attenuated O
HPA O
axis O
activity O
by O
reducing O
the O
corticosterone O
response O
to O
stress B-Symptom_WorkedFor
. O

Bergamot B-Medicinal food
( O
Citrus B-Drug/Scientific name
bergamia I-Drug/Scientific name
, O
Risso B-Drug/Scientific name
) O
is O
a O
fruit O
most O
knowledgeable O
for O
its O
essential O
oil O
( O
BEO O
) O
used O
in O
aromatherapy O
to O
minimize O
symptoms O
of O
stress-induced B-Symptom_WorkedFor
anxiety I-Symptom_WorkedFor
and O
mild O
mood B-Symptom_WorkedFor
disorders I-Symptom_WorkedFor
and O
cancer B-Symptom_WorkedFor
pain I-Symptom_WorkedFor
though O
the O
rational O
basis O
for O
such O
applications O
awaits O
to O
be O
discovered O
. O

The O
behavioural O
and O
EEG O
spectrum O
power O
effects O
of O
BEO O
correlate O
well O
with O
its O
exocytotic O
and O
carrier-mediated O
release O
of O
discrete O
amino O
acids O
endowed O
with O
neurotransmitter O
function O
in O
the O
mammalian O
hippocampus O
supporting O
the O
deduction O
that O
BEO O
is O
able O
to O
interfere O
with O
normal O
and O
pathological O
synaptic O
plasticity O
. O

The O
observed O
neuroprotection O
in O
the O
course O
of O
experimental O
brain O
ischemia O
and O
pain O
does O
support O
this O
view O
. O

In O
conclusion O
, O
the O
data O
yielded O
so O
far O
contribute O
to O
our O
understanding O
of O
the O
mode O
of O
action O
of O
this O
phytocomplex O
on O
nerve O
tissue O
under O
normal O
and O
pathological O
experimental O
conditions O
and O
provide O
a O
rational O
basis O
for O
the O
practical O
use O
of O
BEO O
in O
complementary O
medicine O
. O

The O
opening O
of O
a O
wide O
venue O
for O
future O
research O
and O
translation O
into O
clinical O
settings O
is O
also O
envisaged O
. O

Purpose O
: O
The O
purpose O
of O
this O
study O
was O
to O
identify O
the O
effects O
of O
aromatherapy O
on O
blood B-Symptom_WorkedFor
pressure I-Symptom_WorkedFor
and O
stress B-Symptom_WorkedFor
responses O
of O
clients O
with O
essential O
hypertension B-participant_health
. O

Method O
: O
There O
were O
fifty-two B-#Participants
subjects O
divided O
into O
an O
essential B-Medicinal food
oil I-Medicinal food
group O
, O
placebo O
group O
, O
and O
control O
group O
by O
random O
assignment O
. O

The O
application O
of O
aromatherapy O
was O
the O
inhalation O
method O
of O
blending O
oils B-Medicinal food
with O
lavender B-Other_ingredients
, O
ylangylang B-Other_ingredients
, O
and O
bergamot B-Other_ingredients
once O
daily O
for O
4 B-Duration
weeks I-Duration
. O

To O
evaluate O
the O
effects O
of O
aromatherapy O
, O
blood O
pressure O
and O
pulse O
were O
measured O
two O
times O
a O
week O
and O
serum O
cortisol O
levels O
, O
catecholamine O
levels O
, O
subjective O
stress O
, O
and O
state O
anxiety O
were O
measured O
before O
and O
after O
treatment O
in O
the O
three O
groups O
. O

Data O
was O
analyzed O
by O
repeated O
measures O
of O
ANOVA B-Metric
, O
one-way B-Metric
ANOVA I-Metric
, O
and O
chi B-Metric
( I-Metric
2 I-Metric
) I-Metric
- I-Metric
test I-Metric
using O
the O
SPSS O
10.0 O
program O
. O

Results O
: O
The O
blood O
pressure O
, O
pulse O
, O
subjective O
stress O
, O
state O
anxiety O
, O
and O
serum O
cortisol O
levels O
among O
the O
three O
groups O
were O
significantly O
statistically O
different O
. O

The O
differences O
of O
catecholamine O
among O
the O
three O
groups O
were O
not O
significant O
statistically O
. O

Conclusion O
: O
The O
results O
suggest O
that O
the O
inhalation O
method O
using O
essential O
oils O
can O
be O
considered O
an O
effective O
nursing O
intervention O
that O
reduces O
psychological O
stress B-Symptom_WorkedFor
responses O
and O
serum O
cortisol O
levels O
, O
as O
well O
as O
the O
blood B-Symptom_WorkedFor
pressure I-Symptom_WorkedFor
of O
clients O
with O
essential O
hypertension O
. O

A O
number O
of O
essential O
oils O
are O
currently O
in O
use O
as O
aromatherapy O
agents O
to O
relieve O
anxiety B-Symptom_WorkedFor
, O
stress B-Symptom_WorkedFor
, O
and O
depression B-Symptom_WorkedFor
. O

Popular O
anxiolytic O
oils O
include O
lavender B-Medicinal food
( O
Lavandula B-Drug/Scientific name
angustifolia I-Drug/Scientific name
) O
, O
rose B-Medicinal food
( O
Rosa B-Drug/Scientific name
damascena I-Drug/Scientific name
) O
, O
orange B-Medicinal food
( O
Citrus B-Drug/Scientific name
sinensis I-Drug/Scientific name
) O
, O
bergamot B-Medicinal food
( O
Citrus B-Drug/Scientific name
aurantium I-Drug/Scientific name
) O
, O
lemon B-Medicinal food
( O
Citrus B-Drug/Scientific name
limon I-Drug/Scientific name
) O
, O
sandalwood B-Medicinal food
( O
Santalum B-Drug/Scientific name
album I-Drug/Scientific name
) O
, O
clary B-Medicinal food
sage I-Medicinal food
( O
Salvia B-Drug/Scientific name
sclarea I-Drug/Scientific name
) O
, O
Roman B-Medicinal food
chamomile I-Medicinal food
( O
Anthemis B-Drug/Scientific name
nobilis I-Drug/Scientific name
) O
, O
and O
rose-scented B-Medicinal food
geranium I-Medicinal food
( O
Pelargonium B-Drug/Scientific name
spp I-Drug/Scientific name
. O
) O
. O

This O
review O
discusses O
the O
chemical O
constituents O
and O
CNS O
effects O
of O
these O
aromatherapeutic O
essential O
oils O
, O
as O
well O
as O
recent O
studies O
on O
additional O
essential O
oils O
with O
anxiolytic O
activities O
. O

Purpose O
: O
This O
study O
was O
done O
to O
examine O
the O
effects O
of O
aromatherapy O
on O
stress B-Symptom_WorkedFor
and O
stress O
responses O
in O
adolescents O
. O

Methods O
: O
A O
two-group O
cross-over O
design O
was O
used O
for O
this O
study O
. O

The O
experimental O
treatment O
was O
aroma B-Medicinal food
essential I-Medicinal food
oil I-Medicinal food
inhalation O
and O
the O
placebo O
treatment O
was O
carrier O
oil O
inhalation O
using O
a O
necklace O
. O

The O
sample O
included O
36 B-#Participants
female O
high O
school O
students O
. O

Fisher's B-Metric
exact I-Metric
test I-Metric
, O
t-test B-Metric
, O
and O
paired B-Metric
t-test I-Metric
using O
SPSS O
/ O
WIN O
program O
were O
used O
to O
analyze O
the O
data O
. O

Results O
: O
Stress B-Symptom_WorkedFor
levels O
were O
significantly O
lower O
when O
the O
students O
received O
the O
aroma O
treatment O
compared O
to O
when O
they O
received O
the O
placebo O
treatment O
. O

The O
stress B-Symptom_WorkedFor
responses O
except O
salivary O
IgA O
levels O
were O
significantly O
lower O
when O
the O
students O
received O
the O
aroma O
treatment O
. O

Conclusion O
: O
Aroma O
inhalation O
could O
be O
a O
very O
effective O
stress B-Symptom_WorkedFor
management O
method O
for O
high O
school O
students O
. O

Therefore O
, O
it O
is O
recommended O
that O
this O
program O
be O
used O
in O
clinical O
practice O
as O
an O
effective O
nursing O
intervention O
for O
high O
school O
students O
. O

Citrus B-Drug/Scientific name
bergamia I-Drug/Scientific name
Risso I-Drug/Scientific name
et I-Drug/Scientific name
Poiteau I-Drug/Scientific name
, O
also O
known O
as O
" O
Bergamot B-Medicinal food
, O
" O
is O
a O
plant O
belonging O
to O
the O
Rutaceae O
family O
, O
defined O
as O
a O
hybrid O
of O
bitter O
orange O
and O
lemon O
. O

It O
is O
an O
endemic O
plant O
of O
the O
Calabria O
region O
( O
Italy O
) O
. O

Bergamot B-Medicinal food
fruit O
is O
primarily O
used O
for O
the O
extraction O
of O
its O
essential O
oil O
( O
bergamot O
essential O
oil O
: O
BEO O
) O
, O
employed O
in O
perfume O
, O
cosmetics O
, O
food O
, O
and O
confections O
. O

The O
aim O
of O
this O
review O
was O
to O
collect O
recent O
data O
from O
the O
literature O
on O
C O
. O
bergamia O
essential O
oil O
and O
, O
through O
a O
critical O
analysis O
, O
focus O
on O
safety O
and O
the O
beneficial O
effects O
on O
human O
health O
. O

Clinical O
studies O
on O
the O
therapeutic O
applications O
of O
BEO O
exclusively O
focus O
on O
the O
field O
of O
aromatherapy O
, O
suggesting O
that O
its O
use O
can O
be O
useful O
for O
reducing O
anxiety B-Symptom_WorkedFor
and O
stress B-Symptom_WorkedFor
. O

We O
summarize O
the O
effects O
of O
bergamot B-Medicinal food
( O
extract O
, O
juice O
, O
essential O
oil O
, O
and O
polyphenolic O
fraction O
) O
on O
cardiovascular B-Symptom_TestedFor
, O
bone B-Symptom_TestedFor
, O
inflammatory B-Symptom_TestedFor
, O
skin B-Symptom_TestedFor
diseases I-Symptom_TestedFor
, O
mood B-Symptom_TestedFor
alteration I-Symptom_TestedFor
, O
anxiety B-Symptom_TestedFor
, O
pain B-Symptom_TestedFor
, O
and O
stress B-Symptom_TestedFor
. O

This O
review O
included O
a O
total O
of O
31 O
studies O
( O
20 O
studies O
on O
humans O
with O
1709 B-#Participants
subjects O
and O
11 O
in O
animals O
( O
rats O
and O
mice O
) O
) O
. O

In O
humans O
, O
bergamot-derived B-Medicinal food
extract O
( O
BE O
) O
exerts O
positive O
effects O
on O
hyperlipidemia O
with O
an O
oral O
dose O
from O
150 B-Dosage
mg I-Dosage
to I-Dosage
1000 I-Dosage
mg I-Dosage
/ I-Dosage
day I-Dosage
of O
flavonoids O
administered O
from O
30 B-Duration
to I-Duration
180 I-Duration
days I-Duration
, O
demonstrating O
an O
effect O
on O
body O
weight O
and O
in O
modulating O
total O
cholesterol O
, O
triglycerides O
, O
LDL O
, O
and O
HDL O
. O

Studies O
in O
animals O
confirm O
promising O
data O
on O
glucose O
control O
( O
500 O
/ O
1000 O
mg O
/ O
day O
of O
BE O
with O
a O
treatment O
lasting O
30 O
days O
) O
are O
available O
in O
rats O
. O

In O
animals O
models O
, O
bergamot O
essential O
oil O
( O
BEO O
, O
10 O
mg O
/ O
kg O
or O
20 O
mg O
/ O
kg O
daily O
for O
20 O
weeks O
) O
increases O
bone O
volume O
, O
decreases O
psoriatic O
plaques O
, O
increases O
skin O
collagen O
content O
, O
and O
promotes O
hair O
growth O
. O

Bergamot B-Medicinal food
juice O
( O
20 O
mg O
/ O
kg O
) O
is O
promising O
in O
terms O
of O
pro-inflammatory O
cytokine O
reduction O
. O

In O
humans O
, O
aromatherapy O
( O
from O
15 O
to O
30 O
min O
) O
does O
not O
appear O
to O
be O
useful O
in O
order O
to O
reduce O
stress B-Symptom_TestedFor
, O
anxiety B-Symptom_TestedFor
, O
and B-Symptom_TestedFor
nausea O
, O
compared O
to O
placebo O
. O

Compared O
to O
baseline O
, O
BE O
topical O
application O
and O
BEO O
aromatherapy O
reduce O
blood B-Symptom_WorkedFor
diastolic I-Symptom_WorkedFor
and I-Symptom_WorkedFor
systolic I-Symptom_WorkedFor
pressure I-Symptom_WorkedFor
and O
could O
have O
a O
significant O
effect O
on O
improving B-Symptom_WorkedFor
mental I-Symptom_WorkedFor
conditions I-Symptom_WorkedFor
. O

Preclinical O
studies O
have O
recently O
highlighted O
that O
bergamot B-Medicinal food
essential O
oil O
( O
BEO O
) O
is O
endowed O
with O
remarkable O
neurobiolological O
effects O
. O

BEO O
can O
affect O
synaptic O
transmission O
, O
modulate O
electroencephalographic O
activity O
and O
it O
showed O
neuroprotective O
and O
analgesic O
properties O
. O

The O
phytocomplex O
, O
along O
with O
other O
essential O
oils O
, O
is O
also O
widely O
used O
in O
aromatherapy O
to O
minimize O
symptoms O
of O
stress-induced B-Symptom_WorkedFor
anxiety I-Symptom_WorkedFor
and O
mild O
mood B-Symptom_WorkedFor
disorders I-Symptom_WorkedFor
. O

However O
, O
only O
limited O
preclinical O
evidences O
are O
actually O
available O
. O

This O
study O
examined O
the O
anxiolytic O
/ O
sedative-like O
effects O
of O
BEO O
using O
an O
open O
field O
task O
( O
OFT O
) O
, O
an O
elevated O
plus-maze O
task O
( O
EPM O
) O
, O
and O
a O
forced O
swimming O
task O
( O
FST O
) O
in O
rats O
. O

This O
study O
further O
compared O
behavioural O
effects O
of O
BEO O
to O
those O
of O
the O
benzodiazepine O
diazepam O
. O

Analysis O
of O
data O
suggests O
that O
BEO O
induces O
anxiolytic-like O
/ O
relaxant O
effects O
in O
animal O
behavioural O
tasks O
not O
superimposable O
to O
those O
of O
the O
DZP O
. O

The O
present O
observations O
provide O
further O
insight O
to O
the O
pharmacological O
profile O
of O
BEO O
and O
support O
its O
rational O
use O
in O
aromatherapy O
. O

Objectives O
: O
Dysfunctions O
in O
stress O
biology O
are O
hypothesized O
to O
contribute O
to O
anxiety B-Symptom_WorkedFor
disorders O
, O
and O
to O
be O
ameliorated O
during O
successful O
treatment O
, O
but O
limited O
clinical O
data O
exist O
to O
support O
this O
hypothesis O
. O

We O
evaluated O
whether O
increases O
in O
morning O
cortisol O
and O
the O
diurnal O
cortisol O
slope O
, O
markers O
of O
stress O
biology O
, O
are O
associated O
with O
clinical O
response O
to O
chamomile O
therapy O
among O
subjects O
with O
generalized B-Symptom_WorkedFor
anxiety I-Symptom_WorkedFor
disorder I-Symptom_WorkedFor
( O
GAD B-Symptom_WorkedFor
) O
. O

Methods O
: O
Among O
45 B-#Participants
subjects O
with O
DSM-IV O
diagnosed O
GAD B-Symptom_WorkedFor
in O
an O
open-label O
clinical O
trial O
of O
chamomile B-Medicinal food
, O
salivary O
cortisol O
was O
assessed O
for O
three O
days O
each O
pre O
- O
and O
post-treatment O
, O
at O
8am O
, O
12pm O
, O
4pm O
, O
and O
8pm O
. O

Mixed O
model O
analyses O
assessed O
whether O
GAD B-Symptom_WorkedFor
symptom O
change O
predicted O
the O
degree O
to O
which O
cortisol O
levels O
changed O
during O
treatment O
. O

Results O
: O
Symptom O
improvement O
during O
treatment O
was O
significantly O
associated O
with O
pre-to-post O
treatment O
changes O
in O
cortisol O
. O

Subjects O
who O
experienced O
more O
symptomatic O
improvement O
experienced O
significant O
increases O
in O
their O
morning O
salivary O
cortisol O
( O
β O
= O
0.48 O
, O
p O
< O
0.001 O
) O
, O
and O
a O
greater O
decrease O
in O
cortisol O
from O
morning O
to O
the O
rest O
of O
the O
day O
( O
β O
= O
0.55 O
, O
p O
< O
0.001 O
) O
. O

In O
addition O
, O
at O
baseline O
a O
lower O
cortisol O
level O
( O
β O
= O
- O
0.24 O
, O
p O
= O
0.023 O
) O
and O
a O
lesser O
decrease O
in O
cortisol O
after O
morning O
( O
β O
= O
0.30 O
, O
p O
= O
0.003 O
) O
were O
associated O
with O
greater O
symptomatic O
improvement O
. O

Conclusion O
: O
Increases O
in O
morning O
salivary O
cortisol O
and O
the O
diurnal O
cortisol O
slope O
are O
associated O
with O
symptom O
improvement O
in O
chamomile B-Medicinal food
treatment O
of O
GAD B-Symptom_WorkedFor
. O

Response O
to O
treatment O
for O
GAD B-Symptom_WorkedFor
could O
partially O
stem O
from O
normalization O
of O
stress O
biology O
dysfunction O
, O
but O
further O
work O
involving O
establishing O
abnormalities O
within-sample O
, O
ruling O
out O
of O
confounds O
( O
e.g O
. O
, O
sleep O
) O
, O
and O
a O
placebo O
control O
is O
necessary O
to O
conclude O
an O
amelioration O
effect O
. O

Registration O
code O
: O
NCT01072344 O
. O

URL O
: O
https O
: O
/ O
/ O
clinicaltrials.gov O
/ O
ct2 O
/ O
show O
/ O
NCT01072344 O
. O

A O
number O
of O
essential O
oils O
are O
currently O
in O
use O
as O
aromatherapy O
agents O
to O
relieve O
anxiety B-Symptom_WorkedFor
, O
stress B-Symptom_WorkedFor
, O
and O
depression B-Symptom_WorkedFor
. O

Popular O
anxiolytic O
oils O
include O
lavender B-Medicinal food
( O
Lavandula B-Drug/Scientific name
angustifolia I-Drug/Scientific name
) O
, O
rose B-Medicinal food
( O
Rosa B-Drug/Scientific name
damascena I-Drug/Scientific name
) O
, O
orange B-Medicinal food
( O
Citrus B-Drug/Scientific name
sinensis I-Drug/Scientific name
) O
, O
bergamot B-Medicinal food
( O
Citrus B-Drug/Scientific name
aurantium I-Drug/Scientific name
) O
, O
lemon B-Medicinal food
( O
Citrus B-Drug/Scientific name
limon I-Drug/Scientific name
) O
, O
sandalwood B-Medicinal food
( O
Santalum B-Drug/Scientific name
album I-Drug/Scientific name
) O
, O
clary B-Medicinal food
sage I-Medicinal food
( O
Salvia B-Drug/Scientific name
sclarea I-Drug/Scientific name
) O
, O
Roman B-Medicinal food
chamomile I-Medicinal food
( O
Anthemis B-Drug/Scientific name
nobilis I-Drug/Scientific name
) O
, O
and O
rose-scented B-Medicinal food
geranium I-Medicinal food
( O
Pelargonium B-Drug/Scientific name
spp I-Drug/Scientific name
. I-Drug/Scientific name
) O
. O

This O
review O
discusses O
the O
chemical O
constituents O
and O
CNS O
effects O
of O
these O
aromatherapeutic O
essential O
oils O
, O
as O
well O
as O
recent O
studies O
on O
additional O
essential O
oils O
with O
anxiolytic O
activities O
. O

The O
burning B-Symptom_WorkedFor
mouth I-Symptom_WorkedFor
syndrome I-Symptom_WorkedFor
( O
BMS B-Symptom_WorkedFor
) O
has O
no O
specific O
clinical O
and O
laboratory O
signs O
. O

Its O
etiology O
is O
yet O
to O
be O
elucidated O
, O
but O
it O
is O
considered O
to O
be O
affected O
by O
multifactorial O
, O
psychological O
, O
and O
local O
and O
systemic O
factors O
. O

This O
condition O
is O
considered O
of O
great O
morbidity O
, O
and O
the O
main O
complaint O
of O
patients O
maybe O
associated O
with O
xerostomia O
, O
thirst O
, O
and O
altered O
taste O
. O

The O
present O
study O
aims O
to O
report O
two O
cases O
of O
BMS B-Symptom_WorkedFor
and O
to O
evaluate O
the O
outcome O
of O
cognitive O
therapy O
( O
CT O
) O
plus O
phytotherapy O
in O
the O
control O
of O
BMS B-Symptom_WorkedFor
. O

The O
patients O
were O
female O
, O
Caucasian O
, O
and O
aged O
between O
58 O
and O
69 O
years O
. O

The O
most O
BMS-affected B-Symptom_WorkedFor
anatomical O
parts O
were O
the O
lips O
and O
the O
tongue O
. O

In O
the O
clinical O
approach O
, O
oral O
and O
systemic O
evaluation O
, O
and O
disease O
management O
with O
CT O
plus O
chamomile B-Medicinal food
tea O
were O
done O
. O

The O
patients O
were O
reassured O
, O
and O
their O
response O
to O
therapy O
one O
year O
after O
was O
found O
to O
be O
excellent O
despite O
few O
exacerbations O
in O
periods O
of O
great O
emotional O
stress O
. O

Thus O
, O
we O
conclude O
that O
psychological O
treatment O
is O
vital O
in O
the O
management O
of O
BMS B-Symptom_WorkedFor
, O
as O
CT O
, O
along O
with O
Matricaria O
recutita O
phytotherapy O
, O
displayed O
excellent O
results O
in O
the O
control O
of O
BMS B-Symptom_WorkedFor
. O

Key O
words O
: O
Anxiety B-Symptom_WorkedFor
, O
chamomile B-Medicinal food
tea O
, O
xerostomia O
, O
psychosomatic O
. O

We O
found O
that O
inhaling O
chamomile B-Medicinal food
oil O
vapour O
decreased O
restriction O
stress-induced B-Symptom_WorkedFor
increases O
of O
plasma O
ACTH O
level O
in O
ovariectomized O
rat O
. O

The O
plasma O
ACTH O
level O
decreased O
further O
when O
diazepam B-Other_ingredients
was O
administered O
along O
with O
inhaling O
chamomile B-Medicinal food
oil O
vapour O
. O

Flumazenile O
blocked O
the O
decrease O
in O
plasma O
ACTH O
level O
induced O
by O
inhaled O
chamomile B-Medicinal food
oil O
vapour O
. O

Anxiety B-Symptom_WorkedFor
disorders O
are O
chronic O
and O
functionally O
disabling O
conditions O
with O
high O
psychological O
stress B-Symptom_WorkedFor
, O
characterised O
by O
cognitive O
symptoms O
of O
excessive O
worry O
and O
focus O
difficulties O
and O
physiological O
symptoms O
such O
as O
muscle B-Symptom_WorkedFor
tension I-Symptom_WorkedFor
and O
insomnia B-Symptom_WorkedFor
. O

Gamma-aminobutyric O
acid O
( O
GABA O
) O
is O
an O
inhibitory O
neurotransmitter O
within O
the O
central O
nervous O
system O
and O
is O
a O
key O
target O
of O
pharmacotherapies O
in O
the O
treatment O
of O
anxiety O
. O

Although O
current O
pharmaceutical O
treatments O
are O
often O
efficacious O
, O
they O
may O
cause O
undesirable O
side O
effects O
including O
cognitive O
decrements O
and O
withdrawal O
symptoms O
. O

Plant-based O
" O
phytomedicines O
" O
may O
provide O
novel O
treatment O
options O
, O
to O
act O
as O
an O
adjunctive O
or O
alternative O
to O
existing O
anxiolytic B-Symptom_WorkedFor
medications O
. O

As O
such O
, O
we O
conducted O
a O
systematic O
review O
to O
assess O
the O
current O
body O
of O
literature O
on O
anxiolytic B-Symptom_WorkedFor
phytomedicines O
and O
/ O
or O
phytoconstituents O
. O

An O
open-ended O
search O
to O
5 O
July O
2017 O
was O
conducted O
using O
MEDLINE O
( O
PubMed O
) O
, O
Scopus O
, O
and O
Cochrane O
library O
online O
databases O
and O
performed O
in O
a O
stepped O
format O
from O
preclinical O
to O
clinical O
investigations O
. O

Eligible O
studies O
must O
have O
had O
( O
a O
) O
in O
vitro O
evidence O
of O
GABA-modulating O
activity O
, O
( O
b O
) O
animal O
studies O
using O
anxiety O
models O
to O
test O
an O
anxiolytic O
effect O
, O
and O
( O
c O
) O
human O
clinical O
trials O
. O

Ten O
phytomedicines O
were O
identified O
as O
having O
preclinical O
investigations O
showing O
interaction O
with O
the O
GABA O
system O
, O
in O
addition O
to O
human O
clinical O
trials O
: O
kava B-Medicinal food
, O
valerian B-Medicinal food
, O
pennywort B-Medicinal food
, O
hops B-Medicinal food
, O
chamomile B-Medicinal food
, O
Ginkgo B-Medicinal food
biloba I-Medicinal food
, O
passionflower B-Medicinal food
, O
ashwagandha B-Medicinal food
, O
skullcap B-Medicinal food
, O
and O
lemon B-Symptom_WorkedFor
balm I-Symptom_WorkedFor
. O

Collectively O
, O
the O
literature O
reveals O
preclinical O
and O
clinical O
evidence O
for O
various O
phytomedicines O
modulating O
GABA-pathways O
, O
with O
comparative O
anxiolytic B-Symptom_WorkedFor
effect O
to O
the O
current O
array O
of O
pharmaceuticals O
, O
along O
with O
good O
safety O
and O
tolerability O
profiles O
. O

Rats O
exposed O
to O
stress O
by O
fixation O
develop O
a O
complex O
of O
hormonal O
metabolic O
homeostasis O
disturbances O
( O
as O
evidenced O
by O
changed O
levels O
of O
ACTH O
, O
insulin O
, O
11 O
- O
HOCS O
, O
urea O
, O
glucose O
) O
. O

One O
of O
the O
major O
mechanisms O
of O
these O
disorders O
in O
reduced O
hypothalamus O
sensitivity O
to O
regulatory O
signals O
and O
exhausted O
adrenocortical O
functional O
activity O
, O
developing O
at O
the O
stages O
of O
anxiety B-Symptom_WorkedFor
and O
exhaustion B-Symptom_WorkedFor
of O
the O
adaptation O
syndrome O
, O
respectively O
, O
and O
detectable O
by O
functional O
tests O
with O
dexamethasone O
and O
ACTH O
. O

Administration O
of O
natural O
adaptogens O
( O
Scutellaria B-Drug/Scientific name
baicalensis I-Drug/Scientific name
extract O
and O
its O
active O
principle O
, O
baikalin B-Other_ingredients
flavonoid I-Other_ingredients
) O
was O
conducive O
to O
normalization O
of O
the O
majority O
of O
the O
examined O
parameters O
whatever O
the O
direction O
of O
changes O
. O

Research O
in O
the O
area O
of O
herbal O
psychopharmacology O
has O
revealed O
a O
variety O
of O
promising O
medicines O
that O
may O
provide O
benefit O
in O
the O
treatment O
of O
general O
anxiety B-Symptom_WorkedFor
and O
specific O
anxiety O
disorders O
. O

However O
, O
a O
comprehensive O
review O
of O
plant-based B-Medicinal food
anxiolytics I-Medicinal food
has O
been O
absent O
to O
date O
. O

Thus O
, O
our O
aim O
was O
to O
provide O
a O
comprehensive O
narrative O
review O
of O
plant-based B-Medicinal food
medicines I-Medicinal food
that O
have O
clinical O
and O
/ O
or O
preclinical O
evidence O
of O
anxiolytic O
activity O
. O

We O
present O
the O
article O
in O
two O
parts O
. O

In O
part O
one O
, O
we O
reviewed O
herbal B-Medicinal food
medicines I-Medicinal food
for O
which O
only O
preclinical O
investigations O
for O
anxiolytic O
activity O
have O
been O
performed O
. O

In O
this O
current O
article O
( O
part O
two O
) O
, O
we O
review O
herbal O
medicines O
for O
which O
there O
have O
been O
both O
preclinical O
and O
clinical O
investigations O
of O
anxiolytic O
activity O
. O

A O
search O
of O
MEDLINE O
( O
PubMed O
) O
, O
CINAHL O
, O
Scopus O
and O
the O
Cochrane O
Library O
databases O
was O
conducted O
( O
up O
to O
28 O
October O
2012 O
) O
for O
English O
language O
papers O
using O
the O
search O
terms O
' O
anxiety O
' O
OR O
' O
anxiety O
disorder O
' O
OR O
' O
generalized O
anxiety O
disorder O
' O
OR O
' O
social O
phobia O
' O
OR O
' O
post-traumatic O
stress O
disorder O
' O
OR O
' O
panic O
disorder O
' O
OR O
' O
agoraphobia O
' O
OR O
' O
obsessive O
compulsive O
disorder O
' O
in O
combination O
with O
the O
search O
terms O
' O
Herb O
* O
' O
OR O
' O
Medicinal O
Plants O
' O
OR O
' O
Botanical O
Medicine O
' O
OR O
' O
Chinese O
herb O
* O
' O
, O
in O
addition O
to O
individual O
herbal O
medicines O
. O

This O
search O
of O
the O
literature O
revealed O
1,525 O
papers O
, O
of O
which O
53 O
plants O
were O
included O
in O
the O
review O
( O
having O
at O
least O
one O
study O
using O
the O
whole O
plant O
extract O
) O
. O

Of O
these O
plants O
, O
21 O
had O
human O
clinical O
trial O
evidence O
( O
reviewed O
here O
in O
part O
two O
) O
, O
with O
the O
other O
32 O
having O
solely O
preclinical O
evidence O
( O
reviewed O
in O
part O
one O
) O
. O

Support O
for O
efficacy O
was O
found O
for O
chronic O
use O
( O
i.e O
. O
greater O
than O
one O
day O
) O
of O
the O
following O
herbs O
in O
treating O
a O
range O
of O
anxiety O
disorders O
in O
human O
clinical O
trials O
: O
Piper B-Medicinal food
methysticum I-Medicinal food
, O
Matricaria B-Medicinal food
recutita I-Medicinal food
, O
Ginkgo B-Medicinal food
biloba I-Medicinal food
, O
Scutellaria B-Medicinal food
lateriflora I-Medicinal food
, O
Silybum B-Medicinal food
marianum I-Medicinal food
, O
Passiflora B-Medicinal food
incarnata I-Medicinal food
, O
Withania B-Medicinal food
somniferum I-Medicinal food
, O
Galphimia B-Medicinal food
glauca I-Medicinal food
, O
Centella B-Medicinal food
asiatica I-Medicinal food
, O
Rhodiola B-Medicinal food
rosea I-Medicinal food
, O
Echinacea B-Medicinal food
spp I-Medicinal food
. O
, O
Melissa B-Medicinal food
officinalis I-Medicinal food
and O
Echium B-Medicinal food
amoenum I-Medicinal food
. O

For O
several O
of O
the O
plants O
studied O
, O
conclusions O
need O
to O
be O
tempered O
due O
to O
methodological O
issues O
such O
as O
small O
sample O
sizes O
, O
brief O
intervention O
durations O
and O
non-replication O
. O

Current O
evidence O
does O
not O
support O
Hypericum O
perforatum O
or O
Valeriana O
spp O
. O
for O
any O
anxiety O
disorder O
. O

Acute O
anxiolytic O
activity O
was O
found O
for O
Centella B-Medicinal food
asiatica I-Medicinal food
, O
Salvia B-Medicinal food
spp I-Medicinal food
. O
, O
Melissa B-Medicinal food
officinalis I-Medicinal food
, O
Passiflora B-Medicinal food
incarnata I-Medicinal food
and O
Citrus B-Medicinal food
aurantium I-Medicinal food
. O

Bacopa B-Medicinal food
monnieri I-Medicinal food
has O
shown O
anxiolytic B-Symptom_WorkedFor
effects O
in O
people O
with O
cognitive O
decline O
. O

The O
therapeutic O
application O
of O
psychotropic O
plant-based O
treatments O
for O
anxiety O
disorders O
is O
also O
discussed O
, O
specifically O
Psychotria O
viridis O
and O
Banisteriopsis O
caarti O
( O
ayahuasca O
) O
, O
Psilocybe O
spp O
. O
and O
cannabidiol-enriched O
( O
low O
tetrahydrocannabinol O
( O
Δ O
( O
9 O
) O
- O
THC O
) O
) O
Cannabis O
spp O
. O

Background O
and O
objectives O
: O
Although O
perfectionism O
has O
been O
proposed O
to O
be O
a O
risk O
factor O
for O
the O
development O
of O
anxiety O
, O
research O
on O
perfectionism O
and O
anxiety B-Symptom_WorkedFor
symptoms O
in O
adolescents O
is O
scarce O
and O
inconclusive O
. O

The O
aim O
of O
the O
present O
study O
was O
to O
investigate O
whether O
the O
two O
higher-order O
dimensions O
of O
perfectionism O
- O
perfectionistic O
strivings O
and O
perfectionistic O
concerns O
- O
predict O
the O
development O
and O
maintenance O
of O
anxiety B-Symptom_WorkedFor
symptoms O
. O

An O
additional O
aim O
of O
the O
present O
study O
was O
to O
examine O
potential O
reciprocal O
effects O
of O
anxiety B-Symptom_WorkedFor
symptoms O
predicting O
increases O
in O
perfectionism O
. O

Design O
: O
The O
study O
used O
a O
longitudinal O
design O
with O
three B-Duration
waves I-Duration
spaced I-Duration
4 I-Duration
- I-Duration
5 I-Duration
months I-Duration
apart I-Duration
. O

Methods O
: O
A O
non-clinical O
sample O
of O
489 B-#Participants
adolescents O
aged O
12 O
- O
19 O
years O
completed O
a O
paper-and-pencil O
questionnaire O
. O

Results O
: O
As O
expected O
, O
results O
showed O
a O
positive O
effect O
from O
perfectionistic O
concerns O
to O
anxiety O
symptoms O
, O
but O
the O
effect O
was O
restricted O
to O
middle-to-late O
adolescents O
( O
16 O
- O
19 O
years O
old O
) O
: O
Perfectionistic O
concerns O
predicted O
longitudinal O
increases O
in O
adolescents O
' O
anxiety O
symptoms O
, O
whereas O
perfectionistic O
strivings O
did O
not O
. O

Furthermore O
, O
anxiety O
symptoms O
did O
not O
predict O
increases O
in O
perfectionism O
. O

Conclusions O
: O
Implications O
for O
the O
understanding O
of O
the O
relationship O
between O
perfectionism O
and O
anxiety O
symptoms O
are O
discussed O
. O

Objective O
: O
In O
rodents O
, O
progesterone O
( O
P4 O
) O
pretreatment O
increases O
anxiety B-Symptom_WorkedFor
and O
response O
to O
stressors O
. O

Social O
isolation O
is O
a O
stressor O
that O
generates O
physiological O
and O
behavioural O
stress B-Symptom_WorkedFor
responses O
in O
sheep O
. O

The O
aim O
of O
the O
study O
was O
to O
compare O
the O
stress B-Symptom_WorkedFor
response O
of O
anoestrous O
ewes O
previously O
treated O
or O
not O
with O
P4 O
to O
the O
social O
isolation O
test O
. O

Design O
: O
Ten O
ewes O
received O
P4 O
treatment O
during O
13 O
d O
( O
group O
P4 O
- O
W O
) O
and O
another O
10 O
remained O
untreated O
as O
controls O
( O
group O
Con O
) O
. O

The O
ewes O
were O
individually O
isolated O
in O
a O
novel O
place O
during O
10 O
min O
, O
24 O
h O
after O
the O
end O
of O
P4 O
pretreatment O
and O
their O
behaviours O
were O
recorded O
. O

Cortisol O
and O
P4 O
concentrations O
as O
well O
as O
body O
surface O
temperature O
were O
recorded O
before O
and O
after O
the O
test O
. O

Results O
: O
Ewes O
of O
the O
P4 O
- O
W O
group O
presented O
higher O
cortisol O
levels O
0 O
, O
10 O
, O
20 O
and O
30 O
min O
after O
the O
social O
isolation O
and O
had O
greater O
area O
under O
the O
curve O
of O
cortisol O
compared O
to O
Con O
ewes O
( O
41,785% O
± O
4,156% O
vs O
. O
25,682% O
± O
4,565% O
during O
75 O
min O
) O
. O

Progesterone O
and O
body O
surface O
temperature O
increased O
after O
social O
isolation O
, O
with O
no O
differences O
between O
P4 O
- O
W O
and O
Con O
ewes O
. O

There O
were O
no O
differences O
in O
behavioural O
responses O
to O
social O
isolation O
. O

Conclusions O
: O
P4 O
pretreatment O
appears O
to O
augment O
the O
stress B-Symptom_WorkedFor
response O
to O
social O
isolation O
in O
anoestrous O
ewes O
. O

Mothers O
with O
an O
infant O
in O
the O
neonatal O
intensive O
care O
unit O
( O
NICU O
) O
are O
at O
risk O
for O
depression B-Symptom_WorkedFor
, O
anxiety B-Symptom_WorkedFor
, O
and O
trauma B-Symptom_WorkedFor
symptoms O
, O
with O
negative O
implications O
for O
maternal-infant O
bonding O
, O
maternal O
well-being O
, O
and O
infant O
development O
. O

Few O
interventions O
to O
promote O
NICU O
mothers O
' O
mental O
health O
, O
however O
, O
have O
been O
developed O
or O
tested O
. O

This O
pre-post O
pilot O
study O
assessed O
feasibility O
, O
acceptability O
, O
and O
preliminary O
outcomes O
of O
a O
mindfulness O
intervention O
for O
NICU O
mothers O
. O

Twenty-seven B-#Participants
mothers O
were O
recruited O
from O
a O
university O
NICU O
and O
offered O
a O
mindfulness O
intervention O
via O
introductory O
video O
and O
audio-recorded O
practices O
. O

Participants O
completed O
a O
baseline O
self-report O
survey O
. O

After O
2 O
weeks O
of O
engaging O
with O
intervention O
materials O
, O
participants O
completed O
a O
second O
survey O
and O
in-depth O
interview O
. O

Quantitative O
data O
were O
analyzed O
using O
paired O
t O
tests O
; O
qualitative O
data O
were O
analyzed O
using O
thematic O
coding O
. O

Twenty-four O
women O
( O
89% O
) O
completed O
the O
study O
. O

Quantitative O
data O
indicated O
significant O
improvements O
in O
depressive O
, O
anxiety O
, O
and O
trauma O
symptoms O
, O
negative O
coping O
, O
NICU-related O
stress O
, O
and O
sleep O
( O
p O
< O
0.05 O
) O
. O

Qualitative O
data O
identified O
themes O
of O
perceived O
improvements O
in O
psychological O
distress B-Symptom_WorkedFor
and O
stress B-Symptom_WorkedFor
symptoms O
, O
self-care O
, O
and O
relationships O
. O

Findings O
support O
the O
mindfulness O
intervention's O
feasibility O
, O
acceptability O
, O
and O
potential O
promise O
for O
reducing O
maternal O
distress O
and O
promoting O
well-being O
. O

Use O
of O
video O
and O
audio O
modalities O
may O
facilitate O
program O
sustainability O
and O
scale O
up O
. O

Further O
research O
on O
the O
program O
is O
merited O
. O

The O
aim O
of O
this O
study O
was O
to O
evaluate O
with O
anxiety B-Symptom_WorkedFor
tests O
the O
effect O
of O
resveratrol B-Medicinal food
( O
RSV O
) O
on O
streptozotocin O
( O
STZ O
) O
- O
induced O
diabetic O
mouse O
behavioral O
performance O
at O
the O
second O
and O
fourth O
week O
of O
treatment O
. O

Confirmed O
diabetic O
mice O
( O
> O
250 O
mg O
/ O
dl O
of O
glucose O
in O
blood O
after O
STZ O
injection O
) O
were O
treated O
with O
RSV O
( O
RDM O
, O
n O
= O
12 O
) O
or O
control O
treated O
( O
DM O
, O
n O
= O
12 O
) O
for O
4 O
weeks O
. O

DM O
and O
RDM O
were O
tested O
in O
the O
Open O
Field O
Test O
( O
OFT O
) O
and O
Elevated O
Plus O
Maze O
( O
EPM O
) O
. O

In O
the O
second O
week O
of O
RSV O
treatment O
, O
a O
higher O
grooming O
frequency O
( O
P O
< O
0.05 O
) O
and O
a O
lower O
defecation O
and O
rearing O
frequency O
( O
P O
< O
0.05 O
) O
were O
detected O
in O
the O
OFT O
in O
the O
RDM O
group O
compared O
with O
the O
DM O
. O

There O
was O
a O
higher O
grooming O
frequency O
( O
P O
< O
0.05 O
) O
and O
higher O
percentage O
of O
entries O
in O
open O
arms O
( O
P O
< O
0.05 O
) O
in O
the O
RDM O
group O
than O
in O
the O
DM O
group O
in O
the O
EPM O
. O

However O
, O
in O
the O
fourth O
week O
of O
RSV O
treatment O
, O
the O
only O
effect O
observed O
was O
a O
higher O
grooming O
frequency O
in O
the O
RDM O
group O
than O
in O
the O
DM O
group O
( O
P O
< O
0.05 O
) O
in O
the O
EPM O
. O

In O
conclusion O
, O
RSV O
treatment O
in O
diabetic O
mice O
provoked O
anxiolytic-like O
effects O
in O
both O
tests O
( O
OFT O
and O
EPM O
) O
, O
and O
these O
effects O
were O
observed O
in O
a O
short O
time O
window O
( O
2 O
weeks O
) O
. O

It O
is O
suggested O
that O
RSV O
may O
help O
diabetic O
animals O
to O
adapt O
to O
new O
stressing B-Symptom_WorkedFor
and O
anxiety B-Symptom_WorkedFor
situations O
and O
thus O
to O
improve O
their O
welfare O
. O

Surgery O
can O
be O
proposed O
for O
some O
patients O
affected O
by O
psychiatric O
diseases O
such O
as O
severe O
, O
disabling O
and O
refractory O
affective O
disorders O
( O
depression B-Symptom_TestedFor
) O
, O
OCD B-Symptom_WorkedFor
and O
chronic B-Symptom_TestedFor
anxiety I-Symptom_TestedFor
states O
. O

It O
can O
be O
performed O
after O
a O
period O
of O
evolution O
of O
minimum O
5 O
Years O
and O
after O
all O
other O
classical O
treatments O
have O
failed O
. O

For O
the O
last O
Years O
, O
different O
stereotactic O
techniques O
have O
been O
used O
: O
capsulotomy O
, O
cingulotomy O
, O
subcaudate O
tractotomy O
and O
limbic O
leukotomy O
, O
performed O
by O
radiofrequency B-Medicinal food
thermolesions I-Medicinal food
or O
radiosurgery O
( O
g B-Medicinal food
rays I-Medicinal food
) O
. O

In O
the O
case O
of O
OCD B-Symptom_WorkedFor
, O
these O
procedures O
are O
supposed O
to O
affect O
some O
of O
the O
neural O
circuits O
between O
the O
frontal O
lobes O
and O
different O
structures O
of O
the O
limbic O
system O
, O
considered O
as O
central O
to O
OCD O
symptoms O
. O

As O
they O
cause O
smaller O
cerebral O
lesions O
than O
earlier O
surgical O
techniques O
( O
mostly O
open O
surgery O
techniques O
) O
, O
modern O
stereotactic O
approaches O
have O
less O
clinical O
side O
effects O
, O
primarily O
less O
deficit O
in O
emotional O
reactivity O
and O
motivation O
. O

This O
type O
of O
treatment O
offers O
some O
hope O
to O
patients O
seriously O
disabled O
by O
OCD B-Symptom_WorkedFor
. O

These O
surgeries O
and O
especially O
their O
main O
side O
effects O
are O
mentioned O
briefly O
in O
this O
Article O
. O

The O
most O
current O
indications O
for O
psychosurgery O
are O
severe O
OCD B-Symptom_WorkedFor
and O
chronic O
major O
depressive O
disorder O
. O

The O
level O
of O
stress O
should O
be O
significant O
and O
assessed O
by O
clinical O
and O
social O
functioning O
scale O
scores O
( O
for O
the O
OCD O
: O
Y-BOCS O
> O
25 O
, O
GAF O
> O
50 O
) O
. O

Patients O
affected O
by O
demential O
disorders O
, O
sociopathic O
or O
paranoiac O
personality O
disorder O
, O
substance O
abuse O
should O
be O
excluded O
as O
well O
as O
patients O
aged O
65 O
Years O
over O
and O
less O
than O
18 O
Years O
. O

Several O
studies O
evaluating O
the O
results O
of O
the O
surgical O
treatment O
showed O
significant O
improvement O
in O
54% O
of O
cases O
. O
and O
a O
moderate O
improvement O
in O
27% O
of O
them O
. O

These O
results O
seem O
unchanged O
a O
few O
Years O
later O
in O
56% O
of O
cases O
. O

Despite O
the O
lack O
of O
controlled O
trials O
of O
neurosurgery O
and O
several O
bias O
in O
published O
reports O
, O
evidence O
suggests O
that O
the O
condition O
of O
intractable O
OCD O
patients O
may O
improve O
after O
this O
surgery O
. O

Although O
capsulotomy O
and O
cingulotomy O
are O
mainly O
used O
, O
the O
superiority O
of O
any O
of O
these O
four O
surgical O
techniques O
has O
not O
been O
established O
yet O
. O

In O
this O
Article O
, O
we O
reported O
3 O
" O
malignant O
" O
OCD O
cases O
treated O
by O
different O
psychosurgery O
techniques O
: O
2 O
of O
the O
cases O
showed O
a O
clinical O
improvement O
, O
whereas O
the O
third O
did O
not O
- O
benefit O
from O
surgery O
. O

All O
of O
them O
were O
suffering O
of O
OCD O
since O
childhood O
with O
a O
gradual O
clinical O
impairment O
, O
unless O
the O
- O
second O
patient O
who O
presented O
a O
severe O
impairment O
following O
an O
accident O
causing O
a O
ten-day O
coma O
. O

In O
all O
three O
cases O
social O
consequences O
of O
OCD O
were O
important O
: O
negative O
socio-professional O
and O
family-life O
consequences O
and O
depressive O
complication O
with O
suicide O
risk O
. O

All O
patients O
remained O
unresponsive O
or O
showed O
a O
very O
transient O
reaction O
to O
the O
other O
forms O
of O
therapy O
, O
including O
varied O
pharmacotherapy O
( O
potentiation O
pharmacotherapy O
strategies O
included O
) O
, O
intensive O
psychotherapy O
, O
behavioural O
therapy O
and O
electro-convulsive O
therapy O
. O

Pre O
- O
and O
post-operative O
assessment O
included O
neurological O
, O
radiological O
, O
psychometric O
and O
neuropsychological O
examination O
. O

The O
free O
and O
informed O
consent O
of O
the O
patient O
was O
always O
required O
before O
surgery O
, O
notifying O
the O
nature O
of O
the O
procedure O
, O
the O
potential O
risks O
and O
outcome O
. O

The O
first O
patient O
benefited O
of O
a O
bilateral O
anterior O
cingulotomy O
by O
thermocoagulation O
in O
stereotactic O
conditions O
, O
followed O
, O
four O
years O
later O
, O
by O
a O
second O
complementary O
one O
because O
of O
a O
relapse O
which O
occurred O
a O
few O
months O
after O
the O
first O
intervention O
. O

A O
clinical O
improvement O
was O
noticed O
over O
a O
period O
of O
two O
years O
, O
though O
it O
was O
not O
sufficient O
according O
to O
the O
patient O
. O

The O
second O
patient O
benefited O
of O
a O
stereotactic O
cingulotomy O
associated O
with O
a O
limbic O
leucotomy O
: O
it O
was O
initially O
efficient O
on O
OCD O
as O
well O
as O
on O
thymic O
symptoms O
. O

Nevertheless O
the O
positive O
evolution O
on O
OCD O
is O
not O
perceived O
by O
the O
patient O
and O
has O
not O
been O
assessed O
until O
now O
by O
clinical O
rating O
scales O
. O

Anterior O
cingulotomy O
is O
undergone O
in O
the O
third O
case O
, O
who O
showed O
a O
significant O
improvement O
. O

Despite O
clomipramine O
administered O
secondary O
to O
the O
surgery O
, O
a O
slight O
relapse O
of O
obsessive O
ideas O
was O
noticed O
six O
months O
later O
. O

The O
postoperative O
side O
effects O
were O
transient O
and O
regressive O
after O
a O
few O
months O
; O
they O
were O
observed O
especially O
in O
the O
case O
of O
tractotomy O
( O
oedema O
and O
transient O
frontal O
syndrome O
) O
. O

On O
the O
whole O
, O
morbidity O
seemed O
more O
important O
with O
extensive O
lesions O
, O
whereas O
recurrence O
rate O
may O
be O
higher O
with O
smaller O
lesions O
. O

We O
did O
not O
observe O
any O
consequences O
on O
personality O
or O
on O
cognitive O
functions O
of O
these O
patients O
. O

No O
additional O
- O
deficits O
were O
observed O
after O
surgery O
. O

Further O
research O
is O
needed O
in O
order O
to O
determine O
the O
optimal O
site O
and O
size O
of O
the O
lesions O
in O
terms O
of O
efficacy O
and O
safety O
. O

Although O
psychosurgery O
is O
still O
controversial O
from O
an O
ethical O
view O
point O
, O
this O
treatment O
appears O
to O
be O
an O
ultimate O
solution O
for O
these O
severe O
disabled O
patients O
. O

Psychosurgery O
is O
a O
safe O
and O
relatively O
effective O
treatment O
which O
should O
be O
carried O
out O
by O
an O
expert O
multidisciplinary O
team O
in O
these O
disorders O
; O
surgery O
should O
be O
considered O
as O
part O
of O
an O
entire O
treatment O
program O
including O
an O
appropriate O
psychiatric O
rehabilitation O
part O
. O

Research O
in O
this O
field O
is O
currently O
focused O
on O
MRI-guided O
basal O
ganglia O
stimulation O
techniques O
which O
would O
allow O
to O
target O
specific O
structures O
in O
a O
reversible O
way O
. O

Euthanasia O
of O
unwanted O
or O
sick O
animals O
should O
always O
be O
done O
in O
a O
humane O
manner O
. O

This O
study O
involving O
two O
groups O
of O
12 O
dogs O
evaluated O
a O
two O
step O
method O
of O
euthanasia O
using O
first O
acepromazine O
or O
pentazocine O
then O
inhalation O
of O
carbon B-Medicinal food
monoxide I-Medicinal food
. O

During O
the O
experiment O
, O
behavioral O
reactions O
( O
anxiety B-Symptom_WorkedFor
, O
agitation B-Symptom_WorkedFor
, O
vocalization B-Symptom_WorkedFor
and O
sphincter B-Symptom_WorkedFor
relaxation I-Symptom_WorkedFor
) O
and O
physiological B-Metric
parameters I-Metric
( O
electro-encephalogram O
, O
electrocardiogram O
, O
arterial O
blood O
pressure O
, O
respiratory O
and O
heart O
rates O
and O
serum O
cortisol O
) O
were O
monitored O
. O

The O
results O
showed O
that O
both O
drugs O
modified O
many O
behavioral O
reactions O
and O
physiological O
changes O
associated O
with O
administration O
of O
carbon B-Medicinal food
monoxide I-Medicinal food
. O

Acepromazine B-Other_ingredients
and O
pentazocine B-Other_ingredients
reduced O
by O
25% O
and O
20% O
respectively O
the O
number O
of O
dogs O
that O
showed O
vocalization O
and O
agitation O
. O

In O
acepromazine B-Other_ingredients
premedicated O
dogs O
, O
the O
duration O
of O
these O
signs O
was O
significantly O
diminished O
and O
sphincter O
relaxation O
did O
not O
occur O
in O
more O
than O
50% O
of O
cases O
. O

Furthermore O
, O
with O
the O
use O
of O
acepromazine B-Other_ingredients
, O
no O
significant O
peaks O
or O
drastic O
drops O
were O
noticed O
in O
the O
heart O
and O
respiratory O
rates O
and O
in O
the O
arterial O
blood O
pressure O
. O

These O
manifestations O
are O
usually O
related O
to O
stress B-Symptom_WorkedFor
. O

In O
light O
of O
these O
results O
, O
it O
is O
recommended O
to O
premedicate O
dogs O
with O
acepromazine B-Other_ingredients
before O
submitting O
them O
to O
euthanasia O
by O
carbon B-Medicinal food
monoxide I-Medicinal food
inhalation O
. O

Introduction O
: O
The O
current O
study O
aimed O
at O
investigating O
the O
role O
of O
Nitric B-Medicinal food
Oxide I-Medicinal food
( O
NO O
) O
in O
the O
maintenance O
of O
anxiety B-Symptom_WorkedFor
and O
depression B-Symptom_WorkedFor
induced O
by O
stress B-Symptom_WorkedFor
in O
male O
Wistar O
rats O
using O
intra-Basolateral B-Drug/Scientific name
Amygdala I-Drug/Scientific name
( O
BLA O
) O
injection O
of O
NO O
precursor O
, O
L-arginine O
, O
Nitric O
Oxide O
Synthase O
( O
NOS O
) O
inhibitor O
, O
and O
L-NAME O
. O

Methods O
: O
Two O
23 O
- O
gauge O
stainless O
steel O
cannulas O
were O
placed O
in O
the O
BLA O
, O
stereotaxically O
. O

Seven O
days O
later O
, O
animals O
experienced O
electro O
foot O
shock O
stress B-Symptom_WorkedFor
based O
on O
the O
following O
protocol O
: O
animals O
experienced O
four O
sessions O
of O
stress O
for O
60 O
minutes O
in O
four O
consecutive O
days O
. O

Five O
minutes O
before O
each O
stress B-Symptom_WorkedFor
session O
, O
the O
animals O
received O
different O
doses O
of O
L-arginine O
or O
L-NAME O
( O
1 O
, O
5 O
and O
, O
10 O
μg O
/ O
rat O
) O
or O
saline O
( O
0.5 O
μL O
/ O
rat O
) O
intra-BLA O
. O

Six O
days O
after O
the O
stress O
termination O
, O
animals O
were O
tested O
for O
maintenance O
of O
anxiety-like B-Symptom_WorkedFor
behavior O
( O
elevated O
plus O
maze O
; O
EPM O
) O
and O
eight O
days O
after O
the O
stress B-Symptom_WorkedFor
they O
were O
examined O
for O
depression B-Symptom_WorkedFor
( O
forced O
swimming O
test O
; O
FST O
) O
. O

Results O
: O
Stress B-Symptom_WorkedFor
reduced O
the O
time O
and O
number O
of O
open O
arms O
and O
decreased O
motor O
activity O
on O
EPM O
. O

Stress-induced B-Symptom_WorkedFor
anxiety I-Symptom_WorkedFor
was O
inhibited O
by O
L-arginine O
and O
L-NAME O
( O
1 O
, O
5 O
, O
and O
10 O
μg O
/ O
rat O
) O
. O

L-Arginine O
and O
L-NAME O
induced O
anxiety O
in O
non-stressed O
rats O
. O

Stress O
also O
increased O
the O
immobility O
time O
in O
animals O
in O
FST O
paradigm O
. O

Interestingly O
, O
both O
L-arginine O
and O
L-NAME O
, O
in O
all O
doses O
reduced O
the O
stress O
effect O
. O

Conclusion O
: O
BLA B-Medicinal food
nitric I-Medicinal food
oxide I-Medicinal food
may O
play O
a O
pivotal O
role O
in O
anxiety B-Symptom_WorkedFor
and O
depression B-Symptom_WorkedFor
induced O
by O
stress O
in O
rats O
. O

Since O
the O
effects O
of O
both O
L-arginine O
and O
L-NAME O
were O
similar O
, O
NO O
might O
have O
a O
modulatory O
role O
in O
the O
BLA O
. O

Taking O
a O
population O
of O
women O
most O
of O
whom O
were O
about O
to O
seek O
medication O
from O
their O
general O
practitioner O
for O
stress-induced B-Symptom_WorkedFor
insomnia I-Symptom_WorkedFor
, O
this O
sleep O
laboratory O
study O
examined O
- O
- O
both O
electro B-Medicinal food
- O
physiologically O
and O
psychologically O
- O
- O
the O
immediate O
impact O
of O
temazepam B-Other_ingredients
, O
at O
normal O
prescribed O
dosage O
, O
on O
sleep O
. O

The O
study O
was O
double-blind O
, O
controlled O
with O
random O
allocation O
. O

Temazepam B-Other_ingredients
20 B-Dosage
mg I-Dosage
, O
prepared O
as O
a O
liquid O
in O
a O
soft O
gelatin O
capsule O
, O
reduced O
sleep O
latency O
and O
prolonged O
total O
sleep O
time O
. O

A O
reduction O
in O
stage O
shifts O
to O
Stages O
I O
and O
II O
and O
a O
reduction O
in O
time O
spent O
in O
Stages O
0 O
+ O
I O
suggest O
more O
restful O
sleep O
. O

The O
sleep O
" O
architecture O
" O
( O
including O
REM O
/ O
NREM O
cycling O
, O
total O
SWS O
and O
REM O
time O
) O
was O
relatively O
undisturbed O
. O

Temazepam B-Other_ingredients
would O
seem O
to O
be O
effective O
as O
a O
first-line O
hypnotic O
for O
short-term O
use O
in O
stressed O
patients O
. O

A O
48 O
- O
year-old O
married O
woman O
diagnosed O
with O
rheumatoid B-Symptom_WorkedFor
arthritis I-Symptom_WorkedFor
( O
RA O
) O
in O
2007 O
, O
came O
to O
our O
hospital O
in O
July O
2014 O
with O
the O
complaint O
of O
severe O
pain O
and O
swelling O
over O
multiple O
joints O
, O
especially O
over O
small O
joints O
, O
which O
was O
associated O
with O
stiffness O
( O
more O
in O
morning O
) O
, O
deformities O
of O
fingers O
and O
toes O
, O
with O
disturbed B-Symptom_WorkedFor
sleep I-Symptom_WorkedFor
and O
poor O
quality O
of O
life O
( O
QOL O
) O
for O
the O
past O
7 O
years O
. O

She O
received O
a O
combination O
of O
electro B-Medicinal food
acupuncture I-Medicinal food
( O
14 O
sessions O
) O
, O
massage O
( O
18 O
sessions O
) O
, O
mud O
( O
18 O
sessions O
) O
, O
and O
sauna O
( O
3 O
sessions O
) O
( O
EMMS O
) O
therapies O
for O
30 O
- O
min O
, O
45 O
- O
min O
, O
30 O
- O
min O
, O
and O
15 O
- O
min O
per O
session O
, O
respectively O
for O
3 B-Duration
weeks I-Duration
. O

During O
and O
postintervention O
assessment O
showed O
reduction O
in O
visual O
analog O
scale O
score O
for O
pain B-Symptom_WorkedFor
, O
Depression B-Metric
Anxiety I-Metric
and I-Metric
Stress I-Metric
Scales I-Metric
and O
the O
Pittsburgh B-Metric
Sleep I-Metric
Quality I-Metric
Index I-Metric
scores I-Metric
. O

It O
also O
showed O
an O
increase O
in O
the O
scores O
of O
10 O
- O
Meter O
Walk O
Test O
, O
isometric O
hand-grip O
test O
, O
and O
short O
form O
- O
36 O
version O
- O
2 O
health O
survey O
. O

This O
result O
suggest O
that O
, O
the O
EMMS O
therapy O
might O
be O
considered O
as O
an O
effective O
treatments O
in O
reducing O
pain B-Symptom_WorkedFor
, O
depression B-Symptom_WorkedFor
, O
anxiety B-Symptom_WorkedFor
, O
and O
stress B-Symptom_WorkedFor
with O
improvement O
in O
physical O
functions O
, O
quality O
of O
sleep O
and O
QOL O
in O
patient O
with O
RA O
. O

EMMS O
therapies O
were O
tolerated O
and O
no O
side O
effects O
were O
reported O
by O
the O
patient O
. O

Though O
the O
results O
are O
encouraging O
, O
further O
studies O
are O
required O
with O
larger O
sample O
size O
and O
advanced O
inflammatory O
markers O
. O

In O
preliminarily O
selected O
( O
by O
a O
number O
of O
parameters O
) O
highly O
emotional O
subjects O
, O
evoked O
potentials O
were O
recorded O
from O
parietal O
, O
central O
, O
frontal O
and O
temporal O
cortical O
areas O
, O
in O
the O
first O
part O
of O
the O
experiment O
- O
- O
in O
response O
to O
indifferent O
light B-Medicinal food
flashes I-Medicinal food
( O
which O
served O
as O
a O
signal O
to O
achieve O
a O
precise O
movement O
) O
, O
and O
in O
the O
second O
part O
- O
- O
in O
response O
to O
the O
same O
flashes O
, O
but O
with O
preliminary O
information O
of O
the O
subject O
on O
a O
possible O
electrocutaneous O
stimulation O
( O
in O
case O
of O
an O
error O
in O
task O
performing O
) O
. O

It O
is O
found O
that O
with O
the O
threat O
of O
the O
electro-cutaneous B-Medicinal food
stimulation I-Medicinal food
the O
major O
changes O
are O
observed O
in O
the O
frontal O
, O
temporal O
and O
central O
areas O
. O

An O
increase O
in O
the O
latencies O
of O
the O
IV O
, O
V O
, O
VI O
components O
and O
P300 O
wave O
was O
recorded O
. O

At O
the O
same O
time O
the O
amplitude O
of O
the O
V O
component O
and O
that O
of O
the O
P300 O
wave O
decreased O
. O

The O
IV O
component O
was O
enhanced O
. O

In O
extreme O
situation O
the O
activity O
directed O
to O
avoid O
the O
electrostimulation O
was O
disturbed O
( O
errors O
of O
movement O
performance O
increased O
by O
3.7 O
kg O
) O
. O

The O
cortical O
mechanisms O
of O
the O
organization O
of O
the O
emotional O
behaviour O
in O
extreme O
situations O
are O
discussed O
. O

Subjects O
with O
high O
tested O
anxiety B-Symptom_WorkedFor
which O
correlated O
with O
a O
rapid O
elaboration O
and O
stability O
of O
conditioned O
skin-galvanic O
reflex O
( O
SGR O
) O
to O
a O
signal O
of O
the O
hand O
electro-cutaneous B-Medicinal food
stimulation I-Medicinal food
, O
were O
trained O
to O
prognosticate O
their O
probable O
success O
in O
voluntarily O
suppressing O
the O
conditioned O
SGR O
with O
the O
purpose O
of O
avoiding O
stimulation O
. O

By O
taking O
a O
decision O
in O
assessing O
their O
current O
emotional O
state O
on O
the O
base O
of O
signals O
of O
visual O
feedback O
( O
SGR O
trace O
on O
the O
oscilloscope O
screen O
) O
, O
they O
sanctioned O
the O
probability O
of O
presentation O
to O
them O
of O
the O
conditioned O
stimulus O
from O
a O
certain O
moment O
of O
the O
training O
session O
. O

The O
decision O
was O
preceded O
by O
extinction O
of O
SGR O
waves O
evoked O
by O
mental O
intention O
to O
be O
subjected O
to O
the O
test O
in O
a O
situation O
of O
risk O
. O

Methods O
for O
the O
humane O
killing O
of O
animals O
are O
watched O
critically O
by O
both O
the O
public O
and O
the O
veterinary O
community O
. O

Evaluation O
of O
such O
methods O
requires O
assessment O
of O
efficacy O
as O
well O
as O
emotional O
and O
ethical O
aspects O
. O

Rapidity O
of O
loss O
of O
consciousness O
is O
a O
crucial O
factor O
in O
such O
evaluations O
. O

In O
the O
present O
study O
, O
four O
methods O
for O
piglet O
euthanasia O
were O
compared O
with O
regard O
to O
presence O
of O
indicators O
of O
discomfort O
( O
pain O
, O
anxiety O
, O
stress O
) O
and O
rapidity O
of O
onset O
of O
death O
, O
defined O
as O
the O
absence O
of O
breathing O
, O
heart O
beats O
and O
reflexes O
, O
combined O
with O
isoelectricity O
of O
the O
electro-encephalogram O
( O
EEG O
) O
. O

The O
study O
was O
performed O
on O
piglets O
, O
which O
had O
to O
be O
destroyed O
on O
account O
of O
preventive O
measures O
against O
swine O
fever O
. O

The O
following O
methods O
were O
applied O
: O
CO2 O
98% O
, O
CO2 O
/ O
O2 O
65 O
/ O
35% O
, O
T61 O
and O
pentobarbital O
( O
Euthesate O
) O
injected O
intracardially O
. O

Intracardial O
injections O
of O
T61 O
and O
pentobarbital O
provide O
fast O
unconsciousness O
and O
death O
with O
minimal O
discomfort O
to O
the O
animal O
. O

Depression B-Symptom_WorkedFor
is O
the O
second O
leading O
cause O
of O
disability O
worldwide O
. O

The O
effects O
of O
clinical B-Symptom_WorkedFor
depression I-Symptom_WorkedFor
may O
be O
mediated O
by O
neuroinflammation O
such O
as O
activation O
of O
microglia O
and O
high O
levels O
of O
proinflammatory O
cytokines O
in O
certain O
brain O
areas O
. O

Traditional O
Chinese O
medicine O
techniques O
such O
as O
electro-acupuncture B-Medicinal food
( O
EA O
) O
are O
used O
extensively O
in O
Asia O
to O
treat O
mental O
health O
disorders O
. O

However O
, O
EA O
has O
not O
been O
rigorously O
studied O
in O
treatment O
of O
depression O
. O

This O
study O
was O
designed O
to O
assess O
the O
effectiveness O
of O
EA O
on O
depressive-like B-Symptom_WorkedFor
behavior O
and O
explore O
the O
role O
of O
hippocampal O
neuroinflammation O
in O
the O
potential O
antidepressant O
effect O
of O
EA O
. O

In O
this O
study O
, O
we O
used O
six O
chronic O
unpredictable O
stressors O
daily O
in O
a O
random O
sequence O
for O
10 B-Duration
weeks I-Duration
. O

EA O
were O
performed O
on O
" O
Bai-Hui O
" O
( O
Du O
- O
20 O
) O
( O
+ O
) O
and O
" O
Yang-Ling-Quan O
" O
( O
GB O
- O
34 O
, O
the O
right O
side O
; O
- O
) O
acupoints O
by O
an O
EA O
apparatus O
( O
HANS O
Electronic O
Apparatus O
, O
LH202H O
, O
2 O
/ O
100 O
Hz O
, O
0.3 O
mA O
) O
for O
30 O
min O
once O
every O
other O
day O
for O
last O
4 O
weeks O
. O

The O
behavior O
tests O
including O
open O
field O
test O
and O
forced O
swimming O
test O
, O
which O
are O
widely O
used O
to O
assess O
depressive O
and O
anxiety-like O
behavior O
were O
performed O
on O
the O
Monday O
and O
Tuesday O
of O
the O
eleventh O
week O
. O

The O
results O
showed O
that O
10 B-Duration
week I-Duration
of O
chronic O
unpredictable O
stress O
( O
CUS O
) O
caused O
behavioral O
deficits O
in O
rats O
and O
neuroinflammation O
in O
hippocampus O
, O
such O
as O
increased O
expression O
of O
NLRP3 O
inflammasome O
components O
, O
upregulated O
mRNA O
level O
of O
IL O
- O
1β O
and O
the O
protein O
level O
of O
IL O
- O
1β O
mature O
form O
( O
p17 O
) O
and O
activation O
of O
microglia O
. O

Moreover O
, O
4 O
weeks O
of O
EA O
treatment O
significantly O
attenuated O
behavioral O
deficits O
caused O
by O
CUS O
. O

EA's O
antidepressant O
effect O
was O
accompanied O
by O
markedly O
decreased O
expression O
of O
certain O
NLRP3 O
inflammasome O
components O
and O
matured O
IL O
- O
1β O
. O

Meanwhile O
, O
EA O
treatment O
can O
significantly O
reverse O
CUS-induced O
increases O
in O
P2X7 O
receptor O
, O
Iba O
- O
1 O
, O
IL O
- O
18 O
, O
TNFα O
and O
IL O
- O
6 O
expression O
and O
decreases O
in O
GFAP O
expression O
. O

In O
conclusion O
, O
EA O
exhibited O
the O
antidepressant O
effect O
and O
alleviated O
the O
hippocampal O
neuroinflammation O
. O

These O
findings O
may O
provide O
insight O
into O
the O
role O
of O
hippocampal O
neuroinflammation O
in O
the O
antidepressant O
effect O
of O
EA O
. O

Chronic O
stress O
caused O
by O
3 O
- O
week O
electro-pain O
stimulation O
( O
4 O
h O
daily O
) O
combined O
with O
" O
white O
noise O
" O
, O
resulted O
in O
a O
decrease O
of O
horizontal O
motor O
activity O
of O
rats O
with O
extreme O
types O
of O
behaviour O
, O
i.e O
. O
, O
active O
and O
passive O
. O

No O
changes O
in O
behaviour O
of O
animals O
with O
intermediate O
behavioural O
type O
were O
found O
. O

Long-term O
( O
30 O
days O
) O
adaptation O
to O
hypoxia O
( O
daily O
lifting O
to O
11,000 O
m O
for O
5 O
h O
) O
did O
not O
cause O
changes O
in O
behaviour O
of O
rats O
. O

Combination O
of O
stress O
and O
hypoxia O
caused O
an O
increase O
of O
number O
of O
grooming O
acts O
in O
rats O
with O
passive O
type O
of O
behaviour O
, O
testifying O
to O
their O
increased O
anxiety O
. O

Long-term O
adaptation O
to O
hypoxia O
did O
not O
influence O
the O
degree O
of O
loss O
of O
motor O
activity O
caused O
by O
chronic O
stress O
in O
animals O
with O
active O
and O
passive O
types O
of O
behaviour O
. O

Folate B-Medicinal food
deficiency O
has O
been O
linked O
to O
neurodegenerative O
and O
stress-related B-Symptom_TestedFor
diseases O
such O
as O
stroke B-Symptom_TestedFor
, O
dementia B-Symptom_TestedFor
and O
depression B-Symptom_TestedFor
. O

The O
role O
of O
the O
neurotrophins O
nerve O
growth O
factor O
( O
NGF O
) O
and O
neurotrophin O
- O
3 O
( O
NT O
- O
3 O
) O
in O
stress-related O
disorders O
and O
neurodegeneration O
has O
garnered O
increasing O
attention O
in O
recent O
years O
. O

Uracil O
misincorporation O
is O
involved O
in O
the O
neuropsychiatric O
dysfunction O
induced O
by O
experimental O
folate B-Medicinal food
deprivation O
. O

However O
, O
the O
effects O
of O
folate O
deficiency O
on O
the O
expression O
of O
NGF O
and O
NT O
- O
3 O
in O
brain O
tissue O
have O
not O
yet O
been O
investigated O
. O

In O
a O
2 O
× O
2 O
design O
, O
aged O
mice O
lacking O
uracil-DNA O
N-glycosylase O
( O
Ung O
( O
- O
/ O
- O
) O
) O
versus O
wild-type O
( O
Ung O
( O
+ O
/ O
+ O
) O
) O
controls O
were O
subjected O
to O
a O
folate-deficient O
diet O
versus O
a O
regular O
diet O
for O
three B-Duration
months I-Duration
. O

Independent O
of O
genotype O
, O
folate O
deficiency O
led O
to O
decreased O
NGF O
protein O
levels O
in O
the O
frontal O
cortex O
and O
amygdala O
. O

In O
the O
hippocampus O
, O
NGF O
levels O
were O
increased O
in O
UNG O
( O
- O
/ O
- O
) O
mice O
on O
the O
normal O
diet O
, O
but O
not O
under O
folate B-Medicinal food
deficiency O
, O
while O
in O
UNG O
( O
+ O
/ O
+ O
) O
mice B-Medicinal food
, O
folate O
deprivation O
did O
not O
affect O
hippocampal O
NGF O
content O
. O

NT O
- O
3 O
protein O
concentrations O
were O
neither O
affected O
by O
genotype O
nor O
by O
folate B-Medicinal food
deficiency O
. O

Altogether O
, O
the O
results O
of O
our O
study O
show O
that O
folate O
deficiency O
affects O
NGF O
levels O
in O
the O
frontal O
cortex O
, O
amygdala O
and O
hippocampus O
. O

The O
decrease O
in O
NGF O
content O
in O
the O
hippocampus O
in O
response O
to O
folate B-Medicinal food
deficiency O
in O
Ung O
( O
- O
/ O
- O
) O
mice O
may O
contribute O
to O
their O
phenotype O
of O
enhanced O
anxiety B-Symptom_WorkedFor
and O
despair-like B-Symptom_WorkedFor
behavior I-Symptom_WorkedFor
as O
well O
as O
to O
selective O
hippocampal O
neurodegeneration O
. O

Serum O
folate O
levels O
were O
measured O
at O
30 O
weeks O
' O
gestational O
age O
in O
289 B-#Participants
pregnant O
women O
, O
each O
of O
whom O
had O
been O
provided O
with O
folate B-Medicinal food
supplementation I-Medicinal food
at O
enrollment O
in O
prenatal O
care O
. O

There O
was O
a O
significant O
association O
between O
low O
serum O
folate O
levels O
and O
fetal O
growth O
retardation O
. O

High O
folate O
levels O
were O
most O
likely O
explained O
by O
recent O
folic B-Medicinal food
acid I-Medicinal food
intake O
. O

Therefore O
, O
we O
were O
concerned O
that O
the O
decreased O
fetal O
growth O
associated O
with O
low O
folate O
levels O
may O
have O
been O
related O
to O
a O
combination O
of O
psychological O
and O
behavioral O
characteristics O
for O
which O
low O
serum O
folate O
levels O
were O
only O
a O
surrogate O
measure O
. O

A O
profile O
of O
maternal O
psychosocial O
status O
was O
created O
, O
which O
included O
measures O
of O
depression B-Symptom_WorkedFor
, O
anxiety B-Symptom_WorkedFor
, O
self-esteem O
, O
mastery O
, O
stress B-Symptom_WorkedFor
, O
and O
social O
support O
. O

Poorer O
psychological O
scores O
were O
significantly O
related O
to O
lower O
serum O
folate O
levels O
. O

However O
, O
in O
women O
with O
both O
good O
and O
poor O
psychosocial O
scores O
, O
high O
folate O
levels O
were O
significantly O
associated O
with O
increased O
birth O
weight O
, O
a O
relationship O
that O
persisted O
even O
after O
adjusting O
for O
maternal O
race O
, O
body O
mass O
index O
, O
smoking O
, O
history O
of O
a O
low O
birth O
weight O
infant O
, O
and O
infant O
gender O
. O

Our O
findings O
suggest O
that O
women O
with O
good O
psychosocial O
scores O
are O
more O
likely O
to O
take O
folate B-Medicinal food
, O
but O
that O
the O
use O
of O
folate B-Medicinal food
itself O
is O
related O
to O
a O
lower O
risk O
of O
fetal O
growth O
retardation O
and O
increased O
birth O
weight O
. O

Subfertility O
affects O
one O
in O
seven O
couples O
in O
the O
United O
Kingdom O
and O
is O
associated O
with O
considerable O
patient O
stress B-Symptom_TestedFor
and O
anxiety B-Symptom_TestedFor
. O

The O
RCOG O
, O
with O
the O
publication O
of O
the O
evidence-based O
guidelines O
, O
gives O
us O
clear O
recommendations O
on O
the O
initial O
investigation O
of O
the O
infertile O
couple O
. O

Against O
these O
guidelines O
we O
audited O
patient O
care O
over O
a O
period O
of O
5 B-Duration
months I-Duration
in O
a O
dedicated O
consultant-led O
infertility O
clinic O
. O

Our O
results O
show O
that O
a O
considerable O
number O
of O
patients O
failed O
to O
have O
the O
correct O
advice O
clearly O
documented O
, O
and O
the O
initial O
primary O
care O
investigations O
of O
mid-luteal O
progesterone O
and O
semen O
analysis O
were O
performed O
correctly O
with O
results O
available O
in O
only O
33% O
and O
2% O
of O
occasions O
, O
respectively O
. O

There O
were O
, O
however O
, O
areas O
where O
the O
guidelines O
were O
adhered O
to O
very O
efficiently O
. O

To O
improve O
care O
we O
recommend O
the O
use O
of O
an O
infertility O
referral O
form O
for O
use O
in O
primary O
care O
upon O
which O
the O
practitioners O
can O
fill O
in O
the O
appropriate O
details O
and O
be O
guided O
on O
the O
necessary O
investigations O
. O

Background O
: O
Poor O
maternal O
health O
, O
disadvantageous O
exposures O
during O
pregnancy O
and O
unfavourable O
perinatal O
events O
are O
associated O
with O
adverse O
trajectories O
in O
offspring O
cognitive B-Symptom_TestedFor
development I-Symptom_TestedFor
. O

Aim O
: O
To O
examine O
longitudinal O
associations O
between O
antenatal O
maternal O
, O
perinatal O
and O
maternal O
health O
characteristics O
and O
children's O
early O
cognitive O
development O
across O
executive O
control O
, O
motor O
ability O
and O
receptive O
language O
domains O
. O

Study O
design O
, O
subjects O
and O
outcome O
measures O
: O
Analyses O
comprised O
interview O
and O
observational O
data O
from O
4587 B-#Participants
children O
and O
their O
mothers O
enrolled O
in O
the O
longitudinal O
Growing O
Up O
in O
New O
Zealand O
cohort O
study O
. O

Children's O
executive O
control O
( O
Luria O
hand O
clap O
task O
) O
, O
motor O
skills O
( O
mothers O
' O
report O
) O
and O
receptive O
language O
ability O
( O
Peabody O
Picture O
Vocabulary O
Test O
) O
were O
assessed O
at O
age O
4.5 O
years O
. O

Multivariate O
logistic O
regression O
analyses O
were O
conducted O
, O
controlling O
for O
sociodemographic O
factors O
. O

Results O
: O
Smoking O
pre O
- O
and O
during O
pregnancy O
, O
no O
folate B-Medicinal food
intake O
during O
first O
trimester O
and O
low O
birth O
weight O
were O
risk O
factors O
for O
poorer O
executive O
control O
. O

Perceived O
stress O
during O
pregnancy O
, O
no O
folate B-Medicinal food
intake O
during O
first O
trimester O
and O
low O
birth O
weight O
were O
all O
risk O
factors O
for O
poorer O
motor O
ability O
. O

Smoking O
pre-pregnancy O
, O
antenatal O
anxiety O
and O
no O
folate B-Medicinal food
intake O
during O
first O
trimester O
were O
risk O
factors O
for O
poorer O
receptive O
language O
ability O
. O

Conclusion O
: O
Adverse O
ante O
- O
and O
perinatal O
environments O
are O
associated O
with O
poorer O
executive O
control O
, O
motor O
and O
receptive O
language O
abilities O
in O
early O
childhood O
. O

Improving O
maternal O
education O
and O
support O
especially O
for O
more O
disadvantaged O
mothers O
during O
pregnancy O
may O
reduce O
the O
potential O
deleterious O
impact O
of O
adverse O
ante O
- O
and O
perinatal O
conditions O
on O
children's O
early O
cognition O
. O

Oxidative O
stress O
induced O
interactions O
between O
fatty O
acid O
( O
FA O
) O
and O
one-carbon O
metabolism O
may O
be O
involved O
in O
co-occurrence O
of O
major O
depressive B-Symptom_TestedFor
disorder I-Symptom_TestedFor
( O
MDD O
) O
and O
cardiovascular B-Symptom_TestedFor
disease I-Symptom_TestedFor
( O
CVD O
) O
, O
which O
have O
been O
scarcely O
studied O
together O
. O

In O
137 B-#Participants
recurrent O
MDD-patients B-participant_health
vs O
. O
73 B-#Participants
age O
- O
and O
sex-matched O
healthy O
controls O
, O
we O
simultaneously O
measured O
key O
components O
of O
one-carbon O
metabolism O
in O
plasma O
( O
homocysteine B-Other_ingredients
, O
folate B-Medicinal food
, O
vitamins B-Other_ingredients
B6 I-Other_ingredients
and I-Other_ingredients
B12 I-Other_ingredients
) O
, O
and O
of O
FA-metabolism O
in O
red O
blood O
cell O
membranes O
[ O
main O
polyunsaturated O
fatty O
acids O
( O
PUFAs O
) O
eicosapentaenoic B-Other_ingredients
acid I-Other_ingredients
( O
EPA O
) O
, O
docosahexaenoic B-Other_ingredients
acid I-Other_ingredients
( O
DHA O
) O
, O
and O
arachidonic O
acid O
( O
AA O
) O
and O
structural O
FA-indices O
( O
chain O
length O
, O
unsaturation O
, O
peroxidation O
) O
] O
. O

Results O
show O
significant O
positive O
associations O
of O
folate B-Medicinal food
with O
EPA O
, O
DHA O
, O
and O
the O
peroxidation O
index O
, O
which O
were O
similar O
in O
patients O
and O
controls O
. O

After O
correction O
for O
confounders O
, O
these O
associations O
were O
lost O
except O
for O
EPA O
. O

Associations O
between O
B-vitamins O
and O
FA-parameters O
were O
non-significant O
, O
but O
also O
similar O
in O
patients O
and O
controls O
. O

Homocysteine O
and O
DHA O
were O
significantly O
less O
negatively O
associated O
in O
patients O
than O
in O
controls O
. O

In O
conclusion O
, O
these O
data O
indicate O
similarities O
but O
also O
differences O
in O
associations O
between O
parameters O
of O
one-carbon O
and O
FA-metabolism O
in O
recurrent O
MDD O
patients O
vs O
. O
controls O
, O
which O
may O
reflect O
differences O
in O
handling O
of O
oxidative O
stress O
. O

Further O
research O
should O
test O
the O
consequences O
of O
these O
differences O
, O
particularly O
the O
premature O
development O
of O
CVD O
in O
MDD O
. O

Anxiety B-Symptom_TestedFor
and O
salivary O
cortisol O
were O
measured O
in O
two O
groups O
of O
patients O
with O
recurrent O
aphthous O
ulceration O
. O

One O
group O
of O
patients O
had O
persistent O
aphthae B-participant_health
( O
Group O
1 O
) O
and O
the O
others O
had O
been O
relieved O
of O
their O
aphthae O
following O
correction O
of O
detected O
haematinic O
deficiency O
states O
( O
Group O
2 O
) O
. O

Anxiety B-Symptom_WorkedFor
was O
measured O
using O
the O
Hospital B-Metric
Anxiety I-Metric
and I-Metric
Depression I-Metric
scale I-Metric
and O
radioimmunoassay O
of O
salivary O
cortisol O
. O

There O
was O
a O
statistically O
significant O
increased O
proportion O
of O
borderline O
or O
clinically O
anxious O
patients O
in O
Group O
1 O
compared O
to O
Group O
2 O
( O
P O
< O
0.05 O
) O
. O

Median O
salivary O
cortisol O
levels O
also O
showed O
a O
statistically O
significant O
elevation O
in O
Group O
1 O
( O
P O
< O
0.01 O
) O
. O

It O
is O
concluded O
that O
stress O
may O
play O
a O
role O
in O
the O
aetiology O
of O
recurrent O
aphthous O
stomatitis O
, O
particularly O
in O
patients O
who O
have O
an O
underlying O
anxiety O
trait O
. O

Background O
: O
Anxiety B-Symptom_WorkedFor
combined O
with O
nervousness O
and O
apprehension O
consist O
a O
focal O
response O
to O
different O
life O
conditions O
. O

Lifestyle O
habits O
, O
anxiety O
and O
biochemical O
markers O
are O
in O
a O
constant O
interaction O
. O

Aim O
: O
To O
investigate O
the O
prevalence O
of O
anxiety B-Symptom_WorkedFor
in O
healthy O
adults O
and O
its O
possible O
association O
with O
biochemical O
factors-lipid O
profile O
, O
liver O
markers O
, O
thyroid O
hormones-and O
lifestyle O
habits O
. O

Methods O
: O
Quantitative O
descriptive O
correlation O
study O
. O

A O
total O
of O
100 B-#Participants
healthy O
adults O
participated O
in O
the O
research O
. O

A O
specially O
designed O
questionnaire O
and O
Hamilton's B-Metric
scale I-Metric
were O
used O
. O

Anthropometric O
and O
biochemical O
analyses O
were O
performed O
. O

Findings O
: O
Overall O
, O
61% O
of O
the O
participants O
presented O
moderate O
to O
very O
serious O
anxiety B-participant_health
. O

The O
average O
score O
on O
the O
Hamilton B-Metric
scale I-Metric
was O
13.82 O
( O
± O
9.000 O
) O
, O
with O
men O
exhibiting O
less O
stress O
than O
women O
. O

For O
p O
≤ O
0.05 O
: O
Stress O
was O
positively O
correlated O
with O
impaired O
thyroid O
and O
hepatic O
function O
. O

Hepatic O
function O
was O
affected O
by O
both O
sugar O
products O
and O
water O
melon O
, O
which O
were O
positively O
correlated O
with O
total O
bilirubin O
and O
AST O
/ O
SGOT O
respectively O
. O

Tomato O
, O
peppers O
and O
legumes O
were O
negatively O
correlated O
with O
AST O
/ O
SGOT O
. O

Deep O
fried O
food O
was O
positively O
correlated O
with O
GGT O
and O
triglycerides O
. O

Legumes O
and O
fish O
were O
negatively O
correlated O
with O
CPK O
. O

Regarding O
the O
lipid O
metabolism O
, O
it O
was O
found O
that O
food O
cooked O
with O
oil O
was O
positively O
associated O
with O
uric O
acid O
, O
but O
non-cooked O
olive O
oil O
was O
negatively O
correlated O
with O
the O
risk O
for O
CAD O
. O

Thyroid O
function O
was O
negatively O
correlated O
with O
non-homemade O
food O
and O
pasta O
consumption O
and O
positively O
correlated O
with O
consumption O
of O
whole O
grains O
and O
green O
tea O
. O

Participants O
with O
subclinical O
hypothyroidism O
seemed O
to O
consume O
less O
vitamin B-Medicinal food
B12 I-Medicinal food
, O
folic B-Medicinal food
acid I-Medicinal food
and O
vegetables B-Medicinal food
. O

Conclusion O
: O
No O
direct O
correlation O
between O
lifestyle O
habits O
and O
anxiety O
was O
found O
. O

Nevertheless O
, O
eating O
habits O
influenced O
biochemical O
markers-especially O
the O
thyroid O
hormones-which O
may O
be O
indirectly O
responsible O
for O
anxiety O
and O
related O
moods O
. O

Acne O
vulgaris O
is O
a O
distressing O
skin O
condition O
which O
can O
carry O
with O
it O
significant O
psychological O
disability O
. O

Patients O
with O
acne O
are O
more O
likely O
to O
experience O
anger O
and O
are O
at O
increased O
risk O
of O
depression O
, O
anxiety O
, O
suicidal O
ideation O
. O

Certain O
nutrients O
which O
have O
been O
implicated O
as O
influencing O
the O
pathophysiology O
of O
acne O
have O
also O
been O
identified O
as O
important O
mediators O
of O
human O
cognition O
, O
behavior O
and O
emotions O
. O

Zinc B-Other_ingredients
, O
folic B-Medicinal food
acid I-Medicinal food
, O
selenium B-Other_ingredients
, O
chromium B-Other_ingredients
and O
omega B-Other_ingredients
- I-Other_ingredients
3 I-Other_ingredients
fatty I-Other_ingredients
acids I-Other_ingredients
are O
all O
examples O
of O
nutrients O
which O
have O
been O
shown O
to O
influence O
depression B-Symptom_WorkedFor
, O
anger B-Symptom_WorkedFor
and O
/ O
or O
anxiety B-Symptom_WorkedFor
. O

These O
same O
nutrients O
, O
along O
with O
systemic O
oxidative O
stress O
and O
an O
altered O
intestinal O
microflora O
have O
been O
implicated O
in O
acne O
vulgaris O
. O

It O
is O
our O
contention O
that O
certain O
nutritional O
factors O
, O
a O
weakened O
antioxidant O
defense O
system O
and O
altered O
intestinal O
microflora O
may O
interplay O
to O
increase O
the O
risk O
of O
psychological O
sequelae O
in O
acne O
vulgaris O
. O

Background O
: O
Alcohol O
is O
a O
potent O
teratogen O
inducing O
oxidative O
stress O
as O
well O
as O
a O
massive O
wave O
of O
apoptosis O
in O
the O
developing O
brain O
as O
well O
as O
oxidative O
stress O
. O

It O
affects O
brain O
including O
cerebellum O
, O
hippocampus O
and O
cerebral O
cortex O
resulting O
into O
motor O
and O
cognitive O
deficits O
. O

Alcohol O
depletes O
folic B-Medicinal food
acid I-Medicinal food
from O
the O
body O
which O
is O
essential O
for O
synthesis O
of O
DNA O
, O
RNA O
and O
protein O
during O
cell O
division O
and O
proved O
to O
prevent O
many O
brain O
related O
malformations O
. O

Purpose O
: O
The O
objective O
of O
the O
present O
study O
was O
to O
study O
whether O
folic B-Medicinal food
acid I-Medicinal food
reduces O
behavioral O
impairments O
that O
were O
induced O
by O
prenatal O
exposure O
to O
ethanol O
in O
mice O
. O

Methods O
: O
Pregnant O
mice O
were O
divided O
into O
different O
experimental O
groups O
. O

Group O
I O
termed O
as O
control O
receiving O
distilled O
water O
, O
group O
II O
received O
ethanol O
, O
group O
III O
ethanol B-Other_ingredients
and O
folic B-Medicinal food
acid I-Medicinal food
and O
group O
IV O
folic B-Medicinal food
acid I-Medicinal food
only O
from O
gestational O
days O
6 O
to O
15 O
. O

The O
dams O
were O
allowed O
to O
deliver O
their O
offspring O
naturally O
and O
until O
weaning O
the O
pups O
remained O
with O
their O
natural O
mothers O
. O

At O
the O
age O
of O
8 O
- O
9 O
weeks O
, O
they O
were O
subjected O
to O
battery O
of O
various O
behavioral O
tests O
. O

Results O
: O
The O
alcohol O
exposed O
dams O
showed O
decreased O
motor O
activity O
in O
open O
field O
test O
and O
decreased O
exploration O
and O
increased O
anxiety B-Symptom_WorkedFor
in O
elevated O
maze O
test O
as O
compared O
to O
controls O
. O

Folic B-Medicinal food
acid I-Medicinal food
administration O
reduced O
the O
intensity O
of O
these O
effects O
of O
alcohol O
in O
mice O
. O

Conclusion O
: O
The O
exposure O
to O
alcohol O
in O
utero O
produces O
long O
lasting O
effect O
on O
the O
developing O
pharmacological O
character O
of O
brain O
affecting O
postnatal O
behavioral O
expression O
which O
may O
be O
reduced O
by O
prenatal O
folic B-Medicinal food
acid I-Medicinal food
administration O
. O

Background O
: O
Violence O
associated O
with O
pregnancy O
is O
a O
major O
public O
health O
concern O
, O
but O
little O
is O
known O
about O
it O
in O
recent O
migrant O
women O
. O

This O
study O
looked O
at O
( O
1 O
) O
risk O
factors O
for O
violence O
associated O
with O
pregnancy O
among O
newly O
arrived O
migrant O
women O
in O
Canada O
and O
( O
2 O
) O
if O
those O
who O
experienced O
violence O
associated O
with O
pregnancy O
had O
a O
different O
health O
profile O
or O
use O
of O
healthcare O
services O
for O
themselves O
or O
their O
infants O
during O
pregnancy O
and O
up O
to O
4 O
months O
postpartum O
compared O
to O
other O
childbearing O
migrant O
women O
. O

Methods O
: O
Pregnant O
migrant O
women O
in O
Canada O
< O
5 O
years O
were O
recruited O
in O
12 O
hospitals O
in O
3 O
large O
cities O
between O
2006 O
and O
2009 O
and O
followed O
to O
4 O
months O
postpartum O
. O

Data O
were O
collected O
on O
maternal O
background O
, O
migration O
history O
, O
violence O
associated O
with O
pregnancy O
, O
maternal O
and O
infant O
physical O
and O
mental B-Symptom_TestedFor
health I-Symptom_TestedFor
, O
and O
services O
used O
. O

Results O
: O
Of O
a O
total O
of O
774 B-#Participants
pregnant O
migrant O
women O
, O
59 B-#Participants
( O
7.6% O
) O
women O
reported O
violence B-participant_health
associated O
with O
pregnancy O
. O

Migrant O
women O
who O
experienced O
violence O
, O
compared O
to O
those O
who O
did O
not O
, O
were O
at O
increased O
risk O
of O
violence O
if O
they O
lived O
without O
a O
partner O
, O
were O
asylum O
seekers O
, O
migrated O
< O
2 O
years O
ago O
, O
or O
had O
less O
than O
high O
school O
education O
. O

Women O
who O
reported O
violence O
were O
less O
likely O
to O
have O
up-to-date O
vaccinations O
, O
take O
folic B-Medicinal food
acid I-Medicinal food
before O
pregnancy O
, O
more O
likely O
to O
commence O
prenatal O
care O
after O
3 O
months O
gestation O
and O
to O
not O
use O
contraceptives O
after O
birth O
. O

They O
were O
also O
more O
likely O
to O
have O
a O
history O
of O
miscarriage O
and O
report O
more O
postpartum O
pain O
and O
increased O
bleeding O
. O

They O
were O
also O
more O
likely O
to O
have O
inadequate O
social O
support O
and O
report O
more O
depression O
, O
anxiety O
, O
somatization O
, O
and O
posttraumatic O
stress O
disorder O
( O
PTSD O
) O
on O
standardized O
tests O
. O

No O
differences O
were O
found O
in O
the O
health O
status O
of O
the O
infants O
of O
women O
who O
experienced O
violence O
compared O
to O
those O
who O
did O
not O
. O

Conclusions O
: O
Clinicians O
should O
sensitively O
ask O
recent O
migrant O
women O
( O
asylum O
seekers O
, O
refugees O
, O
and O
nonrefugee O
immigrants O
) O
about O
violence O
associated O
with O
pregnancy O
and O
appropriately O
assess O
, O
treat O
, O
and O
refer O
them O
. O

Purpose O
: O
To O
examine O
the O
relationships O
between O
maternal O
psychosocial O
factors O
and O
dietary O
quality O
and O
explore O
the O
relationships O
among O
dietary O
quality O
and O
selected O
biomarkers O
of O
nutrition O
and O
placental O
development O
. O

Method O
: O
A O
cross-sectional O
design O
in O
18 B-#Participants
low-income B-participant_health
, I-participant_health
pregnant I-participant_health
women O
. O

Results O
: O
Partner O
support O
was O
positively O
related O
to O
vegetable B-Medicinal food
intake O
( O
r O
= O
.54 O
) O
and O
negatively O
related O
to O
intake O
of O
iron O
( O
r O
= O
- O
.68 O
) O
and O
grains O
( O
r O
= O
- O
.67 O
) O
. O

Emotional O
eating O
in O
response O
to O
anger B-Symptom_TestedFor
was O
negatively O
related O
to O
intake O
of O
iron O
- O
( O
r O
/ O
it O
> O
= O
- O
.53 O
) O
and O
folate-rich B-Medicinal food
( O
r O
= O
- O
.75 O
) O
foods O
, O
and O
emotional O
eating O
in O
response O
to O
anxiety B-Symptom_TestedFor
was O
negatively O
related O
to O
intake O
of O
folate-rich B-Medicinal food
foods I-Medicinal food
( O
r O
= O
- O
.51 O
) O
. O

Depressed O
women O
had O
an O
increased O
intake O
of O
calcium-rich B-Medicinal food
foods I-Medicinal food
( O
r O
= O
.60 O
) O
. O

Levels O
of O
vascular O
endothelial O
growth O
factor O
( O
VEGF O
) O
were O
negatively O
related O
to O
depression B-Symptom_TestedFor
( O
r O
= O
- O
.56 O
) O
and O
intake O
of O
foods O
high O
in O
calcium O
( O
r O
= O
- O
.53 O
) O
and O
iron O
( O
r O
= O
- O
.34 O
) O
but O
positively O
related O
to O
serum O
calcium O
levels O
( O
r O
= O
.60 O
) O
. O

VEGF O
was O
negatively O
relationship O
to O
soluble O
fms-like O
tyrosine O
kinase O
1 O
( O
sFlt O
- O
1 O
; O
r O
= O
- O
.56 O
) O
. O

Placental O
growth O
factor O
had O
a O
negative O
relationship O
with O
maternal O
serum O
levels O
of O
albumin O
( O
r O
= O
- O
.61 O
) O
and O
calcium O
( O
r O
= O
- O
.65 O
) O
. O

Conclusions O
: O
Low-income O
pregnant O
women O
who O
eat O
to O
cope O
with O
anger O
and O
anxiety O
may O
have O
an O
inadequate O
intake O
of O
nutrients O
that O
contribute O
to O
positive O
pregnancy O
outcomes O
. O

Placental O
development O
in O
the O
early O
weeks O
of O
pregnancy O
may O
be O
influenced O
by O
maternal O
psychosocial O
and O
nutritional O
status O
. O

More O
research O
is O
needed O
to O
explore O
the O
relationship O
of O
dietary O
quality O
and O
placental O
development O
in O
the O
first O
trimester O
of O
pregnancy O
. O

Depression B-Symptom_WorkedFor
, O
a O
mental O
illness O
characterized O
by O
persistent O
feeling O
of O
sadness O
and O
loss O
of O
interest O
, O
has O
been O
a O
serious O
health O
problem O
worldwide O
. O

Manipulation O
of O
the O
microbiota O
by O
probiotics O
and O
prebiotics O
represents O
a O
novel O
emerging O
strategy O
for O
the O
treatment O
of O
various O
psychiatric O
disorders O
such O
as O
major O
depressive B-Symptom_WorkedFor
disorders I-Symptom_WorkedFor
. O

Here O
, O
we O
show O
that O
one O
water-soluble O
polysaccharide O
from O
Ginkgo B-Medicinal food
biloba I-Medicinal food
leaves O
( O
GPS O
) O
reduced O
stress-induced B-Symptom_WorkedFor
depression I-Symptom_WorkedFor
and O
reversed O
gut O
dysbiosis O
. O

Similar O
to O
the O
antidepressant O
paroxetine O
, O
GPS B-Medicinal food
significantly O
reduced O
the O
immobility O
times O
in O
the O
tail O
suspension O
test O
( O
TST O
) O
and O
forced O
swimming O
test O
( O
FST O
) O
and O
anxiety-like O
behavior O
in O
the O
open O
field O
test O
( O
OFT O
) O
. O

Consistent O
with O
the O
improvement O
of O
depression-like O
behavior O
above O
, O
GPS B-Medicinal food
mice O
had O
elevated O
serotonin O
and O
dopamine O
levels O
in O
multiple O
brain O
regions O
including O
the O
hippocampus O
, O
cerebral O
cortex O
and O
olfactory O
bulb O
, O
relative O
to O
unpredictable O
chronic O
mild O
stress B-Symptom_WorkedFor
( O
UCMS O
) O
treatment O
mice O
. O

GPS O
treatment O
could O
alleviate O
the O
stress-induced O
reduction O
in O
the O
density O
of O
serotonin-positive O
and O
dopamine-positive O
cells O
. O

Fecal O
microbiome O
transplant O
( O
FMT O
) O
combined O
with O
antibiotic O
treatment O
showed O
that O
the O
anti-depressant O
activity O
of O
GPS O
had O
a O
causal O
relationship O
with O
intestinal O
microbes O
. O

By O
performing O
a O
pyrosequencing-based O
analysis O
of O
bacterial O
16S O
rRNA O
( O
V3 O
+ O
V4 O
region O
) O
in O
fecal O
of O
the O
mice O
, O
the O
results O
showed O
that O
GPS O
reversed O
depression-associated O
gut O
dysbiosis O
and O
increased O
the O
richness O
of O
Lactobacillus O
species O
which O
has O
been O
proven O
to O
be O
a O
path O
to O
relieve O
depression B-Symptom_WorkedFor
. O

Our O
results O
demonstrated O
that O
the O
polysaccharide B-Drug/Scientific name
from O
Ginkgo B-Medicinal food
biloba I-Medicinal food
leaves O
might O
be O
a O
promising O
pharmacotherapeutic O
candidate O
for O
treating O
depression B-Symptom_WorkedFor
. O

The O
aim O
of O
this O
study O
was O
to O
investigate O
the O
effects O
of O
Ginkgo B-Medicinal food
biloba I-Medicinal food
extract O
( O
GBE O
) O
on O
cognitive B-Symptom_TestedFor
functions I-Symptom_TestedFor
as O
well O
as O
oxidative O
stress O
and O
brain-derived O
neurotrophic O
factor O
( O
BDNF O
) O
levels O
in O
aged O
female O
rats O
. O

Rats O
were O
divided O
into O
4 O
groups O
according O
to O
age O
( O
young O
vs O
. O
aged O
) O
and O
treatment O
( O
GBE O
vs O
. O
vehicle O
) O
. O

GBE O
or O
vehicle O
was O
given O
for O
30 O
d O
, O
and O
a O
series O
of O
behavioral O
tests O
were O
performed O
. O

Following O
behavioral O
testing O
, O
blood O
samples O
and O
brain O
tissues O
were O
obtained O
for O
analysis O
of O
BDNF O
, O
malondialdehyde O
( O
MDA O
) O
, O
8 O
- O
hydroxy O
- O
2 O
' O
- O
deoxyguanosine O
( O
8 O
- O
OHdG O
) O
, O
and O
glutathione O
levels O
, O
and O
superoxide O
dismutase O
activity O
. O

Locomotor O
activity O
and O
anxiety B-Symptom_WorkedFor
levels O
were O
lower O
in O
the O
aged O
rats O
. O

Based O
on O
Morris O
water O
maze O
probe O
trial O
findings O
, O
GBE O
supplementation O
increased O
the O
number O
of O
platform O
crossings O
in O
the O
aged O
rats O
. O

MDA O
and O
8 O
- O
OHdG O
levels O
were O
lower O
in O
the O
brain O
tissue O
, O
and O
BDNF O
levels O
were O
higher O
in O
plasma O
in O
the O
rates O
treated O
with O
GBE O
. O

Based O
on O
these O
findings O
, O
we O
concluded O
that O
GBE O
supplementation O
improved O
cognitive O
functions O
by O
decreasing O
oxidative O
damage O
and O
increasing O
the O
BDNF O
level O
in O
aged O
female O
rats O
. O

Constituents O
extracted O
from O
the O
leaves O
of O
the O
Ginkgo B-Medicinal food
biloba I-Medicinal food
tree O
possess O
beneficial O
properties O
that O
may O
buffer O
the O
aging B-Symptom_TestedFor
nervous I-Symptom_TestedFor
system I-Symptom_TestedFor
from O
deterioration O
due O
to O
oxidative O
stress O
. O

In O
the O
present O
investigation O
, O
a O
standardized O
extract O
of O
G B-Medicinal food
. I-Medicinal food
biloba I-Medicinal food
( O
EGb B-Medicinal food
761 I-Medicinal food
) O
or O
an O
equal O
volume O
of O
the O
vehicle O
was O
administered O
( O
100 O
mg O
/ O
kg O
/ O
day O
) O
to O
senescent O
( O
20 O
- O
month O
) O
C57BL O
/ O
6 O
male O
mice O
for O
up O
to O
82 O
consecutive O
days O
. O

Animals O
were O
tested O
twice O
in O
the O
Morris O
water O
maze O
( O
MWM O
) O
after O
28 O
and O
70 O
days O
of O
treatment O
. O

No O
differences O
were O
observed O
in O
acquisition O
or O
retention O
of O
performance O
on O
the O
water O
maze O
. O

Elevated-plus O
maze O
( O
EPM O
) O
trials O
were O
conducted O
prior O
to O
and O
subsequent O
to O
the O
chronic O
treatment O
regimen O
. O

Marked O
baseline O
differences O
in O
plus-maze O
performance O
were O
present O
in O
the O
first O
experiment O
. O

A O
second O
experiment O
used O
a O
matched-pairs O
design O
to O
minimize O
preexisting O
differences O
. O

Results O
supported O
the O
hypothesis O
that O
EGb O
761 O
may O
serve O
as O
an O
antistress O
buffer O
, O
attenuating O
the O
increase O
in O
anxiety B-Symptom_WorkedFor
typically O
observed O
in O
animals O
after O
cold O
water O
exposure O
. O

Tissue O
samples O
from O
the O
hippocampus O
and O
cortex O
were O
analyzed O
by O
Western O
blot O
for O
the O
transcription O
factor O
cyclic-AMP O
response O
element O
binding O
( O
CREB O
) O
protein O
. O

EGb O
761 O
had O
no O
significant O
effect O
on O
immunoreactivity O
to O
CREB O
from O
either O
the O
hippocampus O
or O
the O
cerebral O
cortex O
. O

Research O
in O
the O
area O
of O
herbal O
psychopharmacology O
has O
revealed O
a O
variety O
of O
promising O
medicines O
that O
may O
provide O
benefit O
in O
the O
treatment O
of O
general O
anxiety B-Symptom_WorkedFor
and O
specific O
anxiety B-Symptom_WorkedFor
disorders I-Symptom_WorkedFor
. O

However O
, O
a O
comprehensive O
review O
of O
plant-based O
anxiolytics O
has O
been O
absent O
to O
date O
. O

Thus O
, O
our O
aim O
was O
to O
provide O
a O
comprehensive O
narrative O
review O
of O
plant-based O
medicines O
that O
have O
clinical O
and O
/ O
or O
preclinical O
evidence O
of O
anxiolytic O
activity O
. O

We O
present O
the O
article O
in O
two O
parts O
. O

In O
part O
one O
, O
we O
reviewed O
herbal O
medicines O
for O
which O
only O
preclinical O
investigations O
for O
anxiolytic O
activity O
have O
been O
performed O
. O

In O
this O
current O
article O
( O
part O
two O
) O
, O
we O
review O
herbal O
medicines O
for O
which O
there O
have O
been O
both O
preclinical O
and O
clinical O
investigations O
of O
anxiolytic O
activity O
. O

A O
search O
of O
MEDLINE O
( O
PubMed O
) O
, O
CINAHL O
, O
Scopus O
and O
the O
Cochrane O
Library O
databases O
was O
conducted O
( O
up O
to O
28 O
October O
2012 O
) O
for O
English O
language O
papers O
using O
the O
search O
terms O
' O
anxiety O
' O
OR O
' O
anxiety O
disorder O
' O
OR O
' O
generalized O
anxiety O
disorder O
' O
OR O
' O
social O
phobia O
' O
OR O
' O
post-traumatic O
stress O
disorder O
' O
OR O
' O
panic O
disorder O
' O
OR O
' O
agoraphobia O
' O
OR O
' O
obsessive O
compulsive O
disorder O
' O
in O
combination O
with O
the O
search O
terms O
' O
Herb O
* O
' O
OR O
' O
Medicinal O
Plants O
' O
OR O
' O
Botanical O
Medicine O
' O
OR O
' O
Chinese O
herb O
* O
' O
, O
in O
addition O
to O
individual O
herbal O
medicines O
. O

This O
search O
of O
the O
literature O
revealed O
1,525 O
papers O
, O
of O
which O
53 O
plants O
were O
included O
in O
the O
review O
( O
having O
at O
least O
one O
study O
using O
the O
whole O
plant O
extract O
) O
. O

Of O
these O
plants O
, O
21 O
had O
human O
clinical O
trial O
evidence O
( O
reviewed O
here O
in O
part O
two O
) O
, O
with O
the O
other O
32 O
having O
solely O
preclinical O
evidence O
( O
reviewed O
in O
part O
one O
) O
. O

Support O
for O
efficacy O
was O
found O
for O
chronic O
use O
( O
i.e O
. O
greater O
than O
one O
day O
) O
of O
the O
following O
herbs O
in O
treating O
a O
range O
of O
anxiety O
disorders O
in O
human O
clinical O
trials O
: O
Piper O
methysticum O
, O
Matricaria O
recutita O
, O
Ginkgo O
biloba O
, O
Scutellaria O
lateriflora O
, O
Silybum O
marianum O
, O
Passiflora O
incarnata O
, O
Withania O
somniferum O
, O
Galphimia O
glauca O
, O
Centella O
asiatica O
, O
Rhodiola O
rosea O
, O
Echinacea O
spp O
. O
, O
Melissa O
officinalis O
and O
Echium O
amoenum O
. O

For O
several O
of O
the O
plants O
studied O
, O
conclusions O
need O
to O
be O
tempered O
due O
to O
methodological O
issues O
such O
as O
small O
sample O
sizes O
, O
brief O
intervention O
durations O
and O
non-replication O
. O

Current O
evidence O
does O
not O
support O
Hypericum O
perforatum O
or O
Valeriana O
spp O
. O
for O
any O
anxiety O
disorder O
. O

Acute O
anxiolytic O
activity O
was O
found O
for O
Centella B-Medicinal food
asiatica I-Medicinal food
, O
Salvia B-Medicinal food
spp I-Medicinal food
. O
, O
Melissa B-Medicinal food
officinalis I-Medicinal food
, O
Passiflora B-Medicinal food
incarnata I-Medicinal food
and O
Citrus B-Medicinal food
aurantium I-Medicinal food
. O

Bacopa O
monnieri O
has O
shown O
anxiolytic O
effects O
in O
people O
with O
cognitive O
decline O
. O

The O
therapeutic O
application O
of O
psychotropic O
plant-based O
treatments O
for O
anxiety O
disorders O
is O
also O
discussed O
, O
specifically O
Psychotria O
viridis O
and O
Banisteriopsis O
caarti O
( O
ayahuasca O
) O
, O
Psilocybe O
spp O
. O
and O
cannabidiol-enriched O
( O
low O
tetrahydrocannabinol O
( O
Δ O
( O
9 O
) O
- O
THC O
) O
) O
Cannabis O
spp O
. O

Background O
: O
Mental O
disorders O
are O
the O
most O
common O
health O
problems O
in O
the O
worldwide O
population O
. O

Current O
medicines O
against O
these O
conditions O
have O
undesired O
side O
effects O
or O
limited O
effectiveness O
. O

These O
disadvantageous O
pharmacological O
and O
therapeutic O
characteristics O
provoke O
a O
low O
adherence O
to O
treatment O
in O
an O
important O
percentage O
of O
patients O
with O
mental O
disorders O
. O

Since O
ancient O
times O
, O
ethnically O
different O
groups O
have O
been O
using O
plants O
extracts O
as O
medicines O
for O
the O
treatment O
of O
mental O
conditions O
including O
dementia B-Symptom_TestedFor
, O
depression B-Symptom_TestedFor
and O
anxiety B-Symptom_WorkedFor
disorders O
. O

Among O
them O
are O
extracts O
of O
Ginkgo B-Medicinal food
biloba I-Medicinal food
, O
a O
tree O
in O
the O
division O
Gingophyta O
, O
that O
has O
been O
used O
by O
millions O
of O
people O
worldwide O
. O

Objective O
: O
This O
review O
aims O
to O
discuss O
current O
scientific O
evidence O
of O
efficacy O
, O
neuroprotective O
and O
antioxidant O
effects O
as O
mechanism O
of O
action O
, O
side O
effects O
and O
potential O
interaction O
with O
other O
commonly O
prescribed O
anxiolytic O
drugs O
. O

Methods O
: O
A O
PubMed O
search O
of O
preclinical O
studies O
as O
well O
as O
individual O
clinical O
trials O
and O
meta-analysis O
were O
scrutinized O
. O

Results O
: O
Various O
preclinical O
and O
clinical O
studies O
have O
shown O
a O
positive O
effect O
of O
Ginkgo B-Medicinal food
biloba I-Medicinal food
to O
improve O
cognitive O
abilities O
in O
impaired B-participant_health
individuals O
and O
reducing O
anxiety B-Symptom_WorkedFor
under O
pathological O
conditions O
. O

Conclusion O
: O
A O
more O
advanced O
clinical O
research O
is O
needed O
to O
confirm O
the O
efficacy O
of O
Gingko B-Medicinal food
biloba I-Medicinal food
for O
the O
treatment O
of O
anxiety B-Symptom_WorkedFor
in O
different O
health O
conditions O
. O

Exposure O
to O
chronic O
restraint O
stress O
in O
rats O
and O
psychosocial O
stress O
in O
humans O
has O
been O
shown O
to O
alter O
cognitive O
functions O
such O
as O
learning O
and O
memory O
and O
has O
been O
linked O
to O
the O
pathophysiology O
of O
mood O
and O
anxiety O
disorders O
. O

Antianxiety O
or O
sedative O
agents O
used O
in O
the O
management O
of O
stress O
have O
several O
disadvantages O
and O
undesired O
effects O
. O

Therefore O
, O
in O
this O
study O
, O
we O
investigated O
efficacy O
of O
a O
natural O
medicine O
, O
the O
extract O
of O
Ginkgo B-Medicinal food
biloba I-Medicinal food
( O
EGB B-Medicinal food
761 I-Medicinal food
) O
, O
in O
prevention O
and O
treatment O
of O
the O
post-stress B-Symptom_WorkedFor
memory I-Symptom_WorkedFor
dysfunctions I-Symptom_WorkedFor
. O

The O
results O
showed O
that O
chronic O
restraint O
stress O
( O
2 O
h O
for O
21 O
days O
) O
or O
an O
' O
equivalent O
' O
dose O
of O
exogenous B-Other_ingredients
corticosterone I-Other_ingredients
( O
5 B-Dosage
mg I-Dosage
/ I-Dosage
kg I-Dosage
) O
impaired O
nonspatial O
memory O
as O
measured O
by O
an O
object O
recognition O
test O
. O

In O
control O
rats O
, O
EGB B-Medicinal food
761 I-Medicinal food
improved O
spatial O
and O
nonspatial O
memory O
in O
Morris O
water O
maze O
and O
object O
recognition O
tests O
. O

Preventive O
doses O
of O
EGB O
761 O
( O
100 O
mg O
/ O
kg O
) O
normalized O
cognitive O
deficits O
, O
seen O
in O
rats O
chronically O
stressed O
or O
treated O
with O
corticosterone O
in O
object O
recognition O
test O
, O
and O
improved O
memory O
processes O
in O
these O
rats O
measured O
by O
Morris O
water O
maze O
test O
. O

There O
was O
no O
influence O
of O
our O
treatments O
on O
locomotor O
exploratory O
activity O
and O
anxiety O
measured O
in O
open O
field O
and O
elevated O
' O
plus O
' O
maze O
tests O
, O
making O
a O
contribution O
of O
unspecific O
motor O
and O
emotional O
effects O
of O
the O
used O
drugs O
to O
their O
performance O
in O
the O
memory O
tests O
improbable O
. O

Previous O
studies O
have O
suggested O
that O
patients O
with O
chronic O
medical O
conditions O
use O
complementary O
and O
alternative O
medicine O
( O
CAM O
) O
at O
a O
higher O
rate O
than O
the O
general O
population O
. O

Despite O
recent O
interest O
in O
CAM O
for O
cardiovascular O
disease O
, O
few O
data O
are O
available O
regarding O
patterns O
of O
use O
in O
patients O
with O
cardiovascular B-participant_health
disease I-participant_health
in O
the O
United O
States O
. O

This O
study O
used O
the O
2002 O
National O
Health O
Interview O
Survey O
and O
analyzed O
data O
on O
CAM O
use O
in O
10,572 B-#Participants
respondents O
with O
cardiovascular B-participant_health
disease I-participant_health
. O

Among O
those O
with O
cardiovascular O
disease O
, O
36% O
had O
used O
CAM O
( O
excluding O
prayer O
) O
in O
the O
previous O
12 O
months O
. O

The O
most O
commonly O
used O
therapies O
were O
herbal O
products O
( O
18% O
) O
and O
mind-body O
therapies O
( O
17% O
) O
. O

Among O
herbs O
, O
echinacea B-Medicinal food
, O
garlic B-Medicinal food
, O
ginseng B-Medicinal food
, O
ginkgo B-Medicinal food
biloba I-Medicinal food
, O
and O
glucosamine B-Medicinal food
with O
or O
without O
chondroitin O
were O
most O
commonly O
used O
. O

Among O
mind-body O
therapies O
, O
deep-breathing O
exercises O
and O
meditation O
were O
most O
commonly O
used O
. O

Overall O
, O
CAM O
was O
used O
most O
frequently O
for O
musculoskeletal O
complaints O
( O
24% O
of O
respondents O
who O
used O
mind-body O
therapies O
, O
22% O
who O
used O
herbs O
, O
45% O
who O
used O
any O
CAM O
) O
. O

Mind-body O
therapies O
were O
also O
used O
for O
anxiety B-Symptom_TestedFor
or O
depression B-Symptom_TestedFor
( O
23% O
) O
and O
stress B-Symptom_TestedFor
or O
emotional O
health O
and O
wellness O
( O
16% O
) O
. O

Herbs O
were O
commonly O
used O
for O
head O
and O
chest O
colds O
( O
22% O
) O
. O

Fewer O
respondents O
( O
10% O
) O
used O
CAM O
specifically O
for O
their O
cardiovascular B-Symptom_WorkedFor
conditions I-Symptom_WorkedFor
( O
5% O
for O
hypertension O
, O
2% O
for O
coronary O
disease O
, O
3% O
for O
vascular O
insufficiency O
, O
< O
1% O
for O
heart O
failure O
or O
stroke O
) O
. O

Most O
, O
however O
, O
who O
used O
CAM O
for O
their O
cardiovascular O
condition O
perceived O
the O
therapies O
to O
be O
helpful O
( O
80% O
for O
herbs O
, O
94% O
for O
mind-body O
therapies O
) O
. O

CAM O
use O
was O
more O
common O
in O
younger O
respondents O
, O
women O
, O
Asians O
, O
and O
those O
with O
more O
education O
and O
greater O
incomes O
. O

In O
conclusion O
, O
CAM O
use O
, O
particularly O
herbs O
and O
mind-body O
therapies O
, O
is O
common O
in O
the O
United O
States O
in O
patients O
with O
cardiovascular B-Symptom_WorkedFor
disease I-Symptom_WorkedFor
and O
mirrors O
use O
in O
the O
general O
population O
. O

CAM O
use O
specifically O
to O
treat O
cardiovascular O
conditions O
, O
however O
, O
is O
less O
common O
. O

Chronic O
stress B-Symptom_WorkedFor
produces O
some O
morphological O
changes O
in O
rats O
, O
including O
thymus O
weight O
reduction O
, O
adrenal O
hypertrophy O
, O
and O
peptic O
ulcers O
in O
stomach O
. O

Repeated O
administration O
of O
phytoadaptogenic O
drugs O
( O
ginseng B-Medicinal food
and O
bilobil B-Medicinal food
) O
decreased O
these O
stress-induced B-Symptom_WorkedFor
disorders I-Symptom_WorkedFor
. O

The O
antistressor O
activity O
of O
drugs O
was O
attenuated O
upon O
by O
removal O
of O
the O
pineal O
gland O
. O

Histochemical O
and O
morphometric O
investigation O
of O
pineal O
tissues O
in O
stressed O
animals O
showed O
that O
that O
the O
pharmacological O
effect O
was O
accompanied O
by O
increasing O
functional O
activity O
of O
the O
pineal O
gland O
. O

It O
is O
suggested O
that O
pineal B-participant_health
mobilization I-participant_health
may O
participate O
in O
antistressor O
activity O
of O
phytoadaptogenic O
drugs O
. O

Aims O
: O
To O
assess O
the O
effect O
of O
a O
real O
life O
mental O
stress B-Medicinal food
situation O
on O
blood O
pressure O
( O
BP O
) O
and O
heart O
rate O
( O
HR O
) O
in O
students O
undergoing O
a O
medical O
licensing O
examination O
. O

Method O
: O
Prospective O
observational O
study O
of O
121 B-#Participants
medical O
students O
taking O
the O
final O
licensing O
exam O
. O

BP O
and O
HR O
were O
taken O
before O
and O
after O
the O
exam O
. O

Additionally O
, O
BP O
was O
measured O
by O
ambulatory O
BP O
monitoring O
device O
and O
HR O
was O
recorded O
continuously O
by O
an O
HR O
monitor O
belt O
in O
25 O
students O
throughout O
the O
examination O
. O

Major O
findings O
: O
Diastolic O
BP O
( O
DBP O
) O
increased O
from O
81 O
+ O
/ O
- O
10 O
mmHg O
before O
the O
exam O
to O
86 O
+ O
/ O
- O
9 O
mmHg O
( O
p O
= O
0.008 O
) O
during O
the O
exam O
and O
to O
88 O
+ O
/ O
- O
11 O
mmHg O
, O
( O
p O
= O
0.007 O
) O
15 O
min O
after O
the O
exam O
. O

Systolic O
BP O
( O
SBP O
) O
did O
not O
increase O
significantly O
during O
( O
from O
131 O
+ O
/ O
- O
14 O
before O
the O
exam O
to O
136 O
+ O
/ O
- O
18 O
mmHg O
) O
and O
after O
the O
exam O
( O
135 O
+ O
/ O
- O
16 O
mmHg O
) O
. O

HR O
decreased O
during O
( O
to O
100 O
+ O
/ O
- O
18 O
beats O
/ O
min O
, O
p O
< O
0.001 O
) O
, O
and O
after O
the O
exam O
( O
to O
95 O
+ O
/ O
- O
19 O
beats O
/ O
min O
, O
p O
< O
0.001 O
) O
compared O
to O
values O
before O
the O
exam O
( O
114 O
+ O
/ O
- O
19 O
beats O
/ O
min O
) O
. O

SBP O
was O
higher O
in O
male O
students O
compared O
to O
female O
students O
before O
( O
138 O
+ O
/ O
- O
10 O
vs O
125 O
+ O
/ O
- O
18 O
mmHg O
) O
and O
after O
( O
126 O
+ O
/ O
- O
18 O
vs O
115 O
+ O
/ O
- O
17 O
mmHg O
) O
the O
exam O
( O
p O
< O
0.01 O
) O
. O

Conclusion O
: O
Only O
DBP O
increased O
during O
medical O
licensing O
examination O
, O
albeit O
within O
a O
small O
range O
. O

SBP O
did O
not O
change O
significantly O
and O
HR O
decreased O
during O
the O
exam O
. O

Male O
students O
showed O
a O
higher O
SBP O
compared O
to O
female O
students O
. O

Pollinators O
, O
the O
cornerstones O
of O
our O
terrestrial O
ecosystem O
, O
have O
been O
at O
the O
very O
core O
of O
our O
anxiety B-Symptom_WorkedFor
. O

This O
is O
because O
we O
can O
nowadays O
observe O
a O
dangerous O
decline O
in O
the O
number O
of O
insects O
. O

With O
the O
numbers O
of O
pollinators O
dramatically O
declining O
worldwide O
, O
the O
scientific O
community O
has O
been O
growing O
more O
and O
more O
concerned O
about O
the O
future O
of O
insects O
as O
fundamental O
elements O
of O
most O
terrestrial O
ecosystems O
. O

Trying O
to O
address O
this O
issue O
, O
we O
looked O
for O
substances O
that O
might O
increase O
bee O
resistance O
. O

To O
this O
end O
, O
we O
checked O
the O
effects O
of O
plant-based O
adaptogens O
on O
honeybees O
in O
laboratory O
tests O
and O
during O
field O
studies O
on O
30 O
honeybee O
colonies O
during O
two O
seasons O
. O

In O
this O
study O
, O
we O
have O
tested O
extracts O
obtained O
from O
: O
Eleutherococcus B-Medicinal food
senticosus I-Medicinal food
, O
Garcinia B-Medicinal food
cambogia I-Medicinal food
, O
Panax B-Medicinal food
ginseng I-Medicinal food
, O
Ginkgo B-Medicinal food
biloba I-Medicinal food
, O
Schisandra B-Medicinal food
chinensis I-Medicinal food
, O
and O
Camellia B-Medicinal food
sinensis I-Medicinal food
. O

The O
75% O
ethanol B-Other_ingredients
E B-Medicinal food
. I-Medicinal food
senticosus I-Medicinal food
root O
extract O
proved O
to O
be O
the O
most O
effective O
, O
both O
as O
a O
cure O
and O
in O
the O
prophylaxis O
of O
nosemosis O
. O

Therefore O
, O
Eleutherococcus B-Medicinal food
senticosus I-Medicinal food
, O
and O
its O
active O
compounds O
, O
eleutherosides B-Drug/Scientific name
, O
are O
considered O
the O
most O
powerful O
adaptogens O
, O
in O
the O
pool O
of O
all O
extracts O
that O
were O
selected O
for O
screening O
, O
for O
supporting O
immunity O
and O
improving O
resistance O
of O
honeybees O
. O

The O
optimum O
effective O
concentration O
of O
0.4 O
mg O
/ O
mL O
E B-Medicinal food
. I-Medicinal food
senticosus I-Medicinal food
extract I-Medicinal food
responded O
to O
c.a O
. O
5.76 O
, O
2.56 O
and O
0.07 O
µg O
/ O
mL O
of O
eleutheroside B-Drug/Scientific name
B I-Drug/Scientific name
, O
eleutheroside B-Drug/Scientific name
E I-Drug/Scientific name
and O
naringenin B-Drug/Scientific name
, O
respectively O
. O

The O
effect O
of O
E B-Medicinal food
. I-Medicinal food
senticosus I-Medicinal food
extracts O
on O
honeybees O
involved O
a O
similar O
adaptogenic O
response O
as O
on O
other O
animals O
, O
including O
humans O
. O

In O
this O
research O
, O
we O
show O
for O
the O
first O
time O
such O
an O
adaptogenic O
impact O
on O
invertebrates O
, O
i.e O
. O
, O
the O
effect O
on O
honeybees O
stressed O
by O
nosemosis O
. O

We O
additionally O
hypothesised O
that O
these O
adaptogenic O
properties O
were O
connected O
with O
eleutherosides-secondary O
metabolites O
found O
exclusively O
in O
the O
Eleutherococcus B-Medicinal food
genus I-Medicinal food
and O
undetected O
in O
other O
studied O
extracts O
. O

As O
was O
indicated O
in O
this O
study O
, O
eleutherosides B-Drug/Scientific name
are O
very O
stable O
chemically O
and O
can O
be O
found O
in O
extracts O
in O
similar O
amounts O
even O
after O
two O
years O
from O
extraction O
. O

Considering O
the O
role O
bees O
play O
in O
nature O
, O
we O
may O
conclude O
that O
demonstrating O
the O
adaptogenic O
properties O
which O
plant O
extracts O
have O
in O
insects O
is O
the O
most O
significant O
finding O
resulting O
from O
this O
research O
. O

This O
knowledge O
might O
bring O
to O
fruition O
numerous O
economic O
and O
ecological O
benefits O
. O

Background O
: O
Due O
to O
an O
ageing O
population O
in O
Australia O
there O
has O
been O
an O
increase O
in O
the O
number O
of O
older O
adults O
with O
subjective B-participant_health
cognitive I-participant_health
impairment I-participant_health
( O
SCI B-participant_health
) O
, O
a O
self-reported O
decline O
in O
cognitive O
function O
associated O
with O
an O
increased O
risk O
of O
mild O
cognitive O
impairment O
and O
dementia O
. O

There O
is O
no O
current O
, O
recommended O
treatment O
for O
SCI O
; O
therefore O
, O
the O
effectiveness O
of O
a O
supplement O
approved O
by O
the O
Therapeutic O
Goods O
Association O
that O
has O
the O
potential O
to O
enhance O
cognitive O
function O
in O
an O
at-risk O
cohort O
should O
be O
tested O
. O

The O
primary O
aim O
of O
this O
proposed O
research O
is O
to O
determine O
the O
efficacy O
of O
6 B-Duration
months I-Duration
of O
treatment O
with O
BioCeuticals O
Cognition O
Support O
Formula O
® O
( O
containing O
Bacopa B-Medicinal food
monniera I-Medicinal food
( O
brahmi B-Medicinal food
) O
, O
Ginkgo B-Medicinal food
biloba I-Medicinal food
, O
Panax B-Medicinal food
ginseng I-Medicinal food
and O
alpha-lipoic B-Medicinal food
acid I-Medicinal food
) O
on O
cognition O
in O
older O
adults O
with O
SCI B-participant_health
( O
utilising O
the O
CogState O
® O
one O
card O
learning O
and O
identification O
tests O
as O
co-primary O
outcome O
measures O
of O
visual O
short-term O
memory O
and O
attention O
; O
mean O
speed O
( O
ms O
) O
, O
accuracy O
( O
% O
) O
, O
and O
total O
number O
of O
hits O
, O
misses O
, O
and O
anticipations O
) O
compared O
with O
placebo O
. O

The O
secondary O
aims O
are O
to O
assess O
an O
improvement O
in O
other O
cognitive O
domains O
( O
executive O
functioning O
, O
processing O
speed O
, O
and O
working O
memory O
) O
, O
evaluate O
safety O
, O
adverse O
effects O
, O
and O
determine O
efficacy O
on O
mood O
, O
fatigue O
, O
and O
neurocognition O
. O

It O
is O
expected O
that O
improvements O
across O
the O
study O
timepoints O
in O
the O
co-primary O
outcomes O
in O
the O
active O
treatment O
group O
( O
compared O
with O
placebo O
) O
will O
be O
evident O
. O

Method O
: O
One-hundred B-#Participants
and I-#Participants
twenty I-#Participants
participants O
will O
be O
recruited O
for O
the O
randomised O
, O
double-blind O
, O
placebo-controlled O
study O
. O

Participants O
will O
be O
randomly O
assigned O
to O
one O
of O
the O
treatment O
groups O
( O
active O
or O
placebo O
) O
at O
a O
1 O
: O
1 O
ratio O
, O
and O
will O
be O
required O
to O
complete O
a O
series O
of O
cognitive O
( O
using O
CogState O
® O
) O
, O
mood B-Symptom_WorkedFor
( O
using O
the O
Depression B-Metric
, I-Metric
Anxiety I-Metric
, I-Metric
Stress I-Metric
Scale I-Metric
( O
DASS O
- O
42 O
) O
and O
Short B-Metric
Health I-Metric
Anxiety I-Metric
Inventory I-Metric
( O
SHAI O
) O
) O
, O
and O
fatigue B-Symptom_WorkedFor
( O
using O
the O
Functional B-Metric
Assessment I-Metric
of I-Metric
Chronic I-Metric
Illness I-Metric
Therapy I-Metric
Fatigue I-Metric
Scale I-Metric
( O
FACIT-F O
) O
) O
tasks O
at O
baseline O
( O
0 O
months O
) O
, O
the O
midpoint O
( O
3 O
months O
) O
, O
and O
the O
endpoint O
( O
6 O
months O
) O
. O

These O
tasks O
will O
be O
evaluated O
between O
timepoints O
( O
baseline O
vs O
. O
midpoint O
, O
midpoint O
vs O
. O
endpoint O
, O
and O
baseline O
vs O
. O
endpoint O
) O
. O

Neurocognition O
will O
be O
measured O
by O
electroencephalography O
at O
baseline O
and O
at O
the O
endpoint O
in O
half O
of O
the O
participants O
. O

Adverse O
effects O
will O
be O
documented O
over O
the O
6 B-Duration
- I-Duration
month I-Duration
trial O
period O
. O

Discussion O
: O
This O
is O
the O
first O
study O
to O
test O
the O
efficacy O
of O
Cognition O
Support O
Formula O
® O
on O
cognition O
in O
older O
adults O
with O
SCI O
. O

As O
people O
with O
SCI O
have O
an O
increased O
risk O
of O
dementia O
, O
and O
there O
are O
limited O
treatments O
options O
for O
this O
population O
, O
it O
is O
important O
to O
assess O
a O
supplement O
that O
has O
the O
potential O
to O
enhance O
cognitive O
function O
. O

Trial O
registration O
: O
Universal O
Trial O
Number O
( O
UTN O
) O
, O
U1111 O
- O
1196 O
- O
9548 O
. O

Australian O
New O
Zealand O
Clinical O
Trials O
Registry O
, O
ACTRN12617000945325 O
. O

Registered O
on O
30 O
June O
2017 O
. O

Exposure O
to O
chronic O
restraint O
stress O
in O
rats O
and O
psychosocial O
stress O
in O
humans O
has O
been O
shown O
to O
alter O
cognitive O
functions O
such O
as O
learning O
and O
memory O
and O
has O
been O
linked O
to O
the O
pathophysiology O
of O
mood O
and O
anxiety O
disorders O
. O

Antianxiety O
or O
sedative O
agents O
used O
in O
the O
management O
of O
stress O
have O
several O
disadvantages O
and O
side O
effects O
. O

Therefore O
, O
in O
this O
study O
, O
we O
investigated O
efficacy O
of O
a O
natural O
medicine O
, O
the O
extract O
of O
Ginkgo B-Medicinal food
biloba I-Medicinal food
( O
EGB O
761 O
) O
, O
in O
prevention O
and O
treatment O
of O
the O
post-stress B-Symptom_WorkedFor
memory I-Symptom_WorkedFor
dysfunctions I-Symptom_WorkedFor
. O

The O
results O
showed O
that O
chronic O
restraint O
stress O
( O
2h O
for O
21 O
days O
) O
or O
an O
' O
equivalent O
' O
dose O
of O
exogenous B-Other_ingredients
corticosterone I-Other_ingredients
( O
5 B-Dosage
mg I-Dosage
kg I-Dosage
( I-Dosage
- I-Dosage
1 I-Dosage
) I-Dosage
) O
decreased O
re-entry O
latencies O
in O
the O
passive O
avoidance O
situation O
showing O
thus O
impairment O
of O
recall O
. O

Preventive O
doses O
of O
EGB B-Medicinal food
761 I-Medicinal food
( O
100 B-Dosage
mg I-Dosage
kg I-Dosage
( I-Dosage
- I-Dosage
1 I-Dosage
) I-Dosage
) O
, O
given O
30 O
min O
before O
each O
restraint O
stress O
episode O
or O
corticosterone O
injection O
, O
abolished O
cognitive O
deficits O
seen O
in O
unprotected O
rats O
. O

There O
was O
no O
influence O
of O
stress O
, O
corticosterone O
, O
and O
EGB O
761 O
on O
the O
acquisition O
of O
conditioned O
avoidance O
responses O
( O
CARs O
) O
. O

This O
study O
assessed O
the O
effects O
of O
chronic O
treatment O
with O
a O
standardized O
extract O
of O
Ginkgo B-Medicinal food
biloba I-Medicinal food
L I-Medicinal food
. O

( O
EGb O
) O
on O
short-term O
and O
long-term O
memory O
as O
well O
as O
on O
anxiety-like B-Symptom_TestedFor
and O
locomotor O
activity O
using O
the O
plus-maze O
discriminative O
avoidance O
task O
( O
PM-DAT O
) O
. O

Additionally O
, O
we O
evaluated O
the O
antioxidant O
and O
neuroprotective O
effects O
of O
EGb O
on O
the O
prefrontal O
cortex O
( O
PFC O
) O
and O
dorsal O
hippocampus O
( O
DH O
) O
of O
middle-aged O
rats O
using O
the O
comet O
assay O
. O

Twelve-month-old O
male O
Wistar O
rats O
were O
administered O
vehicle O
or O
EGb O
( O
0.5mgkg O
( O
- O
1 O
) O
or O
1.0gkg O
( O
- O
1 O
) O
) O
for O
30days O
. O

Behavioural O
data O
showed O
that O
EGb O
treatment O
improved O
short-term O
memory O
. O

Neither O
an O
anti-anxiety O
effect O
nor O
a O
change O
in O
locomotor O
activity O
was O
observed O
. O

Twenty-four O
hours O
after O
the O
behavioural O
tests O
, O
the O
rats O
were O
decapitated O
, O
and O
the O
PFC O
and O
DH O
were O
quickly O
dissected O
out O
and O
prepared O
for O
the O
comet O
assay O
. O

The O
levels O
of O
DNA O
damage O
in O
the O
PFC O
were O
significantly O
lower O
in O
rats O
that O
were O
treated O
with O
1.0gkg O
( O
- O
1 O
) O
EGb O
. O

Both O
doses O
of O
EGb O
decreased O
H2O2 O
- O
induced O
DNA O
breakage O
in O
cortical O
cells O
, O
whereas O
the O
levels O
of O
DNA O
damage O
in O
the O
EGb-treated O
animals O
were O
significantly O
lower O
than O
those O
in O
the O
control O
animals O
. O

No O
significant O
differences O
in O
the O
level O
of O
DNA O
damage O
in O
hippocampal O
cells O
were O
observed O
among O
the O
experimental O
groups O
. O

EGb O
treatment O
was O
not O
able O
to O
reduce O
H2O2 O
- O
induced O
DNA O
damage O
in O
hippocampal O
cells O
. O

Altogether O
, O
our O
data O
provide O
the O
first O
demonstration O
that O
chronic O
EGb O
treatment O
improved O
the O
short-term O
memory O
of O
middle-aged O
rats O
, O
an O
effect O
that O
could O
be O
associated O
with O
a O
reduction O
in O
free O
radical O
production O
in O
the O
PFC O
. O

These O
data O
suggest O
that O
EGb O
treatment O
might O
increase O
the O
survival O
of O
cortical O
neurons O
and O
corroborate O
and O
extend O
the O
view O
that O
EGb O
has O
protective O
and O
therapeutic O
properties O
. O

Ethnopharmacological O
relevance O
: O
The O
roots O
and O
stem O
bark O
of O
Acanthopanax B-Medicinal food
koreanum I-Medicinal food
Nakai I-Medicinal food
( O
Araliaceae B-Medicinal food
) O
, O
a O
well-known O
herbal O
medicine O
in O
Jeju O
Island O
, O
Korea O
, O
has O
been O
used O
as O
a O
tonic O
agent O
in O
treating O
stress-related B-Symptom_WorkedFor
states O
. O

Despite O
its O
popular O
application O
, O
the O
anti-anxiety O
or O
anti-depressive O
action O
of O
Acanthopanax B-Medicinal food
koreanum I-Medicinal food
is O
not O
yet O
known O
. O

Aim O
of O
the O
study O
: O
This O
study O
aimed O
to O
determine O
the O
effects O
of O
Acanthopanax B-Medicinal food
koreanum I-Medicinal food
on O
stress-induced O
behavioral O
alterations O
such O
as O
anxiety B-Symptom_WorkedFor
and O
depression B-Symptom_WorkedFor
. O

Materials O
and O
methods O
: O
Mice O
in O
the O
acute O
stress O
group O
were O
exposed O
to O
immobilization O
stress O
for O
2h O
followed O
by O
electric O
foot O
shocks O
( O
0.5 O
mA O
in O
1 O
s O
duration O
with O
a O
10 O
s O
inter-shock O
interval O
) O
for O
2 O
min O
, O
while O
sub-chronically O
stressed O
mice O
were O
exposed O
to O
these O
stresses O
for O
2 O
weeks O
, O
once O
per O
day O
. O
70% O
ethanolic O
extract O
of O
Acanthopanax O
koreanum O
( O
EEAK O
) O
( O
25 O
, O
50 O
, O
100 O
, O
or O
200 O
mg O
/ O
kg O
) O
was O
administered O
once O
or O
sub-chronically O
( O
for O
2 O
weeks O
) O
1h O
prior O
to O
stress O
induction O
. O

Anxiety O
- O
or O
depression-like O
behavioral O
changes O
were O
evaluated O
using O
the O
elevated O
plus-maze O
( O
EPM O
) O
test O
and O
the O
forced O
swimming O
test O
( O
FST O
) O
a O
day O
after O
the O
final O
stress O
induction O
. O

Corticosterone O
levels O
and O
spleen O
weight O
were O
measured O
after O
conducting O
all O
the O
behavioral O
assays O
. O

The O
numbers O
of O
BrdU O
- O
or O
DCX-immunopositive O
cells O
in O
the O
hippocampal O
region O
of O
sub-chronically O
stressed O
mice O
were O
measured O
2 O
days O
after O
EEAK O
treatment O
. O

Results O
: O
The O
percentage O
of O
time O
spent O
in O
the O
open O
arms O
was O
decreased O
in O
both O
the O
acutely O
and O
chronically O
stressed O
mice O
. O

In O
the O
FST O
, O
the O
immobility O
time O
was O
increased O
by O
only O
chronic O
stress O
, O
but O
not O
by O
acute O
stress O
. O

Acute O
or O
sub-chronic O
administration O
of O
EEAK O
significantly O
prevented O
the O
anxiety O
- O
or O
depression-like O
behavioral O
changes O
caused O
by O
stress O
. O

EEAK O
also O
attenuated O
stress-induced O
decrease O
and O
increase O
of O
spleen O
weight O
and O
corticosterone O
levels O
, O
respectively O
. O

Furthermore O
, O
the O
sub-chronic O
administration O
of O
EEAK O
( O
100 O
or O
200 O
mg O
/ O
kg O
, O
for O
2 O
weeks O
) O
increased O
the O
number O
of O
BrdU O
- O
, O
doublecortin O
- O
, O
and O
neuropeptide O
Y-positive O
cells O
in O
the O
hippocampal O
region O
of O
the O
sub-chronically O
stressed O
mice O
. O

Conclusion O
: O
EEAK O
attenuated O
the O
behavioral O
and O
biochemical O
changes O
in O
acute O
or O
sub-chronic O
stressed O
mice O
. O

These O
results O
suggest O
the O
therapeutic O
potential O
of O
Acanthopanax B-Medicinal food
koreanum I-Medicinal food
for O
the O
treatment O
of O
stress-related O
neuropsychiatric O
disorders O
including O
anxiety B-Symptom_WorkedFor
disorders O
or O
major O
depressive B-Symptom_WorkedFor
disorder O
. O

Mental O
stress B-Symptom_WorkedFor
, O
such O
as O
anxiety B-Symptom_WorkedFor
and O
conflict O
, O
causes O
physiological O
changes O
, O
such O
as O
changes O
in O
autonomic O
nervous O
activity O
and O
gastric O
ulcers O
. O

In O
addition O
, O
stress B-Symptom_WorkedFor
induces O
glucocorticoids O
and O
changes O
the O
hippocampal O
brain-derived B-Metric
neurotrophic I-Metric
factor I-Metric
( O
BDNF O
) O
expression O
levels O
. O

We O
previously O
reported O
that O
Acanthopanax B-Medicinal food
senticosus I-Medicinal food
HARM I-Medicinal food
( O
ASH B-Medicinal food
) O
prevents O
stress-induced O
gastric O
ulcers O
. O

Thus O
, O
we O
investigated O
the O
potential O
anxiolytic O
effect O
and O
influence O
of O
ASH B-Medicinal food
on O
the O
hippocampus O
BDNF-related B-Metric
protein O
in O
male O
Sprague-Dawley O
rats O
fed O
1% O
and O
5% O
ASH B-Medicinal food
extract-containing O
food O
for O
one O
week O
using O
novelty O
suppressed O
feeding O
( O
NSF O
) O
and O
improved O
elevated O
beam O
walking O
( O
IEBW O
) O
tests O
. O

ASH B-Medicinal food
treatment O
significantly O
decreased O
latency O
to O
eat O
in O
the O
NSF O
test O
and O
increased O
the O
time O
spent O
on O
the O
open O
arm O
in O
the O
IEBW O
test O
. O

ASH5% O
treatment O
showed O
a O
significant O
decrease O
in O
LFnu O
, O
indicative O
of O
sympathetic O
nervous O
activity O
, O
and O
a O
significant O
increase O
in O
HFnu O
, O
indicative O
of O
parasympathetic O
nervous O
activity O
, O
in O
the O
NSF O
test O
. O

In O
addition O
, O
ASH1% O
and O
ASH5% O
treatments O
significantly O
decreased O
LFnu O
and O
significantly O
increased O
HFnu O
in O
the O
IEBW O
test O
. O

ASH5% O
treatment O
significantly O
increased O
hippocampal O
BDNF O
protein O
expression O
in O
both O
Western O
blotting O
and O
immunohistochemistry O
experiments O
. O

Our O
findings O
suggest O
that O
anxiolytic O
effects O
of O
ASH O
occur O
via O
the O
regulation O
of O
autonomic O
function O
and O
increased O
hippocampal O
BDNF O
signaling O
. O

Pollinators O
, O
the O
cornerstones O
of O
our O
terrestrial O
ecosystem O
, O
have O
been O
at O
the O
very O
core O
of O
our O
anxiety B-Symptom_TestedFor
. O

This O
is O
because O
we O
can O
nowadays O
observe O
a O
dangerous O
decline O
in O
the O
number O
of O
insects O
. O

With O
the O
numbers O
of O
pollinators O
dramatically O
declining O
worldwide O
, O
the O
scientific O
community O
has O
been O
growing O
more O
and O
more O
concerned O
about O
the O
future O
of O
insects O
as O
fundamental O
elements O
of O
most O
terrestrial O
ecosystems O
. O

Trying O
to O
address O
this O
issue O
, O
we O
looked O
for O
substances O
that O
might O
increase O
bee O
resistance O
. O

To O
this O
end O
, O
we O
checked O
the O
effects O
of O
plant-based O
adaptogens O
on O
honeybees O
in O
laboratory O
tests O
and O
during O
field O
studies O
on O
30 O
honeybee O
colonies O
during O
two O
seasons O
. O

In O
this O
study O
, O
we O
have O
tested O
extracts O
obtained O
from O
: O
Eleutherococcus O
senticosus O
, O
Garcinia O
cambogia O
, O
Panax O
ginseng O
, O
Ginkgo O
biloba O
, O
Schisandra O
chinensis O
, O
and O
Camellia O
sinensis O
. O

The O
75% O
ethanol B-Other_ingredients
E B-Medicinal food
. I-Medicinal food
senticosus I-Medicinal food
root O
extract O
proved O
to O
be O
the O
most O
effective O
, O
both O
as O
a O
cure O
and O
in O
the O
prophylaxis O
of O
nosemosis O
. O

Therefore O
, O
Eleutherococcus B-Medicinal food
senticosus I-Medicinal food
, O
and O
its O
active O
compounds O
, O
eleutherosides B-Drug/Scientific name
, O
are O
considered O
the O
most O
powerful O
adaptogens O
, O
in O
the O
pool O
of O
all O
extracts O
that O
were O
selected O
for O
screening O
, O
for O
supporting O
immunity B-Symptom_WorkedFor
and O
improving O
resistance O
of O
honeybees O
. O

The O
optimum O
effective O
concentration O
of O
0.4 O
mg O
/ O
mL O
E O
. O
senticosus B-Medicinal food
extract I-Medicinal food
responded O
to O
c.a O
. O
5.76 O
, O
2.56 O
and O
0.07 O
µg O
/ O
mL O
of O
eleutheroside B-Other_ingredients
B I-Other_ingredients
, O
eleutheroside B-Other_ingredients
E I-Other_ingredients
and O
naringenin B-Other_ingredients
, O
respectively O
. O

The O
effect O
of O
E B-Medicinal food
. I-Medicinal food
senticosus I-Medicinal food
extracts I-Medicinal food
on O
honeybees O
involved O
a O
similar O
adaptogenic O
response O
as O
on O
other O
animals O
, O
including O
humans O
. O

In O
this O
research O
, O
we O
show O
for O
the O
first O
time O
such O
an O
adaptogenic O
impact O
on O
invertebrates O
, O
i.e O
. O
, O
the O
effect O
on O
honeybees O
stressed O
by O
nosemosis O
. O

We O
additionally O
hypothesised O
that O
these O
adaptogenic O
properties O
were O
connected O
with O
eleutherosides-secondary O
metabolites O
found O
exclusively O
in O
the O
Eleutherococcus B-Drug/Scientific name
genus I-Drug/Scientific name
and O
undetected O
in O
other O
studied O
extracts O
. O

As O
was O
indicated O
in O
this O
study O
, O
eleutherosides B-Drug/Scientific name
are O
very O
stable O
chemically O
and O
can O
be O
found O
in O
extracts O
in O
similar O
amounts O
even O
after O
two O
years O
from O
extraction O
. O

Considering O
the O
role O
bees O
play O
in O
nature O
, O
we O
may O
conclude O
that O
demonstrating O
the O
adaptogenic O
properties O
which O
plant O
extracts O
have O
in O
insects O
is O
the O
most O
significant O
finding O
resulting O
from O
this O
research O
. O

This O
knowledge O
might O
bring O
to O
fruition O
numerous O
economic O
and O
ecological O
benefits O
. O

To O
evaluate O
the O
therapeutic O
effects O
of O
Chinese O
herbal O
medicine O
( O
CHM O
) O
for O
Alzheimer's B-Symptom_WorkedFor
disease I-Symptom_WorkedFor
( O
AD O
) O
, O
we O
evaluated O
five O
CHMs O
in O
oligomeric O
Aβ25 O
- O
35 O
- O
treated O
mouse O
primary O
hippocampal O
neuronal O
cultures O
. O

The O
aqueous O
extract O
from O
the O
root O
of O
Pueraria B-Medicinal food
lobata I-Medicinal food
( O
Puerariae B-Medicinal food
Radix I-Medicinal food
; O
PR O
) O
showed O
better O
neuroprotective O
effects O
than O
did O
the O
other O
four O
CHM O
aqueous O
extracts O
, O
including O
Gardenia B-Other_ingredients
jasminoides I-Other_ingredients
, O
Eleutherococcus B-Other_ingredients
senticosus I-Other_ingredients
, O
Rhodiola B-Other_ingredients
rosea I-Other_ingredients
, O
and O
Panax B-Other_ingredients
, O
in O
the O
primary O
culture O
treated O
with O
saline O
or O
oligomeric O
Aβ25 O
- O
35 O
. O

Furthermore O
, O
the O
neuroprotective O
effects O
of O
aqueous O
extract O
of O
PR B-Medicinal food
were O
also O
better O
than O
its O
well-known O
active O
compound O
, O
puerarin O
, O
against O
the O
neurotoxicity O
of O
oligomeric O
Aβ25 O
- O
35 O
in O
a O
primary O
culture O
. O

For O
in O
vivo O
experiments O
, O
C57BL O
/ O
6J O
male O
mice O
that O
received O
direct O
infusion O
of O
soluble O
oligomeric O
Aβ25 O
- O
35 O
into O
the O
bilateral O
hippocampal O
CA1 O
subregion O
were O
used O
as O
an O
alternative O
AD O
mouse O
model O
. O

The O
effects O
and O
molecular O
mechanisms O
of O
chronic O
systemic O
administration O
of O
PR O
aqueous O
extract O
were O
evaluated O
in O
the O
alternative O
AD O
model O
. O

PR O
aqueous O
extract O
prevented O
anxiety B-Symptom_WorkedFor
and O
cognitive B-Symptom_WorkedFor
impairment I-Symptom_WorkedFor
in O
mice O
associated O
with O
a O
decrease O
in O
the O
levels O
of O
Aβ O
deposition O
, O
tau O
protein O
phosphorylation O
, O
inflammation O
, O
loss O
of O
noradrenergic O
, O
and O
serotonergic O
neurons O
and O
an O
increase O
in O
the O
levels O
of O
synaptophysin O
and O
insulin O
degrading O
enzyme O
( O
IDE O
) O
against O
the O
toxicity O
of O
oligomeric O
Aβ25 O
- O
35 O
. O

Furthermore O
, O
no O
obvious O
damage O
to O
the O
liver O
and O
kidney O
was O
detected O
after O
chronic O
systemic O
administration O
of O
PR O
aqueous O
extract O
. O

Therefore O
, O
using O
PR O
could O
be O
a O
safer O
, O
more O
effective O
therapeutic O
strategy O
than O
using O
its O
active O
compound O
puerarin O
to O
prevent O
both O
cognitive O
and O
noncognitive O
dysfunction O
and O
related O
pathological O
features O
of O
AD O
. O

We O
previously O
found O
that O
the O
water O
extract O
of O
Eleutherococcus B-Medicinal food
senticosus I-Medicinal food
leaves I-Medicinal food
( O
ES B-Medicinal food
extract I-Medicinal food
) O
enhanced O
cognitive O
function O
in O
normal O
mice O
. O

Our O
study O
also O
revealed O
that O
the O
water O
extract O
of O
rhizomes B-Medicinal food
of I-Medicinal food
Drynaria I-Medicinal food
fortunei I-Medicinal food
( O
DR B-Medicinal food
extract I-Medicinal food
) O
enhanced O
memory O
function O
in O
Alzheimer's O
disease O
model O
mice O
. O

In O
addition O
, O
our O
previous O
experiments O
suggested O
that O
a O
combined O
treatment O
of O
ES O
and O
DR O
extracts O
synergistically O
improved O
memory O
and O
anti-stress B-Symptom_WorkedFor
response O
in O
mice O
. O

Although O
those O
two O
botanical O
extracts O
are O
expected O
to O
be O
beneficial O
for O
neuropsychological O
function O
, O
no O
clinical O
data O
has O
ever O
been O
reported O
. O

Therefore O
, O
we O
performed O
a O
placebo-controlled O
, O
randomized O
, O
double-blind O
study O
to O
evaluate O
cognitive O
enhancement O
and O
anti-stress B-Symptom_WorkedFor
effects O
by O
the O
intake O
of O
a O
combined O
extract O
in O
healthy O
volunteers O
. O

The O
intake O
period O
was O
12 B-Duration
weeks I-Duration
. O

The O
Japanese O
version O
of O
the O
Repeatable B-Metric
Battery I-Metric
for I-Metric
the I-Metric
Assessment I-Metric
of I-Metric
Neuropsychological I-Metric
Status I-Metric
( O
RBANS O
) O
test O
was O
used O
for O
neurocognitive O
assessment O
. O

The O
combined O
treatment O
of O
ES O
and O
DR O
extracts O
significantly O
increased O
the O
figure O
recall O
subscore O
of O
RBANS O
( O
p O
= O
0.045 O
) O
in O
an O
intergroup O
comparison O
. O

Potentiation O
of O
language O
domain O
( O
( O
p O
= O
0.040 O
) O
, O
semantic O
fluency O
( O
p O
= O
0.021 O
) O
and O
figure O
recall O
( O
p O
= O
0.052 O
) O
was O
shown O
by O
the O
extracts O
( O
in O
intragroup O
comparison O
) O
. O

In O
anti-stress O
response O
, O
the O
anxiety O
/ O
uncertainly O
score O
was O
improved O
by O
the O
extract O
in O
an O
intragroup O
comparison O
( O
p O
= O
0.022 O
) O
. O

No O
adverse O
effects O
were O
observed O
. O

The O
combined O
treatment O
of O
ES O
and O
DR O
extracts O
appear O
to O
safely O
enhance O
a O
part O
of O
cognitive O
function O
in O
healthy O
adults O
. O

Aim O
: O
There O
are O
few O
published O
studies O
on O
the O
triggers O
of O
binge B-Symptom_TestedFor
eating I-Symptom_TestedFor
in O
anorexia O
nervosa O
of O
binge O
/ O
purging O
subtype O
( O
BPAN O
) O
, O
bulimia O
nervosa O
( O
BN O
) O
and O
binge B-Symptom_TestedFor
eating I-Symptom_TestedFor
disorder I-Symptom_TestedFor
( O
BED O
) O
. O

Patients O
and O
methods O
: O
We O
validated O
in O
29 B-#Participants
patients O
( O
10 O
BPAN O
, O
10 O
BN O
and O
9 O
BED O
) O
the O
perspicuity O
, O
the O
clarity O
and O
the O
intra O
- O
( O
doubles O
) O
and O
inter O
- O
( O
test-retest O
) O
reproducibility O
of O
a O
24 O
- O
item O
Start O
questionnaire O
on O
the O
triggers O
of O
binge O
eating O
. O

Then O
the O
Start O
questionnaire O
was O
administered O
to O
176 O
patients O
( O
65 O
BPAN O
, O
62 O
BN O
and O
59 O
BED O
patients O
) O
being O
27.5 O
+ O
9.1 O
yr O
old O
, O
having O
15 O
+ O
9 O
binge O
eating O
( O
BE O
) O
episodes O
/ O
week O
, O
with O
a O
mean O
binge O
duration O
of O
1 O
hr O
36min O
( O
+ O
38min O
) O
/ O
day O
. O

Results O
: O
BE O
episodes O
occurred O
mainly O
during O
the O
second O
part O
of O
the O
day O
: O
afternoon O
after O
work O
( O
67% O
of O
the O
patients O
) O
, O
" O
tea O
" O
time O
( O
55% O
) O
, O
evening O
after O
dinner O
( O
42% O
) O
and O
at O
night O
( O
22% O
) O
. O

The O
principal O
place O
for O
BE O
episodes O
was O
at O
home O
( O
96% O
) O
. O

The O
BED O
patients O
avoided O
binges O
at O
the O
parents O
' O
home O
( O
89% O
) O
more O
often O
than O
the O
BPAN O
( O
62% O
, O
P O
< O
0.02 O
) O
. O

The O
binges O
occurred O
mainly O
in O
the O
living O
room O
( O
44% O
) O
, O
in O
the O
kitchen O
( O
43% O
) O
, O
and O
less O
in O
the O
bedroom O
( O
31% O
) O
. O

Hunger O
pangs O
seemed O
to O
be O
a O
trigger O
of O
binges O
in O
31% O
of O
the O
patients O
, O
and O
a O
stronger O
trigger O
in O
BED O
( O
42% O
) O
than O
in O
the O
BPAN O
and O
BN O
patients O
( O
24% O
; O
P O
= O
0.04 O
) O
. O

Binge O
eating O
episodes O
could O
occur O
despite O
a O
high O
satiety O
level O
( O
just O
after O
lunch O
or O
dinner O
) O
in O
29% O
of O
the O
BN O
and O
in O
16% O
of O
the O
BED O
patients O
( O
P O
< O
0.02 O
) O
. O

Concerning O
food O
, O
the O
major O
triggers O
were O
high O
energy-density O
food O
( O
77% O
) O
and O
comfort O
food O
( O
60% O
) O
, O
such O
as O
chocolate O
, O
cakes O
, O
bread O
and O
pasta O
. O

The O
food O
consumed O
for O
binge O
episodes O
( O
in-binge O
food O
) O
was O
more O
often O
a O
strong O
trigger O
than O
the O
other O
food O
( O
not O
used O
for O
binges O
) O
: O
olfaction O
( O
19% O
versus O
10% O
) O
, O
sight O
( O
52% O
versus O
25% O
) O
and O
placing O
in O
the O
mouth O
( O
71% O
versus O
26% O
; O
P O
< O
0.02 O
for O
all O
, O
in O
the O
3 O
groups O
) O
. O

Being O
tired O
could O
be O
a O
strong O
trigger O
in O
37% O
of O
the O
patients O
, O
but O
" O
being O
aroused O
" O
in O
the O
other O
38 O
% O
of O
the O
patients O
. O

Stressful O
events O
( O
65% O
) O
, O
anxiety O
( O
74% O
) O
, O
" O
being O
under O
pressure O
" O
or O
irritated O
( O
51% O
and O
55% O
) O
were O
of O
course O
major O
triggers O
in O
a O
majority O
of O
the O
patients O
, O
as O
well O
as O
sadness O
( O
61% O
) O
, O
feeling O
of O
powerlessness O
( O
62% O
) O
, O
inefficiency O
( O
73% O
) O
and O
depressive O
state O
( O
71% O
) O
. O

Flashback O
from O
traumatism O
( O
sexual O
trauma O
in O
17% O
of O
the O
patients O
) O
was O
a O
strong O
trigger O
of O
binges O
more O
often O
in O
BPAN O
and O
BED O
( O
44% O
) O
than O
in O
BN O
( O
23% O
; O
P O
< O
0.05 O
) O
. O

The O
binge O
eating O
was O
painful O
( O
and O
" O
not O
at O
all O
a O
pleasure O
" O
) O
in O
69% O
of O
the O
patients O
, O
but O
could O
also O
be O
a O
relaxing O
behavior O
in O
31% O
of O
the O
patients O
, O
more O
often O
in O
the O
BED O
( O
43% O
) O
than O
in O
the O
BPAN O
patients O
( O
20% O
; O
P O
< O
0.05 O
) O
. O

The O
binge O
eating O
behavior O
was O
quoted O
as O
obsessive O
in O
63% O
of O
BPAN O
, O
92% O
of O
BN O
and O
only O
34% O
of O
BED O
patients O
( O
P O
< O
0.001 O
) O
. O

The O
patients O
said O
that O
they O
were O
unable O
to O
avoid O
the O
binge O
( O
76% O
of O
the O
patients O
) O
, O
more O
often O
in O
BPAN O
and O
BN O
than O
in O
BED O
patients O
( O
P O
< O
0.01 O
) O
. O

As O
a O
whole O
, O
62% O
of O
BPAN O
, O
89% O
of O
BN O
and O
only O
4 O
% O
of O
BED O
patients O
( O
P O
< O
0.05 O
) O
were O
unable O
to O
avoid O
purging O
( O
vomiting O
) O
. O

In O
12% O
of O
the O
cases O
, O
there O
was O
a O
pleasure O
felt O
when O
binging O
. O

For O
the O
other O
patients O
, O
shame O
, O
filth O
and O
incapacity O
were O
the O
feelings O
related O
to O
binges O
in O
58% O
of O
the O
BPAN O
, O
45% O
of O
BN O
and O
43% O
of O
BED O
patients O
( O
P O
< O
0.04 O
) O
. O

The O
global O
score O
of O
addiction O
( O
zero O
= O
not O
addicted O
, O
10 O
= O
very O
addicted O
) O
was O
8.56 O
+ O
1.2 O
in O
BPAN O
, O
8.42 O
+ O
1.5 O
in O
BN O
and O
6.74 O
+ O
1.1 O
in O
BED O
patients O
( O
NS O
between O
BPAN O
and O
BN O
; O
P O
< O
0.01 O
between O
BPAN O
and O
BN O
on O
the O
one O
hand O
and O
BED O
on O
the O
other O
) O
. O

Conclusion O
: O
The O
present O
study O
has O
demonstrated O
the O
usefulness O
of O
the O
Start O
questionnaire O
. O

It O
also O
evidences O
the O
key O
role O
of O
intrinsic O
factors O
, O
both O
metabolic O
and O
emotional O
, O
as O
strong O
triggers O
for O
binge O
eating O
episodes O
in O
BPAN O
, O
BN O
and O
BED O
. O

It O
has O
also O
demonstrated O
the O
role O
of O
environmental O
determinants O
. O

Catechin B-Drug/Scientific name
is O
an O
active O
ingredient O
of O
green B-Medicinal food
tea I-Medicinal food
. O

It O
is O
reported O
to O
inhibit O
corticosteroid-induced O
anxiety B-Symptom_WorkedFor
and O
depression-like B-Symptom_WorkedFor
symptoms O
. O

Considering O
the O
complex O
nature O
of O
depression O
, O
effects O
of O
catechin B-Drug/Scientific name
need O
to O
be O
studied O
in O
a O
clinically O
relevant O
depression O
model O
. O

The O
present O
study O
was O
designed O
to O
explore O
the O
antidepressant O
effect O
of O
catechin O
in O
Sprague O
Dawley O
rats O
subjected O
to O
chronic O
unpredictable O
mild O
stress O
( O
CUMS O
) O
. O

Animals O
were O
subjected O
to O
CUMS O
and O
treated O
with O
( O
+ O
) O
- O
catechin B-Drug/Scientific name
( O
50 O
mg O
/ O
kg O
) O
or O
escitalopram B-Other_ingredients
( O
10 O
mg O
/ O
kg O
) O
orally O
; O
a O
CUMS O
control O
and O
a O
vehicle O
control O
that O
was O
not O
exposed O
to O
CUMS O
were O
also O
established O
. O

Various O
stressors O
were O
applied O
daily O
in O
an O
unpredictable O
manner O
for O
8 O
weeks O
achieve O
CUMS O
. O

Sucrose O
preference O
test O
were O
performed O
after O
4 O
and O
8 O
weeks O
and O
forced O
swim O
tests O
( O
FSTs O
) O
were O
conducted O
at O
weeks O
4 O
, O
6 O
and O
8 O
. O

At O
the O
end O
of O
week O
8 O
, O
animals O
were O
sacrificed O
and O
the O
brain O
homogenate O
was O
studied O
for O
antioxidant O
parameters O
. O

Compared O
with O
the O
vehicle O
control O
, O
animals O
of O
the O
CUMS O
control O
group O
showed O
a O
significant O
decrease O
in O
sucrose O
intake O
. O

Catechin B-Drug/Scientific name
and O
escitalopram B-Other_ingredients
treatment O
significantly O
improved O
the O
sucrose O
intake O
compared O
with O
the O
CUMS O
control O
. O

A O
similar O
trend O
was O
observed O
in O
the O
FSTs O
, O
where O
catechin B-Drug/Scientific name
and O
escitalopram B-Other_ingredients
treatment O
significantly O
reduced O
the O
immobility O
time O
, O
and O
antioxidant O
parameters O
, O
including O
catalase O
, O
glutathione O
and O
superoxide O
dismutase O
levels O
were O
recovered O
in O
treated O
animals O
compared O
with O
the O
CUMS O
control O
. O

Thus O
, O
it O
was O
concluded O
that O
catechin B-Drug/Scientific name
reverses O
CUMS-induced O
depression O
in O
rats O
by O
ameliorating O
oxidative O
stress O
, O
which O
may O
help O
to O
develop O
a O
novel O
treatment O
for O
major O
depressive B-Symptom_WorkedFor
disorder I-Symptom_WorkedFor
. O

The O
green B-Medicinal food
tea I-Medicinal food
amino B-Drug/Scientific name
acid I-Drug/Scientific name
, O
L-theanine B-Drug/Scientific name
( O
L-THE B-Drug/Scientific name
) O
is O
associated O
with O
several O
health O
benefits O
, O
including O
improvements O
in O
mood O
, O
cognition O
and O
a O
reduction O
of O
stress O
and O
anxiety-like O
symptoms O
. O

This O
systematic O
review O
evaluated O
the O
effect O
of O
pure O
L-THE B-Drug/Scientific name
intake O
, O
in O
the O
form O
of O
orally O
administered O
nutritional O
supplements O
, O
on O
stress O
responses O
and O
anxiety O
levels O
in O
human O
randomised O
controlled O
trials O
. O

Following O
the O
Preferred O
Reporting O
Items O
for O
Systematic O
Reviews O
and O
Meta-Analyses O
( O
PRISMA O
) O
checklist O
, O
9 O
peer-reviewed O
journal O
articles O
were O
identified O
where O
L-THE B-Drug/Scientific name
as O
a O
supplement O
was O
compared O
to O
a O
control O
. O

Our O
findings O
suggest O
that O
supplementation O
of O
200 B-Dosage
- I-Dosage
400 I-Dosage
mg I-Dosage
/ I-Dosage
day I-Dosage
of O
L-THE B-Drug/Scientific name
may O
assist O
in O
the O
reduction O
of O
stress B-Symptom_WorkedFor
and O
anxiety B-Symptom_WorkedFor
in O
people O
exposed O
to O
stressful O
conditions O
. O

Despite O
this O
finding O
, O
longer-term O
and O
larger O
cohort O
clinical O
studies O
, O
including O
those O
where O
L-THE O
is O
incorporated O
into O
the O
diet O
regularly O
, O
are O
needed O
to O
clinically O
justify O
the O
use O
of O
L-THE B-Drug/Scientific name
as O
a O
therapeutic O
agent O
to O
reduce O
stress B-Symptom_WorkedFor
and O
anxiety B-Symptom_WorkedFor
in O
people O
exposed O
to O
stressful O
conditions O
. O

The O
aim O
of O
the O
study O
was O
to O
investigate O
opinions O
among O
Danish O
patients O
and O
physicians O
on O
causes O
of O
peptic B-Symptom_TestedFor
ulcer I-Symptom_TestedFor
disease I-Symptom_TestedFor
. O

Fifty-nine B-#Participants
patients O
with O
an O
ulcer B-participant_health
history O
and O
77 B-#Participants
physicians O
with O
a O
special O
interest O
in O
gastroenterology O
participated O
. O

They O
were O
given O
a O
questionnaire O
listing O
16 O
possible O
causes O
of O
peptic O
ulcer O
and O
indicated O
for O
each O
whether O
they O
believed O
it O
was O
a O
contributory O
cause O
of O
the O
disease O
. O

The O
patients O
stated O
0 O
- O
10 O
causes O
each O
( O
median O
, O
4 O
) O
, O
and O
the O
physicians O
3 O
- O
12 O
causes O
( O
median O
, O
6 O
) O
( O
p O
< O
0.01 O
) O
. O

Younger O
physicians O
stated O
more O
causes O
than O
did O
the O
older O
ones O
( O
p O
< O
0.01 O
) O
, O
and O
female O
physicians O
stated O
more O
causes O
than O
did O
their O
male O
colleagues O
( O
p O
< O
0.01 O
) O
. O

Seventy-five O
per O
cent O
of O
the O
patients O
indicated O
that O
psychologic O
factors O
, O
such O
as O
grief B-Symptom_TestedFor
, O
anxiety B-Symptom_TestedFor
, O
and O
stress B-Symptom_TestedFor
, O
were O
contributory O
causes O
of O
peptic B-Symptom_TestedFor
ulcer I-Symptom_TestedFor
disease I-Symptom_TestedFor
, O
whereas O
only O
around O
40% O
believed O
that O
coffee B-Medicinal food
/ I-Medicinal food
tea I-Medicinal food
, O
alcohol O
, O
smoking O
, O
side O
effects O
of O
medicine O
, O
and O
working O
conditions O
played O
a O
causal O
role O
. O

Around O
95% O
of O
the O
physicians O
indicated O
that O
medical O
drugs O
and O
smoking O
were O
contributory O
causes O
of O
peptic B-Symptom_TestedFor
ulcer I-Symptom_TestedFor
disease I-Symptom_TestedFor
, O
and O
around O
80% O
that O
alcohol O
and O
psychologic O
factors O
were O
so O
. O

Only O
30 O
- O
40% O
of O
the O
physicians O
believed O
that O
coffee B-Medicinal food
/ I-Medicinal food
tea I-Medicinal food
, O
food O
habits O
, O
infection O
, O
and O
working O
conditions O
could O
play O
a O
causal O
role O
in O
ulcer B-Symptom_TestedFor
disease I-Symptom_TestedFor
. O

It O
is O
concluded O
that O
the O
opinion O
on O
causal O
agents O
in O
peptic B-Symptom_TestedFor
ulcer I-Symptom_TestedFor
disease I-Symptom_TestedFor
differ O
considerably O
among O
both O
patients O
and O
physicians O
. O

Opinions O
on O
causes O
of O
diseases O
may O
influence O
the O
way O
we O
treat O
and O
advise O
our O
patients O
, O
and O
attempts O
should O
thus O
be O
made O
to O
unify O
our O
knowledge O
and O
interpretations O
of O
causes O
of O
diseases O
to O
reach O
more O
solid O
ground O
in O
counselling O
our O
patients O
. O

L-theanine B-Drug/Scientific name
( O
γ-glutamylethylamide B-Drug/Scientific name
) O
is O
an O
amino O
acid O
found O
primarily O
in O
the O
green B-Medicinal food
tea I-Medicinal food
plant O
. O

This O
study O
explored O
the O
effects O
of O
an O
L-theanine-based B-Medicinal food
nutrient O
drink O
on O
mood O
responses O
to O
a O
cognitive O
stressor O
. O

Additional O
measures O
included O
an O
assessment O
of O
cognitive O
performance O
and O
resting O
state O
alpha O
oscillatory O
activity O
using O
magnetoencephalography O
( O
MEG O
) O
. O

Thirty-four B-#Participants
healthy O
adults O
aged O
18 O
- O
40 O
participated O
in O
this O
double-blind O
, O
placebo-controlled O
, O
balanced O
crossover O
study O
. O

The O
primary O
outcome O
measure O
, O
subjective O
stress B-Symptom_WorkedFor
response O
to O
a O
multitasking O
cognitive O
stressor O
, O
was O
significantly O
reduced O
one O
hour O
after O
administration O
of O
the O
L-theanine B-Drug/Scientific name
drink O
when O
compared O
to O
placebo O
. O

The O
salivary O
cortisol O
response O
to O
the O
stressor O
was O
reduced O
three O
hours O
post-dose O
following O
active O
treatment O
. O

No O
treatment-related O
cognitive O
performance O
changes O
were O
observed O
. O

Resting O
state O
alpha O
oscillatory O
activity O
was O
significantly O
greater O
in O
posterior O
MEG O
sensors O
after O
active O
treatment O
compared O
to O
placebo O
two O
hours O
post-dose O
; O
however O
, O
this O
effect O
was O
only O
apparent O
for O
those O
higher O
in O
trait O
anxiety O
. O

This O
change O
in O
resting O
state O
alpha O
oscillatory O
activity O
was O
not O
correlated O
with O
the O
change O
in O
subjective O
stress B-Symptom_WorkedFor
response O
or O
the O
cortisol O
response O
, O
suggesting O
further O
research O
is O
required O
to O
assess O
the O
functional O
relevance O
of O
these O
treatment-related O
changes O
in O
resting O
alpha O
activity O
. O

These O
findings O
further O
support O
the O
anti-stress B-Symptom_WorkedFor
effects O
of O
L-theanine B-Drug/Scientific name
. O

The O
model O
of O
accelerated O
senescence O
with O
the O
prolonged O
administration O
of O
d-galactose B-Other_ingredients
is O
used O
in O
anti-aging B-Symptom_TestedFor
studies O
because O
it O
mimics O
several O
aging-associated O
alterations O
such O
as O
increase O
of O
oxidative O
stress O
and O
decline O
of O
cognition O
. O

However O
, O
there O
is O
no O
standardized O
protocol O
for O
this O
aging O
model O
, O
and O
recently O
some O
reports O
have O
questioned O
its O
effectiveness O
. O

To O
clarify O
this O
issue O
, O
we O
used O
a O
model O
of O
high-dose O
d-galactose B-Other_ingredients
on O
1 O
- O
month-old O
male O
Wistar O
rats O
and O
studied O
the O
hippocampus O
, O
one O
of O
the O
most O
affected O
brain O
regions O
. O

In O
one O
group O
( O
n O
= O
10 O
) O
, O
d-galactose B-Other_ingredients
was O
daily O
administered O
intraperitoneally O
( O
300 O
mg O
/ O
kg O
) O
during O
8 O
weeks O
whereas O
age-matched O
controls O
( O
n O
= O
10 O
) O
were O
injected O
intraperitoneally O
with O
saline O
. O

A O
third O
group O
( O
n O
= O
10 O
) O
was O
treated O
with O
the O
same O
dose O
of O
d-galactose B-Other_ingredients
and O
with O
oral O
epigallocatechin B-Drug/Scientific name
- I-Drug/Scientific name
3 I-Drug/Scientific name
- I-Drug/Scientific name
gallate I-Drug/Scientific name
( O
EGCG O
) O
( O
2 O
grams O
/ O
L O
) O
, O
a O
green B-Medicinal food
tea I-Medicinal food
catechin B-Drug/Scientific name
with O
anti-oxidant O
and O
neuroprotective O
properties O
. O

After O
treatments O
, O
animals O
were O
submitted O
to O
open-field O
, O
elevated O
plus-maze O
and O
Morris O
water O
maze O
tests O
, O
and O
neurogenesis O
in O
the O
dentate O
gyrus O
subgranular O
layer O
was O
quantified O
. O

There O
were O
no O
significant O
alterations O
when O
the O
three O
groups O
were O
compared O
in O
the O
number O
of O
doublecortin O
- O
and O
Ki O
- O
67 O
- O
immunoreactive O
cells O
, O
and O
also O
on O
anxiety O
levels O
, O
spatial O
learning O
, O
and O
memory O
. O

Therefore O
, O
d-galactose B-Other_ingredients
was O
not O
effective O
in O
the O
induction O
of O
accelerated O
aging B-Symptom_TestedFor
, O
and O
EGCG O
administered O
to O
d-galactose-treated B-Other_ingredients
animals O
did O
not O
improve O
behavior O
and O
had O
no O
effects O
on O
neurogenesis B-Symptom_TestedFor
. O

We O
conclude O
that O
daily O
300 O
mg O
/ O
kg O
of O
d-galactose B-Other_ingredients
administered O
intraperitoneally O
may O
not O
be O
a O
suitable O
model O
for O
inducing O
age-related O
neurobehavioral O
alterations O
in O
young O
male O
Wistar O
rats O
. O

More O
studies O
are O
necessary O
to O
obtain O
a O
reliable O
and O
reproducible O
model O
of O
accelerated O
senescence O
in O
rodents O
using O
d-galactose B-Other_ingredients
. O

Purpose O
of O
review O
: O
We O
review O
the O
influence O
of O
nutrition O
and O
lifestyle O
on O
bladder B-Symptom_TestedFor
cancer I-Symptom_TestedFor
incidence O
and O
recurrence O
and O
summarize O
food O
items O
, O
diets O
and O
lifestyle O
practices O
that O
physicians O
may O
wish O
to O
prioritize O
for O
discussion O
with O
their O
patients O
. O

Recent O
findings O
: O
Recent O
study O
results O
suggest O
an O
association O
between O
bladder B-Symptom_TestedFor
cancer I-Symptom_TestedFor
incidence O
and O
several O
food O
items O
including O
meat B-Medicinal food
, O
fruit B-Medicinal food
, O
vegetables B-Medicinal food
, O
milk B-Medicinal food
products I-Medicinal food
and O
oil B-Medicinal food
. O

Micronutrient O
deficiency O
is O
associated O
with O
bladder B-Symptom_TestedFor
cancer I-Symptom_TestedFor
risk O
; O
however O
, O
it O
remains O
unclear O
if O
micronutrient O
supplementation O
can O
modify O
bladder B-Symptom_TestedFor
cancer I-Symptom_TestedFor
incidence O
. O

Furthermore O
, O
total O
fluid O
intake O
, O
alcohol O
, O
coffee B-Medicinal food
and O
tea B-Medicinal food
seem O
to O
have O
no O
influence O
on O
bladder O
cancer O
incidence O
. O

There O
is O
weak O
evidence O
that O
stress B-Symptom_TestedFor
, O
anxiety B-Symptom_TestedFor
and O
lack O
of O
sleep B-Symptom_TestedFor
may O
increase O
the O
risk O
of O
developing O
bladder B-Symptom_TestedFor
cancer I-Symptom_TestedFor
, O
whereas O
exercise O
may O
reduce O
the O
risk O
of O
dying O
from O
it O
. O

Summary O
: O
Several O
dietary O
items O
and O
life O
styles O
are O
associated O
with O
bladder B-Symptom_TestedFor
cancer I-Symptom_TestedFor
incidence O
and O
recurrence O
. O

However O
, O
besides O
smoking O
cessation O
, O
there O
is O
no O
evidence O
that O
a O
certain O
diet O
or O
lifestyle O
can O
decrease O
bladder B-Symptom_TestedFor
cancer I-Symptom_TestedFor
incidence O
. O

The O
computer-controlled O
local O
anesthesia O
system O
and O
the O
TEA O
system O
present O
21st-century O
alternatives O
to O
the O
traditional O
syringe O
. O

The O
TEA O
system O
is O
a O
non-invasive O
form O
of O
anesthesia O
that O
blocks O
pain O
electronically O
, O
using O
the O
same O
cellular O
mechanism O
as O
local O
chemical O
anesthesia O
. O

Targeted O
electronic O
anesthesia O
provides O
pain O
control O
for O
restorative O
dental O
procedures O
without O
the O
use O
of O
needles O
or O
postoperative O
discomfort O
, O
numbness O
, O
and O
swelling O
. O

The O
computer-assisted O
system O
outperforms O
syringes O
for O
traditional O
injections O
. O

This O
new O
system O
generates O
a O
precisely O
controlled O
anesthetic O
flow O
rate O
that O
eliminates O
the O
need O
for O
the O
operator O
to O
use O
thumb O
pressure O
to O
administer O
the O
injection O
. O

The O
lightweight O
pen-grasp O
handle O
results O
in O
greater O
tactile O
feedback O
, O
precision O
, O
operator O
ease O
, O
and O
patient O
comfort O
. O

The O
greatest O
advantage O
may O
be O
in O
the O
new O
techniques O
that O
it O
makes O
available O
. O

With O
these O
techniques O
, O
a O
dentist O
can O
target O
the O
teeth O
to O
achieve O
profound O
pulpal O
anesthesia O
, O
often O
without O
the O
annoying O
side O
effects O
of O
facial O
numbness O
. O

With O
this O
new O
advanced O
system O
in O
the O
maxillary O
arch O
, O
the O
AMSA O
injection O
offers O
clinical O
advantages O
over O
traditional O
anesthesia O
techniques O
, O
according O
to O
Dr O
. O

Mark O
Friedman O
, O
whom O
I O
consulted O
with O
earlier O
this O
year O
. O

In O
the O
mandibular O
arch O
, O
a O
safe O
and O
predictable O
PDL O
injection O
technique O
may O
replace O
the O
need O
for O
an O
inferior O
alveolar O
block O
in O
numerous O
clinical O
situations O
. O

The O
use O
of O
these O
modified O
injection O
techniques O
can O
have O
a O
positive O
influence O
on O
patient O
safety O
, O
patient O
comfort O
, O
and O
office O
productivity O
. O

Both O
of O
these O
systems O
take O
the O
fear O
and O
anxiety O
out O
of O
dental O
injections O
. O

They O
offer O
exciting O
advanced O
technology O
for O
local O
pain O
control O
. O

Significantly O
, O
if O
patient O
stress O
and O
anxiety O
are O
reduced O
, O
the O
operator O
immediately O
benefits O
. O

New O
horizons O
in O
local O
anesthesia O
offer O
improved O
opportunities O
for O
patient O
comfort O
using O
computer-controlled O
local O
anesthetic O
systems O
and O
TEA O
. O

Theanine B-Drug/Scientific name
is O
an O
analog O
of O
glutamate O
and O
the O
major O
aminoacid O
in O
green B-Medicinal food
tea I-Medicinal food
. O

It O
has O
received O
growing O
attention O
in O
recent O
years O
because O
of O
its O
beneficial O
effects O
on O
the O
central O
nervous O
system O
. O

Theanine B-Drug/Scientific name
was O
shown O
to O
increase O
levels O
of O
brain-derived O
neurotrophic O
factor O
and O
to O
stimulate O
neurogenesis B-Symptom_WorkedFor
. O

Anti-stress B-Symptom_WorkedFor
and O
calming B-Symptom_WorkedFor
effects O
of O
theanine B-Drug/Scientific name
are O
the O
most O
apparent O
and O
well-studied O
. O

A O
number O
of O
studies O
showed O
neuroprotective O
effects O
of O
theanine B-Drug/Scientific name
after O
an O
ischemic O
cerebral O
injury O
or O
the O
exposure O
to O
toxic O
chemicals O
. O

It O
also O
improved O
cognitive O
function O
including O
attention O
, O
memory O
and O
learning O
. O

Recent O
studies O
demonstrated O
a O
promising O
role O
of O
theanine B-Drug/Scientific name
in O
augmentation O
therapy O
for O
major B-Symptom_WorkedFor
depressive I-Symptom_WorkedFor
disorder I-Symptom_WorkedFor
and O
schizophrenia B-Symptom_WorkedFor
. O

Theoretical O
grounds O
for O
using O
theanine B-Drug/Scientific name
in O
treatment O
of O
bipolar B-Symptom_WorkedFor
disorder I-Symptom_WorkedFor
, O
anxiety B-Symptom_WorkedFor
disorder I-Symptom_WorkedFor
and O
some O
neurodegenerative B-Symptom_WorkedFor
disorders I-Symptom_WorkedFor
are O
discussed O
. O

P001 O
- O
Sepsis O
impairs O
the O
capillary O
response O
within O
hypoxic O
capillaries O
and O
decreases O
erythrocyte O
oxygen-dependent O
ATP O
efflux O
R O
. O

M O
. O

Bateman O
, O
M O
. O

D O
. O

Sharpe O
, O
J O
. O

E O
. O

Jagger O
, O
C O
. O

G O
. O

Ellis O
P002 O
- O
Lower O
serum O
immunoglobulin O
G2 O
level O
does O
not O
predispose O
to O
severe O
flu O
. O

J O
. O

Solé-Violán O
, O
M O
. O

López-Rodríguez O
, O
E O
. O

Herrera-Ramos O
, O
J O
. O

Ruíz-Hernández O
, O
L O
. O

Borderías O
, O
J O
. O

Horcajada O
, O
N O
. O

González-Quevedo O
, O
O O
. O

Rajas O
, O
M O
. O

Briones O
, O
F O
. O

Rodríguez O
de O
Castro O
, O
C O
. O

Rodríguez O
Gallego O
P003 O
- O
Brain O
protective O
effects O
of O
intravenous O
immunoglobulin O
through O
inhibition O
of O
complement O
activation O
and O
apoptosis O
in O
a O
rat O
model O
of O
sepsis O
F O
. O

Esen O
, O
G O
. O

Orhun O
, O
P O
. O

Ergin O
Ozcan O
, O
E O
. O

Senturk O
, O
C O
. O

Ugur O
Yilmaz O
, O
N O
. O

Orhan O
, O
N O
. O

Arican O
, O
M O
. O

Kaya O
, O
M O
. O

Kucukerden O
, O
M O
. O

Giris O
, O
U O
. O

Akcan O
, O
S O
. O

Bilgic O
Gazioglu O
, O
E O
. O

Tuzun O
P004 O
- O
Adenosine O
a1 O
receptor O
dysfunction O
is O
associated O
with O
leukopenia O
: O
A O
possible O
mechanism O
for O
sepsis-induced O
leukopenia O
R O
. O

Riff O
, O
O O
. O

Naamani O
, O
A O
. O

Douvdevani O
P005 O
- O
Analysis O
of O
neutrophil O
by O
hyper O
spectral O
imaging O
- O
A O
preliminary O
report O
R O
. O

Takegawa O
, O
H O
. O

Yoshida O
, O
T O
. O

Hirose O
, O
N O
. O

Yamamoto O
, O
H O
. O

Hagiya O
, O
M O
. O

Ojima O
, O
Y O
. O

Akeda O
, O
O O
. O

Tasaki O
, O
K O
. O

Tomono O
, O
T O
. O

Shimazu O
P006 O
- O
Chemiluminescent O
intensity O
assessed O
by O
eaa O
predicts O
the O
incidence O
of O
postoperative O
infectious O
complications O
following O
gastrointestinal O
surgery O
S O
. O

Ono O
, O
T O
. O

Kubo O
, O
S O
. O

Suda O
, O
T O
. O

Ueno O
, O
T O
. O

Ikeda O
P007 O
- O
Serial O
change O
of O
c1 O
inhibitor O
in O
patients O
with O
sepsis O
– O
A O
prospective O
observational O
study O
T O
. O

Hirose O
, O
H O
. O

Ogura O
, O
H O
. O

Takahashi O
, O
M O
. O

Ojima O
, O
J O
. O

Kang O
, O
Y O
. O

Nakamura O
, O
T O
. O

Kojima O
, O
T O
. O

Shimazu O
P008 O
- O
Comparison O
of O
bacteremia O
and O
sepsis O
on O
sepsis O
related O
biomarkers O
T O
. O

Ikeda O
, O
S O
. O

Suda O
, O
Y O
. O

Izutani O
, O
T O
. O

Ueno O
, O
S O
. O

Ono O
P009 O
- O
The O
changes O
of O
procalcitonin O
levels O
in O
critical O
patients O
with O
abdominal O
septic O
shock O
during O
blood O
purification O
T O
. O

Taniguchi O
, O
M O
. O

O O
P010 O
- O
Validation O
of O
a O
new O
sensitive O
point O
of O
care O
device O
for O
rapid O
measurement O
of O
procalcitonin O
C O
. O

Dinter O
, O
J O
. O

Lotz O
, O
B O
. O

Eilers O
, O
C O
. O

Wissmann O
, O
R O
. O

Lott O
P011 O
- O
Infection O
biomarkers O
in O
primary O
care O
patients O
with O
acute O
respiratory O
tract O
infections O
– O
Comparison O
of O
procalcitonin O
and O
C-reactive O
protein O
M O
. O

M O
. O

Meili O
, O
P O
. O

S O
. O

Schuetz O
P012 O
- O
Do O
we O
need O
a O
lower O
procalcitonin O
cut O
off O
? O

H O
. O

Hawa O
, O
M O
. O

Sharshir O
, O
M O
. O

Aburageila O
, O
N O
. O

Salahuddin O
P013 O
- O
The O
predictive O
role O
of O
C-reactive O
protein O
and O
procalcitonin O
biomarkers O
in O
central O
nervous O
system O
infections O
with O
extensively O
drug O
resistant O
bacteria O
V O
. O

Chantziara O
, O
S O
. O

Georgiou O
, O
A O
. O

Tsimogianni O
, O
P O
. O

Alexandropoulos O
, O
A O
. O

Vassi O
, O
F O
. O

Lagiou O
, O
M O
. O

Valta O
, O
G O
. O

Micha O
, O
E O
. O

Chinou O
, O
G O
. O

Michaloudis O
P014 O
- O
Changes O
in O
endotoxin O
activity O
assay O
and O
procalcitonin O
levels O
after O
direct O
hemoperfusion O
with O
polymyxin-b O
immobilized O
fiber O
A O
. O

Kodaira O
, O
T O
. O

Ikeda O
, O
S O
. O

Ono O
, O
T O
. O

Ueno O
, O
S O
. O

Suda O
, O
Y O
. O

Izutani O
, O
H O
. O

Imaizumi O
P015 O
- O
Diagnostic O
usefullness O
of O
combination O
biomarkers O
on O
ICU O
admission O
M O
. O

V O
. O

De O
la O
Torre-Prados O
, O
A O
. O

Garcia-De O
la O
Torre O
, O
A O
. O

Enguix-Armada O
, O
A O
. O

Puerto-Morlan O
, O
V O
. O

Perez-Valero O
, O
A O
. O

Garcia-Alcantara O
P016 O
- O
Platelet O
function O
analysis O
utilising O
the O
PFA O
- O
100 O
does O
not O
predict O
infection O
, O
bacteraemia O
, O
sepsis O
or O
outcome O
in O
critically O
ill O
patients O
N O
. O

Bolton O
, O
J O
. O

Dudziak O
, O
S O
. O

Bonney O
, O
A O
. O

Tridente O
, O
P O
. O

Nee O
P017 O
- O
Extracellular O
histone O
H3 O
levels O
are O
inversely O
correlated O
with O
antithrombin O
levels O
and O
platelet O
counts O
and O
are O
associated O
with O
mortality O
in O
sepsis O
patients O
G O
. O

Nicolaes O
, O
M O
. O

Wiewel O
, O
M O
. O

Schultz O
, O
K O
. O

Wildhagen O
, O
J O
. O

Horn O
, O
R O
. O

Schrijver O
, O
T O
. O

Van O
der O
Poll O
, O
C O
. O

Reutelingsperger O
P018 O
- O
Il O
- O
8 O
: O
is O
this O
a O
more O
reliable O
biomarker O
for O
sepsis O
severity O
than O
CRP O
, O
Procalcitonin O
, O
E-selectin O
, O
IL O
- O
6 O
and O
TNF O
- O
[ O
alpha O
] O
S O
. O

Pillai O
, O
G O
. O

Davies O
, O
G O
. O

Mills O
, O
R O
. O

Aubrey O
, O
K O
. O

Morris O
, O
P O
. O

Williams O
, O
P O
. O

Evans O
P019 O
- O
Relation O
between O
adrenomedullin O
and O
short-term O
outcome O
in O
ICU O
patients O
: O
Results O
from O
the O
frog O
ICU O
study O
E O
. O

G O
. O

Gayat O
, O
J O
. O

Struck O
, O
A O
. O

Cariou O
, O
N O
. O

Deye O
, O
B O
. O

Guidet O
, O
S O
. O

Jabert O
, O
J O
. O

Launay O
, O
M O
. O

Legrand O
, O
M O
. O

Léone O
, O
M O
. O

Resche-Rigon O
, O
E O
. O

Vicaut O
, O
A O
. O

Vieillard-Baron O
, O
A O
. O

Mebazaa O
P020 O
- O
Impact O
of O
disease O
severity O
assessment O
on O
performance O
of O
heparin-binding O
protein O
for O
the O
prediction O
of O
septic O
shock O
R O
. O

Arnold O
, O
M O
. O

Capan O
, O
A O
. O

Linder O
, O
P O
. O

Akesson O
P021 O
- O
Kinetics O
and O
prognostic O
value O
of O
presepsin O
( O
sCD14 O
) O
in O
septic O
patients O
. O

A O
pilot O
study O
M O
. O

Popescu O
, O
D O
. O

Tomescu O
P022 O
- O
Comparison O
of O
CD64 O
levels O
performed O
by O
the O
facs O
and O
accellix O
systems O
C O
. O

L O
. O

Sprung O
, O
R O
. O

Calderon O
Morales O
, O
G O
. O

Munteanu O
, O
E O
. O

Orenbuch-Harroch O
, O
P O
. O

Levin O
, O
H O
. O

Kasdan O
, O
A O
. O

Reiter O
, O
T O
. O

Volker O
, O
Y O
. O

Himmel O
, O
Y O
. O

Cohen O
, O
J O
. O

Meissonnier O
P023 O
- O
Diagnosing O
sepsis O
in O
5 O
minutes O
: O
Nanofluidic O
technology O
study O
with O
pancreatic-stone O
protein O
( O
PSP O
/ O
reg O
) O
L O
. O

Girard O
, O
F O
. O

Rebeaud O
P024 O
- O
How O
nanotechnology-based O
approaches O
could O
contribute O
to O
sepsis O
prevention O
, O
diagnosis O
and O
treatment O
I O
. O

Herrmann O
P025 O
- O
Il7r O
transcriptional O
expression O
analysis O
during O
septic O
shock O
B O
. O

Delwarde O
, O
E O
. O

Peronnet O
, O
E O
. O

Cerrato O
, O
F O
. O

Venet O
, O
A O
. O

Lepape O
, O
T O
. O

Rimmelé O
, O
G O
. O

Monneret O
, O
J O
. O

Textoris O
P026 O
- O
Disbalance O
of O
microbial O
metabolites O
of O
aromatic O
acids O
affects O
the O
severity O
in O
critically O
ill O
patients O
N O
. O

Beloborodova O
, O
V O
. O

Moroz O
, O
A O
. O

Osipov O
, O
A O
. O

Bedova O
, O
Y O
. O

Sarshor O
, O
A O
. O

Pautova O
, O
A O
. O

Sergeev O
, O
E O
. O

Chernevskaya O
P027 O
- O
Copeptin O
predicts O
10 O
- O
year O
all-cause O
mortality O
in O
community O
patients O
J O
. O

Odermatt O
, O
R O
. O

Bolliger O
, O
L O
. O

Hersberger O
, O
M O
. O

Ottiger O
, O
M O
. O

Christ-Crain O
, O
B O
. O

Mueller O
, O
P O
. O

Schuetz O
P028 O
- O
Identification O
of O
differential O
proteomic O
response O
in O
septic O
patients O
secondary O
to O
community O
and O
hospital O
acquired O
pneumonia O
N O
. O

K O
. O

Sharma O
, O
A O
. O

K O
. O

Tashima O
, O
M O
. O

K O
. O

Brunialti O
, O
F O
. O

R O
. O

Machado O
, O
M O
. O

Assuncao O
, O
O O
. O

Rigato O
, O
R O
. O

Salomao O
P029 O
- O
Monocyte O
HLA-DR O
expression O
in O
community-acquired O
bacteremic O
sepsis O
- O
dynamics O
associated O
to O
aetiology O
and O
prediction O
of O
secondary O
sepsis O
S O
. O

C O
. O

Cajander O
, O
G O
. O

Rasmussen O
, O
E O
. O

Tina O
, O
B O
. O

Söderquist O
, O
J O
. O

Källman O
, O
K O
. O

Strålin O
P030 O
- O
Soluble O
B O
- O
and O
T-lymphocyte O
attenuator O
: O
A O
possible O
prognostic O
marker O
in O
sepsis O
A O
. O

L O
. O

Lange O
, O
J O
. O

S O
. O

Sundén-Cullberg O
, O
A O
. O

M O
. O

Magnuson O
, O
O O
. O

H O
. O

Hultgren O
P031 O
- O
Fractal O
dimension O
: O
A O
new O
biomarker O
for O
quantifying O
clot O
microstructure O
in O
patients O
across O
the O
sepsis O
spectrum O
G O
. O

Davies O
, O
S O
. O

Pillai O
, O
G O
. O

Mills O
, O
R O
. O

Aubrey O
, O
K O
. O

Morris O
, O
P O
. O

Williams O
, O
P O
. O

Evans O
P032 O
- O
Comparison O
between O
the O
new O
biomarker O
for O
coagulation O
, O
clot O
microstructure O
( O
Df O
) O
with O
rotational O
thromboelastometry O
( O
ROTEM O
) O
in O
patients O
across O
the O
sepsis O
spectrum O
S O
. O

Pillai O
, O
G O
. O

Davies O
, O
G O
. O

Mills O
, O
R O
. O

Aubrey O
, O
K O
. O

Morris O
, O
P O
. O

Williams O
, O
P O
. O

Evans O
P033 O
- O
Changes O
in O
fibrinolysis O
across O
the O
sepsis O
spectrum O
: O
The O
use O
of O
rotational O
thromboelastometry O
( O
ROTEM O
) O
lysis O
index O
( O
LI60 O
) O
and O
D-Dimer O
concentration O
S O
. O

Pillai O
, O
G O
. O

Davies O
, O
G O
. O

Mills O
, O
R O
. O

Aubrey O
, O
K O
. O

Morris O
, O
P O
. O

Williams O
, O
P O
. O

Evans O
P034 O
- O
The O
intensive O
care O
infection O
score O
– O
a O
promising O
marker O
for O
the O
prediction O
of O
infection O
and O
its O
severity O
. O

P O
. O

Van O
der O
Geest O
, O
M O
. O

Mohseni O
, O
J O
. O

Linssen O
, O
R O
. O

De O
Jonge O
, O
S O
. O

Duran O
, O
J O
. O

Groeneveld O
P035 O
- O
Challenges O
in O
the O
clinical O
diagnosis O
of O
sepsis O
R O
. O

Miller O
III O
, O
B O
. O

K O
. O

Lopansri O
, O
L O
. O

C O
. O

McHugh O
, O
A O
. O

Seldon O
, O
J O
. O

P O
. O

Burke O
P036 O
- O
Does O
zero O
heat O
flux O
thermometry O
more O
accurately O
identify O
sepsis O
on O
intensive O
care O
? O

J O
. O

Johnston O
, O
R O
. O

Reece-Anthony O
, O
A O
. O

Bond O
, O
A O
. O

Molokhia O
P037 O
- O
Advancing O
quality O
( O
AQ O
) O
sepsis O
programme O
: O
Improving O
early O
identification O
& O
treatment O
of O
sepsis O
in O
North O
West O
England O
. O

C O
. O

Mcgrath O
, O
E O
. O

Nsutebu O
P038 O
- O
Prehospital O
transport O
of O
acute O
septic O
patients O
P O
. O

Bank O
Pedersen O
, O
D O
. O

Pilsgaard O
Henriksen O
, O
S O
. O

Mikkelsen O
, O
A O
. O

Touborg O
Lassen O
P039 O
- O
Vasodilatory O
plant O
extracts O
gel O
as O
an O
alternative O
treatment O
for O
fever O
in O
critically O
ill O
patients O
R O
. O

Tincu O
, O
C O
. O

Cobilinschi O
, O
D O
. O

Tomescu O
, O
Z O
. O

Ghiorghiu O
, O
R O
. O

Macovei O
P040 O
- O
Host O
response O
and O
outcome O
of O
hypothermic O
sepsis O
M O
. O

A O
. O

Wiewel O
, O
M O
. O

B O
. O

Harmon O
, O
L O
. O

A O
. O

Van O
Vught O
, O
B O
. O

P O
. O

Scicluna O
, O
A O
. O

J O
. O

Hoogendijk O
, O
J O
. O

Horn O
, O
A O
. O

H O
. O

Zwinderman O
, O
O O
. O

L O
. O

Cremer O
, O
M O
. O

J O
. O

Bonten O
, O
M O
. O

J O
. O

Schultz O
, O
T O
. O

Van O
der O
Poll O
, O
N O
. O

P O
. O

Juffermans O
, O
W O
. O

J O
. O

Wiersinga O
P041 O
- O
Septic O
shock O
alert O
over O
SIRS O
criteria O
has O
an O
impact O
on O
outcome O
but O
needs O
to O
be O
revised O
G O
. O

Eren O
, O
Y O
Tekdos O
, O
M O
. O

Dogan O
, O
O O
. O

Acicbe O
, O
E O
. O

Kaya O
, O
O O
. O

Hergunsel O
P042 O
- O
Association O
between O
previous O
prescription O
of O
βblockers O
and O
mortality O
rate O
among O
septic O
patients O
: O
A O
retrospective O
observational O
study O
S O
. O

Alsolamy O
, O
G O
. O

Ghamdi O
, O
L O
. O

Alswaidan O
, O
S O
. O

Alharbi O
, O
F O
. O

Alenezi O
, O
Y O
. O

Arabi O
P043 O
- O
Recognition O
and O
treatment O
of O
sepsis O
on O
labour O
ward O
– O
teaching O
& O
information O
resources O
can O
improve O
knowledge O
J O
. O

Heaton O
, O
A O
. O

Boyce O
, O
L O
. O

Nolan O
, O
J O
. O

Johnston O
, O
A O
. O

Dukoff-Gordon O
, O
A O
. O

Dean O
, O
A O
. O

Molokhia O
P044 O
- O
Culture O
negative O
sepsis O
in O
the O
ICU O
– O
what O
is O
unique O
to O
this O
patient O
population O
? O

T O
. O

Mann O
Ben O
Yehudah O
P045 O
- O
Organ O
dysfunction O
in O
severe O
sepsis O
patients O
identified O
in O
administrative O
data O
in O
Germany O
, O
2007 O
- O
2013 O
C O
. O

Fleischmann O
, O
D O
. O

Thomas-Rueddel O
, O
C O
. O

Haas O
, O
U O
. O

Dennler O
, O
K O
. O

Reinhart O
P046 O
- O
A O
comparison O
of O
residents O
’ O
knowledge O
regarding O
; O
the O
Surviving O
Sepsis O
Campaign O
2012 O
guideline O
O O
. O

Suntornlohanakul O
, O
B O
. O

Khwannimit O
P047 O
- O
Effectiveness O
of O
a O
septic O
shock O
bundle O
to O
improve O
outcomes O
in O
the O
ICU O
F O
. O

Breckenridge O
, O
A O
. O

Puxty O
P048 O
- O
Dose O
of O
norepinephrine O
in O
the O
first O
24 O
hours O
as O
a O
parameter O
evaluating O
the O
effectiveness O
of O
treatment O
in O
patients O
with O
severe O
sepsis O
and O
septic O
shock O
P O
. O

Szturz O
, O
P O
. O

Folwarzcny O
, O
J O
. O

Svancara O
, O
R O
. O

Kula O
, O
P O
. O

Sevcik O
P049 O
- O
Norepinephrine O
or O
vasopressin O
+ O
norepinephrine O
in O
septic O
shock O
. O

A O
retrospective O
series O
of O
39 O
patients O
L O
. O

Caneva O
, O
A O
. O

Casazza O
, O
E O
. O

Bellazzi O
, O
S O
. O

Marra O
, O
L O
. O

Pagani O
, O
M O
. O

Vetere O
, O
R O
. O

Vanzino O
, O
D O
. O

Ciprandi O
, O
R O
. O

Preda O
, O
R O
. O

Boschi O
, O
L O
. O

Carnevale O
P050 O
- O
Methylene O
blue O
effectiveness O
as O
contributory O
treatment O
in O
patients O
with O
septic O
shock O
V O
. O

Lopez O
, O
M O
. O

Aguilar O
Arzapalo O
, O
L O
. O

Barradas O
, O
A O
. O

Escalante O
, O
J O
. O

Gongora O
, O
M O
. O

Cetina O
P051 O
- O
Coagulation O
disorders O
in O
patients O
with O
severe O
sepsis O
and O
DIC O
evaluated O
with O
thromboelastometry O
. O

B O
Adamik O
, O
D O
Jakubczyk O
, O
A O
Kübler O
P052 O
- O
Frequency O
and O
outcome O
of O
early O
sepsis-associated O
coagulopathy O
A O
. O

Radford O
, O
T O
. O

Lee O
, O
J O
. O

Singer O
, O
J O
. O

Boyd O
, O
D O
. O

Fineberg O
, O
M O
. O

Williams O
, O
J O
. O

Russell O
P053 O
- O
Assessment O
of O
coagulopathy O
in O
cancer O
patients O
with O
severe O
sepsis O
or O
septic O
shock O
. O

A O
case-control O
pilot O
study O
E O
. O

Scarlatescu O
, O
D O
. O

Tomescu O
, O
G O
. O

Droc O
, O
S O
. O

Arama O
P054 O
- O
Thromboelastometry O
in O
critically O
ill O
patients O
with O
disseminated O
intravascular O
coagulation O
M O
. O

Müller O
, O
M O
. O

Straat O
, O
S O
. O

S O
. O

Zeerleder O
, O
N O
. O

P O
. O

Juffermans O
P055 O
- O
Cessation O
of O
a O
preexisting O
chronic O
antiplatelet O
therapy O
is O
associated O
with O
increased O
mortality O
rates O
in O
severe O
sepsis O
and O
septic O
shock O
C O
. O

F O
. O

Fuchs O
, O
C O
. O

S O
. O

Scheer O
, O
S O
. O

W O
. O

Wauschkuhn O
, O
M O
. O

V O
. O

Vollmer O
, O
K O
. O

M O
. O

Meissner O
, O
S O
. O

K O
. O

Kuhn O
, O
K O
. O

H O
. O

Hahnenkamp O
, O
S O
. O

R O
. O

Rehberg O
, O
M O
. O

G O
. O

Gründling O
P056 O
- O
Neutrophil O
Extracellular O
Traps O
( O
NETs O
) O
production O
under O
hypoxic O
condition O
N O
. O

Yamamoto O
, O
M O
. O

Ojima O
, O
S O
. O

Hamaguchi O
, O
T O
. O

Hirose O
, O
Y O
. O

Akeda O
, O
R O
. O

Takegawa O
, O
O O
. O

Tasaki O
, O
T O
. O

Shimazu O
, O
K O
. O

Tomono O
P057 O
- O
Impact O
of O
ultraviolet O
air O
sterilizer O
in O
intensive O
care O
unit O
room O
, O
and O
clinical O
outcomes O
of O
patients O
E O
. O

Gómez-Sánchez O
, O
M O
. O

Heredia-Rodríguez O
, O
E O
. O

Álvarez-Fuente O
, O
M O
. O

Lorenzo-López O
, O
E O
. O

Gómez-Pesquera O
, O
M O
. O

Aragón-Camino O
, O
P O
. O

Liu-Zhu O
, O
A O
. O

Sánchez-López O
, O
A O
. O

Hernández-Lozano O
, O
M O
. O

T O
. O

Peláez-Jareño O
, O
E O
. O

Tamayo O
P058 O
- O
Focus O
of O
infection O
in O
severe O
sepsis O
- O
comparison O
of O
administrative O
data O
and O
prospective O
cohorts O
from O
Germany O
D O
. O

O O
. O

Thomas-Rüddel O
, O
C O
. O

Fleischmann O
, O
C O
. O

Haas O
, O
U O
. O

Dennler O
, O
K O
. O

Reinhart O
P059 O
- O
“ O
Zero O
CLABSI O
” O
– O
can O
we O
get O
there O
? O

Obstacles O
on O
the O
4 O
year O
journey O
and O
our O
strategies O
to O
overcome O
them O
– O
experience O
from O
an O
Indian O
ICU O
V O
. O

Adora O
, O
A O
. O

Kar O
, O
A O
. O

Chakraborty O
, O
S O
. O

Roy O
, O
A O
. O

Bandyopadhyay O
, O
M O
. O

Das O
P060 O
- O
Novel O
molecular O
techniques O
to O
identify O
central O
venous O
catheter O
( O
CVC O
) O
associated O
blood O
stream O
infections O
( O
BSIs O
) O
T O
. O

Mann O
Ben O
Yehudah O
, O
G O
. O

Ben O
Yehudah O
, O
M O
. O

Salim O
, O
N O
. O

Kumar O
, O
L O
. O

Arabi O
, O
T O
. O

Burger O
, O
P O
. O

Lephart O
, O
E O
. O

Toth-martin O
P061 O
- O
Zero O
clabsi O
” O
– O
can O
we O
get O
there O
? O

Obstacles O
on O
the O
4 O
year O
journey O
and O
our O
strategies O
to O
overcome O
them O
– O
experience O
from O
an O
Indian O
ICU O
R O
. O

Rao O
, O
A O
. O

Kar O
, O
A O
. O

Chakraborty O
P062 O
- O
Prevention O
of O
central O
line-associated O
bloodstream O
infections O
in O
intensive O
care O
units O
: O
An O
international O
online O
survey O
C O
. O

Valencia O
, O
N O
. O

Hammami O
, O
S O
. O

Blot O
, O
J O
. O

L O
. O

Vincent O
, O
M O
. O

L O
. O

Lambert O
P063 O
- O
30 O
days O
antimicrobial O
efficacy O
of O
non-leaching O
central O
venous O
catheters O
J O
. O

Brunke O
, O
T O
. O

Riemann O
, O
I O
. O

Roschke O
P064 O
- O
Efficacy O
of O
noble O
metal O
alloy-coated O
catheter O
in O
prevention O
of O
bacteriuria O
R O
. O

Tincu O
, O
C O
. O

Cobilinschi O
, O
D O
. O

Tomescu O
, O
Z O
. O

Ghiorghiu O
, O
R O
. O

Macovei O
P065 O
- O
Predicting O
bacteremic O
urinary O
tract O
infection O
in O
community O
setting O
: O
A O
prospective O
observational O
study O
S O
. O

Nimitvilai O
, O
K O
. O

Jintanapramote O
, O
S O
. O

Jarupongprapa O
P066 O
- O
Eight-year O
analysis O
of O
acinetobacter O
spp O
. O
monobacteremia O
in O
surgical O
and O
medical O
intensive O
care O
units O
at O
university O
hospital O
in O
Lithuania O
D O
. O

Adukauskiene O
, O
D O
. O

Valanciene O
P067 O
- O
Group O
A O
and O
group O
B O
streptococcal O
infections O
in O
intensive O
care O
unit O
– O
our O
experience O
in O
a O
tertiary O
centre O
G O
. O

Bose O
, O
V O
. O

Lostarakos O
, O
B O
. O

Carr O
P068 O
- O
Improved O
detection O
of O
spontaneous O
bacterial O
peritonitis O
by O
uritop O
+ O
tm O
strip O
test O
and O
inoculation O
of O
blood O
culture O
bottles O
with O
ascitic O
fluid O
S O
. O

Khedher O
, O
A O
. O

Maaoui O
, O
A O
. O

Ezzamouri O
, O
M O
. O

Salem O
P069 O
- O
Increased O
risk O
of O
cellulitis O
in O
patients O
with O
congestive O
heart O
failure O
: O
a O
population O
based O
cohort O
study O
J O
. O

Chen O
P070 O
- O
Outcomes O
of O
severe O
cellulitis O
and O
necrotizing O
fasciitis O
in O
the O
critically O
ill O
D O
. O

R O
. O

Cranendonk O
, O
L O
. O

A O
. O

Van O
Vught O
, O
M O
. O

A O
. O

Wiewel O
, O
O O
. O

L O
. O

Cremer O
, O
J O
. O

Horn O
, O
M O
. O

J O
. O

Bonten O
, O
M O
. O

J O
. O

Schultz O
, O
T O
. O

Van O
der O
Poll O
, O
W O
. O

J O
. O

Wiersinga O
P071 O
- O
Botulism O
outbreak O
associated O
with O
people O
who O
inject O
drugs O
( O
PWIDs O
) O
in O
Scotland O
. O

M O
. O

Day O
, O
G O
. O

Penrice O
, O
K O
. O

Roy O
, O
P O
. O

Robertson O
, O
G O
. O

Godbole O
, O
B O
. O

Jones O
, O
M O
. O

Booth O
, O
L O
. O

Donaldson O
P072 O
- O
Surveillance O
of O
ESBL-producing O
enterobacteriaceae O
fecal O
carriers O
in O
the O
ICU O
Y O
. O

Kawano O
, O
H O
. O

Ishikura O
P073 O
- O
Prevalence O
of O
ESBL O
and O
carbapenemase O
producing O
uropathogens O
in O
a O
newly O
opened O
hospital O
in O
south O
India O
S O
. O

Sreevidya O
, O
N O
. O

Brahmananda O
Reddy O
, O
P O
. O

Muraray O
Govind O
, O
R O
. O

Pratheema O
, O
J O
. O

Devachandran O
Apollo O
Speciality O
Hospital O
- O
OMR O
, O
Chennai O
, O
India O
P074 O
- O
Prevalence O
, O
risk O
factors O
and O
outcomes O
of O
methicillin-resistant O
staphylococcus O
aureus O
nasal O
colonization O
in O
critically O
ill O
patients O
H O
. O

Al-Dorzi O
, O
M O
. O

Almutairi O
, O
B O
. O

Alhamadi O
, O
A O
. O

Crizaldo O
Toledo O
, O
R O
. O

Khan O
, O
B O
. O

Al O
Raiy O
, O
Y O
. O

Arabi O
P075 O
- O
Multidrug-resistant O
Acinetobacter O
baumannii O
infection O
in O
intensive O
care O
unit O
patients O
in O
a O
hospital O
with O
building O
construction O
: O
Is O
there O
an O
association O
? O

H O
. O

Talaie O
P076 O
- O
Multidrug-resistant O
organisms O
in O
a O
Dutch O
ICU O
J O
. O

A O
. O

Van O
Oers O
, O
A O
. O

Harts O
, O
E O
. O

Nieuwkoop O
, O
P O
. O

Vos O
P077 O
- O
Epidemiology O
and O
risk O
factors O
of O
ICU O
acquired O
infections O
caused O
by O
multidrug-resistant O
gram O
negative O
bacilli O
Y O
. O

Boussarsar O
, O
F O
. O

Boutouta O
, O
S O
. O

Kamoun O
, O
I O
. O

Mezghani O
, O
S O
. O

Koubaji O
, O
A O
. O

Ben O
Souissi O
, O
A O
. O

Riahi O
, O
M O
. O

S O
. O

Mebazaa O
P078 O
- O
Improving O
outcomes O
of O
severe O
infections O
by O
multidrug-resistant O
pathogens O
with O
polyclonal O
IgM-enriched O
immunoglobulins O
E O
. O

Giamarellos-Bourboulis O
, O
N O
. O

Tziolos O
, O
C O
. O

Routsi O
, O
C O
. O

Katsenos O
, O
I O
. O

Tsangaris O
, O
I O
. O

Pneumatikos O
, O
G O
. O

Vlachogiannis O
, O
V O
. O

Theodorou O
, O
A O
. O

Prekates O
, O
E O
. O

Antypa O
, O
V O
. O

Koulouras O
, O
N O
. O

Kapravelos O
, O
C O
. O

Gogos O
, O
E O
. O

Antoniadou O
, O
K O
. O

Mandragos O
, O
A O
. O

Armaganidis O
P079 O
- O
Must O
change O
the O
medical O
practice O
in O
ICU O
? O

A O
. O

R O
. O

Robles O
Caballero O
, O
B O
. O

Civantos O
, O
J O
. O

C O
. O

Figueira O
, O
J O
. O

López O
P080 O
- O
Mediterranean O
spotted O
fever O
in O
an O
infectious O
diseases O
intensive O
care O
unit O
A O
. O

Silva-Pinto O
, O
F O
. O

Ceia O
, O
A O
. O

Sarmento O
, O
L O
. O

Santos O
P081 O
- O
Clinical O
features O
and O
outcomes O
of O
patients O
with O
Middle O
East O
respiratory O
syndrome O
requiring O
admission O
to O
a O
saudi O
intensive O
care O
unit O
: O
A O
retrospective O
analysis O
of O
31 O
cases O
G O
. O

Almekhlafi O
, O
Y O
. O

Sakr O
P082 O
- O
The O
ICU O
response O
to O
a O
hospital O
outbreak O
of O
Middle O
East O
respiratory O
syndrome O
coronavirus O
infection O
H O
. O

Al-Dorzi O
, O
R O
. O

Khan O
, O
S O
. O

Baharoon O
, O
A O
. O

Aldawood O
, O
A O
. O

Matroud O
, O
J O
. O

Alchin O
, O
S O
. O

Al O
Johani O
, O
H O
. O

Balkhy O
, O
Y O
. O

Arabi O
P083 O
- O
Middle O
East O
respiratory O
syndrome O
: O
Surveillance O
data O
analysis O
S O
. O

Alsolamy O
, O
S O
. O

Y O
. O

Yousif O
, O
B O
. O

O O
. O

Alotabi O
, O
A O
. O

S O
. O

Alsaawi O
P085 O
- O
Use O
of O
Taqman O
array O
card O
molecular O
diagnostics O
in O
severe O
pneumonia O
: O
A O
case O
series O
J O
. O

Ang O
, O
MD O
Curran O
, O
D O
. O

Enoch O
, O
V O
. O

Navapurkar O
, O
A O
. O

Conway O
Morris O
P086 O
- O
‘ O
BUNS O
’ O
: O
An O
investigation O
protocol O
improves O
the O
ICU O
management O
of O
pneumonia O
R O
. O

Sharvill O
, O
J O
. O

Astin O
P087 O
- O
Pneumonia O
in O
patients O
following O
secondary O
peritonitis O
: O
epidemiological O
features O
and O
impact O
on O
mortality O
M O
. O

Heredia-Rodríguez O
, O
E O
. O

Gómez-Sánchez O
, O
M O
. O

T O
. O

Peláez-Jareño O
, O
E O
. O

Gómez-Pesquera O
, O
M O
. O

Lorenzo-López O
, O
P O
. O

Liu-Zhu O
, O
M O
. O

Aragón-Camino O
, O
A O
. O

Hernández-Lozano O
, O
A O
. O

Sánchez-López O
, O
E O
. O

Álvarez-Fuente O
, O
E O
. O

Tamayo O
P088 O
- O
The O
use O
of O
the O
“ O
CURB O
- O
65 O
score O
” O
by O
emergency O
room O
clinicians O
in O
a O
large O
teaching O
hospital O
J O
. O

Patel O
, O
C O
. O

Kruger O
P089 O
- O
Incidence O
of O
community O
acquired O
pneumonia O
with O
viral O
infection O
in O
mechanically O
ventilated O
patients O
in O
the O
medical O
intensive O
care O
unit O
J O
. O

O O
’ O
Neal O
, O
H O
. O

Rhodes O
, O
J O
. O

Jancik O
P090 O
- O
The O
SAATELLITE O
Study O
: O
Prevention O
of O
S O
aureus O
Nosocomial O
Pneumonia O
( O
NP O
) O
with O
MEDI4893 O
, O
a O
Human O
Monoclonal O
Antibody O
( O
mAb O
) O
Against O
S O
aureus O
B O
. O

François O
, O
P O
. O

F O
. O

Laterre O
, O
P O
. O

Eggimann O
, O
A O
. O

Torres O
, O
M O
. O

Sánchez O
, O
P O
. O

F O
. O

Dequin O
, O
G O
. O

L O
. O

Bassi O
, O
J O
. O

Chastre O
, O
H O
. O

S O
. O

Jafri O
P091 O
- O
Risk O
factors O
and O
microbiological O
profile O
for O
nosocomial O
infections O
in O
trauma O
patients O
M O
. O

Ben O
Romdhane O
, O
Z O
. O

Douira O
, O
S O
. O

Kamoun O
, O
M O
. O

Bousselmi O
, O
A O
. O

Ben O
Souissi O
, O
Y O
. O

Boussarsar O
, O
A O
. O

Riahi O
, O
M.S O
. O

Mebazaa O
P092 O
- O
Correlation O
between O
percentages O
of O
ventilated O
patients O
developed O
vap O
and O
use O
of O
antimicrobial O
agents O
in O
ICU O
patients O
. O

A O
. O

Vakalos O
, O
V O
. O

Avramidis O
P093 O
- O
A O
comparison O
of O
two O
ventilator O
associated O
pneumonia O
surveillance O
techniques O
T O
. O

H O
. O

Craven O
, O
G O
. O

Wojcik O
, O
K O
. O

Kefala O
, O
J O
. O

McCoubrey O
, O
J O
. O

Reilly O
, O
R O
. O

Paterson O
, O
D O
. O

Inverarity O
, O
I O
. O

Laurenson O
, O
T O
. O

S O
. O

Walsh O
P094 O
- O
Lung O
ultrasound O
before O
and O
after O
fiberbronchoscopy O
- O
modifications O
may O
improve O
ventilator-associated O
pneumonia O
diagnosis O
S O
. O

Mongodi O
, O
B O
. O

Bouhemad O
, O
A O
. O

Orlando O
, O
A O
. O

Stella O
, O
G O
. O

Via O
, O
G O
. O

Iotti O
, O
A O
. O

Braschi O
, O
F O
. O

Mojoli O
P095 O
- O
Comparing O
the O
accuracy O
of O
predictors O
of O
mortality O
in O
ventilator-associated O
pneumonia O
M O
. O

Haliloglu O
, O
B O
. O

Bilgili O
, O
U O
. O

Kasapoglu O
, O
I O
. O

Sayan O
, O
M O
. O

Süzer O
Aslan O
, O
A O
. O

Yalcın O
, O
I O
. O

Cinel O
P096 O
- O
Impact O
of O
pRBCs O
transfusion O
on O
percentage O
of O
ventilated O
patients O
developed O
VAP O
in O
ICU O
patients O
A O
. O

Vakalos O
, O
V O
. O

Avramidis O
P097 O
- O
The O
impact O
of O
a O
series O
of O
interventions O
on O
the O
rate O
of O
ventilator O
associated O
pneumonia O
in O
a O
large O
teaching O
hospital O
H O
. O

E O
. O

Ellis O
, O
K O
. O

Bauchmuller O
, O
D O
. O

Miller O
, O
A O
Temple O
P098 O
- O
The O
EVADE O
study O
: O
Prevention O
of O
Nosocomial O
Pneumonia O
( O
NP O
) O
caused O
by O
P O
aeruginosa O
with O
MEDI3902 O
, O
a O
Novel O
Bispecific O
Monoclonal O
Antibody O
, O
against O
P O
aeruginosa O
virulence O
factors O
J O
. O

Chastre O
, O
B O
. O

François O
, O
A O
. O

Torres O
, O
C O
. O

E O
. O

Luyt O
, O
M O
. O

Sánchez O
, O
M O
. O

Singer O
, O
H O
. O

S O
. O

Jafri O
P099 O
- O
Short-term O
inhaled O
colistin O
adjunctive O
therapy O
for O
ventilator-associated O
pneumonia O
Y O
. O

Nassar O
, O
M O
. O

S O
. O

Ayad O
P100 O
- O
Effect O
of O
aerosolised O
colistin O
on O
weaning O
from O
mechanical O
ventilation O
A O
. O

Trifi O
, O
S O
. O

Abdellatif O
, O
F O
. O

Daly O
, O
R O
. O

Nasri O
, O
S O
. O

Ben O
Lakhal O
P101 O
- O
Septic O
shock O
is O
an O
independent O
risk O
factor O
for O
colistin-induced O
severe O
acute O
kidney O
injury O
: O
a O
retrospective O
cohort O
study O
B O
. O

Bilgili O
, O
M O
. O

Haliloglu O
, O
F O
. O

Gul O
, O
I O
. O

Cinel O
P102 O
- O
Nosocomial O
pneumonia O
- O
emphasis O
on O
inhaled O
tobramycin O
A O
. O

Kuzovlev O
, O
A O
. O

Shabanov O
, O
S O
. O

Polovnikov O
, O
V O
. O

Moroz O
P103 O
- O
In O
vitro O
evaluation O
of O
amikacin O
inhale O
and O
commercial O
nebulizers O
in O
a O
mechanical O
ventilator O
N O
. O

Kadrichu O
, O
T O
. O

Dang O
, O
K O
. O

Corkery O
, O
P O
. O

Challoner O
P104 O
- O
The O
effects O
of O
nebulized O
amikacin O
/ O
fosfomycin O
and O
systemic O
meropenem O
on O
severe O
amikacin-resistant O
meropenem-susceptible O
P.aeruginosa O
pneumonia O
G O
. O

Li O
Bassi O
, O
E O
. O

Aguilera O
, O
C O
. O

Chiurazzi O
, O
C O
. O

Travierso O
, O
A O
. O

Motos O
, O
L O
. O

Fernandez O
, O
R O
. O

Amaro O
, O
T O
. O

Senussi O
, O
F O
. O

Idone O
, O
J O
. O

Bobi O
, O
M O
. O

Rigol O
, O
A O
. O

Torres O
P105 O
- O
Optimization O
of O
gentamicin O
peak O
concentrations O
in O
critically O
ill O
patients O
C O
. O

J O
. O

Hodiamont O
, O
N O
. O

P O
. O

Juffermans O
, O
J O
. O

M O
. O

Janssen O
, O
C O
. O

S O
. O

Bouman O
, O
R O
. O

A O
. O

Mathôt O
, O
M O
. O

D O
. O

De O
Jong O
, O
R O
. O

M O
. O

Van O
Hest O
P106 O
- O
Systematic O
review O
of O
cefepime O
induced O
neurotoxicity O
L O
. O

Payne O
, O
G O
. O

L O
. O

Fraser O
P107 O
- O
Unasyn O
® O
causes O
QT O
prolongation O
during O
treatment O
of O
intensive O
care O
patients O
B O
. O

Tudor O
, O
M O
. O

Lahner O
, O
G O
. O

Roth O
, O
C O
. O

Krenn O
P108 O
- O
Comparative O
study O
between O
teicoplanin O
and O
vancomycin O
in O
methicillin-resistant O
staphylococcus O
aureus O
( O
mrsa O
) O
infectious O
of O
toxicological O
intensive O
care O
unit O
( O
ticu O
) O
patients O
– O
Tehran O
, O
Iran O
H O
. O

Talaie O
P109 O
- O
Phage O
therapy O
against O
antimicrobial O
resistance O
, O
design O
of O
the O
first O
clinical O
study O
phagoburn O
P O
. O

Jault O
, O
J O
. O

Gabard O
, O
T O
. O

Leclerc O
, O
S O
. O

Jennes O
, O
Y O
. O

Que O
, O
A O
. O

Rousseau O
, O
F O
. O

Ravat O
P110 O
- O
Antibiotic O
dosing O
errors O
in O
critically O
ill O
patients O
with O
severe O
sepsis O
or O
septic O
shock O
H O
. O

Al-Dorzi O
, O
A O
. O

Eissa O
, O
S O
. O

Al-Harbi O
, O
T O
. O

Aldabbagh O
, O
R O
. O

Khan O
, O
Y O
. O

Arabi O
P111 O
- O
Does O
empiric O
antifungal O
therapy O
improve O
survival O
in O
septic O
critically O
ill O
patients O
? O

( O
immunocompromised O
excluded O
) O
A O
. O

Trifi O
, O
S O
. O

Abdellatif O
, O
F O
. O

Daly O
, O
R O
. O

Nasri O
, O
S O
. O

Ben O
Lakhal O
P112 O
- O
Neurocysticercosis-Qatar O
experience O
F O
. O

Paramba O
, O
N O
. O

Purayil O
, O
V O
. O

Naushad O
, O
O O
. O

Mohammad O
, O
V O
. O

Negi O
, O
P O
. O

Chandra O
P113 O
- O
Early O
indicators O
in O
acute O
haemorrhagic O
shock O
A O
. O

Kleinsasser O
P114 O
- O
Filtering O
of O
red O
blood O
cells O
reduces O
the O
inflammatory O
response O
of O
pulmonary O
cells O
in O
an O
in O
vitro O
model O
of O
mechanical O
ventilation O
M O
. O

R O
. O

Witrz O
, O
J O
. O

F O
. O

Buchner-Doeven O
, O
A O
. O

M O
. O

Tuip-de O
Boer O
, O
J O
. O

C O
. O

Goslings O
, O
N O
. O

P O
. O

Juffermans O
P115 O
- O
Microparticles O
from O
red O
blood O
cell O
transfusion O
induce O
a O
pro-coagulant O
and O
pro-inflammatory O
endothelial O
cell O
response O
M O
. O

Van O
Hezel O
, O
M O
. O

Straat O
, O
A O
Boing O
, O
R O
Van O
Bruggen O
, O
N O
Juffermans O
P116 O
- O
The O
contribution O
of O
cytokines O
on O
thrombosis O
development O
during O
hospitalization O
in O
ICU O
D O
. O

Markopoulou O
, O
K O
. O

Venetsanou O
, O
V O
. O

Kaldis O
, O
D O
. O

Koutete O
, O
D O
. O

Chroni O
, O
I O
. O

Alamanos O
P117 O
- O
Prophylactic O
enoxaparin O
dosing O
and O
adjustment O
through O
anti-xa O
monitoring O
in O
an O
inpatient O
burn O
unit O
L O
. O

Koch O
, O
J O
. O

Jancik O
, O
H O
. O

Rhodes O
, O
E O
. O

Walter O
P118 O
- O
Determination O
of O
optimal O
cut-off O
values O
of O
haemoglobin O
, O
platelet O
count O
and O
fibrinogen O
at O
24 O
hours O
after O
injury O
associated O
with O
mortality O
in O
trauma O
patients O
K O
. O

Maekawa O
, O
M O
. O

Hayakawa O
, O
S O
. O

Kushimoto O
, O
A O
. O

Shiraishi O
, O
H O
. O

Kato O
, O
J O
. O

Sasaki O
, O
H O
. O

Ogura O
, O
T O
. O

Matauoka O
, O
T O
. O

Uejima O
, O
N O
. O

Morimura O
, O
H O
. O

Ishikura O
, O
A O
. O

Hagiwara O
, O
M O
. O

Takeda O
P119 O
- O
Trauma-induced O
coagulopathy O
- O
prothrombin O
complex O
concentrate O
vs O
fresh O
frozen O
plasma O
O O
. O

Tarabrin O
, O
S O
. O

Shcherbakow O
, O
D O
. O

Gavrychenko O
, O
G O
. O

Mazurenko O
, O
V O
. O

Ivanova O
, O
O O
. O

Chystikov O
P120 O
- O
First O
study O
to O
prove O
the O
superiority O
of O
prothrombin O
complex O
concentrates O
on O
mortality O
rate O
over O
fresh O
frozen O
plasma O
in O
patients O
with O
acute O
bleeding O
C O
. O

Plourde O
, O
J O
. O

Lessard O
, O
J O
. O

Chauny O
, O
R O
. O

Daoust O
P121 O
- O
Prothrombin O
complex O
concentrate O
vs O
fresh O
frozen O
plasma O
in O
obstetric O
massive O
bleeding O
S O
. O

Shcherbakow O
, O
O O
. O

Tarabrin O
, O
D O
. O

Gavrychenko O
, O
G O
. O

Mazurenko O
, O
O O
. O

Chystikov O
P122 O
- O
Impact O
of O
FFP O
transfusion O
on O
VAP O
in O
ICU O
patients O
A O
. O

Vakalos O
, O
V O
. O

Avramidis O
P123 O
- O
Preoperative O
platelet O
function O
test O
and O
the O
thrombin O
generation O
assay O
are O
predictive O
for O
blood O
loss O
after O
cardiac O
surgery O
L O
. O

Kropman O
, O
L O
. O

In O
het O
Panhuis O
, O
J O
. O

Konings O
, O
D O
. O

Huskens O
, O
E O
. O

Schurgers O
, O
M O
. O

Roest O
, O
B O
. O

De O
Laat O
, O
M O
. O

Lance O
P124 O
- O
Rotational O
thromboelastometry O
versus O
standard O
coagulation O
tests O
before O
surgical O
interventions O
M O
. O

Durila O
, O
P O
. O

Lukas O
, O
M O
. O

Astraverkhava O
, O
J O
. O

Jonas O
P125 O
- O
Correction O
of O
impaired O
clot O
quality O
and O
stability O
by O
fibrinogen O
and O
activated O
prothrombin O
complex O
concentrate O
in O
a O
model O
of O
severe O
thrombocytopenia O
I O
. O

Budnik O
, O
B O
. O

Shenkman O
P126 O
- O
Assessment O
of O
point-of-care O
prothrombin O
time O
analyzer O
as O
a O
monitor O
after O
cardiopulmonary O
bypass O
H O
. O

Hayami O
, O
Y O
. O

Koide O
, O
T O
. O

Goto O
P127 O
- O
Disseminated O
intravascular O
coagulation O
( O
dic O
) O
is O
underdiagnosed O
in O
critically O
ill O
patients O
: O
do O
we O
need O
d-dimer O
measurements O
? O

R O
. O

Iqbal O
, O
Y O
. O

Alhamdi O
, O
N O
. O

Venugopal O
, O
S O
. O

Abrams O
, O
C O
. O

Downey O
, O
C O
. O

H O
. O

Toh O
, O
I O
. O

D O
. O

Welters O
P128 O
- O
Validity O
of O
the O
age-adjusted O
d-dimer O
cutoff O
in O
patients O
with O
COPD O
B O
. O

Bombay O
, O
J O
. O

M O
. O

Chauny O
, O
R O
. O

D O
. O

Daoust O
, O
J O
. O

L O
. O

Lessard O
, O
M O
. O

M O
. O

Marquis O
, O
J O
. O

P O
. O

Paquet O
P129 O
- O
A O
scoping O
review O
of O
strategies O
for O
prevention O
and O
management O
of O
bleeding O
following O
paediatric O
cardiopulmonary O
bypass O
surgery O
K O
. O

Siemens O
, O
D O
. O

Sangaran O
, O
B O
. O

J O
. O

Hunt O
, O
A O
. O

Durward O
, O
A O
. O

Nyman O
, O
I O
. O

A O
. O

Murdoch O
, O
S O
. O

M O
. O

Tibby O
P130 O
- O
Nadir O
hemoglobulin O
during O
cardiopulmonary O
bypass O
: O
impact O
on O
postoperative O
morbidity O
and O
mortality O
F O
. O

Ampatzidou O
, O
D O
. O

Moisidou O
, O
E O
. O

Dalampini O
, O
M O
. O

Nastou O
, O
E O
. O

Vasilarou O
, O
V O
. O

Kalaizi O
, O
H O
. O

Chatzikostenoglou O
, O
G O
. O

Drossos O
P131 O
- O
Red O
blood O
cell O
transfusion O
do O
not O
influence O
the O
prognostic O
value O
of O
RDW O
in O
critically O
ill O
patients O
S O
. O

Spadaro O
, O
A O
. O

Fogagnolo O
, O
T O
. O

Fiore O
, O
A O
. O

Schiavi O
, O
V O
. O

Fontana O
, O
F O
. O

Taccone O
, O
C O
. O

Volta O
P132 O
- O
Reasons O
for O
admission O
in O
the O
paediatric O
intensive O
care O
unit O
and O
the O
need O
for O
blood O
and O
blood O
products O
transfusions O
E O
. O

Chochliourou O
, O
E O
. O

Volakli O
, O
A O
. O

Violaki O
, O
E O
. O

Samkinidou O
, O
G O
. O

Evlavis O
, O
V O
. O

Panagiotidou O
, O
M O
. O

Sdougka O
P133 O
- O
The O
implementation O
of O
a O
massive O
haemorrhage O
protocol O
( O
mhp O
) O
for O
the O
management O
of O
major O
trauma O
: O
a O
ten O
year O
, O
single-centre O
study O
R O
. O

Mothukuri O
, O
C O
. O

Battle O
, O
K O
. O

Guy O
, O
G O
. O

Mills O
, O
P O
. O

Evans O
P134 O
- O
An O
integrated O
major O
haemorrhage O
protocol O
for O
pre-hospital O
and O
retrieval O
medical O
teams O
J O
. O

Wijesuriya O
, O
S O
. O

Keogh O
P135 O
- O
The O
impact O
of O
transfusion O
thresholds O
on O
mortality O
and O
cardiovascular O
events O
in O
patients O
with O
cardiovascular O
disease O
( O
non-cardiac O
surgery O
) O
: O
a O
systematic O
review O
and O
meta-analysis O
A O
. O

Docherty O
, O
R O
. O

O O
’ O
Donnell O
, O
S O
. O

Brunskill O
, O
M O
. O

Trivella O
, O
C O
. O

Doree O
, O
L O
. O

Holst O
, O
M O
. O

Parker O
, O
M O
. O

Gregersen O
, O
J O
. O

Almeida O
, O
T O
. O

Walsh O
, O
S O
. O

Stanworth O
P136 O
- O
The O
relationship O
between O
poor O
pre-operative O
immune O
status O
and O
outcome O
from O
cardiac O
surgery O
is O
specific O
to O
the O
peri-operative O
antigenic O
threat O
S O
. O

Moravcova O
, O
J O
. O

Mansell O
, O
A O
. O

Rogers O
, O
R O
. O

A O
. O

Smith O
, O
C O
. O

Hamilton-Davies O
P137 O
- O
Impact O
of O
simple O
clinical O
practice O
guidelines O
for O
reducing O
post-operative O
atrial O
fibrillation O
after O
cardiac O
surgery O
. O

A O
. O

Omar O
, O
M O
. O

Allam O
, O
O O
. O

Bilala O
, O
A O
. O

Kindawi O
, O
H O
. O

Ewila O
P138 O
- O
Dexamethasone O
administration O
during O
cardiopulmonary O
bypass O
has O
no O
beneficial O
effects O
on O
elective O
postoperative O
cardiac O
surgery O
patients O
F O
. O

Ampatzidou O
, O
D O
. O

Moisidou O
, O
M O
. O

Nastou O
, O
E O
. O

Dalampini O
, O
A O
. O

Malamas O
, O
E O
. O

Vasilarou O
, O
G O
. O

Drossos O
P139 O
- O
Intra-aortic O
balloon O
counterpulsation O
in O
patients O
undergoing O
cardiac O
surgery O
( O
IABCS O
) O
: O
preliminary O
results O
G O
. O

Ferreira O
, O
J O
. O

Caldas O
, O
J O
. O

Fukushima O
, O
E O
. O

A O
. O

Osawa O
, O
E O
. O

Arita O
, O
L O
. O

Camara O
, O
S O
. O

Zeferino O
, O
J O
. O

Jardim O
, O
F O
. O

Gaioto O
, O
L O
. O

Dallan O
, O
F O
. O

B O
. O

Jatene O
, O
R O
. O

Kalil O
Filho O
, O
. O
F O
Galas O
, O
L O
. O

A O
. O

Hajjar O
P140 O
- O
Effects O
of O
low-dose O
atrial O
natriuretic O
peptide O
infusion O
on O
cardiac O
surgery-associated O
acute O
kidney O
injury O
C O
. O

Mitaka O
, O
T O
. O

Ohnuma O
, O
T O
. O

Murayama O
, O
F O
. O

Kunimoto O
, O
M O
. O

Nagashima O
, O
T O
. O

Takei O
, O
M O
. O

Tomita O
P141 O
- O
Acute O
kidney O
injury O
influence O
on O
high O
sensitive O
troponin O
measurements O
after O
cardiac O
surgery O
A O
. O

Omar O
, O
K O
. O

Mahmoud O
, O
S O
. O

Hanoura O
, O
S O
. O

Sudarsanan O
, O
P O
. O

Sivadasan O
, O
H O
. O

Othamn O
, O
Y O
. O

Shouman O
, O
R O
. O

Singh O
, O
A O
. O

Al O
Khulaifi O
P142 O
- O
Complex O
evaluation O
of O
endothelial O
dysfunction O
markers O
for O
prognosis O
of O
outcomes O
in O
patients O
undergoing O
cardiac O
surgery O
I O
. O

Mandel O
, O
S O
. O

Mikheev O
, O
I O
. O

Suhodolo O
, O
V O
. O

Kiselev O
, O
Y O
. O

Svirko O
, O
Y O
. O

Podoksenov O
P143 O
- O
New-onset O
atrial O
fibrillation O
in O
intensive O
care O
: O
incidence O
, O
management O
and O
outcome O
S O
. O

A O
. O

Jenkins O
, O
R O
. O

Griffin O
P144 O
- O
One O
single O
spot O
measurement O
of O
the O
sublingual O
microcirculation O
during O
acute O
pulmonary O
hypertension O
in O
a O
pig O
model O
of O
shock O
M O
. O

S O
. O

Tovar O
Doncel O
, O
A O
. O

Lima O
, O
C O
. O

Aldecoa O
, O
C O
. O

Ince O
P145 O
- O
Assessment O
of O
levosimendan O
as O
a O
therapeutic O
option O
to O
recruit O
the O
microcirculation O
in O
cardiogenic O
shock O
– O
initial O
experience O
in O
cardiac O
ICU O
A O
. O

Taha O
, O
A O
. O

Shafie O
, O
M O
. O

Mostafa O
, O
N O
. O

Syed O
, O
H O
. O

Hon O
P146 O
- O
Terlipressin O
vs O
. O
norepinephrine O
in O
the O
Potential O
Multiorgan O
Donor O
( O
PMD O
) O
F O
. O

Righetti O
, O
E O
. O

Colombaroli O
, O
G O
. O

Castellano O
P147 O
- O
Echocardiography O
in O
the O
potential O
heart O
donor O
exposed O
to O
substitution O
hormonotherapy O
F O
. O

Righetti O
, O
E O
. O

Colombaroli O
P148 O
- O
Machine O
learning O
can O
reduce O
rate O
of O
monitor O
alarms O
M O
. O

Hravnak O
, O
L O
. O

C O
. O

Chen O
, O
A O
. O

D O
. O

Dubrawski O
, O
G O
. O

C O
. O

Clermont O
, O
M O
. O

R O
. O

Pinsky O
P149 O
- O
Peripherally O
inserted O
central O
catheters O
placed O
in O
the O
ICU O
S O
. O

Gonzalez O
, O
D O
. O

Macias O
, O
J O
. O

Acosta O
, O
P O
. O

Jimenez O
, O
A O
. O

Loza O
, O
A O
. O

Lesmes O
, O
F O
. O

Lucena O
, O
C O
. O

Leon O
P150 O
- O
Recordings O
of O
abnormal O
central O
venous O
pressure O
waveform O
morphology O
during O
an O
episode O
of O
pulmonary O
hypertension O
in O
a O
porcine O
shock O
model O
M O
. O

S O
. O

Tovar O
Doncel O
, O
C O
. O

Ince O
, O
C O
. O

Aldecoa O
, O
A O
. O

Lima O
P151 O
- O
Ultrasound O
guided O
central O
venous O
access O
technique O
among O
French O
intensivists O
M O
. O

Bastide O
, O
J O
. O

Richecoeur O
, O
E O
. O

Frenoy O
, O
C O
. O

Lemaire O
, O
B O
. O

Sauneuf O
, O
F O
. O

Tamion O
, O
S O
. O

Nseir O
, O
D O
. O

Du O
Cheyron O
, O
H O
. O

Dupont O
, O
J O
. O

Maizel O
P152 O
- O
Predictive O
ability O
of O
the O
Pv-aCO2 O
gap O
in O
patients O
with O
shock O
M O
. O

Shaban O
, O
R O
. O

Kolko O
, O
N O
. O

Salahuddin O
, O
M O
. O

Sharshir O
, O
M O
. O

AbuRageila O
, O
A O
. O

AlHussain O
P153 O
- O
Comparison O
of O
echocardiography O
and O
pulmonary O
artery O
catheter O
measurements O
of O
hemodynamic O
parameters O
in O
critical O
ill O
patients O
P O
. O

Mercado O
, O
J O
. O

Maizel O
, O
L O
. O

Kontar O
, O
D O
. O

Titeca O
, O
F O
. O

Brazier O
, O
A O
. O

Riviere O
, O
M O
. O

Joris O
, O
T O
. O

Soupison O
, O
B O
. O

De O
Cagny O
, O
M O
. O

Slama O
P154 O
- O
The O
volume O
clamp O
method O
for O
noninvasive O
cardiac O
output O
measurement O
in O
postoperative O
cardiothoracic O
surgery O
patients O
: O
a O
comparison O
with O
intermittent O
pulmonary O
artery O
thermodilution O
J O
. O

Wagner O
, O
A O
. O

Körner O
, O
M O
. O

Kubik O
, O
S O
. O

Kluge O
, O
D O
. O

Reuter O
, O
B O
. O

Saugel O
P155 O
- O
Hemodynamic O
monitoring O
in O
patients O
with O
septic O
shock O
( O
SS O
) O
– O
CPCCO O
( O
continuous O
pulse O
contour O
cardiac O
output O
) O
vs O
. O

TEE O
( O
transesophageal O
echocardiography O
) O
E O
. O

Colombaroli O
, O
F O
. O

Righetti O
, O
G O
. O

Castellano O
P156 O
- O
Cardiac O
output O
measurement O
with O
transthoracic O
echocardiography O
in O
critically O
ill O
patients O
: O
a O
pragmatic O
clinical O
study O
T O
. O

Tran O
, O
D O
. O

De O
Bels O
, O
A O
. O

Cudia O
, O
M O
. O

Strachinaru O
, O
P O
. O

Ghottignies O
, O
J O
. O

Devriendt O
, O
C O
. O

Pierrakos O
P157 O
- O
Left O
ventricular O
outflow O
tract O
velocity O
time O
integral O
correlates O
with O
stroke O
volume O
index O
in O
mechanically O
ventilated O
patients O
Ó O
. O

Martínez O
González O
, O
R O
. O

Blancas O
, O
J O
. O

Luján O
, O
D O
. O

Ballesteros O
, O
C O
. O

Martínez O
Díaz O
, O
A O
. O

Núñez O
, O
C O
. O

Martín O
Parra O
, O
B O
. O

López O
Matamala O
, O
M O
. O

Alonso O
Fernández O
, O
M O
. O

Chana O
P158 O
- O
Transpulmonary O
thermodilution O
( O
TPTD O
) O
derived O
from O
femoral O
vs O
. O
jugular O
central O
venous O
catheter O
: O
validation O
of O
a O
previously O
published O
correction O
formula O
and O
a O
proprietary O
correction O
formula O
for O
global O
end-diastolic O
volume O
index O
( O
GEDVI O
) O
W O
. O

Huber O
, O
M O
. O

Eckmann O
, O
F O
. O

Elkmann O
, O
A O
. O

Gruber O
, O
I O
. O

Klein O
, O
R O
. O

M O
. O

Schmid O
, O
T O
. O

Lahmer O
P160 O
- O
Dynamic O
arterial O
elastance O
calculated O
with O
lidcoplus O
monitor O
does O
not O
predict O
changes O
in O
arterial O
pressure O
after O
a O
fluid O
challenge O
in O
postsurgical O
patients O
D O
. O

Bastoni O
, O
H O
. O

Aya O
, O
L O
. O

Toscani O
, O
L O
. O

Pigozzi O
, O
A O
. O

Rhodes O
, O
M O
. O

Cecconi O
P159 O
- O
Venous O
return O
driving O
pressure O
and O
resistance O
in O
acute O
blood O
volume O
changes O
P O
. O

W O
. O

Moller O
, O
S O
. O

Sondergaard O
, O
S O
. O

M O
. O

Jakob O
, O
J O
. O

Takala O
, O
D O
. O

Berger O
P160 O
- O
Dynamic O
arterial O
elastance O
calculated O
with O
lidcoplus O
monitor O
does O
not O
predict O
changes O
in O
arterial O
pressure O
after O
a O
fluid O
challenge O
in O
postsurgical O
patients O
D O
. O

Bastoni O
, O
H O
. O

Aya O
, O
L O
. O

Toscani O
, O
L O
. O

Pigozzi O
, O
A O
. O

Rhodes O
, O
M O
. O

Cecconi O
P161 O
- O
Analysis O
of O
duration O
of O
post-operative O
goal-directed O
therapy O
protocol O
C O
. O

Ostrowska O
, O
H O
. O

Aya O
, O
A O
. O

Abbas O
, O
J O
. O

Mellinghoff O
, O
C O
. O

Ryan O
, O
D O
. O

Dawson O
, O
A O
. O

Rhodes O
, O
M O
. O

Cecconi O
P162 O
- O
Hemodynamic O
optimization O
– O
back O
to O
square O
one O
? O

M O
. O

Cronhjort O
, O
O O
. O

Wall O
, O
E O
. O

Nyberg O
, O
R O
. O

Zeng O
, O
C O
. O

Svensen O
, O
J O
. O

Mårtensson O
, O
E O
. O

Joelsson-Alm O
P163 O
- O
Effectiveness O
of O
fluid O
thoracic O
content O
measurement O
by O
bioimpedance O
guiding O
intravascular O
volume O
optimization O
in O
patients O
with O
septic O
shock O
M O
. O

Aguilar O
Arzapalo O
, O
L O
. O

Barradas O
, O
V O
. O

Lopez O
, O
M O
. O

Cetina O
P164 O
- O
A O
systematic O
review O
on O
the O
role O
of O
internal O
jugular O
vein O
ultrasound O
measurements O
in O
assessment O
of O
volume O
status O
in O
critical O
shock O
patients O
N O
. O

Parenti O
, O
C O
. O

Palazzi O
, O
L O
. O

A O
. O

Amidei O
, O
F O
. O

B O
. O

Borrelli O
, O
S O
. O

C O
. O

Campanale O
, O
F O
. O

T O
. O

Tagliazucchi O
, O
G O
. O

S O
. O

Sedoni O
, O
D O
. O

L O
. O

Lucchesi O
, O
E O
. O

C O
. O

Carella O
, O
A O
. O

L O
Luciani O
P165 O
- O
Importance O
of O
recognizing O
dehydration O
in O
medical O
Intensive O
Care O
Unit O
M O
. O

Mackovic O
, O
N O
. O

Maric O
, O
M O
. O

Bakula O
P166 O
- O
Effect O
of O
volume O
for O
a O
fluid O
challenge O
in O
septic O
patients O
H O
. O

Aya O
, O
A O
. O

Rhodes O
, O
R O
. O

M O
. O

Grounds O
, O
N O
. O

Fletcher O
, O
M O
. O

Cecconi O
P167 O
- O
Fluid O
bolus O
practices O
in O
a O
large O
Australian O
intensive O
care O
unit O
B O
. O

Avard O
, O
P O
. O

Zhang O
P168 O
- O
Liberal O
late O
fluid O
management O
is O
associated O
with O
longer O
ventilation O
duration O
and O
worst O
outcome O
in O
severe O
trauma O
patients O
: O
a O
retrospective O
cohort O
of O
294 O
patients O
M O
. O

Mezidi O
, O
J O
. O

Charbit O
, O
M O
. O

Ould-Chikh O
, O
P O
. O

Deras O
, O
C O
. O

Maury O
, O
O O
. O

Martinez O
, O
X O
. O

Capdevila O
P169 O
- O
Association O
of O
fluids O
and O
outcomes O
in O
emergency O
department O
patients O
hospitalized O
with O
community-acquired O
pneumonia O
P O
. O

Hou O
, O
W O
. O

Z O
. O

Linde-Zwirble O
, O
I O
. O

D O
. O

Douglas O
, O
N O
. O

S O
. O

Shapiro O
P170 O
- O
Association O
of O
positive O
fluid O
balance O
with O
poor O
outcome O
in O
medicosurgical O
ICU O
patients O
A O
. O

Ben O
Souissi O
, O
I O
. O

Mezghani O
, O
Y O
. O

Ben O
Aicha O
, O
S O
. O

Kamoun O
, O
B O
. O

Laribi O
, O
B O
. O

Jeribi O
, O
A O
. O

Riahi O
, O
M O
. O

S O
. O

Mebazaa O
P171 O
- O
Impact O
of O
fluid O
balance O
to O
organ O
dysfunction O
in O
critically O
ill O
patients O
C O
. O

Pereira O
, O
R O
. O

Marinho O
, O
R O
. O

Antunes O
, O
A O
. O

Marinho O
P172 O
- O
Volume O
bolus O
in O
ICU O
patients O
: O
do O
we O
need O
to O
balance O
our O
crystalloids O
? O

M O
. O

Crivits O
, O
M O
. O

Raes O
, O
J O
. O

Decruyenaere O
, O
E O
. O

Hoste O
P173 O
- O
The O
use O
of O
6 O
% O
HES O
solution O
do O
not O
reduce O
total O
fluid O
requirement O
in O
the O
therapy O
of O
patients O
with O
burn O
shock O
V O
. O

Bagin O
, O
V O
. O

Rudnov O
, O
A O
. O

Savitsky O
, O
M O
. O

Astafyeva O
, O
I O
. O

Korobko O
, O
V O
. O

Vein O
P174 O
- O
Electron O
microscopic O
assessment O
of O
acute O
kidney O
injury O
in O
septic O
sheep O
resuscitated O
with O
crystalloids O
or O
different O
colloids O
T O
. O

Kampmeier O
, O
P O
. O

Arnemann O
, O
M O
. O

Hessler O
, O
A O
. O

Wald O
, O
K O
. O

Bockbreder O
, O
A O
. O

Morelli O
, O
H O
. O

Van O
Aken O
, O
S O
. O

Rehberg O
, O
C O
. O

Ertmer O
P175 O
- O
Alterations O
of O
conjunctival O
microcirculation O
in O
a O
sheep O
model O
of O
haemorrhagic O
shock O
and O
resuscitation O
with O
0.9 O
% O
saline O
or O
balanced O
tetrastarch O
P O
. O

Arnemann O
, O
M O
. O

Hessler O
, O
T O
. O

Kampmeier O
, O
S O
. O

Rehberg O
, O
H O
. O

Van O
Aken O
, O
C O
. O

Ince O
, O
C O
. O

Ertmer O
P176 O
- O
A O
single O
centre O
nested O
pilot O
study O
investigating O
the O
effect O
of O
using O
0.9 O
% O
saline O
or O
Plasma-Lyte O
148 O
® O
as O
crystalloid O
fluid O
therapy O
on O
gastrointestinal O
feeding O
intolerance O
in O
mechanically O
ventilated O
patients O
receiving O
nasogastric O
enteral O
nutrition O
S O
. O

Reddy O
, O
M O
. O

Bailey O
, O
R O
. O

Beasley O
, O
R O
. O

Bellomo O
, O
D O
. O

Mackle O
, O
A O
. O

Psirides O
, O
P O
. O

Young O
P177 O
- O
A O
single O
centre O
nested O
pilot O
study O
investigating O
the O
effect O
on O
post-operative O
bleeding O
of O
using O
0.9 O
% O
saline O
or O
Plasma-Lyte O
® O
148 O
as O
crystalloid O
fluid O
therapy O
in O
adults O
in O
ICU O
after O
heart O
surgery O
S O
. O

Reddy O
, O
M O
. O

Bailey O
, O
R O
. O

Beasley O
, O
R O
. O

Bellomo O
, O
D O
. O

Mackle O
, O
P O
. O

Young O
P178 O
- O
Extreme O
hypernatremia O
and O
sepsis O
in O
a O
patient O
with O
Huntington O
’ O
s O
dementia O
: O
a O
conundrum O
in O
fluid O
management O
H O
. O

Venkatesh O
, O
S O
. O

Ramachandran O
, O
A O
. O

Basu O
, O
H O
. O

Nair O
P179 O
- O
Diagnosis O
and O
management O
of O
severe O
hypernatraemia O
in O
the O
critical O
care O
setting O
S O
. O

Egan O
, O
J O
. O

Bates O
P180 O
- O
Correlation O
between O
arterial O
blood O
gas O
and O
electrolyte O
disturbances O
during O
hospitalization O
and O
outcome O
in O
critically O
ill O
patients O
S O
. O

Oliveira O
, O
N O
. O

R O
. O

Rangel O
Neto O
, O
F O
. O

Q O
. O

Reis O
P181 O
- O
Missing O
the O
“ O
I O
” O
in O
MUDPILES O
– O
a O
rare O
cause O
of O
high O
anion O
gap O
metabolic O
acidosis O
( O
HAGMA O
) O
C O
. O

P O
. O

Lee O
, O
X O
. O

L O
. O

Lin O
, O
C O
. O

Choong O
, O
K O
. O

M O
. O

Eu O
, O
W O
. O

Y O
. O

Sim O
, O
K O
. O

S O
. O

Tee O
, O
J O
. O

Pau O
, O
J O
. O

Abisheganaden O
P182 O
- O
Plasma O
NGAL O
and O
urinary O
output O
: O
potential O
parameters O
for O
early O
initiation O
of O
renal O
replacement O
therapy O
K O
. O

Maas O
, O
H O
. O

De O
Geus O
P183 O
- O
Renal O
replacement O
therapy O
for O
critically O
ill O
patients O
: O
an O
intermittent O
continuity O
E O
. O

Lafuente O
, O
R O
. O

Marinho O
, O
J O
. O

Moura O
, O
R O
. O

Antunes O
, O
A O
. O

Marinho O
P184 O
- O
A O
survey O
of O
practices O
related O
to O
renal O
replacement O
therapy O
in O
critically O
ill O
patients O
in O
the O
north O
of O
England O
. O

T O
. O

E O
. O

Doris O
, O
D O
. O

Monkhouse O
, O
T O
. O

Shipley O
, O
S O
. O

Kardasz O
, O
I O
Gonzalez O
P185 O
- O
High O
initiation O
creatinine O
associated O
with O
lower O
28 O
- O
day O
mortality O
in O
critically O
ill O
patients O
necessitating O
continuous O
renal O
replacement O
therapy O
S O
. O

Stads O
, O
A O
. O

J O
. O

Groeneveld O
P186 O
- O
The O
impact O
of O
Karnofsky O
performance O
scale O
on O
outcomes O
in O
acute O
kidney O
injury O
patients O
receiving O
renal O
replacement O
therapy O
on O
the O
intensive O
care O
unit O
I O
. O

Elsayed O
, O
N O
. O

Ward O
, O
A O
. O

Tridente O
, O
A O
. O

Raithatha O
P187 O
- O
Severe O
hypophosphatemia O
during O
citrate-anticoagulated O
CRRT O
A O
. O

Steuber O
, O
C O
. O

Pelletier O
, O
S O
. O

Schroeder O
, O
E O
. O

Michael O
, O
T O
. O

Slowinski O
, O
D O
. O

Kindgen-Milles O
P188 O
- O
Citrate O
regional O
anticoagulation O
for O
post O
dilution O
continuous O
renal O
replacement O
therapy O
S O
. O

Ghabina O
P189 O
- O
Citrate O
18 O
mmol O
/ O
l O
improves O
anticoagulation O
during O
RRT O
with O
adsorbing O
filters O
F O
. O

Turani O
, O
A O
. O

Belli O
, O
S O
. O

Busatti O
, O
G O
. O

Barettin O
, O
F O
. O

Candidi O
, O
F O
. O

Gargano O
, O
R O
. O

Barchetta O
, O
M O
. O

Falco O
P190 O
- O
Calcium O
gluconate O
instead O
of O
calcium O
chloride O
in O
citrate-anticoagulated O
CVVHD O
O O
. O

Demirkiran O
, O
M O
. O

Kosuk O
, O
S O
. O

Bozbay O
P191 O
- O
Enhanced O
clearance O
of O
interleukin O
- O
6 O
with O
continuous O
veno-venous O
haemodialysis O
( O
CVVHD O
) O
using O
Ultraflux O
EMiC2 O
vs O
. O

Ultraflux O
AV1000S O
V O
. O

Weber O
, O
J O
. O

Hartmann O
, O
S O
. O

Harm O
, O
I O
. O

Linsberger O
, O
T O
. O

Eichhorn O
, O
G O
. O

Valicek O
, O
G O
. O

Miestinger O
, O
C O
. O

Hoermann O
P192 O
- O
Removal O
of O
bilirubin O
with O
a O
new O
adsorbent O
system O
: O
in O
vitro O
kinetics O
S O
. O

Faenza O
, O
D O
. O

Ricci O
, O
E O
. O

Mancini O
, O
C O
. O

Gemelli O
, O
A O
. O

Cuoghi O
, O
S O
. O

Magnani O
, O
M O
. O

Atti O
P193 O
- O
Case O
series O
of O
patients O
with O
severe O
sepsis O
and O
septic O
shock O
treated O
with O
a O
new O
extracorporeal O
sorbent O
T O
. O

Laddomada O
, O
A O
. O

Doronzio O
, O
B O
. O

Balicco O
P194 O
- O
In O
vitro O
adsorption O
of O
a O
broad O
spectrum O
of O
inflammatory O
mediators O
with O
CytoSorb O
® O
hemoadsorbent O
polymer O
beads O
M O
. O

C O
. O

Gruda O
, O
P O
. O

O O
’ O
Sullivan O
, O
V O
. O

P O
. O

Dan O
, O
T O
. O

Guliashvili O
, O
A O
. O

Scheirer O
, O
T O
. O

D O
. O

Golobish O
, O
V O
. O

J O
. O

Capponi O
, O
P O
. O

P O
. O

Chan O
P195 O
- O
Observations O
in O
early O
vs O
. O
late O
use O
of O
cytosorb O
therapy O
in O
critically O
ill O
patients O
K O
. O

Kogelmann O
, O
M O
. O

Drüner O
, O
D O
. O

Jarczak O
P196 O
- O
Oxiris O
membrane O
decreases O
endotoxin O
during O
rrt O
in O
septic O
patients O
with O
basal O
EAA O
> O
0,6 O
F O
. O

Turani O
, O
A O
. O

B O
. O

Belli O
, O
S O
. O

M O
. O

Martni O
, O
V O
. O

C O
. O

Cotticelli O
, O
F O
. O

Mounajergi O
, O
R O
. O

Barchetta O
P197 O
- O
An O
observational O
prospective O
study O
on O
the O
onset O
of O
augmented O
renal O
clearance O
: O
the O
first O
report O
S O
. O

Morimoto O
, O
H O
. O

Ishikura O
P198 O
- O
An O
ultrasound O
- O
guided O
algorithm O
for O
the O
management O
of O
oliguria O
in O
severe O
sepsis O
I O
. O

Hussain O
, O
N O
. O

Salahuddin O
, O
A O
. O

Nadeem O
, O
K O
. O

Ghorab O
, O
K O
. O

Maghrabi O
P199 O
- O
Ultrasound O
in O
acute O
kidney O
injury O
( O
aki O
) O
. O

First O
findings O
of O
farius O
, O
an O
education-programme O
in O
structural O
ultrasonography O
S O
. O

K O
. O

Kloesel O
, O
C O
. O

Goldfuss O
, O
A O
. O

Stieglitz O
, O
A O
. O

S O
. O

Stieglitz O
, O
L O
. O

Krstevska O
, O
G O
. O

Albuszies O
P200 O
- O
Effectiveness O
of O
renal O
angina O
index O
score O
predicting O
acute O
kidney O
injury O
on O
critically O
ill O
patients O
M O
. O

Aguilar O
Arzapalo O
, O
L O
. O

Barradas O
, O
V O
. O

Lopez O
, O
A O
. O

Escalante O
, O
G O
. O

Jimmy O
, O
M O
. O

Cetina O
P201 O
- O
Time O
length O
below O
blood O
pressure O
thresholds O
and O
progression O
of O
acute O
kidney O
injury O
in O
critically O
ill O
patients O
with O
or O
without O
sepsis O
: O
a O
retrospective O
, O
exploratory O
cohort O
study O
J O
. O

Izawa O
, O
T O
. O

Iwami O
, O
S O
. O

Uchino O
, O
M O
. O

Takinami O
, O
T O
. O

Kitamura O
, O
T O
. O

Kawamura O
P202 O
- O
Anaemia O
does O
not O
affect O
renal O
recovery O
in O
acute O
kidney O
injury O
J O
. O

G O
. O

Powell-Tuck O
, O
S O
. O

Crichton O
, O
M O
. O

Raimundo O
, O
L O
. O

Camporota O
, O
D O
. O

Wyncoll O
, O
M O
. O

Ostermann O
P203 O
- O
Estimated O
glomerular O
filtration O
rate O
based O
on O
serum O
creatinine O
: O
actual O
practice O
in O
Dutch O
ICU O
’ O
s O
A O
. O

Hana O
, O
H O
. O

R O
. O

De O
Geus O
P204 O
- O
Comparison O
of O
estimated O
glomerular O
filtration O
rate O
calculated O
by O
mdrd O
, O
ckd-epi-serum-creatinine O
and O
ckd-epi-cystatin-c O
in O
adult O
critically O
ill O
patients O
H O
. O

R O
. O

De O
Geus O
, O
A O
. O

Hana O
P205 O
- O
Early O
diagnosis O
of O
septic O
acute O
kidney O
injury O
in O
medical O
critical O
care O
patients O
with O
a O
urine O
cell O
cycle O
arrest O
marker O
: O
insulin O
like O
growth O
factor O
binding O
protein O
- O
7 O
( O
IGFBP O
- O
7 O
) O
M O
. O

Aydogdu O
, O
N O
. O

Boyaci O
, O
S O
. O

Yuksel O
, O
G O
. O

Gursel O
, O
A O
. O

B O
. O

Cayci O
Sivri O
P206 O
- O
Urinary O
neutrophil O
gelatinase-associated O
lipocalin O
as O
early O
biomarker O
of O
severe O
acute O
kidney O
injury O
in O
intensive O
care O
J O
. O

Meza-Márquez O
, O
J O
. O

Nava-López O
, O
R O
. O

Carrillo-Esper O
P207 O
- O
Shrunken O
pore O
syndrome O
is O
associated O
with O
a O
sharp O
rise O
in O
mortality O
in O
patients O
undergoing O
elective O
coronary O
artery O
bypass O
grafting O
A O
. O

Dardashti O
, O
A O
. O

Grubb O
P208 O
- O
The O
biomarker O
nephrocheck O
™ O
can O
discriminate O
the O
septic O
shock O
patients O
with O
an O
akin O
1 O
or O
2 O
acute O
renal O
failure O
who O
will O
not O
progress O
toward O
the O
akin O
3 O
level O
J O
. O

Maizel O
, O
M O
. O

Wetzstein O
, O
D O
. O

Titeca O
, O
L O
. O

Kontar O
, O
F O
. O

Brazier O
, O
B O
. O

De O
Cagny O
, O
A O
. O

Riviere O
, O
T O
. O

Soupison O
, O
M O
. O

Joris O
, O
M O
. O

Slama O
P209 O
- O
A O
worldwide O
multicentre O
evaluation O
of O
acute O
kidney O
injury O
in O
septic O
and O
non-septic O
critically O
ill O
patients O
: O
the O
intensive O
care O
over O
nations O
( O
icon O
) O
audit O
E O
. O

Peters O
, O
H O
. O

Njimi O
, O
P O
. O

Pickkers O
, O
J O
. O

L O
. O

Vincent O
P210 O
- O
Does O
enhanced O
recovery O
after O
surgery O
reduce O
the O
incidence O
of O
acute O
kidney O
injury O
in O
those O
undergoing O
major O
gynae-oncological O
surgery O
? O

M O
. O

Waraich O
, O
J O
. O

Doyle O
, O
T O
. O

Samuels O
, O
L O
. O

Forni O
P211 O
- O
Identification O
of O
risk O
factors O
for O
the O
development O
of O
acute O
kidney O
injury O
after O
lower O
limb O
arthroplasty O
N O
. O

Desai O
, O
R O
. O

Baumber O
, O
P O
. O

Gunning O
, O
A O
. O

Sell O
P212 O
- O
Incidences O
and O
associations O
of O
acute O
kidney O
injury O
after O
major O
trauma O
S O
. O

Lin O
, O
H O
. O

Torrence O
, O
M O
. O

O O
’ O
Dwyer O
, O
C O
. O

Kirwan O
, O
J O
. O

Prowle O
P213 O
- O
Acute O
kidney O
injury O
of O
major O
trauma O
patients O
T O
Kim O
P214 O
- O
Trajectory O
of O
serum O
creatinine O
after O
major O
surgery O
and O
the O
diagnosis O
of O
acute O
kidney O
injury O
M O
. O

E O
. O

O O
’ O
Connor O
, O
R O
. O

W O
. O

Hewson O
, O
C O
. O

J O
. O

Kirwan O
, O
R O
. O

M O
. O

Pearse O
, O
J O
. O

Prowle O
P215 O
- O
Epidemiology O
of O
acute O
kidney O
injury O
after O
cardiac O
surgery O
. O

A O
single O
center O
retrospective O
study O
S O
. O

Hanoura O
, O
A O
. O

Omar O
, O
H O
. O

Othamn O
, O
S O
. O

Sudarsanan O
, O
M O
. O

Allam O
, O
M O
. O

Maksoud O
, O
R O
. O

Singh O
, O
A O
. O

Al O
Khulaifi O
P216 O
- O
Post-operative O
acute O
kidney O
injury O
after O
major O
non-cardiac O
surgery O
and O
its O
association O
with O
death O
in O
the O
following O
year O
M O
. O

E O
. O

O O
’ O
Connor O
, O
R O
. O

W O
. O

Hewson O
, O
C O
. O

J O
. O

Kirwan O
, O
R O
. O

M O
. O

Pearse O
, O
J O
. O

Prowle O
P217 O
- O
Factors O
affecting O
acute O
renal O
failure O
in O
intensive O
care O
unit O
and O
effect O
of O
these O
factors O
on O
mortality O
O O
. O

Uzundere O
, O
D O
. O

Memis O
, O
M O
. O

Ýnal O
, O
A O
. O
, O
N O
. O

Turan O
P218 O
- O
Results O
of O
the O
live O
kidney O
transplantations O
according O
to O
national O
data O
of O
turkish O
organ O
and O
tissue O
information O
system O
M O
. O

A O
. O

Aydin O
, O
H O
. O

Basar O
, O
I O
. O

Sencan O
, O
A O
. O

Kapuagasi O
, O
M O
. O

Ozturk O
, O
Z O
. O

Uzundurukan O
, O
D O
. O

Gokmen O
, O
A O
. O

Ozcan O
, O
C O
. O

Kaymak O
P219 O
- O
Anaesthesia O
procedure O
and O
intensive O
therapy O
in O
patients O
with O
neck O
phlegmon O
V O
. O

A O
. O

Artemenko O
, O
A O
. O

Budnyuk O
P220 O
- O
Nasal O
high O
flow O
oygen O
for O
acute O
respiratory O
failure O
: O
a O
systematic O
review O
R O
. O

Pugh O
, O
S O
. O

Bhandari O
P221 O
- O
Setting O
optimal O
flow O
rate O
during O
high O
flow O
nasal O
cannula O
support O
: O
preliminary O
results O
T O
. O

Mauri O
, O
C O
. O

Turrini O
, O
T O
. O

Langer O
, O
P O
. O

Taccone O
, O
C O
. O

A O
. O

Volta O
, O
C O
. O

Marenghi O
, O
L O
. O

Gattinoni O
, O
A O
. O

Pesenti O
P222 O
- O
Dose O
to O
dose O
consistency O
across O
two O
different O
gas O
flow O
rates O
using O
cystic O
fibrosis O
and O
normal O
adult O
breathing O
profiles O
during O
nasal O
high O
flow O
oxygen O
therapy O
L O
. O

Sweeney O
, O
A O
. O

O O
’ O
Sullivan O
, O
P O
. O

Kelly O
, O
E O
. O

Mukeria O
, O
R O
. O

MacLoughlin O
P223 O
- O
Final O
results O
of O
an O
evaluation O
of O
airway O
medix O
closed O
suction O
system O
compared O
to O
a O
standard O
closed O
suction O
system O
M O
. O

Pfeffer O
, O
J O
. O

T O
. O

Thomas O
, O
G O
. O

B O
. O

Bregman O
, O
G O
. O

K O
. O

Karp O
, O
E O
. O

K O
. O

Kishinevsky O
, O
D O
. O

S O
. O

Stavi O
, O
N O
. O

A O
. O

Adi O
P224 O
- O
Different O
cuff O
materials O
and O
different O
leak O
tests O
- O
one O
size O
does O
not O
fit O
all O
T O
. O

Poropat O
, O
R O
. O

Knafelj O
P225 O
- O
Observational O
study O
on O
the O
value O
of O
the O
cuff-leak O
test O
and O
the O
onset O
of O
upper O
airway O
obstruction O
after O
extubation O
E O
. O

Llopart O
, O
M O
. O

Batlle O
, O
C O
. O

De O
Haro O
, O
J O
. O

Mesquida O
, O
A O
. O

Artigas O
P226 O
- O
A O
device O
for O
emergency O
transtracheal O
lung O
ventilation O
D O
. O

Pavlovic O
, O
L O
. O

Lewerentz O
, O
A O
. O

Spassov O
, O
R O
. O

Schneider O
P227 O
- O
Long-term O
outcome O
and O
health-related O
quality O
of O
life O
in O
patients O
discharged O
from O
the O
intensive O
care O
unit O
with O
a O
tracheostomy O
and O
with O
or O
without O
prolonged O
mechanical O
ventilation O
S O
. O

De O
Smet O
, O
S O
. O

De O
Raedt O
, O
E O
. O

Derom O
, O
P O
Depuydt O
, O
S O
. O

Oeyen O
, O
D O
. O

Benoit O
, O
J O
. O

Decruyenaere O
P228 O
- O
Ultrasound-guided O
percutaneous O
dilational O
tracheostomy O
versus O
bronchoscopy-guided O
percutaneous O
dilational O
tracheostomy O
in O
critically O
ill O
patients O
( O
trachus O
) O
: O
a O
randomized O
clinical O
trial O
A O
. O

Gobatto O
, O
B O
. O

Bese O
, O
P O
. O

Tierno O
, O
L O
. O

Melro O
, O
P O
. O

Mendes O
, O
F O
. O

Cadamuro O
, O
M O
. O

Park O
, O
L O
. O

M O
. O

Malbouisson O
P229 O
- O
Is O
it O
safe O
to O
discharge O
patients O
with O
tracheostomy O
from O
the O
ICU O
to O
the O
ward O
? O

B O
. O

C O
. O

Civanto O
, O
J O
. O

L O
. O

Lopez O
, O
A O
. O

Robles O
, O
J O
. O

Figueira O
, O
S O
. O

Yus O
, O
A O
. O

Garcia O
P230 O
- O
The O
application O
of O
tracheostomy O
in O
children O
in O
ICU O
A O
. O

Oglinda O
, O
G O
. O

Ciobanu O
, O
C O
. O

Oglinda O
, O
L O
. O

Schirca O
, O
T O
. O

Sertinean O
, O
V O
. O

Lupu O
P231 O
- O
The O
impact O
of O
passive O
humidifiers O
on O
aerosol O
drug O
delivery O
during O
mechanical O
ventilation O
P O
. O

Kelly O
, O
A O
. O

O O
’ O
Sullivan O
, O
L O
. O

Sweeney O
, O
R O
. O

MacLoughlin O
P232 O
- O
Evaluation O
of O
vibrating O
mesh O
and O
jet O
nebuliser O
performance O
at O
two O
different O
attachment O
setups O
in O
line O
with O
a O
humidifier O
nebuliser O
system O
A O
. O

O O
’ O
Sullivan O
, O
P O
. O

Kelly O
, O
L O
. O

Sweeney O
, O
E O
. O

Mukeria O
, O
M O
. O

Wolny O
, O
R O
. O

MacLoughlin O
P233 O
- O
Psv-niv O
versus O
cpap O
in O
the O
treatment O
of O
acute O
cardiogenic O
pulmonary O
edema O
A O
. O

Pagano O
, O
F O
. O

Numis O
, O
G O
. O

Vison O
, O
L O
. O

Saldamarco O
, O
T O
. O

Russo O
, O
G O
. O

Porta O
, O
F O
. O

Paladino O
P234 O
- O
Noninvasive O
ventilation O
in O
patients O
with O
haematologic O
malignancy O
: O
a O
retrospective O
review O
C O
. O

Bell O
, O
J O
. O

Liu O
, O
J O
. O

Debacker O
, O
C O
. O

Lee O
, O
E O
. O

Tamberg O
, O
V O
. O

Campbell O
, O
S O
. O

Mehta O
P235 O
- O
Use O
of O
non-invasive O
ventilation O
in O
infectious O
diseases O
besides O
classical O
indications O
A O
. O

Silva-Pinto O
, O
A O
. O

Sarmento O
, O
L O
. O

Santos O
P236 O
- O
The O
impact O
of O
fragility O
on O
noninvasive O
mechanical O
ventilation O
application O
and O
results O
in O
the O
ICU O
Ý O
. O

Kara O
, O
F O
. O

Yýldýrým O
, O
A O
. O

Zerman O
, O
Z O
. O

Güllü O
, O
N O
. O

Boyacý O
, O
B O
. O

Basarýk O
Aydogan O
, O
Ü O
. O

Gaygýsýz O
, O
K O
. O

Gönderen O
, O
G O
. O

Arýk O
, O
M O
. O

Turkoglu O
, O
M O
. O

Aydogdu O
, O
G O
. O

Aygencel O
, O
Z O
. O

Ülger O
, O
G O
. O

Gursel O
P237 O
- O
Effects O
of O
metabolic O
alkalosis O
on O
noninvasive O
ventilation O
success O
and O
ICU O
outcome O
in O
patients O
with O
hypercapnic O
respiratory O
failure O
N O
. O

Boyacý O
, O
Z O
. O

Isýkdogan O
, O
Ö O
. O

Özdedeoglu O
, O
Z O
. O

Güllü O
, O
M O
. O

Badoglu O
, O
U O
. O

Gaygýsýz O
, O
M O
. O

Aydogdu O
, O
G O
. O

Gursel O
P238 O
- O
Asynchrony O
index O
and O
breathing O
patterns O
of O
acute O
exacerbation O
copd O
patients O
assisted O
with O
noninvasive O
pressure O
support O
ventilation O
and O
neurally O
adjusted O
ventilatory O
assist O
N O
. O

Kongpolprom O
, O
C O
. O

Sittipunt O
P239 O
- O
High O
frequency O
jet O
ventilation O
for O
severe O
acute O
hypoxemia O
A O
. O

Eden O
, O
Y O
. O

Kokhanovsky O
, O
S O
. O

Bursztein O
– O
De O
Myttenaere O
, O
R O
. O

Pizov O
P240 O
- O
HFOV O
revisited O
: O
a O
7 O
year O
retrospective O
analysis O
of O
patients O
receiving O
HFOV O
who O
met O
oscillate O
trial O
entry O
criteria O
L O
. O

Neilans O
, O
N O
. O

MacIntyre O
P241 O
- O
Implementation O
of O
a O
goal-directed O
mechanical O
ventilation O
order O
set O
driven O
by O
respiratory O
therapists O
can O
improve O
compliance O
with O
best O
practices O
for O
mechanical O
ventilation O
M O
. O

Radosevich O
, O
B O
. O

Wanta O
, O
V O
. O

Weber O
, O
T O
. O

Meyer O
, O
N O
. O

Smischney O
, O
D O
. O

Brown O
, O
D O
. O

Diedrich O
P242 O
- O
A O
reduction O
in O
tidal O
volumes O
for O
ventilated O
patients O
on O
ICU O
calculated O
from O
IBW O
. O
can O
it O
minimise O
mortality O
in O
comparison O
to O
traditional O
strategies O
? O

A O
. O

Fuller O
, O
P O
. O

McLindon O
, O
K O
. O

Sim O
P243 O
- O
Predictive O
value O
of O
lung O
aeration O
scoring O
using O
lung O
ultrasound O
in O
weaning O
failure O
M O
. O

Shoaeir O
, O
K O
. O

Noeam O
, O
A O
. O

Mahrous O
, O
R O
. O

Matsa O
, O
A O
. O

Ali O
P244 O
- O
Conventional O
versus O
automated O
weaning O
from O
mechanical O
ventilation O
using O
SmartCare O
™ O
C O
. O

Dridi O
, O
S O
. O

Koubaji O
, O
S O
. O

Kamoun O
, O
F O
. O

Haddad O
, O
A O
. O

Ben O
Souissi O
, O
B O
. O

Laribi O
, O
A O
. O

Riahi O
, O
M O
. O

S O
. O

Mebazaa O
P245 O
- O
Ultrasonographic O
evaluation O
protocol O
for O
weaning O
from O
mechanichal O
ventilation O
A O
. O

Pérez-Calatayud O
, O
R O
. O

Carrillo-Esper O
, O
A O
. O

Zepeda-Mendoza O
, O
M O
. O

Diaz-Carrillo O
, O
E O
. O

Arch-Tirado O
P246 O
- O
Diaphragm O
ultrasonography O
: O
a O
method O
for O
weaning O
patients O
from O
mechanical O
ventilation O
S O
. O

Carbognin O
, O
L O
. O

Pelacani O
, O
F O
. O

Zannoni O
, O
A O
. O

Agnoli O
, O
G O
. O

Gagliardi O
P247 O
- O
Dorsal O
diaphragmatic O
excursion O
tracks O
transpulmonary O
pressure O
in O
ventilated O
ARDS O
patients O
: O
a O
potential O
non-invasive O
indicator O
of O
lung O
recruitment O
? O

R O
. O

Cho O
, O
A O
. O

Adams O
, O
S O
. O

Lunos O
, O
S O
. O

Ambur O
, O
R O
. O

Shapiro O
, O
M O
. O

Prekker O
P248 O
- O
Pulse O
oximetry O
in O
the O
icu O
patient O
: O
is O
the O
perfusion O
index O
of O
any O
value O
? O

M O
. O

Thijssen O
, O
L O
. O

Janssen O
, O
N O
. O

Foudraine O
P249 O
- O
Ventilation O
is O
a O
better O
assessment O
of O
respiratory O
status O
than O
EtCO2 O
C O
. O

J O
. O

Voscopoulos O
, O
J O
. O

Freeman O
P250 O
- O
Evaluation O
of O
the O
relationship O
between O
non-invasive O
minute O
ventilation O
and O
end-tidal O
CO2 O
in O
patients O
undergoing O
general O
vs O
spinal O
anesthesia O
C O
. O

J O
. O

Voscopoulos O
, O
J O
. O

Freeman O
, O
E O
. O

George O
P251 O
- O
Respiratory O
volume O
monitoring O
provides O
early O
warning O
of O
respiratory O
depression O
and O
can O
be O
used O
to O
reduce O
false O
alarms O
in O
non-intubated O
patients O
C O
. O

J O
. O

Voscopoulos O
, O
D O
. O

Eversole O
, O
J O
. O

Freeman O
, O
E O
. O

George O
P252 O
- O
P O
/ O
i O
index O
: O
a O
predictive O
edi-derived O
weaning O
index O
during O
nava O
S O
. O

Muttini O
, O
R O
. O

Bigi O
, O
G O
. O

Villani O
, O
N O
. O

Patroniti O
P253 O
- O
Adequacy O
of O
ventilation O
in O
patients O
receiving O
opioids O
in O
the O
post O
anesthesia O
care O
unit O
: O
minute O
ventilation O
versus O
respiratory O
rate O
G O
. O

Williams O
, O
C O
. O

J O
. O

Voscopoulos O
, O
J O
. O

Freeman O
, O
E O
. O

George O
P254 O
- O
Comparison O
of O
regional O
and O
global O
expiratory O
time O
constants O
measured O
by O
electrical O
impedance O
tomography O
( O
EIT O
) O
A O
. O

Waldmann O
, O
S O
. O

Böhm O
, O
W O
. O

Windisch O
, O
S O
. O

Strassmann O
, O
C O
. O

Karagiannidis O
P255 O
- O
Electrical O
impedance O
tomography O
: O
robustness O
of O
a O
new O
pixel O
wise O
regional O
expiratory O
time O
constant O
calculation O
A O
. O

Waldmann O
, O
S O
. O

Böhm O
, O
W O
. O

Windisch O
, O
S O
. O

Strassmann O
, O
C O
. O

Karagiannidis O
P256 O
- O
Validation O
of O
regional O
and O
global O
expiratory O
time O
constant O
measurement O
by O
electrical O
impedance O
tomography O
in O
ards O
and O
obstructive O
pulmonary O
diseases O
C O
. O

K O
. O

Karagiannidis O
, O
A O
. O

W O
. O

Waldmann O
, O
S O
. O

B O
. O

Böhm O
, O
S O
. O

Strassmann O
, O
W O
. O

W O
. O

Windisch O
P257 O
- O
Transpulmonary O
pressure O
in O
a O
model O
with O
elastic O
recoiling O
lung O
and O
expanding O
chest O
wall O
P O
. O

Persson O
, O
S O
. O

Lundin O
, O
O O
. O

Stenqvist O
P258 O
- O
Lactate O
in O
pleural O
and O
abdominal O
effusion O
G O
. O

Porta O
, O
F O
. O

Numis O
, O
C O
. O

S O
. O

Serra O
, O
A O
. O

P O
. O

Pagano O
, O
M O
. O

M O
. O

Masarone O
, O
L O
. O

R O
. O

Rinaldi O
, O
A O
. O

A O
. O

Amelia O
, O
M O
. O

F O
. O

Fascione O
, O
L O
. O

A O
. O

Adinolfi O
, O
E O
. O

R O
. O

Ruggiero O
P259 O
- O
Outcome O
of O
patients O
admitted O
to O
the O
intensive O
care O
with O
pulmonary O
fibrosis O
F O
. O

Asota O
, O
K O
. O

O O
’ O
Rourke O
, O
S O
. O

Ranjan O
, O
P O
. O

Morgan O
P260 O
- O
Sedation O
and O
analgesia O
practice O
in O
extra-corporeal O
membrane O
oxygenation O
( O
ECMO O
) O
- O
treated O
patients O
with O
acute O
respiratory O
distress O
syndrome O
( O
ARDS O
) O
: O
a O
retrospective O
study O
J O
. O

W O
. O

DeBacker O
, O
E O
. O

Tamberg O
, O
L O
. O

O O
’ O
Neill O
, O
L O
. O

Munshi O
, O
L O
. O

Burry O
, O
E O
. O

Fan O
, O
S O
. O

Mehta O
P261 O
- O
Characteristics O
and O
outcomes O
of O
patients O
deemed O
not O
eligible O
when O
referred O
for O
veno-venous O
extracorporeal O
membrane O
oxygenation O
( O
vv-ECMO O
) O
S O
. O

Poo O
, O
K O
. O

Mahendran O
, O
J O
. O

Fowles O
, O
C O
. O

Gerrard O
, O
A O
. O

Vuylsteke O
P262 O
- O
The O
SAVE O
SMR O
for O
veno-arterial O
ECMO O
R O
. O

Loveridge O
, O
C O
. O

Chaddock O
, O
S O
. O

Patel O
, O
V O
. O

Kakar O
, O
C O
. O

Willars O
, O
T O
. O

Hurst O
, O
C O
. O

Park O
, O
T O
. O

Best O
, O
A O
. O

Vercueil O
, O
G O
. O

Auzinger O
P263 O
- O
A O
simplified O
score O
to O
predict O
early O
( O
48 O
h O
) O
mortality O
in O
patients O
being O
considered O
for O
VA-ECMO O
A O
. O

Borgman O
, O
A O
. O

G O
. O

Proudfoot O
, O
E O
. O

Grins O
, O
K O
. O

E O
. O

Emiley O
, O
J O
. O

Schuitema O
, O
S O
. O

J O
. O

Fitch O
, O
G O
. O

Marco O
, O
J O
. O

Sturgill O
, O
M O
. O

G O
. O

Dickinson O
, O
M O
. O

Strueber O
, O
A O
. O

Khaghani O
, O
P O
. O

Wilton O
, O
S O
. O

M O
. O

Jovinge O
P264 O
- O
Lung O
function O
six O
months O
post O
extra O
corporeal O
membrane O
oxygenation O
( O
ECMO O
) O
for O
severe O
acute O
respiratory O
failure O
in O
adult O
survivors O
C O
. O

Sampson O
, O
S O
. O

Harris-Fox O
P265 O
- O
Bicarbonate O
dialysis O
removes O
carbon O
dioxide O
in O
hypoventilated O
rodents O
. O

M O
. O

E O
. O

Cove O
, O
L O
. O

H O
. O

Vu O
, O
A O
. O

Sen O
, O
W O
. O

J O
. O

Federspiel O
, O
J O
. O

A O
. O

Kellum O
P266 O
- O
Procalcitonin O
as O
predictor O
of O
primary O
graft O
dysfunction O
and O
mortality O
in O
post-lung O
transplantation O
C O
. O

Mazo O
Torre O
, O
J O
. O

Riera O
, O
S O
. O

Ramirez O
, O
B O
. O

Borgatta O
, O
L O
. O

Lagunes O
, O
J O
. O

Rello O
P267 O
- O
New O
molecular O
biomarkers O
of O
acute O
respiratory O
distress O
syndrome O
in O
abdominal O
sepsis O
A O
. O

K O
. O

Kuzovlev O
, O
V O
. O

Moroz O
, O
A O
. O

Goloubev O
, O
S O
. O

Polovnikov O
, O
S O
. O

Nenchuk O
P268 O
- O
Tight O
junction O
’ O
s O
proteins O
claudin O
- O
5 O
and O
regulation O
by O
tnf O
in O
experimental O
murine O
lung O
injury O
model O
of O
ali O
/ O
ards O
V O
. O

Karavana O
, O
C O
. O

Glynos O
, O
A O
. O

Asimakos O
, O
K O
. O

Pappas O
, O
C O
. O

Vrettou O
, O
M O
. O

Magkou O
, O
E O
. O

Ischaki O
, O
G O
. O

Stathopoulos O
, O
S O
. O

Zakynthinos O
P269 O
- O
Cell O
counts O
in O
endobronchial O
aspirate O
to O
assess O
airway O
inflammation O
in O
ARDS O
patients O
: O
a O
pilot O
study O
S O
. O

Spadaro O
, O
I O
. O

Kozhevnikova O
, O
F O
. O

Dalla O
Corte O
, O
S O
. O

Grasso O
, O
P O
. O

Casolari O
, O
G O
. O

Caramori O
, O
C O
. O

Volta O
P270 O
- O
Epidemiological O
and O
clinical O
profile O
of O
patients O
with O
acute O
respiratory O
distress O
syndrome O
in O
the O
surgical O
intensive O
care O
unit O
surgical O
, O
hospital O
JRA O
, O
Antananarivo O
T O
. O

Andrianjafiarinoa O
, O
T O
. O

Randriamandrato O
, O
T O
. O

Rajaonera O
P271 O
- O
Effect O
of O
high O
PEEP O
after O
recruitment O
maneuver O
on O
right O
ventricular O
function O
in O
ARDS O
. O

Is O
it O
good O
for O
the O
lung O
and O
for O
the O
heart O
? O

S O
. O

El-Dash O
, O
ELV O
Costa O
, O
MR O
Tucci O
, O
F O
Leleu O
, O
L O
Kontar O
, O
B O
. O

De O
Cagny O
, O
F O
. O

Brazier O
, O
D O
. O

Titeca O
, O
G O
. O

Bacari-Risal O
, O
J O
. O

Maizel O
, O
M O
. O

Amato O
, O
M O
. O

Slama O
P272 O
- O
Effect O
of O
recruitment O
maneuver O
on O
left O
ventricular O
systolic O
strain O
P O
. O

Mercado O
, O
J O
. O

Maizel O
, O
L O
. O

Kontar O
, O
D O
. O

Titeca O
, O
F O
. O

Brazier O
, O
A O
. O

Riviere O
, O
M O
. O

Joris O
, O
T O
. O

Soupison O
, O
B O
. O

De O
Cagny O
, O
S O
. O

El O
Dash O
, O
M O
. O

Slama O
P273 O
- O
Inhaled O
nitric O
oxide O
– O
is O
switching O
supplier O
cost O
effective O
? O

Remmington O
, O
A O
. O

Fischer O
, O
S O
. O

Squire O
, O
M O
. O

Boichat O
P274 O
- O
Epidemiological O
study O
of O
severe O
acute O
pancreatitis O
in O
Japan O
, O
comparison O
of O
the O
etiology O
and O
the O
patient O
outcomes O
on O
1159 O
patients O
. O

H O
. O

Honzawa O
, O
H O
. O

Yasuda O
, O
T O
. O

Adati O
, O
S O
. O

Suzaki O
, O
M O
. O

Horibe O
, O
M O
. O

Sasaki O
, O
M O
. O

Sanui O
P275 O
- O
Extracorporeal O
liver O
support O
therapy O
. O

Experience O
in O
an O
intensive O
care O
unit O
R O
. O

Marinho O
, O
J O
. O

Daniel O
, O
H O
. O

Miranda O
, O
A O
. O

Marinho O
P276 O
- O
Accuracy O
of O
mortality O
prediction O
models O
in O
acute O
versus O
acute-on-chronic O
liver O
failure O
in O
the O
intensive O
care O
setting O
K O
. O

Milinis O
, O
M O
. O

Cooper O
, O
G O
. O

R O
. O

Williams O
, O
E O
. O

McCarron O
, O
S O
. O

Simants O
, O
I O
. O

Patanwala O
, O
I O
. O

Welters O
P277 O
- O
Risk O
of O
coronary O
artery O
disease O
in O
patients O
with O
chronic O
liver O
disease O
: O
a O
population O
based O
cohort O
study O
Y O
. O

Su O
P278 O
- O
20 O
years O
of O
liver O
transplantation O
in O
Santiago O
de O
Compostela O
( O
Spain O
) O
. O

Experience O
review O
J O
. O

Fernández O
Villanueva O
, O
R O
. O

Fernández O
Garda O
, O
A O
. O

López O
Lago O
, O
E O
. O

Rodríguez O
Ruíz O
, O
R O
. O

Hernández O
Vaquero O
, O
S O
. O

Tomé O
Martínez O
de O
Rituerto O
, O
E O
. O

Varo O
Pérez O
P279 O
- O
Diarrhea O
is O
a O
risk O
factor O
for O
liver O
injury O
and O
may O
lead O
to O
intestinal O
failure O
associated O
liver O
disease O
in O
critical O
illness O
N O
. O

Lefel O
, O
F O
. O

Schaap O
, O
D O
. O

Bergmans O
, O
S O
. O

Olde O
Damink O
, O
M O
. O

Van O
de O
Poll O
P280 O
- O
Bowel O
care O
on O
the O
intensive O
care O
unit O
: O
constipation O
guideline O
compliance O
and O
complications O
K O
. O

Tizard O
, O
C O
. O

Lister O
, O
L O
. O

Poole O
P281 O
- O
Malnutrition O
assessed O
by O
phase O
angle O
determines O
outcomes O
in O
low O
risk O
cardiac O
surgery O
patients O
D O
. O

Ringaitiene O
, O
D O
. O

Gineityte O
, O
V O
. O

Vicka O
, O
I O
. O

Norkiene O
, O
J O
. O

Sipylaite O
P282 O
- O
Preoperative O
fasting O
times O
in O
an O
irish O
hospital O
A O
. O

O O
’ O
Loughlin O
, O
V O
. O

Maraj O
, O
J O
. O

Dowling O
P283 O
- O
Costs O
and O
final O
outcome O
of O
early O
x O
delayed O
feeding O
in O
a O
private O
Brazil O
ICU O
M O
. O

B O
. O

Velasco O
, O
D O
. O

M O
. O

Dalcomune O
, O
E O
. O

B O
. O

Dias O
, O
S O
. O

L O
. O

Fernandes O
P284 O
- O
Can O
ventilator O
derived O
energy O
expenditure O
measurements O
replace O
indirect O
calorimetry O
? O

T O
. O

Oshima O
, O
S O
. O

Graf O
, O
C O
. O

Heidegger O
, O
L O
. O

Genton O
, O
V O
. O

Karsegard O
, O
Y O
. O

Dupertuis O
, O
C O
. O

Pichard O
P285 O
- O
Revisiting O
the O
refeeding O
syndrome O
: O
results O
of O
a O
systematic O
review O
N O
. O

Friedli O
, O
Z O
. O

Stanga O
, O
B O
. O

Mueller O
, O
P O
. O

Schuetz O
P286 O
- O
Compliance O
with O
the O
new O
protocol O
for O
parenteral O
nutrition O
in O
our O
ICU O
L O
. O

Vandersteen O
, O
B O
. O

Stessel O
, O
S O
. O

Evers O
, O
A O
. O

Van O
Assche O
, O
L O
. O

Jamaer O
, O
J O
. O

Dubois O
P287 O
- O
Nutrition O
may O
be O
another O
treatment O
in O
the O
intensive O
care O
unit O
where O
less O
is O
more O
? O

R O
. O

Marinho O
, O
H O
. O

Castro O
, O
J O
. O

Moura O
, O
J O
. O

Valente O
, O
P O
. O

Martins O
, O
P O
. O

Casteloes O
, O
C O
. O

Magalhaes O
, O
S O
. O

Cabral O
, O
M O
. O

Santos O
, O
B O
. O

Oliveira O
, O
A O
. O

Salgueiro O
, O
A O
. O

Marinho O
P288 O
- O
Should O
we O
provide O
more O
protein O
to O
critically O
ill O
patients O
? O

R O
. O

Marinho O
, O
M O
. O

Santos O
, O
E O
. O

Lafuente O
, O
H O
. O

Castro O
, O
S O
. O

Cabral O
, O
J O
. O

Moura O
, O
P O
. O

Martins O
, O
B O
. O

Oliveira O
, O
A O
. O

Salgueiro O
, O
S O
. O

Duarte O
, O
S O
. O

Castro O
, O
M O
. O

Melo O
, O
P O
. O

Casteloes O
, O
A O
. O

Marinho O
P289 O
Protein O
provision O
in O
an O
adult O
intensive O
care O
unit O
S O
. O

Gray O
P290 O
- O
Prevalence O
and O
clinical O
outcomes O
of O
vitamin O
d O
deficiency O
in O
the O
medical O
critically O
ill O
patients O
in O
Songklanagarind O
hospital O
K O
. O

Maipang O
, O
R O
. O

Bhurayanontachai O
P291 O
- O
Vitamin O
d O
deficiency O
strongly O
predicts O
adverse O
medical O
outcome O
across O
different O
medical O
inpatient O
populations O
: O
results O
from O
a O
prospective O
study O
L O
. O

G O
. O

Grädel O
, O
P O
. O

Schütz O
P292 O
- O
Omega O
- O
3 O
fatty O
acids O
in O
patients O
undergoing O
cardiac O
surgery O
: O
a O
systematic O
review O
and O
meta-analysis O
P O
. O

Langlois O
, O
W O
. O

Manzanares O
P293 O
- O
Can O
5 O
- O
hydroxytriptophan O
prevent O
post-traumatic O
stress O
disorder O
in O
critically O
ill O
patients O
? O

R O
. O

Tincu O
, O
C O
. O

Cobilinschi O
, O
D O
. O

Tomescu O
, O
Z O
. O

Ghiorghiu O
, O
R O
. O

Macovei O
P294 O
- O
Parenteral O
selenium O
in O
the O
critically O
ill O
: O
an O
updated O
systematic O
review O
and O
meta-analysis O
W O
. O

Manzanares O
, O
P O
. O

Langlois O
, O
M O
. O

Lemieux O
, O
G O
. O

Elke O
, O
F O
. O

Bloos O
, O
K O
. O

Reinhart O
, O
D O
. O

Heyland O
P295 O
- O
Probiotics O
in O
the O
critically O
ill O
: O
an O
updated O
systematic O
review O
and O
meta-analysis O
P O
. O

Langlois O
, O
M O
. O

Lemieux O
, O
I O
. O

Aramendi O
, O
D O
. O

Heyland O
, O
W O
. O

Manzanares O
P296 O
- O
Diabetes O
with O
hyperglycemic O
crisis O
episodes O
may O
be O
associated O
with O
higher O
risk O
of O
pancreatic O
cancer O
: O
a O
population-based O
cohort O
study O
Y O
. O

Su O
P297 O
- O
Incidence O
of O
hypoglycemia O
in O
an O
intensive O
care O
unit O
depending O
on O
insulin O
protocol O
R O
. O

Marinho O
, O
N O
. O

Babo O
, O
A O
. O

Marinho O
P298 O
- O
Severity O
of O
the O
diseases O
is O
two-dimensionally O
correlated O
to O
blood O
glucose O
, O
including O
blood O
glucose O
variability O
, O
especially O
in O
moderately O
to O
severely O
ill O
patients O
with O
glucose O
intolerance O
. O

M O
. O

Hoshino O
, O
Y O
. O

Haraguchi O
, O
S O
. O

Kajiwara O
, O
T O
. O

Mitsuhashi O
, O
T O
. O

Tsubata O
, O
M O
. O

Aida O
P299 O
- O
A O
study O
of O
glycemic O
control O
by O
subcutaneous O
glargine O
injection O
transition O
from O
continuous O
regular O
insulin O
infusion O
in O
critically O
ill O
patients O
T O
. O

Rattanapraphat O
, O
R O
. O

Bhurayanontachai O
, O
C O
. O

Kongkamol O
, O
B O
. O

Khwannimit O
P300 O
- O
Glycemic O
control O
in O
Portuguese O
intensive O
care O
unit O
R O
. O

Marinho O
, O
M O
. O

Santos O
, O
H O
. O

Castro O
, O
E O
. O

Lafuente O
, O
A O
. O

Salgueiro O
, O
S O
. O

Cabral O
, O
P O
. O

Martins O
, O
J O
. O

Moura O
, O
B O
. O

Oliveira O
, O
M O
. O

Melo O
, O
B O
. O

Xavier O
, O
J O
. O

Valente O
, O
C O
. O

Magalhaes O
, O
P O
. O

Casteloes O
, O
A O
. O

Marinho O
P301 O
- O
Impact O
of O
hyperglycemia O
duration O
on O
the O
day O
of O
operation O
on O
short-term O
outcome O
of O
cardiac O
surgery O
patients O
D O
. O

Moisidou O
, O
F O
. O

Ampatzidou O
, O
C O
. O

Koutsogiannidis O
, O
M O
. O

Moschopoulou O
, O
G O
. O

Drossos O
P302 O
- O
Lactate O
levels O
in O
diabetic O
ketoacidosis O
patients O
at O
ICU O
admissions O
G O
. O

Taskin O
, O
M O
. O

Çakir O
, O
AK O
Güler O
, O
A O
. O

Taskin O
, O
N O
. O

Öcal O
, O
S O
. O

Özer O
, O
L O
. O

Yamanel O
P303 O
- O
Intensive O
care O
implications O
of O
merging O
heart O
attack O
centre O
units O
in O
London O
J O
. O

M O
. O

Wong O
, O
C O
. O

Fitton O
, O
S O
. O

Anwar O
, O
S O
. O

Stacey O
P304 O
- O
Special O
characteristics O
of O
in-hospital O
cardiac O
arrests O
M O
. O

Aggou O
, O
B O
. O

Fyntanidou O
, O
S O
. O

Patsatzakis O
, O
E O
. O

Oloktsidou O
, O
K O
. O

Lolakos O
, O
E O
. O

Papapostolou O
, O
V O
. O

Grosomanidis O
P305 O
- O
Clinical O
evaluation O
of O
ICU-admitted O
patients O
who O
were O
resuscitated O
in O
the O
general O
medicine O
ward O
S O
. O

Suda O
, O
T O
. O

Ikeda O
, O
S O
. O

Ono O
, O
T O
. O

Ueno O
, O
Y O
. O

Izutani O
P306 O
- O
Serious O
game O
evaluation O
of O
a O
one-hour O
training O
basic O
life O
support O
session O
for O
secondary O
school O
students O
: O
new O
tools O
for O
future O
bystanders O
S O
. O

Gaudry O
, O
V O
. O

Desailly O
, O
P O
. O

Pasquier O
, O
PB O
Brun O
, O
AT O
Tesnieres O
, O
JD O
Ricard O
, O
D O
. O

Dreyfuss O
, O
A O
. O

Mignon O
P307 O
- O
Public O
and O
clinical O
staff O
perceptions O
and O
knowledge O
of O
CPR O
compared O
to O
local O
and O
national O
data O
J O
. O

C O
White O
, O
A O
. O

Molokhia O
, O
A O
. O

Dean O
, O
A O
. O

Stilwell O
, O
G O
. O

Friedlaender O
P308 O
Dispatcher-assisted O
telephone O
cardiopulmonary O
resuscitation O
using O
a O
French-language O
compression-ventilation O
pediatric O
protocol O
M O
. O

Peters O
, O
S O
. O

Stipulante O
, O
A O
. O

Delfosse O
, O
AF O
Donneau O
, O
A O
. O

Ghuysen O
P309 O
Dantrolene O
versus O
amiodarone O
for O
resuscitation O
– O
an O
experimental O
study O
C O
. O

Feldmann O
, O
D O
. O

Freitag O
, O
W O
. O

Dersch O
, O
M O
. O

Irqsusi O
, O
D O
. O

Eschbach O
, O
T O
. O

Steinfeldt O
, O
H O
. O

Wulf O
, O
T O
. O

Wiesmann O
P310 O
Long O
term O
survival O
and O
functional O
neurological O
outcome O
in O
comatose O
survivors O
undergoing O
therapeutic O
hypothermia O
N O
. O

Kongpolprom O
, O
J O
. O

Cholkraisuwat O
P311 O
Impact O
of O
kidney O
disease O
on O
mortality O
and O
neurological O
outcome O
in O
out-of-hospital O
cardiac O
arrest O
: O
a O
prospective O
observational O
study O
S O
. O

Beitland O
, O
E O
. O

Nakstad O
, O
H O
. O

Stær-Jensen O
, O
T O
. O

Drægni O
, O
G O
. O

Andersen O
, O
D O
. O

Jacobsen O
, O
C O
. O

Brunborg O
, O
B O
. O

Waldum-Grevbo O
, O
K O
. O

Sunde O
P312 O
ICU O
dependency O
of O
patients O
admitted O
after O
primary O
percutaneous O
coronary O
intervention O
( O
PPCI O
) O
following O
out O
of O
the O
hospital O
cardiac O
arrest O
K O
. O

Hoyland O
, O
D O
. O

Pandit O
P313 O
Prognostic O
indicators O
and O
outcome O
prediction O
model O
for O
patients O
with O
return O
of O
spontaneous O
circulation O
from O
cardiopulmonary O
arrest O
: O
comprehensive O
registry O
of O
in-hospital O
intensive O
care O
on O
OHCA O
survival O
( O
critical O
) O
study O
in O
Osaka O
, O
Japan O
K O
. O

Hayakawa O
P314 O
Cerebral O
oxygen O
saturation O
during O
resuscitation O
in O
a O
porcine O
model O
of O
cardiac O
arrest O
E O
. O

Oloktsidou O
, O
K O
. O

Kotzampassi O
, O
B O
. O

Fyntanidou O
, O
S O
. O

Patsatzakis O
, O
L O
. O

Loukipoudi O
, O
E O
. O

Doumaki O
, O
V O
. O

Grosomanidis O
P315 O
Presumption O
of O
cardiopulmonary O
resuscitation O
for O
sustaining O
cerebral O
oxidation O
using O
regional O
cerebral O
saturation O
of O
oxygen O
: O
observational O
cohort O
study O
( O
press O
study O
) O
H O
. O

Yasuda O
P316 O
EEG O
reactivity O
in O
patients O
after O
cardiac O
arrest O
: O
a O
close O
look O
at O
stimuli O
MM O
Admiraal O
, O
M O
. O

Van O
Assen O
, O
MJ O
Van O
Putten O
, O
M O
. O

Tjepkema-Cloostermans O
, O
AF O
Van O
Rootselaar O
, O
J O
. O

Horn O
P317 O
Prognostic O
value O
of O
neuron-specific O
enolase O
after O
cardiac O
arrest O
F O
. O

Ragusa O
, O
A O
. O

Marudi O
, O
S O
. O

Baroni O
, O
A O
. O

Gaspari O
, O
E O
. O

Bertellini O
P318 O
Correlation O
between O
electroencephalographic O
findings O
and O
serum O
neuron O
specific O
enolase O
with O
outcome O
of O
post O
cardiac O
arrest O
patients O
A O
. O

Taha O
, O
T O
. O

Abdullah O
, O
S O
. O

Abdel O
Monem O
P319 O
Introduction O
of O
a O
targeted O
temperature O
management O
strategy O
following O
cardiac O
arrest O
in O
a O
district O
general O
hospital O
intensive O
care O
unit O
. O

S O
. O

Alcorn O
, O
S O
. O

McNeill O
, O
S O
. O

Russell O
P320 O
The O
evolution O
of O
cerebral O
oxygen O
saturation O
in O
post-cardiac O
arrest O
patients O
treated O
with O
therapeutic O
hypothermia O
W O
. O

Eertmans O
, O
C O
. O

Genbrugge O
, O
I O
. O

Meex O
, O
J O
. O

Dens O
, O
F O
. O

Jans O
, O
C O
. O

De O
Deyne O
P321 O
Prognostic O
factors O
and O
neurological O
outcomes O
of O
therapeutic O
hypothermia O
in O
comatose O
survivors O
from O
cardiac O
arrest O
: O
8 O
- O
year O
single O
center O
experience O
J O
. O

Cholkraisuwat O
, O
N O
. O

Kongpolprom O
P322 O
Adherence O
to O
targeted O
temperature O
management O
after O
out O
of O
hospital O
cardiac O
arrest O
B O
. O

Avard O
, O
R O
. O

Burns O
P323 O
Implementation O
of O
a O
therapeutic O
hypothermia O
protocol O
for O
comatose O
survivors O
of O
out-of-hospital O
cardiac O
arrest O
. O

A O
. O

Patarchi O
, O
T O
. O

Spina O
P324 O
Factors O
associated O
with O
ventilator O
weaning O
after O
targeted O
temperature O
management O
for O
cardiac O
arrest O
patients O
in O
japan O
H O
. O

Tanaka O
, O
N O
. O

Otani O
, O
S O
. O

Ode O
, O
S O
. O

Ishimatsu O
P325 O
Differential O
activation O
of O
c-fos O
in O
paraventricular O
nuclei O
of O
the O
hypothalamus O
and O
thalamus O
of O
the O
rat O
following O
myocardial O
infarction O
J O
. O

Cho O
, O
J O
. O

B O
. O

Moon O
, O
C O
. O

W O
. O

Park O
, O
T O
. O

G O
. O

Ohk O
, O
M O
. O

C O
. O

Shin O
, O
M O
. O

H O
. O

Won O
P326 O
Monitoring O
of O
cTroponin O
I O
in O
patients O
with O
acute O
ischemic O
stroke O
- O
predictor O
of O
inhospital O
mortality O
S O
. O

Dakova O
, O
Z O
. O

Ramsheva O
, O
K O
. O

Ramshev O
P327 O
Hyperthermic O
preconditioning O
severely O
accelerates O
neuronal O
damage O
in O
the O
gerbil O
ischemic O
hippocampal O
dentate O
gyrus O
via O
decreasing O
sods O
expressions O
J O
. O

Cho O
, O
J O
. O

B O
. O

Moon O
, O
C O
. O

W O
. O

Park O
, O
T O
. O

G O
. O

Ohk O
, O
M O
. O

C O
. O

Shin O
P328 O
Failure O
in O
neuroprotection O
of O
remote O
limb O
ischemic O
post O
conditioning O
in O
the O
hippocampus O
of O
a O
gerbil O
model O
of O
transient O
cerebral O
ischemia O
J O
. O

Cho O
, O
J O
. O

B O
. O

Moon O
, O
C O
. O

W O
. O

Park O
, O
T O
. O

G O
. O

Ohk O
, O
M O
. O

C O
. O

Shin O
P329 O
Brain O
death O
and O
admission O
diagnosis O
in O
neurologic O
intensive O
care O
unit O
, O
a O
correlation O
? O

A O
Marudi O
, O
S O
Baroni O
, O
A O
Gaspari O
, O
E O
Bertellini O
P330 O
Brain O
magnetic O
resonance O
imaging O
findings O
in O
patients O
with O
septic O
shock O
G O
. O

Orhun O
, O
E O
. O

Senturk O
, O
P O
. O

E O
. O

Ozcan O
, O
S O
. O

Sencer O
, O
C O
. O

Ulusoy O
, O
E O
. O

Tuzun O
, O
F O
. O

Esen O
P331 O
Benefits O
of O
L-carnitine O
in O
valproic O
acid O
induced O
encephalopathy O
R O
. O

Tincu O
, O
C O
. O

Cobilinschi O
, O
D O
. O

Tomescu O
, O
Z O
. O

Ghiorghiu O
, O
R O
. O

Macovei O
P332Automatic O
analysis O
of O
EEG O
reactivity O
in O
comatose O
patients O
M O
. O

Van O
Assen O
, O
M O
. O

M O
. O

Admiraal O
, O
M O
. O

J O
. O

Van O
Putten O
, O
M O
. O

Tjepkema-Cloostermans O
, O
A O
. O

F O
. O

Van O
Rootselaar O
, O
J O
. O

Horn O
P333 O
Usefulness O
of O
common O
ICU O
severity O
scoring O
systems O
in O
predicting O
outcome O
after O
spontaneous O
intracerebral O
hemorrhage O
M O
. O

Fallenius O
, O
M O
. O

B O
. O

Skrifvars O
, O
M O
. O

Reinikainen O
, O
S O
. O

Bendel O
, O
R O
. O

Raj O
P334 O
Evalution O
of O
patients O
with O
suspected O
subarachnoid O
haemorrhage O
and O
negative O
ct O
imaging O
M O
. O

Abu-Habsa O
, O
C O
. O

Hymers O
, O
A O
. O

Borowska O
, O
H O
. O

Sivadhas O
, O
S O
. O

Sahiba O
, O
S O
. O

Perkins O
P335 O
Timing O
of O
endovascular O
and O
surgical O
treatment O
for O
aneurysmal O
subarachnoid O
haemorrhage O
: O
early O
but O
not O
so O
fast O
. O

J O
. O

Rubio O
, O
J O
. O

A O
. O

Rubio O
, O
R O
. O

Sierra O
P336 O
Red O
blood O
cell O
transfusion O
in O
aneurysmal O
subarachnoid O
hemorrhage O
– O
the O
Sahara O
cohort O
study O
S O
. O

English O
, O
M O
. O

Chasse O
, O
A O
. O

Turgeon O
, O
F O
. O

Lauzier O
, O
D O
. O

Griesdale O
, O
A O
. O

Garland O
, O
D O
. O

Fergusson O
, O
R O
. O

Zarychanski O
, O
A O
. O

Tinmouth O
, O
C O
. O

Van O
Walraven O
, O
K O
. O

Montroy O
, O
J O
. O

Ziegler O
, O
R O
. O

Dupont O
Chouinard O
, O
R O
. O

Carignan O
, O
A O
. O

Dhaliwal O
, O
C O
. O

Lum O
, O
J O
. O

Sinclair O
, O
G O
. O

Pagliarello O
, O
L O
. O

McIntyre O
P337 O
- O
Aneurysmal O
subarachnoid O
hemorrhage O
and O
anemia O
: O
a O
canadian O
multi-centre O
retrospective O
cohort O
study O
S O
. O

English O
, O
M O
. O

Chasse O
, O
A O
. O

Turgeon O
, O
F O
. O

Lauzier O
, O
D O
. O

Griesdale O
, O
A O
. O

Garland O
, O
D O
. O

Fergusson O
, O
R O
. O

Zarychanski O
, O
A O
. O

Tinmouth O
, O
C O
. O

Van O
Walraven O
, O
K O
. O

Montroy O
, O
J O
. O

Ziegler O
, O
R O
. O

Dupont O
Chouinard O
, O
R O
. O

Carignan O
, O
A O
. O

Dhaliwal O
, O
C O
. O

Lum O
, O
J O
. O

Sinclair O
, O
G O
. O

Pagliarello O
, O
L O
. O

McIntyre O
P338 O
- O
Does O
the O
neutrophil-to-lymphocyte O
( O
NLR O
) O
ratio O
predict O
symptomatic O
vasospasm O
or O
delayed O
cerebral O
ischemia O
( O
DCI O
) O
after O
aneurysmal O
subarachnoid O
haemorrhage O
( O
SAH O
) O
? O

T O
. O

Groza O
, O
N O
. O

Moreau O
, O
D O
. O

Castanares-Zapatero O
, O
P O
. O

Hantson O
P339 O
- O
ICU-acquired O
infections O
in O
aneurysmal O
subarachnoid O
hemorrhage O
patients O
: O
impact O
on O
ICU O
and O
hospital O
length O
of O
stay O
M O
. O

Carbonara O
, O
F O
. O

Ortolano O
, O
T O
. O

Zoerle O
, O
S O
. O

Magnoni O
, O
S O
. O

Pifferi O
, O
V O
. O

Conte O
, O
N O
. O

Stocchetti O
P340 O
- O
Cerebral O
metabolic O
effects O
of O
normobaric O
hyperoxia O
during O
the O
acute O
phase O
of O
aneurysmal O
subarachnoid O
hemorrhage O
L O
. O

Carteron O
, O
T O
. O

Suys O
, O
C O
. O

Patet O
, O
H O
. O

Quintard O
, O
M O
. O

Oddo O
P341 O
- O
Postoperative O
care O
for O
elective O
craniotomy O
: O
where O
is O
best O
done O
? O

J O
. O

A O
. O

Rubio O
, O
J O
. O

Rubio O
, O
R O
. O

Sierra O
P342 O
- O
5 O
- O
year O
follow-up O
of O
patients O
after O
transplantation O
of O
organs O
from O
donors O
from O
neurocritical O
care O
V O
. O

Spatenkova O
, O
E O
. O

Pokorna O
, O
P O
. O

Suchomel O
P343 O
- O
Evaluation O
of O
levetiracetam O
pharmacokinetics O
after O
severe O
traumatic O
brain O
injury O
in O
neurocritical O
care O
patients O
at O
a O
level O
one O
trauma O
center O
N O
. O

Ebert O
, O
J O
. O

Jancik O
, O
H O
. O

Rhodes O
P344 O
- O
Model O
based O
time O
series O
cluster O
analysis O
to O
determine O
unique O
patient O
states O
in O
traumatic O
brain O
injury O
T O
. O

Bylinski O
, O
C O
. O

Hawthorne O
, O
M O
. O

Shaw O
, O
I O
. O

Piper O
, O
J O
. O

Kinsella O
P345 O
- O
Brain O
compartment O
monitoring O
capabilities O
from O
ICP O
to O
BI O
( O
bioimpedance O
) O
during O
HS O
( O
hypertonic O
saline O
) O
administration O
. O

State O
of O
art O
simulation O
outcome O
depending O
on O
brain O
swelling O
type O
A O
. O

K O
. O

Kink O
, O
I O
. O

R O
. O

Rätsep O
P346 O
- O
Transfusion O
of O
red O
blood O
cells O
in O
patients O
with O
traumatic O
brain O
injury O
admitted O
to O
Canadian O
trauma O
health O
centers O
: O
a O
multicenter O
cohort O
study O
A O
. O

Boutin O
, O
L O
. O

Moore O
, O
M O
. O

Chasse O
, O
R O
. O

Zarychanski O
, O
F O
. O

Lauzier O
, O
S O
. O

English O
, O
L O
. O

McIntyre O
, O
J O
. O

Lacroix O
, O
D O
. O

Griesdale O
, O
P O
. O

Lessard-Bonaventure O
, O
A O
. O

F O
. O

Turgeon O
P347 O
- O
Hemoglobin O
thresholds O
and O
red O
blood O
cell O
transfusions O
in O
adult O
patients O
with O
moderate O
or O
severe O
traumatic O
brain O
injury O
: O
a O
retrospective O
cohort O
study O
A O
. O

Boutin O
, O
L O
. O

Moore O
, O
R O
. O

Green O
, O
P O
. O

Lessard-Bonaventure O
, O
M O
. O

Erdogan O
, O
M O
. O

Butler O
, O
F O
. O

Lauzier O
, O
M O
. O

Chasse O
, O
S O
. O

English O
, O
L O
. O

McIntyre O
, O
R O
. O

Zarychanski O
, O
J O
. O

Lacroix O
, O
D O
. O

Griesdale O
, O
P O
. O

Desjardins O
, O
D O
. O

A O
. O

Fergusson O
, O
A O
. O

F O
. O

Turgeon O
P348 O
- O
Characteristics O
of O
patients O
with O
gunshot O
wounds O
to O
the O
head O
- O
an O
observational O
Brazilian O
study O
B O
. O

Goncalves O
, O
B O
. O

Vidal O
, O
C O
. O

Valdez O
, O
A O
. O

C O
. O

Rodrigues O
, O
L O
. O

Miguez O
, O
G O
. O

Moralez O
P349 O
- O
Base O
excess O
as O
predictor O
for O
ICU O
admission O
and O
the O
injury O
severity O
in O
blunt O
trauma O
patients O
T O
. O

Hong O
P350 O
- O
Enhancement O
of O
usual O
emergency O
department O
care O
with O
proadrenomedullin O
to O
improve O
outcome O
prediction O
- O
Results O
from O
the O
multi-national O
, O
prospective O
, O
observational O
TRIAGE O
study O
A O
. O

Kutz O
, O
P O
. O

Hausfater O
, O
D O
. O

Amin O
, O
T O
. O

Struja O
, O
S O
. O

Haubitz O
, O
A O
. O

Huber O
, O
B O
. O

Mueller O
, O
P O
. O

Schuetz O
P351 O
- O
Developing O
an O
innovative O
emergency O
medicine O
point-of-care O
simulation O
programme O
T O
. O

Brown O
, O
J O
. O

Collinson O
, O
C O
. O

Pritchett O
, O
T O
. O

Slade O
P352 O
- O
The O
InSim O
program O
: O
an O
in O
situ O
simulation O
program O
for O
junior O
trainees O
in O
intensive O
care O
M O
. O

Le O
Guen O
, O
S O
. O

Hellings O
, O
R O
. O

Ramsaran O
P353 O
- O
Impact O
of O
excessive O
and O
inappropriate O
troponin O
testing O
in O
the O
emergency O
setting O
how O
good O
are O
we O
A O
. O

Alsheikhly O
P354 O
- O
The O
development O
of O
time O
tracking O
monitor O
at O
emergency O
department O
T O
. O

Abe O
P355 O
- O
Role O
of O
focussed O
echocardiography O
in O
emergency O
assessment O
of O
syncope O
L O
. O

Kanapeckaite O
, O
M O
. O

Abu-Habsa O
, O
R O
. O

Bahl O
P356 O
- O
Insertion O
of O
an O
open-ended O
14 O
- O
gauge O
catheter O
through O
the O
chest O
wall O
causes O
a O
significant O
pneumothorax O
in O
a O
self-ventilating O
swine O
model O
M O
. O

Q O
Russell O
, O
K O
. O

J O
. O

Real O
, O
M O
. O

Abu-Habsa O
, O
R O
. O

M O
. O

Lyon O
, O
N O
. O

P O
. O

Oveland O
P357 O
- O
Ez-io O
® O
intraosseous O
access O
teaching O
in O
the O
workplace O
using O
a O
mobile O
‘ O
tea O
trolley O
’ O
training O
method O
J O
. O

Penketh O
, O
M O
. O

Mcdonald O
, O
F O
. O

Kelly O
P358 O
- O
Black O
widow O
envenomation O
in O
Saudi O
Arabia O
: O
a O
prospective O
observational O
case O
series O
M O
. O

Alfafi O
, O
S O
. O

Alsolamy O
, O
W O
. O

Almutairi O
, O
B O
. O

Alotaibi O
P359 O
- O
Mechanical O
ventilation O
in O
patients O
with O
overdose O
not O
yet O
intubated O
on O
icu O
admission O
A O
. O

E O
. O

Van O
den O
Berg O
, O
Y O
. O

Schriel O
, O
L O
. O

Dawson O
, O
I O
. O

A O
. O

Meynaar O
P360 O
- O
Central O
nervous O
system O
depressants O
poisoning O
and O
ventilator O
associated O
pneumonia O
: O
an O
underrated O
risk O
factor O
in O
toxicological O
intensive O
care O
unit O
H O
. O

Talaie O
P361 O
- O
Acute O
barium O
intoxication O
treated O
with O
hemodiafiltration O
D O
. O

Silva O
, O
S O
. O

Fernandes O
, O
J O
. O

Gouveia O
, O
J O
. O

Santos O
Silva O
P362 O
- O
Major O
trauma O
presenting O
to O
the O
emergency O
department O
. O
the O
spectrum O
of O
cycling O
injuries O
in O
Ireland O
J O
. O

Foley O
, O
A O
. O

Kaskovagheorgescu O
, O
D O
. O

Evoy O
, O
J O
. O

Cronin O
, O
J O
. O

Ryan O
P363 O
- O
Burns O
from O
French O
military O
operations O
: O
a O
14 O
- O
year O
retrospective O
observational O
analysis O
. O

M O
. O

Huck O
, O
C O
. O

Hoffmann O
, O
J O
. O

Renner O
, O
P O
. O

Laitselart O
, O
N O
. O

Donat O
, O
A O
. O

Cirodde O
, O
J O
. O

V O
. O

Schaal O
, O
Y O
. O

Masson O
, O
A O
. O

Nau O
, O
T O
. O

Leclerc O
P364 O
- O
A O
comparison O
of O
mortality O
scores O
in O
burns O
patients O
on O
the O
intensive O
care O
unit O
. O

O O
. O

Howarth O
, O
K O
. O

Davenport O
, O
P O
. O

Jeanrenaud O
, O
S O
. O

Raftery O
P365 O
- O
Clasification O
of O
pain O
and O
its O
treatment O
and O
an O
intensive O
care O
rehabiliation O
clinic O
P O
. O

MacTavish O
, O
H O
. O

Devine O
, O
J O
. O

McPeake O
, O
M O
. O

Daniel O
, O
J O
. O

Kinsella O
, O
T O
. O

Quasim O
P366 O
- O
Pain O
management O
adequacy O
in O
critical O
care O
areas O
, O
the O
process O
and O
the O
barriers O
perceived O
by O
critical O
care O
nurses O
S O
. O

Alrabiee O
, O
A O
. O

Alrashid O
, O
S O
. O

Alsolamy O
P367 O
- O
Pain O
assessment O
in O
critically O
ill O
adult O
patients O
: O
validation O
of O
the O
Turkish O
version O
of O
the O
critical-care O
pain O
observation O
tool O
O O
. O

Gundogan O
, O
C O
. O

Bor O
, O
E O
. O

Akýn O
Korhan O
, O
K O
. O

Demirag O
, O
M O
. O

Uyar O
P368 O
- O
An O
audit O
of O
pain O
and O
sedation O
assessments O
in O
the O
intensive O
care O
unit O
: O
recommendations O
for O
clinical O
practice O
F O
. O

Frame O
, O
C O
. O

Ashton O
, O
L O
. O

Bergstrom O
Niska O
P369 O
- O
Impact O
of O
pharmaceutical O
care O
on O
treatment O
of O
pain O
and O
agitation O
in O
medical O
intensive O
care O
unit O
P O
. O

Dilokpattanamongkol O
, O
T O
. O

Suansanae O
, O
C O
. O

Suthisisang O
, O
S O
. O

Morakul O
, O
C O
. O

Karnjanarachata O
, O
V O
. O

Tangsujaritvijit O
P370 O
- O
Agitation O
in O
trauma O
ICU O
, O
prevention O
and O
outcome O
S O
. O

Mahmood O
, O
H O
. O

Al O
Thani O
, O
A O
. O

Almenyar O
P371 O
Correlation O
between O
percentages O
of O
ventilated O
patients O
developed O
vap O
and O
use O
of O
sedative O
agents O
in O
icu O
patients O
. O

A O
. O

Vakalos O
, O
V O
. O

Avramidis O
P372 O
- O
Improving O
recording O
of O
sedation O
events O
in O
the O
Emergency O
Department O
: O
The O
implementation O
of O
the O
SIVA O
International O
Taskforce O
adverse O
event O
reporting O
tool O
for O
procedural O
sedation O
R O
. O

Sharvill O
, O
J O
. O

Penketh O
P373 O
- O
Impact O
of O
sedative O
drug O
use O
on O
the O
length O
of O
mechanical O
ventilation O
S O
. O

E O
. O

Morton O
, O
Y O
. O

S O
. O

Chiew O
, O
C O
. O

Pretty O
, O
J O
. O

G O
. O

Chase O
, O
G O
. O

M O
. O

Shaw O
P374 O
- O
Co-administration O
of O
nitric O
oxide O
and O
sevoflurane O
using O
anaconda O
R O
. O

Knafelj O
, O
P O
. O

Kordis O
P375 O
- O
A O
retrospective O
study O
of O
the O
use O
of O
Dexmedetomidine O
in O
an O
oncological O
critical O
care O
setting O
S O
. O

Patel O
, O
V O
. O

Grover O
P376 O
- O
Dexmedetomidine O
and O
posttraumatic O
stress O
disorder O
incidence O
in O
alcohol O
withdrawal O
icu O
patients O
I O
. O

Kuchyn O
, O
K O
. O

Bielka O
P377 O
- O
Hemodynamic O
effects O
of O
dexmedetomidine O
in O
a O
porcine O
model O
of O
septic O
shock O
Z O
. O

Aidoni O
, O
V O
. O

Grosomanidis O
, O
K O
. O

Kotzampassi O
, O
G O
. O

Stavrou O
, O
B O
. O

Fyntanidou O
, O
S O
. O

Patsatzakis O
, O
C O
. O

Skourtis O
P378 O
- O
Ketamine O
for O
analgosedation O
in O
severe O
hypoxic O
respiratory O
failure O
S O
. O

D O
. O

Lee O
, O
K O
. O

Williams O
, O
I O
. O

D O
. O

Weltes O
P379 O
- O
Madness O
from O
the O
moon O
? O

lunar O
cycle O
and O
the O
incidence O
of O
delirium O
on O
the O
intensive O
care O
unit O
S O
. O

Berhane O
, O
C O
. O

Arrowsmith O
, O
C O
. O

Peters O
, O
S O
. O

Robert O
P380 O
- O
Impaired O
dynamic O
cerebral O
autoregulation O
after O
coronary O
artery O
bypass O
grafting O
and O
association O
with O
postoperative O
delirium O
J O
. O

Caldas O
, O
R O
. O

B O
. O

Panerai O
, O
T O
. O

G O
. O

Robinson O
, O
L O
. O

Camara O
, O
G O
. O

Ferreira O
, O
E O
. O

Borg-Seng-Shu O
, O
M O
. O

De O
Lima O
Oliveira O
, O
N O
. O

C O
. O

Mian O
, O
L O
. O

Santos O
, O
R O
. O

Nogueira O
, O
S O
. O

P O
. O

Zeferino O
, O
M O
. O

Jacobsen O
Teixeira O
, O
F O
. O

Galas O
, O
L O
. O

A O
. O

Hajjar O
P381 O
- O
Risk O
factors O
predicting O
prolonged O
intensive O
care O
unit O
length O
of O
stay O
after O
major O
elective O
surgery O
. O

P O
. O

Killeen O
, O
M O
. O

McPhail O
, O
W O
. O

Bernal O
, O
J O
. O

Maggs O
, O
J O
. O

Wendon O
, O
T O
. O

Hughes O
P382 O
- O
Systemic O
inflammatory O
response O
syndrome O
criteria O
and O
hospital O
mortality O
prediction O
in O
a O
brazilian O
cohort O
of O
critically O
ill O
patients O
L O
. O

U O
. O

Taniguchi O
, O
E O
. O

M O
. O

Siqueira O
, O
J O
. O

M O
. O

Vieira O
Jr O
, O
L O
. O

C O
. O

Azevedo O
P383 O
- O
Evaluating O
the O
efficacy O
of O
a O
risk O
predictor O
panel O
in O
identifying O
patients O
at O
elevated O
risk O
of O
morbidity O
following O
emergency O
admission O
A O
. O

N O
. O

Ahmad O
, O
M O
. O

Abu-Habsa O
, O
R O
. O

Bahl O
, O
E O
. O

Helme O
, O
S O
. O

Hadfield O
, O
R O
. O

Loveridge O
P384 O
- O
A O
retrospective O
comparison O
of O
outcomes O
for O
elective O
surgical O
patients O
admitted O
post-operatively O
to O
the O
critical O
care O
unit O
or O
general O
ward O
J O
. O

Shak O
, O
C O
. O

Senver O
, O
R O
. O

Howard-Griffin O
P385 O
- O
Effect O
of O
obesity O
on O
mortality O
in O
surgical O
critically O
ill O
patients O
. O

P O
. O

Wacharasint O
, O
P O
. O

Fuengfoo O
, O
N O
. O

Sukcharoen O
, O
R O
. O

Rangsin O
P386 O
- O
The O
national O
early O
warning O
score O
( O
news O
) O
reliably O
improves O
adverse O
clinical O
outcome O
prediction O
in O
community-acquired O
pneumonia O
- O
results O
from O
a O
6 O
year O
follow-up O
D O
. O

Sbiti-Rohr O
, O
P O
. O

Schuetz O
P387 O
- O
Clinical O
usefulness O
of O
the O
charlson O
¡ O
¯ O
s O
weighted O
index O
of O
comorbidities O
_ O
as O
prognostic O
factor O
in O
patients O
with O
prolonged O
acute O
mechanical O
ventilation O
H O
. O

Na O
, O
S O
. O

Song O
, O
S O
. O

Lee O
, O
E O
. O

Jeong O
, O
K O
. O

Lee O
P388 O
- O
Comparison O
of O
mortality O
prediction O
scoring O
systems O
in O
patients O
with O
cirrhosis O
admitted O
to O
general O
intensive O
care O
unit O
M O
. O

Cooper O
, O
K O
. O

Milinis O
, O
G O
. O

Williams O
, O
E O
. O

McCarron O
, O
S O
. O

Simants O
, O
I O
. O

Patanwala O
, O
I O
. O

D O
. O

Welters O
P389 O
- O
Impact O
of O
admission O
source O
and O
time O
of O
admission O
on O
outcome O
of O
pediatric O
intensive O
care O
patients O
: O
retrospective O
15 O
years O
study O
E O
. O

Zoumpelouli O
, O
EA O
Volakli O
, O
V O
. O

Chrysohoidou O
, O
S O
. O

Georgiou O
, O
K O
. O

Charisopoulou O
, O
E O
. O

Kotzapanagiotou O
, O
V O
. O

Panagiotidou O
, O
K O
. O

Manavidou O
, O
Z O
. O

Stathi O
, O
M O
. O

Sdougka O
P390 O
- O
Heart O
rate O
variability O
and O
outcomes O
prediction O
in O
critical O
illness O
N O
. O

Salahuddin O
, O
B O
. O

AlGhamdi O
, O
Q O
. O

Marashly O
, O
K O
. O

Zaza O
, O
M O
. O

Sharshir O
, O
M O
. O

Khurshid O
, O
Z O
. O

Ali O
, O
M O
. O

Malgapo O
, O
M O
. O

Jamil O
, O
A O
. O

Shafquat O
, O
M O
. O

Shoukri O
, O
M O
. O

Hijazi O
P391 O
- O
The O
incidence O
and O
outcome O
of O
hyperlactatemia O
in O
the O
post O
anaesthesia O
care O
unit O
T O
. O

Abe O
, O
S O
. O

Uchino O
, O
M O
. O

Takinami O
P392 O
- O
Correlation O
between O
arterial O
blood O
gas O
disturbances O
and O
arterial O
lactate O
levels O
during O
hospitalization O
and O
outcome O
in O
critically O
septic O
patients O
N O
. O

R O
. O

Rangel O
Neto O
, O
S O
. O

Oliveira O
, O
F O
. O

Q O
. O

Reis O
, O
F O
. O

A O
. O

Rocha O
P393 O
- O
External O
validation O
of O
saps O
3 O
and O
mpm O
iii O
scores O
in O
48,816 O
patients O
from O
72 O
brazilian O
icus O
G O
. O

Moralez O
, O
K O
. O

Ebecken O
, O
L O
. O

S O
. O

Rabello O
, O
M O
. O

F O
. O

Lima O
, O
R O
. O

Hatum O
, O
F O
. O

V O
. O

De O
Marco O
, O
A O
. O

Alves O
, O
J O
. O

E O
. O

Pinto O
, O
M O
. O

Godoy O
, O
P O
. O

E O
. O

Brasil O
, O
F O
. O

A O
. O

Bozza O
, O
J O
. O

I O
. O

Salluh O
, O
M O
. O

Soares O
P394 O
- O
The O
frailty O
penalty O
: O
pre-admission O
functional O
status O
confounds O
mortality O
prediction O
models O
in O
critically O
ill O
patients O
J O
. O

Krinsley O
, O
G O
. O

Kang O
P395 O
- O
‘ O
sooner O
rather O
than O
later O
” O
: O
how O
delayed O
discharge O
from O
critical O
care O
leads O
to O
increased O
out O
of O
hours O
discharges O
and O
subsequent O
increase O
in O
in-hospital O
mortality O
. O

J O
. O

Perry O
, O
H O
. O

Hines O
P396 O
- O
Identifying O
poor O
outcome O
patient O
groups O
in O
a O
resource-constrained O
critical O
care O
unit O
K O
. O

M O
. O

Wilkinson O
, O
C O
. O

Tordoff O
, O
B O
. O

Sloan O
, O
M O
. O

C O
. O

Bellamy O
P397 O
- O
Effects O
of O
icu O
weekend O
admission O
and O
discharge O
on O
mortality O
. O

E O
. O

Moreira O
, O
F O
. O

Verga O
, O
M O
. O

Barbato O
, O
G O
. O

Burghi O
P398 O
- O
Organizational O
factors O
, O
outcomes O
and O
resource O
use O
in O
9,946 O
cancer O
patients O
admitted O
to O
70 O
ICUs O
M O
Soares O
, O
U O
. O

V O
. O

Silva O
, O
L O
. O

C O
. O

Azevedo O
, O
A O
. O

P O
. O

Torelly O
, O
J O
. O

M O
. O

Kahn O
, O
D O
. O

C O
. O

Angus O
, O
M O
. O

F O
. O

Knibel O
, O
P O
. O

E O
. O

Brasil O
, O
F O
. O

A O
. O

Bozza O
, O
J O
. O

I O
. O

Salluh O
P399 O
- O
Evaluation O
of O
oncological O
critically O
ill O
patients O
, O
severity O
score O
and O
outcome O
compared O
to O
not O
oncological O
in O
a O
particular O
hospital O
cti O
. O

M O
. O

B O
. O

Velasco O
, O
D O
. O

M O
. O

Dalcomune O
P400 O
- O
Outcomes O
of O
patients O
admitted O
to O
a O
large O
uk O
critical O
care O
department O
with O
palliative O
oncological O
diagnoses O
R O
. O

Marshall O
, O
T O
. O

Gilpin O
, O
A O
. O

Tridente O
, O
A O
. O

Raithatha O
P401 O
- O
Predictors O
of O
mortality O
in O
febrile O
neutropenic O
patients O
with O
haematological O
malignancies O
admitted O
to O
an O
intensive O
care O
unit O
of O
a O
cancer O
center O
D O
. O

Mota O
, O
B O
. O

Loureiro O
, O
J O
. O

Dias O
, O
O O
. O

Afonso O
, O
F O
. O

Coelho O
, O
A O
. O

Martins O
, O
F O
. O

Faria O
P402 O
- O
Patients O
with O
hematologic O
malignancies O
requiring O
invasive O
mechanical O
ventilation O
: O
characteristics O
and O
predictors O
of O
mortality O
H O
. O

Al-Dorzi O
, O
H O
. O

Al O
Orainni O
, O
F O
. O

AlEid O
, O
H O
. O

Tlaygeh O
, O
A O
. O

Itani O
, O
A O
. O

Hejazi O
, O
Y O
. O

Arabi O
P403 O
- O
Patient-important O
outcomes O
in O
randomized O
controlled O
trials O
in O
critically O
ill O
patients O
: O
a O
systematic O
review O
S O
. O

Gaudry O
, O
J O
. O

Messika O
, O
J O
. O

D O
. O

Ricard O
, O
S O
. O

Guillo O
, O
B O
. O

Pasquet O
, O
E O
. O

Dubief O
, O
D O
. O

Dreyfuss O
, O
F O
. O

Tubach O
P404 O
- O
Alopecia O
in O
survivors O
of O
critical O
illness O
: O
a O
qualitative O
study O
C O
. O

Battle O
, O
K O
. O

James O
, O
P O
. O

Temblett O
P405 O
- O
The O
impact O
of O
mental O
health O
on O
icu O
admission O
L O
. O

Davies O
, O
C O
. O

Battle O
, O
C O
. O

Lynch O
P406 O
- O
Cognitive O
impairment O
5 O
years O
after O
ICU O
discharge O
S O
. O

Pereira O
, O
S O
. O

Cavaco O
, O
J O
. O

Fernandes O
, O
I O
. O

Moreira O
, O
E O
. O

Almeida O
, O
F O
. O

Seabra O
Pereira O
, O
M O
. O

Malheiro O
, O
F O
. O

Cardoso O
, O
I O
. O

Aragão O
, O
T O
. O

Cardoso O
P407 O
- O
Apache O
ii O
versus O
apache O
iv O
for O
octagenerians O
in O
medical O
icu O
M O
. O

Fister O
, O
R O
. O

Knafelj O
P408 O
- O
Outcomes O
of O
octagenarians O
in O
an O
indian O
icu O
P O
. O

Muraray O
Govind O
, O
N O
. O

Brahmananda O
Reddy O
, O
R O
. O

Pratheema O
, O
E O
. O

D O
. O

Arul O
, O
J O
. O

Devachandran O
P409 O
- O
Mortality O
and O
outcomes O
in O
elderly O
patients O
80 O
years O
of O
age O
or O
older O
admitted O
to O
the O
icu O
M O
. O

B O
. O

Velasco O
, O
D O
. O

M O
. O

Dalcomune O
P410 O
- O
Octagenerians O
in O
medical O
icu O
- O
adding O
days O
to O
life O
or O
life O
to O
days O
? O

R O
. O

Knafelj O
, O
M O
. O

Fister O
P411 O
- O
The O
very O
elderly O
admitted O
to O
intensive O
care O
unit O
: O
outcomes O
and O
economic O
evaluation O
N O
. O

Chin-Yee O
, O
G O
. O

D O
’ O
Egidio O
, O
K O
. O

Thavorn O
, O
D O
. O

Heyland O
, O
K O
. O

Kyeremanteng O
P412 O
- O
The O
very O
elderly O
in O
intensive O
care O
: O
relationship O
between O
acuity O
of O
illness O
and O
long-term O
mortality O
A O
. O

G O
. O

Murchison O
, O
K O
. O

Swalwell O
, O
J O
. O

Mandeville O
, O
D O
. O

Stott O
P413 O
- O
Acquired O
weakness O
in O
an O
oncological O
intensive O
care O
unit O
I O
. O

Guerreiro O
P414 O
- O
Musculoskeletal O
problems O
in O
intensive O
care O
unit O
( O
ICU O
) O
patients O
post-discharge O
H O
. O

Devine O
, O
P O
. O

MacTavish O
, O
J O
. O

McPeake O
, O
T O
. O

Quasim O
, O
J O
. O

Kinsella O
, O
M O
. O

Daniel O
P415 O
- O
Premorbid O
obesity O
, O
but O
not O
nutrition O
, O
prevents O
critical O
illness-induced O
muscle O
wasting O
and O
weakness O
C O
. O

Goossens O
M O
. O

B O
. O

Marques O
, O
S O
. O

Derde O
, O
S O
. O

Vander O
Perre O
, O
T O
. O

Dufour O
, O
S O
. O

E O
. O

Thiessen O
, O
F O
. O

Güiza O
, O
T O
. O

Janssens O
, O
G O
. O

Hermans O
, O
I O
. O

Vanhorebeek O
, O
K O
. O

De O
Bock O
, O
G O
. O

Van O
den O
Berghe O
, O
L O
. O

Langouche O
P416 O
- O
Physical O
outcome O
measures O
for O
critical O
care O
patients O
following O
intensive O
care O
unit O
( O
icu O
) O
discharge O
H O
. O

Devine O
, O
P O
. O

MacTavish O
, O
T O
. O

Quasim O
, O
J O
. O

Kinsella O
, O
M O
. O

Daniel O
, O
J O
. O

McPeake O
P417 O
- O
Improving O
active O
mobilisation O
in O
a O
general O
intensive O
care O
unit O
B O
. O

Miles O
, O
S O
. O

Madden O
, O
H O
. O

Devine O
P418 O
- O
Mobilization O
in O
patients O
on O
vasoactive O
drugs O
use O
– O
a O
pilot O
study O
. O

M O
. O

Weiler O
, O
P O
. O

Marques O
, O
C O
. O

Rodrigues O
, O
M O
. O

Boeira O
, O
K O
. O

Brenner O
, O
C O
. O

Leães O
, O
A O
. O

Machado O
, O
R O
. O

Townsend O
, O
J O
. O

Andrade O
P419 O
- O
Pharmacy O
intervention O
at O
an O
intensive O
care O
rehabilitation O
clinic O
P O
. O

MacTavish O
, O
J O
. O

McPeake O
, O
H O
. O

Devine O
, O
J O
. O

Kinsella O
, O
M O
. O

Daniel O
, O
R O
. O

Kishore O
, O
C O
. O

Fenlon O
, O
T O
. O

Quasim O
P420 O
- O
Interactive O
gaming O
is O
feasible O
and O
potentially O
increases O
icu O
patients O
’ O
motivation O
to O
be O
engaged O
in O
rehabilitation O
programs O
T O
. O

Fiks O
, O
A O
. O

Ruijter O
, O
M O
. O

Te O
Raa O
, O
P O
. O

Spronk O
P421 O
- O
Simulation-based O
design O
of O
a O
robust O
stopping O
rule O
to O
ensure O
patient O
safety O
Y O
. O

S O
. O

Chiew O
, O
P O
. O

Docherty O
, O
J O
. O

Dickson O
, O
E O
. O

Moltchanova O
, O
C O
. O

Scarrot O
, O
C O
. O

Pretty O
, O
G O
. O

M O
. O

Shaw O
, O
J O
. O

G O
. O

Chase O
P422 O
- O
Are O
daily O
blood O
tests O
on O
the O
intensive O
care O
unit O
necessary O
? O

T O
. O

Hall O
, O
W O
. O

C O
. O

Ngu O
, O
J O
. O

M O
. O

Jack O
, O
P O
. O

Morgan O
P423 O
- O
Measuring O
urine O
output O
in O
ward O
patients O
: O
is O
it O
helpful O
? O

B O
. O

Avard O
, O
A O
. O

Pavli O
, O
X O
. O

Gee O
P424 O
- O
The O
incidence O
of O
pressure O
ulcers O
in O
an O
adult O
mixed O
intensive O
care O
unit O
in O
turkey O
C O
. O

Bor O
, O
E O
. O

Akin O
Korhan O
, O
K O
. O

Demirag O
, O
M O
. O

Uyar O
P425 O
- O
Intensivist O
/ O
patient O
ratios O
in O
closed O
ICUs O
in O
Alexandria O
, O
Egypt O
; O
an O
overview O
M O
. O

Shirazy O
, O
A O
. O

Fayed O
P426 O
- O
Eicu O
( O
electronic O
intensive O
care O
unit O
) O
: O
impact O
on O
ALOS O
( O
average O
length O
of O
stay O
) O
in O
a O
developing O
country O
like O
India O
S O
. O

Gupta O
, O
A O
. O

Kaushal O
, O
S O
. O

Dewan O
, O
A O
. O

Varma O
P427 O
- O
Predicting O
deterioration O
in O
general O
ward O
using O
early O
deterioration O
indicator O
E O
. O

Ghosh O
, O
L O
. O

Yang O
, O
L O
. O

Eshelman O
, O
B O
. O

Lord O
, O
E O
. O

Carlson O
P428 O
- O
High O
impact O
enhanced O
critical O
care O
outreach O
- O
the O
imobile O
service O
: O
making O
a O
difference O
E O
. O

Helme O
, O
R O
. O

Broderick O
, O
S O
. O

Hadfield O
, O
R O
. O

Loveridge O
P429 O
- O
Impact O
of O
bed O
availability O
and O
cognitive O
load O
on O
intensive O
care O
unit O
( O
ICU O
) O
bed O
allocation O
: O
a O
vignette-based O
trial O
J O
. O

Ramos O
, O
D O
. O

Forte O
P430 O
- O
Characteristics O
of O
critically O
ill O
patients O
admitted O
through O
the O
emergency O
department O
F O
. O

Yang O
, O
P O
. O

Hou O
P431 O
- O
Admission O
to O
critical O
care O
: O
the O
quantification O
of O
functional O
reserve O
J O
. O

Dudziak O
, O
J O
. O

Feeney O
, O
K O
. O

Wilkinson O
, O
K O
. O

Bauchmuller O
, O
K O
. O

Shuker O
, O
M O
. O

Faulds O
, O
A O
. O

Raithatha O
, O
D O
. O

Bryden O
, O
L O
. O

England O
, O
N O
. O

Bolton O
, O
A O
. O

Tridente O
P432 O
- O
Admission O
to O
critical O
care O
: O
the O
importance O
of O
frailty O
K O
. O

Bauchmuller O
, O
K O
Shuker O
, O
A O
Tridente O
, O
M O
Faulds O
, O
A O
Matheson O
, O
J O
. O

Gaynor O
, O
D O
Bryden O
, O
S O
South O
Yorkshire O
Hospitals O
Research O
Collaboration O
P433 O
- O
Development O
of O
an O
instrument O
to O
aid O
triage O
decisions O
for O
intensive O
care O
unit O
admission O
J O
. O

Ramos O
, O
B O
. O

Peroni O
, O
R O
. O

Daglius-Dias O
, O
L O
. O

Miranda O
, O
C O
. O

Cohen O
, O
C O
. O

Carvalho O
, O
I O
. O

Velasco O
, O
D O
. O

Forte O
P434 O
- O
Using O
selective O
serotonin O
re-uptake O
inhibitors O
and O
serotonin-norepinephrine O
re-uptake O
inhibitors O
in O
critical O
care O
: O
a O
systematic O
review O
of O
the O
evidence O
for O
benefit O
or O
harm O
J O
. O

M O
. O

Kelly O
, O
A O
. O

Neill O
, O
G O
. O

Rubenfeld O
, O
N O
. O

Masson O
, O
A O
. O

Min O
P435 O
- O
Measuring O
adaptive O
coping O
of O
hospitalized O
patients O
with O
a O
severe O
medical O
condition O
: O
the O
sickness O
insight O
in O
coping O
questionnaire O
( O
sicq O
) O
E O
. O

Boezeman O
, O
J O
. O

Hofhuis O
, O
A O
. O

Hovingh O
, O
R O
. O

De O
Vries O
, O
P O
. O

Spronk O
P436 O
- O
Results O
of O
a O
national O
survey O
regarding O
intensive O
care O
medicine O
training O
G O
. O

Cabral-Campello O
, O
I O
. O

Aragão O
, O
T O
. O

Cardoso O
P437 O
- O
Work O
engagement O
among O
healthcare O
professionals O
in O
the O
intensive O
care O
unit O
M O
. O

Van O
Mol O
, O
M O
. O

Nijkamp O
, O
E O
. O

Kompanje O
P438 O
- O
Empowering O
the O
intensive O
care O
practitioners O
. O
is O
it O
a O
burnout O
ameliorating O
intervention O
? O

P O
. O

Ostrowski O
, O
A O
. O

Omar O
P439 O
- O
Icu O
patients O
suffer O
from O
circadian O
rhythm O
desynchronisation O
K O
. O

Kiss O
, O
B O
. O

Köves O
, O
V O
. O

Csernus O
, O
Z O
. O

Molnár O
P440 O
- O
Noise O
reduction O
in O
the O
ICU O
: O
feasible O
? O

Y O
. O

Hoydonckx O
, O
S O
. O

Vanwing O
, O
B O
. O

Stessel O
, O
A O
. O

Van O
Assche O
, O
L O
. O

Jamaer O
, O
J O
. O

Dubois O
P441 O
- O
Accidental O
removal O
of O
invasive O
devices O
in O
the O
critical O
patient O
into O
the O
bed-washing O
. O
does O
the O
presence O
of O
professional O
nurse O
modify O
his O
incidence O
? O

V O
. O

Medo O
, O
R O
. O

Galvez O
, O
J O
. O

P O
. O

Miranda O
P442 O
- O
Deprivation O
of O
liberty O
safeguards O
( O
dols O
) O
: O
audit O
of O
compliance O
in O
a O
of O
a O
16 O
- O
bed O
specialist O
cancer O
critical O
care O
unit O
. O

C O
. O

Stone O
, O
T O
. O

Wigmore O
P443 O
- O
Use O
of O
a O
modified O
cristal O
score O
to O
predict O
futility O
of O
critical O
care O
in O
the O
elderly O
Y O
. O

Arunan O
, O
A O
. O

Wheeler O
, O
K O
. O

Bauchmuller O
, O
D O
. O

Bryden O
P444 O
- O
Improvement O
of O
Referral O
Rate O
to O
Palliative O
Care O
for O
Patients O
with O
Poor O
Prognosis O
in O
Neurosurgical O
Intensive O
Care O
Unit O
Y O
. O

Wong O
, O
C O
. O

Poi O
, O
C O
. O

Gu O
P445 O
- O
Factors O
associated O
with O
limitation O
of O
life O
supporting O
care O
( O
lsc O
) O
in O
a O
medico-surgical O
intermediate O
care O
unit O
, O
and O
outcome O
of O
patients O
with O
lsc O
limitation O
: O
a O
monocentric O
, O
six-month O
study O
. O

P O
. O

Molmy O
, O
N O
. O

Van O
Grunderbeeck O
, O
O O
. O

Nigeon O
, O
M O
. O

Lemyze O
, O
D O
. O

Thevenin O
, O
J O
. O

Mallat O
P446 O
- O
Palliative O
care O
consultation O
and O
intensive O
care O
unit O
admission O
request O
: O
a O
cohort O
study O
J O
. O

Ramos O
, O
M O
. O

Correa O
, O
R O
. O

T O
. O

Carvalho O
, O
D O
. O

Forte O
P447 O
- O
Nursing O
and O
medicine O
together O
in O
postsurgical O
intensive O
care O
unit O
: O
situations O
of O
prognostic O
conflict O
at O
the O
end O
of O
life O
. O
our O
critical O
care O
nurses O
suffer O
with O
our O
medical O
activism O
? O

A O
. O

Fernandez O
, O
C O
. O

McBride O
P448 O
- O
End O
of O
life O
who O
may O
decide O
E O
. O

Koonthalloor O
, O
C O
. O

Walsh O
P449 O
- O
Correctly O
diagnosing O
death O
A O
. O

Webber O
, O
M O
. O

Ashe O
, O
K O
. O

Smith O
, O
P O
. O

Jeanrenaud O
P450 O
- O
Skin O
procurement O
performed O
by O
intensive O
care O
physicians O
: O
yes O
, O
we O
can O
. O

A O
. O

Marudi O
, O
S O
. O

Baroni O
, O
F O
. O

Ragusa O
, O
E O
. O

Bertellini O
P451 O
- O
Death O
analysis O
in O
pediatric O
intensive O
care O
patients O
E O
. O

A O
. O

Volakli O
, O
E O
. O

Chochliourou O
, O
M O
. O

Dimitriadou O
, O
A O
. O

Violaki O
, O
P O
. O

Mantzafleri O
, O
E O
. O

Samkinidou O
, O
O O
. O

Vrani O
, O
A O
. O

Arbouti O
, O
T O
. O

Varsami O
, O
M O
. O

Sdougka O
P452 O
- O
The O
potential O
impact O
of O
euthanasia O
on O
organ O
donation O
: O
analysis O
of O
data O
from O
belgium O
J O
. O

A O
. O

Bollen O
, O
T O
. O

C O
. O

Van O
Smaalen O
, O
W O
. O

C O
. O

De O
Jongh O
, O
M O
. O

M O
. O

Ten O
Hoopen O
, O
D O
. O

Ysebaert O
, O
L O
. O

W O
. O

Van O
Heurn O
, O
W O
. O

N O
. O

Van O
Mook O
P453 O
- O
Communication O
within O
an O
intensive O
care O
setting O
K O
. O

Sim O
, O
A O
. O

Fuller O
P454 O
- O
Development O
and O
implementation O
of O
a O
longitudinal O
communication O
curriculum O
for O
critical O
care O
medicine O
fellows O
A O
. O

Roze O
des O
Ordons O
, O
P O
. O

Couillard O
, O
C O
. O

Doig O
P455 O
- O
Staff-family O
conflict O
in O
a O
multi-ethnic O
intensive O
care O
unit O
R O
. O

V O
. O

Van O
Keer O
, O
R O
. O

D O
. O

Deschepper O
, O
A O
. O

F O
. O

Francke O
, O
L O
. O

H O
. O

Huyghens O
, O
J O
. O

B O
. O

Bilsen O
P456 O
- O
Does O
the O
source O
of O
admission O
to O
critical O
care O
affect O
family O
satisfaction O
? O

B O
. O

Nyamaizi O
, O
C O
. O

Dalrymple O
, O
A O
. O

Molokhia O
, O
A O
. O

Dobru O
P457 O
- O
A O
simple O
alternative O
to O
the O
family O
satisfaction O
survey O
( O
fs-icu O
) O
E O
. O

Marrinan O
, O
A O
. O

Ankuli O
, O
A O
. O

Molokhia O
P458 O
- O
A O
study O
to O
explore O
the O
experiences O
of O
patient O
and O
family O
volunteers O
in O
a O
critical O
care O
environment O
: O
a O
phenomenological O
analysis O
J O
. O

McPeake O
, O
R O
. O

Struthers O
, O
R O
. O

Crawford O
, O
H O
. O

Devine O
, O
P O
. O

Mactavish O
, O
T O
. O

Quasim O
P459 O
- O
Prevalence O
and O
risk O
factors O
of O
anxiety O
and O
depression O
in O
relatives O
of O
burn O
patients O
. O

P O
. O

Morelli O
, O
M O
. O

Degiovanangelo O
, O
F O
. O

Lemos O
, O
V O
. O

MArtinez O
, O
F O
. O

Verga O
, O
J O
. O

Cabrera O
, O
G O
. O

Burghi O
P460 O
- O
Guidance O
of O
visiting O
children O
at O
an O
adult O
intensive O
care O
unit O
( O
icu O
) O
A O
. O

Rutten O
, O
S O
. O

Van O
Ieperen O
, O
S O
. O

De O
Geer O
, O
M O
. O

Van O
Vugt O
, O
E O
. O

Der O
Kinderen O
P461 O
- O
Visiting O
policies O
in O
Italian O
pediatric O
ICUs O
: O
an O
update O
A O
. O

Giannini O
, O
G O
Miccinesi O
, O
T O
Marchesi O
, O
E O
Prandi O

Anxiety O
disorders O
are O
highly O
prevalent O
in O
modern O
societies O
, O
and O
are O
ranked O
the O
sixth O
most O
important O
contributor O
of O
non-fatal O
negative O
health O
outcomes O
. O

L-theanine B-Drug/Scientific name
is O
an O
amino O
acid O
naturally O
found O
in O
green B-Medicinal food
tea I-Medicinal food
( O
Camellia B-Drug/Scientific name
sinensis I-Drug/Scientific name
) O
and O
some O
other O
plant O
extracts O
, O
and O
recent O
clinical O
studies O
have O
proposed O
promising O
adjuvant O
effects O
of O
L-theanine B-Drug/Scientific name
for O
the O
negative O
impact O
of O
anxiety B-Symptom_WorkedFor
and O
psychological B-Symptom_WorkedFor
stress I-Symptom_WorkedFor
on O
health O
. O

In O
this O
integrative O
narrative O
review O
, O
we O
aimed O
to O
appraise O
and O
further O
discuss O
the O
effects O
of O
L-theanine B-Drug/Scientific name
administration O
on O
anxiety B-Symptom_WorkedFor
disorders I-Symptom_WorkedFor
and O
psychological B-Symptom_WorkedFor
stress I-Symptom_WorkedFor
. O

Published O
data O
suggests O
that O
L-theanine B-Drug/Scientific name
administered O
at O
daily O
doses O
ranging O
from O
200 B-Dosage
to I-Dosage
400 I-Dosage
mg I-Dosage
for O
up O
to O
8 B-Duration
weeks I-Duration
are O
safe O
and O
induce O
anxiolytic O
and O
anti-stress O
effects O
in O
acute B-participant_health
and I-participant_health
chronic I-participant_health
conditions I-participant_health
. O

L-theanine B-Drug/Scientific name
at O
doses O
lower O
and O
higher O
than O
these O
may O
also O
show O
promising O
therapeutic O
potential O
; O
however O
, O
a O
more O
thorough O
investigation O
through O
randomized O
double-blind O
placebo-controlled O
crossover O
clinical O
trials O
are O
necessary O
to O
elucidate O
its O
effects O
for O
longer O
periods O
, O
providing O
further O
insights O
for O
meta-analyses O
and O
the O
development O
of O
recommendation O
guidelines O
. O

Additionally O
, O
animal O
studies O
investigating O
a O
higher O
dosage O
, O
its O
combination O
with O
other O
pharmacological O
compounds O
and O
associated O
metabolic O
comorbidities O
are O
recommended O
, O
as O
cases O
of O
hepatotoxicity O
associated O
with O
the O
consumption O
of O
green B-Medicinal food
tea I-Medicinal food
extract O
have O
been O
reported O
. O

Objective O
: O
To O
investigate O
the O
effects O
of O
smoking O
, O
alcohol O
, O
and O
caffeine O
consumption O
and O
socio-economic O
factors O
and O
psychosocial O
stress O
on O
birth O
weight O
. O

Design O
: O
Prospective O
population O
study O
. O

Setting O
: O
District O
general O
hospital O
in O
inner O
London O
. O

Participants O
: O
A O
consecutive O
series O
of O
1860 O
white O
women O
booking O
for O
delivery O
were O
approached O
. O
136 O
Refused O
and O
211 O
failed O
to O
complete O
the O
study O
for O
other O
reasons O
( O
moved O
, O
abortion O
, O
subsequent O
refusal O
) O
, O
leaving O
a O
sample O
of O
1513 B-#Participants
. O

Women O
who O
spoke O
no O
English O
, O
booked O
after O
24 O
weeks O
, O
had O
insulin O
dependent O
diabetes O
, O
or O
had O
a O
multiple O
pregnancy B-participant_health
were O
excluded O
. O

Measurements O
: O
Data O
were O
obtained O
by O
research O
interviewers O
at O
booking O
( O
general O
health O
questionnaire O
, O
modified O
Paykel's O
interview O
, O
and O
Eysenck O
personality O
questionnaire O
) O
and O
at O
17 O
, O
28 O
, O
and O
36 O
weeks O
' O
gestation O
and O
from O
the O
structured O
antenatal O
and O
obstetric O
record O
. O

Variables O
assessed O
included O
smoking O
, O
alcohol O
consumption O
, O
caffeine O
consumption O
, O
and O
over O
40 O
indicators O
of O
socio-economic O
state O
and O
psychosocial O
stress O
, O
including O
social O
class O
, O
tenure O
of O
accommodations O
, O
education O
, O
employment O
, O
income O
, O
anxiety O
and O
depression O
, O
stressful O
life O
events O
, O
social O
stress O
, O
social O
support O
, O
personality O
, O
and O
attitudes O
to O
pregnancy O
. O

Birth O
weight O
was O
corrected O
for O
gestation O
and O
adjusted O
for O
maternal O
height O
, O
parity O
, O
and O
baby's O
sex O
. O

Main O
results O
: O
Smoking O
was O
the O
most O
important O
single O
factor O
( O
5% O
reduction O
in O
corrected O
birth O
weight O
) O
. O

Passive O
smoking O
was O
not O
significant O
( O
0.5% O
reduction O
) O
. O

After O
smoking O
was O
controlled O
for O
, O
alcohol O
had O
an O
effect O
only O
in O
smokers O
and O
the O
effects O
of O
caffeine O
became O
non-significant O
. O

Only O
four O
of O
the O
socioeconomic O
and O
stress O
factors O
significantly O
reduced O
birth O
weight O
and O
these O
effects O
became O
non-significant O
after O
smoking O
was O
controlled O
for O
. O

Conclusions O
: O
Social O
and O
psychological O
factors O
have O
little O
or O
no O
direct O
effect O
on O
birth O
weight O
corrected O
for O
gestational O
age O
( O
fetal O
growth O
) O
, O
and O
the O
main O
environmental O
cause O
of O
its O
variation O
in O
this O
population O
was O
smoking O
. O

Primary O
dysmenorrhea B-Symptom_WorkedFor
occurs O
in O
as O
many O
as O
50% O
of O
female O
adolescents O
and O
is O
associated O
with O
significant O
decreases O
in O
academic O
performance O
, O
sports O
participation O
, O
and O
socialization O
with O
peers O
. O

Complementary O
and O
alternative O
medicine O
treatment O
options O
are O
of O
interest O
to O
patients O
and O
health O
care O
providers O
. O

The O
use O
of O
rose B-Medicinal food
tea I-Medicinal food
to O
alleviate O
menstrual B-Symptom_WorkedFor
pain I-Symptom_WorkedFor
has O
long O
been O
a O
part O
of O
folk O
knowledge O
around O
the O
world O
but O
has O
not O
been O
studied O
scientifically O
. O

To O
determine O
the O
effectiveness O
of O
drinking O
rose O
tea O
as O
an O
intervention O
for O
reducing O
pain O
and O
psychophysiologic O
distress O
in O
adolescents O
with O
primary O
dysmenorrhea B-participant_health
, O
130 B-#Participants
female O
adolescents O
were O
randomly O
assigned O
to O
an O
experimental O
( O
n O
= O
70 O
) O
and O
a O
control O
( O
n O
= O
60 O
) O
group O
. O

Preintervention O
and O
postintervention O
data O
at O
1 O
month O
, O
3 O
months O
, O
and O
6 O
months O
were O
gathered O
on O
the O
biopsychosocial O
outcomes O
of O
dysmenorrhea B-Symptom_WorkedFor
. O

The O
results O
showed O
that O
compared O
with O
the O
control O
group O
, O
the O
experimental O
group O
perceived O
less O
menstrual B-Symptom_WorkedFor
pain I-Symptom_WorkedFor
, O
distress B-Symptom_WorkedFor
, O
and O
anxiety B-Symptom_WorkedFor
and O
showed O
greater O
psychophysiologic O
well-being O
through O
time O
, O
at O
1 O
, O
3 O
, O
and O
6 O
months O
after O
the O
interventions O
. O

Findings O
suggest O
that O
drinking O
rose B-Medicinal food
tea I-Medicinal food
is O
a O
safe O
, O
readily O
available O
, O
and O
simple O
treatment O
for O
dysmenorrhea B-Symptom_WorkedFor
, O
which O
female O
adolescents O
may O
take O
to O
suit O
their O
individual O
needs O
. O

Nicotine O
exposure O
during O
pregnancy O
induces O
oxidative O
stress O
and O
leads O
to O
behavioral O
alterations O
in O
early O
childhood O
and O
young O
adulthood O
. O

The O
current O
study O
aimed O
to O
investigate O
the O
possible O
protective O
effects O
of O
green B-Medicinal food
tea I-Medicinal food
( O
Camellia B-Drug/Scientific name
sinensis I-Drug/Scientific name
) O
against O
perinatal O
nicotine-induced O
behavioral O
alterations O
and O
oxidative O
stress O
in O
mice O
newborns O
. O

Pregnant O
mice O
received O
50 O
mg O
/ O
kg O
C B-Drug/Scientific name
. I-Drug/Scientific name
sinensis I-Drug/Scientific name
on O
gestational O
day O
1 O
( O
PD1 O
) O
to O
postnatal O
day O
15 O
( O
D15 O
) O
and O
were O
subcutaneously O
injected O
with O
0.25 O
mg O
/ O
kg O
nicotine B-Other_ingredients
from O
PD12 O
to O
D15 O
. O

Nicotine-exposed O
newborns O
showed O
significant O
delay O
in O
eye O
opening O
and O
hair O
appearance O
and O
declined O
body O
weight O
at O
birth O
and O
at O
D21 O
. O

Nicotine O
induced O
neuromotor O
alterations O
in O
both O
male O
and O
female O
newborns O
evidenced O
by O
the O
suppressed O
righting O
, O
rotating O
, O
and O
cliff O
avoidance O
reflexes O
. O

Nicotine-exposed O
newborns O
exhibited O
declined O
memory O
, O
learning O
, O
and O
equilibrium O
capabilities O
, O
as O
well O
as O
marked O
anxiety O
behavior O
. O

C B-Drug/Scientific name
. I-Drug/Scientific name
sinensis I-Drug/Scientific name
significantly O
improved O
the O
physical B-Symptom_WorkedFor
development I-Symptom_WorkedFor
, O
neuromotor B-Symptom_WorkedFor
maturation I-Symptom_WorkedFor
, O
and O
behavioral B-Symptom_WorkedFor
performance I-Symptom_WorkedFor
in O
nicotine-exposed O
male O
and O
female O
newborns O
. O

In O
addition O
, O
C B-Drug/Scientific name
. I-Drug/Scientific name
sinensis I-Drug/Scientific name
prevented O
nicotine-induced O
tissue O
injury O
and O
lipid O
peroxidation O
and O
enhanced O
antioxidant O
defenses O
in O
the O
cerebellum O
and O
medulla O
oblongata O
of O
male O
and O
female O
newborns O
. O

In O
conclusion O
, O
this O
study O
shows O
that O
C B-Drug/Scientific name
. I-Drug/Scientific name
sinensis I-Drug/Scientific name
confers O
protective O
effects O
against O
perinatal O
nicotine-induced O
neurobehavioral O
alterations O
, O
tissue O
injury O
, O
and O
oxidative O
stress O
in O
mice O
newborns O
. O

Gynostemma B-Drug/Scientific name
pentaphyllum I-Drug/Scientific name
is O
a O
traditional O
oriental O
medicinal O
herb O
used O
as O
tea B-Medicinal food
since O
ancient O
time O
. O

Among O
Gynostemma O
species O
, O
G B-Drug/Scientific name
. I-Drug/Scientific name
pentaphyllum I-Drug/Scientific name
has O
more O
active O
chemical O
components O
and O
better O
therapeutic O
effect O
. O

It O
is O
used O
to O
cure O
depression B-Symptom_WorkedFor
, O
diabetes B-Symptom_WorkedFor
, O
anxiety B-Symptom_WorkedFor
, O
hyperlipidemia B-Symptom_WorkedFor
, O
fatigue B-Symptom_WorkedFor
, O
immunity B-Symptom_WorkedFor
, O
cancer B-Symptom_WorkedFor
, O
and O
oxidative B-Symptom_WorkedFor
stress I-Symptom_WorkedFor
. O

Overexploitation O
of O
G B-Drug/Scientific name
. I-Drug/Scientific name
pentaphyllum I-Drug/Scientific name
for O
its O
medicinal O
benefits O
has O
been O
on O
a O
rise O
, O
due O
to O
which O
they O
are O
adulterated O
or O
mistakenly O
identified O
with O
other O
members O
of O
Gynostemma O
species O
. O

Hence O
, O
we O
used O
chloroplast O
universal O
regions O
such O
as O
ycf3 O
, O
accD O
, O
petD O
, O
psbB O
and O
their O
polymorphism O
to O
distinguish O
G B-Drug/Scientific name
. I-Drug/Scientific name
pentaphyllum I-Drug/Scientific name
from O
other O
Gynostemma O
species O
. O

By O
using O
the O
species-specific O
primers O
derived O
from O
the O
above O
regions O
, O
we O
established O
a O
multiplex O
allele-specific O
PCR O
for O
the O
authentication O
of O
G B-Drug/Scientific name
. I-Drug/Scientific name
pentaphyllum I-Drug/Scientific name
from O
other O
species O
. O

Thus O
the O
PCR O
reaction O
produced O
unique O
amplicons O
of O
size O
244 O
bp O
and O
438 O
bp O
for O
G B-Drug/Scientific name
. I-Drug/Scientific name
pentaphyllum I-Drug/Scientific name
amplified O
by O
the O
primers O
flanking O
ycf3 O
, O
and O
accD O
regions O
respectively O
. O

While O
a O
607 O
bp O
, O
and O
787 O
bp O
amplicons O
from O
the O
primers O
targeting O
psbB O
, O
and O
petD O
regions O
distinguished O
G B-Other_ingredients
. I-Other_ingredients
longipes I-Other_ingredients
, O
G B-Other_ingredients
. I-Other_ingredients
burmanicum I-Other_ingredients
, O
and O
G B-Other_ingredients
. I-Other_ingredients
pubescens I-Other_ingredients
species O
. O

Moreover O
, O
these O
primers O
were O
successful O
to O
analyze O
the O
dried O
tea B-Medicinal food
samples O
of O
Gynostemma O
as O
well O
. O

Thus O
, O
the O
developed O
molecular O
markers O
could O
authenticate O
different O
Gynostemma O
species O
as O
well O
as O
its O
products O
thereby O
preventing O
the O
mistaken-identity O
of O
this O
medicinal O
herb O
. O

When O
people O
attend O
a O
Japanese O
Tea O
Ceremony O
, O
they O
often O
remark O
that O
it O
had O
a O
calming B-Symptom_WorkedFor
effect O
on O
them O
. O

The O
Tea O
Ceremony O
can O
be O
much O
more O
than O
that O
, O
however O
. O

Serious O
practitioners O
of O
tea B-Medicinal food
develop O
a O
mind O
set O
and O
body O
control O
that O
enables O
them O
to O
transform O
tension-producing O
details O
of O
everyday O
life O
into O
moments O
of O
beauty O
, O
meaningfulness O
and O
tranquility O
. O

This O
effect O
comes O
from O
ritualizing O
ordinary O
chores O
and O
giving O
them O
an O
esthetic O
dimension O
and O
a O
noble O
motivation O
. O

Such O
discipline O
of O
mind O
and O
body O
also O
enables O
tea O
people O
to O
concentrate O
solely O
on O
the O
present O
moment O
, O
thereby O
shutting O
out O
worries O
about O
the O
past O
and O
anxieties B-Symptom_WorkedFor
about O
the O
future O
. O

Introduction O
: O
Acquired B-Symptom_TestedFor
brain I-Symptom_TestedFor
injury I-Symptom_TestedFor
( O
ABI O
) O
during O
childhood O
typically O
causes O
behavior O
problems O
in O
the O
child O
and O
high O
levels O
of O
stress O
in O
the O
family O
. O

The O
aims O
of O
this O
study O
are O
: O
( O
1 O
) O
to O
investigate O
the O
effectiveness O
and O
feasibility O
of O
a O
parenting O
intervention O
in O
improving O
behavior O
and O
self-regulation O
in O
Mexican O
children O
with O
ABI O
compared O
to O
telephone O
support O
; O
( O
2 O
) O
to O
investigate O
the O
effectiveness O
and O
feasibility O
of O
a O
parenting O
intervention O
in O
improving O
parenting O
skills O
, O
parent O
self-efficacy O
and O
decreasing O
parental O
stress O
in O
parents O
of O
children O
with O
ABI O
compared O
to O
telephone O
support O
. O

Our O
secondary O
aims O
are O
( O
1 O
) O
to O
explore O
the O
impact O
that O
parent O
characteristics O
have O
on O
the O
intervention O
outcomes O
; O
( O
2 O
) O
to O
investigate O
if O
changes O
are O
maintained O
3 O
months O
after O
the O
intervention O
. O

Methods O
: O
The O
research O
design O
is O
a O
blind O
randomized O
controlled O
trial O
( O
RCT O
) O
. O

Eligible O
participants O
include O
children O
with O
a O
diagnosis O
of O
ABI O
, O
between O
6 O
and O
12 O
years O
of O
age O
, O
and O
their O
parents O
. O

Sixty-six B-#Participants
children O
and O
their O
parents O
will O
be O
randomly O
allocated O
to O
either O
a O
parenting O
program O
group O
or O
telephone O
support O
group O
. O

The O
parenting O
program O
involves O
six O
face-to-face O
weekly O
group O
sessions O
of O
2.5 O
h O
each O
. O

Participants O
in O
the O
control O
group O
receive O
an O
information O
sheet O
with O
behavioral O
strategies O
, O
and O
six O
weekly O
phone O
calls O
, O
in O
which O
strategies O
to O
improve O
academic O
skills O
are O
provided O
. O

Children O
and O
their O
parents O
are O
evaluated O
by O
blind O
assessors O
before O
the O
intervention O
, O
immediately O
after O
the O
intervention O
and O
3 O
- O
months O
post-intervention O
. O

Discussion O
: O
This O
study O
will O
be O
the O
first O
to O
evaluate O
the O
efficacy O
and O
feasibility O
of O
a O
parenting O
program O
for O
Mexican O
parents O
of O
children O
with O
ABI O
. O

Trial O
identifier O
: O
ACTRN12617000360314 O
. O

Therapies O
targeting O
central O
stress O
mechanisms O
are O
fundamental O
for O
the O
development O
of O
successful O
treatment O
strategies O
. O

Ocimum B-Medicinal food
sanctum I-Medicinal food
( O
OS B-Medicinal food
) O
is O
an O
Indian O
medicinal O
plant O
traditionally O
used O
for O
the O
treatment O
of O
various O
stress-related B-Symptom_WorkedFor
conditions O
. O

Previously O
, O
we O
have O
isolated O
and O
characterized O
three O
OS B-Medicinal food
compounds O
; O
Ocimarin B-Drug/Scientific name
, O
Ocimumoside B-Drug/Scientific name
A I-Drug/Scientific name
and O
Ocimumoside B-Drug/Scientific name
B I-Drug/Scientific name
. O

However O
, O
their O
role O
in O
modulating O
chronic O
stress-induced B-Symptom_WorkedFor
central O
changes O
is O
unexplored O
. O

Thus O
, O
in O
the O
present O
study O
the O
efficacy O
of O
these O
OS B-Medicinal food
compounds O
have O
been O
evaluated O
on O
the O
chronic O
unpredictable O
stress O
( O
CUS O
) O
- O
induced O
alterations O
in O
the O
monoaminergic O
and O
antioxidant O
systems O
in O
the O
frontal O
cortex O
, O
striatum O
and O
hippocampus O
, O
along O
with O
the O
changes O
in O
the O
plasma O
corticosterone O
levels O
. O

CUS O
( O
two O
different O
types O
of O
stressors O
daily O
for O
seven O
days O
) O
resulted O
in O
a O
significant O
elevation O
of O
plasma O
corticosterone O
level O
, O
which O
was O
reversed O
to O
control O
levels O
by O
pretreatment O
with O
Ocimumoside B-Drug/Scientific name
A I-Drug/Scientific name
and I-Drug/Scientific name
B I-Drug/Scientific name
( O
40 B-Dosage
mg I-Dosage
/ I-Dosage
kg I-Dosage
p.o I-Dosage
. I-Dosage
) O
, O
while O
Ocimarin O
showed O
no O
effect O
. O

The O
levels O
of O
NA O
, O
DA O
and O
5 O
- O
HT O
were O
significantly O
decreased O
in O
all O
the O
three O
brain O
regions O
by O
CUS O
, O
with O
a O
selective O
increase O
of O
DA O
metabolites O
. O

A O
significant O
decrease O
in O
the O
glutathione O
( O
GSH O
) O
content O
, O
the O
activities O
of O
superoxide O
dismutase O
and O
catalase O
with O
a O
significant O
increase O
in O
the O
glutathione O
peroxidase O
activity O
and O
lipid O
peroxidation O
was O
observed O
in O
all O
the O
three O
regions O
of O
the O
brain O
by O
CUS O
. O

The O
OS B-Medicinal food
compounds O
alone O
did O
not O
cause O
any O
significant O
change O
in O
the O
baseline O
values O
of O
these O
parameters O
. O

However O
, O
Ocimumoside B-Drug/Scientific name
A I-Drug/Scientific name
and I-Drug/Scientific name
B I-Drug/Scientific name
( O
40 B-Dosage
mg I-Dosage
/ I-Dosage
kg I-Dosage
body I-Dosage
p.o I-Dosage
. I-Dosage
) O
attenuated O
these O
CUS-induced O
alterations O
with O
an O
efficacy O
similar O
to O
that O
of O
standard O
anti-stress O
( O
Panax B-Other_ingredients
quinquefolium I-Other_ingredients
; O
100 B-Dosage
mg I-Dosage
/ I-Dosage
kg I-Dosage
p.o I-Dosage
. O
) O
and O
antioxidant O
( O
Melatonin B-Other_ingredients
; O
20 B-Dosage
mg I-Dosage
/ I-Dosage
kg I-Dosage
i.p I-Dosage
. I-Dosage
) O
drugs O
. O

While O
, O
Ocimarin O
failed O
to O
modulate O
these O
CUS-induced O
alterations O
. O

Therefore O
, O
this O
is O
the O
first O
report O
which O
identified O
the O
anti-stress O
activity O
of O
novel O
Ocimumoside B-Drug/Scientific name
A I-Drug/Scientific name
and I-Drug/Scientific name
B I-Drug/Scientific name
at O
the O
level O
of O
central O
monoamines O
and O
antioxidant O
properties O
, O
implicating O
their O
therapeutic O
importance O
in O
the O
prevention O
of O
stress-related B-Symptom_WorkedFor
disorders I-Symptom_WorkedFor
. O

Introduction O
: O
Ocimum B-Drug/Scientific name
sanctum I-Drug/Scientific name
( O
OS B-Drug/Scientific name
) O
, O
known O
as O
Holy B-Medicinal food
basil I-Medicinal food
, O
has O
been O
documented O
to O
possess O
neuroprotective O
, O
cognition-enhancing O
and O
stress O
relieving O
effects O
in O
animal O
models O
. O

However O
there O
is O
paucity O
of O
clinical O
studies O
to O
document O
these O
effects O
. O

Materials O
and O
methods O
: O
Effect O
of O
OS B-Drug/Scientific name
on O
parameters O
related O
to O
cognition B-Symptom_WorkedFor
and O
stress B-Symptom_WorkedFor
in O
humans O
was O
evaluated O
with O
administration O
of O
300 B-Dosage
milligram I-Dosage
capsules O
of O
ethanolic O
leaf O
extracts O
of O
Ocimum B-Drug/Scientific name
sanctum I-Drug/Scientific name
( O
EtOS B-Drug/Scientific name
) O
or O
placebo O
per O
day O
, O
over O
30 O
days O
. O

Results O
: O
Intra-group O
comparison O
of O
Sternberg B-Metric
and I-Metric
Stroop I-Metric
test I-Metric
showed O
improvement O
in O
both O
the O
placebo O
and O
EtOS B-Drug/Scientific name
groups O
, O
however O
, O
the O
improvement O
stabilized O
after O
day O
15 O
in O
the O
placebo O
group O
. O

Intergroup O
comparison O
revealed O
a O
significant O
improvement O
of O
the O
following O
cognitive O
parameters O
in O
the O
EtOS B-Drug/Scientific name
as O
compared O
to O
the O
placebo O
: O
reaction O
time O
( O
RT O
) O
and O
error O
rate O
( O
ER O
) O
of O
Sternberg O
test O
, O
RT O
of O
neutral O
task O
of O
Stroop O
, O
RT O
and O
ER O
of O
interference O
task O
of O
Stroop O
. O

The O
intra-group O
comparison O
of O
P300 O
latency O
, O
salivary O
cortisol O
, O
and O
State-Trait O
Anxiety O
Inventory O
showed O
improvement O
over O
time O
in O
the O
EtOS B-Drug/Scientific name
group O
alone O
, O
though O
the O
inter-group O
difference O
was O
significant O
in O
the O
P300 O
latency O
alone O
. O

There O
were O
no O
changes O
in O
heart O
rate O
( O
HR O
) O
, O
AHR O
, O
or O
galvanic O
skin O
response O
( O
GSR O
) O
or O
AGSR O
. O

Conclusion O
: O
Ocimum B-Drug/Scientific name
sanctum I-Drug/Scientific name
leaf O
extract O
seems O
to O
have O
potential O
cognition-enhancing O
properties O
in O
humans O
. O

Ocimumn B-Drug/Scientific name
sanctum I-Drug/Scientific name
, O
an O
Indian O
medicinal O
plant O
, O
has O
been O
on O
trial O
for O
its O
role O
in O
generalized B-Symptom_WorkedFor
anxiety I-Symptom_WorkedFor
disorder I-Symptom_WorkedFor
( O
GAD O
) O
in O
hospital O
based O
clinical O
set-up O
. O

Hamilton's B-Metric
brief I-Metric
psychiatric I-Metric
rating I-Metric
scale I-Metric
( O
BPRS O
) O
and O
thorough O
clinical O
investigations O
were O
used O
to O
screen O
the O
subjects O
. O

Thirty-five B-#Participants
subjects O
( O
21 O
male O
and O
14 O
female O
; O
average O
age O
38.4 O
years O
) O
were O
medicated O
with O
the O
plant O
extract O
in O
a O
fixed O
dose O
regime O
( O
500 B-Dosage
mg I-Dosage
/ I-Dosage
capsule I-Dosage
, I-Dosage
twice I-Dosage
daily I-Dosage
, O
p.o O
. O
after O
meal O
) O
. O

They O
were O
thoroughly O
investigated O
clinically O
and O
using O
standard O
questionnaires O
based O
on O
different O
psychological O
rating O
scale O
at O
baseline O
( O
day O
0 O
) O
, O
mid-term O
( O
day O
30 O
) O
and O
final O
( O
day O
60 O
) O
. O

The O
observations O
exhibited O
that O
, O
O B-Drug/Scientific name
. I-Drug/Scientific name
sanctum I-Drug/Scientific name
significantly O
( O
p O
< O
0.001 O
) O
attenuated O
generalized B-Symptom_WorkedFor
anxiety I-Symptom_WorkedFor
disorders I-Symptom_WorkedFor
and O
also O
attenuated O
its O
correlated O
stress B-Symptom_WorkedFor
and O
depression B-Symptom_WorkedFor
. O

It O
further O
significantly O
( O
p O
< O
0.001 O
) O
improved O
the O
willingness O
to O
adjustment O
and O
attention O
in O
human O
. O

Therefore O
, O
it O
may O
be O
concluded O
that O
O B-Drug/Scientific name
. I-Drug/Scientific name
sanctum I-Drug/Scientific name
may O
be O
useful O
in O
the O
treatment O
of O
GAD B-Symptom_WorkedFor
in O
human O
and O
may O
be O
a O
promising O
anxiolytic O
agent O
in O
near O
future O
. O

Objective O
: O
The O
aim O
of O
this O
study O
was O
to O
study O
the O
ameliorative O
effects O
of O
Ocimum B-Medicinal food
sanctum I-Medicinal food
and O
Camellia B-Medicinal food
sinensis I-Medicinal food
on O
stress-induced B-Symptom_WorkedFor
anxiety I-Symptom_WorkedFor
and O
depression B-Symptom_WorkedFor
. O

Materials O
and O
methods O
: O
The O
study O
was O
carried O
out O
using O
male O
albino O
rats O
( O
200 O
± O
50 O
g O
) O
. O

The O
effect O
of O
O B-Medicinal food
. I-Medicinal food
sanctum I-Medicinal food
and O
C B-Medicinal food
. I-Medicinal food
sinensis I-Medicinal food
was O
evaluated O
for O
anxiety B-Symptom_WorkedFor
and O
depression B-Symptom_WorkedFor
using O
elevated O
plus O
maze O
( O
EPM O
) O
test O
, O
open O
field O
test O
( O
OFT O
) O
, O
forced O
swim O
test O
( O
FST O
) O
, O
and O
tail O
suspension O
test O
( O
TST O
) O
. O

Result O
: O
Restraint O
stress O
( O
3 O
h O
/ O
day O
for O
six O
consecutive O
days O
) O
induced O
a O
significant O
reduction O
in O
both O
the O
percentage O
number O
of O
entries O
and O
time O
spent O
in O
open O
arms O
in O
EPM O
, O
and O
these O
changes O
were O
reversed O
with O
post-treatment O
of O
aqueous O
extract O
of O
O B-Medicinal food
. I-Medicinal food
sanctum I-Medicinal food
and O
C B-Medicinal food
. I-Medicinal food
sinensis I-Medicinal food
( O
100 O
mg O
/ O
kg O
for O
6 O
days O
) O
. O

Restraint O
stress-induced O
( O
a O
) O
increased O
latency O
and O
( O
b O
) O
decreased O
ambulation O
and O
rearing O
were O
also O
reversed O
by O
O B-Medicinal food
. I-Medicinal food
sanctum I-Medicinal food
and O
C B-Medicinal food
. I-Medicinal food
sinensis I-Medicinal food
in O
OFT O
. O

A O
significant O
increase O
in O
immobility O
period O
was O
observed O
in O
FST O
and O
TST O
after O
restraint O
stress O
. O

O B-Medicinal food
. I-Medicinal food
sanctum I-Medicinal food
and O
C B-Medicinal food
. I-Medicinal food
sinensis I-Medicinal food
significantly O
reduced O
the O
immobility O
times O
of O
rats O
in O
FST O
and O
TST O
. O

Conclusion O
: O
O B-Medicinal food
. I-Medicinal food
sanctum I-Medicinal food
and O
C B-Medicinal food
. I-Medicinal food
sinensis I-Medicinal food
possess O
anxiolytic O
and O
antidepressant O
activities O
. O

HISTORY O
AND O
OBJECTIVE O
: O
The O
aim O
of O
this O
study O
was O
to O
study O
the O
anxiolytic O
effects O
of O
Ocimum B-Medicinal food
sanctum I-Medicinal food
stress-induced B-Symptom_WorkedFor
anxiety I-Symptom_WorkedFor
. O

Materials O
and O
methods O
: O
The O
study O
was O
carried O
out O
using O
male O
albino O
rats O
( O
200 O
± O
50 O
gm O
) O
, O
male O
albino O
mice O
( O
25 O
± O
100 O
) O
the O
effect O
of O
O B-Symptom_WorkedFor
. I-Symptom_WorkedFor
sanctum I-Symptom_WorkedFor
evaluated O
for O
anxiety B-Symptom_WorkedFor
and O
depression B-Symptom_WorkedFor
using O
forced O
swim O
test O
FST O
and O
rotarod O
test O
. O

Results O
: O
Restraint O
stress O
( O
3 O
hours O
/ O
day O
for O
six O
consecutive O
days O
) O
induced O
a O
significant O
reduction O
. O

It O
was O
significantly O
decreases O
the O
mobility O
period O
during O
stress O
. O

The O
standard O
deviation O
values O
are O
14.4 O
and O
9.26 O
and O
is O
statistically O
significant O
( O
p O
= O
0.001 O
) O
. O

In O
rotarod O
test O
, O
( O
a O
) O
increased O
latency O
and O
( O
b O
) O
decreased O
ambulation O
and O
rearing O
were O
also O
reversed O
by O
O B-Medicinal food
. I-Medicinal food
sanctum I-Medicinal food
. O

A O
significant O
increase O
in O
immobility O
period O
was O
observed O
in O
FST O
and O
TST O
after O
restraint O
stress O
. O

O B-Medicinal food
. I-Medicinal food
sanctum I-Medicinal food
and O
C B-Medicinal food
. I-Medicinal food
sinensis I-Medicinal food
significantly O
reduced O
the O
immobility O
times O
of O
rats O
in O
FST O
and O
TST O
. O

Conclusion O
: O
Ocimum B-Medicinal food
sanctum I-Medicinal food
possess O
significant O
antistress O
activity O
but O
the O
magnitude O
and O
efficacy O
for O
relieving O
stress O
is O
less O
, O
when O
compare O
to O
standard O
anxiolytic O
agent O
, O
i.e O
. O

Alprazolam B-Other_ingredients
. O

Ethnopharmacological O
relevance O
: O
Ocimum B-Medicinal food
species O
are O
traditionally O
used O
for O
the O
treatment O
of O
anxiety B-Symptom_WorkedFor
, O
nerve B-Symptom_WorkedFor
pain I-Symptom_WorkedFor
, O
convulsions B-Symptom_WorkedFor
and O
a O
variety O
of O
neurodegenerative B-Symptom_WorkedFor
disorders I-Symptom_WorkedFor
. O

The O
present O
study O
was O
undertaken O
to O
evaluate O
the O
anti-amnesic O
effect O
of O
O B-Medicinal food
. I-Medicinal food
basilicum I-Medicinal food
L I-Medicinal food
. I-Medicinal food
, O
O B-Medicinal food
. I-Medicinal food
sanctum I-Medicinal food
L I-Medicinal food
. I-Medicinal food
and O
O B-Medicinal food
. I-Medicinal food
gratissimum I-Medicinal food
L I-Medicinal food
. I-Medicinal food
extracts O
using O
in-vitro O
and O
in-vivo O
models O
. O

Materials O
and O
methods O
: O
In-vitro O
acetylcholinesterase O
( O
AChE O
) O
inhibitory O
and O
antioxidant O
activities O
of O
hydro-methanol O
extracts O
of O
plants O
were O
evaluated O
using O
Ellman B-Metric
and I-Metric
DPPH I-Metric
and I-Metric
FRAP I-Metric
assays I-Metric
, O
respectively O
. O

The O
most O
active O
extract O
i.e O
. O

O B-Medicinal food
. I-Medicinal food
basilicum I-Medicinal food
extract O
( O
OBE B-Medicinal food
) O
was O
further O
explored O
for O
the O
possible O
anti-amnesic O
activity O
in O
mouse O
model O
of O
scopolamine O
induced O
amnesia O
using O
behavioral O
models O
( O
elevated O
plus O
maze O
and O
passive O
shock O
avoidance O
task O
) O
. O

Brain O
AChE O
activity O
, O
oxidative O
profile O
and O
histopathological O
studies O
were O
assessed O
to O
outline O
the O
anti-amnesic O
mechanism O
of O
the O
extract O
. O

Results O
: O
Significant O
antioxidant O
and O
AChE O
inhibition O
activity O
was O
observed O
with O
all O
prepared O
extracts O
and O
however O
, O
OBE O
showed O
most O
marked O
free O
radical O
scavenging O
, O
reducing O
power O
and O
AChE O
inhibition O
( O
IC50 O
0.65 O
± O
0.15mg O
/ O
ml O
) O
activity O
. O

Basil B-Medicinal food
leaves I-Medicinal food
were O
standardized O
with O
respect O
to O
content O
of O
7 O
phenolic B-Other_ingredients
acids I-Other_ingredients
using O
a O
HPLC-PDA O
method O
. O

A O
TLC O
densitometric O
method O
was O
employed O
to O
determine O
the O
quercetin O
content O
in O
the O
leaves O
. O

The O
in-vivo O
studies O
showed O
that O
OBE O
pre-treatment O
( O
200 O
and O
400mg O
/ O
kg O
, O
p.o O
. O
) O
reversed O
the O
memory O
deficit O
induced O
by O
scopolamine O
in O
mice O
, O
evident O
by O
significant O
( O
p O
< O
0.05 O
) O
decrease O
in O
the O
transfer O
latency O
time O
and O
increase O
in O
step O
down O
latency O
in O
elevated O
plus O
maze O
and O
passive O
shock O
avoidance O
task O
, O
respectively O
. O

Moreover O
, O
OBE O
significantly O
reduced O
the O
brain O
AChE O
activity O
and O
oxidative O
stress O
. O

Further O
, O
histopathological O
examination O
of O
brain O
tissues O
displayed O
decrease O
in O
vacuolated O
cytoplasm O
and O
increase O
in O
pyramidal O
cells O
in O
hippocampal O
and O
cortical O
regions O
with O
OBE O
pre-treatment O
. O

Conclusion O
: O
OBE B-Medicinal food
possesses O
antioxidant O
and O
AChE O
inhibitory O
activity O
. O

These O
biochemical O
changes O
are O
responsible O
for O
the O
anti-amnesic B-Symptom_WorkedFor
and O
neuroprotective B-Symptom_WorkedFor
activities O
of O
O B-Medicinal food
. I-Medicinal food
basilicum I-Medicinal food
which O
may O
be O
attributed O
to O
the O
presence O
of O
phenolic O
and O
flavonoid O
compounds O
. O

This O
can O
be O
developed O
as O
an O
effective O
anti-amnesic B-Symptom_WorkedFor
drug O
. O

Background O
and O
purpose O
: O
Reducing O
dental O
anxiety O
is O
a O
major O
aspect O
of O
childmanagement O
in O
dental O
visits O
. O

This O
crossover O
randomized O
clinical O
trial O
was O
designed O
to O
determine O
the O
effect O
of O
lavender B-Medicinal food
aromatherapy O
on O
anxiety B-Symptom_WorkedFor
level O
during O
dental O
treatment O
and O
pain B-Symptom_WorkedFor
perception O
during O
dental O
injection O
in O
children O
. O

Materials O
and O
methods O
: O
Twenty-four B-#Participants
children O
aged O
7 O
- O
9 O
years O
received O
restorative O
treatment O
with O
lavender B-Medicinal food
aromatherapy O
in O
the O
intervention O
session O
and O
without O
aroma O
in O
the O
control O
session O
. O

Salivary O
cortisol O
and O
pulse O
rate O
were O
measured O
to O
evaluate O
child's O
anxiety B-Symptom_WorkedFor
level O
and O
the O
Face B-Metric
Rating I-Metric
Scale I-Metric
( O
FRS O
) O
was O
used O
for O
assessing O
the O
pain B-Symptom_WorkedFor
perception O
during O
injection O
in O
both O
visits O
. O

Results O
: O
The O
treatment O
effect O
on O
salivary O
cortisol O
, O
pulse O
rate O
, O
and O
FRS O
score O
was O
- O
8.01 O
± O
0.92 O
nmol O
/ O
l O
, O
- O
11.17 O
± O
1.28 O
( O
in O
minutes O
) O
, O
and O
- O
2.00 O
± O
0.41 O
respectively O
, O
which O
was O
statistically O
significant O
( O
P O
< O
0.001 O
) O
. O

Conclusion O
: O
Lavender B-Medicinal food
aromatherapy O
can O
decrease O
dental B-Symptom_WorkedFor
anxiety I-Symptom_WorkedFor
and O
experienced O
pain B-Symptom_WorkedFor
in I-Symptom_WorkedFor
dental I-Symptom_WorkedFor
setting I-Symptom_WorkedFor
. O

Purpose O
: O
The O
purpose O
of O
this O
study O
is O
to O
identify O
the O
effect O
of O
aroma O
inhalation O
on O
stress B-Symptom_WorkedFor
responses O
( O
physical O
symptoms O
, O
levels O
of O
anxiety B-Symptom_WorkedFor
, O
perceived O
stresses B-Symptom_WorkedFor
) O
of O
nursing O
students O
. O

Method O
: O
This O
study O
was O
a O
quasi-experimental O
research O
using O
a O
non-equivalent O
pre-post O
design O
and O
was O
conducted O
from O
June O
1 O
to O
June O
5 O
, O
2002 O
. O

The O
subjects O
consisted O
of O
77 B-#Participants
junior O
nursing O
students O
who O
were O
divided O
into O
39 O
experimental O
group O
members O
and O
38 O
control O
group O
members O
. O

A O
pretest O
and O
Post-test O
were O
conducted O
to O
measure O
body O
symptoms O
, O
the O
level O
of O
anxiety B-Symptom_WorkedFor
, O
and O
the O
level O
of O
perceived O
stress B-Symptom_WorkedFor
. O

In O
the O
experimental O
group O
, O
aromas O
were O
given O
using O
an O
aroma O
lamp O
, O
lavender B-Medicinal food
, O
peppermint B-Medicinal food
, O
rosemary B-Medicinal food
and O
Clary-Sage B-Medicinal food
. O

In O
the O
control O
group O
, O
the O
treatment O
was O
not O
administered O
. O

Result O
: O
As O
a O
result O
of O
administering O
aroma O
inhalation O
to O
nursing O
students O
, O
their O
physical O
symptoms O
decreased O
, O
their O
anxiety B-Symptom_WorkedFor
scores O
were O
low O
, O
and O
their O
perceived B-Symptom_WorkedFor
stress I-Symptom_WorkedFor
scores O
were O
low O
, O
showing O
that O
aroma O
inhalation O
could O
be O
a O
very O
effective O
stress B-Symptom_WorkedFor
management I-Symptom_WorkedFor
method O
. O

Conclusion O
: O
Nursing O
educators O
should O
play O
an O
important O
role O
in O
contributing O
to O
college O
students O
' O
physical O
and O
psychological O
health O
by O
helping O
enhance O
their O
recognition O
of O
stress B-Symptom_WorkedFor
management I-Symptom_WorkedFor
and O
effectively O
relieving O
their O
stress B-Symptom_WorkedFor
using O
essential O
oils O
. O

Purpose O
: O
Appearance-related B-Symptom_TestedFor
stress I-Symptom_TestedFor
may O
result O
from O
appearance-focused O
events O
such O
as O
seeing O
one's O
reflection O
, O
seeing O
media O
images O
, O
and O
shopping O
for O
clothes O
. O

The O
purpose O
of O
this O
study O
was O
to O
examine O
the O
prospective O
association O
between O
momentary O
appearance-related B-Symptom_TestedFor
stress I-Symptom_TestedFor
and O
eating B-Symptom_TestedFor
disorder I-Symptom_TestedFor
( I-Symptom_TestedFor
ED I-Symptom_TestedFor
) I-Symptom_TestedFor
behaviors I-Symptom_TestedFor
( O
i.e O
. O
, O
binge B-Symptom_TestedFor
eating I-Symptom_TestedFor
and O
vomiting B-Symptom_TestedFor
) O
among O
women O
with O
anorexia B-participant_health
nervosa I-participant_health
( O
AN O
) O
using O
ecological B-Metric
momentary I-Metric
assessment I-Metric
( O
EMA O
) O
. O

We O
hypothesized O
that O
appearance-related O
stress O
at O
Time O
1 O
would O
predict O
binge O
eating O
and O
vomiting O
at O
Time O
2 O
, O
and O
that O
this O
prospective O
association O
would O
be O
mediated O
by O
momentary O
anxiety O
at O
Time O
2 O
( O
controlling O
for O
anxiety O
at O
Time O
1 O
) O
. O

Methods O
: O
Women O
with O
AN O
completed O
a O
2 B-Duration
- I-Duration
week I-Duration
EMA O
protocol O
involving O
repeated O
daily O
assessments O
of O
experiences O
and O
behaviors O
. O

Results O
: O
Momentary O
appearance-related B-Symptom_TestedFor
stress I-Symptom_TestedFor
preceded O
binge B-Symptom_TestedFor
eating I-Symptom_TestedFor
and O
vomiting B-Symptom_TestedFor
, O
and O
momentary O
anxiety B-Symptom_TestedFor
mediated O
the O
prospective O
association O
between O
appearance-related O
stress O
and O
ED O
behaviors O
. O

Conclusions O
: O
Targeted O
momentary O
interventions O
delivered O
in O
the O
natural O
environment O
that O
address O
appearance-related B-Symptom_TestedFor
stress I-Symptom_TestedFor
may O
have O
utility O
in O
the O
treatment O
of O
ED O
behaviors O
. O

Lavender B-Medicinal food
essential O
oil O
is O
traditionally O
used O
and O
approved O
by O
the O
European O
Medicines O
Agency O
( O
EMA O
) O
as O
herbal O
medicine O
to O
relieve O
stress B-Symptom_WorkedFor
and O
anxiety B-Symptom_WorkedFor
. O

Some O
animal O
and O
clinical O
studies O
reveal O
positive O
results O
in O
models O
of O
anxiety B-Symptom_WorkedFor
and O
depression B-Symptom_WorkedFor
although O
very O
little O
research O
has O
been O
done O
on O
molecular O
mechanisms O
. O

Our O
work O
consisted O
of O
evaluating O
the O
effects O
of O
lavender B-Medicinal food
( O
Lavandula B-Drug/Scientific name
angustifolia I-Drug/Scientific name
) O
essential O
oil O
on O
central O
nervous O
system O
well-established O
targets O
, O
such O
as O
MAO-A O
, O
SERT O
, O
GABAAand O
NMDA O
receptors O
as O
well O
as O
in O
vitro O
models O
of O
neurotoxicity O
. O

The O
results O
showed O
that O
lavender B-Medicinal food
essential O
oil O
and O
its O
main O
components O
exert O
affinity O
for O
the O
glutamate O
NMDA-receptor O
in O
a O
dose-dependent O
manner O
with O
an O
IC50 O
value O
of O
0.04 O
μl O
/ O
mL O
for O
lavender B-Medicinal food
oil O
. O

In O
addition O
, O
lavender B-Medicinal food
and O
linalool B-Other_ingredients
were O
also O
able O
to O
bind O
the O
serotonin O
transporter O
( O
SERT O
) O
whereas O
they O
did O
not O
show O
affinity O
for O
GABAA-benzodiazepine O
receptor O
. O

In O
three O
different O
models O
of O
neurotoxicity O
, O
lavender B-Medicinal food
did O
not O
enhance O
the O
neurotoxic O
insult O
and O
improved O
viability O
of O
SH-SY5Y O
cells O
treated O
with O
hydrogen O
peroxide O
. O

According O
to O
our O
data O
, O
the O
anxiolytic B-Symptom_WorkedFor
and O
antidepressant-like B-Symptom_WorkedFor
effects O
attributed O
to O
lavender B-Medicinal food
may O
be O
due O
to O
an O
antagonism O
on O
the O
NMDA-receptor O
and O
inhibition O
of O
SERT O
. O

This O
study O
suggests O
that O
lavender B-Medicinal food
essential O
oil O
may O
exert O
pharmacological O
properties O
via O
modulating O
the O
NMDA O
receptor O
, O
the O
SERT O
as O
well O
as O
neurotoxicity O
induced O
by O
hydrogen O
peroxide O
. O

Anxiety B-Symptom_WorkedFor
disorders I-Symptom_WorkedFor
are O
some O
of O
the O
most O
common O
psychiatric O
disorders O
, O
with O
potentially O
debilitating O
consequences O
on O
individual O
function O
. O

Existing O
pharmacotherapies O
for O
anxiety B-Symptom_WorkedFor
disorders O
are O
limited O
by O
delay O
to O
therapeutic O
effect O
, O
dependence O
, O
tolerance O
, O
withdrawal O
, O
and O
abuse O
potential O
. O

Therefore O
, O
safe O
and O
evidence-based O
complementary O
or O
alternative O
therapies O
may O
be O
important O
allies O
in O
the O
care O
of O
patients O
with O
anxiety O
disorders O
. O

Essential O
oils O
are O
lipophilic O
and O
concentrated O
botanical O
extracts O
that O
exhibit O
many O
properties O
of O
drugs O
, O
although O
they O
are O
not O
Food O
and O
Drug O
Administration O
approved O
and O
have O
limitations O
characteristic O
of O
herbal O
preparations O
. O

Lavender B-Medicinal food
essential O
oil O
has O
an O
extensive O
anecdotal O
history O
of O
anxiolytic O
benefit O
that O
has O
recently O
been O
supported O
by O
clinical O
efficacy O
studies O
. O

The O
2 O
primary O
terpenoid O
constituents O
of O
lavender B-Medicinal food
essential O
oil O
, O
linalool B-Drug/Scientific name
and O
linalyl B-Drug/Scientific name
acetate I-Drug/Scientific name
, O
may O
produce O
an O
anxiolytic O
effect O
in O
combination O
via O
inhibition O
of O
voltage-gated O
calcium O
channels O
, O
reduction O
of O
5HT1A O
receptor O
activity O
, O
and O
increased O
parasympathetic O
tone O
. O

The O
objectives O
of O
this O
article O
are O
to O
provide O
a O
brief O
overview O
of O
lavender B-Medicinal food
oil O
in O
aromatherapy O
, O
explore O
variability O
in O
the O
constituents O
of O
lavender B-Medicinal food
oil O
, O
summarize O
its O
pharmacology O
and O
safety O
profile O
, O
as O
well O
as O
describe O
its O
body O
of O
research O
that O
has O
been O
conducted O
for O
anxiety B-Symptom_WorkedFor
. O

Sleep B-Symptom_WorkedFor
and O
anxiety B-Symptom_WorkedFor
problems O
occur O
in O
hemodialysis B-participant_health
( O
HD B-participant_health
) O
patients O
due O
to O
physical O
symptoms O
, O
lifestyle O
changes O
, O
and O
psychosocial O
changes O
. O

To O
remove O
these O
sleep B-Symptom_WorkedFor
and O
anxiety B-Symptom_WorkedFor
problems O
, O
lavender B-Medicinal food
oil O
inhalation O
is O
one O
of O
the O
nonpharmacological O
treatment O
options O
with O
less O
adverse O
effects O
than O
pharmacological O
methods O
. O

The O
purpose O
of O
this O
study O
was O
to O
determine O
the O
effect O
of O
lavender B-Medicinal food
oil O
application O
via O
inhalation O
pathway O
on O
HD B-participant_health
patients O
' O
anxiety B-Symptom_WorkedFor
level O
and O
sleep B-Symptom_WorkedFor
quality O
. O

The O
study O
was O
conducted O
with O
34 B-#Participants
HD B-participant_health
patients O
who O
have O
been O
on O
HD O
treatment O
at O
2 O
dialysis O
centers O
. O

The O
patients O
of O
the O
intervention O
group O
( O
n O
= O
17 O
) O
were O
told O
to O
drip O
2 O
drops O
into O
the O
box O
and O
to O
place O
it O
15 O
to O
20 O
cm O
away O
from O
the O
pillow O
, O
30 O
minutes O
before O
going O
to O
bed O
for O
1 B-Duration
week I-Duration
. O

Control O
group O
( O
n O
= O
17 O
) O
received O
no O
intervention O
. O

Data O
were O
collected O
with O
questionnaire O
form O
, O
Visual B-Metric
Analog I-Metric
Scale I-Metric
, O
and O
Hamilton B-Metric
Anxiety I-Metric
Assessment I-Metric
Scale I-Metric
with O
a O
face-to-face O
interview O
. O

Subjective O
sleep B-Symptom_WorkedFor
quality O
of O
the O
intervention O
group O
was O
higher O
than O
that O
of O
control O
group O
, O
mean O
Visual B-Metric
Analog I-Metric
Scale I-Metric
daytime O
sleepiness O
score O
declined O
( O
P O
< O
.05 O
) O
, O
and O
mean O
score O
of O
sleep O
duration O
increased O
( O
P O
< O
.001 O
) O
in O
the O
intervention O
group O
. O

However O
, O
the O
differences O
of O
mean O
score O
of O
time O
for O
falling O
asleep O
between O
the O
2 O
groups O
were O
not O
different O
. O

The O
mean O
score O
of O
total O
and O
subdimensions O
of O
Hamilton B-Metric
Anxiety I-Metric
Assessment I-Metric
Scale I-Metric
of O
intervention O
group O
and O
control O
group O
was O
significantly O
different O
( O
P O
< O
.001 O
) O
. O

These O
study O
results O
provide O
new O
promising O
information O
about O
the O
effect O
of O
lavender B-Medicinal food
inhalation O
on O
sleep B-Symptom_WorkedFor
problems O
and O
anxiety B-Symptom_WorkedFor
and O
these O
have O
made O
significant O
contributions O
to O
nursing O
, O
especially O
for O
dialysis O
nurses O
. O

A O
number O
of O
essential O
oils O
are O
currently O
in O
use O
as O
aromatherapy O
agents O
to O
relieve O
anxiety B-Symptom_WorkedFor
, O
stress B-Symptom_WorkedFor
, O
and O
depression B-Symptom_WorkedFor
. O

Popular O
anxiolytic O
oils O
include O
lavender B-Medicinal food
( O
Lavandula B-Drug/Scientific name
angustifolia I-Drug/Scientific name
) O
, O
rose B-Medicinal food
( O
Rosa B-Drug/Scientific name
damascena I-Drug/Scientific name
) O
, O
orange B-Medicinal food
( O
Citrus B-Drug/Scientific name
sinensis I-Drug/Scientific name
) O
, O
bergamot B-Medicinal food
( O
Citrus B-Drug/Scientific name
aurantium I-Drug/Scientific name
) O
, O
lemon B-Medicinal food
( O
Citrus B-Drug/Scientific name
limon I-Drug/Scientific name
) O
, O
sandalwood B-Medicinal food
( O
Santalum B-Drug/Scientific name
album I-Drug/Scientific name
) O
, O
clary B-Medicinal food
sage I-Medicinal food
( O
Salvia B-Drug/Scientific name
sclarea I-Drug/Scientific name
) O
, O
Roman B-Medicinal food
chamomile I-Medicinal food
( O
Anthemis B-Drug/Scientific name
nobilis I-Drug/Scientific name
) O
, O
and O
rose-scented B-Medicinal food
geranium I-Medicinal food
( O
Pelargonium B-Drug/Scientific name
spp I-Drug/Scientific name
. O
) O
. O

This O
review O
discusses O
the O
chemical O
constituents O
and O
CNS O
effects O
of O
these O
aromatherapeutic O
essential O
oils O
, O
as O
well O
as O
recent O
studies O
on O
additional O
essential O
oils O
with O
anxiolytic O
activities O
. O

Lavender B-Medicinal food
is O
a O
popular O
treatment O
for O
stress B-Symptom_WorkedFor
and O
mild O
anxiety B-Symptom_WorkedFor
in O
Europe O
and O
the O
USA O
. O

The O
present O
study O
investigated O
the O
effects O
of O
( O
Lavandula B-Drug/Scientific name
angustifolia I-Drug/Scientific name
Mill I-Drug/Scientific name
. I-Drug/Scientific name

( O
Lamiaceae B-Drug/Scientific name
) O
) O
lavender B-Medicinal food
odour O
inhalation O
over O
2 B-Duration
weeks I-Duration
or O
24 O
h O
periods O
, O
on O
gerbil O
behaviour O
in O
the O
elevated O
plus O
maze O
in O
mature O
male O
and O
female O
gerbils O
, O
and O
compared O
results O
with O
the O
effects O
of O
diazepam B-Other_ingredients
( O
1 O
mg O
/ O
kg O
) O
i.p O
. O
after O
30 O
min O
and O
2 B-Duration
- I-Duration
week I-Duration
administration O
. O

Traditional O
measures O
of O
open O
entries O
showed O
an O
increasing O
trend O
over O
the O
2 O
weeks O
exposure O
, O
whereas O
ethological O
measures O
indicative O
of O
anxiety B-Symptom_WorkedFor
; O
stretch-attend O
frequency O
and O
percentage O
protected O
head-dips O
, O
were O
significantly O
lower O
. O

Exploratory O
behaviour O
, O
total O
head-dip O
frequency O
, O
increased O
after O
24 O
h O
lavender O
and O
2 O
weeks O
exposure O
. O

These O
results O
are O
comparable O
with O
diazepam B-Other_ingredients
administration O
. O

There O
were O
sex O
differences O
in O
protected O
head-dip O
an O
ethological O
indicator O
of O
anxiety B-Symptom_WorkedFor
: O
females O
showed O
a O
significant O
decrease O
in O
protected O
head-dips O
compared O
to O
both O
males O
and O
to O
female O
controls O
. O

In O
conclusion O
exposure O
to O
lavender B-Medicinal food
odour O
may O
have O
an O
anxiolytic O
profile O
in O
gerbils O
similar O
to O
that O
of O
the O
anxiolytic O
diazepam O
. O

In O
addition O
, O
prolonged O
, O
2 B-Duration
- I-Duration
week I-Duration
lavender B-Medicinal food
odour O
exposure O
increased O
exploratory O
behaviour O
in O
females O
indicating O
a O
further O
decrease O
in O
anxiety B-Symptom_WorkedFor
in O
this O
sex O
. O

Interventions O
delivered O
via O
mobile O
apps O
show O
particular O
promise O
in O
tackling O
the O
burden O
of O
common O
mental O
disorders O
. O

Appropriately O
targeting O
these O
interventions O
to O
at-risk O
populations O
is O
critical O
to O
their O
success O
. O

This O
pilot O
study O
aimed O
to O
assess O
the O
usability O
, O
feasibility O
, O
acceptability O
, O
and O
preliminary O
effects O
of O
an O
app-based O
intervention O
designed O
to O
target O
depressive B-Symptom_WorkedFor
symptoms O
in O
a O
stressed O
working O
population O
. O

Anchored O
, O
a O
smartphone O
app O
including O
a O
30 B-Duration
- I-Duration
day I-Duration
program O
of O
mindfulness O
and O
cognitive O
and O
behavioural O
therapeutic O
components O
, O
was O
tested O
in O
a O
pre-post O
pilot O
study O
with O
participants O
recruited O
via O
social O
media O
advertisements O
. O

Eligible O
participants O
( O
N O
= O
81 B-#Participants
) O
were O
Australian O
adults O
who O
were O
employed O
and O
reported O
elevated O
stress O
levels O
on O
a O
single-item O
screening O
measure O
. O

Follow-up O
assessment O
occurred O
5 O
weeks O
after O
baseline O
. O

The O
primary O
outcome O
measure O
was O
change O
in O
depressive O
symptoms O
, O
with O
secondary O
outcomes O
measuring O
change O
in O
anxiety B-Symptom_WorkedFor
, O
wellbeing O
, O
stress B-Symptom_WorkedFor
, O
resilience O
, O
exercise O
, O
alcohol O
use O
, O
absenteeism O
, O
and O
work O
performance O
. O

User O
feedback O
and O
in-app O
data O
were O
analysed O
to O
assess O
engagement O
and O
intervention O
adherence O
. O

At O
follow-up O
, O
there O
were O
significant O
reductions O
in O
depressive B-Symptom_WorkedFor
symptoms O
( O
t61 O
= O
6.35 O
; O
p O
< O
0.001 O
) O
and O
anxiety B-Symptom_WorkedFor
symptoms O
( O
t60 O
= O
7.35 O
; O
p O
< O
0.001 O
) O
, O
along O
with O
significantly O
reduced O
cases O
of O
likely O
new O
onset O
depression O
compared O
to O
baseline O
( O
24% O
vs O
. O
6% O
, O
p O
= O
0.012 O
) O
. O

Significant O
improvements O
were O
also O
seen O
in O
wellbeing O
( O
t60 O
= O
- O
5.64 O
; O
p O
< O
0.001 O
) O
, O
resilience O
( O
t60 O
= O
- O
3.89 O
; O
p O
< O
0.001 O
) O
, O
stress O
( O
t61 O
= O
11.18 O
; O
p O
< O
0.001 O
) O
, O
and O
alcohol O
use O
( O
t60 O
= O
3.40 O
; O
p O
= O
0.001 O
) O
. O

Participants O
reported O
no O
significant O
changes O
in O
work O
performance O
, O
absenteeism O
or O
exercise O
. O

There O
were O
satisfactory O
levels O
of O
app O
usability O
, O
feasibility O
, O
and O
acceptability O
. O

Most O
participants O
found O
the O
app O
easy O
to O
use O
( O
93.2% O
) O
, O
understood O
the O
app O
content O
well O
( O
83.0% O
) O
, O
and O
rated O
the O
app O
highly O
or O
very O
highly O
overall O
( O
72.9% O
) O
. O

User O
feedback O
suggestions O
were O
predominantly O
focused O
on O
improving O
app O
navigation O
and O
user O
interface O
. O

This O
pilot O
study O
provides O
encouraging O
evidence O
that O
Anchored O
has O
potentially O
beneficial O
effects O
, O
and O
is O
usable O
, O
feasible O
, O
and O
acceptable O
as O
an O
app-based O
intervention O
for O
the O
working O
population O
experiencing O
elevated O
stress B-Symptom_WorkedFor
. O

Further O
testing O
of O
Anchored O
in O
a O
randomised O
controlled O
trial O
is O
required O
to O
investigate O
its O
efficacy O
as O
an O
intervention O
for O
workplace O
mental O
ill-health O
. O

Background O
: O
Pregnancy O
after O
perinatal O
death O
is O
characterised O
by O
elevated O
stress B-Symptom_TestedFor
and O
anxiety B-Symptom_TestedFor
, O
increasing O
the O
risk O
of O
adverse O
short-term O
and O
long-term O
outcomes O
. O

Objectives O
: O
This O
metasynthesis O
aimed O
to O
improve O
understanding O
of O
parents O
' O
experiences O
of O
maternity O
care O
in O
pregnancy O
after O
stillbirth O
or O
neonatal O
death O
. O

Search O
strategy O
: O
Six O
electronic O
databases O
were O
searched O
using O
predefined O
search O
terms O
. O

Selection O
criteria O
: O
English O
language O
studies O
using O
qualitative O
methods O
to O
explore O
the O
experiences O
of O
parents O
in O
pregnancy O
after O
perinatal O
loss O
, O
were O
included O
subject O
to O
quality O
appraisal O
framework O
. O

Data O
collection O
and O
analysis O
: O
Searches O
were O
initiated O
in O
December O
2011 O
and O
finalised O
in O
March O
2013 O
. O

Studies O
were O
synthesised O
using O
an O
interpretive O
approach O
derived O
from O
meta-ethnography O
. O

Main O
results O
: O
Fourteen O
studies O
were O
included O
in O
the O
synthesis O
, O
graded O
A O
( O
no O
or O
few O
flaws O
, O
high O
trustworthiness O
; O
n O
= O
5 O
) O
, O
B O
( O
some O
flaws O
, O
unlikely O
to O
affect O
trustworthiness O
; O
n O
= O
5 O
) O
and O
C O
( O
some O
flaws O
, O
possible O
impact O
on O
trustworthiness O
; O
n O
= O
4 O
) O
. O

Three O
main O
themes O
were O
identified O
; O
co-existence O
of O
emotions O
, O
helpful O
and O
unhelpful O
coping O
activities O
and O
seeking O
reasssurance O
through O
interactions O
. O

Conclusion O
: O
Parents O
' O
experiences O
of O
pregnancy O
are O
profoundly O
altered O
by O
previous O
perinatal O
death O
; O
conflicted O
emotions O
, O
extreme O
anxiety O
, O
isolation O
and O
a O
lack O
of O
trust O
in O
a O
good O
outcome O
are O
commonly O
reported O
. O

Emotional O
and O
psychological O
support O
improves O
parents O
' O
experiences O
of O
subsequent O
pregnancy O
, O
but O
the O
absence O
of O
an O
evidence O
base O
may O
limit O
consistent O
delivery O
of O
optimal O
care O
within O
current O
services O
. O

Context O
: O
Healthcare O
clinicians O
often O
endure O
stress B-Symptom_WorkedFor
over O
long O
periods O
of O
time O
. O

The O
burden O
of O
witnessing O
death O
and O
disability O
, O
complex O
work O
duties O
, O
long O
and O
irregular O
hours O
, O
the O
threat O
of O
errors O
, O
and O
tensions O
between O
colleagues O
result O
in O
emotional O
strain O
, O
anxiety O
, O
depression O
, O
burnout O
and O
in O
the O
worst O
case O
: O
suicide O
. O

The O
Caregiver O
Support O
Team O
was O
designed O
to O
provide O
emotional O
first O
aid O
to O
clinicians O
in O
the O
healthcare O
environment O
in O
the O
moment O
of O
need O
and O
triage O
those O
who O
would O
benefit O
from O
ongoing O
care O
. O

Objective O
/ O
intervention O
: O
To O
test O
the O
feasibility O
of O
providing O
a O
Caregiver O
Support O
Team O
to O
provide O
emotional O
first O
aid O
in O
the O
workplace O
. O

This O
project O
is O
an O
extension O
of O
our O
previously O
reported O
Code O
Lavender O
initiative O
. O

Hypotheses O
: O
After O
stressful O
events O
in O
the O
workplace O
, O
staff O
will O
provide O
, O
receive O
, O
and O
recommend O
the O
Caregiver O
Support O
Team O
to O
others O
. O

The O
Caregiver O
Support O
Team O
will O
be O
used O
and O
accepted O
by O
clinicians O
, O
improve O
Professional B-Metric
Quality I-Metric
of I-Metric
Life I-Metric
Scale I-Metric
( O
ProQoL O
) O
scores O
, O
general O
job O
satisfaction O
and O
feeling O
cared O
for O
in O
the O
workplace O
. O

Method O
/ O
sample O
: O
We O
describe O
a O
pilot O
program O
. O

Following O
the O
completion O
of O
a O
Code O
Lavender O
pilot O
, O
physicians O
and O
staff O
on O
4 O
hospital O
units O
provided O
nominations O
for O
peer O
supporters O
: O
someone O
they O
would O
trust O
in O
a O
time O
of O
emotional O
need O
. O

These O
peer O
supporters O
were O
provided O
8 O
hours O
of O
training O
by O
a O
psychologist O
and O
voluntarily O
sought O
to O
find O
those O
in O
the O
workplace O
who O
were O
affected O
by O
workplace O
stress O
and O
provide O
emotional O
support O
. O

Feasibility O
data O
and O
ProQoL O
scores O
were O
collected O
at O
baseline O
and O
3 O
months O
. O

Results O
: O
At O
baseline O
, O
59% O
( O
n O
= O
44 O
) O
reported O
symptomatic O
stress O
caused O
by O
the O
workplace O
. O

Main O
causes O
of O
stress O
were O
emotional O
responses O
of O
patients O
/ O
families O
, O
disputes O
with O
colleagues O
, O
and O
negative O
clinical O
outcomes O
. O

Colleagues O
were O
reported O
as O
the O
most O
frequently O
used O
source O
of O
support O
following O
workplace O
stress O
. O

A O
Caregiver O
Support O
Team O
intervention O
was O
received O
by O
40% O
of O
respondents O
; O
100% O
found O
it O
helpful O
and O
100% O
would O
recommend O
it O
to O
others O
. O

No O
significant O
changes O
were O
demonstrated O
before O
and O
after O
the O
intervention O
in O
ProQoL O
Scores O
, O
or O
job O
satisfaction O
. O

The O
emotion O
of O
feeling O
cared-for O
improved O
. O

Staff O
spontaneously O
requested O
emotional O
debriefings O
through O
peer O
supporters O
. O

One O
suicide O
was O
prevented O
. O

Conclusions O
: O
The O
Caregiver O
Support O
Team O
was O
positively O
received O
. O

The O
organization O
received O
budgetary O
support O
from O
our O
hospital O
to O
disseminate O
the O
program O
system-wide O
. O

Additional O
interventions O
are O
needed O
to O
overcome O
the O
root O
cause O
of O
workplace O
stressors O
. O

A O
formal O
link O
between O
Risk O
Management O
is O
being O
developed O
to O
identify O
cases O
which O
warrant O
emotional O
( O
vs O
. O
clinical O
only O
or O
both O
) O
debriefing O
/ O
group O
processing O
. O

S1 O
Health O
literacy O
and O
health O
education O
in O
adolescence O
Catarina O
Cardoso O
Tomás O
S2 O
The O
effect O
of O
a O
walking O
program O
on O
the O
quality O
of O
life O
and O
well-being O
of O
people O
with O
schizophrenia O
Emanuel O
Oliveira O
, O
D O
. O

Sousa O
, O
M O
. O

Uba-Chupel O
, O
G O
. O

Furtado O
, O
C O
. O

Rocha O
, O
A O
. O

Teixeira O
, O
P O
. O

Ferreira O
S3 O
Diagnosis O
and O
innovative O
treatments O
- O
the O
way O
to O
a O
better O
medical O
practice O
Celeste O
Alves O
S4 O
Simulation-based O
learning O
and O
how O
it O
is O
a O
high O
contribution O
Stefan O
Gisin O
S5 O
Formative O
research O
about O
acceptability O
, O
utilization O
and O
promotion O
of O
a O
home O
fortification O
programme O
with O
micronutrient O
powders O
( O
MNP O
) O
in O
the O
Autonomous O
Region O
of O
Príncipe O
, O
São O
Tomé O
and O
Príncipe O
Elisabete O
Catarino O
, O
Nelma O
Carvalho O
, O
Tiago O
Coucelo O
, O
Luís O
Bonfim O
, O
Carina O
Silva O
S6 O
Safety O
culture O
of O
the O
patient O
: O
a O
reflexion O
about O
the O
therapeutic O
approach O
on O
the O
patient O
with O
vocal O
pathology O
Débora O
Franco O
S7 O
About O
wine O
, O
fortune O
cookies O
and O
patient O
experience O
Jesús O
Alcoba O
González O
O1 O
The O
psychological O
impact O
on O
the O
emergency O
crews O
after O
the O
disaster O
event O
on O
February O
20 O
, O
2010 O
Helena O
G O
. O

Jardim O
, O
Rita O
Silva O
O2 O
Musculoskeletal O
disorders O
in O
midwives O
Cristina O
L O
. O

Baixinho O
, O
Mª O
Helena O
Presado O
, O
Mª O
Fátima O
Marques O
, O
Mário O
E O
. O

Cardoso O
O3 O
Negative O
childhood O
experiences O
and O
fears O
of O
compassion O
: O
Implications O
for O
psychological O
difficulties O
in O
adolescence O
Marina O
Cunha O
, O
Joana O
Mendes O
, O
Ana O
Xavier O
, O
Ana O
Galhardo O
, O
Margarida O
Couto O
O4 O
Optimal O
age O
to O
give O
the O
first O
dose O
of O
measles O
vaccine O
in O
Portugal O
João O
G O
. O

Frade O
, O
Carla O
Nunes O
, O
João O
R O
. O

Mesquita O
, O
Maria O
S O
. O

Nascimento O
, O
Guilherme O
Gonçalves O
O5 O
Functional O
assessment O
of O
elderly O
in O
primary O
care O
Conceição O
Castro O
, O
Alice O
Mártires O
, O
Mª O
João O
Monteiro O
, O
Conceição O
Rainho O
O6 O
Smoking O
and O
coronary O
events O
in O
a O
population O
of O
Spanish O
health-care O
centre O
: O
An O
observational O
study O
Francisco O
P O
. O

Caballero O
, O
Fatima O
M O
. O

Monago O
, O
Jose O
T O
. O

Guerrero O
, O
Rocio O
M O
. O

Monago O
, O
Africa O
P O
. O

Trigo O
, O
Milagros O
L O
. O

Gutierrez O
, O
Gemma O
M O
. O

Milanés O
, O
Mercedes O
G O
. O

Reina O
, O
Ana O
G O
. O

Villanueva O
, O
Ana O
S O
. O

Piñero O
, O
Isabel O
R O
. O

Aliseda O
, O
Francisco O
B O
. O

Ramirez O
O7 O
Prevalence O
of O
musculoskeletal O
injuries O
in O
Portuguese O
musicians O
Andrea O
Ribeiro O
, O
Ana O
Quelhas O
, O
Conceição O
Manso O
O8 O
Hip O
fractures O
, O
psychotropic O
drug O
consumption O
and O
comorbidity O
in O
patients O
of O
a O
primary O
care O
practice O
in O
Spain O
Francisco O
P O
. O

Caballero O
, O
Jose O
T O
. O

Guerrero O
, O
Fatima O
M O
. O

Monago O
, O
Rafael O
B O
. O

Santos O
, O
Nuria O
R O
. O

Jimenez O
, O
Cristina O
G O
. O

Nuñez O
, O
Inmaculada O
R O
. O

Gomez O
, O
Mª O
Jose O
L O
. O

Fernandez O
, O
Laura O
A O
. O

Marquez O
, O
Ana O
L O
. O

Moreno O
, O
Mª O
Jesus O
Tena O
Huertas O
, O
Francisco O
B O
. O

Ramirez O
O9 O
The O
role O
of O
self-criticism O
and O
shame O
in O
social O
anxiety O
in O
a O
clinical O
SAD O
sample O
Daniel O
Seabra O
, O
Mª O
Céu O
Salvador O
O10 O
Obstruction O
and O
infiltration O
: O
a O
proposal O
of O
a O
quality O
indicator O
Luciene O
Braga O
, O
Pedro O
Parreira O
, O
Anabela O
Salgueiro-Oliveira O
, O
Cristina O
Arreguy-Sena O
, O
Bibiana O
F O
. O

Oliveira O
, O
Mª O
Adriana O
Henriques O
O11 O
Balance O
and O
anxiety O
and O
depression O
symptoms O
in O
old O
age O
people O
Joana O
Santos O
, O
Sara O
Lebre O
, O
Alda O
Marques O
O12 O
Prevalence O
of O
postural O
changes O
and O
risk O
factors O
in O
school O
children O
and O
adolescents O
in O
a O
northern O
region O
( O
Porto O
) O
Clarinda O
Festas O
, O
Sandra O
Rodrigues O
, O
Andrea O
Ribeiro O
, O
José O
Lumini O
O13 O
Ischemic O
stroke O
vs O
. O
haemorrhagic O
stroke O
survival O
rate O
Ana O
G O
. O

Figueiredo O
O14 O
Chronobiological O
factors O
as O
responsible O
for O
the O
appearance O
of O
locomotor O
pathology O
in O
adolescents O
Francisco O
J O
. O

Hernandez-Martinez O
, O
Liliana O
Campi O
, O
Mª O
Pino O
Quintana-Montesdeoca O
, O
Juan O
F O
. O

Jimenez-Diaz O
, O
Bienvenida O
C O
. O

Rodriguez-De-Vera O
O15 O
Risk O
of O
malnutrition O
in O
the O
elderly O
of O
Bragança O
Alexandra O
Parente O
, O
Mª O
Augusta O
Mata O
, O
Ana O
Mª O
Pereira O
, O
Adília O
Fernandes O
, O
Manuel O
Brás O
O16 O
A O
Lifestyle O
Educational O
Programme O
for O
primary O
care O
diabetic O
patients O
: O
the O
design O
of O
a O
complex O
nursing O
intervention O
Mª O
Rosário O
Pinto O
, O
Pedro O
Parreira O
, O
Marta O
L O
. O

Basto O
, O
Ana O
C O
. O

Rei O
, O
Lisete O
M O
. O

Mónico O
O17 O
Medication O
adherence O
in O
elderly O
people O
Gilberta O
Sousa O
, O
Clementina O
Morna O
, O
Otília O
Freitas O
, O
Gregório O
Freitas O
, O
Ana O
Jardim O
, O
Rita O
Vasconcelos O
O18 O
Hospitalization O
for O
cervical O
cancer O
of O
residents O
in O
the O
metropolitan O
region O
of O
Porto O
Alegre O
, O
Southern O
Brazil O
, O
2012 O
to O
2014 O
Lina O
G O
. O

Horta O
, O
Roger O
S O
. O

Rosa O
, O
Luís O
F O
. O

Kranz O
, O
Rita O
C O
. O

Nugem O
, O
Mariana O
S O
. O

Siqueira O
, O
Ronaldo O
Bordin O
O19 O
Oncologic O
assistance O
of O
high O
complexity O
: O
evaluation O
of O
regulating O
accesses O
Rosiane O
Kniess O
, O
Josimari O
T O
. O

Lacerda O
O20 O
Perceived O
barriers O
for O
using O
health O
care O
services O
by O
the O
older O
population O
as O
seen O
by O
the O
social O
sector O
: O
findings O
from O
the O
Vila O
Nova O
de O
Gaia O
Gerontological O
Plan O
Joana O
Guedes O
, O
Idalina O
Machado O
, O
Sidalina O
Almeida O
, O
Adriano O
Zilhão O
, O
Helder O
Alves O
, O
Óscar O
Ribeiro O
O21 O
Sleep O
difficulties O
and O
depressive O
symptoms O
in O
college O
students O
Ana O
P O
. O

Amaral O
, O
Ana O
Santos O
, O
Joana O
Monteiro O
, O
Mª O
Clara O
Rocha O
, O
Rui O
Cruz O
O22 O
Psychopathological O
symptoms O
and O
medication O
use O
in O
higher O
education O
Ana O
P O
. O

Amaral O
, O
Marina O
Lourenço O
, O
Mª O
Clara O
Rocha O
, O
Rui O
Cruz O
O23 O
Sexually O
transmitted O
diseases O
in O
higher O
education O
institutions O
Sandra O
Antunes O
, O
Verónica O
Mendonça O
, O
Isabel O
Andrade O
, O
Nádia O
Osório O
, O
Ana O
Valado O
, O
Armando O
Caseiro O
, O
António O
Gabriel O
, O
Anabela O
C O
. O

Martins O
, O
Fernando O
Mendes O
O24 O
Alcohol O
consumption O
and O
suicide O
ideation O
in O
higher O
education O
students O
Lídia O
Cabral O
, O
Manuela O
Ferreira O
, O
Amadeu O
Gonçalves O
O25 O
Quality O
of O
life O
in O
university O
students O
Tatiana O
D O
. O

Luz O
, O
Leonardo O
Luz O
, O
Raul O
Martins O
O26 O
Male O
and O
female O
adolescent O
antisocial O
behaviour O
: O
characterizing O
vulnerabilities O
in O
a O
Portuguese O
sample O
Alice O
Morgado O
, O
Maria O
L O
. O

Vale-Dias O
O27 O
Risk O
factors O
for O
mental O
health O
in O
higher O
education O
students O
of O
health O
sciences O
Rui O
Porta-Nova O
O28 O
International O
classification O
of O
functioning O
disability O
and O
health O
as O
reflexive O
reasoning O
in O
primary O
attention O
in O
health O
Tânia O
C O
. O

Fleig O
, O
Éboni O
M O
. O

Reuter O
, O
Miriam O
B O
. O

Froemming O
, O
Sabrina O
L O
. O

Guerreiro O
, O
Lisiane O
L O
. O

Carvalho O
O29 O
Risk O
factors O
and O
cardiovascular O
disease O
in O
Portalegre O
Daniel O
Guedelha O
, O
P O
. O

Coelho O
, O
A O
. O

Pereira O
O30 O
Health O
status O
of O
the O
elderly O
population O
living O
in O
Portalegre O
historic O
city O
centre O
: O
A O
longitudinal O
study O
António O
Calha O
, O
Raul O
Cordeiro O
O31 O
Student O
’ O
s O
sleep O
in O
higher O
education O
: O
sleep O
quality O
among O
students O
of O
the O
IPB O
Ana O
Gonçalves O
, O
Ana O
Certo O
, O
Ana O
Galvão O
, O
Mª O
Augusta O
Mata O
O32 O
Trend O
in O
mortality O
from O
cervical O
cancer O
in O
the O
metropolitan O
area O
of O
Florianópolis O
, O
state O
of O
Santa O
Catarina O
, O
Brazil O
, O
2000 O
to O
2013 O
Aline O
Welter O
, O
Elayne O
Pereira O
, O
Sandra O
Ribeiro O
, O
Marcia O
Kretzer O
O33 O
Adherence O
to O
treatment O
in O
the O
elderly O
in O
an O
urban O
environment O
in O
Spain O
Juan-Fernando O
Jiménez-Díaz O
, O
Carla O
Jiménez-Rodríguez O
, O
Francisco-José O
Hernández-Martínez O
, O
Bienvenida-Del-Carmen O
Rodríguez-De-Vera O
, O
Alexandre O
Marques-Rodrigues O
O34 O
Beira O
Baixa O
Blood O
Pressure O
Study O
( O
Study O
PABB O
) O
Patrícia O
Coelho O
, O
Tiago O
Bernardes O
, O
Alexandre O
Pereira O
O35 O
Trends O
in O
cervical O
cancer O
mortality O
statistics O
in O
Santa O
Catarina O
State O
, O
Brazil O
, O
by O
age O
group O
and O
macro-region O
, O
from O
2000 O
to O
2013 O
Patrícia O
Sousa O
, O
João O
G O
. O

Filho O
, O
Nazare O
Nazario O
, O
Marcia O
Kretzer O
O36 O
Sleep O
problems O
among O
Portuguese O
adolescents O
: O
a O
public O
health O
issue O
Odete O
Amaral O
, O
António O
Garrido O
, O
Nélio O
Veiga O
, O
Carla O
Nunes O
, O
Ana O
R O
. O

Pedro O
, O
Carlos O
Pereira O
O37 O
Association O
between O
body O
fat O
and O
health-related O
quality O
of O
life O
in O
patients O
with O
type O
2 O
diabetes O
António O
Almeia O
, O
Helder O
M O
. O

Fernandes O
, O
Carlos O
Vasconcelos O
, O
Nelson O
Sousa O
, O
Victor O
M O
. O

Reis O
, O
M O
. O

João O
Monteiro O
, O
Romeu O
Mendes O
O38 O
Therapy O
adherence O
and O
polypharmacy O
in O
non-institutionalized O
elderly O
from O
Amares O
county O
, O
Portugal O
Isabel O
C O
. O

Pinto O
, O
Tânia O
Pires O
, O
João O
Gama O
O39 O
Prevalence O
of O
surgical O
site O
infection O
in O
adults O
at O
a O
hospital O
unit O
in O
the O
North O
of O
Portugal O
Vera O
Preto O
, O
Norberto O
Silva O
, O
Carlos O
Magalhães O
, O
Matilde O
Martins O
O40 O
Frailty O
phenotype O
in O
old O
age O
: O
implications O
to O
intervention O
Mafalda O
Duarte O
, O
Constança O
Paúl O
, O
Ignácio O
Martín O
O41 O
Portuguese O
women O
: O
sexual O
symptoms O
in O
perimenopause O
Arminda O
A O
. O

Pinheiro O
O42 O
Predictive O
ability O
of O
the O
Perinatal O
Depression O
Screening O
and O
Prevention O
Tool O
– O
preliminary O
results O
of O
the O
categorical O
approach O
Sandra O
Xavier O
, O
Julieta O
Azevedo O
, O
Elisabete O
Bento O
, O
Cristiana O
Marques O
, O
Mariana O
Marques O
, O
António O
Macedo O
, O
Ana O
T O
. O

Pereira O
O43 O
Aging O
and O
muscle O
strength O
in O
patients O
with O
type O
2 O
diabetes O
: O
cross O
sectional O
analysis O
José O
P O
. O

Almeida O
, O
António O
Almeida O
, O
Josiane O
Alves O
, O
Nelson O
Sousa O
, O
Francisco O
Saavedra O
, O
Romeu O
Mendes O
O44 O
Accessibility O
of O
the O
elderly O
in O
the O
prevention O
of O
hypertension O
in O
a O
family O
health O
unit O
Ana O
S O
. O

Maia O
, O
Michelle O
T O
. O

Oliveira O
, O
Anderson O
R O
. O

Sousa O
, O
Paulo O
P O
. O

Ferreira O
, O
Luci O
S O
. O

Lopes O
, O
Eujcely O
C O
. O

Santiago O
O45 O
Community O
Health O
screenings O
and O
self-reported O
chronic O
diseases O
Sílvia O
Monteiro O
, O
Ângelo O
Jesus O
, O
Armanda O
Colaço O
, O
António O
Carvalho O
, O
Rita O
P O
. O

Silva O
, O
Agostinho O
Cruz O
O46 O
Evaluation O
of O
indoor O
air O
quality O
in O
Kindergartens O
Ana O
Ferreira O
, O
Catarina O
Marques O
, O
João O
P O
. O

Figueiredo O
, O
Susana O
Paixão O
O47 O
Atmospheric O
exposure O
to O
chemical O
agents O
under O
the O
occupational O
activity O
of O
pathology O
technicians O
Ana O
Ferreira O
, O
Carla O
Lopes O
, O
Fernando O
Moreira O
, O
João O
P O
. O

Figueiredo O
O48 O
Occupational O
exposure O
to O
air O
pollutants O
in O
night O
entertainment O
venues O
workers O
Ana O
Ferreira O
, O
Diana O
Ribeiro O
, O
Fernando O
Moreira O
, O
João O
P O
. O

Figueiredo O
, O
Susana O
Paixão O
O49 O
Beliefs O
and O
attitudes O
of O
young O
people O
towards O
breastfeeding O
Telma O
Fernandes O
, O
Diogo O
Amado O
, O
Jéssica O
Leal O
, O
Marcelo O
Azevedo O
, O
Sónia O
Ramalho O
O50 O
Profiling O
informal O
caregivers O
: O
surveying O
needs O
in O
the O
care O
of O
the O
elderly O
Catarina O
Mangas O
, O
Jaime O
Ribeiro O
, O
Rita O
Gonçalves O
O51 O
Visual O
health O
in O
teenagers O
Amélia O
F O
Nunes O
, O
Ana O
R O
. O

Tuna O
, O
Carlos O
R O
. O

Martins O
, O
Henriqueta O
D O
. O

Forte O
O52 O
Amenable O
mortality O
and O
the O
geographic O
accessibility O
to O
healthcare O
in O
Portugal O
Cláudia O
Costa O
, O
José O
A O
. O

Tenedório O
, O
Paula O
Santana O
O53 O
Bacterial O
contamination O
of O
door O
handles O
in O
a O
São O
Paulo O
See O
Metropolitan O
Cathedral O
public O
restrooms O
in O
Brazil O
J O
. O

A O
. O

Andrade O
, O
J O
. O

L O
. O

Pinto O
, O
C O
. O

Campofiorito O
, O
S O
. O

Nunes O
, O
A O
. O

Carmo O
, O
A O
. O

Kaliniczenco O
, O
B O
. O

Alves O
, O
F O
. O

Mendes O
, O
C O
. O

Jesus O
, O
F O
. O

Fonseca O
, O
F O
. O

Gehrke O
O54 O
Adherence O
of O
patients O
to O
rehabilitation O
programmes O
Carlos O
Albuquerque O
, O
Rita O
Batista O
, O
Madalena O
Cunha O
, O
António O
Madureira O
, O
Olivério O
Ribeiro O
, O
Rosa O
Martins O
O55 O
Prevalence O
of O
malnutrition O
among O
Portuguese O
elderly O
living O
in O
nursing O
homes O
: O
preliminary O
results O
of O
the O
PEN O
- O
3S O
project O
Teresa O
Madeira O
, O
Catarina O
Peixoto-Plácido O
, O
Nuno O
Santos O
, O
Osvaldo O
Santos O
, O
Astrid O
Bergland O
, O
Asta O
Bye O
, O
Carla O
Lopes O
, O
Violeta O
Alarcão O
, O
Beatriz O
Goulão O
, O
Nuno O
Mendonça O
, O
Paulo O
Nicola O
, O
João O
G O
. O

Clara O
O56 O
Relation O
between O
emotional O
intelligence O
and O
mental O
illness O
in O
health O
students O
João O
Gomes O
, O
Ana O
Querido O
, O
Catarina O
Tomás O
, O
Daniel O
Carvalho O
, O
Marina O
Cordeiro O
P1 O
Fall O
risk O
factors O
in O
people O
older O
than O
50 O
years O
old O
– O
a O
pilot O
report O
Marlene O
C O
. O

Rosa O
, O
Alda O
Marques O
P2 O
What O
about O
the O
Portuguese O
oldest O
old O
? O

A O
global O
overview O
using O
census O
data O
Daniela O
Brandão O
, O
Óscar O
Ribeiro O
, O
Lia O
Araújo O
, O
Constança O
Paúl O
P3 O
Prevalence O
of O
injuries O
in O
senior O
amateur O
volleyball O
athletes O
in O
Alentejo O
and O
Algarve O
clubs O
, O
Portugal O
: O
factors O
associated O
Beatriz O
Minghelli O
, O
Sylvina O
Richaud O
P4 O
Shame O
feelings O
and O
quality O
of O
life O
: O
the O
role O
of O
acceptance O
and O
decentring O
Ana O
L O
. O

Mendes O
, O
Joana O
Marta-Simões O
, O
Inês O
A O
. O

Trindade O
, O
Cláudia O
Ferreira O
P5 O
Assessment O
of O
social O
support O
during O
deployment O
in O
portuguese O
colonial O
war O
veterans O
Teresa O
Carvalho O
, O
Marina O
Cunha O
, O
José O
Pinto-Gouveia O
P6 O
Hospitalization O
for O
acute O
viral O
bronchiolitis O
of O
residents O
in O
the O
metropolitan O
region O
of O
Porto O
Alegre O
, O
Southern O
Brazil O
, O
2012 O
to O
2014 O
Morgana O
C O
. O

Fernandes O
, O
Roger O
S O
. O

Rosa O
, O
Rita O
C O
. O

Nugem O
, O
Luís O
F O
. O

Kranz O
, O
Mariana O
S O
. O

Siqueira O
, O
Ronaldo O
Bordin O
P7 O
Falls-risk O
screening O
– O
an O
opportunity O
for O
preventing O
falls O
in O
the O
elderly O
from O
Nordeste O
Anabela O
C O
. O

Martins O
, O
Anabela O
Medeiros O
, O
Rafaela O
Pimentel O
, O
Andreia O
Fernandes O
, O
Carlos O
Mendonça O
, O
Isabel O
Andrade O
, O
Susana O
Andrade O
, O
Ruth O
L O
. O

Menezes O
P8 O
Aging O
provokes O
chronodisruption O
in O
mature O
people O
in O
temperature O
circadian O
rhythm O
Rafael O
Bravo O
, O
Marta O
Miranda O
, O
Lierni O
Ugartemendia O
, O
José O
Mª O
Tena O
, O
Francisco O
L O
. O

Pérez-Caballero O
, O
Lorena O
Fuentes-Broto O
, O
Ana O
B O
. O

Rodríguez O
, O
Barriga O
Carmen O
P9 O
The O
influence O
of O
climate O
and O
pollution O
factors O
in O
dengue O
cases O
of O
great O
ABC O
region O
, O
São O
Paulo O
M O
. O

A O
. O

Carneiro O
, O
J O
. O

N O
. O

Domingues O
, O
S O
. O

Paixão O
, O
J O
. O

Figueiredo O
, O
V O
. O

B O
. O

Nascimento O
, O
C O
. O

Jesus O
, O
F O
Mendes O
, O
F O
. O

Gehrke O
, O
B O
. O

Alves O
, O
L O
. O

Azzalis O
, O
F O
. O

Fonseca O
P10 O
Visual O
function O
and O
impact O
of O
visual O
therapy O
in O
children O
with O
learning O
disabilities O
: O
a O
pilot O
study O
Ana O
R O
. O

Martins O
, O
Amélia O
Nunes O
, O
Arminda O
Jorge O
P11 O
Edentulism O
and O
the O
need O
of O
oral O
rehabilitation O
among O
institutionalized O
elderly O
Nélio O
Veiga O
, O
Ana O
Amorim O
, O
André O
Silva O
, O
Liliana O
Martinho O
, O
Luís O
Monteiro O
, O
Rafael O
Silva O
, O
Carina O
Coelho O
, O
Odete O
Amaral O
, O
Inês O
Coelho O
, O
Carlos O
Pereira O
, O
André O
Correia O
P12 O
Therapy O
adherence O
of O
outpatients O
in O
the O
pharmacy O
services O
of O
a O
hospital O
unit O
Diana O
Rodrigues O
, O
Nídia O
Marante O
, O
Pedro O
Silva O
, O
Sara O
Carvalho O
, O
André O
Rts O
Araujo O
, O
Maximiano O
Ribeiro O
, O
Paula O
Coutinho O
, O
Sandra O
Ventura O
, O
Fátima O
Roque O
P13 O
Universal O
access O
and O
comprehensive O
care O
of O
oral O
health O
: O
an O
availability O
study O
Cristina O
Calvo O
, O
Manoela O
Reses O
P14 O
Is O
the O
respiratory O
function O
of O
children O
a O
predictor O
of O
air O
quality O
? O

Coimbra O
as O
a O
case O
study O
Jorge O
Conde O
, O
Ana O
Ferreira O
, O
João O
Figueiredo O
P15 O
Meaning-in-life O
of O
college O
students O
David O
Silva O
, O
Luís O
Seiça O
, O
Raquel O
Soares O
, O
Ricardo O
Mourão O
, O
Teresa O
Kraus O
O57 O
Training O
needs O
for O
nurses O
in O
palliative O
care O
Ana O
C O
. O

Abreu O
, O
José O
M O
. O

Padilha O
, O
Júlia O
M O
. O

Alves O
O58 O
Impact O
of O
computerized O
information O
systems O
in O
the O
global O
nurses O
’ O
workload O
: O
nurses O
’ O
perceptions O
and O
real-time O
Paulino O
Sousa O
, O
Manuel O
Oliveira O
, O
Joana O
Sousa O
O59 O
The O
perspective O
of O
health O
care O
professionals O
on O
self-care O
in O
hereditary O
neurodegenerative O
disease O
: O
a O
qualitative O
study O
Sónia O
Novais O
, O
Felismina O
Mendes O
O60 O
Contribution O
for O
health-related O
physical O
fitness O
reference O
values O
in O
healthy O
adolescents O
Joana O
Pinto O
, O
Joana O
Cruz O
, O
Alda O
Marques O
School O
of O
Health O
Sciences O
, O
University O
of O
Aveiro O
, O
3810 O
- O
193 O
Aveiro O
, O
Portugal O
O61 O
Perception O
of O
learning O
, O
satisfaction O
and O
self-efficacy O
of O
nursing O
students O
about O
High-Fidelity O
Simulation O
Hugo O
Duarte O
, O
Maria O
Dos O
Anjos O
Dixe O
, O
Pedro O
Sousa O
O62 O
Analysis O
of O
statements O
of O
diagnosis O
about O
health O
deviation O
in O
self-care O
requisites O
customized O
in O
a O
Nursing O
Practice O
Support O
System O
( O
SAPE O
® O
) O
: O
Management O
of O
therapeutic O
regimen O
Inês O
Cruz O
, O
Fernanda O
Bastos O
, O
Filipe O
Pereira O
O63 O
Hybrid O
management O
and O
hospital O
governance O
: O
doctors O
and O
nurses O
as O
managers O
Francisco O
L O
. O

Carvalho O
, O
Teresa O
T O
. O

Oliveira O
, O
Vítor O
R O
. O

Raposo O
O64 O
Time O
management O
in O
health O
professionals O
Conceição O
Rainho O
, O
José O
C O
. O

Ribeiro O
, O
Isabel O
Barroso O
, O
Vítor O
Rodrigues O
O65 O
Financial O
rewards O
and O
wellbeing O
in O
primary O
health O
care O
Carmo O
Neves O
, O
Teresa O
C O
. O

Oliveira O
O66 O
Patient O
safety O
promotion O
in O
the O
operating O
room O
Bárbara O
Oliveira O
, O
Mª O
Carminda O
Morais O
, O
Pilar O
Baylina O
O67 O
Difficulties O
and O
needs O
of O
pre-graduate O
nursing O
students O
in O
the O
area O
of O
Geriatrics O
/ O
Gerontology O
Rogério O
Rodrigues O
, O
Zaida O
Azeredo O
, O
Corália O
Vicente O
O68 O
Teaching O
and O
learning O
sexuality O
in O
nursing O
education O
Hélia O
Dias O
, O
Margarida O
Sim-Sim O
O69 O
Entrepreneurial O
Motivations O
Questionnaire O
: O
AFC O
and O
CFA O
in O
academy O
Pedro O
Parreira O
, O
Anabela O
Salgueiro-Oliveira O
, O
Amélia O
Castilho O
, O
Rosa O
Melo O
, O
João O
Graveto O
, O
José O
Gomes O
, O
Marina O
Vaquinhas O
, O
Carla O
Carvalho O
, O
Lisete O
Mónico O
, O
Nuno O
Brito O
O70 O
Nursing O
intervention O
to O
patient O
with O
Permanent O
Pacemakers O
and O
Implantable O
Cardioverter O
Defibrillators O
: O
a O
qualitative O
analysis O
Cassilda O
Sarroeira O
, O
José O
Amendoeira O
, O
Fátima O
Cunha O
, O
Anabela O
Cândido O
, O
Patrícia O
Fernandes O
, O
Helena O
R O
. O

Silva O
, O
Elsa O
Silva O
O71 O
Alcohol O
consumption O
among O
nursing O
students O
: O
where O
does O
education O
fail O
? O

Isabel O
Barroso O
, O
Leila O
Lapa O
, O
Cristina O
Antunes O
O72 O
Labour O
stress O
in O
nursing O
Ana O
Gonçalves O
, O
Ana O
Galvão O
, O
Mª O
José O
Gomes O
, O
Susana O
R O
. O

Escanciano O
O73 O
The O
influence O
of O
safe O
staff O
nursing O
in O
patient O
satisfaction O
with O
nursing O
care O
Maria O
Freitas O
, O
Pedro O
Parreira O
, O
João O
Marôco O
O74 O
Intention O
to O
use O
eHealth O
strategies O
with O
nursing O
students O
Ana O
R O
. O

Fernandes O
, O
Cremilde O
Cabral O
, O
Samuel O
Alves O
, O
Pedro O
Sousa O
O75 O
Community O
Based O
Mental O
Health O
: O
contributions O
of O
an O
interdisciplinary O
international O
program O
for O
students O
in O
higher O
health O
education O
António O
Ferreira O
, O
Fernanda O
Príncipe O
, O
Ulla-Maija O
Seppänen O
, O
Margarida O
Ferreira O
, O
Maribel O
Carvalhais O
, O
Marilene O
Silva O
O76 O
Study O
of O
satisfaction O
at O
work O
of O
graduates O
in O
nursing O
: O
2002 O
- O
2014 O
Manuela O
Ferreira O
, O
Joana O
Silva O
, O
Jéssica O
Neves O
, O
Diana O
Costa O
, O
Bruno O
Santos O
, O
Soraia O
Duarte O
O77 O
Health O
professionals O
’ O
attitudes O
towards O
breastfeeding O
Sílvia O
Marques O
, O
Sónia O
Ramalho O
, O
Isabel O
Mendes O
O78 O
Continuity O
of O
nursing O
care O
to O
person O
with O
type O
2 O
diabetes O
Clarisse O
Louro O
, O
Eva O
Menino O
, O
Maria O
Dixe O
, O
Sara O
S O
. O

Dias O
O79 O
Stigma O
toward O
mental O
illness O
among O
future O
health O
professionals O
Marina O
Cordeiro O
, O
Catarina O
Tomás O
, O
Ana O
Querido O
, O
Daniel O
Carvalho O
, O
João O
Gomes O
O80 O
Working O
with O
fears O
and O
anxieties O
of O
medical O
students O
in O
search O
of O
a O
humanized O
care O
Frederico O
C O
. O

Valim O
, O
Joyce O
O O
. O

Costa O
, O
Lúcia O
G O
. O

Bernardes O
P16 O
Surgical O
paediatrics O
patients O
’ O
psycho O
prophylaxis O
at O
a O
teaching O
hospital O
Helena O
Prebianchi O
P17 O
Patient-perceived O
outcomes O
in O
physiotherapy O
– O
a O
pilot O
study O
Marlene O
Cristina O
Rosa O
P18 O
Building O
competencies O
for O
managers O
in O
nursing O
Narcisa O
Gonçalves O
, O
Maria O
M O
. O

Martins O
, O
Paulina O
Kurcgant O
P19 O
Theoretical O
basis O
underlying O
physiotherapy O
practice O
in O
stroke O
rehabilitation O
André O
Vieira O
P20 O
When O
the O
life-cycle O
ends O
: O
the O
nurse O
’ O
s O
confrontation O
with O
death O
Sandrina O
Bento O
, O
Sérgio O
Deodato O
, O
Isabel O
Rabiais O
P21 O
Nursing O
students O
’ O
opinion O
about O
the O
supervision O
relationship O
during O
their O
first O
clinical O
experience O
Laura O
Reis O
P22 O
Nursing O
Relational O
Laboratory O
: O
Pedagogical O
, O
dialogic O
and O
critical O
project O
Ana O
Torres O
, O
Sérgio O
Soares O
, O
Margarida O
Ferreira O
, O
Pedro O
Graça O
P23 O
Job O
satisfaction O
of O
bioscientists O
at O
a O
Lisbon O
hospital O
Céu O
Leitão O
, O
Renato O
Abreu O
, O
Fernando O
Bellém O
, O
Ana O
Almeida O
, O
Edna O
Ribeiro-Varandas O
, O
Ana O
Tavares O
P24 O
Sociodemographic O
and O
professional O
profile O
of O
nurses O
and O
its O
relation O
with O
the O
importance O
of O
family O
in O
nursing O
practices O
João O
G O
. O

Frade O
, O
Carolina O
Henriques O
, O
Eva O
Menino O
, O
Clarisse O
Louro O
, O
Célia O
Jordão O
P25 O
Professional O
satisfaction O
of O
rehabilitation O
nurses O
Sofia O
Neco O
, O
Carminda O
Morais O
, O
Pedro O
Ferreira O
P26 O
The O
person O
living O
with O
a O
stoma O
: O
the O
formalization O
of O
knowledge O
in O
nursing O
Carla O
R O
. O

Silva O
, O
Alice O
Brito O
, O
Antónia O
Silva O
P27 O
Validation O
of O
the O
Portuguese O
versions O
of O
the O
nursing O
students O
’ O
perceptions O
of O
learning O
and O
learner O
satisfaction O
with O
simulation O
tool O
Hugo O
Duarte O
, O
Maria O
Dos O
Anjos O
Dixe O
, O
Pedro O
Sousa O
P28 O
Physiotherapists O
’ O
perceived O
knowledge O
on O
technologies O
for O
electronic O
health O
records O
for O
physiotherapy O
Gabriela O
Postolache O
, O
Raul O
Oliveira O
, O
Isabel O
Moreira O
, O
Luísa O
Pedro O
, O
Sónia O
Vicente O
, O
Samuel O
Domingos O
, O
Octavian O
Postolache O
P29 O
Quality O
of O
life O
and O
physical O
activity O
of O
medicine O
undergraduate O
students O
in O
the O
University O
of O
Southern O
Santa O
Catarina O
, O
Brazil O
Darlen O
Silva O
, O
João O
G O
. O

Filho O
, O
Nazare O
Nazario O
, O
Marcia O
Kretzer O
, O
Dulcineia O
Schneider O
P30 O
The O
curricular O
skills O
for O
decision O
making O
education O
in O
a O
Nursing O
Degree O
Fátima O
M O
. O

Marques O
P31 O
Effect O
of O
nurses O
’ O
mobilization O
in O
satisfaction O
at O
work O
and O
turnover O
: O
An O
empirical O
study O
in O
the O
hospital O
setting O
Pedro O
Parreira O
, O
Carla O
Carvalho O
, O
Lisete O
M O
. O

Mónico O
, O
Carlos O
Pinto O
, O
Sara O
Vicente O
, O
São O
João O
Breda O
P32 O
Entrepreneurial O
skills O
of O
students O
of O
polytechnic O
higher O
education O
in O
Portugal O
: O
Business O
influences O
José O
H O
. O

Gomes O
, O
Rosa O
Melo O
, O
Pedro O
Parreira O
, O
Anabela O
Salgueiro O
, O
João O
Graveto O
, O
Marina O
Vaquinhas O
, O
Amélia O
Castilho O
P33 O
Design O
and O
assessment O
of O
e-learning O
modules O
for O
Pharmacology O
Ângelo O
Jesus O
, O
Nuno O
Duarte O
, O
José O
C O
. O

Lopes O
, O
Hélder O
Nunes O
, O
Agostinho O
Cruz O
P34 O
Perspective O
of O
nurses O
involved O
in O
an O
action-research O
study O
on O
the O
changes O
observed O
in O
care O
provision O
: O
results O
from O
a O
focus O
group O
Anabela O
Salgueiro-Oliveira O
, O
Pedro O
Parreira O
, O
Marta O
L O
. O

Basto O
, O
Luciene O
M O
. O

Braga O
P35 O
Use O
of O
peer O
feedback O
by O
nursing O
students O
during O
clinical O
training O
: O
teacher O
’ O
s O
perception O
António O
Ferreira O
, O
Beatriz O
Araújo O
, O
José O
M O
. O

Alves O
, O
Margarida O
Ferreira O
, O
Maribel O
Carvalhais O
, O
Marilene O
Silva O
, O
Sónia O
Novais O
P36 O
What O
’ O
s O
new O
on O
endotracheal O
suctioning O
recommendations O
Ana O
S O
. O

Sousa O
, O
Cândida O
Ferrito O
P37 O
Assessment O
of O
the O
nurses O
satisfaction O
on O
the O
Central O
Region O
of O
Portugal O
Pedro O
L O
. O

Ferreira O
, O
Alexandre O
Rodrigues O
, O
Margarida O
Ferreira O
, O
Isabel O
Oliveira O
P38 O
Study O
of O
graduate O
’ O
s O
satisfaction O
with O
the O
school O
of O
nursing O
Manuela O
Ferreira O
, O
Jéssica O
Neves O
, O
Diana O
Costa O
, O
Soraia O
Duarte O
, O
Joana O
Silva O
, O
Bruno O
Santos O
P39 O
Partnership O
between O
the O
school O
of O
nursing O
and O
the O
hospital O
: O
Supervisors O
´ O
perspectives O
Cristina O
Martins O
, O
Ana O
P O
. O

Macedo O
, O
Odete O
Araújo O
, O
Cláudia O
Augusto O
, O
Fátima O
Braga O
, O
Lisa O
Gomes O
, O
Maria O
A O
. O

Silva O
, O
Rafaela O
Rosário O
P40 O
Coping O
strategies O
of O
college O
students O
Luís O
Pimenta O
, O
Diana O
Carreira O
, O
Patrícia O
Teles O
, O
Teresa O
Barros O
P41 O
Emotional O
intelligence O
and O
mental O
health O
stigma O
in O
health O
students O
Catarina O
Tomás O
, O
Ana O
Querido O
, O
Daniel O
Carvalho O
, O
João O
Gomes O
, O
Marina O
Cordeiro O
P42 O
Stigma O
of O
mental O
health O
assessment O
: O
Comparison O
between O
health O
courses O
Daniel O
Carvalho O
, O
Ana O
Querido O
, O
Catarina O
Tomás O
, O
João O
Gomes O
, O
Marina O
Cordeiro O
O81 O
Short O
- O
and O
long-term O
effects O
of O
pulmonary O
rehabilitation O
in O
mild O
COPD O
Cristina O
Jácome O
, O
Alda O
Marques O
O82 O
Phonological O
awareness O
programme O
for O
preschool O
children O
Sylvie O
Capelas O
, O
Andreia O
Hall O
, O
Dina O
Alves O
, O
Marisa O
Lousada O
O83 O
REforma O
ATIVA O
: O
An O
efficient O
health O
promotion O
program O
to O
be O
implemented O
during O
retirement O
Mª O
Helena O
Loureiro O
, O
Ana O
Camarneiro O
, O
Margarida O
Silva O
, O
Aida O
Mendes O
, O
Ana O
Pedreiro O
O84 O
Intervention O
for O
men O
who O
batter O
women O
, O
a O
case O
report O
Anne O
G.Silva O
, O
Elza O
S O
. O

Coelho O
O85 O
Immediate O
effects O
of O
Bowen O
Therapy O
on O
muscle O
tone O
and O
flexibility O
Flávio O
Melo O
, O
Fernando O
Ribeiro O
, O
Rui O
Torres O
, O
Rui O
Costa O
O86 O
Predictive O
equation O
for O
incremental O
shuttle O
walk O
test O
in O
adolescents O
Tânia O
Pinho O
, O
Cristina O
Jácome O
, O
Alda O
Marques O
O87 O
Life O
satisfaction O
and O
psychopathology O
in O
institutionalized O
elderly O
people O
: O
The O
results O
of O
an O
adapted O
Mindfulness-Based O
Stress O
Reduction O
program O
Bárbara O
Cruz O
, O
Daniel O
Seabra O
, O
Diogo O
Carreira O
, O
Maria O
Ventura O
O88 O
Outcome O
changes O
in O
COPD O
rehabilitation O
: O
exploring O
the O
relationship O
between O
physical O
activity O
and O
health-related O
outcomes O
Joana O
Cruz O
, O
Dina O
Brooks O
, O
Alda O
Marques O
O89 O
Assessing O
the O
effectiveness O
of O
a O
Complex O
Nursing O
Intervention O
M O
Rosário O
Pinto O
, O
Pedro O
Parreira O
, O
Marta O
Lima-Basto O
, O
Miguel O
Neves O
, O
Lisete O
M O
. O

Mónico O
O90 O
Psychotherapeutic O
intervention O
in O
addiction O
disorders O
: O
Change O
in O
psychopathological O
symptoms O
and O
emotional O
states O
Carla O
Bizarro O
, O
Marina O
Cunha O
, O
Ana O
Galhardo O
, O
Couto O
Margarida O
, O
Ana O
P O
. O

Amorim O
, O
Eduardo O
Silva O
O91 O
Economic O
impact O
of O
a O
nursing O
intervention O
program O
to O
promote O
self-management O
in O
COPD O
Susana O
Cruz O
, O
José O
M O
. O

Padilha O
, O
Jorge O
Valente O
O92 O
Multimodal O
acute O
pain O
management O
during O
uterine O
artery O
embolization O
in O
treatment O
of O
uterine O
myomas O
José O
T O
. O

Guerrero O
, O
Francisco O
P O
. O

Caballero O
, O
Rafael O
B O
. O

Santos O
, O
Estefania O
P O
. O

Gonzalez O
, O
Fátima O
M O
. O

Monago O
, O
Lierni O
U O
. O

Ugalde O
, O
Marta O
M O
. O

Vélez O
, O
Maria O
J O
. O

Tena O
O93 O
Fluid O
administration O
strategies O
in O
major O
surgery O
: O
Goal-directed O
therapy O
José O
T O
. O

Guerrero O
, O
Rafael O
Bravo O
, O
Francisco O
L O
. O

Pérez-Caballero O
, O
Isabel O
A O
. O

Becerra O
, O
Mª O
Elizabeth O
Agudelo O
, O
Guadalupe O
Acedo O
, O
Roberto O
Bajo O
O94 O
Development O
and O
implementation O
of O
a O
self-management O
educational O
programme O
using O
lay-led O
’ O
s O
in O
adolescents O
Spina O
Bifida O
: O
A O
pilot O
study O
Isabel O
Malheiro O
, O
Filomena O
Gaspar O
, O
Luísa O
Barros O
O95 O
Influence O
of O
chair-based O
yoga O
exercises O
on O
salivary O
anti-microbial O
proteins O
in O
institutionalized O
frail-elderly O
women O
: O
a O
preliminary O
study O
Guilherme O
Furtado O
, O
Mateus O
Uba-Chupel O
, O
Mariana O
Marques O
, O
Luís O
Rama O
, O
Margarida O
Braga O
, O
José O
P O
. O

Ferreira O
, O
Ana O
Mª O
Teixeira O
O96 O
High O
intensity O
interval O
training O
vs O
moderate O
intensity O
continuous O
training O
impact O
on O
diabetes O
2 O
João O
Cruz O
, O
Tiago O
Barbosa O
, O
Ângela O
Simões O
, O
Luís O
Coelho O
O97 O
Family O
caregiver O
of O
people O
with O
pressure O
ulcer O
: O
Nursing O
intervention O
plan O
Alexandre O
Rodrigues O
, O
Juan-Fernando O
Jiménez-Díaz O
, O
Francisco O
Martinez-Hernández O
, O
Bienvenida O
Rodriguez-De-Vera O
, O
Pedro O
Ferreira O
, O
Alexandrina O
Rodrigues O
O98 O
Chronic O
effects O
of O
exercise O
on O
motor O
memory O
consolidation O
in O
elderly O
people O
André O
Ramalho O
, O
João O
Petrica O
, O
Pedro O
Mendes O
, O
João O
Serrano O
, O
Inês O
Santo O
, O
António O
Rosado O
O99 O
Impression O
cytology O
of O
the O
ocular O
surface O
: O
Collection O
technique O
and O
sample O
processing O
Paula O
Mendonça O
, O
Kátia O
Freitas O
O100 O
Does O
sport O
practice O
affect O
the O
reaction O
time O
in O
neuromuscular O
activity O
? O

Dora O
Ferreira O
, O
António O
Brito O
, O
Renato O
Fernandes O
O101 O
Efficiency O
of O
the O
enteral O
administration O
of O
fibbers O
in O
the O
treatment O
of O
chronic O
obstipation O
Sofia O
Gomes O
, O
Fernando O
Moreira O
, O
Cláudia O
Pinho O
, O
Rita O
Oliveira O
, O
Ana O
I O
. O

Oliveira O
O102 O
Fast O
decalcifier O
in O
compact O
bone O
and O
spongy O
bone O
Paula O
Mendonça O
, O
Ana O
P O
. O

Casimiro O
, O
Patrícia O
Martins O
, O
Iryna O
Silva O
O103 O
Health O
promotion O
in O
the O
elderly O
– O
Intervention O
project O
in O
dementia O
Diana O
Evangelista O
O104 O
Prevention O
of O
musculoskeletal O
disorders O
through O
an O
exercise O
protocol O
held O
in O
labour O
context O
Catarina O
Leitão O
, O
Fábia O
Velosa O
, O
Nélio O
Carecho O
, O
Luís O
Coelho O
O105 O
Knowledge O
of O
teachers O
and O
other O
education O
agents O
on O
diabetes O
type O
1 O
: O
Effectiveness O
of O
an O
intervention O
program O
Eva O
Menino O
, O
Anjos O
Dixe O
, O
Helena O
Catarino O
, O
Fátima O
Soares O
, O
Ester O
Gama O
, O
Clementina O
Gordo O
O106 O
Treatment O
of O
diabetic O
peripheral O
neuropathic O
pain O
: O
a O
systematic O
review O
of O
clinical O
trials O
of O
phase O
II O
and O
III O
Eliana O
Moreira O
, O
Cristiana O
Midões O
, O
Marlene O
Santos O
O107 O
New O
drugs O
for O
osteoporosis O
treatment O
: O
Systematic O
review O
of O
clinical O
trials O
of O
phase O
II O
and O
III O
Sara O
Machado O
, O
Vânia O
P O
. O

Oliveira O
, O
Marlene O
Santos O
O108 O
Promoting O
hope O
at O
the O
end O
of O
life O
: O
Effectiveness O
of O
an O
Intervention O
Programme O
Ana O
Querido O
, O
Anjos O
Dixe O
, O
Rita O
Marques O
, O
Zaida O
Charepe O
P43 O
Psychomotor O
therapy O
effects O
on O
adaptive O
behaviour O
and O
motor O
proficiency O
of O
adults O
with O
intellectual O
disability O
Ana O
Antunes O
, O
Sofia O
Santos O
P44 O
The O
effect O
of O
exercise O
therapy O
in O
multiple O
sclerosis O
– O
a O
single O
study O
case O
Marlene O
C O
. O

Rosa O
P45 O
Physical O
condition O
and O
self-efficacy O
in O
people O
with O
fall O
risk O
– O
a O
preliminary O
study O
Marlene O
C O
. O

Rosa O
, O
Silvana O
F O
. O

Marques O
P46 O
Shock O
waves O
: O
their O
effectiveness O
in O
improving O
the O
symptoms O
of O
calcifying O
tendinitis O
of O
the O
shoulder O
Beatriz O
Minghelli O
, O
Eulália O
Caro O
P47 O
Pacifier O
– O
construction O
and O
pilot O
application O
of O
a O
parenting O
intervention O
for O
parents O
of O
babies O
until O
six O
months O
in O
primary O
health O
care O
Mª O
José O
Luís O
, O
Teresa O
Brandão O
P48 O
The O
influence O
of O
Motor O
Imagery O
in O
fine O
motor O
skills O
of O
individuals O
with O
disabilities O
Pedro O
Mendes O
, O
Daniel O
Marinho O
, O
João O
Petrica O
, O
Diogo O
Monteiro O
, O
Rui O
Paulo O
, O
João O
Serrano O
, O
Inês O
Santo O
P49 O
Evaluation O
of O
the O
effects O
of O
a O
walking O
programme O
on O
the O
fall O
risk O
factors O
in O
older O
people O
– O
a O
longitudinal O
pilot O
study O
Lina O
Monteiro O
, O
Fátima O
Ramalho O
, O
Rita O
Santos-Rocha O
, O
Sónia O
Morgado O
, O
Teresa O
Bento O
P50 O
Nursing O
intervention O
programme O
in O
lifestyles O
of O
adolescents O
Gilberta O
Sousa O
, O
Otília O
Freitas O
, O
Isabel O
Silva O
, O
Gregório O
Freitas O
, O
Clementina O
Morna O
, O
Rita O
Vasconcelos O
P51 O
The O
person O
submitted O
to O
hip O
replacement O
rehabilitation O
, O
at O
home O
Tatiana O
Azevedo O
, O
Salete O
Soares O
, O
Jacinta O
Pisco O
P52 O
Effects O
of O
Melatonin O
use O
in O
the O
treatment O
of O
neurovegetative O
diseases O
Paulo O
P O
. O

Ferreira O
, O
Efrain O
O O
. O

Olszewer O
, O
Michelle O
T O
. O

Oliveira O
, O
Anderson O
R O
. O

Sousa O
, O
Ana O
S O
. O

Maia O
, O
Sebastião O
T O
. O

Oliveira O
P53 O
Review O
of O
Phytotherapy O
and O
other O
natural O
substances O
in O
alcohol O
abuse O
and O
alcoholism O
Erica O
Santos O
, O
Ana O
I O
. O

Oliveira O
, O
Carla O
Maia O
, O
Fernando O
Moreira O
, O
Joana O
Santos O
, O
Maria O
F O
. O

Mendes O
, O
Rita O
F O
. O

Oliveira O
, O
Cláudia O
Pinho O
P54 O
Dietary O
programme O
impact O
on O
biochemical O
markers O
in O
diabetics O
: O
systematic O
review O
Eduarda O
Barreira O
, O
Ana O
Pereira O
, O
Josiana O
A O
. O

Vaz O
, O
André O
Novo O
P55 O
Biological O
approaches O
to O
knee O
osteoarthritis O
: O
platelet-rich O
plasma O
and O
hyaluronic O
acid O
Luís O
D O
. O

Silva O
, O
Bruno O
Maia O
, O
Eduardo O
Ferreira O
, O
Filipa O
Pires O
, O
Renato O
Andrade O
, O
Luís O
Camarinha O
P56 O
Platelet-rich O
plasma O
and O
hyaluronic O
acid O
intra-articular O
injections O
for O
the O
treatment O
of O
ankle O
osteoarthritis O
Luís O
D O
. O

Silva O
, O
Bruno O
Maia O
, O
Eduardo O
Ferreira O
, O
Filipa O
Pires O
, O
Renato O
Andrade O
, O
Luís O
Camarinha O
P57 O
The O
impact O
of O
preventive O
measures O
in O
the O
incidence O
of O
diabetic O
foot O
ulcers O
: O
a O
systematic O
review O
Ana O
F O
. O

César O
, O
Mariana O
Poço O
, O
David O
Ventura O
, O
Raquel O
Loura O
, O
Pedro O
Gomes O
, O
Catarina O
Gomes O
, O
Cláudia O
Silva O
, O
Elsa O
Melo O
, O
João O
Lindo O
P58 O
Dating O
violence O
among O
young O
adolescents O
Joana O
Domingos O
, O
Zaida O
Mendes O
, O
Susana O
Poeta O
, O
Tiago O
Carvalho O
, O
Catarina O
Tomás O
, O
Helena O
Catarino O
, O
Mª O
Anjos O
Dixe O
P59 O
Physical O
activity O
and O
motor O
memory O
in O
pedal O
dexterity O
André O
Ramalho O
, O
António O
Rosado O
, O
Pedro O
Mendes O
, O
Rui O
Paulo O
, O
Inês O
Garcia O
, O
João O
Petrica O
P60 O
The O
effects O
of O
whole O
body O
vibration O
on O
the O
electromyographic O
activity O
of O
thigh O
muscles O
Sandra O
Rodrigues O
, O
Rui O
Meneses O
, O
Carlos O
Afonso O
, O
Luís O
Faria O
, O
Adérito O
Seixas O
P61 O
Mental O
health O
promotion O
in O
the O
workplace O
Marina O
Cordeiro O
, O
Paulo O
Granjo O
, O
José O
C O
. O

Gomes O
P62 O
Influence O
of O
physical O
exercise O
on O
the O
self-perception O
of O
body O
image O
in O
elderly O
women O
: O
A O
systematic O
review O
of O
qualitative O
studies O
Nelba O
R O
. O

Souza O
, O
Guilherme O
E O
. O

Furtado O
, O
Saulo O
V O
. O

Rocha O
, O
Paula O
Silva O
, O
Joana O
Carvalho O
O109 O
Psychometric O
properties O
of O
the O
Portuguese O
version O
of O
the O
Éxamen O
Geronto-Psychomoteur O
( O
P-EGP O
) O
Marina O
Ana O
Morais O
, O
Sofia O
Santos O
, O
Paula O
Lebre O
, O
Ana O
Antunes O
O110 O
Symptoms O
of O
depression O
in O
the O
elderly O
population O
of O
Portugal O
, O
Spain O
and O
Italy O
António O
Calha O
O111 O
Emotion O
regulation O
strategies O
and O
psychopathology O
symptoms O
: O
A O
comparison O
between O
adolescents O
with O
and O
without O
deliberate O
self-harm O
Ana O
Xavier O
, O
Marina O
Cunha O
, O
José O
Pinto-Gouveia O
O112 O
Prevalence O
of O
physical O
disability O
in O
people O
with O
leprosy O
Liana O
Alencar O
, O
Madalena O
Cunha O
, O
António O
Madureira O
O113 O
Quality O
of O
life O
and O
self-esteem O
in O
type O
1 O
and O
type O
2 O
diabetes O
mellitus O
patients O
Ilda O
Cardoso O
, O
Ana O
Galhardo O
, O
Fernanda O
Daniel O
, O
Vítor O
Rodrigues O
O114 O
Cross-cultural O
comparison O
of O
gross O
motor O
coordination O
in O
children O
from O
Brazil O
and O
Portugal O
Leonardo O
Luz O
, O
Tatiana O
Luz O
, O
Maurício O
R O
. O

Ramos O
, O
Dayse O
C O
. O

Medeiros O
, O
Bruno O
M O
. O

Carmo O
, O
André O
Seabra O
, O
Cristina O
Padez O
, O
Manuel O
C O
. O

Silva O
O115 O
Electrocardiographic O
differences O
between O
African O
and O
Caucasian O
people O
António O
Rodrigues O
, O
Patrícia O
Coelho O
, O
Alexandre O
Coelho O
O116 O
Factors O
associated O
with O
domestic O
, O
sexual O
and O
other O
types O
of O
violence O
in O
the O
city O
of O
Palhoça O
- O
Brazil O
Madson O
Caminha O
, O
Filipe O
Matheus O
, O
Elenice O
Mendes O
, O
Jony O
Correia O
, O
Marcia O
Kretzer O
O117 O
Tinnitus O
prevalence O
study O
of O
users O
of O
a O
hospital O
of O
public O
management O
- O
Spain O
Francisco O
J O
. O

Hernandez-Martinez O
, O
Juan O
F O
. O

Jimenez-Diaz O
, O
Bienvendida O
C O
. O

Rodriguez-De-Vera O
, O
Carla O
Jimenez-Rodriguez O
, O
Yadira O
Armas-Gonzalez O
O118 O
Difficulties O
experienced O
by O
parents O
of O
children O
with O
diabetes O
mellitus O
of O
preschool O
age O
in O
therapeutic O
and O
nutritional O
management O
Cátia O
Rodrigues O
, O
Rosa O
Pedroso O
O119 O
E-mental O
health O
- O
“ O
nice O
to O
have O
” O
or O
“ O
must O
have O
” O
? O

Exploring O
the O
attitudes O
towards O
e-mental O
health O
in O
the O
general O
population O
Jennifer O
Apolinário-Hagen O
, O
Viktor O
Vehreschild O
O120 O
Violence O
against O
children O
and O
adolescents O
and O
the O
role O
of O
health O
professionals O
: O
Knowing O
how O
to O
identify O
and O
care O
Milene O
Veloso O
, O
Celina O
Magalhães O
, O
Isabel O
Cabral O
, O
Maira O
Ferraz O
O121 O
Marital O
violence O
. O

A O
study O
in O
the O
Algarve O
population O
Filipe O
Nave O
, O
Emília O
Costa O
, O
Filomena O
Matos O
, O
José O
Pacheco O
O122 O
Clinical O
factors O
and O
adherence O
to O
treatment O
in O
ischemic O
heart O
disease O
António O
Dias O
, O
Carlos O
Pereira O
, O
João O
Duarte O
, O
Madalena O
Cunha O
, O
Daniel O
Silva O
O123 O
Can O
religiosity O
improve O
optimism O
in O
participants O
in O
states O
of O
illness O
, O
when O
controlling O
for O
life O
satisfaction O
? O

Lisete O
M O
. O

Mónico O
, O
Valentim O
R O
. O

Alferes O
, O
Mª O
São O
João O
Brêda O
, O
Carla O
Carvalho O
, O
Pedro O
M O
. O

Parreira O
O124 O
Empowerment O
, O
knowledge O
and O
quality O
of O
life O
of O
people O
with O
diabetes O
type O
2 O
in O
the O
Alto O
Minho O
Health O
Local O
Unit O
Mª O
Carminda O
Morais O
, O
Pedro O
Ferreira O
, O
Rui O
Pimenta O
, O
José O
Boavida O
O125 O
Antihypertensive O
therapy O
adherence O
among O
hypertensive O
patients O
from O
Bragança O
county O
, O
Portugal O
Isabel O
C O
. O

Pinto O
, O
Tânia O
Pires O
, O
Catarina O
Silva O
O126 O
Subjective O
perception O
of O
sexual O
achievement O
- O
An O
exploratory O
study O
on O
people O
with O
overweight O
Maria O
Ribeiro O
, O
Maria O
Viega-Branco O
, O
Filomena O
Pereira O
, O
Ana O
Mª O
Pereira O
O127 O
Physical O
activity O
level O
and O
associated O
factors O
in O
hypertensive O
individuals O
registered O
in O
the O
family O
health O
strategy O
of O
a O
basic O
health O
unit O
from O
the O
city O
of O
Palhoça O
, O
Santa O
Catarina O
, O
Brazil O
Fabrícia O
M O
. O

Almeida O
, O
Gustavo O
L O
. O

Estevez O
, O
Sandra O
Ribeiro O
, O
Marcia O
R O
. O

Kretzer O
O128 O
Perception O
of O
functional O
fitness O
and O
health O
in O
non-institutionalised O
elderly O
from O
rural O
areas O
Paulo O
V O
. O

João O
, O
Paulo O
Nogueira O
, O
Sandra O
Novais O
, O
Ana O
Pereira O
, O
Lara O
Carneiro O
, O
Maria O
Mota O
O129 O
Medication O
adherence O
in O
patients O
with O
type O
2 O
diabetes O
mellitus O
treated O
at O
primary O
health O
care O
in O
Coimbra O
Rui O
Cruz O
, O
Luiz O
Santiago O
, O
Carlos O
Fontes-Ribeiro O
O130 O
Multivariate O
association O
between O
body O
mass O
index O
and O
multi-comorbidities O
in O
elderly O
people O
living O
in O
low O
socio-economic O
status O
context O
Guilherme O
Furtado O
, O
Saulo O
V O
. O

Rocha O
, O
André O
P O
. O

Coutinho O
, O
João O
S O
. O

Neto O
, O
Lélia O
R O
. O

Vasconcelos O
, O
Nelba O
R O
. O

Souza O
, O
Estélio O
Dantas O
O131 O
Metacognition O
, O
rumination O
and O
experiential O
avoidance O
in O
Borderline O
Personality O
Disorder O
Alexandra O
Dinis O
, O
Sérgio O
Carvalho O
, O
Paula O
Castilho O
, O
José O
Pinto-Gouveia O
O132 O
Health O
issues O
in O
a O
vulnerable O
population O
: O
nursing O
consultation O
in O
a O
public O
bathhouse O
in O
Lisbon O
Alexandra O
Sarreira-Santos O
, O
Amélia O
Figueiredo O
, O
Lurdes O
Medeiros-Garcia O
, O
Paulo O
Seabra O
O133 O
The O
perception O
of O
quality O
of O
life O
in O
people O
with O
multiple O
sclerosis O
accompanied O
in O
External O
Consultation O
of O
the O
Local O
Health O
Unit O
of O
Alto O
Minho O
Rosa O
Rodrigues O
, O
Mª O
Carminda O
Morais O
, O
Paula O
O O
. O

Fernandes O
O134 O
Representation O
of O
interaction O
established O
between O
immigrant O
women O
and O
nurse O
during O
pregnancy O
to O
postpartum O
, O
from O
the O
perspective O
of O
immigrant O
women O
Conceição O
Santiago O
, O
Mª O
Henriqueta O
Figueiredo O
, O
Marta O
L O
. O

Basto O
O135 O
Illness O
perceptions O
and O
medication O
adherence O
in O
hypertension O
Teresa O
Guimarães O
, O
André O
Coelho O
, O
Anabela O
Graça O
, O
Ana O
M O
. O

Silva O
, O
Ana O
R O
. O

Fonseca O
O136 O
A O
Portuguese O
study O
on O
adults O
’ O
intimate O
partner O
violence O
, O
interpersonal O
trust O
and O
hope O
Luz O
Vale-Dias O
, O
Bárbara O
Minas O
, O
Graciete O
Franco-Borges O
P63 O
QOL O
’ O
predictors O
of O
people O
with O
intellectual O
disability O
and O
general O
population O
Cristina O
Simões O
, O
Sofia O
Santos O
P64 O
Content O
validation O
of O
the O
Communication O
Disability O
Profile O
( O
CDP O
) O
- O
Portuguese O
Version O
Ana O
Serra O
, O
Maria O
Matos O
, O
Luís O
Jesus O
P65 O
Study O
of O
biochemical O
and O
haematological O
changes O
in O
football O
players O
Ana O
S O
. O

Tavares O
, O
Ana O
Almeida O
, O
Céu O
Leitão O
, O
Edna O
Varandas O
, O
Renato O
Abreu O
, O
Fernando O
Bellém O
P66 O
Body O
image O
dissatisfaction O
in O
inflammatory O
bowel O
disease O
: O
exploring O
the O
role O
of O
chronic O
illness-related O
shame O
Inês O
A O
. O

Trindade O
, O
Cláudia O
Ferreira O
, O
José O
Pinto-Gouveia O
, O
Joana O
Marta-Simões O
P67 O
Obesity O
and O
sleep O
in O
the O
adult O
population O
- O
a O
systematic O
review O
Odete O
Amaral O
, O
Cristiana O
Miranda O
, O
Pedro O
Guimarães O
, O
Rodrigo O
Gonçalves O
, O
Nélio O
Veiga O
, O
Carlos O
Pereira O
P68 O
Frequency O
of O
daytime O
sleepiness O
and O
obstructive O
sleep O
apnea O
risk O
in O
COPD O
patients O
Tânia O
C O
. O

Fleig O
, O
Elisabete O
A O
. O

San-Martin O
, O
Cássia O
L O
. O

Goulart O
, O
Paloma O
B O
. O

Schneiders O
, O
Natacha O
F O
. O

Miranda O
, O
Lisiane O
L O
. O

Carvalho O
, O
Andrea O
G O
. O

Silva O
P69 O
Working O
with O
immigrant-origin O
clients O
: O
discourses O
and O
practices O
of O
health O
professionals O
Joana O
Topa O
, O
Conceição O
Nogueira O
, O
Sofia O
Neves O
P70 O
Systemic O
Lupus O
Erythematosus O
– O
what O
are O
audiovestibular O
changes O
? O

Rita O
Ventura O
, O
Cristina O
Nazaré O
P71 O
Mental O
disorders O
in O
the O
oldest O
old O
: O
findings O
from O
the O
Portuguese O
national O
hospitalization O
database O
Daniela O
Brandão O
, O
Alberto O
Freitas O
, O
Óscar O
Ribeiro O
, O
Constança O
Paúl O
P72 O
Recurrence O
analysis O
in O
postural O
control O
in O
children O
with O
cerebral O
palsy O
Cristiana O
Mercê O
, O
Marco O
Branco O
, O
Pedro O
Almeida O
, O
Daniela O
Nascimento O
, O
Juliana O
Pereira O
, O
David O
Catela O
P73 O
The O
experience O
of O
self-care O
in O
the O
elderly O
with O
COPD O
: O
contributions O
to O
reflect O
proximity O
care O
Helga O
Rafael O
P74 O
Culturally O
competent O
nurses O
: O
managing O
unpredictability O
in O
clinical O
practice O
with O
immigrants O
Alcinda O
C O
. O

Reis O
O137 O
Paediatric O
speech O
and O
language O
screening O
: O
An O
instrument O
for O
health O
professionals O
Ana O
Mendes O
, O
Ana O
R O
. O

Valente O
, O
Marisa O
Lousada O
O138 O
Anthropometric O
and O
nutritional O
assessment O
in O
bodybuilders O
Diana O
Sousa O
, O
Ana O
L O
. O

Baltazar O
, O
Mª O
Helena O
Loureiro O
O139 O
Computerized O
adventitious O
respiratory O
sounds O
in O
children O
with O
lower O
respiratory O
tract O
infections O
Ana O
Oliveira O
, O
José O
Aparício O
, O
Alda O
Marques O
O140 O
Role O
of O
computerized O
respiratory O
sounds O
as O
a O
marker O
in O
LRTI O
Alda O
Marques O
, O
Ana O
Oliveira O
, O
Joana O
Neves O
, O
Rodrigo O
Ayoub O
O141 O
Confirmatory O
factor O
analysis O
of O
the O
Personal O
Wellbeing O
Index O
in O
people O
with O
chronic O
kidney O
disease O
Luís O
Sousa O
, O
Cristina O
Marques-Vieira O
, O
Sandy O
Severino O
, O
Helena O
José O
O142 O
Phonological O
awareness O
skills O
in O
school O
aged O
children O
Inês O
Cadorio O
, O
Marisa O
Lousada O
O143 O
Assessment O
of O
early O
memories O
of O
warmth O
and O
safeness O
in O
interaction O
with O
peers O
: O
its O
relationship O
with O
psychopathology O
in O
adolescence O
Marina O
Cunha O
, O
Diogo O
Andrade O
, O
Ana O
Galhardo O
, O
Margarida O
Couto O
O144 O
The O
molecular O
effects O
induced O
by O
single O
shot O
irradiation O
on O
a O
diffuse O
large O
B O
cell O
lymphoma O
cell O
line O
Fernando O
Mendes O
, O
Cátia O
Domingues O
, O
Susann O
Schukg O
, O
Ana O
M O
. O

Abrantes O
, O
Ana O
C O
. O

Gonçalves O
, O
Tiago O
Sales O
, O
Ricardo O
Teixo O
, O
Rita O
Silva O
, O
Jéssica O
Estrela O
, O
Mafalda O
Laranjo O
, O
João O
Casalta-Lopes O
, O
Clara O
Rocha O
, O
Paulo O
C O
. O

Simões O
, O
Ana O
B O
. O

Sarmento-Ribeiro O
, O
Mª O
Filomena O
Botelho O
, O
Manuel O
S O
. O

Rosa O
O145 O
Morpho-functional O
characterization O
of O
cardiac O
chambers O
by O
Transthoracic O
Echocardiography O
, O
in O
young O
athletes O
of O
gymnastics O
competition O
Virgínia O
Fonseca O
, O
Diogo O
Colaço O
, O
Vanessa O
Neves O
O146 O
Prevalence O
of O
the O
antibodies O
of O
the O
new O
histo-blood O
system O
– O
FORS O
system O
Carlos O
Jesus O
, O
Camilla O
Hesse O
, O
Clara O
Rocha O
, O
Nádia O
Osório O
, O
Ana O
Valado O
, O
Armando O
Caseiro O
, O
António O
Gabriel O
, O
Lola O
Svensson O
, O
Fernando O
Mendes O
, O
Wafa O
A O
. O

Siba O
, O
Cristina O
Pereira O
, O
Jorge O
Tomaz O
O147 O
Assessment O
of O
the O
war-related O
perceived O
threat O
in O
Portuguese O
Colonial O
War O
Veterans O
Teresa O
Carvalho O
, O
José O
Pinto-Gouveia O
, O
Marina O
Cunha O
O148 O
Pulse O
transit O
time O
estimation O
for O
continuous O
blood O
pressure O
measurement O
: O
A O
comparative O
study O
Diana O
Duarte O
, O
Nuno O
V O
. O

Lopes O
, O
Rui O
Fonseca-Pinto O
O149 O
Blood O
pressure O
assessment O
during O
standard O
clinical O
manoeuvres O
: O
A O
non-invasive O
PPT O
based O
approach O
Diana O
Duarte O
, O
Nuno O
V O
. O

Lopes O
, O
Rui O
Fonseca-Pinto O
O150 O
Development O
and O
initial O
validation O
of O
the O
Activities O
and O
Participation O
Profile O
related O
to O
Mobility O
( O
APPM O
) O
Anabela O
C O
. O

Martins O
O151 O
MEASYCare O
- O
2010 O
Standard–A O
geriatric O
evaluation O
system O
in O
primary O
health O
care O
: O
Reliability O
and O
validity O
of O
the O
latest O
version O
in O
Portugal O
Piedade O
Brandão O
, O
Laura O
Martins O
, O
Margarida O
Cardoso O
O152 O
Interrater O
and O
intrarater O
reliability O
and O
agreement O
of O
the O
range O
of O
shoulder O
flexion O
in O
the O
standing O
upright O
position O
through O
photographic O
assessment O
Nuno O
Morais O
, O
Joana O
Cruz O
O153 O
Three-dimensional O
biofabrication O
techniques O
for O
tissue O
regeneration O
Nuno O
Alves O
, O
Paula O
Faria O
, O
Artur O
Mateus O
, O
Pedro O
Morouço O
O154 O
A O
new O
computer O
tool O
for O
biofabrication O
applied O
to O
tissue O
engineering O
Nuno O
Alves O
, O
Nelson O
Ferreira O
, O
Artur O
Mateus O
, O
Paula O
Faria O
, O
Pedro O
Morouço O
O155 O
Development O
and O
psychometric O
qualities O
of O
a O
scale O
to O
measure O
the O
functional O
independence O
of O
adolescents O
with O
motor O
impairment O
Isabel O
Malheiro O
, O
Filomena O
Gaspar O
, O
Luísa O
Barros O
O156 O
Organizational O
Trust O
in O
Health O
services O
: O
Exploratory O
and O
Confirmatory O
factor O
analysis O
of O
the O
Organizational O
Trust O
Inventory O
- O
Short O
Form O
( O
OTI-SF O
) O
Pedro O
Parreira O
, O
Andreia O
Cardoso O
, O
Lisete O
Mónico O
, O
Carla O
Carvalho O
, O
Albino O
Lopes O
, O
Anabela O
Salgueiro-Oliveira O
O157 O
Thermal O
symmetry O
: O
An O
indicator O
of O
occupational O
task O
asymmetries O
in O
physiotherapy O
Adérito O
Seixas O
, O
Valter O
Soares O
, O
Tiago O
Dias O
, O
Ricardo O
Vardasca O
, O
Joaquim O
Gabriel O
, O
Sandra O
Rodrigues O
O158 O
A O
study O
of O
ICT O
active O
monitoring O
adoption O
in O
stroke O
rehabilitation O
Hugo O
Paredes O
, O
Arsénio O
Reis O
, O
Sara O
Marinho O
, O
Vítor O
Filipe O
, O
João O
Barroso O
O159 O
Paranoia O
Checklist O
( O
Portuguese O
Version O
) O
: O
Preliminary O
studies O
in O
a O
mixed O
sample O
of O
patients O
and O
healthy O
controls O
Carolina O
Da O
Motta O
, O
Célia O
B O
. O

Carvalho O
, O
José O
Pinto-Gouveia O
, O
Ermelindo O
Peixoto O
O160 O
Reliability O
and O
validity O
of O
the O
Composite O
Scale O
on O
Morningness O
: O
European O
Portuguese O
version O
, O
in O
adolescents O
and O
young O
adults O
Ana O
A O
. O

Gomes O
, O
Vanessa O
Costa O
, O
Diana O
Couto O
, O
Daniel O
R O
. O

Marques O
, O
José O
A O
. O

Leitão O
, O
José O
Tavares O
, O
Maria O
H O
. O

Azevedo O
, O
Carlos O
F O
. O

Silva O
O161 O
Evaluation O
scale O
of O
patient O
satisfaction O
with O
nursing O
care O
: O
Psychometric O
properties O
evaluation O
João O
Freitas O
, O
Pedro O
Parreira O
, O
João O
Marôco O
O162 O
Impact O
of O
fibromyalgia O
on O
quality O
of O
life O
: O
Comparing O
results O
from O
generic O
instruments O
and O
FIQR O
Miguel O
A O
. O

Garcia-Gordillo O
, O
Daniel O
Collado-Mateo O
, O
Gang O
Chen O
, O
Angelo O
Iezzi O
, O
José O
A O
. O

Sala O
, O
José O
A O
. O

Parraça O
, O
Narcis O
Gusi O
O163 O
Preliminary O
study O
of O
the O
adaptation O
and O
validation O
of O
the O
Rating O
Scale O
of O
Resilient O
Self O
: O
Resilience O
, O
self-harm O
and O
suicidal O
ideation O
in O
adolescents O
Jani O
Sousa O
, O
Mariana O
Marques O
, O
Jacinto O
Jardim O
, O
Anabela O
Pereira O
, O
Sónia O
Simões O
, O
Marina O
Cunha O
O164 O
Development O
of O
the O
first O
pressure O
ulcer O
in O
inpatient O
setting O
: O
Focus O
on O
length O
of O
stay O
Pedro O
Sardo O
, O
Jenifer O
Guedes O
, O
João O
Lindo O
, O
Paulo O
Machado O
, O
Elsa O
Melo O
O165 O
Forms O
of O
Self-Criticizing O
and O
Self-Reassuring O
Scale O
: O
Adaptation O
and O
early O
findings O
in O
a O
sample O
of O
Portuguese O
children O
Célia O
B O
. O

Carvalho O
, O
Joana O
Benevides O
, O
Marina O
Sousa O
, O
Joana O
Cabral O
, O
Carolina O
Da O
Motta O
O166 O
Predictive O
ability O
of O
the O
Perinatal O
Depression O
Screening O
and O
Prevention O
Tool O
– O
Preliminary O
results O
of O
the O
dimensional O
approach O
Ana O
T O
. O

Pereira O
, O
Sandra O
Xavier O
, O
Julieta O
Azevedo O
, O
Elisabete O
Bento O
, O
Cristiana O
Marques O
, O
Rosa O
Carvalho O
, O
Mariana O
Marques O
, O
António O
Macedo O
O167 O
Psychometric O
properties O
of O
the O
BaSIQS-Basic O
Scale O
on O
insomnia O
symptoms O
and O
quality O
of O
sleep O
, O
in O
adults O
and O
in O
the O
elderly O
Ana O
M O
. O

Silva O
, O
Juliana O
Alves O
, O
Ana O
A O
. O

Gomes O
, O
Daniel O
R O
. O

Marques O
, O
Mª O
Helena O
Azevedo O
, O
Carlos O
Silva O
O168 O
Enlightening O
the O
human O
decision O
in O
health O
: O
The O
skin O
melanocytic O
classification O
challenge O
Ana O
Mendes O
, O
Huei O
D O
. O

Lee O
, O
Newton O
Spolaôr O
, O
Jefferson O
T O
. O

Oliva O
, O
Wu O
F O
. O

Chung O
, O
Rui O
Fonseca-Pinto O
O169 O
Test-retest O
reliability O
household O
life O
study O
and O
health O
questionnaire O
Pomerode O
( O
SHIP-BRAZIL O
) O
Keila O
Bairros O
, O
Cláudia O
D O
. O

Silva O
, O
Clóvis O
A O
. O

Souza O
, O
Silvana O
S O
. O

Schroeder O
O170 O
Characterization O
of O
sun O
exposure O
behaviours O
among O
medical O
students O
from O
Nova O
Medical O
School O
Elsa O
Araújo O
, O
Helena O
Monteiro O
, O
Ricardo O
Costa O
, O
Sara O
S O
. O

Dias O
, O
Jorge O
Torgal O
O171 O
Spirituality O
in O
pregnant O
women O
Carolina O
G O
. O

Henriques O
, O
Luísa O
Santos O
, O
Elisa O
F O
. O

Caceiro O
, O
Sónia O
A O
. O

Ramalho O
O172 O
Polypharmacy O
in O
older O
patients O
with O
cancer O
Rita O
Oliveira O
, O
Vera O
Afreixo O
, O
João O
Santos O
, O
Priscilla O
Mota O
, O
Agostinho O
Cruz O
, O
Francisco O
Pimentel O
O173 O
Quality O
of O
life O
of O
caregivers O
of O
people O
with O
advanced O
chronic O
disease O
: O
Translation O
and O
validation O
of O
the O
quality O
of O
life O
in O
life O
threatening O
illness O
- O
family O
carer O
version O
( O
QOLLTI-C-PT O
) O
Rita O
Marques O
, O
Mª O
Anjos O
Dixe O
, O
Ana O
Querido O
, O
Patrícia O
Sousa O
O174 O
The O
psychometric O
properties O
of O
the O
brief O
Other O
as O
Shamer O
Scale O
for O
Children O
( O
OAS-C O
) O
: O
preliminary O
validation O
studies O
in O
a O
sample O
of O
Portuguese O
children O
Joana O
Benevides O
, O
Carolina O
Da O
Motta O
, O
Marina O
Sousa O
, O
Suzana O
N O
. O

Caldeira O
, O
Célia O
B O
. O

Carvalho O
O175 O
Measuring O
emotional O
intelligence O
in O
health O
care O
students O
– O
Revalidation O
of O
WLEIS-P O
Ana O
Querido O
, O
Catarina O
Tomás O
, O
Daniel O
Carvalho O
, O
João O
Gomes O
, O
Marina O
Cordeiro O
O176 O
Health O
indicators O
in O
prenatal O
assistance O
: O
The O
impact O
of O
computerization O
and O
of O
under-production O
in O
basic O
health O
centres O
Joyce O
O O
. O

Costa O
, O
Frederico O
C O
. O

Valim O
, O
Lígia O
C O
. O

Ribeiro O
O177 O
Hope O
genogram O
: O
Assessment O
of O
resources O
and O
interaction O
patterns O
in O
the O
family O
of O
the O
child O
with O
cerebral O
palsy O
Zaida O
Charepe O
, O
Ana O
Querido O
, O
Mª O
Henriqueta O
Figueiredo O
O178 O
The O
influence O
of O
childbirth O
type O
in O
postpartum O
quality O
of O
life O
Priscila O
S O
. O

Aquino O
, O
Samila O
G O
. O

Ribeiro O
, O
Ana O
B O
. O

Pinheiro O
, O
Paula O
A O
. O

Lessa O
, O
Mirna O
F O
. O

Oliveira O
, O
Luísa O
S O
. O

Brito O
, O
Ítalo O
N O
. O

Pinto O
, O
Alessandra O
S O
. O

Furtado O
, O
Régia O
B O
. O

Castro O
, O
Caroline O
Q O
. O

Aquino O
, O
Eveliny O
S O
. O

Martins O
O179 O
Women O
’ O
s O
beliefs O
about O
pap O
smear O
test O
and O
cervical O
cancer O
: O
influence O
of O
social O
determinants O
Ana O
B O
Pinheiro O
, O
Priscila O
S O
. O

Aquino O
, O
Lara O
L O
. O

Oliveira O
, O
Patrícia O
C O
. O

Pinheiro O
, O
Caroline O
R O
. O

Sousa O
, O
Vívien O
A O
. O

Freitas O
, O
Tatiane O
M O
. O

Silva O
, O
Adman O
S O
. O

Lima O
, O
Caroline O
Q O
. O

Aquino O
, O
Karizia O
V O
. O

Andrade O
, O
Camila O
A O
. O

Oliveira O
, O
Eglidia O
F O
. O

Vidal O
O180 O
Validity O
of O
the O
Portuguese O
version O
of O
the O
ASI O
- O
3 O
: O
Is O
anxiety O
sensitivity O
a O
unidimensional O
or O
multidimensional O
construct O
? O

Ana O
Ganho-Ávila O
, O
Mariana O
Moura-Ramos O
, O
Óscar O
Gonçalves O
, O
Jorge O
Almeida O
O181 O
Lifestyles O
of O
higher O
education O
students O
: O
the O
influence O
of O
self-esteem O
and O
psychological O
well-being O
Armando O
Silva O
, O
Irma O
Brito O
, O
João O
Amado O
P75 O
Assessing O
the O
quality O
of O
life O
of O
persons O
with O
significant O
intellectual O
disability O
: O
Portuguese O
version O
of O
Escala O
de O
San O
Martín O
António O
Rodrigo O
, O
Sofia O
Santos O
, O
Fernando O
Gomes O
P76 O
Childhood O
obesity O
and O
breastfeeding O
- O
A O
systematic O
review O
Marlene O
C O
. O

Rosa O
, O
Silvana O
F O
. O

Marques O
P77 O
Cross-cultural O
adaptation O
of O
the O
Foot O
and O
Ankle O
Ability O
Measure O
( O
FAAM O
) O
for O
the O
Portuguese O
population O
Sara O
Luís O
, O
Luís O
Cavalheiro O
, O
Pedro O
Ferreira O
, O
Rui O
Gonçalves O
P78 O
Cross-cultural O
adaptation O
of O
the O
Patient-Rated O
Wrist O
Evaluation O
score O
( O
PRWE O
) O
for O
the O
Portuguese O
population O
Rui O
S O
. O

Lopes O
, O
Luís O
Cavalheiro O
, O
Pedro O
Ferreira O
, O
Rui O
Gonçalves O
P79 O
Cross-cultural O
adaptation O
of O
the O
Myocardial O
Infraction O
Dimensional O
Assessment O
Scale O
( O
MIDAS O
) O
for O
Brazilian O
Portuguese O
language O
Bruno O
H O
. O

Fiorin O
, O
Marina O
S O
. O

Santos O
, O
Edmar O
S O
. O

Oliveira O
, O
Rita O
L O
. O

Moreira O
, O
Elizabete O
A O
. O

Oliveira O
, O
Braulio O
L O
. O

Filho O
P80 O
The O
revised O
Portuguese O
version O
of O
the O
Three-Factor O
Eating O
Questionnaire O
: O
A O
confirmatory O
factor O
analysis O
Lara O
Palmeira O
, O
Teresa O
Garcia O
, O
José O
Pinto-Gouveia O
, O
Marina O
Cunha O
P81 O
Assessing O
weight-related O
psychological O
inflexibility O
: O
An O
exploratory O
factor O
analysis O
of O
the O
AAQW O
’ O
s O
Portuguese O
version O
Sara O
Cardoso O
, O
Lara O
Palmeira O
, O
Marina O
Cunha O
; O
José O
Pinto-Gouveia O
P82 O
Validation O
of O
the O
Body O
Appreciation O
Scale O
- O
2 O
for O
Portuguese O
women O
Joana O
Marta-Simões O
, O
Ana O
L O
. O

Mendes O
, O
Inês O
A O
. O

Trindade O
, O
Sara O
Oliveira O
, O
Cláudia O
Ferreira O
P83 O
The O
Portuguese O
validation O
of O
the O
Dietary O
Intent O
Scale O
Ana O
L O
. O

Mendes O
, O
Joana O
Marta-Simões O
, O
Inês O
A O
. O

Trindade O
, O
Cláudia O
Ferreira O
P84 O
Construction O
and O
validation O
of O
the O
Inventory O
of O
Marital O
Violence O
( O
IVC O
) O
Filipe O
Nave O
P85 O
Portable O
continuous O
blood O
pressure O
monitor O
system O
Mariana O
Campos O
, O
Iris O
Gaudêncio O
, O
Fernando O
Martins O
, O
Lino O
Ferreira O
, O
Nuno O
Lopes O
, O
Rui O
Fonseca-Pinto O
P86 O
Construction O
and O
validation O
of O
the O
Scale O
of O
Perception O
of O
the O
Difficulties O
in O
Caring O
for O
the O
Elderly O
( O
SPDCE O
) O
Rogério O
Rodrigues O
, O
Zaida O
Azeredo O
, O
Corália O
Vicente O
P87 O
Development O
and O
validation O
of O
a O
comfort O
rating O
scale O
for O
the O
elderly O
hospitalized O
with O
chronic O
illness O
Joana O
Silva O
, O
Patrícia O
Sousa O
, O
Rita O
Marques O
P88 O
Construction O
and O
validation O
of O
the O
Postpartum O
Paternal O
Quality O
of O
Life O
Questionnaire O
( O
PP-QOL O
) O
Isabel O
Mendes O
, O
Rogério O
Rodrigues O
, O
Zaida O
Azeredo O
, O
Corália O
Vicente O
P89 O
Infrared O
thermal O
imaging O
: O
A O
tool O
for O
assessing O
diabetic O
foot O
ulcers O
Ricardo O
Vardasca O
, O
Ana O
R O
. O

Marques O
, O
Adérito O
Seixas O
, O
Rui O
Carvalho O
, O
Joaquim O
Gabriel O
P90 O
Pressure O
ulcers O
in O
an O
intensive O
care O
unit O
: O
An O
experience O
report O
Paulo O
P O
. O

Ferreira O
, O
Michelle O
T O
. O

Oliveira O
, O
Anderson O
R O
. O

Sousa O
, O
Ana O
S O
. O

Maia O
, O
Sebastião O
T O
. O

Oliveira O
, O
Pablo O
O O
. O

Costa O
, O
Maiza O
M O
. O

Silva O
P91 O
Validation O
of O
figures O
used O
in O
evocations O
: O
instrument O
to O
capture O
representations O
Cristina O
Arreguy-Sena O
, O
Nathália O
Alvarenga-Martins O
, O
Paulo O
F O
. O

Pinto O
, O
Denize O
C O
. O

Oliveira O
, O
Pedro O
D O
. O

Parreira O
, O
Antônio O
T O
. O

Gomes O
, O
Luciene O
M O
. O

Braga O
P92 O
Telephone O
assistance O
to O
decrease O
burden O
in O
informal O
caregivers O
of O
stroke O
older O
people O
: O
Monitoring O
and O
diagnostic O
evaluation O
Odete O
Araújo O
, O
Isabel O
Lage O
, O
José O
Cabrita O
, O
Laetitia O
Teixeira O
P93 O
Hope O
of O
informal O
caregivers O
of O
people O
with O
chronic O
and O
advanced O
disease O
Rita O
Marques O
, O
Mª O
Anjos O
Dixe O
, O
Ana O
Querido O
, O
Patrícia O
Sousa O
P94 O
Functionality O
and O
quality O
information O
from O
the O
Portuguese O
National O
Epidemiological O
Surveillance O
System O
Sara O
Silva O
, O
Eugénio O
Cordeiro O
, O
João O
Pimentel O
P95 O
Resting O
metabolic O
rate O
objectively O
measured O
vs O
. O

Harris O
and O
Benedict O
formula O
Vera O
Ferro-Lebres O
, O
Juliana O
A O
. O

Souza O
, O
Mariline O
Tavares O
O182 O
Characteristics O
of O
non-urgent O
patients O
: O
Cross-sectional O
study O
of O
an O
emergency O
department O
Mª O
Anjos O
Dixe O
, O
Pedro O
Sousa O
, O
Rui O
Passadouro O
, O
Teresa O
Peralta O
, O
Carlos O
Ferreira O
, O
Georgina O
Lourenço O
O183 O
Physical O
fitness O
and O
health O
in O
children O
of O
the O
1st O
Cycle O
of O
Education O
João O
Serrano O
, O
João O
Petrica O
, O
Rui O
Paulo O
, O
Samuel O
Honório O
, O
Pedro O
Mendes O
O184 O
The O
impact O
of O
physical O
activity O
on O
sleep O
quality O
, O
in O
children O
Alexandra O
Simões O
, O
Lucinda O
Carvalho O
, O
Alexandre O
Pereira O
O185 O
What O
is O
the O
potential O
for O
using O
Information O
and O
Communication O
Technologies O
in O
Arterial O
Hypertension O
self-management O
? O

Sara O
Silva O
, O
Paulino O
Sousa O
, O
José O
M O
. O

Padilha O
O186 O
Exploring O
psychosocial O
factors O
associated O
with O
risk O
of O
falling O
in O
older O
patients O
undergoing O
haemodialysis O
Daniela O
Figueiredo O
, O
Carolina O
Valente O
, O
Alda O
Marques O
O187 O
Development O
of O
pressure O
ulcers O
on O
the O
face O
in O
patients O
undergoing O
non-invasive O
ventilation O
Patrícia O
Ribas O
, O
Joana O
Sousa O
, O
Frederico O
Brandão O
, O
Cesar O
Sousa O
, O
Matilde O
Martins O
O188 O
The O
elder O
hospitalized O
: O
Limiting O
factors O
of O
comfort O
Patrícia O
Sousa O
, O
Rita O
Marques O
O189 O
Physical O
activity O
and O
health O
state O
self-perception O
by O
Portuguese O
adults O
Francisco O
Mendes O
, O
Rosina O
Fernandes O
, O
Emília O
Martins O
, O
Cátia O
Magalhães O
, O
Patrícia O
Araújo O
O190 O
Satisfaction O
with O
social O
support O
in O
the O
elderly O
of O
the O
district O
of O
Bragança O
Carla O
Grande O
, O
Mª O
Augusta O
Mata O
, O
Juan O
G O
. O

Vieitez O
O191 O
Prevalence O
of O
death O
by O
traumatic O
brain O
injury O
and O
associated O
factors O
in O
intensive O
care O
unit O
of O
a O
general O
hospital O
, O
Brazil O
Bruna O
Bianchini O
, O
Nazare O
Nazario O
, O
João O
G O
. O

Filho O
, O
Marcia O
Kretzer O
O192 O
Relation O
between O
family O
caregivers O
burden O
and O
health O
status O
of O
elderly O
dependents O
Tânia O
Costa O
, O
Armando O
Almeida O
, O
Gabriel O
Baffour O
O193 O
Phenomena O
sensitive O
to O
nursing O
care O
in O
day O
centre O
Armando O
Almeida O
, O
Tânia O
Costa O
, O
Gabriel O
Baffour O
O194 O
Frailty O
: O
what O
do O
the O
elderly O
think O
? O

Zaida O
Azeredo O
, O
Carlos O
Laranjeira O
, O
Magda O
Guerra O
, O
Ana O
P O
. O

Barbeiro O
O195 O
The O
therapeutic O
self-care O
as O
a O
nursing-sensitive O
outcome O
: O
A O
correlational O
study O
Regina O
Ferreira O
O196 O
Phonetic-phonological O
acquisition O
for O
the O
European O
Portuguese O
from O
18 O
months O
to O
6 O
years O
and O
12 O
months O
Sara O
Lopes O
, O
Liliana O
Nunes O
, O
Ana O
Mendes O
O197 O
Quality O
of O
life O
of O
patients O
undergoing O
liver O
transplant O
surgery O
Julian O
Martins O
, O
Dulcineia O
Schneider O
, O
Marcia O
Kretzer O
, O
Flávio O
Magajewski O
O198 O
Professional O
competences O
in O
health O
: O
views O
of O
older O
people O
from O
different O
European O
Countries O
Célia O
Soares O
, O
António O
Marques O
O199 O
Life O
satisfaction O
of O
working O
adults O
due O
to O
the O
number O
of O
hours O
of O
weekly O
exercise O
Marco O
Batista O
, O
Ruth O
J O
. O

Castuera O
, O
Helena O
Mesquita O
, O
António O
Faustino O
, O
Jorge O
Santos O
, O
Samuel O
Honório O
O200 O
Therapeutic O
itinerary O
of O
women O
with O
breast O
cancer O
in O
Santa O
Maria O
City O
/ O
RS O
Betina O
P O
. O

Vizzotto O
, O
Leticia O
Frigo O
, O
Hedioneia O
F O
. O

Pivetta O
O201 O
The O
breastfeeding O
prevalence O
at O
4 O
months O
: O
Maternal O
experience O
as O
a O
determining O
factor O
Dolores O
Sardo O
O202 O
The O
impact O
of O
the O
transition O
to O
parenthood O
in O
health O
and O
well-being O
Cristina O
Martins O
, O
Wilson O
Abreu O
, O
Mª O
Céu O
Figueiredo O
P96 O
Self-determined O
motivation O
and O
well-being O
in O
Portuguese O
active O
adults O
of O
both O
genders O
Marco O
Batista O
, O
Ruth O
Jimenez-Castuera O
, O
João O
Petrica O
, O
João O
Serrano O
, O
Samuel O
Honório O
, O
Rui O
Paulo O
, O
Pedro O
Mendes O
P97 O
The O
geriatric O
care O
: O
ways O
and O
means O
of O
comforting O
Patrícia O
Sousa O
, O
Rita O
Marques O
P98 O
The O
influence O
of O
relative O
age O
, O
subcutaneous O
adiposity O
and O
physical O
growth O
on O
Castelo O
Branco O
under O
- O
15 O
soccer O
players O
2015 O
António O
Faustino O
, O
Paulo O
Silveira O
, O
João O
Serrano O
, O
Rui O
Paulo O
, O
Pedro O
Mendes O
, O
Samuel O
Honório O
P99 O
Data O
for O
the O
diagnostic O
process O
focused O
on O
self-care O
– O
managing O
medication O
regime O
: O
An O
integrative O
literature O
review O
Catarina O
Oliveira O
, O
Fernanda O
Bastos O
, O
Inês O
Cruz O
P100 O
Art O
therapy O
as O
mental O
health O
promotion O
for O
children O
Cláudia O
K O
. O

Rodriguez O
, O
Márcia O
R O
. O

Kretzer O
, O
Nazaré O
O O
. O

Nazário O
P101 O
Chemical O
characterization O
of O
fungal O
chitosan O
for O
industrial O
applications O
Pedro O
Cruz O
, O
Daniela O
C O
. O

Vaz O
, O
Rui O
B O
. O

Ruben O
, O
Francisco O
Avelelas O
, O
Susana O
Silva O
, O
Mª O
Jorge O
Campos O
P102 O
The O
impact O
of O
caring O
older O
people O
at O
home O
Maria O
Almeida O
, O
Liliana O
Gonçalves O
, O
Lígia O
Antunes O
P103 O
Development O
of O
the O
first O
pressure O
ulcer O
in O
an O
inpatient O
setting O
: O
Focus O
on O
patients O
’ O
characteristics O
Pedro O
Sardo O
, O
Jenifer O
Guedes O
, O
João O
Simões O
, O
Paulo O
Machado O
, O
Elsa O
Melo O
P104 O
Association O
between O
General O
Self-efficacy O
and O
Physical O
Activity O
among O
Adolescents O
Susana O
Cardoso O
, O
Osvaldo O
Santos O
, O
Carla O
Nunes O
, O
Isabel O
Loureiro O
O203 O
Characterization O
of O
the O
habits O
of O
online O
acquisition O
of O
medicinal O
products O
in O
Portugal O
Flávia O
Santos O
, O
Gilberto O
Alves O
O204 O
Waiting O
room O
– O
A O
space O
for O
health O
education O
Cláudia O
Soar O
, O
Teresa O
O O
. O

Marsi O
O205 O
Safey O
culture O
evaluation O
in O
hospitalized O
children O
Ernestina O
Silva O
, O
Dora O
Pedrosa O
, O
Andrea O
Leça O
, O
Daniel O
Silva O
O206 O
Sexual O
Self-awareness O
and O
Body O
Image O
Ana O
Galvão O
, O
Maria O
Gomes O
, O
Paula O
Fernandes O
, O
Ana O
Noné O
O207 O
Perception O
of O
a O
Portuguese O
population O
regarding O
the O
acquisition O
and O
consumption O
of O
functional O
foods O
Jaime O
Combadão O
, O
Cátia O
Ramalhete O
, O
Paulo O
Figueiredo O
, O
Patrícia O
Caeiro O
O208 O
The O
work O
process O
in O
primary O
health O
care O
: O
evaluation O
in O
municipalities O
of O
southern O
Brazil O
Karine O
C O
. O

Fontana O
, O
Josimari O
T O
. O

Lacerda O
, O
Patrícia O
O O
. O

Machado O
O209 O
Exploration O
and O
evaluation O
of O
potential O
probiotic O
lactic O
acid O
bacteria O
isolated O
from O
Amazon O
buffalo O
milk O
Raphaelle O
Borges O
, O
Flávio O
Barbosa O
, O
Dayse O
Sá O
O210 O
Road O
safety O
for O
children O
: O
Using O
children O
’ O
s O
observation O
, O
as O
a O
passenger O
Germana O
Brunhoso O
, O
Graça O
Aparício O
, O
Amâncio O
Carvalho O
O211 O
Perception O
and O
application O
of O
quality-by-design O
by O
the O
Pharmaceutical O
industry O
in O
Portugal O
Ana O
P O
. O

Garcia O
, O
Paula O
O O
. O

Fernandes O
, O
Adriana O
Santos O
O212 O
Oral O
health O
among O
Portuguese O
children O
and O
adolescents O
: O
a O
public O
health O
issue O
Nélio O
Veiga O
, O
Carina O
Brás O
, O
Inês O
Carvalho O
, O
Joana O
Batalha O
, O
Margarida O
Glória O
, O
Filipa O
Bexiga O
, O
Inês O
Coelho O
, O
Odete O
Amaral O
, O
Carlos O
Pereira O
O213 O
Plant O
species O
as O
a O
medicinal O
resource O
in O
Igatu-Chapada O
Diamantina O
( O
Bahia O
, O
Brazil O
) O
Cláudia O
Pinho O
, O
Nilson O
Paraíso O
, O
Ana O
I O
. O

Oliveira O
, O
Cristóvão O
F O
. O

Lima O
, O
Alberto O
P O
. O

Dias O
O214 O
Characterization O
of O
cognitive O
and O
functional O
performance O
in O
everyday O
tasks O
: O
Implications O
for O
health O
in O
institutionalised O
older O
adults O
Pedro O
Silva O
, O
Mário O
Espada O
, O
Mário O
Marques O
, O
Ana O
Pereira O
O215 O
BMI O
and O
the O
perception O
of O
the O
importance O
given O
to O
sexuality O
in O
obese O
and O
overweight O
people O
Ana O
Mª O
Pereira O
, O
Mª O
Veiga-Branco O
, O
Filomena O
Pereira O
, O
Maria O
Ribeiro O
O216 O
Analysis O
and O
comparison O
of O
microbiological O
contaminations O
of O
two O
different O
composition O
pacifiers O
Vera O
Lima O
, O
Ana O
I O
. O

Oliveira O
, O
Cláudia O
Pinho O
, O
Graça O
Cruz O
, O
Rita O
F O
. O

Oliveira O
, O
Luísa O
Barreiros O
, O
Fernando O
Moreira O
O217 O
Experiences O
of O
couple O
relationships O
in O
the O
transition O
to O
retirement O
Ana O
Camarneiro O
, O
Mª O
Helena O
Loureiro O
, O
Margarida O
Silva O
O218 O
Preventive O
and O
corrective O
treatment O
of O
drug-induced O
calcium O
deficiency O
: O
an O
analysis O
in O
a O
community O
pharmacy O
setting O
Catarina O
Duarte O
, O
Ângelo O
Jesus O
, O
Agostinho O
Cruz O
O219 O
Profile O
of O
mood O
states O
in O
physically O
active O
elderly O
subjects O
: O
Is O
there O
a O
relation O
with O
health O
perception O
? O

Maria O
Mota O
, O
Sandra O
Novais O
, O
Paulo O
Nogueira O
, O
Ana O
Pereira O
, O
Lara O
Carneiro O
, O
Paulo O
V O
. O

João O
O220 O
( O
Un O
) O
Safety O
behaviour O
at O
work O
: O
the O
role O
of O
education O
towards O
a O
health O
and O
safety O
culture O
Teresa O
Maneca O
Lima O
O221 O
Analysis O
of O
the O
entrepreneurial O
profile O
of O
students O
attending O
higher O
education O
in O
Portugal O
: O
the O
Carland O
Entrepreneurship O
Index O
application O
Anabela O
Salgueiro-Oliveira O
, O
Marina O
Vaquinhas O
, O
Pedro O
Parreira O
, O
Rosa O
Melo O
, O
João O
Graveto O
, O
Amélia O
Castilho O
, O
José O
H O
. O

Gomes O
O222 O
Evaluation O
of O
welfare O
and O
quality O
of O
life O
of O
pregnant O
working O
women O
regarding O
the O
age O
of O
the O
pregnant O
María O
S O
. O

Medina O
, O
Valeriana O
G O
. O

Blanco O
O223 O
Psychological O
wellbeing O
protection O
among O
unemployed O
and O
temporary O
workers O
: O
Uncovering O
effective O
community-based O
interventions O
with O
a O
Delphi O
panel O
Osvaldo O
Santos O
, O
Elisa O
Lopes O
, O
Ana O
Virgolino O
, O
Alexandra O
Dinis O
, O
Sara O
Ambrósio O
, O
Inês O
Almeida O
, O
Tatiana O
Marques O
, O
Mª O
João O
Heitor O
O224 O
Chilean O
population O
norms O
derived O
from O
the O
Health-related O
quality O
of O
life O
SF O
- O
6D O
Miguel O
A O
. O

Garcia-Gordillo O
, O
Daniel O
Collado-Mateo O
, O
Pedro O
R O
. O

Olivares O
, O
José O
A O
. O

Parraça O
, O
José O
A O
. O

Sala O
O225 O
Motivation O
of O
college O
students O
toward O
Entrepreneurship O
: O
The O
influence O
of O
social O
and O
economic O
instability O
Amélia O
Castilho O
, O
João O
Graveto O
, O
Pedro O
Parreira O
, O
Anabela O
Oliveira O
, O
José O
H O
. O

Gomes O
, O
Rosa O
Melo O
, O
Marina O
Vaquinhas O
O226 O
Use O
of O
aromatic O
and O
medicinal O
plants O
, O
drugs O
and O
herbal O
products O
in O
Bragança O
city O
Mónia O
Cheio O
, O
Agostinho O
Cruz O
, O
Olívia O
R O
. O

Pereira O
O227 O
Edible O
flowers O
as O
new O
novel O
foods O
concept O
for O
health O
promotion O
Sara O
Pinto O
, O
Adriana O
Oliveira O
, O
M O
. O

Conceição O
Manso O
, O
Carla O
Sousa O
, O
Ana O
F O
. O

Vinha O
O228 O
The O
influence O
of O
leisure O
activities O
on O
the O
health O
and O
welfare O
of O
older O
people O
living O
in O
nursing O
homes O
Mª O
Manuela O
Machado O
, O
Margarida O
Vieira O
O229 O
Risk O
of O
falling O
, O
fear O
of O
falling O
and O
functionality O
in O
community-dwelling O
older O
adults O
Beatriz O
Fernandes O
, O
Teresa O
Tomás O
, O
Diogo O
Quirino O
O230 O
Musculoskeletal O
pain O
and O
postural O
habits O
in O
children O
and O
teenage O
students O
Gustavo O
Desouzart O
, O
Rui O
Matos O
, O
Magali O
Bordini O
, O
Pedro O
Mouroço O
O231 O
What's O
different O
in O
Southern O
Europe O
? O

The O
question O
of O
citizens O
’ O
participation O
in O
health O
systems O
Ana O
R O
. O

Matos O
, O
Mauro O
Serapioni O
O232 O
Occupational O
stress O
in O
Portuguese O
police O
officers O
Teresa O
Guimarães O
, O
Virgínia O
Fonseca O
, O
André O
Costa O
, O
João O
Ribeiro O
, O
João O
Lobato O
O233 O
Is O
occupational O
therapy O
culturally O
relevant O
to O
promote O
mental O
health O
in O
Burkina O
Faso O
? O

Inmaculada O
Z O
. O

Martin O
, O
Anita O
Björklund O
P105 O
Pay-for-performance O
satisfaction O
and O
quality O
in O
primary O
care O
Aida O
I O
. O

Tavares O
, O
Pedro O
Ferreira O
, O
Rui O
Passadouro O
P106 O
Economic O
development O
through O
life O
expectancy O
lenses O
Sónia O
Morgado O
P107 O
What O
is O
the O
effectiveness O
of O
exercise O
on O
smoking O
cessation O
to O
prevent O
clinical O
complications O
of O
smoking O
? O

Nuno O
Tavares O
, O
João O
Valente O
, O
Anabela O
C O
. O

Martins O
P108 O
A O
systematic O
review O
of O
the O
effects O
of O
yoga O
on O
mental O
health O
Patrícia O
Araújo O
, O
Rosina O
Fernandes O
, O
Francisco O
Mendes O
, O
Cátia O
Magalhães O
, O
Emília O
Martins O
P109 O
Healthy O
lifestyle O
: O
comparison O
between O
higher O
education O
students O
that O
lived O
until O
adult O
age O
in O
rural O
and O
urban O
environment O
Pedro O
Mendes O
, O
Rui O
Paulo O
, O
António O
Faustino O
, O
Helena O
Mesquita O
, O
Samuel O
Honório O
, O
Marco O
Batista O
P110 O
Evaluation O
of O
the O
Mobile O
Emergency O
Care O
Service O
( O
SAMU O
) O
in O
Brazil O
Josimari O
T O
. O

Lacerda O
, O
Angela O
B O
. O

Ortiga O
, O
Mª O
Cristina O
Calvo O
, O
Sônia O
Natal O
P111 O
Bioactive O
compounds O
- O
antioxidant O
activity O
of O
tropical O
fruits O
Marta O
Pereira O
P112 O
Use O
of O
non-pharmacological O
methods O
to O
relieve O
pain O
in O
labour O
Manuela O
Ferreira O
, O
Ana O
R O
. O

Prata O
, O
Paula O
Nelas O
, O
João O
Duarte O
P113 O
Mechanical O
safety O
of O
pacifiers O
sold O
in O
Portuguese O
pharmacies O
and O
childcare O
stores O
Juliana O
Carneiro O
, O
Ana O
I O
. O

Oliveira O
, O
Cláudia O
Pinho O
, O
Cristina O
Couto O
, O
Rita O
F O
. O

Oliveira O
, O
Fernando O
Moreira O
P114 O
The O
importance O
of O
prenatal O
consultation O
: O
Information O
to O
pregnant O
women O
given O
on O
a O
unit O
of O
primary O
care O
Ana O
S O
. O

Maia O
, O
Michelle O
T O
. O

Oliveira O
, O
Anderson O
R O
. O

Sousa O
, O
Paulo O
P O
. O

Ferreira O
, O
Géssica O
M O
. O

Souza O
, O
Lívia O
F O
. O

Almada O
, O
Milena O
A O
. O

Conceição O
, O
Eujcely O
C O
. O

Santiago O
P115 O
Influence O
of O
different O
backpack O
loading O
conditions O
on O
neck O
and O
lumbar O
muscles O
activity O
of O
elementary O
school O
children O
Sandra O
Rodrigues O
, O
Gabriela O
Domingues O
, O
Irina O
Ferreira O
, O
Luís O
Faria O
, O
Adérito O
Seixas O
P116 O
Efficacy O
and O
safety O
of O
dry O
extract O
Hedera O
helix O
in O
the O
treatment O
of O
productive O
cough O
Ana O
R O
. O

Costa O
, O
Ângelo O
Jesus O
, O
Américo O
Cardoso O
, O
Alexandra O
Meireles O
, O
Armanda O
Colaço O
, O
Agostinho O
Cruz O
P117 O
A O
portrait O
of O
the O
evaluation O
processes O
of O
education O
groups O
in O
primary O
health O
care O
Viviane O
L O
. O

Vieira O
, O
Kellem O
R O
. O

Vincha O
, O
Ana O
Mª O
Cervato-Mancuso O
P118 O
Benefits O
of O
vitamins O
C O
and O
E O
in O
sensorineural O
hearing O
loss O
: O
a O
review O
Melissa O
Faria O
, O
Cláudia O
Reis O
P119 O
BODY O
SNAPSHOT O
– O
a O
web-integrated O
anthropometric O
evaluation O
system O
Marco O
P O
. O

Cova O
, O
Rita O
T O
. O

Ascenso O
, O
Henrique O
A O
. O

Almeida O
, O
Eunice O
G O
. O

Oliveira O
P120 O
Anthropometric O
evaluation O
and O
variation O
during O
pregnancy O
Miguel O
Santana O
, O
Rafael O
Pereira O
, O
Eunice O
G O
. O

Oliveira O
, O
Henrique O
A O
. O

Almeida O
, O
Rita O
T O
. O

Ascenso O
P121 O
Knowledge O
of O
college O
students O
on O
the O
amendments O
of O
their O
eating O
habits O
and O
physical O
activity O
index O
in O
the O
transition O
to O
higher O
education O
Rita O
Jesus O
, O
Rodrigo O
Tapadas O
, O
Carolina O
Tim-Tim O
, O
Catarina O
Cezanne O
, O
Matilde O
Lagoa O
, O
Sara O
S O
. O

Dias O
, O
Jorge O
Torgal O
P122 O
Muscular O
activity O
of O
a O
rally O
race O
car O
driver O
João O
Lopes O
, O
Henrique O
Almeida O
, O
Sandra O
Amado O
, O
Luís O
Carrão O
O234 O
Literacy O
and O
results O
in O
health O
Madalena O
Cunha O
, O
Luís O
Saboga-Nunes O
, O
Carlos O
Albuquerque O
, O
Olivério O
Ribeiro O
O235 O
Literacy O
promotion O
and O
empowerment O
of O
type O
2 O
diabetics O
elderly O
in O
four O
family O
health O
units O
of O
the O
group O
of O
health O
centers O
of O
Dão O
Lafões O
Suzete O
Oliveira O
, O
Mª O
Carminda O
Morais O
O236 O
Mediterranean O
diet O
, O
health O
and O
life O
quality O
among O
Portuguese O
children O
Emília O
Martins O
, O
Francisco O
Mendes O
, O
Rosina O
Fernandes O
, O
Cátia O
Magalhães O
, O
Patrícia O
Araújo O
O237 O
Health O
literacy O
, O
from O
data O
to O
action O
- O
translation O
, O
validation O
and O
application O
of O
the O
European O
Health O
Literacy O
Survey O
in O
Portugal O
( O
HLS-EU-PT O
) O
Ana O
R O
. O

Pedro O
, O
Odete O
Amaral O
, O
Ana O
Escoval O
O238 O
Oral O
health O
literacy O
evaluation O
in O
a O
Portuguese O
military O
population O
Victor O
Assunção O
, O
Henrique O
Luís O
, O
Luís O
Luís O
O239 O
Preferences O
to O
Internet-based O
cognitive O
behavioural O
therapy O
– O
do O
attachment O
orientations O
matter O
? O

Jennifer O
Apolinário-Hagen O
, O
Viktor O
Vehreschild O
O240 O
A O
comparative O
transnational O
study O
in O
health O
literacy O
between O
Austria O
and O
Portugal O
Ulrike O
Fotschl O
, O
Gerald O
Lirk O
, O
Anabela O
C O
. O

Martins O
, O
Isabel O
Andrade O
, O
Fernando O
Mendes O
O241 O
Health O
literacy O
and O
social O
behaviours O
: O
relationship O
with O
sexually O
transmitted O
diseases O
? O

Verónica O
Mendonça O
, O
Sandra O
Antunes O
, O
Isabel O
Andrade O
, O
Nádia O
Osório O
, O
Ana O
Valado O
, O
Armando O
Caseiro O
, O
António O
Gabriel O
, O
Anabela O
C O
. O

Martins O
, O
Fernando O
Mendes O
O242 O
Parenting O
styles O
and O
attachment O
to O
parents O
: O
what O
relationships O
? O

Paula O
A O
. O

Silva O
, O
Lisete O
M O
. O

Mónico O
, O
Pedro O
M O
. O

Parreira O
, O
Carla O
Carvalho O
O243 O
Work-life O
balance O
in O
health O
professionals O
and O
professors O
: O
comparative O
study O
of O
workers O
with O
shift O
work O
and O
fixed O
schedule O
Carla O
Carvalho O
, O
Pedro O
M O
. O

Parreira O
, O
Lisete O
M O
. O

Mónico O
, O
Joana O
Ruivo O
O244 O
Technology O
literacy O
in O
self-management O
of O
diabetes O
Vânia O
Silva O
, O
Paulino O
Sousa O
, O
José O
M O
. O

Padilha O
O245 O
Satisfaction O
with O
therapeutic O
education O
and O
its O
relationship O
with O
clinical O
variables O
in O
children O
with O
type O
1 O
diabetes O
Vera O
Ferraz O
, O
Graça O
Aparício O
, O
João O
Duarte O
O246 O
Nutrition-related O
knowledge O
in O
middle-age O
and O
older O
patients O
with O
type O
2 O
diabetes O
Carlos O
Vasconcelos O
, O
António O
Almeida O
, O
Joel O
Neves O
, O
Telma O
Correia O
, O
Helena O
Amorim O
, O
Romeu O
Mendes O
O247 O
Validating O
the O
HLS-EU O
- O
( O
PT O
) O
questionnaire O
to O
measure O
health O
literacy O
in O
adolescents O
( O
CrAdLiSa O
project O
: O
HLS-EU-PT O
) O
Luís O
Saboga-Nunes O
, O
Madalena O
Cunha O
, O
Carlos O
Albuquerque O
O248 O
Health O
education O
in O
people O
with O
coronary O
heart O
disease O
: O
Experience O
of O
the O
cardiology O
department O
of O
a O
hospital O
on O
the O
outskirts O
of O
Lisbon O
Elsa O
S O
. O

Pereira O
, O
Leonino O
S O
. O

Santos O
, O
Ana O
S O
. O

Reis O
, O
Helena O
R O
. O

Silva O
, O
João O
Rombo O
, O
Jorge O
C O
. O

Fernandes O
, O
Patrícia O
Fernandes O
O249 O
Information O
and O
training O
needs O
of O
informal O
caregivers O
of O
individuals O
with O
stroke O
sequelae O
: O
a O
qualitative O
survey O
Jaime O
Ribeiro O
, O
Catarina O
Mangas O
, O
Ana O
Freire O
O250 O
Prevention O
of O
psychoactive O
substances O
consumption O
in O
students O
from O
6th O
grade O
of O
Albergaria-a-Velha O
´ O
s O
School O
Group O
Sara O
Silva O
, O
Irene O
Francisco O
, O
Ana O
Oliveira O
O251 O
Promoting O
healthy O
sexuality O
: O
shared O
responsibility O
for O
family O
, O
youth O
and O
educators O
Helena O
Catarino O
, O
Mª O
Anjos O
Dixe O
, O
Mª O
Clarisse O
Louro O
O252 O
Sexual O
risk O
behaviour O
in O
adolescents O
and O
young O
people O
Saudade O
Lopes O
, O
Anjos O
Dixe O
O253 O
Knowledge O
of O
school O
staff O
on O
type O
1 O
diabetes O
Mª O
Anjos O
Dixe O
, O
Eva O
Menino O
, O
Helena O
Catarino O
, O
Fátima O
Soares O
, O
Ana O
P O
. O

Oliveira O
, O
Sara O
Gordo O
, O
Teresa O
Kraus O
O254 O
Sexual O
health O
in O
adolescents O
: O
the O
impact O
of O
information O
search O
in O
literacy O
Catarina O
Tomás O
, O
Paulo O
Queirós O
, O
Teresa O
Rodrigues O
P123 O
Improving O
basic O
life O
support O
skills O
in O
adolescents O
through O
a O
training O
programme O
Pedro O
Sousa O
, O
João O
G O
. O

Frade O
, O
Catarina O
Lobão O
P124 O
Difficulties O
in O
sexual O
education O
reported O
by O
basic O
education O
teachers O
in O
the O
city O
of O
Foz O
do O
Iguaçu O
- O
Brazil O
Cynthia O
B O
. O

Moura O
, O
Laysa O
C O
. O

Dreyer O
, O
Vanize O
Meneghetti O
, O
Priscila O
P O
. O

Cabral O
P125 O
Breast O
cancer O
survivors O
: O
subjects O
and O
resources O
for O
information O
. O

A O
qualitative O
systematic O
review O
Francisca O
Pinto O
, O
Paulino O
Sousa O
, O
Mª O
Raquel O
Esteves O
P126 O
Relationship O
between O
health O
literacy O
and O
prevalence O
of O
STI O
in O
Biomedical O
Laboratory O
Science O
students O
Sofia O
Galvão O
, O
Ite O
Tytgat O
, O
Isabel O
Andrade O
, O
Nádia O
Osório O
, O
Ana O
Valado O
, O
Armando O
Caseiro O
, O
António O
Gabriel O
, O
Anabela O
C O
. O

Martins O
, O
Fernando O
Mendes O
P127 O
Health O
literacy O
, O
risk O
behaviours O
and O
sexually O
transmitted O
diseases O
among O
blood O
donors O
Mónica O
Casas-Novas O
, O
Helena O
Bernardo O
, O
Isabel O
Andrade O
, O
Gracinda O
Sousa O
, O
Ana O
P O
. O

Sousa O
, O
Clara O
Rocha O
, O
Pedro O
Belo O
, O
Nádia O
Osório O
, O
Ana O
Valado O
, O
Armando O
Caseiro O
, O
António O
Gabriel O
, O
Anabela O
C O
. O

Martins O
, O
Fernando O
Mendes O
P128 O
Promoting O
literacy O
in O
pregnancy O
health-care O
Fátima O
Martins O
, O
Montserrat O
Pulido-Fuentes O
P129 O
The O
lifestyles O
of O
the O
operating O
assistants O
of O
education O
Isabel O
Barroso O
, O
Gil O
Cabral O
, O
M O
. O

João O
Monteiro O
, O
Conceição O
Rainho O
P130 O
Experiences O
of O
service-learning O
health O
and O
the O
literary O
art O
: O
reflections O
about O
the O
health O
education O
Alessandro O
Prado O
, O
Yara O
M O
. O

Carvalho O
P131 O
Life O
long O
swimming O
– O
a O
European O
Erasmus O
+ O
project O
Maria O
Campos O
, O
Liliana O
Moreira O
, O
José O
Ferreira O
, O
Ana O
Teixeira O
, O
Luís O
Rama O

Black O
Americans O
comprise O
13% O
of O
the O
US O
population O
, O
yet O
data O
suggests O
that O
they O
represent O
23% O
of O
those O
fatally O
shot O
by O
police O
officers O
. O

Data O
on O
non-lethal O
encounters O
with O
police O
in O
the O
Black O
community O
is O
less O
available O
but O
can O
understandably O
result O
in O
emotional B-Symptom_TestedFor
trauma I-Symptom_TestedFor
, O
stress B-Symptom_TestedFor
responses I-Symptom_TestedFor
, O
and O
depressive B-Symptom_TestedFor
symptoms I-Symptom_TestedFor
. O

The O
aim O
of O
this O
systematic O
literature O
review O
is O
to O
assess O
if O
interactions O
with O
the O
police O
are O
associated O
with O
mental O
health O
outcomes O
among O
Black O
Americans O
. O

Following O
pre-defined O
inclusion O
criteria O
, O
11 O
articles O
were O
reviewed O
. O

Using O
a O
quality O
assessment O
tool O
, O
eight O
studies O
received O
a O
fair O
quality O
rating O
, O
two O
studies O
a O
poor O
rating O
, O
and O
one O
study O
received O
a O
good O
rating O
. O

The O
types O
of O
police O
interaction O
reported O
among O
study O
participants O
included O
police O
use O
of O
force O
during O
arrest O
, O
police O
stops O
, O
police O
searches O
, O
exposure O
to O
police O
killings O
, O
and O
interactions O
with O
police O
in O
the O
court O
system O
and O
varied O
mental O
health O
outcomes O
. O

Most O
of O
the O
studies O
( O
6 O
of O
11 O
) O
reviewed O
found O
statistically O
significant O
associations O
between O
police O
interactions O
and O
mental O
health O
( O
psychotic O
experiences O
, O
psychological O
distress O
, O
depression O
, O
PTSD O
, O
anxiety O
, O
suicidal O
ideation O
and O
attempts O
) O
, O
indicating O
a O
nearly O
twofold O
higher O
prevalence O
of O
poor O
mental O
health O
among O
those O
reporting O
a O
prior O
police O
interaction O
compared O
to O
those O
with O
no O
interaction O
. O

Although O
better O
quality O
studies O
are O
needed O
, O
findings O
suggest O
an O
association O
between O
police O
interactions O
and O
negative O
mental O
health O
outcomes O
. O

Changes O
in O
law O
enforcement O
policy O
, O
development O
and O
implementation O
of O
a O
validated O
instrument O
for O
police O
experiences O
, O
improved O
community O
outreach O
, O
a O
federally O
mandated O
review O
of O
policy O
and O
practice O
in O
police O
departments O
, O
and O
expanded O
police O
training O
initiatives O
could O
reduce O
the O
potential O
negative O
mental O
health O
impact O
of O
police O
interactions O
on O
Black O
Americans O
. O

Background O
: O
The O
course O
and O
predictors O
of O
women O
׳ O
s O
mood O
following O
childbirth O
have O
informed O
clinically O
significant O
phenomena O
, O
such O
as O
postpartum B-Symptom_WorkedFor
depression I-Symptom_WorkedFor
( O
PPD O
) O
, O
with O
some O
contradictory O
findings O
due O
to O
methodological O
limitations O
. O

It O
is O
important O
to O
further O
investigate O
mood O
during O
this O
unique O
period O
of O
time O
to O
inform O
assessment O
and O
improve O
interventions O
. O

Methods O
: O
Recently O
delivered O
mothers O
( O
n O
= O
216 O
) O
recruited O
from O
the O
maternity O
unit O
at O
a O
University O
hospital O
completed O
sociodemographic O
questions O
and O
the O
Daily O
Experiences O
Questionnaire O
( O
DEQ O
) O
, O
a O
measure O
of O
Negative O
Affect O
( O
NA O
) O
and O
Positive O
Affect O
( O
PA O
) O
, O
for O
10 B-Duration
consecutive I-Duration
days I-Duration
. O

The O
Structured O
Clinical O
Interview O
for O
DSM-IV O
was O
administered O
to O
assess O
postpartum B-Symptom_WorkedFor
depression I-Symptom_WorkedFor
diagnosis O
. O

Results O
: O
Growth O
curve O
modeling O
( O
GCM O
) O
techniques O
revealed O
average O
trends O
in O
mood O
following O
delivery O
. O

NA O
changed O
in O
a O
curvilinear O
fashion O
with O
a O
peak O
at O
day O
5 O
. O

PA O
declined O
rapidly O
during O
the O
days O
immediately O
following O
delivery O
and O
then O
stabilized O
. O

Women O
diagnosed O
with O
PPD O
experienced O
higher O
overall O
levels O
of O
NA O
and O
lower O
levels O
of O
PA O
from O
delivery O
to O
10 O
days O
postpartum O
. O

Patterns O
of O
mood O
varied O
as O
a O
function O
of O
neuroticism O
and O
several O
well-established O
sociodemographic O
variables O
. O

Limitations O
: O
Small O
sample O
size O
and O
relatively O
few O
ethnic O
minority O
participants O
may O
affect O
generalizability O
of O
the O
findings O
. O

Conclusions O
: O
NA O
changed O
in O
a O
pattern O
consistent O
with O
the O
" O
peaking O
phenomenon O
" O
. O

Well-established O
risk O
factors O
of O
the O
blues O
had O
significant O
associations O
with O
mood O
from O
delivery O
to O
day O
10 O
. O

Increased O
understanding O
into O
the O
nature O
of O
NA O
and O
PA O
in O
the O
early O
postpartum O
, O
and O
its O
role O
in O
identifying O
women O
susceptible O
to O
experiencing O
PPD O
, O
can O
inform O
screening O
and O
therapeutic O
interventions O
for O
PPD O
. O

A O
wealth O
of O
research O
has O
examined O
psychological O
responses O
to O
trauma B-Symptom_TestedFor
among O
male O
military O
service O
members O
, O
but O
few O
studies O
have O
examined O
sex O
differences O
in O
response O
to O
trauma O
, O
such O
as O
coping O
strategies O
. O

This O
study O
assessed O
coping O
strategies O
used O
by O
male O
and O
female O
U.S O
. O
service O
members O
completing O
an O
intensely O
stressful O
mock-captivity O
exercise O
, O
compared O
strategies O
by O
sex O
, O
and O
assessed O
the O
relationship O
between O
coping O
and O
posttraumatic B-Symptom_TestedFor
stress I-Symptom_TestedFor
symptoms O
( O
PTSS O
) O
. O

Two B-#Participants
hundred I-#Participants
service O
members O
( O
78% O
male O
) O
completed O
self-report O
surveys O
before O
and O
after O
mock O
captivity O
. O

Surveys O
assessed O
demographics O
, O
service O
characteristics O
, O
PTSS O
, O
and O
coping O
strategies O
used O
during O
mock O
captivity O
. O

Participants O
used O
seven O
coping O
strategies O
: O
denial O
, O
self-blame O
, O
religion O
, O
self-distraction O
, O
behavioral O
disengagement O
, O
positive O
reframing O
, O
and O
planning O
. O

Women O
used O
denial O
( O
p O
≤ O
.05 O
) O
, O
self-blame O
( O
p O
≤ O
.05 O
) O
, O
and O
positive O
reinterpretation O
( O
p O
≤ O
.05 O
) O
strategies O
more O
frequently O
than O
men O
, O
and O
they O
had O
higher O
PTSS O
levels O
following O
the O
exercise O
. O

Structural O
equation O
modeling O
showed O
that O
the O
relationship O
between O
sex O
and O
PTSS O
was O
fully O
mediated O
by O
coping O
strategies O
. O

The O
results O
of O
this O
study O
suggest O
that O
reducing O
the O
use O
of O
maladaptive O
coping O
strategies O
may O
mitigate O
PTSS O
among O
females O
. O

Future O
efforts O
should O
target O
improving O
coping O
during O
highly O
stressful O
and O
traumatic O
experiences O
. O

Objective O
: O
Melissa B-Drug/Scientific name
officinalis I-Drug/Scientific name
( O
lemon B-Medicinal food
balm I-Medicinal food
) O
and O
Valeriana B-Drug/Scientific name
officinalis I-Drug/Scientific name
( O
valerian B-Medicinal food
) O
have O
been O
used O
both O
traditionally O
and O
contemporaneously O
as O
mild O
sedatives O
, O
anxiolytics O
and O
hypnotics O
. O

Recent O
research O
has O
suggested O
that O
both O
may O
attenuate O
laboratory O
induced O
stress B-Symptom_TestedFor
. O

As O
the O
two O
herbs O
are O
most O
often O
sold O
in O
combination O
with O
each O
other O
the O
current O
study O
assessed O
the O
anxiolytic O
properties O
of O
such O
a O
combination O
during O
laboratory-induced O
stress O
. O

Methods O
: O
In O
this O
double-blind O
, O
placebo-controlled O
, O
randomized O
, O
balanced O
cross-over O
experiment O
, O
24 B-#Participants
healthy O
volunteers O
received O
three O
separate O
single O
doses O
( O
600 B-Dosage
mg I-Dosage
, O
1200 B-Dosage
mg I-Dosage
, O
1800 B-Dosage
mg I-Dosage
) O
of O
a O
standardized O
product O
containing O
M B-Medicinal food
. I-Medicinal food
officinalis I-Medicinal food
and I-Medicinal food
V I-Medicinal food
. I-Medicinal food
officinalis I-Medicinal food
extracts O
, O
plus O
a O
placebo O
, O
on O
separate O
days O
separated O
by O
a O
7 O
day O
wash O
out O
period O
. O

Modulation O
of O
mood B-Symptom_TestedFor
and O
anxiety B-Symptom_TestedFor
were O
assessed O
during O
pre-dose O
and O
1 O
h O
, O
3 O
h O
and O
6 O
h O
post-dose O
completions O
of O
a O
20 O
min O
version O
of O
the O
Defined B-Metric
Intensity I-Metric
Stressor I-Metric
Simulation I-Metric
( I-Metric
DISS I-Metric
) I-Metric
battery I-Metric
. I-Metric

Cognitive O
performance O
on O
the O
four O
concurrent O
tasks O
of O
the O
battery O
was O
also O
assessed O
. O

Results O
: O
The O
results O
showed O
that O
the O
600 O
mg O
dose O
of O
the O
combination O
ameliorated O
the O
negative O
effects O
of O
the O
DISS O
on O
ratings O
of O
anxiety O
. O

However O
, O
the O
highest O
dose O
( O
1800 O
mg O
) O
showed O
an O
increase O
in O
anxiety O
that O
was O
less O
marked O
but O
which O
reached O
significance O
during O
one O
testing O
session O
. O

In O
addition O
, O
all O
three O
doses O
led O
to O
decrements O
in O
performance O
on O
the O
Stroop B-Metric
task I-Metric
module O
within O
the O
battery O
, O
and O
the O
two O
lower O
doses O
led O
to O
decrements O
on O
the O
overall O
score O
generated O
on O
the O
DISS O
battery O
. O

Conclusions O
: O
These O
results O
suggest O
that O
a O
combination O
of O
Melissa B-Drug/Scientific name
officinalis I-Drug/Scientific name
and O
Valeriana B-Drug/Scientific name
officinalis I-Drug/Scientific name
possesses O
anxiolytic O
properties O
that O
deserve O
further O
investigation O
. O

Objective O
: O
To O
determine O
the O
relative O
importance O
of O
psychosocial O
factors O
in O
arthritis B-Symptom_TestedFor
diagnosis O
in O
an O
ageing O
cohort O
of O
Australian O
women O
. O

Methods O
: O
This O
study O
focused O
on O
10,509 B-#Participants
women O
from O
the O
1946 O
- O
1951 O
cohort O
who O
responded O
to O
questions O
on O
arthritis B-Symptom_TestedFor
in O
the O
fifth O
mailed O
population-based O
survey O
of O
the O
Australian O
Longitudinal O
Study O
on O
Women's O
Health O
conducted O
in O
2007 O
. O

Results O
: O
Arthritis B-Symptom_TestedFor
was O
characterised O
by O
widespread O
psychosocial O
concerns O
, O
particularly O
relating O
to O
chronic O
stress B-Symptom_TestedFor
and O
poor O
mental B-Symptom_TestedFor
health I-Symptom_TestedFor
. O

Univariate O
analyses O
revealed O
that O
in O
comparison O
to O
women O
without O
stress O
, O
women O
with O
moderate O
/ O
high O
stress O
levels O
had O
a O
2.5 O
- O
fold O
increase O
in O
reporting O
arthritis O
. O

Experiencing O
ongoing O
negative O
interpersonal O
life O
events O
concerning O
illness O
of O
a O
family O
member O
/ O
close O
friend O
and O
relationship O
difficulties O
was O
also O
associated O
with O
a O
1.4 O
- O
fold O
increase O
in O
the O
reporting O
of O
arthritis O
. O

Likewise O
, O
significantly O
reduced O
levels O
of O
optimism O
and O
perceived O
social O
support O
were O
noted O
( O
all O
associations O
p O
< O
.001 O
) O
. O

Psychiatric O
diagnosis O
was O
also O
associated O
with O
a O
two-fold O
increase O
in O
having O
arthritis O
( O
p O
< O
.001 O
) O
. O

Following O
adjustment O
for O
behavioural O
, O
demographic O
and O
health-related O
characteristics O
, O
anxiety B-Symptom_TestedFor
was O
the O
only O
psychosocial O
factor O
associated O
with O
arthritis O
( O
OR O
= O
1.4 O
, O
95% O
CI O
= O
1.2 O
, O
1.7 O
; O
p O
< O
.001 O
) O
. O

Conclusion O
: O
This O
study O
examined O
, O
epidemiologically O
, O
the O
relative O
importance O
of O
psychosocial O
factors O
in O
arthritis O
in O
an O
ageing O
cohort O
of O
Australian O
women O
. O

The O
findings O
from O
this O
population-based O
study O
indicate O
that O
women O
with O
arthritis O
are O
more O
likely O
to O
report O
a O
range O
of O
psychosocial-related O
problems O
, O
particularly O
with O
regard O
to O
chronic O
stress O
perception O
and O
anxiety O
. O

Longitudinal O
analyses O
are O
required O
to O
examine O
the O
processes O
by O
which O
stress O
and O
psychosocial O
factors O
may O
contribute O
to O
arthritis O
risk O
and O
poor O
adaptation O
in O
terms O
of O
health-related O
quality O
of O
life O
. O

Objective O
: O
This O
study O
aimed O
at O
identifying O
supportive O
care O
needs O
of O
patients O
with O
head B-Symptom_TestedFor
and I-Symptom_TestedFor
neck I-Symptom_TestedFor
cancer I-Symptom_TestedFor
( O
HNC-P O
) O
immediately O
post-treatment O
, O
finding O
early O
predictors O
of O
unmet O
needs O
, O
and O
contrasting O
how O
immediate O
post-treatment O
needs O
differed O
from O
needs O
in O
longer-term O
survivorship O
. O

Methods O
: O
Prospective O
longitudinal O
study O
of O
223 B-#Participants
consecutive O
adults O
( O
313 O
approached O
; O
72% O
participation O
) O
newly O
diagnosed O
with O
a O
first O
occurrence O
of O
primary O
HNC O
. O

Patients O
completed O
the O
Supportive O
Care O
Needs O
Survey-Short O
Form O
( O
SCNS O
) O
, O
the O
Structured O
Clinical O
Interview O
for O
DSM-IV O
, O
and O
other O
outcomes O
. O

Medical O
chart O
reviews O
were O
conducted O
. O

Results O
: O
A O
total O
of O
68% O
of O
patients O
( O
n O
= O
145 O
/ O
223 O
) O
completed O
the O
SCNS O
. O

The O
multiple O
linear O
regression O
indicated O
that O
when O
controlled O
for O
medical O
variables O
, O
patients O
presented O
higher O
levels O
of O
unmet O
needs O
when O
they O
presented O
with O
higher O
level O
of O
anxiety O
upon O
HNC O
diagnosis O
( O
p O
= O
0.03 O
) O
, O
higher O
neuroticism O
( O
p O
= O
0.03 O
) O
, O
and O
more O
stressful O
life O
events O
in O
the O
year O
pre-diagnosis O
( O
p O
= O
0.01 O
) O
. O

Patients O
immediately O
post-treatment O
had O
a O
wider O
variety O
of O
unmet O
needs O
compared O
with O
those O
in O
extended O
survivorship O
, O
with O
psychological O
unmet O
needs O
most O
prevalent O
at O
both O
time O
points O
. O

Immediately O
post-treatment O
, O
patients O
needed O
more O
support O
regarding O
pain O
( O
p O
= O
0.04 O
) O
and O
worries O
about O
treatment O
results O
( O
p O
= O
0.05 O
) O
, O
whereas O
patients O
in O
longer-term O
survivorship O
needed O
more O
support O
regarding O
anxiety O
( O
p O
= O
0.02 O
) O
, O
changes O
in O
sexual O
relationships O
( O
p O
= O
0.04 O
) O
, O
and O
fear O
of O
death O
and O
dying O
( O
p O
= O
0.001 O
) O
. O

Conclusion O
: O
This O
study O
identifies O
areas O
needing O
further O
development O
to O
improve O
quality O
of O
care O
for O
HNC-P O
in O
the O
immediate O
post-treatment O
period O
, O
as O
well O
as O
early O
determinants O
of O
unmet O
needs O
. O

HNC O
clinics O
may O
want O
to O
routinely O
screen O
for O
anxiety O
, O
neuroticism O
, O
and O
burden O
from O
other O
life O
events O
, O
to O
pro-actively O
address O
needs O
upon O
treatment O
completion O
and O
alleviate O
disease O
burden O
. O

Dietary O
supplements O
are O
widely O
used O
for O
desired O
effects O
on O
memory B-Symptom_TestedFor
, O
insomnia B-Symptom_TestedFor
, O
mood B-Symptom_TestedFor
and O
anxiety B-Symptom_TestedFor
. O

This O
review O
focuses O
on O
supplements O
which O
have O
anxiolytic O
or O
mild O
relaxation O
properties O
and O
enhance O
mood O
. O

For O
example O
, O
Kava B-Medicinal food
( O
Piper B-Drug/Scientific name
methysticum I-Drug/Scientific name
) O
is O
reported O
to O
have O
anaxiolytic O
actions O
and O
to O
reduce O
tension O
through O
skeletal O
muscle B-Symptom_WorkedFor
relaxation I-Symptom_WorkedFor
. O

Dried O
passion B-Medicinal food
flower I-Medicinal food
( O
genus B-Drug/Scientific name
Passiflora I-Drug/Scientific name
) O
is O
reported O
to O
reduce O
insomnia B-Symptom_WorkedFor
and O
hysteria B-Symptom_WorkedFor
. O

Skullcap B-Medicinal food
( O
genus B-Drug/Scientific name
Scutellaria I-Drug/Scientific name
) O
, O
hops B-Medicinal food
( O
Humulus B-Drug/Scientific name
lupulus I-Drug/Scientific name
) O
, O
lemon B-Medicinal food
balm I-Medicinal food
( O
Melissa B-Drug/Scientific name
officinalis I-Drug/Scientific name
) O
and O
Valerian B-Medicinal food
( O
Valeriana B-Drug/Scientific name
officinalis I-Drug/Scientific name
) O
root O
are O
all O
herbs O
reported O
as O
anaxiolytic B-Symptom_WorkedFor
calming O
agents O
. O

Further O
, O
extracts O
of O
Magnolia B-Medicinal food
and O
Phellondendron B-Medicinal food
bark I-Medicinal food
are O
mild O
sedatives B-Symptom_WorkedFor
. O

Supplements O
such O
as O
gamma-aminobutyric O
acid O
( O
GABA O
) O
, O
theanine O
, O
tryptophan O
and O
5 O
- O
hydroxytryptophan O
( O
5 O
- O
HTP O
) O
are O
reported O
to O
promote O
relaxation O
. O

In O
general O
, O
these O
supplements O
appear O
to O
act O
as O
GABA O
receptor O
agonists O
or O
to O
boost O
GABA O
levels O
, O
although O
Kava B-Medicinal food
inhibits O
both O
norephinephrine O
uptake O
and O
sodium O
and O
potassium O
channels O
and O
5 O
- O
HTP O
may O
act O
through O
elevation O
of O
serotonin O
. O

While O
questions O
remain O
in O
the O
literature O
regarding O
the O
medicinal O
value O
of O
these O
supplements O
in O
treating O
mood B-Symptom_TestedFor
and O
anxiety B-Symptom_TestedFor
disorders O
, O
based O
on O
cellular O
and O
animal O
studies O
as O
well O
as O
human O
clinical O
trials O
the O
literature O
supports O
a O
role O
for O
these O
preparations O
as O
useful O
alternatives O
in O
the O
management O
of O
the O
stress B-Symptom_TestedFor
and O
anxiety B-Symptom_TestedFor
of O
everyday O
life O
. O

Objectives O
. O

To O
specify O
symptoms O
and O
measure O
prevalence O
of O
psychological B-Symptom_TestedFor
distress I-Symptom_TestedFor
among O
incarcerated O
people O
in O
long-term O
solitary O
confinement.Methods O
. O

We O
gathered O
data O
via O
semistructured O
, O
in-depth O
interviews O
; O
Brief B-Metric
Psychiatric I-Metric
Rating I-Metric
Scale I-Metric
( O
BPRS O
) O
assessments O
; O
and O
systematic O
reviews O
of O
medical O
and O
disciplinary O
files O
for O
106 B-#Participants
randomly O
selected O
people O
in O
solitary O
confinement O
in O
the O
Washington O
State O
Department O
of O
Corrections O
in O
2017 O
. O

We O
performed O
1 O
- O
year O
follow-up O
interviews O
and O
BPRS O
assessments O
with O
80 O
of O
these O
incarcerated O
people O
, O
and O
we O
present O
the O
results O
of O
our O
qualitative O
content O
analysis O
and O
descriptive O
statistics.Results O
. O

BPRS O
results O
showed O
clinically O
significant O
symptoms O
of O
depression B-Symptom_TestedFor
, O
anxiety B-Symptom_TestedFor
, O
or O
guilt O
among O
half O
of O
our O
research O
sample O
. O

Administrative O
data O
showed O
disproportionately O
high O
rates O
of O
serious O
mental O
illness O
and O
self-harming O
behavior O
compared O
with O
general O
prison O
populations O
. O

Interview O
content O
analysis O
revealed O
additional O
symptoms O
, O
including O
social O
isolation O
, O
loss O
of O
identity O
, O
and O
sensory O
hypersensitivity.Conclusions O
. O

Our O
coordinated O
study O
of O
rating O
scale O
, O
interview O
, O
and O
administrative O
data O
illustrates O
the O
public O
health O
crisis O
of O
solitary O
confinement O
. O

Because O
95% O
or O
more O
of O
all O
incarcerated O
people O
, O
including O
those O
who O
experienced O
solitary O
confinement O
, O
are O
eventually O
released O
, O
understanding O
disproportionate O
psychopathology O
matters O
for O
developing O
prevention O
policies O
and O
addressing O
the O
unique O
needs O
of O
people O
who O
have O
experienced O
solitary O
confinement O
, O
an O
extreme O
element O
of O
mass O
incarceration O
. O

Objective O
: O
We O
examined O
the O
use O
of O
particular O
cognitive O
strategies O
for O
regulating O
negative O
emotion O
in O
relation O
to O
mood O
and O
temperament O
in O
BD-I O
, O
unaffected O
relatives O
of O
bipolar O
patients O
( O
UR O
) O
, O
and O
healthy O
controls O
( O
HC O
) O
. O

Method O
: O
Participants O
were O
105 B-#Participants
patients O
with O
BD-I O
, O
124 O
UR O
, O
and O
63 O
HC O
; O
all O
participants O
completed O
the O
Cognitive B-Metric
Emotion I-Metric
Regulation I-Metric
Questionnaire I-Metric
( O
CERQ O
) O
, O
the O
Depression B-Metric
Anxiety I-Metric
Stress I-Metric
Scales I-Metric
( O
DASS O
) O
, O
and O
the O
Hypomanic B-Metric
Personality I-Metric
Scale I-Metric
( O
HPS O
) O
. O

Results O
: O
The O
BD-I O
group O
reported O
more O
frequent O
use O
of O
rumination O
, O
catastrophizing O
and O
self-blame O
, O
and O
less O
frequent O
use O
of O
putting O
into O
perspective O
, O
in O
response O
to O
negative O
life O
events O
, O
relative O
to O
the O
UR O
and O
HC O
groups O
. O

In O
BD-I O
, O
more O
frequent O
use O
of O
rumination O
was O
associated O
with O
increased O
DASS O
and O
HPS O
scores O
. O

By O
contrast O
, O
within O
the O
UR O
group O
, O
more O
frequent O
use O
of O
catastrophizing O
and O
self-blame O
were O
associated O
with O
increased O
DASS O
and O
HPS O
scores O
. O

In O
all O
participants O
, O
less O
frequent O
use O
of O
adaptive O
cognitive O
reframing O
strategies O
( O
e.g O
. O
putting O
into O
perspective O
) O
were O
associated O
with O
increased O
DASS O
scores O
. O

Conclusion O
: O
Both O
BD-I O
and O
UR O
groups O
reported O
more O
frequent O
use O
of O
maladaptive O
regulatory O
strategies O
previously O
associated O
with O
depression B-Symptom_TestedFor
. O

Emotion O
regulation O
strategies O
of O
catastrophizing O
, O
self-blame O
, O
and O
cognitive O
reframing O
techniques O
may O
be O
associated O
with O
vulnerability O
for O
mood O
disorders O
, O
with O
the O
latter O
active O
within O
the O
general O
population O
regardless O
of O
biological O
vulnerability O
to O
disorder O
. O

This O
research O
aimed O
to O
identify O
modifiable O
risk O
factors O
for O
poor O
psychological B-Symptom_TestedFor
functioning I-Symptom_TestedFor
six O
months O
post-operatively O
, O
using O
a O
chronic O
illness O
model O
to O
explain O
the O
relationships O
between O
risk O
factors O
. O

Consecutive O
elective O
CABG O
patients O
( O
N O
= O
119 O
) O
completed O
self-report O
measures O
including O
optimism O
, O
illness O
representations O
, O
self-rated O
health O
, O
social O
support O
, O
coping O
methods O
, O
depression B-Symptom_TestedFor
, O
anxiety B-Symptom_TestedFor
and O
PTSD O
symptomatology O
in O
a O
repeated O
measures O
design O
. O

Poor O
pre-operative O
psychological O
functioning O
was O
the O
strongest O
psychological O
risk O
factor O
for O
adverse O
psychological O
functioning O
six O
months O
post-operatively O
. O

Longitudinal O
support O
for O
the O
chronic O
illness O
model O
examined O
was O
limited O
. O

Further O
research O
to O
identify O
modifiable O
risk O
factors O
and O
pre-operative O
psychopathology O
screening O
to O
determine O
individuals O
at-risk O
of O
poor O
psychological O
outcome O
is O
recommended O
. O

Background O
: O
Despite O
advances O
in O
the O
treatment O
of O
cardiovascular O
diseases O
in O
recent O
decades O
, O
patients O
experience O
high O
levels O
of O
depression B-Symptom_WorkedFor
, O
anxiety B-Symptom_WorkedFor
, O
stress B-Symptom_WorkedFor
, O
and O
insomnia B-Symptom_WorkedFor
. O

Since O
the O
calming O
effect O
of O
Melissa B-Drug/Scientific name
officinalis I-Drug/Scientific name
( O
MO B-Drug/Scientific name
) O
has O
been O
known O
, O
this O
study O
aimed O
to O
determine O
the O
effects O
of O
MO B-Drug/Scientific name
supplementation O
on O
depression B-Symptom_WorkedFor
, O
anxiety B-Symptom_WorkedFor
, O
stress B-Symptom_WorkedFor
, O
and O
sleep B-Symptom_WorkedFor
disturbances I-Symptom_WorkedFor
in O
patients O
with O
chronic B-participant_health
stable I-participant_health
angina I-participant_health
( O
CSA B-participant_health
) O
. O

Methods O
: O
In O
this O
double-blind O
placebo-controlled O
clinical O
trial O
, O
80 B-#Participants
patients O
with O
CSA B-participant_health
were O
divided O
randomly O
into O
two O
groups O
( O
taking O
3 B-Dosage
g I-Dosage
MO B-Drug/Scientific name
supplement O
or O
placebo O
daily O
for O
8 B-Duration
weeks I-Duration
) O
. O

The O
shortened O
21 O
- O
item O
version O
of O
the O
depression B-Metric
, I-Metric
anxiety I-Metric
and I-Metric
stress I-Metric
scale I-Metric
( O
DASS O
- O
21 O
) O
test O
and O
Pittsburgh B-Metric
sleep I-Metric
quality I-Metric
index I-Metric
were O
done O
before O
and O
after O
the O
intervention O
. O

Results O
: O
At O
the O
end O
of O
the O
study O
, O
the O
intervention O
group O
receiving O
MO B-Drug/Scientific name
capsules O
had O
a O
significant O
reduction O
in O
scores O
of O
depression B-Symptom_WorkedFor
, O
anxiety B-Symptom_WorkedFor
, O
stress B-Symptom_WorkedFor
, O
and O
total O
sleep B-Symptom_WorkedFor
disturbance I-Symptom_WorkedFor
, O
compared O
with O
the O
placebo O
group O
( O
P O
< O
0.05 O
) O
. O

Conclusions O
: O
The O
results O
showed O
that O
8 O
- O
week O
supplementation O
with O
3 B-Dosage
g I-Dosage
MO B-Drug/Scientific name
can O
decrease O
depression B-Symptom_WorkedFor
, O
anxiety B-Symptom_WorkedFor
, O
stress B-Symptom_WorkedFor
, O
and O
sleep B-Symptom_WorkedFor
disorder I-Symptom_WorkedFor
in O
patients O
with O
CSA O
. O

Introduction O
: O
Studies O
have O
found O
that O
increased O
mobile O
phone O
use O
( O
MPU O
) O
is O
associated O
with O
multiple O
health O
issues O
such O
as O
depression B-Symptom_TestedFor
, O
disordered B-Symptom_TestedFor
sleep I-Symptom_TestedFor
and O
pain B-Symptom_TestedFor
. O

However O
, O
the O
current O
situation O
and O
interrelationships O
of O
these O
problems O
remain O
unexplored O
in O
the O
Hong O
Kong O
population O
. O

Objectives O
: O
This O
study O
aimed O
to O
understand O
the O
situation O
and O
problematic O
use O
of O
mobile O
phones O
by O
Hong O
Kong O
secondary O
school O
students O
and O
to O
investigate O
depressive O
symptoms O
, O
bodily O
pain O
and O
daytime O
sleepiness O
and O
the O
associations O
of O
these O
factors O
with O
MPU O
in O
Hong O
Kong O
secondary O
school O
students O
. O

Methods O
: O
This O
quantitative O
cross-sectional O
design O
study O
was O
based O
on O
self-administered O
questionnaires O
completed O
at O
five O
secondary O
schools O
. O

The O
questionnaire O
comprised O
five O
sections O
: O
MPU O
as O
measured O
by O
the O
Chinese O
version O
of O
the O
10 O
- O
Item O
Mobile O
Phone O
Problem O
Use O
Scale O
( O
CMPPUS O
- O
10 O
) O
; O
depressive O
symptoms O
according O
to O
the O
Depression O
Anxiety O
Stress O
Scale O
- O
21 O
Chinese O
Version O
( O
DASS O
- O
21 O
) O
; O
bodily O
pain O
according O
to O
the O
Brief O
Pain O
Inventory O
Short O
Form O
Chinese O
( O
BPISF-C O
) O
; O
daytime O
sleepiness O
as O
measured O
using O
the O
Chinese O
version O
of O
the O
Epworth O
Sleepiness O
Scale O
( O
CESS O
) O
and O
socio-demographic O
questions O
. O

Results O
: O
A O
total O
of O
686 O
students O
were O
recruited O
. O

The O
CMPPUS O
- O
10 O
score O
correlated O
positively O
with O
the O
average O
daily O
duration O
of O
MPU O
and O
the O
presence O
of O
depression O
, O
daytime O
sleepiness O
and O
bodily O
pain O
. O

Problematic O
mobile O
phone O
users O
received O
significantly O
higher O
scores O
for O
depression O
severity O
, O
bodily O
pain O
and O
daytime O
sleepiness O
. O

Health O
problems O
were O
significantly O
more O
severe O
in O
female O
than O
in O
male O
students O
. O

Bodily O
pain O
and O
daytime O
sleepiness O
mediated O
the O
relationship O
of O
MPU O
with O
depression O
. O

Conclusions O
: O
Problematic O
MPU O
was O
associated O
with O
depression O
, O
bodily O
pain O
and O
daytime O
sleepiness O
. O

These O
findings O
will O
inform O
further O
studies O
of O
MPU-related O
health O
problems O
. O

Aim O
To O
describe O
and O
investigate O
correlations O
among O
anxiety B-Symptom_TestedFor
, O
stress B-Symptom_TestedFor
and O
depression B-Symptom_TestedFor
and O
identify O
their O
relationship O
with O
sociodemographic O
and O
clinical O
characteristics O
of O
patients O
with O
heart O
failure O
. O

Methods O
: O
This O
is O
an O
analytical O
cross-sectional O
study O
. O

Sociodemographic O
and O
clinical O
characteristics O
were O
collected O
, O
along O
with O
levels O
of O
anxiety O
, O
stress O
and O
depression O
from O
309 O
outpatients O
. O

Results O
: O
The O
mean O
levels O
of O
stress O
, O
anxiety O
and O
depression O
were O
correlated O
but O
low O
. O

Time O
since O
diagnosis O
, O
the O
disease's O
functional O
class O
, O
family O
income O
, O
and O
smoking O
influenced O
stress O
. O

Functional O
class O
and O
Chagas O
disease O
influenced O
anxiety O
and O
depression O
. O

Being O
unemployed O
and O
smoking O
influenced O
anxiety O
, O
while O
being O
a O
homeowner O
influenced O
depression O
. O

Conclusion O
: O
These O
findings O
should O
be O
considered O
when O
planning O
nursing O
interventions O
. O

Magnolol B-Medicinal food
is O
a O
traditional O
Chinese O
medicine O
from O
the O
root O
and O
bark O
of O
Magnolia B-Drug/Scientific name
officinalis I-Drug/Scientific name
. O

It O
has O
long O
been O
used O
to O
treat O
anxiety B-Symptom_WorkedFor
, O
cough B-Symptom_WorkedFor
, O
headache B-Symptom_WorkedFor
and O
allergies B-Symptom_WorkedFor
, O
as O
well O
as O
a O
variety O
of O
inflammations O
. O

Lung O
inflammation O
is O
a O
key O
event O
in O
the O
pathogenesis O
of O
asthma O
and O
chronic O
obstructive O
pulmonary O
disease O
. O

The O
present O
study O
sought O
to O
examine O
the O
effects O
of O
magnolol B-Medicinal food
on O
tumor O
necrosis O
factor O
( O
TNF O
) O
- O
α-induced O
upregulation O
of O
intercellular O
adhesion O
molecule O
- O
1 O
( O
ICAM O
- O
1 O
) O
, O
activation O
of O
the O
nuclear O
factor O
( O
NF O
) O
- O
κB O
and O
mitogen-activated O
protein O
kinase O
( O
MAPK O
) O
signaling O
pathway O
in O
cultured O
human O
pulmonary O
epithelial O
cells O
, O
and O
adhesion O
of O
human O
macrophage-like O
U937 O
cells O
to O
A549 O
cells O
. O

A549 O
cells O
were O
incubated O
with O
magnolol B-Medicinal food
at O
25 B-Dosage
and I-Dosage
50 I-Dosage
μmol I-Dosage
/ I-Dosage
l I-Dosage
. O

Then O
, O
20 O
ng O
/ O
ml O
TNF-α O
was O
used O
to O
activate O
the O
cells O
. O

Magnolol B-Medicinal food
inhibited O
the O
growth O
of O
human O
pulmonary O
epithelial O
A549 O
cells O
in O
a O
dose O
- O
and O
time-dependent O
manner O
. O

Magnolol B-Medicinal food
suppressed O
the O
adhesion O
of O
U937 O
cells O
to O
TNF-α-induced O
A549 O
cells O
. O

In O
cultured O
human O
pulmonary O
epithelial O
A549 O
cells O
, O
magnolol O
decreased O
TNF-α-induced O
upregulation O
of O
ICAM O
- O
1 O
. O

Magnolol B-Medicinal food
repressed O
TNF-α-induced O
activation O
of O
NF-κB O
and O
mitogen-activated O
protein O
kinase O
( O
MAPK O
) O
signaling O
pathways O
in O
A549 O
cells O
by O
inhibiting O
phosphorylation O
of O
NF-κB O
, O
p38 O
, O
extracellular O
signal-regulated O
kinase O
( O
ERK O
) O
1 O
/ O
2 O
, O
and O
stress-activated O
protein O
kinase O
( O
SAPK O
) O
/ O
c-Jun O
N-terminal O
kinase O
( O
JNK O
) O
. O

These O
findings O
support O
the O
hypothesis O
that O
magnolol B-Medicinal food
inhibits O
the O
inflammatory O
process O
in O
lung O
epithelial O
A549 O
cells O
by O
suppressing O
the O
ICAM O
- O
1 O
and O
NF-κB O
and O
MAPK O
signaling O
pathways O
. O

Taken O
together O
, O
these O
results O
indicate O
that O
magnolol B-Medicinal food
offers O
significant O
potential O
as O
a O
therapeutic O
treatment O
for O
inflammatory O
diseases O
of O
the O
lungs O
including O
asthma B-Symptom_WorkedFor
, O
sepsis B-Symptom_WorkedFor
, O
and O
chronic B-Symptom_WorkedFor
obstructive I-Symptom_WorkedFor
pulmonary I-Symptom_WorkedFor
disease I-Symptom_WorkedFor
. O

Objective O
: O
Fatigue B-Symptom_TestedFor
is O
common O
among O
cancer O
patients O
and O
adversely O
impacts O
quality O
of O
life O
. O

As O
such O
, O
it O
is O
important O
to O
measure O
fatigue B-Symptom_TestedFor
accurately O
in O
a O
way O
that O
is O
not O
burdensome O
to O
patients O
. O

The O
7 O
- O
item O
Patient O
Reported O
Outcome O
Measurement O
Information O
System O
( O
PROMIS O
) O
Cancer O
Fatigue O
Short O
Form O
scale O
was O
recently O
developed O
using O
item O
response O
theory O
( O
IRT O
) O
. O

The O
current O
study O
evaluated O
the O
psychometric O
properties O
of O
this O
scale O
in O
two O
samples O
of O
cancer O
patients O
using O
classical O
test O
theory O
( O
CTT O
) O
. O

Methods O
: O
Two O
samples O
were O
used O
: O
121 B-#Participants
men O
with O
prostate B-participant_health
cancer I-participant_health
and O
136 B-#Participants
patients O
scheduled O
to O
undergo O
hematopoietic O
cell O
transplantation O
( O
HCT O
) O
for O
hematologic B-participant_health
cancer I-participant_health
. O

All O
participants O
completed O
the O
PROMIS O
Cancer O
Fatigue O
Short O
Form O
as O
well O
as O
validated O
measures O
of O
fatigue O
, O
vitality O
, O
and O
depression O
. O

HCT O
patients O
also O
completed O
measures O
of O
anxiety O
, O
perceived O
stress O
, O
and O
a O
clinical O
interview O
designed O
to O
identify O
cases O
of O
cancer-related O
fatigue O
. O

Results O
: O
PROMIS B-Metric
Cancer I-Metric
Fatigue I-Metric
Short I-Metric
Form I-Metric
items O
loaded O
on O
a O
single O
factor O
( O
CFI B-Metric
= O
0.948 O
) O
and O
the O
scale O
demonstrated O
good O
internal O
consistency O
reliability O
in O
both O
samples O
( O
Cronbach's O
alphas O
> O
0.86 O
) O
. O

Correlations O
with O
psychosocial O
measures O
were O
significant O
( O
p O
values O
< O
.0001 O
) O
and O
in O
the O
expected O
direction O
, O
offering O
evidence O
for O
convergent O
and O
concurrent O
validity O
. O

PROMIS B-Metric
Fatigue I-Metric
scores I-Metric
were O
significantly O
higher O
in O
patients O
who O
met O
case O
definition O
criteria O
for O
cancer-related O
fatigue O
( O
p O
< O
.0001 O
) O
, O
demonstrating O
criterion O
validity O
. O

Conclusion O
: O
The O
current O
study O
provides O
evidence O
that O
the O
PROMIS B-Metric
Cancer I-Metric
Fatigue I-Metric
Short I-Metric
Form I-Metric
is O
a O
reliable O
and O
valid O
measure O
of O
fatigue B-Symptom_TestedFor
in O
cancer B-participant_health
patients O
. O

Despite O
numerous O
individual O
studies O
of O
psychological O
factors O
( O
depression B-Symptom_TestedFor
, O
anxiety B-Symptom_TestedFor
, O
distress B-Symptom_TestedFor
) O
related O
to O
genetic O
testing O
for O
inherited O
cancer O
syndromes O
( O
CGT O
) O
, O
there O
has O
been O
no O
systematic O
review O
of O
the O
psychological O
factors O
are O
measured O
among O
individuals O
at O
increased O
risk O
for O
hereditary O
breast O
, O
ovarian O
, O
or O
colon O
cancer O
. O

Our O
review O
provides O
an O
analysis O
of O
psychological O
factors O
in O
studies O
of O
CGT O
and O
discusses O
the O
instruments O
most O
commonly O
used O
to O
measure O
them O
. O

We O
performed O
a O
literature O
search O
using O
three O
major O
OVID O
databases O
from O
1993 O
to O
January O
2003 O
. O

In O
the O
19 O
studies O
that O
met O
our O
inclusion O
criteria O
, O
the O
most O
commonly O
assessed O
psychological O
factors O
were O
distress B-Symptom_TestedFor
, O
anxiety B-Symptom_TestedFor
, O
and O
depression B-Symptom_TestedFor
. O

These O
factors O
were O
most O
often O
measured O
by O
the O
impact B-Metric
of I-Metric
event I-Metric
scale I-Metric
( O
IES O
) O
, O
the O
state-trait B-Metric
anxiety I-Metric
inventory I-Metric
( O
STAI O
) O
, O
and O
the O
Centers B-Metric
for I-Metric
Epidemiologic I-Metric
Studies I-Metric
and I-Metric
Depression I-Metric
scale I-Metric
( O
CES-D O
) O
, O
respectively O
. O

Our O
results O
show O
deficits O
in O
the O
existing O
body O
of O
literature O
on O
psychological O
factors O
associated O
with O
CGT O
including O
limited O
documentation O
of O
psychometrics O
and O
variability O
in O
instrumentation O
. O

Objective O
: O
To O
examine O
the O
abilities O
of O
theanine B-Medicinal food
and O
houpu B-Medicinal food
extracts I-Medicinal food
( O
HE O
) O
to O
reverse O
behavioral O
indexes O
( O
separation O
vocalization O
, O
stress-induced B-Symptom_WorkedFor
analgesia I-Symptom_WorkedFor
and O
activity O
) O
. O

Method O
: O
7 O
- O
day-old O
chicks O
received O
IP O
injection O
of O
theanine B-Medicinal food
and O
HE B-Medicinal food
30 O
min O
before O
being O
tested O
in O
the O
presence O
of O
three O
social O
companions O
or O
in O
isolation O
for O
3 O
- O
min O
observation O
period O
. O

Dependent O
measures O
were O
: O
a O
) O
Chicks O
were O
placed O
into O
an O
infrared O
ray O
device O
to O
calculate O
their O
spontaneous O
activities O
by O
a O
computer O
program O
b O
) O
record O
the O
separation O
vocalizations O
for O
every O
chick O
. O
c O
) O
In O
the O
experiment O
of O
stress-induced O
analgesia O
, O
50 O
uL O
of O
formalin O
( O
0.1% O
) O
was O
injected O
into O
the O
plantar O
of O
the O
animal O
foot O
to O
index O
stress-induced O
analgesia O
( O
i O
. O
e O
. O
foot-lift O
frequency O
, O
foot-lift O
duration O
and O
peck O
frequency O
) O
. O

Result O
: O
In O
the O
experiments O
, O
isolated O
chicks O
exhibited O
more O
vocalizations O
( O
P O
< O
0.01 O
) O
and O
fewer O
pain-related O
behaviors O
than O
non-isolated O
chicks O
( O
P O
< O
0.01 O
) O
. O

Theanine B-Medicinal food
( O
12.5 O
, O
25 O
, O
50 O
mg O
x O
kg O
( O
- O
1 O
) O
) O
and O
HE O
( O
25 O
mg O
x O
kg O
( O
- O
1 O
) O
) O
decrease O
separately O
the O
tendency O
( O
dB O
) O
of O
the O
principal O
frequency O
( O
P O
< O
0.05 O
, O
P O
< O
0.01 O
) O
; O
The O
stress O
induced O
analgesia O
can O
be O
reversed O
by O
theanine B-Medicinal food
in O
25 O
, O
50 O
mg O
x O
kg O
( O
- O
1 O
) O
. O

Both O
of O
the O
materials O
do O
not O
affect O
the O
spontaneous O
activities O
in O
this O
chick O
model O
without O
causing O
sedation O
. O

Conclusion O
: O
These O
results O
suggest O
that O
theanine O
and O
HE O
in O
the O
dosages O
may O
be O
useful O
in O
modulating O
anxiety B-Symptom_WorkedFor
states O
. O

They O
are O
seems O
no O
synergism O
in O
the O
chick O
model O
. O

Honokiol B-Drug/Scientific name
, O
a O
component O
of O
the O
herb O
Magnolia B-Medicinal food
officinalis I-Medicinal food
, O
exhibits O
antioxidant O
, O
anti-inflammatory O
and O
anxiolytic O
properties O
, O
increases O
seizure O
threshold O
, O
and O
promotes O
neurite O
outgrowth O
. O

Because O
stroke O
has O
become O
the O
second O
leading O
cause O
of O
death O
in O
industrialized O
countries O
, O
an O
effective O
neuroprotectant O
is O
urgently O
required O
. O

In O
this O
study O
, O
we O
attempted O
to O
elucidate O
in O
a O
mouse O
cerebral O
ischaemia O
model O
whether O
honokiol B-Drug/Scientific name
could O
be O
a O
neuroprotectant O
. O

Adult O
male O
Institute O
of O
Cancer O
Research O
( O
ICR O
) O
mice O
were O
subjected O
to O
middle O
cerebral O
artery O
occlusion O
for O
45 O
min O
. O

Honokiol B-Drug/Scientific name
( O
10 O
microg O
/ O
kg O
in O
0.2 O
ml O
of O
saline B-Other_ingredients
) O
or O
control O
vehicle O
was O
intraperitoneally O
administered O
twice O
, O
15 O
min O
. O
before O
and O
60 O
min O
. O
after O
the O
induction O
of O
ischaemia O
. O

Cerebral O
ischaemia O
induced O
by O
this O
method O
was O
associated O
with O
an O
increase O
in O
synaptosomal O
production O
of O
reactive O
oxygen O
species O
, O
with O
decreases O
in O
synaptosomal O
mitochondrial O
membrane O
potential O
( O
DeltaPsim O
) O
and O
synaptosomal O
mitochondrial O
metabolic O
function O
, O
and O
with O
reductions O
in O
Na O
( O
+ O
) O
, O
K O
( O
+ O
) O
- O
ATPase O
activities O
of O
tissues O
isolated O
from O
selected O
brain O
regions O
. O

Administration O
of O
honokiol B-Drug/Scientific name
resulted O
in O
significant O
reductions O
in O
brain O
infarct O
volume O
and O
in O
synaptosomal O
production O
of O
reactive O
oxygen O
species O
. O

The O
decreases O
in O
synaptosomal O
mitochondrial O
membrane O
potential O
, O
synaptosomal O
mitochondrial O
metabolic O
function O
and O
tissue O
Na O
( O
+ O
) O
, O
K O
( O
+ O
) O
- O
ATPase O
activities O
observed O
in O
the O
ischaemic O
brains O
were O
also O
attenuated O
by O
honokiol B-Drug/Scientific name
treatments O
. O

It O
is O
concluded O
that O
honokiol B-Drug/Scientific name
can O
protect O
brain O
against O
ischaemic O
reperfusion O
injury O
and O
preserve O
mitochondrial O
function O
from O
oxidative O
stress O
. O

Regarding O
therapeutic O
application O
, O
further O
studies O
are O
needed O
to O
assess O
the O
efficacy O
and O
safety O
of O
honokiol B-Drug/Scientific name
in O
clinical O
situations O
. O

Introduction O
: O
Informal O
family O
caregivers O
( O
FCG O
) O
are O
an O
integral O
and O
crucial O
human O
component O
in O
the O
cancer B-participant_health
care I-participant_health
continuum O
. O

However O
, O
research O
and O
interventions O
to O
help O
alleviate O
documented O
anxiety B-Symptom_TestedFor
and O
burden O
on O
this O
group O
is O
lacking O
. O

To O
address O
the O
absence O
of O
effective O
interventions O
, O
we O
developed O
the O
electronic O
Support O
Network O
Assessment O
Program O
( O
eSNAP O
) O
which O
aims O
to O
automate O
the O
capture O
and O
visualization O
of O
social O
support O
, O
an O
important O
target O
for O
overall O
FCG O
support O
. O

This O
study O
seeks O
to O
describe O
the O
preliminary O
efficacy O
and O
outcomes O
of O
the O
eSNAP O
intervention O
. O

Methods O
: O
Forty O
FCGs O
were O
enrolled O
into O
a O
longitudinal O
, O
two-group O
randomized O
design O
to O
compare O
the O
eSNAP O
intervention O
in O
caregivers O
of O
patients O
with O
primary O
brain O
tumors O
against O
controls O
who O
did O
not O
receive O
the O
intervention O
. O

Participants O
were O
followed O
for O
six B-Duration
weeks I-Duration
with O
questionnaires O
to O
assess O
demographics O
, O
caregiver O
burden O
, O
anxiety O
, O
depression O
, O
and O
social O
support O
. O

Questionnaires O
given O
at O
baseline O
( O
T1 O
) O
and O
then O
3 O
- O
weeks O
( O
T2 O
) O
, O
and O
6 O
- O
weeks O
( O
T3 O
) O
post O
baseline O
questionnaire O
. O

Results O
: O
FCGs O
reported O
high O
caregiver O
burden O
and O
distress O
at O
baseline O
, O
with O
burden O
remaining O
stable O
over O
the O
course O
of O
the O
study O
. O

The O
intervention O
group O
was O
significantly O
less B-Symptom_WorkedFor
depressed I-Symptom_WorkedFor
, O
but O
anxiety B-Symptom_TestedFor
remained O
stable O
across O
groups O
. O

Conclusions O
: O
With O
the O
lessons O
learned O
and O
feedback O
obtained O
from O
FCGs O
, O
this O
study O
is O
the O
first O
step O
to O
developing O
an O
effective O
social O
support O
intervention O
to O
support O
FCGs O
and O
healthcare O
providers O
in O
improving O
cancer O
care O
. O

Dietary O
supplements O
are O
widely O
used O
for O
desired O
effects O
on O
memory O
, O
insomnia O
, O
mood O
and O
anxiety O
. O

This O
review O
focuses O
on O
supplements O
which O
have O
anxiolytic O
or O
mild O
relaxation O
properties O
and O
enhance O
mood O
. O

For O
example O
, O
Kava B-Medicinal food
( O
Piper B-Drug/Scientific name
methysticum I-Drug/Scientific name
) O
is O
reported O
to O
have O
anaxiolytic B-Symptom_WorkedFor
actions I-Symptom_WorkedFor
and O
to O
reduce O
tension O
through O
skeletal O
muscle B-Symptom_WorkedFor
relaxation I-Symptom_WorkedFor
. O

Dried B-Medicinal food
passion I-Medicinal food
flower I-Medicinal food
( O
genus B-Drug/Scientific name
Passiflora I-Drug/Scientific name
) O
is O
reported O
to O
reduce O
insomnia B-Symptom_WorkedFor
and O
hysteria B-Symptom_WorkedFor
. O

Skullcap B-Medicinal food
( O
genus B-Drug/Scientific name
Scutellaria I-Drug/Scientific name
) O
, O
hops B-Medicinal food
( O
Humulus B-Drug/Scientific name
lupulus I-Drug/Scientific name
) O
, O
lemon B-Medicinal food
balm I-Medicinal food
( O
Melissa B-Drug/Scientific name
officinalis I-Drug/Scientific name
) O
and O
Valerian B-Medicinal food
( O
Valeriana B-Drug/Scientific name
officinalis I-Drug/Scientific name
) O
root O
are O
all O
herbs O
reported O
as O
anaxiolytic B-Symptom_WorkedFor
calming I-Symptom_WorkedFor
agents O
. O

Further O
, O
extracts O
of O
Magnolia O
and O
Phellondendron O
bark O
are O
mild O
sedatives O
. O

Supplements O
such O
as O
gamma-aminobutyric B-Other_ingredients
acid I-Other_ingredients
( O
GABA O
) O
, O
theanine B-Other_ingredients
, O
tryptophan B-Other_ingredients
and O
5 B-Other_ingredients
- I-Other_ingredients
hydroxytryptophan I-Other_ingredients
( O
5 O
- O
HTP O
) O
are O
reported O
to O
promote O
relaxation O
. O

In O
general O
, O
these O
supplements O
appear O
to O
act O
as O
GABA O
receptor O
agonists O
or O
to O
boost O
GABA O
levels O
, O
although O
Kava B-Medicinal food
inhibits O
both O
norephinephrine O
uptake O
and O
sodium O
and O
potassium O
channels O
and O
5 O
- O
HTP O
may O
act O
through O
elevation O
of O
serotonin O
. O

While O
questions O
remain O
in O
the O
literature O
regarding O
the O
medicinal O
value O
of O
these O
supplements O
in O
treating O
mood O
and O
anxiety O
disorders O
, O
based O
on O
cellular O
and O
animal O
studies O
as O
well O
as O
human O
clinical O
trials O
the O
literature O
supports O
a O
role O
for O
these O
preparations O
as O
useful O
alternatives O
in O
the O
management O
of O
the O
stress B-Symptom_WorkedFor
and O
anxiety B-Symptom_WorkedFor
of O
everyday O
life O
. O

Background O
: O
Recent O
research O
has O
established O
correlations O
between O
stress O
, O
anxiety O
, O
insomnia O
and O
excess O
body O
weight O
and O
these O
correlations O
have O
significant O
implications O
for O
health O
. O

This O
study O
measured O
the O
effects O
of O
a O
proprietary O
blend O
of O
extracts O
of O
Magnolia B-Medicinal food
officinalis I-Medicinal food
and O
Phellodendron B-Other_ingredients
amurense I-Other_ingredients
( O
Relora B-Drug/Scientific name
) O
on O
anxiety B-Symptom_TestedFor
, O
stress B-Symptom_TestedFor
and O
sleep B-Symptom_TestedFor
in O
healthy O
premenopausal B-participant_health
women O
. O

Methods O
: O
This O
randomized O
, O
parallel O
, O
placebo O
controlled O
clinical O
study O
was O
conducted O
with O
healthy O
, O
overweight O
( O
BMI O
25 O
to O
34.9 O
) O
, O
premenopausal O
female O
adults O
, O
between O
the O
ages O
of O
20 O
and O
50 O
years O
, O
who O
typically O
eat O
more O
in O
response O
to O
stressful O
situations O
and O
scores O
above O
the O
national O
mean O
for O
women O
on O
self-reporting O
anxiety B-Symptom_TestedFor
. O

The O
intervention O
was O
Relora B-Drug/Scientific name
( O
250 B-Dosage
mg I-Dosage
capsules I-Dosage
) O
or O
identical O
placebo O
3 O
times O
daily O
for O
6 B-Duration
weeks I-Duration
. O

Anxiety B-Symptom_TestedFor
as O
measured O
by O
the O
Spielberger B-Metric
STATE-TRAIT I-Metric
questionnaires O
, O
salivary O
amylase O
and O
cortisol O
levels O
, O
Likert B-Metric
Scales I-Metric
/ I-Metric
Visual I-Metric
Analog I-Metric
Scores I-Metric
for O
sleep B-Symptom_TestedFor
quality O
and O
latency O
, O
appetite O
, O
and O
clinical O
markers O
of O
safety O
. O

The O
study O
was O
conducted O
by O
Miami O
Research O
Associates O
, O
a O
clinical O
research O
organization O
in O
Miami O
, O
FL O
. O

Results O
: O
The O
intent-to-treat O
population O
consisted O
of O
40 O
subjects O
with O
26 B-#Participants
participants O
completing O
the O
study O
. O

There O
were O
no O
significant O
adverse O
events O
. O

Relora B-Drug/Scientific name
was O
effective O
, O
in O
comparison O
to O
placebo O
, O
in O
reducing O
temporary O
, O
transitory B-Symptom_WorkedFor
anxiety I-Symptom_WorkedFor
as O
measured O
by O
the O
Spielberger B-Metric
STATE I-Metric
anxiety I-Metric
questionnaire I-Metric
. O

It O
was O
not O
effective O
in O
reducing O
long-standing O
feelings O
of O
anxiety O
or O
depression B-Symptom_TestedFor
as O
measured O
using O
the O
Spielberger B-Metric
TRAIT I-Metric
questionnaire I-Metric
. O

Other O
assessments O
conducted O
in O
this O
study O
including O
salivary O
cortisol O
and O
amylase O
levels O
, O
appetite O
, O
body O
morphology O
and O
sleep O
quality O
/ O
latency O
were O
not O
significantly O
changed O
by O
Relora B-Drug/Scientific name
in O
comparison O
to O
placebo O
. O

Conclusion O
: O
This O
pilot O
study O
indicates O
that O
Relora B-Drug/Scientific name
may O
offer O
some O
relief O
for O
premenopausal O
women O
experiencing O
mild O
transitory B-Symptom_WorkedFor
anxiety I-Symptom_WorkedFor
. O

There O
were O
no O
safety O
concerns O
or O
significant O
adverse O
events O
observed O
in O
this O
study O
. O

Background O
: O
Magnolia B-Medicinal food
( O
Magnolia B-Drug/Scientific name
officinalis I-Drug/Scientific name
) O
and O
Phellodendron B-Medicinal food
( O
Phellodendron B-Drug/Scientific name
amurense I-Drug/Scientific name
) O
barks O
are O
medicinal O
plants O
commonly O
used O
as O
traditional O
remedies O
for O
reducing O
stress B-Symptom_WorkedFor
and O
anxiety B-Symptom_WorkedFor
. O

Modern O
dietary O
supplements O
are O
intended O
to O
induce O
relaxation O
and O
reduce O
stress B-Symptom_WorkedFor
as O
well O
as O
stress-related B-Symptom_WorkedFor
eating I-Symptom_WorkedFor
. O

Previous O
studies O
have O
shown O
the O
combination O
of O
Magnolia B-Medicinal food
/ I-Medicinal food
Phellodendron I-Medicinal food
( O
MP O
) O
to O
reduce O
both O
cortisol O
exposure O
and O
the O
perception O
of O
stress O
/ O
anxiety O
, O
while O
improving O
weight B-Symptom_TestedFor
loss I-Symptom_TestedFor
in O
subjects O
with O
stress-related B-Symptom_TestedFor
eating I-Symptom_TestedFor
. O

Competitive O
athletes O
are O
" O
stressed O
" O
by O
their O
intense O
exercise O
regimens O
in O
addition O
to O
their O
normal O
activities O
of O
daily O
living O
and O
thus O
may O
benefit O
from O
a O
natural O
therapy O
intended O
to O
modulate O
baseline O
perceptions O
of O
stress B-Symptom_WorkedFor
and O
stress O
hormone O
exposure O
. O

Methods O
: O
We O
assessed O
salivary O
cortisol O
exposure O
and O
psychological O
mood O
state O
in O
56 B-#Participants
subjects O
( O
35 O
men O
and O
21 O
women O
) O
screened O
for O
moderate O
stress O
and O
supplemented O
with O
a O
standardized O
/ O
patented O
MP O
combination O
( O
Relora B-Drug/Scientific name
® I-Drug/Scientific name
, O
Next O
Pharmaceuticals O
) O
or O
Placebo O
for O
4 B-Duration
weeks I-Duration
. O

Results O
: O
After O
4 O
weeks O
of O
supplementation O
, O
salivary O
cortisol O
exposure O
was O
significantly O
( O
p O
< O
0.05 O
) O
lower O
( O
- O
18% O
) O
in O
the O
Relora B-Drug/Scientific name
group O
compared O
to O
Placebo O
. O

Compared O
to O
Placebo O
, O
the O
Relora B-Drug/Scientific name
group O
had O
significantly O
better O
( O
p O
< O
0.05 O
) O
mood O
state O
parameters O
, O
including O
lower O
indices O
of O
Overall O
Stress O
( O
- O
11% O
) O
, O
Tension O
( O
- O
13% O
) O
, O
Depression O
( O
- O
20% O
) O
, O
Anger O
( O
- O
42% O
) O
, O
Fatigue O
( O
- O
31% O
) O
, O
and O
Confusion O
( O
- O
27% O
) O
, O
and O
higher O
indices O
of O
Global O
Mood O
State O
( O
+ O
11% O
) O
and O
Vigor O
( O
+ O
18% O
) O
. O

Conclusion O
: O
These O
results O
indicate O
that O
daily O
supplementation O
with O
a O
combination O
of O
Magnolia B-Medicinal food
bark I-Medicinal food
extract I-Medicinal food
and O
Phellodendron B-Medicinal food
bark I-Medicinal food
extract I-Medicinal food
( O
Relora B-Drug/Scientific name
® O
) O
reduces O
cortisol O
exposure O
and O
perceived O
daily O
stress O
, O
while O
improving O
a O
variety O
of O
mood O
state O
parameters O
, O
including O
lower O
fatigue O
and O
higher O
vigor O
. O

These O
results O
suggest O
an O
effective O
natural O
approach O
to O
modulating O
the O
detrimental O
health O
effects O
of O
chronic O
stress O
in O
moderately O
stressed O
adults O
. O

Future O
studies O
should O
examine O
the O
possible O
performance O
and O
recovery O
benefits O
of O
Relora B-Drug/Scientific name
supplementation O
in O
athletes O
overstressed O
by O
the O
physical O
and O
psychological O
demands O
of O
training O
and O
competition O
. O

In O
traditional O
Asian O
medicinal O
systems O
, O
preparations O
of O
the O
root O
and O
stem O
bark O
of O
Magnolia B-Medicinal food
species O
are O
widely O
used O
to O
treat O
anxiety B-Symptom_WorkedFor
and O
other O
nervous O
disturbances O
. O

The O
biphenyl-type B-Drug/Scientific name
neolignans I-Drug/Scientific name
honokiol I-Drug/Scientific name
and O
magnolol B-Drug/Scientific name
are O
the O
main O
constituents O
of O
Magnolia O
bark O
extracts O
. O

In O
the O
central O
nervous O
system O
, O
Magnolia B-Medicinal food
bark O
preparations O
that O
contain O
honokiol B-Drug/Scientific name
are O
thought O
to O
primarily O
interact O
with O
γ-aminobutyric O
acid O
A O
( O
GABAA O
) O
receptors O
. O

However O
, O
stress B-Symptom_WorkedFor
responses O
inherently O
involve O
the O
noradrenergic O
system O
, O
which O
has O
not O
been O
investigated O
in O
the O
pharmacological O
mechanism O
of O
honokiol B-Drug/Scientific name
. O

We O
present O
here O
interactions O
of O
honokiol B-Drug/Scientific name
and O
other O
synthesized B-Other_ingredients
biphenyl-type I-Other_ingredients
neolignans I-Other_ingredients
and O
diphenylmethane B-Other_ingredients
analogs I-Other_ingredients
with O
the O
norepinephrine B-Other_ingredients
transporter I-Other_ingredients
( O
NET O
) O
, O
which O
is O
responsible O
for O
the O
synaptic O
clearance O
of O
norepinephrine O
and O
the O
target O
of O
many O
anxiolytics O
. O

Of O
the O
synthesized O
compounds O
, O
16 O
are O
new O
chemical O
entities O
, O
which O
are O
fully O
characterized O
. O

The O
52 O
compounds O
tested O
show O
mild O
, O
non-potent O
interactions O
with O
NET O
( O
IC50 O
> O
100 O
µM O
) O
. O

It O
is O
thus O
likely O
that O
the O
observed O
anxiolytic O
effects O
of O
, O
e.g O
. O
, O
Magnolia B-Medicinal food
preparations O
, O
are O
not O
due O
to O
direct O
interaction O
with O
the O
noradrenergic O
system O
. O

Most O
caregiving O
literature O
has O
focused O
on O
women O
, O
who O
have O
traditionally O
taken O
on O
caregiving O
roles O
. O

However O
, O
more O
research O
is O
needed O
to O
clarify O
the O
mixed O
evidence O
regarding O
the O
impact O
of O
gender O
on O
caregiver O
/ O
patient O
psychological O
outcomes O
, O
especially O
in O
an O
advanced O
cancer O
context O
. O

In O
this O
paper O
, O
we O
examine O
gender O
differences O
in O
caregiver O
stress B-Symptom_TestedFor
, O
burden B-Symptom_TestedFor
, O
anxiety B-Symptom_TestedFor
, O
depression B-Symptom_TestedFor
, O
and O
coping O
styles O
, O
as O
well O
as O
how O
caregiver O
gender O
impacts O
patient O
outcomes O
in O
the O
context O
of O
advanced O
cancer B-participant_health
. O

Eighty-eight B-#Participants
patients O
with O
advanced O
cancer B-participant_health
and O
their O
caregivers O
completed O
psychosocial O
surveys O
. O

All O
couples O
were O
heterosexual O
and O
most O
caregivers O
were O
women O
( O
71.6% O
) O
. O

Female O
caregivers O
reported O
significantly O
higher O
levels O
of O
perceived O
stress O
, O
depression O
, O
anxiety O
, O
and O
social O
strain O
compared O
with O
male O
caregivers O
, O
and O
female O
patients O
of O
male O
caregivers O
were O
more O
likely O
to O
use O
social O
support O
as O
a O
coping O
style O
compared O
with O
male O
patients O
of O
female O
caregivers O
. O

These O
findings O
highlight O
the O
potential O
differences O
between O
male O
and O
female O
caregivers O
' O
needs O
and O
psychological O
health O
. O

Research O
in O
the O
area O
of O
herbal O
psychopharmacology O
has O
revealed O
a O
variety O
of O
promising O
medicines O
that O
may O
provide O
benefit O
in O
the O
treatment O
of O
general O
anxiety B-Symptom_TestedFor
and O
specific O
anxiety B-Symptom_TestedFor
disorders I-Symptom_TestedFor
. O

However O
, O
a O
comprehensive O
review O
of O
plant-based O
anxiolytics O
has O
been O
absent O
to O
date O
. O

Thus O
, O
our O
aim O
was O
to O
provide O
a O
comprehensive O
narrative O
review O
of O
plant-based O
medicines O
that O
have O
clinical O
and O
/ O
or O
preclinical O
evidence O
of O
anxiolytic B-Symptom_TestedFor
activity I-Symptom_TestedFor
. O

We O
present O
the O
article O
in O
two O
parts O
. O

In O
part O
one O
, O
we O
reviewed O
herbal O
medicines O
for O
which O
only O
preclinical O
investigations O
for O
anxiolytic B-Symptom_TestedFor
activity I-Symptom_TestedFor
have O
been O
performed O
. O

In O
this O
current O
article O
( O
part O
two O
) O
, O
we O
review O
herbal O
medicines O
for O
which O
there O
have O
been O
both O
preclinical O
and O
clinical O
investigations O
of O
anxiolytic O
activity O
. O

A O
search O
of O
MEDLINE O
( O
PubMed O
) O
, O
CINAHL O
, O
Scopus O
and O
the O
Cochrane O
Library O
databases O
was O
conducted O
( O
up O
to O
28 O
October O
2012 O
) O
for O
English O
language O
papers O
using O
the O
search O
terms O
' O
anxiety O
' O
OR O
' O
anxiety O
disorder O
' O
OR O
' O
generalized O
anxiety O
disorder O
' O
OR O
' O
social O
phobia O
' O
OR O
' O
post-traumatic O
stress O
disorder O
' O
OR O
' O
panic O
disorder O
' O
OR O
' O
agoraphobia O
' O
OR O
' O
obsessive O
compulsive O
disorder O
' O
in O
combination O
with O
the O
search O
terms O
' O
Herb O
* O
' O
OR O
' O
Medicinal O
Plants O
' O
OR O
' O
Botanical O
Medicine O
' O
OR O
' O
Chinese O
herb O
* O
' O
, O
in O
addition O
to O
individual O
herbal O
medicines O
. O

This O
search O
of O
the O
literature O
revealed O
1,525 O
papers O
, O
of O
which O
53 O
plants O
were O
included O
in O
the O
review O
( O
having O
at O
least O
one O
study O
using O
the O
whole O
plant O
extract O
) O
. O

Of O
these O
plants O
, O
21 O
had O
human O
clinical O
trial O
evidence O
( O
reviewed O
here O
in O
part O
two O
) O
, O
with O
the O
other O
32 O
having O
solely O
preclinical O
evidence O
( O
reviewed O
in O
part O
one O
) O
. O

Support O
for O
efficacy O
was O
found O
for O
chronic O
use O
( O
i.e O
. O
greater O
than O
one O
day O
) O
of O
the O
following O
herbs O
in O
treating O
a O
range O
of O
anxiety O
disorders O
in O
human O
clinical O
trials O
: O
Piper O
methysticum O
, O
Matricaria O
recutita O
, O
Ginkgo O
biloba O
, O
Scutellaria O
lateriflora O
, O
Silybum O
marianum O
, O
Passiflora O
incarnata O
, O
Withania O
somniferum O
, O
Galphimia O
glauca O
, O
Centella O
asiatica O
, O
Rhodiola O
rosea O
, O
Echinacea O
spp O
. O
, O
Melissa O
officinalis O
and O
Echium O
amoenum O
. O

For O
several O
of O
the O
plants O
studied O
, O
conclusions O
need O
to O
be O
tempered O
due O
to O
methodological O
issues O
such O
as O
small O
sample O
sizes O
, O
brief O
intervention O
durations O
and O
non-replication O
. O

Current O
evidence O
does O
not O
support O
Hypericum O
perforatum O
or O
Valeriana O
spp O
. O
for O
any O
anxiety B-Symptom_WorkedFor
disorder O
. O

Acute O
anxiolytic O
activity O
was O
found O
for O
Centella B-Medicinal food
asiatica I-Medicinal food
, O
Salvia B-Medicinal food
spp I-Medicinal food
. O
, O
Melissa B-Medicinal food
officinalis I-Medicinal food
, O
Passiflora B-Medicinal food
incarnata I-Medicinal food
and O
Citrus B-Medicinal food
aurantium I-Medicinal food
. O

Bacopa O
monnieri O
has O
shown O
anxiolytic O
effects O
in O
people O
with O
cognitive O
decline O
. O

The O
therapeutic O
application O
of O
psychotropic O
plant-based O
treatments O
for O
anxiety B-Symptom_WorkedFor
disorders O
is O
also O
discussed O
, O
specifically O
Psychotria B-Medicinal food
viridis I-Medicinal food
and O
Banisteriopsis B-Medicinal food
caarti I-Medicinal food
( O
ayahuasca B-Medicinal food
) O
, O
Psilocybe B-Medicinal food
spp I-Medicinal food
. O
and O
cannabidiol-enriched B-Medicinal food
( O
low O
tetrahydrocannabinol O
( O
Δ O
( O
9 O
) O
- O
THC O
) O
) O
Cannabis O
spp O
. O

Stress B-Symptom_TestedFor
is O
an O
increasing O
problem O
that O
can O
result O
in O
various O
psychiatric O
and O
somatoform O
symptoms O
. O

Among O
others O
, O
benzodiazepines O
and O
valerian O
preparations O
are O
used O
to O
treat O
stress B-Symptom_TestedFor
symptoms O
. O

The O
aim O
of O
this O
study O
was O
to O
investigate O
whether O
the O
prescription O
of O
a O
fixed O
herbal O
extract O
combination O
of O
valerian B-Medicinal food
, O
lemon B-Medicinal food
balm I-Medicinal food
, O
passionflower B-Medicinal food
, O
and O
butterbur B-Medicinal food
( O
Ze B-Drug/Scientific name
185 I-Drug/Scientific name
) O
changes O
the O
prescription O
pattern O
of O
benzodiazepines B-Other_ingredients
in O
hospitalized O
psychiatric B-participant_health
patients O
. O

In O
a O
retrospective O
case-control O
study O
, O
anonymized O
medical O
record O
data O
from O
3,252 B-#Participants
psychiatric B-participant_health
in-house O
patients O
were O
analysed O
over O
a O
3.5 B-Duration
- I-Duration
year I-Duration
period O
. O

Cases O
( O
n O
= O
1,548 O
) O
with O
a O
prescription O
of O
Ze B-Drug/Scientific name
185 I-Drug/Scientific name
and O
controls O
( O
n O
= O
1,704 O
) O
were O
matched O
by O
age O
, O
gender O
, O
hospitalization O
interval O
, O
and O
main O
International B-Metric
Classification I-Metric
of I-Metric
Diseases I-Metric
, I-Metric
Version I-Metric
10 I-Metric
F-diagnoses I-Metric
. O

The O
primary O
objective O
was O
to O
investigate O
the O
effect O
of O
Ze B-Drug/Scientific name
185 I-Drug/Scientific name
on O
the O
prescription O
pattern O
of O
benzodiazepines B-Other_ingredients
. O

Secondary O
objectives O
investigated O
the O
prescriptions O
of O
concomitant O
drugs O
and O
effectiveness O
of O
the O
hospital O
stay O
. O

Distribution O
of O
drug O
classes O
was O
analysed O
using O
the O
WHO's O
anatomic-therapeutic-chemical O
code O
. O

Data O
showed O
that O
both O
treatment O
modalities O
had O
a O
comparable O
clinical O
effectiveness O
but O
with O
significantly O
less O
prescriptions O
of O
benzodiazepines B-Other_ingredients
in O
the O
Ze B-Drug/Scientific name
185 I-Drug/Scientific name
group O
( O
p O
= O
.006 O
) O
. O

This O
is O
of O
clinical O
importance O
because O
suitable O
alternatives O
to O
benzodiazepines O
are O
desirable O
. O

To O
obtain O
more O
support O
for O
this O
hypothesis O
, O
a O
dedicated O
randomized O
, O
controlled O
clinical O
trial O
monitoring O
drug O
safety O
is O
required O
. O

Background O
: O
Anxiety B-Symptom_TestedFor
is O
a O
very O
common O
mental O
health O
problem O
in O
the O
general O
population O
and O
in O
the O
primary O
care O
setting O
. O

Herbal O
medicines O
are O
popularly O
used O
worldwide O
and O
could O
be O
an O
option O
for O
treating O
anxiety B-Symptom_TestedFor
if O
shown O
to O
be O
effective O
and O
safe O
. O

Passiflora B-Medicinal food
( O
passionflower B-Medicinal food
extract I-Medicinal food
) O
is O
one O
of O
these O
compounds O
. O

Objectives O
: O
To O
investigate O
the O
effectiveness O
and O
safety O
of O
passiflora B-Medicinal food
for O
treating O
any O
anxiety B-Symptom_TestedFor
disorder O
. O

Search O
strategy O
: O
The O
following O
sources O
were O
used O
: O
electronic O
databases O
: O
Cochrane O
Collaboration O
Depression O
, O
Anxiety O
and O
Neurosis O
Cochrane O
Controlled O
Trials O
Register O
( O
CCDANCTR-Studies O
) O
, O
Medline O
and O
Lilacs O
; O
Cross-checking O
references O
; O
contact O
with O
authors O
of O
included O
studies O
and O
manufacturers O
of O
passiflora B-Medicinal food
. O

Selection O
criteria O
: O
Relevant O
randomised O
and O
quasi-randomised O
controlled O
trials O
of O
passiflora B-Medicinal food
using O
any O
dose O
, O
regime O
, O
or O
method O
of O
administration O
for O
people O
with O
any O
primary O
diagnosis O
of O
general O
anxiety O
disorder O
, O
anxiety O
neurosis O
, O
chronic O
anxiety O
status O
or O
any O
other O
mental O
health O
disorder O
in O
which O
anxiety B-Symptom_TestedFor
is O
a O
core O
symptom O
( O
panic O
disorder O
, O
obsessive O
compulsive O
disorder O
, O
social O
phobia O
, O
agoraphobia O
, O
other O
types O
of O
phobia O
, O
postraumatic O
stress O
disorder O
) O
. O

Effectiveness O
was O
measured O
using O
clinical O
outcome O
measures O
such O
as O
Hamilton B-Metric
Anxiety I-Metric
Scale I-Metric
( I-Metric
HAM-A I-Metric
) O
and O
other O
scales O
for O
anxiety O
symptoms O
. O

Data O
collection O
and O
analysis O
: O
Two O
reviewers O
independently O
selected O
the O
trials O
found O
through O
the O
search O
strategy O
, O
extracted O
data O
, O
performed O
the O
trial O
quality O
analyses O
and O
entered O
data O
. O

Where O
any O
disagreements O
occured O
, O
the O
third O
reviewer O
was O
consulted O
. O

Methodological O
quality O
of O
the O
trials O
included O
in O
this O
review O
was O
assessed O
using O
the O
criteria O
described O
in O
the O
Cochrane O
Handbook O
. O

For O
dichotomous O
outcomes O
, O
relative O
risk O
with O
95% O
confidence O
intervals O
( O
CI O
) O
were O
calculated O
, O
and O
for O
continuous O
outcomes O
, O
weighted O
mean O
difference O
with O
95% O
CI O
was O
used O
. O

Main O
results O
: O
Two O
studies O
, O
with O
a O
total O
of O
198 B-#Participants
participants O
, O
were O
eligible O
for O
inclusion O
in O
this O
review O
. O

Based O
on O
one O
study O
, O
a O
lack O
of O
difference O
in O
the O
efficacy O
of O
benzodiazepines O
and O
passiflora O
was O
indicated O
. O

Dropout O
rates O
were O
similar O
between O
the O
two O
interventions O
. O

Although O
the O
findings O
from O
one O
study O
suggested O
an O
improvement O
in O
job O
performance O
in O
favour O
of O
passiflora B-Medicinal food
( O
post-hoc O
outcome O
) O
and O
one O
study O
showed O
a O
lower O
rate O
of O
drowsiness O
as O
a O
side O
effect O
with O
passiflora O
as O
compared O
with O
mexazolam O
, O
neither O
of O
these O
findings O
reached O
statistical O
significance O
. O

Authors O
' O
conclusions O
: O
RCTs O
examining O
the O
effectiveness O
of O
passiflora O
for O
anxiety O
are O
too O
few O
in O
number O
to O
permit O
any O
conclusions O
to O
be O
drawn O
. O

RCTs O
with O
larger O
samples O
that O
compare O
the O
effectiveness O
of O
passiflora B-Medicinal food
with O
placebo O
and O
other O
types O
of O
medication O
, O
including O
antidepressants B-Symptom_TestedFor
, O
are O
needed O
. O

Dietary O
supplements O
are O
widely O
used O
for O
desired O
effects O
on O
memory B-Symptom_WorkedFor
, O
insomnia B-Symptom_WorkedFor
, O
mood B-Symptom_WorkedFor
and O
anxiety B-Symptom_WorkedFor
. O

This O
review O
focuses O
on O
supplements O
which O
have O
anxiolytic O
or O
mild O
relaxation O
properties O
and O
enhance O
mood O
. O

For O
example O
, O
Kava B-Medicinal food
( O
Piper B-Drug/Scientific name
methysticum I-Drug/Scientific name
) O
is O
reported O
to O
have O
anaxiolytic O
actions O
and O
to O
reduce O
tension O
through O
skeletal O
muscle B-Symptom_WorkedFor
relaxation I-Symptom_WorkedFor
. O

Dried B-Medicinal food
passion I-Medicinal food
flower I-Medicinal food
( O
genus B-Drug/Scientific name
Passiflora I-Drug/Scientific name
) O
is O
reported O
to O
reduce O
insomnia B-Symptom_WorkedFor
and O
hysteria B-Symptom_WorkedFor
. O

Skullcap B-Medicinal food
( O
genus B-Drug/Scientific name
Scutellaria I-Drug/Scientific name
) O
, O
hops B-Medicinal food
( O
Humulus B-Drug/Scientific name
lupulus I-Drug/Scientific name
) O
, O
lemon B-Medicinal food
balm I-Medicinal food
( O
Melissa B-Drug/Scientific name
officinalis I-Drug/Scientific name
) O
and O
Valerian B-Medicinal food
( O
Valeriana B-Drug/Scientific name
officinalis I-Drug/Scientific name
) O
root O
are O
all O
herbs O
reported O
as O
anaxiolytic B-Symptom_WorkedFor
calming I-Symptom_WorkedFor
agents O
. O

Further O
, O
extracts O
of O
Magnolia O
and O
Phellondendron O
bark O
are O
mild O
sedatives O
. O

Supplements O
such O
as O
gamma-aminobutyric B-Other_ingredients
acid I-Other_ingredients
( O
GABA O
) O
, O
theanine B-Other_ingredients
, O
tryptophan B-Other_ingredients
and O
5 B-Other_ingredients
- I-Other_ingredients
hydroxytryptophan I-Other_ingredients
( O
5 O
- O
HTP O
) O
are O
reported O
to O
promote O
relaxation O
. O

In O
general O
, O
these O
supplements O
appear O
to O
act O
as O
GABA O
receptor O
agonists O
or O
to O
boost O
GABA O
levels O
, O
although O
Kava B-Medicinal food
inhibits O
both O
norephinephrine O
uptake O
and O
sodium O
and O
potassium O
channels O
and O
5 O
- O
HTP O
may O
act O
through O
elevation O
of O
serotonin O
. O

While O
questions O
remain O
in O
the O
literature O
regarding O
the O
medicinal O
value O
of O
these O
supplements O
in O
treating O
mood O
and O
anxiety B-Symptom_WorkedFor
disorders O
, O
based O
on O
cellular O
and O
animal O
studies O
as O
well O
as O
human O
clinical O
trials O
the O
literature O
supports O
a O
role O
for O
these O
preparations O
as O
useful O
alternatives O
in O
the O
management O
of O
the O
stress B-Symptom_WorkedFor
and O
anxiety B-Symptom_WorkedFor
of O
everyday O
life O
. O

Anxiety B-Symptom_TestedFor
disorders O
are O
chronic O
and O
functionally O
disabling O
conditions O
with O
high O
psychological O
stress O
, O
characterised O
by O
cognitive O
symptoms O
of O
excessive O
worry O
and O
focus O
difficulties O
and O
physiological O
symptoms O
such O
as O
muscle B-Symptom_TestedFor
tension I-Symptom_TestedFor
and O
insomnia B-Symptom_TestedFor
. O

Gamma-aminobutyric O
acid O
( O
GABA O
) O
is O
an O
inhibitory O
neurotransmitter O
within O
the O
central O
nervous O
system O
and O
is O
a O
key O
target O
of O
pharmacotherapies O
in O
the O
treatment O
of O
anxiety B-Symptom_TestedFor
. O

Although O
current O
pharmaceutical O
treatments O
are O
often O
efficacious O
, O
they O
may O
cause O
undesirable O
side O
effects O
including O
cognitive O
decrements O
and O
withdrawal O
symptoms O
. O

Plant-based O
" O
phytomedicines O
" O
may O
provide O
novel O
treatment O
options O
, O
to O
act O
as O
an O
adjunctive O
or O
alternative O
to O
existing O
anxiolytic O
medications O
. O

As O
such O
, O
we O
conducted O
a O
systematic O
review O
to O
assess O
the O
current O
body O
of O
literature O
on O
anxiolytic O
phytomedicines O
and O
/ O
or O
phytoconstituents O
. O

An O
open-ended O
search O
to O
5 O
July O
2017 O
was O
conducted O
using O
MEDLINE O
( O
PubMed O
) O
, O
Scopus O
, O
and O
Cochrane O
library O
online O
databases O
and O
performed O
in O
a O
stepped O
format O
from O
preclinical O
to O
clinical O
investigations O
. O

Eligible O
studies O
must O
have O
had O
( O
a O
) O
in O
vitro O
evidence O
of O
GABA-modulating O
activity O
, O
( O
b O
) O
animal O
studies O
using O
anxiety O
models O
to O
test O
an O
anxiolytic O
effect O
, O
and O
( O
c O
) O
human O
clinical O
trials O
. O

Ten O
phytomedicines O
were O
identified O
as O
having O
preclinical O
investigations O
showing O
interaction O
with O
the O
GABA O
system O
, O
in O
addition O
to O
human O
clinical O
trials O
: O
kava B-Medicinal food
, O
valerian B-Medicinal food
, O
pennywort B-Medicinal food
, O
hops B-Medicinal food
, O
chamomile B-Medicinal food
, O
Ginkgo B-Medicinal food
biloba I-Medicinal food
, O
passionflower B-Medicinal food
, O
ashwagandha B-Medicinal food
, O
skullcap B-Medicinal food
, O
and O
lemon B-Medicinal food
balm I-Medicinal food
. O

Collectively O
, O
the O
literature O
reveals O
preclinical O
and O
clinical O
evidence O
for O
various O
phytomedicines O
modulating O
GABA-pathways O
, O
with O
comparative O
anxiolytic O
effect O
to O
the O
current O
array O
of O
pharmaceuticals O
, O
along O
with O
good O
safety O
and O
tolerability O
profiles O
. O

Background O
: O
Considering O
the O
negative O
effects O
of O
stress B-Symptom_TestedFor
on O
health O
, O
there O
is O
a O
growing O
interest O
in O
stress-reducing O
interventions O
. O

The O
present O
study O
examines O
the O
effects O
of O
a O
fixed O
combination O
of O
valerian B-Medicinal food
, O
passion B-Medicinal food
flower I-Medicinal food
, O
lemon B-Medicinal food
balm I-Medicinal food
, O
and O
butterbur B-Medicinal food
extracts O
( O
Ze B-Drug/Scientific name
185 I-Drug/Scientific name
) O
on O
biological O
and O
affective O
responses O
to O
a O
standardized O
psychosocial O
stress B-Symptom_TestedFor
paradigm O
. O

Purpose O
: O
The O
aim O
of O
the O
present O
study O
was O
to O
investigate O
the O
efficacy O
of O
Ze B-Drug/Scientific name
185 I-Drug/Scientific name
on O
cortisol O
and O
anxiety B-Symptom_WorkedFor
stress B-Symptom_TestedFor
responses O
to O
acute O
psychosocial O
stress O
in O
healthy O
subjects O
. O

Study O
design O
: O
This O
study O
was O
a O
randomized O
, O
placebo-controlled O
, O
double O
blind O
study O
with O
3 O
parallel O
groups O
. O

Methods O
: O
72 B-#Participants
healthy O
male O
participants O
were O
randomized O
to O
3 O
groups O
( O
Ze O
185 O
, O
placebo O
or O
no O
treatment O
) O
during O
4 O
days O
prior O
to O
a O
standardized O
psychosocial O
stress B-Symptom_TestedFor
paradigm O
. O

Principle O
outcomes O
were O
salivary O
cortisol O
and O
self-reported O
anxiety B-Symptom_WorkedFor
responses O
to O
stress O
assessed O
at O
the O
fourth O
day O
. O

Results O
: O
The O
stress O
paradigm O
induced O
significant O
and O
large O
cortisol O
and O
self-reported O
anxiety O
responses O
. O

Groups O
did O
not O
differ O
significantly O
in O
their O
salivary O
cortisol O
response O
to O
stress O
, O
but O
participants O
in O
the O
Ze B-Drug/Scientific name
185 I-Drug/Scientific name
condition O
showed O
significantly O
attenuated O
responses O
in O
self-reported O
anxiety B-Symptom_WorkedFor
in O
comparison O
to O
placebo O
( O
F O
( O
3 O
, O
41 O
) O
= O
3.33 O
, O
p O
= O
0.03 O
) O
and O
no O
treatment O
( O
F O
( O
3 O
, O
43 O
) O
= O
2.77 O
, O
p O
= O
0.05 O
) O
. O

Conclusion O
: O
The O
results O
show O
that O
Ze B-Drug/Scientific name
185 I-Drug/Scientific name
significantly O
attenuated O
the O
subjective O
emotional O
stress O
response O
during O
an O
acute O
stress O
situation O
, O
without O
affecting O
biological O
stress O
responses O
. O

Given O
that O
a O
circumscribed O
biological O
stress O
response O
is O
to O
be O
considered O
as O
an O
adaptive O
mechanism O
, O
Ze B-Drug/Scientific name
185 I-Drug/Scientific name
reduces O
self-reported O
anxiety B-Symptom_WorkedFor
response O
to O
stress O
without O
affecting O
assumingly O
adaptive O
biological O
stress O
responses O
. O

Passiflora B-Drug/Scientific name
incarnata I-Drug/Scientific name
L I-Drug/Scientific name
. O
has O
been O
used O
as O
a O
medicinal O
plant O
in O
South O
America O
and O
Europe O
since O
the O
16th O
century O
. O

Previous O
pharmacological O
studies O
focused O
mainly O
on O
the O
plant's O
sedative O
, O
anxiolytic B-Symptom_TestedFor
, O
and O
anticonvulsant O
effects O
on O
the O
central O
nervous O
system O
and O
its O
supporting O
role O
in O
the O
treatment O
of O
addiction B-Symptom_TestedFor
. O

The O
aim O
of O
the O
present O
study O
was O
to O
evaluate O
the O
behavioral O
and O
neurochemical O
effects O
of O
long-term O
oral O
administration O
of O
P B-Medicinal food
. I-Medicinal food
incarnata I-Medicinal food
. O

The O
passionflower B-Medicinal food
extract I-Medicinal food
( O
30 O
, O
100 O
, O
or O
300 O
mg O
/ O
kg O
body O
weight O
/ O
day O
) O
was O
given O
to O
4 O
- O
week-old O
male O
Wistar O
rats O
via O
their O
drinking O
water O
. O

Tests O
were O
conducted O
after O
7 B-Duration
weeks I-Duration
of O
treatment O
. O

Spatial O
memory O
was O
assessed O
in O
a O
water O
maze O
, O
and O
the O
levels O
of O
amino O
acids O
, O
monoamines O
, O
and O
their O
metabolites O
were O
evaluated O
in O
select O
brain O
regions O
by O
high B-Metric
performance I-Metric
liquid I-Metric
chromatography I-Metric
( O
HPLC O
) O
. O

We O
observed O
reduced O
anxiety B-Symptom_WorkedFor
and O
dose-dependent O
improvement O
of O
memory B-Symptom_WorkedFor
in O
rats O
given O
passionflower B-Medicinal food
compared O
to O
the O
control O
group O
. O

In O
addition O
, O
hippocampal O
glutamic O
acid O
and O
cortical O
serotonin O
content O
were O
depleted O
, O
with O
increased O
levels O
of O
metabolites O
and O
increased O
turnover O
. O

Thus O
, O
our O
results O
partially O
confirmed O
the O
proposed O
mechanism O
of O
action O
of O
P O
. O
incarnata O
involving O
GABAA O
receptors O
. O

Copyright O
© O
2016 O
John O
Wiley O
& O
Sons O
, O
Ltd O
. O

Several O
Passiflora B-Medicinal food
species O
have O
been O
used O
widely O
as O
a O
folk O
medicine O
due O
to O
their O
sedative B-Symptom_WorkedFor
and O
anxiolytic B-Symptom_WorkedFor
activities O
. O

In O
Brazil O
, O
a O
number O
of O
native O
plants O
of O
the O
genus B-Medicinal food
Passiflora I-Medicinal food
exist O
, O
but O
only O
Passiflora B-Drug/Scientific name
edulis I-Drug/Scientific name
f I-Drug/Scientific name
. I-Drug/Scientific name
flavicarpa I-Drug/Scientific name
( O
PE O
) O
and O
Passiflora B-Drug/Scientific name
alata I-Drug/Scientific name
( O
PA O
) O
are O
of O
commercial O
value O
. O

Thus O
, O
the O
aim O
of O
the O
present O
study O
was O
to O
investigate O
the O
sedative B-Symptom_TestedFor
effects O
of O
aqueous O
extracts O
obtained O
from O
the O
pericarp O
as O
well O
as O
from O
the O
leaves O
of O
PE O
and O
PA O
in O
mice O
using O
radiotelemetry O
. O

Aqueous O
extracts O
from O
PE O
and O
PA O
were O
tested O
for O
effects O
on O
locomotion O
over O
180 O
min O
in O
300 O
mg O
/ O
kg O
, O
600 O
mg O
/ O
kg O
and O
1200 O
mg O
/ O
kg O
, O
in O
male O
C57BL O
/ O
6J O
mice O
after O
oral O
administration O
. O

For O
validation O
of O
the O
telemetry O
system O
, O
caffeine B-Other_ingredients
( O
negative O
control O
) O
and O
midazolam B-Other_ingredients
( O
positive O
control O
) O
were O
used O
. O

All O
tested O
extracts O
decreased O
locomotor O
activity O
in O
a O
dose-dependent O
manner O
in O
comparison O
to O
the O
control O
group O
. O

The O
two O
lower O
concentrations O
of O
each O
extract O
showed O
the O
highest O
decrease O
in O
locomotion O
after O
24 O
min O
, O
while O
1200 O
mg O
/ O
kg O
had O
a O
significant O
sedative O
effect O
already O
after O
18 O
min O
. O

Interestingly O
, O
aqueous O
extracts O
of O
PA O
were O
more O
active O
in O
comparison O
to O
aqueous O
extracts O
of O
PE O
and O
the O
pericarp O
extracts O
of O
both O
plants O
showed O
more O
pronounced O
effects O
on O
locomotor O
activity O
if O
compared O
to O
leaf O
extracts O
. O

In O
conclusion O
, O
the O
present O
study O
represents O
an O
innovative O
, O
objective O
approach O
to O
measure O
sedative O
effects O
of O
plant O
extracts O
with O
minimized O
handling-related O
stress O
and O
remote O
data O
collection O
. O

Research O
in O
the O
area O
of O
herbal O
psychopharmacology O
has O
revealed O
a O
variety O
of O
promising O
medicines O
that O
may O
provide O
benefit O
in O
the O
treatment O
of O
general O
anxiety O
and O
specific O
anxiety O
disorders O
. O

However O
, O
a O
comprehensive O
review O
of O
plant-based O
anxiolytics O
has O
been O
absent O
to O
date O
. O

Thus O
, O
our O
aim O
was O
to O
provide O
a O
comprehensive O
narrative O
review O
of O
plant-based O
medicines O
that O
have O
clinical O
and O
/ O
or O
preclinical O
evidence O
of O
anxiolytic O
activity O
. O

We O
present O
the O
article O
in O
two O
parts O
. O

In O
part O
one O
, O
we O
reviewed O
herbal O
medicines O
for O
which O
only O
preclinical O
investigations O
for O
anxiolytic O
activity O
have O
been O
performed O
. O

In O
this O
current O
article O
( O
part O
two O
) O
, O
we O
review O
herbal O
medicines O
for O
which O
there O
have O
been O
both O
preclinical O
and O
clinical O
investigations O
of O
anxiolytic O
activity O
. O

A O
search O
of O
MEDLINE O
( O
PubMed O
) O
, O
CINAHL O
, O
Scopus O
and O
the O
Cochrane O
Library O
databases O
was O
conducted O
( O
up O
to O
28 O
October O
2012 O
) O
for O
English O
language O
papers O
using O
the O
search O
terms O
' O
anxiety O
' O
OR O
' O
anxiety O
disorder O
' O
OR O
' O
generalized O
anxiety O
disorder O
' O
OR O
' O
social O
phobia O
' O
OR O
' O
post-traumatic O
stress O
disorder O
' O
OR O
' O
panic O
disorder O
' O
OR O
' O
agoraphobia O
' O
OR O
' O
obsessive O
compulsive O
disorder O
' O
in O
combination O
with O
the O
search O
terms O
' O
Herb O
* O
' O
OR O
' O
Medicinal O
Plants O
' O
OR O
' O
Botanical O
Medicine O
' O
OR O
' O
Chinese O
herb O
* O
' O
, O
in O
addition O
to O
individual O
herbal O
medicines O
. O

This O
search O
of O
the O
literature O
revealed O
1,525 O
papers O
, O
of O
which O
53 O
plants O
were O
included O
in O
the O
review O
( O
having O
at O
least O
one O
study O
using O
the O
whole O
plant O
extract O
) O
. O

Of O
these O
plants O
, O
21 O
had O
human O
clinical O
trial O
evidence O
( O
reviewed O
here O
in O
part O
two O
) O
, O
with O
the O
other O
32 O
having O
solely O
preclinical O
evidence O
( O
reviewed O
in O
part O
one O
) O
. O

Support O
for O
efficacy O
was O
found O
for O
chronic O
use O
( O
i.e O
. O
greater O
than O
one O
day O
) O
of O
the O
following O
herbs O
in O
treating O
a O
range O
of O
anxiety B-Symptom_WorkedFor
disorders O
in O
human O
clinical O
trials O
: O
Piper B-Medicinal food
methysticum I-Medicinal food
, O
Matricaria B-Medicinal food
recutita I-Medicinal food
, O
Ginkgo B-Medicinal food
biloba I-Medicinal food
, O
Scutellaria B-Medicinal food
lateriflora I-Medicinal food
, O
Silybum B-Medicinal food
marianum I-Medicinal food
, O
Passiflora B-Medicinal food
incarnata I-Medicinal food
, O
Withania B-Medicinal food
somniferum I-Medicinal food
, O
Galphimia B-Medicinal food
glauca I-Medicinal food
, O
Centella B-Medicinal food
asiatica I-Medicinal food
, O
Rhodiola B-Medicinal food
rosea I-Medicinal food
, O
Echinacea B-Medicinal food
spp I-Medicinal food
. O
, O
Melissa B-Medicinal food
officinalis I-Medicinal food
and O
Echium B-Medicinal food
amoenum I-Medicinal food
. O

For O
several O
of O
the O
plants O
studied O
, O
conclusions O
need O
to O
be O
tempered O
due O
to O
methodological O
issues O
such O
as O
small O
sample O
sizes O
, O
brief O
intervention O
durations O
and O
non-replication O
. O

Current O
evidence O
does O
not O
support O
Hypericum B-Medicinal food
perforatum I-Medicinal food
or O
Valeriana B-Medicinal food
spp I-Medicinal food
. I-Medicinal food
for O
any O
anxiety B-Symptom_WorkedFor
disorder O
. O

Acute O
anxiolytic O
activity O
was O
found O
for O
Centella B-Medicinal food
asiatica I-Medicinal food
, O
Salvia B-Medicinal food
spp I-Medicinal food
. I-Medicinal food
, O
Melissa B-Medicinal food
officinalis I-Medicinal food
, O
Passiflora B-Medicinal food
incarnata I-Medicinal food
and O
Citrus B-Medicinal food
aurantium I-Medicinal food
. O

Bacopa B-Medicinal food
monnieri I-Medicinal food
has O
shown O
anxiolytic O
effects O
in O
people O
with O
cognitive O
decline O
. O

The O
therapeutic O
application O
of O
psychotropic O
plant-based O
treatments O
for O
anxiety B-Symptom_WorkedFor
disorders O
is O
also O
discussed O
, O
specifically O
Psychotria B-Medicinal food
viridis I-Medicinal food
and O
Banisteriopsis B-Medicinal food
caarti I-Medicinal food
( O
ayahuasca B-Medicinal food
) O
, O
Psilocybe B-Medicinal food
spp I-Medicinal food
. O
and O
cannabidiol-enriched O
( O
low O
tetrahydrocannabinol O
( O
Δ O
( O
9 O
) O
- O
THC O
) O
) O
Cannabis B-Medicinal food
spp I-Medicinal food
. O

Objective O
: O
The O
aim O
of O
this O
study O
is O
to O
investigate O
the O
effects O
of O
rhodiola B-Medicinal food
rosea I-Medicinal food
on O
oxidative O
stress B-Symptom_WorkedFor
, O
anxiety B-Symptom_WorkedFor
and O
depression B-Symptom_WorkedFor
in O
patients O
with O
OSA B-participant_health
. O

Method O
: O
Ninety B-#Participants
patients O
with O
moderate O
and O
severe O
OSA B-participant_health
patients O
with O
negative O
emotions O
diagnosed O
by O
PSG O
, O
self-rating B-Metric
depression I-Metric
scale I-Metric
（ O
SDS O
） O
and O
self-rating B-Metric
anxiety I-Metric
scale I-Metric
（ O
SAS O
） O
were O
selected O
from O
the O
respiratory O
department O
of O
our O
hospital O
from O
February O
2015 O
to O
February O
2018 O
. O

According O
to O
the O
random O
number O
table O
method O
, O
the O
patients O
were O
randomly O
divided O
into O
non-invasive O
ventilator O
group O
, O
rhodiola B-Medicinal food
rosea I-Medicinal food
+ O
non-invasive O
ventilator O
group O
and O
rhodiola B-Medicinal food
rosea I-Medicinal food
group O
, O
with O
30 O
cases O
in O
each O
group O
. O

Patients O
in O
the O
non-invasive O
ventilator O
group O
were O
treated O
with O
continuous O
positive O
airway O
pressure O
（ O
CPAP O
） O
for O
3 B-Duration
months I-Duration
, O
and O
those O
in O
the O
rhodiola B-Medicinal food
rosea I-Medicinal food
+ O
non-invasive O
ventilator O
group O
were O
treated O
with O
oral O
rhodiola B-Medicinal food
capsules I-Medicinal food
for O
3 B-Duration
months I-Duration
on O
the O
basis O
of O
CPAP O
, O
and O
those O
in O
the O
rhodiola B-Medicinal food
rosea I-Medicinal food
treatment O
group O
were O
treated O
with O
pure O
oral O
rhodiola B-Medicinal food
capsules I-Medicinal food
for O
3 B-Duration
months I-Duration
. O

The O
changes O
of O
SDS O
and O
SAS O
before O
and O
after O
the O
three O
groups O
were O
compared O
, O
and O
the O
changes O
of O
serum O
SOD O
and O
MDA O
were O
detected O
by O
immunoenzyme-linked O
adsorption O
for O
comparative O
analysis O
. O

Result O
: O
There O
were O
no O
significant O
differences O
in O
SDS O
and O
SAS O
scores O
between O
the O
three O
groups O
（ O
P O
> O
0.05 O
） O
. O

SDS O
and O
SAS O
scores O
of O
patients O
in O
the O
rhodiola B-Medicinal food
rosea I-Medicinal food
+ O
non-invasive O
ventilator O
group O
decreased O
after O
treatment O
（ O
P O
< O
0.05 O
） O
compared O
with O
those O
in O
the O
non-invasive O
ventilator O
group O
. O

SDS O
and O
SAS O
scores O
of O
patients O
in O
the O
rhodiola O
treatment O
group O
increased O
after O
treatment O
（ O
P O
< O
0.05 O
） O
. O

Compared O
with O
those O
in O
the O
rhodiola O
treatment O
group O
, O
SDS O
and O
SAS O
scores O
of O
patients O
in O
the O
rhodiola O
+ O
non-invasive O
breathing O
group O
decreased O
after O
treatment O
（ O
P O
< O
0.05 O
） O
. O

Three O
group O
patients O
were O
no O
significant O
difference O
in O
serum O
SOD O
and O
malondialdehyde O
（ O
MDA O
） O
before O
treatment O
（ O
P O
> O
0.05 O
） O
. O

Compared O
with O
before O
treatment O
, O
serum O
SOD O
level O
were O
all O
increased O
and O
MDA O
level O
were O
all O
decreased O
in O
the O
three O
groups O
after O
treatment O
（ O
P O
< O
0.05 O
） O
. O

Compared O
with O
noninvasive O
breathing O
unit O
after O
treatment O
, O
rhodiola O
+ O
noninvasive O
breathing O
unit O
after O
treatment O
in O
patients O
with O
elevated O
levels O
of O
serum O
SOD O
, O
MDA O
level O
decreased O
（ O
P O
< O
0.05 O
） O
, O
and O
for O
the O
treatment O
group O
after O
treatment O
in O
patients O
with O
serum O
SOD O
levels O
drop O
, O
the O
MDA O
levels O
（ O
P O
< O
0.05 O
） O
, O
and O
the O
after O
rhodiola B-Medicinal food
rosea I-Medicinal food
treatment O
group O
compared O
, O
rhodiola O
+ O
noninvasive O
breathing O
unit O
after O
treatment O
in O
patients O
with O
elevated O
levels O
of O
serum O
SOD O
, O
MDA O
level O
decreased O
（ O
P O
< O
0.05 O
） O
. O

Conclusion O
: O
Rhodiola B-Medicinal food
may O
improve O
the O
negative O
emotions O
such O
as O
anxiety B-Symptom_WorkedFor
and O
depression B-Symptom_WorkedFor
by O
inhibiting O
oxygen O
free O
radicals O
and O
lipid O
peroxidation O
in O
patients O
with O
OSA O
. O

Recent O
studies O
focused O
on O
the O
pharmacology O
and O
feasibility O
of O
herbal O
compounds O
as O
a O
potential O
strategy O
to O
target O
a O
variety O
of O
human O
diseases O
ranging O
from O
metabolic O
to O
brain O
disorders O
. O

Accordingly O
, O
bioactive O
ingredients O
which O
are O
found O
within O
a O
variety O
of O
herbal O
compounds O
are O
reported O
to O
produce O
both O
neuroprotective O
and O
psychotropic O
activities O
which O
may O
help O
to O
combat O
mental O
disorders O
such O
as O
depression O
, O
anxiety O
, O
sleep O
disturbances O
and O
cognitive O
alterations O
. O

In O
the O
present O
manuscript O
, O
we O
focus O
on O
three O
herbs O
which O
appear O
effective O
in O
mitigating O
anxiety B-Symptom_WorkedFor
or O
depression B-Symptom_WorkedFor
with O
favourable O
risk-benefit O
profiles O
, O
namely O
Scutellaria B-Medicinal food
baicalensis I-Medicinal food
( O
S B-Medicinal food
. I-Medicinal food
baicalensis I-Medicinal food
) O
, O
Hericium B-Medicinal food
erinaceus I-Medicinal food
( O
H B-Medicinal food
. I-Medicinal food
erinaceus I-Medicinal food
) O
and O
Rhodiola B-Medicinal food
rosea I-Medicinal food
( O
R B-Medicinal food
. I-Medicinal food
rosea I-Medicinal food
) O
. O

These O
three O
traditional O
folk O
medicinal O
herbs O
target O
the O
main O
biochemical O
events O
that O
are O
implicated O
in O
mental O
disorders O
, O
mimicking O
, O
to O
some O
extent O
, O
the O
mechanisms O
of O
action O
of O
conventional O
antidepressants O
and O
mood O
stabilizers O
with O
a O
wide O
margin O
of O
tolerability O
. O

In O
detail O
, O
they O
rescue O
alterations O
in O
neurotransmitter O
and O
neuro-endocrine O
systems O
, O
stimulate O
neurogenesis O
and O
the O
synthesis O
of O
neurotrophic O
factors O
, O
and O
they O
counteract O
oxidative O
stress O
, O
mitochondrial O
dysfunction O
and O
inflammation O
. O

Albeit O
the O
encouraging O
results O
that O
emerge O
from O
both O
experimental O
and O
clinical O
evidence O
, O
further O
studies O
are O
needed O
to O
confirm O
and O
better O
understand O
the O
mental-health O
promoting O
, O
and O
specifically O
, O
the O
antidepressant O
effects O
of O
these O
herbs O
. O

This O
trial O
evaluated O
the O
impact O
of O
a O
Rhodiola B-Medicinal food
rosea I-Medicinal food
L I-Medicinal food
. O
extract O
on O
self-reported O
anxiety B-Symptom_TestedFor
, O
stress B-Symptom_TestedFor
, O
cognition B-Symptom_TestedFor
, O
and O
other O
mood B-Symptom_TestedFor
symptoms I-Symptom_TestedFor
. O

Eighty B-#Participants
mildly O
anxious B-participant_health
participants O
were O
randomized O
into O
two O
different O
groups O
of O
either O
Rhodiola B-Medicinal food
rosea I-Medicinal food
L O
( O
2 B-Dosage
× I-Dosage
200 I-Dosage
mg I-Dosage
dose I-Dosage
Vitano B-Drug/Scientific name
® O
, O
1 O
tablet O
taken O
before O
breakfast O
and O
1tablet O
before O
lunch O
) O
or O
a O
control O
condition O
( O
no O
treatment O
) O
. O

Self-report O
measures O
and O
cognitive O
tests O
were O
completed O
at O
four O
testing O
sessions O
over O
a O
period O
of O
14 B-Duration
days I-Duration
. O

Relative O
to O
the O
controls O
, O
the O
experimental O
group O
demonstrated O
a O
significant O
reduction O
in O
self-reported O
, O
anxiety B-Symptom_WorkedFor
, O
stress B-Symptom_WorkedFor
, O
anger B-Symptom_WorkedFor
, O
confusion B-Symptom_WorkedFor
and O
depression B-Symptom_WorkedFor
at O
14 B-Duration
days I-Duration
and O
a O
significant O
improvements O
in O
total O
mood O
. O

No O
relevant O
differences O
in O
cognitive O
performance O
between O
the O
groups O
were O
observed O
. O

Rhodiola B-Medicinal food
rosea I-Medicinal food
L I-Medicinal food
( O
Vitano B-Drug/Scientific name
® O
) O
presented O
a O
favourable O
safety O
tolerability O
profile O
. O

Although O
this O
was O
a O
non-placebo O
controlled O
trial O
, O
it O
is O
unlikely O
that O
the O
findings O
were O
the O
result O
of O
placebo O
effects O
as O
changes O
appeared O
gradual O
and O
were O
specific O
to O
certain O
psychological O
measures O
. O

However O
, O
we O
cannot O
determine O
a O
causal O
relationship O
; O
further O
investigations O
are O
recommended O
to O
support O
the O
effects O
of O
Rhodiola B-Medicinal food
rosea I-Medicinal food
L I-Medicinal food
. I-Medicinal food
extract O
on O
stress B-Symptom_WorkedFor
related O
symptoms O
. O

nan O

Background O
: O
Rhodiola B-Medicinal food
rosea I-Medicinal food
L I-Medicinal food
. I-Medicinal food

Crassulaceae B-Medicinal food
, O
root O
( O
Golden B-Medicinal food
Root I-Medicinal food
, O
Arctic B-Medicinal food
Root I-Medicinal food
) O
is O
a O
high-value O
herbal O
medicinal O
product O
, O
registered O
in O
the O
UK O
for O
the O
treatment O
of O
stress-induced B-Symptom_WorkedFor
fatigue I-Symptom_WorkedFor
, O
exhaustion B-Symptom_WorkedFor
and O
anxiety B-Symptom_WorkedFor
based O
on O
traditional O
use O
and O
used O
throughout O
Europe O
as O
a O
herbal O
medicinal O
product O
for O
similar O
indications O
. O

Numerous O
unregistered O
supplements O
are O
also O
available O
. O

There O
are O
several O
Chinese O
species O
used O
in O
traditional O
Chinese O
medicine O
( O
TCM O
) O
, O
including O
Rhodiola B-Drug/Scientific name
crenulata I-Drug/Scientific name
( O
Hook.f O
. O
& O
Thomoson O
) O
that O
is O
believed O
to O
be O
a O
common O
adulterant O
in O
the O
R B-Medicinal food
. I-Medicinal food
rosea I-Medicinal food
value O
chain O
. O

Aims O
: O
The O
project O
is O
embedded O
in O
a O
larger O
study O
aiming O
to O
investigate O
the O
diverse O
value O
chains O
that O
lead O
to O
the O
production O
of O
R B-Medicinal food
. I-Medicinal food
rosea I-Medicinal food
as O
an O
herbal O
medicinal O
product O
or O
supplement O
. O

Here O
we O
focus O
on O
a O
comparison O
of O
the O
quality O
of O
the O
finished O
products O
and O
assess O
any O
phytochemical O
variation O
between O
products O
registered O
under O
the O
Traditional O
Herbal O
Medicine O
Products O
Directive O
( O
THMPD O
) O
and O
products O
obtained O
from O
the O
market O
without O
any O
registration O
( O
i.e O
. O
generally O
unlicensed O
supplements O
) O
. O

Our O
key O
aim O
is O
to O
establish O
the O
extent O
of O
the O
problem O
in O
terms O
of O
adulteration O
of O
consumer O
products O
claiming O
to O
contain O
R B-Medicinal food
. I-Medicinal food
rosea I-Medicinal food
( O
or O
R B-Drug/Scientific name
. I-Drug/Scientific name
crenulata I-Drug/Scientific name
) O
. O

Methods O
: O
Approximately O
40 O
commercial O
products O
( O
granulated O
powders O
and O
extracts O
) O
were O
sourced O
from O
different O
suppliers O
. O

We O
analysed O
these O
samples O
using O
high O
performance O
thin O
layer O
chromatography O
( O
HPTLC O
) O
, O
mass O
spectrometry O
( O
MS O
) O
and O
( O
1 O
) O
H O
NMR O
spectroscopy O
coupled O
with O
multi-variate O
analysis O
software O
following O
a O
method O
previously O
developed O
by O
our O
group O
for O
the O
analysis O
of O
turmeric O
products O
. O

Results O
: O
We O
investigate O
the O
phytochemistry O
of O
the O
different O
species O
and O
assess O
the O
potential O
of O
R B-Drug/Scientific name
. I-Drug/Scientific name
crenulata I-Drug/Scientific name
as O
an O
adulterant O
at O
the O
end O
of O
the O
R B-Medicinal food
. I-Medicinal food
rosea I-Medicinal food
value O
chains O
. O

The O
consistency O
of O
the O
products O
varies O
significantly O
. O

Approximately O
one O
fifth O
of O
commercial O
products O
that O
claimed O
to O
be O
R B-Medicinal food
. I-Medicinal food
rosea I-Medicinal food
did O
not O
contain O
rosavin O
( O
the O
key O
reference O
markers O
used O
to O
distinguish O
R O
. O
rosea O
from O
related O
species O
) O
. O

Moreover O
some O
products O
appeared O
not O
to O
contain O
salidroside O
, O
another O
marker O
compound O
found O
in O
other O
Rhodiola O
species O
. O

Approximately O
80% O
of O
the O
remaining O
commercial O
products O
were O
lower O
in O
rosavin O
content O
than O
the O
registered O
products O
and O
appeared O
to O
be O
adulterated O
with O
other O
Rhodiola O
species O
. O

Conclusions O
: O
The O
variation O
in O
phytochemical O
constituents O
present O
in O
Rhodiola O
products O
available O
to O
European O
buyers O
via O
the O
internet O
and O
other O
sources O
is O
a O
major O
cause O
for O
concern O
. O

Adulteration O
with O
different O
species O
, O
and O
other O
sometimes O
unknown O
adulterants O
, O
appears O
to O
be O
commonplace O
. O

Good O
quality O
systems O
and O
manufacturing O
practices O
, O
including O
those O
required O
under O
the O
THMPD O
, O
enable O
consumers O
to O
have O
confidence O
that O
products O
are O
authentic O
and O
meet O
a O
high O
specification O
for O
quality O
and O
safety O
. O

To O
evaluate O
the O
therapeutic O
effects O
of O
Chinese O
herbal O
medicine O
( O
CHM O
) O
for O
Alzheimer's B-Symptom_WorkedFor
disease I-Symptom_WorkedFor
( O
AD B-Symptom_WorkedFor
) O
, O
we O
evaluated O
five O
CHMs O
in O
oligomeric O
Aβ25 O
- O
35 O
- O
treated O
mouse O
primary O
hippocampal O
neuronal O
cultures O
. O

The O
aqueous O
extract O
from O
the O
root O
of O
Pueraria B-Medicinal food
lobata I-Medicinal food
( O
Puerariae B-Drug/Scientific name
Radix I-Drug/Scientific name
; O
PR B-Drug/Scientific name
) O
showed O
better O
neuroprotective O
effects O
than O
did O
the O
other O
four O
CHM O
aqueous O
extracts O
, O
including O
Gardenia B-Medicinal food
jasminoides I-Medicinal food
, O
Eleutherococcus B-Medicinal food
senticosus I-Medicinal food
, O
Rhodiola B-Medicinal food
rosea I-Medicinal food
, O
and O
Panax B-Medicinal food
, O
in O
the O
primary O
culture O
treated O
with O
saline O
or O
oligomeric O
Aβ25 O
- O
35 O
. O

Furthermore O
, O
the O
neuroprotective O
effects O
of O
aqueous O
extract O
of O
PR B-Drug/Scientific name
were O
also O
better O
than O
its O
well-known O
active O
compound O
, O
puerarin O
, O
against O
the O
neurotoxicity O
of O
oligomeric O
Aβ25 O
- O
35 O
in O
a O
primary O
culture O
. O

For O
in O
vivo O
experiments O
, O
C57BL O
/ O
6J O
male O
mice O
that O
received O
direct O
infusion O
of O
soluble O
oligomeric O
Aβ25 O
- O
35 O
into O
the O
bilateral O
hippocampal O
CA1 O
subregion O
were O
used O
as O
an O
alternative O
AD B-Symptom_WorkedFor
mouse O
model O
. O

The O
effects O
and O
molecular O
mechanisms O
of O
chronic O
systemic O
administration O
of O
PR B-Drug/Scientific name
aqueous O
extract O
were O
evaluated O
in O
the O
alternative O
AD B-Symptom_WorkedFor
model O
. O

PR B-Drug/Scientific name
aqueous O
extract O
prevented O
anxiety B-Symptom_WorkedFor
and O
cognitive B-Symptom_WorkedFor
impairment I-Symptom_WorkedFor
in O
mice O
associated O
with O
a O
decrease O
in O
the O
levels O
of O
Aβ O
deposition O
, O
tau O
protein O
phosphorylation O
, O
inflammation O
, O
loss O
of O
noradrenergic O
, O
and O
serotonergic O
neurons O
and O
an O
increase O
in O
the O
levels O
of O
synaptophysin O
and O
insulin O
degrading O
enzyme O
( O
IDE O
) O
against O
the O
toxicity O
of O
oligomeric O
Aβ25 O
- O
35 O
. O

Furthermore O
, O
no O
obvious O
damage O
to O
the O
liver O
and O
kidney O
was O
detected O
after O
chronic O
systemic O
administration O
of O
PR B-Drug/Scientific name
aqueous O
extract O
. O

Therefore O
, O
using O
PR B-Drug/Scientific name
could O
be O
a O
safer O
, O
more O
effective O
therapeutic O
strategy O
than O
using O
its O
active O
compound O
puerarin O
to O
prevent O
both O
cognitive O
and O
noncognitive O
dysfunction O
and O
related O
pathological O
features O
of O
AD B-Symptom_WorkedFor
. O

In O
the O
present O
study O
, O
effect O
of O
curcumin B-Medicinal food
( O
10 O
and O
20mg O
/ O
kg O
) O
, O
an O
active O
constituent O
of O
Curcuma O
longa O
was O
evaluated O
for O
its O
antianxiety-like B-Symptom_WorkedFor
activity O
in O
mice O
subjected O
to O
immobilization-induced O
restraint O
stress O
for O
6h O
. O

The O
effect O
on O
anxiety O
was O
assessed O
by O
employing O
elevated O
plus O
maze O
, O
open O
field O
test O
, O
light O
/ O
dark O
test O
and O
social O
interaction O
test O
. O

Only O
the O
higher O
dose O
( O
20mg O
/ O
kg O
, O
i.p O
. O
) O
of O
curcumin B-Medicinal food
produced O
significant O
antianxiety-like B-Symptom_WorkedFor
effect O
in O
stressed O
mice O
. O

Pre-treatment O
with O
aminoguanidine B-Other_ingredients
( O
50mg O
/ O
kg O
; O
i.p O
. O
) O
, O
an O
inducible O
nitric O
oxide O
synthase O
inhibitor O
significantly O
enhanced O
the O
anxiolytic-like B-Symptom_WorkedFor
effect O
of O
curcumin B-Medicinal food
in O
stressed O
mice O
as O
compared O
to O
curcumin B-Medicinal food
and O
aminoguanidine B-Other_ingredients
per O
se O
in O
stressed O
mice O
. O

Pretreatment O
with O
7 B-Other_ingredients
- I-Other_ingredients
nitroindazole I-Other_ingredients
( O
20mg O
/ O
kg O
) O
, O
a O
neuronal O
nitric O
oxide O
synthase O
inhibitor O
did O
not O
significantly O
affect O
the O
antianxiety-like B-Symptom_WorkedFor
response O
of O
curcumin B-Medicinal food
in O
stressed O
mice O
as O
compared O
to O
curcumin B-Medicinal food
per O
se O
. O

Restraint O
stress O
significantly O
increased O
plasma O
nitrite O
levels O
in O
mice O
. O

Curcumin B-Medicinal food
( O
20mg O
/ O
kg O
, O
i.p O
. O
) O
and O
aminoguanidine B-Other_ingredients
significantly O
decreased O
plasma O
nitrite O
levels O
in O
stressed O
mice O
. O

The O
combination O
of O
aminoguanidine B-Other_ingredients
and O
curcumin B-Medicinal food
significantly O
decreased O
the O
plasma O
nitrite O
levels O
as O
compared O
to O
curcumin B-Medicinal food
and O
aminoguanidine O
per O
se O
in O
stressed O
mice O
. O

Curcumin B-Medicinal food
and O
aminoguanidine B-Other_ingredients
did O
not O
produce O
any O
significant O
change O
in O
brain O
GABA O
contents O
of O
the O
animals O
. O

Diazepam B-Other_ingredients
( O
2mg O
/ O
kg O
) O
produced O
significant O
anxiolytic-like B-Symptom_WorkedFor
effect O
only O
in O
unstressed O
mice O
, O
but O
could O
not O
exert O
significant O
anxiolysis O
in O
stressed O
mice O
. O

However O
, O
diazepam B-Symptom_WorkedFor
significantly O
increased O
GABA O
contents O
in O
both O
unstressed O
and O
stressed O
mice O
as O
compared O
to O
respective O
control O
groups O
. O

These O
findings O
suggest O
the O
possible O
involvement O
of O
only O
inducible O
NOS O
and O
not O
neuronal O
NOS O
in O
antianxiety-like B-Symptom_WorkedFor
effect O
of O
curcumin B-Medicinal food
. O

Irritable B-Symptom_TestedFor
bowel I-Symptom_TestedFor
syndrome I-Symptom_TestedFor
( O
IBS O
) O
is O
induced O
by O
dysfunction O
of O
central O
nervous O
and O
peripheral O
intestinal O
systems O
, O
which O
affects O
an O
estimated O
10 O
- O
15% O
population O
worldwide O
annually O
. O

Stress-related O
psychiatric O
disorders O
including O
depression B-Symptom_WorkedFor
and O
anxiety B-Symptom_WorkedFor
are O
often O
comorbid O
with O
gastrointestinal O
function O
disorder O
, O
such O
as O
IBS O
. O

However O
, O
the O
mechanism O
of O
IBS O
still O
remains O
unknown O
. O

Curcumin B-Medicinal food
is O
a O
biologically O
active O
phytochemical O
presents O
in O
turmeric B-Medicinal food
and O
has O
pharmacological O
actions O
that O
benefit O
patients O
with O
depression B-Symptom_WorkedFor
and O
anxiety B-Symptom_WorkedFor
. O

Our O
study O
found O
that O
IBS O
rats O
showed O
depression O
- O
and O
anxiety-like O
behaviors O
associated O
with O
decreased O
5 O
- O
HT O
( O
serotonin O
) O
, O
BDNF O
( O
Brain-derived O
neurotrophic O
factor O
) O
and O
pCREB O
( O
phosphorylation O
of O
cAMP O
response O
element-binding O
protein O
) O
expression O
in O
the O
hippocampus O
after O
chronic O
acute O
combining O
stress O
( O
CAS O
) O
. O

However O
, O
these O
decreased O
parameters O
were O
obviously O
increased O
in O
the O
colonic O
after O
CAS O
. O

Curcumin B-Medicinal food
( O
40 O
mg O
/ O
kg O
) O
reduced O
the O
immobility O
time O
of O
forced O
swimming O
and O
the O
number O
of O
buried O
marbles O
in O
behavioral O
tests O
of O
CAS O
rats O
. O

Curcumin B-Medicinal food
also O
decreased O
the O
number O
of O
fecal O
output O
and O
abdominal O
withdrawal O
reflex O
( O
AWR O
) O
scores O
in O
response O
to O
graded O
distention O
. O

Moreover O
, O
curcumin B-Medicinal food
increased O
serotonin O
, O
BDNF O
and O
pCREB O
levels O
in O
the O
hippocampus O
, O
but O
they O
were O
decreased O
in O
the O
colonic O
of O
CAS O
rats O
. O
5 O
- O
HT O
( O
1A O
) O
receptor O
antagonist O
NAN O
- O
190 O
reversed O
the O
effects O
of O
curcumin O
on O
behaviors O
and O
the O
changes O
of O
intestine O
, O
pCREB O
and O
BDNF O
expression O
, O
which O
are O
related O
to O
IBS O
. O

These O
results O
suggested O
that O
curcumin B-Medicinal food
exerts O
the O
effects O
on O
IBS O
through O
regulating O
neurotransmitters O
, O
BDNF O
and O
CREB O
signaling O
both O
in O
the O
brain O
and O
peripheral O
intestinal O
system O
. O

Curcumin B-Medicinal food
is O
a O
major O
diarylheptanoid O
component O
of O
Curcuma O
longa O
with O
traditional O
usage O
for O
anxiety B-Symptom_WorkedFor
and O
depression B-Symptom_WorkedFor
. O

It O
has O
been O
known O
for O
the O
anti-inflammatory B-Symptom_WorkedFor
, O
antistress B-Symptom_WorkedFor
, O
and O
neurotropic B-Symptom_WorkedFor
effects I-Symptom_WorkedFor
. O

Here O
we O
examined O
curcumin B-Medicinal food
effect O
in O
neural O
plasticity O
and O
cell O
viability O
. O
60 O
- O
channel O
multielectrode O
array O
was O
applied O
on O
organotypic O
hippocampal O
slice O
cultures O
( O
OHSCs O
) O
to O
monitor O
the O
effect O
of O
10 O
μM O
curcumin B-Medicinal food
in O
long-term B-Symptom_WorkedFor
depression I-Symptom_WorkedFor
( O
LTD O
) O
through O
low-frequency O
stimulation O
( O
LFS O
) O
to O
the O
Schaffer O
collaterals O
and O
commissural O
pathways O
. O

Cell O
viability O
was O
assayed O
by O
propidium O
iodide O
uptake O
test O
in O
OHSCs O
. O

In O
addition O
, O
the O
influence O
of O
oral O
curcumin B-Medicinal food
administration O
on O
rat O
behavior O
was O
assessed O
with O
the O
forced O
swim O
test O
( O
FST O
) O
. O

Finally O
, O
protein O
expression O
levels O
of O
brain-derived O
neurotrophic O
factor O
( O
BDNF O
) O
and O
cyclooxygenase O
- O
2 O
( O
COX O
- O
2 O
) O
were O
measured O
by O
Western O
blot O
in O
chronically O
stressed O
rats O
. O

Our O
results O
demonstrated O
that O
10 O
μM O
curcumin B-Medicinal food
attenuated O
LTD O
and O
reduced O
cell O
death O
. O

It O
also O
recovered O
the O
behavior O
immobility O
of O
FST O
, O
rescued O
the O
attenuated O
BDNF O
expression O
, O
and O
inhibited O
the O
enhancement O
of O
COX O
- O
2 O
expression O
in O
stressed O
animals O
. O

These O
findings O
indicate O
that O
curcumin B-Medicinal food
can O
enhance O
postsynaptic O
electrical O
reactivity O
and O
cell O
viability O
in O
intact O
neural O
circuits O
with O
antidepressant-like B-Symptom_WorkedFor
effects O
, O
possibly O
through O
the O
upregulation O
of O
BDNF O
and O
reduction O
of O
inflammatory O
factors O
in O
the O
brain O
. O

Posttraumatic B-participant_health
stress I-participant_health
disorder I-participant_health
( O
PTSD B-participant_health
) O
is O
a O
trauma-induced O
psychiatric O
disease O
characterized O
by O
impaired O
hyperarousal O
, O
fear O
extermination O
, O
depression O
, O
anxiety O
, O
and O
amnesic O
symptoms O
that O
may O
include O
the O
release O
of O
monoamines O
in O
the O
dread O
circuit O
. O

Curcumin B-Medicinal food
( O
CUR B-Medicinal food
) O
, O
a O
major O
diarylheptanoid O
and O
polyphenolic O
component O
of O
Curcuma O
longa O
, O
reportedly O
possesses O
several O
pharmacological O
features O
, O
including O
antidiabetic O
, O
antiatherosclerotic O
, O
anticancer O
, O
and O
neuropsychiatric O
actions O
. O

But O
the O
anxiolytic-like O
effects O
of O
CUR B-Medicinal food
and O
its O
mechanism O
of O
action O
in O
PTSD B-participant_health
are O
unclear O
. O

The O
current O
research O
measured O
some O
anxiety-related O
behavioral O
responses O
to O
examine O
the O
effects O
of O
CUR B-Medicinal food
on O
symptoms O
of O
anxiety B-Symptom_WorkedFor
in O
rats O
after O
single O
prolonged O
stress O
( O
SPS O
) O
exposure O
by O
reversing O
the O
serotonin O
( O
5 O
- O
HT O
) O
dysfunction O
. O

Rats O
received O
CUR B-Medicinal food
( O
20 O
, O
50 O
, O
or O
100 O
mg O
/ O
kg O
, O
i.p O
. O
, O
once O
daily O
) O
for O
14 O
days O
after O
SPS O
exposure O
. O

Administration O
of O
CUR B-Medicinal food
significantly O
increased O
the O
number O
of O
central O
zone O
crossings O
in O
the O
open O
field O
test O
and O
reduced O
grooming O
behavior O
in O
the O
elevated O
plus O
maze O
( O
EPM O
) O
test O
and O
increased O
the O
number O
of O
open-arm O
visits O
on O
the O
EPM O
test O
. O

CUR B-Medicinal food
administration O
significantly O
reduced O
freezing O
response O
to O
contextual O
fear O
conditioning O
. O

CUR B-Medicinal food
recovered O
neurochemical O
abnormalities O
and O
SPS-induced O
decreased O
5 O
- O
HT O
tissue O
levels O
in O
the O
hippocampus O
, O
amygdala O
, O
and O
striatum O
. O

These O
results O
suggested O
that O
CUR B-Medicinal food
has O
anxiolytic-like B-Symptom_WorkedFor
effects O
on O
biochemical O
and O
behavioral O
symptoms O
associated O
with O
anxiety B-Symptom_WorkedFor
. O

Thus O
, O
CUR B-Medicinal food
may O
be O
a O
useful O
agent O
to O
alleviate O
or O
treat O
psychiatric O
disorders O
similar O
to O
those O
observed O
in O
patients O
with O
PTSD B-participant_health
. O

Background O
: O
Rhodiola B-Medicinal food
rosea I-Medicinal food
L I-Medicinal food
. I-Medicinal food

Crassulaceae B-Medicinal food
, O
root O
( O
Golden B-Medicinal food
Root I-Medicinal food
, O
Arctic B-Medicinal food
Root I-Medicinal food
) O
is O
a O
high-value O
herbal O
medicinal O
product O
, O
registered O
in O
the O
UK O
for O
the O
treatment O
of O
stress-induced B-Symptom_WorkedFor
fatigue I-Symptom_WorkedFor
, O
exhaustion B-Symptom_WorkedFor
and O
anxiety B-Symptom_WorkedFor
based O
on O
traditional O
use O
and O
used O
throughout O
Europe O
as O
a O
herbal O
medicinal O
product O
for O
similar O
indications O
. O

Numerous O
unregistered O
supplements O
are O
also O
available O
. O

There O
are O
several O
Chinese O
species O
used O
in O
traditional O
Chinese O
medicine O
( O
TCM O
) O
, O
including O
Rhodiola B-Drug/Scientific name
crenulata I-Drug/Scientific name
( O
Hook.f O
. O
& O
Thomoson O
) O
that O
is O
believed O
to O
be O
a O
common O
adulterant O
in O
the O
R B-Medicinal food
. I-Medicinal food
rosea I-Medicinal food
value O
chain O
. O

Aims O
: O
The O
project O
is O
embedded O
in O
a O
larger O
study O
aiming O
to O
investigate O
the O
diverse O
value O
chains O
that O
lead O
to O
the O
production O
of O
R O
. O
rosea O
as O
an O
herbal O
medicinal O
product O
or O
supplement O
. O

Here O
we O
focus O
on O
a O
comparison O
of O
the O
quality O
of O
the O
finished O
products O
and O
assess O
any O
phytochemical O
variation O
between O
products O
registered O
under O
the O
Traditional O
Herbal O
Medicine O
Products O
Directive O
( O
THMPD O
) O
and O
products O
obtained O
from O
the O
market O
without O
any O
registration O
( O
i.e O
. O
generally O
unlicensed O
supplements O
) O
. O

Our O
key O
aim O
is O
to O
establish O
the O
extent O
of O
the O
problem O
in O
terms O
of O
adulteration O
of O
consumer O
products O
claiming O
to O
contain O
R B-Medicinal food
. I-Medicinal food
rosea I-Medicinal food
( O
or O
R B-Drug/Scientific name
. I-Drug/Scientific name
crenulata I-Drug/Scientific name
) O
. O

Methods O
: O
Approximately O
40 O
commercial O
products O
( O
granulated O
powders O
and O
extracts O
) O
were O
sourced O
from O
different O
suppliers O
. O

We O
analysed O
these O
samples O
using O
high O
performance O
thin O
layer O
chromatography O
( O
HPTLC O
) O
, O
mass O
spectrometry O
( O
MS O
) O
and O
( O
1 O
) O
H O
NMR O
spectroscopy O
coupled O
with O
multi-variate O
analysis O
software O
following O
a O
method O
previously O
developed O
by O
our O
group O
for O
the O
analysis O
of O
turmeric O
products O
. O

Results O
: O
We O
investigate O
the O
phytochemistry O
of O
the O
different O
species O
and O
assess O
the O
potential O
of O
R B-Drug/Scientific name
. I-Drug/Scientific name
crenulata I-Drug/Scientific name
as O
an O
adulterant O
at O
the O
end O
of O
the O
R B-Medicinal food
. I-Medicinal food
rosea I-Medicinal food
value O
chains O
. O

The O
consistency O
of O
the O
products O
varies O
significantly O
. O

Approximately O
one O
fifth O
of O
commercial O
products O
that O
claimed O
to O
be O
R B-Medicinal food
. I-Medicinal food
rosea I-Medicinal food
did O
not O
contain O
rosavin O
( O
the O
key O
reference O
markers O
used O
to O
distinguish O
R B-Medicinal food
. I-Medicinal food
rosea I-Medicinal food
from O
related O
species O
) O
. O

Moreover O
some O
products O
appeared O
not O
to O
contain O
salidroside O
, O
another O
marker O
compound O
found O
in O
other O
Rhodiola O
species O
. O

Approximately O
80% O
of O
the O
remaining O
commercial O
products O
were O
lower O
in O
rosavin O
content O
than O
the O
registered O
products O
and O
appeared O
to O
be O
adulterated O
with O
other O
Rhodiola O
species O
. O

Conclusions O
: O
The O
variation O
in O
phytochemical O
constituents O
present O
in O
Rhodiola O
products O
available O
to O
European O
buyers O
via O
the O
internet O
and O
other O
sources O
is O
a O
major O
cause O
for O
concern O
. O

Adulteration O
with O
different O
species O
, O
and O
other O
sometimes O
unknown O
adulterants O
, O
appears O
to O
be O
commonplace O
. O

Good O
quality O
systems O
and O
manufacturing O
practices O
, O
including O
those O
required O
under O
the O
THMPD O
, O
enable O
consumers O
to O
have O
confidence O
that O
products O
are O
authentic O
and O
meet O
a O
high O
specification O
for O
quality O
and O
safety O
. O

Chronic O
exposure O
to O
stress B-Symptom_TestedFor
is O
a O
well-known O
risk O
factor O
for O
the O
development O
of O
mood B-Symptom_TestedFor
and O
anxiety B-Symptom_TestedFor
disorders I-Symptom_TestedFor
. O

Promoting O
resilience O
to O
stress B-Symptom_TestedFor
may O
prevent O
the O
development O
of O
these O
disorders O
, O
but O
resilience-enhancing O
compounds O
are O
not O
yet O
clinically O
available O
. O

One O
compound O
that O
has O
shown O
promise O
in O
the O
clinical O
setting O
is O
curcumin B-Medicinal food
, O
a O
polyphenol O
compound O
found O
in O
the O
rhizome O
of O
the O
turmeric B-Medicinal food
plant O
( O
Curcuma O
longa O
) O
with O
known O
anti-inflammatory O
and O
antidepressant O
properties O
. O

Here O
, O
we O
tested O
the O
efficacy O
of O
1.5% O
dietary O
curcumin B-Medicinal food
at O
promoting O
resilience O
to O
chronic O
social B-Symptom_WorkedFor
defeat I-Symptom_WorkedFor
stress I-Symptom_WorkedFor
( O
CSDS O
) O
in O
129 O
/ O
SvEv O
mice O
, O
a O
strain O
that O
we O
show O
is O
highly O
susceptible O
to O
this O
type O
of O
stress B-Symptom_WorkedFor
. O

We O
found O
that O
administration O
of O
curcumin O
during O
CSDS O
produced O
a O
4.5 O
- O
fold O
increase O
in O
stress B-Symptom_WorkedFor
resilience O
, O
as O
measured O
by O
the O
social O
interaction O
test O
. O

Although O
the O
overall O
effects O
of O
curcumin B-Medicinal food
were O
striking O
, O
we O
identified O
two O
distinct O
responses O
to O
curcumin B-Medicinal food
. O

While O
64% O
of O
defeated O
mice O
on O
curcumin B-Medicinal food
were O
resilient O
( O
responders O
) O
, O
the O
remaining O
36% O
of O
mice O
were O
susceptible O
to O
the O
effects O
of O
stress B-Symptom_WorkedFor
( O
non-responders O
) O
. O

Interestingly O
, O
responders O
released O
less O
corticosterone O
following O
acute O
restraint O
stress O
and O
had O
lower O
levels O
of O
peripheral O
IL O
- O
6 O
than O
nonresponders O
, O
implicating O
a O
role O
for O
the O
NF-κB O
pathway O
in O
treatment O
response O
. O

Importantly O
, O
curcumin B-Medicinal food
also O
prevented O
anxiety-like B-Symptom_WorkedFor
behavior O
in O
both O
responders O
and O
non-responders O
in O
the O
elevated-plus O
maze O
and O
open O
field O
test O
. O

Collectively O
, O
our O
findings O
provide O
the O
first O
preclinical O
evidence O
that O
curcumin B-Medicinal food
promotes O
resilience O
to O
CSDS O
and O
suggest O
that O
curcumin B-Medicinal food
may O
prevent O
the O
emergence O
of O
a O
range O
of O
anxiety-like B-Symptom_WorkedFor
symptoms O
when O
given O
to O
individuals O
during O
exposure O
to O
chronic O
social O
stress O
. O

Stress B-Symptom_WorkedFor
plays O
a O
potential O
role O
in O
the O
onset O
and O
exacerbation O
of O
depression B-Symptom_WorkedFor
. O

Chronic O
restraint O
stress B-Symptom_WorkedFor
in O
rats O
, O
and O
psychosocial O
stress O
in O
humans O
, O
is O
implicated O
in O
the O
pathophysiology O
of O
mood O
and O
anxiety B-Symptom_WorkedFor
disorders I-Symptom_WorkedFor
. O

Oxidative O
damage O
is O
an O
established O
outcome O
of O
restraint O
stress O
, O
which O
has O
been O
suggested O
to O
induce O
many O
damaging O
processes O
contributing O
to O
the O
pathology O
of O
stress-induced B-Symptom_WorkedFor
depression I-Symptom_WorkedFor
. O

However O
, O
the O
modulatory O
role O
of O
clinically O
effective O
antidepressants O
, O
such O
as O
fluoxetine B-Other_ingredients
, O
in O
attenuating O
oxidative O
stress O
has O
not O
been O
well O
characterized O
. O

Therefore O
, O
the O
current O
study O
was O
designed O
to O
investigate O
the O
antioxidant O
effects O
of O
chronic O
treatment O
with O
fluoxetine B-Other_ingredients
in O
animals O
submitted O
to O
restraint O
stress B-Symptom_WorkedFor
. O

The O
antioxidant O
potential O
of O
the O
antidepressant O
fluoxetine B-Other_ingredients
was O
compared O
with O
that O
of O
turmeric B-Medicinal food
, O
used O
as O
a O
standard O
since O
it O
integrates O
both O
antioxidant O
and O
antidepressant O
properties O
. O

Chronic O
fluoxetine B-Other_ingredients
administration O
to O
stressed O
animals O
for O
21 O
days O
prevented O
restraint O
stress-induced O
oxidative O
damage O
with O
an O
efficacy O
similar O
to O
that O
of O
turmeric B-Medicinal food
, O
as O
evidenced O
by O
significant O
enhancement O
of O
key O
endogenous O
antioxidant O
defense O
components O
, O
comprising O
the O
free-radical O
scavenging O
enzymes O
, O
superoxide O
: O
superoxide O
oxidoreductase O
( O
EC O
1.15.1.1 O
) O
, O
hydrogen-peroxide O
: O
hydrogen-peroxide O
oxidoreductase O
( O
EC O
1.11.1.6 O
) O
, O
glutathione O
S-transferase O
( O
EC O
2.5.1.18 O
) O
and O
glutathione O
: O
NADP O
( O
+ O
) O
oxidoreductase O
( O
EC O
1.8.1.7 O
) O
, O
as O
well O
as O
non-enzymatic O
antioxidants O
, O
GSH O
, O
glucose O
and O
uric O
acid O
, O
which O
were O
severely O
depleted O
by O
restraint O
stress O
in O
animals O
receiving O
no O
treatment O
. O

Oxidative O
stress O
markers O
, O
( O
S O
) O
- O
lactate O
: O
NAD O
( O
+ O
) O
oxidoreductase O
activity O
( O
EC O
1.1.1.27 O
) O
, O
malondialdehyde O
levels O
( O
lipid O
peroxidation O
product O
) O
and O
protein O
carbonyl O
content O
were O
also O
significantly O
decreased O
following O
fluoxetine O
treatment O
. O

Both O
these O
drugs O
when O
given O
alone O
to O
non-stressed O
animals O
did O
not O
alter O
basal O
levels O
of O
antioxidant O
defense O
components O
and O
oxidative O
stress O
markers O
significantly O
. O

Our O
findings O
suggest O
that O
the O
therapeutic O
efficacy O
of O
fluoxetine B-Other_ingredients
may O
be O
mediated O
, O
at O
least O
partially O
, O
via O
reversal O
of O
oxidative O
damage O
as O
demonstrated O
by O
protective O
enhancement O
of O
antioxidant O
status O
following O
a O
stress-induced B-Symptom_WorkedFor
decline O
. O

In O
addition O
, O
this O
study O
demonstrates O
important O
implications O
for O
pharmacological O
interventions O
targeting O
cellular O
antioxidants O
as O
a O
promising O
strategy O
for O
protecting O
against O
oxidative O
insults O
in O
stress-induced B-Symptom_WorkedFor
depression I-Symptom_WorkedFor
. O

Context O
: O
The O
prevalence O
of O
overweight O
and O
obesity O
and O
associated O
comorbidities O
has O
progressively O
risen O
. O

Curcumin B-Medicinal food
, O
the O
active O
ingredient O
in O
turmeric B-Medicinal food
, O
and O
turmeric B-Medicinal food
aqueous O
extract O
, O
a O
concentrated O
form O
, O
have O
been O
reported O
to O
have O
beneficial O
effects O
in O
treatment O
of O
cardiovascular B-Symptom_WorkedFor
diseases I-Symptom_WorkedFor
and O
their O
risk O
factors O
. O

However O
, O
turmeric B-Medicinal food
has O
not O
been O
studied O
in O
its O
natural O
form O
. O

Objective O
: O
The O
present O
study O
planned O
to O
evaluate O
the O
beneficial O
effects O
of O
turmeric B-Medicinal food
in O
its O
natural O
form O
on O
obesity-related O
, O
cardiovascular-disease B-Symptom_WorkedFor
risk I-Symptom_WorkedFor
factors I-Symptom_WorkedFor
in O
overweight B-participant_health
or O
obese B-participant_health
females O
. O

Design O
: O
The O
study O
used O
a O
pre-post O
, O
single-arm O
design O
. O

Setting O
: O
The O
study O
took O
place O
in O
the O
Department O
of O
Physiology O
at O
Imam O
Abdulrahman O
Bin O
Faisal O
University O
( O
Dammam O
, O
Saudi O
Arabia O
) O
. O

Participants O
: O
The O
participants O
were O
36 B-#Participants
young O
female O
students O
at O
the O
university O
, O
with O
a O
body O
mass O
index O
≥ O
23 O
kg O
/ O
m2 O
. O

Intervention O
: O
Participants O
received O
a O
daily O
dose O
of O
2 B-Dosage
g I-Dosage
/ I-Dosage
d I-Dosage
of O
turmeric B-Medicinal food
in O
capsules O
for O
90 B-Duration
d I-Duration
. O

Outcome O
measures O
: O
Anthropometric O
measures O
, O
blood O
pressure O
, O
serum O
homocysteine O
, O
and O
mental O
health O
status O
- O
stress O
, O
anxiety O
, O
depression O
scores-were O
recorded O
at O
baseline O
and O
postintervention O
. O

Dietary O
intake O
and O
physical O
activity O
( O
confounding O
variables O
) O
were O
also O
measured O
. O

Results O
: O
The O
following O
anthropometric O
measures O
were O
reduced O
significantly O
between O
baseline O
and O
postintervention O
: O
( O
1 O
) O
body O
weight O
- O
73.47 O
vs O
72.45 O
kg O
( O
P O
= O
.04 O
) O
, O
( O
2 O
) O
body O
mass O
index O
- O
28.75 O
vs O
28.27 O
kg O
/ O
m2 O
( O
P O
= O
.02 O
) O
, O
( O
3 O
) O
waist O
circumference O
- O
81.85 O
vs O
77.96 O
cm O
( O
P O
= O
.01 O
) O
, O
( O
4 O
) O
hip O
circumference O
- O
102.72 O
vs O
98.10 O
cm O
( O
P O
= O
.001 O
) O
, O
( O
5 O
) O
body O
fat O
% O
- O
34.34 O
vs O
32.58 O
( O
P O
= O
.00 O
) O
, O
( O
6 O
) O
systolic O
blood O
pressure O
- O
119.12 O
vs O
115.92 O
mm O
Hg O
( O
P O
= O
.04 O
) O
, O
and O
( O
7 O
) O
anxiety O
scores O
- O
7.88 O
vs O
4.73 O
( O
P O
= O
.03 O
) O
, O
as O
compared O
by O
paired O
t O
test O
. O

Homocysteine O
levels O
and O
stress O
and O
depression O
scores O
showed O
no O
significant O
changes O
. O

Dietary O
intake O
and O
physical O
activity O
did O
not O
vary O
significantly O
throughout O
the O
study O
period O
. O

Conclusion O
: O
Turmeric B-Medicinal food
has O
the O
ability O
to O
reduce O
weight B-Symptom_WorkedFor
, O
decrease B-Symptom_WorkedFor
body I-Symptom_WorkedFor
fat I-Symptom_WorkedFor
percentage O
, O
lower O
systolic O
blood B-Symptom_WorkedFor
pressure I-Symptom_WorkedFor
, O
and O
relieve O
anxiety B-Symptom_WorkedFor
for O
young O
, O
obese O
and O
overweight O
females O
, O
when O
given O
at O
2 B-Dosage
g I-Dosage
/ I-Dosage
d I-Dosage
for O
90 B-Duration
d I-Duration
. O

Anxiety B-Symptom_WorkedFor
is O
one O
of O
the O
most O
common O
mental O
disorders O
sharing O
extreme O
or O
pathological O
anxiety B-Symptom_WorkedFor
states O
as O
the O
primary O
disturbance O
in O
mood O
or O
emotional O
tone O
, O
with O
increased O
fear O
and O
exaggerated O
acute O
stress B-Symptom_WorkedFor
responses O
. O

Medicinal O
plants O
are O
very O
variable O
, O
but O
some O
of O
them O
are O
used O
as O
a O
spice O
such O
as O
curcumin B-Medicinal food
( O
Curcuma B-Drug/Scientific name
longa I-Drug/Scientific name
) O
. O

Curcumin B-Medicinal food
shows O
a O
wide O
range O
of O
pharmacological O
potentialities O
, O
however O
, O
little O
is O
known O
about O
its O
anxiolytic B-Symptom_WorkedFor
properties O
. O

The O
aim O
of O
our O
study O
was O
to O
assess O
the O
anti-anxiety O
potential O
of O
curcumin B-Medicinal food
extract O
against O
experimental O
lead O
induced-anxiety O
in O
rats O
. O

Experiments O
were O
carried O
out O
on O
male O
Wistar O
rats O
intoxicated O
acutely O
with O
an O
intraperitoneal O
injection O
of O
Pb O
( O
25mg O
/ O
kg O
B.W O
. O
) O
and O
/ O
or O
concomitantly O
with O
administration O
of O
curcumin O
( O
30 O
mg O
/ O
kg O
B.W O
. O
) O
for O
3 O
days O
. O

Using O
immunohistochemistry O
and O
anxiety O
assessment O
tests O
( O
dark O
light O
box O
and O
elevated O
plus O
maze O
) O
, O
we O
evaluated O
, O
respectively O
, O
the O
expression O
of O
serotonin O
( O
5HT O
) O
in O
the O
dorsal O
raphe O
nucleus O
( O
DRN O
) O
and O
the O
anxiety O
state O
in O
our O
animals O
. O

Our O
results O
showed O
, O
for O
the O
first O
time O
, O
a O
noticeable O
anxiolytic B-Symptom_WorkedFor
effect O
of O
curcumin B-Medicinal food
against O
lead O
induced O
anxiety B-Symptom_WorkedFor
in O
rats O
and O
this O
may O
possibly O
result O
from O
modulation O
of O
central O
neuronal O
monoaminergic O
neurotransmission O
, O
especially O
serotonin O
, O
which O
has O
shown O
a O
significant O
reduction O
of O
the O
immunoreactivity O
within O
the O
DRN O
. O

Background O
: O
Curcumin B-Medicinal food
, O
the O
principal O
curcuminoid O
derived O
from O
the O
spice O
turmeric B-Medicinal food
, O
influences O
several O
biological O
mechanisms O
associated O
with O
major B-Symptom_WorkedFor
depression I-Symptom_WorkedFor
, O
namely O
those O
associated O
with O
monoaminergic O
activity O
, O
immune-inflammatory O
and O
oxidative O
and O
nitrosative O
stress O
pathways O
, O
hypothalamus-pituitary-adrenal O
( O
HPA O
) O
axis O
activity O
and O
neuroprogression O
. O

We O
hypothesised O
that O
curcumin B-Medicinal food
would O
be O
effective O
for O
the O
treatment O
of O
depressive B-Symptom_WorkedFor
symptoms O
in O
individuals O
with O
major B-participant_health
depressive I-participant_health
disorder I-participant_health
. O

Methods O
: O
In O
a O
randomised O
, O
double-blind O
, O
placebo-controlled O
study O
, O
56 B-#Participants
individuals O
with O
major B-participant_health
depressive I-participant_health
disorder I-participant_health
were O
treated O
with O
curcumin B-Medicinal food
( O
500 B-Dosage
mg I-Dosage
twice I-Dosage
daily I-Dosage
) O
or O
placebo O
for O
8 B-Duration
weeks I-Duration
. O

The O
primary O
measure O
was O
the O
Inventory B-Metric
of I-Metric
Depressive I-Metric
Symptomatology I-Metric
self-rated I-Metric
version I-Metric
( O
IDS-SR30 B-Metric
) O
. O

Secondary O
outcomes O
included O
IDS-SR30 B-Metric
factor O
scores O
and O
the O
Spielberger B-Metric
State-Trait I-Metric
Anxiety I-Metric
Inventory I-Metric
( O
STAI B-Metric
) O
. O

Results O
: O
From O
baseline O
to O
week O
4 O
, O
both O
curcumin O
and O
placebo O
were O
associated O
with O
improvements O
in O
IDS-SR30 B-Metric
total O
score O
and O
most O
secondary O
outcome O
measures O
. O

From O
weeks O
4 O
to O
8 O
, O
curcumin B-Medicinal food
was O
significantly O
more O
effective O
than O
placebo O
in O
improving O
several O
mood-related O
symptoms O
, O
demonstrated O
by O
a O
significant O
group O
x O
time O
interaction O
for O
IDS-SR30 B-Metric
total O
score O
( O
F1 O
, O
53 O
= O
4.22 O
, O
p O
= O
.045 O
) O
and O
IDS-SR30 O
mood O
score O
( O
F1 O
, O
53 O
= O
6.51 O
, O
p O
= O
.014 O
) O
, O
and O
a O
non-significant O
trend O
for O
STAI B-Metric
trait O
score O
( O
F1 O
, O
48 O
= O
2.86 O
, O
p O
= O
.097 O
) O
. O

Greater O
efficacy O
from O
curcumin B-Medicinal food
treatment O
was O
identified O
in O
a O
subgroup O
of O
individuals O
with O
atypical O
depression B-Symptom_WorkedFor
. O

Conclusions O
: O
Partial O
support O
is O
provided O
for O
the O
antidepressant B-Symptom_WorkedFor
effects O
of O
curcumin B-Medicinal food
in O
people O
with O
major B-participant_health
depressive I-participant_health
disorder I-participant_health
, O
evidenced O
by O
benefits O
occurring O
4 O
to O
8 O
weeks O
after O
treatment O
. O

Limitations O
: O
Investigations O
with O
larger O
sample O
sizes O
, O
over O
extended O
treatment O
periods O
, O
and O
with O
varying O
curcumin B-Medicinal food
dosages O
are O
required O
. O

Background O
: O
Anxiety B-Symptom_TestedFor
disorders O
are O
very O
common O
mental O
health O
problems O
in O
the O
general O
population O
and O
in O
primary O
care O
settings O
. O

Herbal O
medicines O
are O
popular O
and O
used O
worldwide O
and O
might O
be O
considered O
as O
a O
treatment O
option O
for O
anxiety B-Symptom_TestedFor
if O
shown O
to O
be O
effective O
and O
safe O
. O

Objectives O
: O
To O
investigate O
the O
effectiveness O
and O
safety O
of O
valerian B-Medicinal food
for O
treating O
anxiety B-Symptom_TestedFor
disorders O
. O

Search O
strategy O
: O
Electronic O
searches O
: O
The O
Cochrane O
Collaboration O
Depression O
, O
Anxiety O
and O
Neurosis O
Cochrane O
Controlled O
Trials O
Register O
( O
CCDANCTR-Studies O
and O
CCDANCTR-References O
) O
searched O
on O
04 O
/ O
08 O
/ O
2006 O
, O
MEDLINE O
, O
Lilacs O
. O

References O
of O
all O
identified O
studies O
were O
inspected O
for O
additional O
studies O
. O

First O
authors O
of O
each O
included O
study O
, O
manufacturers O
of O
valerian B-Medicinal food
products O
, O
and O
experts O
in O
the O
field O
were O
contacted O
for O
information O
regarding O
unpublished O
trials O
. O

Selection O
criteria O
: O
Randomised O
controlled O
trials O
( O
RCTs O
) O
and O
quasi-randomised O
trials O
of O
valerian O
extract O
of O
any O
dose O
, O
regime O
, O
or O
method O
of O
administration O
, O
for O
people O
with O
any O
primary O
diagnosis O
of O
general O
anxiety O
disorder O
, O
anxiety O
neurosis O
, O
chronic O
anxiety O
status O
, O
or O
any O
other O
disorder O
in O
which O
anxiety B-Symptom_TestedFor
is O
the O
primary O
symptom O
( O
panic O
disorder O
, O
obsessive O
compulsive O
disorder O
, O
social O
phobia O
, O
agoraphobia O
, O
other O
types O
of O
phobia O
, O
postraumatic O
stress O
disorder O
) O
. O

Effectiveness O
was O
measured O
using O
clinical O
outcome O
measures O
and O
other O
scales O
for O
anxiety B-Symptom_TestedFor
symptoms O
. O

Data O
collection O
and O
analysis O
: O
Two O
review O
authors O
independently O
applied O
inclusion O
criteria O
, O
extracted O
and O
entered O
data O
, O
and O
performed O
the O
trial O
quality O
assessments O
. O

Where O
disagreements O
occurred O
, O
the O
third O
review O
author O
was O
consulted O
. O

Methodological O
quality O
of O
included O
trials O
was O
assessed O
using O
Cochrane O
Handbook O
criteria O
. O

For O
dichotomous O
outcomes O
, O
relative O
risk O
( O
RR O
) O
was O
calculated O
, O
and O
for O
continuous O
outcomes O
, O
the O
weighted O
mean O
difference O
( O
WMD O
) O
was O
calculated O
, O
with O
their O
respective O
95% O
confidence O
intervals O
. O

Main O
results O
: O
One O
RCT O
involving O
36 O
patients O
wih O
generalised O
anxiety O
disorder O
was O
eligible O
for O
inclusion O
. O

This O
was O
a O
4 B-Duration
week I-Duration
pilot O
study O
of O
valerian B-Medicinal food
, O
diazepam B-Other_ingredients
and O
placebo O
. O

There O
were O
no O
significant O
differences O
between O
the O
valerian O
and O
placebo O
groups O
in O
HAM-A B-Metric
total O
scores O
, O
or O
in O
somatic O
and O
psychic O
factor O
scores O
. O

Similarly O
, O
there O
were O
no O
significant O
differences O
in O
HAM-A B-Metric
scores O
between O
the O
valerian B-Medicinal food
and O
diazepam B-Other_ingredients
groups O
, O
although O
based O
on O
STAI-Trait B-Metric
scores I-Metric
, O
significantly O
greater O
symptom O
improvement O
was O
indicated O
in O
the O
diazepam O
group O
. O

There O
were O
no O
significant O
differences O
between O
the O
three O
groups O
in O
the O
number O
of O
patients O
reporting O
side O
effects O
or O
in O
dropout O
rates O
. O

Authors O
' O
conclusions O
: O
Since O
only O
one O
small O
study O
is O
currently O
available O
, O
there O
is O
insufficient O
evidence O
to O
draw O
any O
conclusions O
about O
the O
efficacy O
or O
safety O
of O
valerian B-Medicinal food
compared O
with O
placebo O
or O
diazepam B-Other_ingredients
for O
anxiety B-Symptom_TestedFor
disorders O
. O

RCTs O
involving O
larger O
samples O
and O
comparing O
valerian O
with O
placebo O
or O
other O
interventions O
used O
to O
treat O
of O
anxiety B-Symptom_TestedFor
disorders O
, O
such O
as O
antidepressants O
, O
are O
needed O
. O

Objective O
: O
Melissa B-Drug/Scientific name
officinalis I-Drug/Scientific name
( O
lemon B-Medicinal food
balm I-Medicinal food
) O
and O
Valeriana B-Drug/Scientific name
officinalis I-Drug/Scientific name
( O
valerian B-Medicinal food
) O
have O
been O
used O
both O
traditionally O
and O
contemporaneously O
as O
mild O
sedatives B-Symptom_WorkedFor
, O
anxiolytics B-Symptom_WorkedFor
and O
hypnotics B-Symptom_WorkedFor
. O

Recent O
research O
has O
suggested O
that O
both O
may O
attenuate O
laboratory O
induced O
stress B-Symptom_TestedFor
. O

As O
the O
two O
herbs O
are O
most O
often O
sold O
in O
combination O
with O
each O
other O
the O
current O
study O
assessed O
the O
anxiolytic O
properties O
of O
such O
a O
combination O
during O
laboratory-induced O
stress B-Symptom_TestedFor
. O

Methods O
: O
In O
this O
double-blind O
, O
placebo-controlled O
, O
randomized O
, O
balanced O
cross-over O
experiment O
, O
24 B-#Participants
healthy O
volunteers O
received O
three O
separate O
single O
doses O
( O
600 B-Dosage
mg I-Dosage
, O
1200 B-Dosage
mg I-Dosage
, O
1800 B-null
mg I-null
) O
of O
a O
standardized O
product O
containing O
M B-Medicinal food
. I-Medicinal food
officinalis I-Medicinal food
and I-Medicinal food
V I-Medicinal food
. I-Medicinal food
officinalis I-Medicinal food
extracts I-Medicinal food
, O
plus O
a O
placebo O
, O
on O
separate O
days O
separated O
by O
a O
7 O
day O
wash O
out O
period O
. O

Modulation O
of O
mood B-Symptom_TestedFor
and O
anxiety B-Symptom_TestedFor
were O
assessed O
during O
pre-dose O
and O
1 O
h O
, O
3 O
h O
and O
6 O
h O
post-dose O
completions O
of O
a O
20 O
min O
version O
of O
the O
Defined B-Metric
Intensity I-Metric
Stressor I-Metric
Simulation I-Metric
( I-Metric
DISS I-Metric
) I-Metric
battery I-Metric
. O

Cognitive O
performance O
on O
the O
four O
concurrent O
tasks O
of O
the O
battery O
was O
also O
assessed O
. O

Results O
: O
The O
results O
showed O
that O
the O
600 O
mg O
dose O
of O
the O
combination O
ameliorated O
the O
negative O
effects O
of O
the O
DISS O
on O
ratings O
of O
anxiety O
. O

However O
, O
the O
highest O
dose O
( O
1800 O
mg O
) O
showed O
an O
increase O
in O
anxiety O
that O
was O
less O
marked O
but O
which O
reached O
significance O
during O
one O
testing O
session O
. O

In O
addition O
, O
all O
three O
doses O
led O
to O
decrements O
in O
performance O
on O
the O
Stroop O
task O
module O
within O
the O
battery O
, O
and O
the O
two O
lower O
doses O
led O
to O
decrements O
on O
the O
overall O
score O
generated O
on O
the O
DISS O
battery O
. O

Conclusions O
: O
These O
results O
suggest O
that O
a O
combination O
of O
Melissa O
officinalis O
and O
Valeriana O
officinalis O
possesses O
anxiolytic O
properties O
that O
deserve O
further O
investigation O
. O

Aim O
& O
scope O
: O
Hysterosalpingography O
( O
HSG O
) O
is O
the O
radiographic O
evaluation O
of O
the O
uterine O
cavity O
and O
fallopian O
tubes O
, O
which O
is O
generally O
assumed O
as O
a O
stressful O
and O
painful O
procedure O
. O

This O
study O
aims O
to O
determine O
effect O
of O
oral O
Valeric B-Medicinal food
capsules O
on O
anxiety B-Symptom_TestedFor
severity O
in O
women O
under O
Hysterosalpingography O
. O

Method O
& O
examination O
: O
This O
study O
, O
as O
a O
double-blind O
clinical O
trial O
, O
was O
conducted O
on O
64 B-#Participants
infertile B-participant_health
women O
undergoing O
hysterosalpingography O
, O
who O
referred O
to O
radiology O
ward O
at O
Comprehensive O
Women's O
hospital O
. O

To O
measure O
anxiety B-Symptom_TestedFor
, O
visual B-Metric
analog I-Metric
anxiety I-Metric
scale I-Metric
was O
used O
90 O
minutes O
before O
starting O
procedure O
, O
individuals O
in O
intervention O
group O
( O
n O
= O
32 O
) O
received O
a O
single O
dose O
( O
1,500 B-Dosage
mg I-Dosage
) O
of O
3 B-Dosage
Valeric B-Drug/Scientific name
capsules I-Drug/Scientific name
, O
together O
with O
routine O
prophylaxy B-Other_ingredients
, O
where O
routine O
prophylaxis O
contains O
Mefenamic B-Other_ingredients
acid I-Other_ingredients
250mg B-Dosage
capsules O
in O
30 O
minutes O
before O
procedure O
, O
and O
the O
same O
capsules O
were O
prescribed O
to O
placebo O
group O
( O
n O
= O
32 O
) O
with O
the O
same O
instruction O
. O

Anxiety B-Symptom_TestedFor
severity O
before O
and O
once O
90 O
minutes O
after O
intervention O
in O
both O
groups O
were O
measured O
and O
compared O
. O

Results O
: O
There O
was O
no O
difference O
on O
anxiety O
severity O
before O
intervention O
in O
both O
groups O
( O
p O
= O
0.26 O
) O
, O
and O
the O
groups O
were O
homogeneous O
; O
after O
intervention O
, O
a O
significant O
difference O
on O
anxiety O
severity O
was O
reported O
in O
both O
groups O
( O
p O
< O
0 O
/ O
0001 O
) O
, O
and O
anxiety O
score O
in O
intervention O
group O
compared O
to O
placebo O
reduced O
statistically O
. O

Conclusion O
: O
Present O
study O
indicated O
that O
Valeric B-Medicinal food
was O
effective O
on O
reducing O
anxiety B-Symptom_WorkedFor
in O
women O
undergoing O
hysterosalpingography O
. O

Stress B-Symptom_TestedFor
is O
an O
increasing O
problem O
that O
can O
result O
in O
various O
psychiatric O
and O
somatoform O
symptoms O
. O

Among O
others O
, O
benzodiazepines B-Other_ingredients
and O
valerian B-Medicinal food
preparations O
are O
used O
to O
treat O
stress B-Symptom_TestedFor
symptoms O
. O

The O
aim O
of O
this O
study O
was O
to O
investigate O
whether O
the O
prescription O
of O
a O
fixed O
herbal O
extract O
combination O
of O
valerian B-Medicinal food
, O
lemon B-Medicinal food
balm I-Medicinal food
, O
passionflower B-Medicinal food
, O
and O
butterbur B-Medicinal food
( O
Ze B-Drug/Scientific name
185 I-Drug/Scientific name
) O
changes O
the O
prescription O
pattern O
of O
benzodiazepines B-Other_ingredients
in O
hospitalized O
psychiatric B-participant_health
patients O
. O

In O
a O
retrospective O
case-control O
study O
, O
anonymized O
medical O
record O
data O
from O
3,252 B-#Participants
psychiatric B-participant_health
in-house O
patients O
were O
analysed O
over B-Duration
a I-Duration
3.5 I-Duration
- I-Duration
year I-Duration
period O
. O

Cases O
( O
n O
= O
1,548 O
) O
with O
a O
prescription O
of O
Ze B-Drug/Scientific name
185 I-Drug/Scientific name
and O
controls O
( O
n O
= O
1,704 O
) O
were O
matched O
by O
age O
, O
gender O
, O
hospitalization O
interval O
, O
and O
main O
International B-Metric
Classification I-Metric
of I-Metric
Diseases I-Metric
, I-Metric
Version I-Metric
10 I-Metric
F-diagnoses I-Metric
. O

The O
primary O
objective O
was O
to O
investigate O
the O
effect O
of O
Ze B-Drug/Scientific name
185 I-Drug/Scientific name
on O
the O
prescription O
pattern O
of O
benzodiazepines B-Other_ingredients
. O

Secondary O
objectives O
investigated O
the O
prescriptions O
of O
concomitant O
drugs O
and O
effectiveness O
of O
the O
hospital O
stay O
. O

Distribution O
of O
drug O
classes O
was O
analysed O
using O
the O
WHO's O
anatomic-therapeutic-chemical O
code O
. O

Data O
showed O
that O
both O
treatment O
modalities O
had O
a O
comparable O
clinical O
effectiveness O
but O
with O
significantly O
less O
prescriptions O
of O
benzodiazepines B-Other_ingredients
in O
the O
Ze B-Drug/Scientific name
185 I-Drug/Scientific name
group O
( O
p O
= O
.006 O
) O
. O

This O
is O
of O
clinical O
importance O
because O
suitable O
alternatives O
to O
benzodiazepines B-Other_ingredients
are O
desirable O
. O

To O
obtain O
more O
support O
for O
this O
hypothesis O
, O
a O
dedicated O
randomized O
, O
controlled O
clinical O
trial O
monitoring O
drug O
safety O
is O
required O
. O

Valerian B-Medicinal food
root I-Medicinal food
is O
the O
most O
commonly O
used O
herbal O
supplement O
for O
sedation O
and O
anxiolysis O
, O
but O
it O
is O
unknown O
whether O
it O
may O
affect O
functional O
brain O
connectivity O
. O

Our O
goal O
was O
to O
use O
electroencephalography O
( O
EEG O
) O
to O
investigate O
whether O
valerian B-Medicinal food
root I-Medicinal food
extract I-Medicinal food
( O
VRE O
) O
affects O
resting-state O
connectivity O
changes O
and O
whether O
such O
changes O
are O
associated O
with O
clinical O
symptoms O
. O

This O
4 O
- O
week O
, O
double-blinded O
, O
randomized O
, O
placebo-controlled O
clinical O
trial O
was O
conducted O
with O
64 B-#Participants
nonclinical O
volunteers O
suffering O
psychological B-participant_health
stress I-participant_health
. O

The O
participants O
received O
VRE B-Medicinal food
( O
100 B-Dosage
mg I-Dosage
) O
or O
a O
placebo O
thrice O
daily O
. O

We O
examined O
VRE's O
therapeutic O
effects O
on O
anxiety B-Symptom_TestedFor
and O
stress-related B-Symptom_TestedFor
psychological O
constructs O
. O

Functional O
brain O
connectivity O
changes O
were O
measured O
as O
EEG O
coherence O
in O
the O
alpha O
and O
theta O
frequency O
bands O
. O

The O
VRE O
and O
placebo O
groups O
both O
exhibited O
significant O
postintervention O
improvements O
on O
all O
clinical O
scales O
, O
but O
no O
significant O
between-group O
differences O
in O
these O
changes O
were O
noted O
. O

Compared O
with O
the O
placebo O
group O
, O
the O
VRE O
group O
exhibited O
significantly O
greater O
increases O
in O
frontal O
brain O
region O
alpha O
coherence O
across O
four O
electrode O
pairs O
, O
and O
these O
changes O
were O
significantly O
correlated O
with O
anxiolysis O
. O

The O
VRE O
group O
also O
exhibited O
significantly O
greater O
decreases O
in O
theta O
coherence O
across O
another O
four O
electrodes O
pairs O
. O

Our O
findings O
indicate O
that O
VRE O
alters O
functional O
brain O
connectivity O
in O
relation O
to O
anxiety B-Symptom_WorkedFor
. O

Further O
EEG O
studies O
are O
needed O
to O
confirm O
VRE's O
neurophysiological O
effects O
. O

Dietary O
supplements O
are O
widely O
used O
for O
desired O
effects O
on O
memory O
, O
insomnia O
, O
mood O
and O
anxiety O
. O

This O
review O
focuses O
on O
supplements O
which O
have O
anxiolytic O
or O
mild O
relaxation O
properties O
and O
enhance O
mood O
. O

For O
example O
, O
Kava B-Medicinal food
( O
Piper B-Drug/Scientific name
methysticum I-Drug/Scientific name
) O
is O
reported O
to O
have O
anaxiolytic O
actions O
and O
to O
reduce O
tension O
through O
skeletal O
muscle B-Symptom_WorkedFor
relaxation I-Symptom_WorkedFor
. O

Dried B-Medicinal food
passion I-Medicinal food
flower I-Medicinal food
( O
genus B-Drug/Scientific name
Passiflora I-Drug/Scientific name
) O
is O
reported O
to O
reduce O
insomnia B-Symptom_WorkedFor
and O
hysteria B-Symptom_WorkedFor
. O

Skullcap B-Medicinal food
( O
genus B-Drug/Scientific name
Scutellaria I-Drug/Scientific name
) O
, O
hops B-Medicinal food
( O
Humulus B-Drug/Scientific name
lupulus I-Drug/Scientific name
) O
, O
lemon B-Medicinal food
balm I-Medicinal food
( O
Melissa B-Drug/Scientific name
officinalis I-Drug/Scientific name
) O
and O
Valerian B-Medicinal food
( O
Valeriana B-Drug/Scientific name
officinalis I-Drug/Scientific name
) O
root O
are O
all O
herbs O
reported O
as O
anaxiolytic B-Symptom_WorkedFor
calming I-Symptom_WorkedFor
agents O
. O

Further O
, O
extracts O
of O
Magnolia B-Medicinal food
and O
Phellondendron B-Medicinal food
bark I-Medicinal food
are O
mild O
sedatives O
. O

Supplements O
such O
as O
gamma-aminobutyric B-Other_ingredients
acid I-Other_ingredients
( O
GABA O
) O
, O
theanine B-Other_ingredients
, O
tryptophan B-Other_ingredients
and O
5 B-Other_ingredients
- I-Other_ingredients
hydroxytryptophan I-Other_ingredients
( O
5 O
- O
HTP O
) O
are O
reported O
to O
promote O
relaxation O
. O

In O
general O
, O
these O
supplements O
appear O
to O
act O
as O
GABA O
receptor O
agonists O
or O
to O
boost O
GABA O
levels O
, O
although O
Kava B-Medicinal food
inhibits O
both O
norephinephrine O
uptake O
and O
sodium O
and O
potassium O
channels O
and O
5 O
- O
HTP O
may O
act O
through O
elevation O
of O
serotonin O
. O

While O
questions O
remain O
in O
the O
literature O
regarding O
the O
medicinal O
value O
of O
these O
supplements O
in O
treating O
mood O
and O
anxiety B-Symptom_WorkedFor
disorders O
, O
based O
on O
cellular O
and O
animal O
studies O
as O
well O
as O
human O
clinical O
trials O
the O
literature O
supports O
a O
role O
for O
these O
preparations O
as O
useful O
alternatives O
in O
the O
management O
of O
the O
stress O
and O
anxiety O
of O
everyday O
life O
. O

Psychiatric O
patients O
often O
suffer O
from O
stress B-Symptom_WorkedFor
, O
anxiety B-Symptom_WorkedFor
and O
depression B-Symptom_WorkedFor
. O

Various O
plant O
extracts O
are O
known O
to O
fight O
stress B-Symptom_WorkedFor
( O
valerian B-Medicinal food
) O
, O
anxiety B-Symptom_WorkedFor
( O
passion B-Medicinal food
flower I-Medicinal food
) O
or O
depression B-Symptom_WorkedFor
( O
St O
. O

John's B-Medicinal food
wort I-Medicinal food
) O
. O

NEURAPAS B-Drug/Scientific name
® O
balance O
is O
a O
mixture O
of O
these O
three O
extracts O
and O
has O
been O
designed O
to O
cover O
this O
complex O
of O
psychiatric O
conditions O
. O

The O
study O
was O
initiated O
to O
quantitatively O
assess O
the O
effect O
of O
this O
combination O
on O
brain O
electric O
activity O
. O

Method O
: O
Quantitative B-Metric
electroencephalogram I-Metric
( O
EEG O
) O
current B-Metric
source I-Metric
density I-Metric
( O
CSD O
) O
recording O
from O
16 B-#Participants
healthy O
male O
and O
female O
human O
volunteers O
( O
average O
age O
49 O
years O
) O
was O
used O
in O
a O
randomized O
, O
placebo-controlled O
cross O
over O
study O
. O

Recordings O
were O
performed O
0 O
. O
5 O
, O
1 O
. O
5 O
, O
3 O
and O
4 O
hours O
after O
administration O
of O
the O
preparations O
under O
the O
conditions O
of O
6 O
min O
eyes O
open O
and O
5 O
min O
d2 O
concentration O
test O
, O
mathematical O
calculation O
test O
and O
memory O
test O
, O
respectively O
. O

All O
variables O
( O
electric O
power O
within O
6 O
frequency O
ranges O
at O
17 O
electrode O
positions O
) O
were O
fed O
into O
a O
linear O
discriminant O
analysis O
( O
eyes O
open O
condition O
) O
. O

In O
the O
presence O
of O
mental O
load O
these O
variables O
were O
used O
to O
construct O
brain O
maps O
of O
frequency O
changes O
. O

Results O
: O
Under O
the O
condition O
of O
mental O
load O
, O
centro-parietal O
spectral O
power O
remained O
statistically O
significantly O
lower O
within O
alpha1 O
, O
alpha2 O
and O
beta1 O
frequencies O
in O
the O
presence O
of O
verum O
in O
comparison O
to O
placebo O
. O

Discriminant O
analysis O
revealed O
a O
difference O
to O
placebo O
3 O
and O
4 O
hours O
after O
intake O
of O
6 B-Dosage
tablets O
of O
NEURAPAS B-Drug/Scientific name
® O
balance O
. O

Data O
location O
within O
the O
polydimensional O
space O
was O
projected O
into O
the O
area O
of O
the O
effects O
of O
sedative O
and O
anti-depressive O
reference O
drugs O
tested O
earlier O
under O
identical O
conditions O
. O

Results O
appeared O
closer O
to O
the O
effects O
of O
fluoxetine B-Other_ingredients
than O
to O
St O
. O

John's B-Medicinal food
wort I-Medicinal food
. I-Medicinal food

Conclusions O
: O
Analysis O
of O
the O
neurophysiological O
changes O
following O
the O
intake O
of O
NEURAPAS B-Drug/Scientific name
® O
balance O
revealed O
a O
similarity O
of O
frequency O
changes O
to O
those O
of O
calming B-Symptom_WorkedFor
and O
anti-depressive B-Symptom_WorkedFor
drugs O
on O
the O
EEG O
without O
impairment O
of O
cognition O
. O

Trial O
registration O
: O
ClinicalTrials.gov O
: O
NCT01047605 O
. O

Introduction O
: O
Rational O
phytotherapy O
is O
a O
modern O
concept O
of O
using O
plant-originated O
drugs O
which O
has O
emerged O
from O
the O
need O
to O
improve O
phytotherapy O
in O
order O
to O
make O
the O
use O
of O
herbal O
remedies O
more O
efficient O
and O
safer O
. O

The O
aim O
of O
this O
study O
was O
to O
give O
the O
health-care O
workers O
more O
information O
on O
the O
manufacturing O
process O
of O
high O
quality O
phytopreparation B-Drug/Scientific name
following O
principles O
of O
Good O
Manufacturing O
Practice O
and O
Good O
Laboratory O
Practice O
on O
the O
example O
of O
herbal O
sedative O
, O
Odoval O
S O
capsules O
. O

Material O
and O
methods O
: O
This O
study O
was O
designed O
to O
reflect O
the O
production O
process O
of O
a O
high-quality O
and O
safe O
herbal O
remedy O
, O
starting O
from O
defining O
the O
formulation O
and O
the O
production O
procedure O
to O
the O
quality O
control O
of O
raw O
materials O
, O
characterization O
of O
the O
final O
product O
, O
and O
testing O
stability O
of O
active O
ingredients O
in O
the O
capsules O
. O

Results O
: O
Formulation O
of O
the O
phytopreparation B-Drug/Scientific name
, O
validation O
of O
the O
production O
process O
, O
quality O
control O
and O
stability O
testing O
, O
all O
together O
have O
resulted O
in O
the O
production O
of O
capsules O
with O
defined O
valeric B-Medicinal food
acid I-Medicinal food
content O
( O
1 B-Dosage
mg I-Dosage
valeric B-Medicinal food
acid I-Medicinal food
per O
capsule O
) O
. O

Discussion O
: O
The O
preparation O
is O
recommended O
to O
relieve O
the O
symptoms O
caused O
by O
chronic B-Symptom_WorkedFor
stress I-Symptom_WorkedFor
( O
anxiety B-Symptom_WorkedFor
, O
irritability B-Symptom_WorkedFor
, O
fatigue B-Symptom_WorkedFor
, O
lack B-Symptom_WorkedFor
of I-Symptom_WorkedFor
concentration I-Symptom_WorkedFor
, O
heart B-Symptom_WorkedFor
palpitations I-Symptom_WorkedFor
) O
and O
for O
mild O
insomnia B-Symptom_WorkedFor
. O

Conclusion O
: O
This O
paper O
presents O
the O
complete O
cycle O
of O
the O
production O
of O
a O
phytopreparation O
on O
the O
example O
of O
a O
new O
herbal O
sedative O
- O
- O
Odoval B-Drug/Scientific name
S I-Drug/Scientific name
capsules I-Drug/Scientific name
. O

Valeriana B-Medicinal food
wallichii I-Medicinal food
, O
an O
Indian O
medicinal O
plant O
, O
has O
been O
on O
trial O
for O
its O
role O
in O
stress B-Symptom_WorkedFor
disorders O
in O
hospital O
based O
clinical O
set-up O
. O

Hamilton's B-Metric
Brief I-Metric
Psychiatric I-Metric
Rating I-Metric
Scale I-Metric
( O
BPRS O
) O
was O
used O
and O
thorough O
clinical O
investigations O
were O
carried O
out O
to O
screen O
the O
subjects O
. O

Thirty-three B-#Participants
subjects O
( O
20 O
male O
and O
13 O
female O
; O
average O
age O
34.2 O
years O
) O
were O
medicated O
with O
the O
plant O
extract O
in O
a O
fixed O
dose O
regime O
( O
500 B-Dosage
mg I-Dosage
/ I-Dosage
capsule I-Dosage
, O
twice O
daily O
, O
p.o O
. O
after O
meal O
) O
. O

They O
were O
thoroughly O
investigated O
clinically O
and O
using O
standard O
questionnaires O
based O
on O
different O
psychological O
rating O
scale O
at O
baseline O
( O
day O
0 O
) O
, O
mid-term O
( O
day O
30 O
) O
and O
final O
( O
day O
60 O
) O
. O

The O
observations O
exhibited O
that O
, O
V B-Medicinal food
wallichii I-Medicinal food
not O
only O
significantly O
( O
p O
< O
0.001 O
) O
attenuated O
stress B-Symptom_WorkedFor
and O
anxiety B-Symptom_WorkedFor
, O
but O
also O
significantly O
( O
p O
< O
0.001 O
) O
improved O
depression B-Symptom_WorkedFor
and O
also O
enhanced O
the O
willingness O
to O
adjustment O
. O

Nevertheless O
it O
did O
not O
alter O
memory O
, O
concentration O
or O
attention O
of O
the O
volunteers O
. O

The O
results O
suggest O
that O
V B-Medicinal food
wallichii I-Medicinal food
may O
be O
useful O
in O
the O
treatment O
of O
stress O
related O
disorders O
in O
human O
and O
may O
be O
a O
promising O
anti-stress O
agent O
in O
near O
future O
. O

Aims O
: O
To O
assess O
the O
effect O
of O
a O
real O
life O
mental O
stress B-Symptom_TestedFor
situation O
on O
blood O
pressure O
( O
BP O
) O
and O
heart O
rate O
( O
HR O
) O
in O
students O
undergoing O
a O
medical O
licensing O
examination O
. O

Method O
: O
Prospective O
observational O
study O
of O
121 B-#Participants
medical O
students O
taking O
the O
final O
licensing O
exam O
. O

BP O
and O
HR O
were O
taken O
before O
and O
after O
the O
exam O
. O

Additionally O
, O
BP O
was O
measured O
by O
ambulatory O
BP O
monitoring O
device O
and O
HR O
was O
recorded O
continuously O
by O
an O
HR O
monitor O
belt O
in O
25 O
students O
throughout O
the O
examination O
. O

Major O
findings O
: O
Diastolic O
BP O
( O
DBP O
) O
increased O
from O
81 O
+ O
/ O
- O
10 O
mmHg O
before O
the O
exam O
to O
86 O
+ O
/ O
- O
9 O
mmHg O
( O
p O
= O
0.008 O
) O
during O
the O
exam O
and O
to O
88 O
+ O
/ O
- O
11 O
mmHg O
, O
( O
p O
= O
0.007 O
) O
15 O
min O
after O
the O
exam O
. O

Systolic O
BP O
( O
SBP O
) O
did O
not O
increase O
significantly O
during O
( O
from O
131 O
+ O
/ O
- O
14 O
before O
the O
exam O
to O
136 O
+ O
/ O
- O
18 O
mmHg O
) O
and O
after O
the O
exam O
( O
135 O
+ O
/ O
- O
16 O
mmHg O
) O
. O

HR O
decreased O
during O
( O
to O
100 O
+ O
/ O
- O
18 O
beats O
/ O
min O
, O
p O
< O
0.001 O
) O
, O
and O
after O
the O
exam O
( O
to O
95 O
+ O
/ O
- O
19 O
beats O
/ O
min O
, O
p O
< O
0.001 O
) O
compared O
to O
values O
before O
the O
exam O
( O
114 O
+ O
/ O
- O
19 O
beats O
/ O
min O
) O
. O

SBP O
was O
higher O
in O
male O
students O
compared O
to O
female O
students O
before O
( O
138 O
+ O
/ O
- O
10 O
vs O
125 O
+ O
/ O
- O
18 O
mmHg O
) O
and O
after O
( O
126 O
+ O
/ O
- O
18 O
vs O
115 O
+ O
/ O
- O
17 O
mmHg O
) O
the O
exam O
( O
p O
< O
0.01 O
) O
. O

Conclusion O
: O
Only O
DBP O
increased O
during O
medical O
licensing O
examination O
, O
albeit O
within O
a O
small O
range O
. O

SBP O
did O
not O
change O
significantly O
and O
HR O
decreased O
during O
the O
exam O
. O

Male O
students O
showed O
a O
higher O
SBP O
compared O
to O
female O
students O
. O

In O
a O
previous O
study O
, O
we O
demonstrated O
that O
a O
Valeriana B-Medicinal food
officinalis I-Medicinal food
extract O
could O
attenuate O
increases O
in O
serum O
corticosterone O
levels O
in O
a O
mouse O
model O
of O
physical O
and O
psychological O
stress B-Symptom_WorkedFor
. O

In O
addition O
, O
our O
results O
showed O
that O
the O
extract O
could O
modulate O
serotonin O
( O
5 O
- O
HT O
) O
and O
norepinephrine O
( O
NE O
) O
turnover O
in O
the O
hippocampus O
and O
amygdala O
region O
. O

In O
this O
study O
, O
we O
intended O
to O
investigate O
the O
effects O
of O
valerenic B-Drug/Scientific name
acid I-Drug/Scientific name
( O
VA O
) O
, O
the O
main O
component O
of O
V B-Medicinal food
. I-Medicinal food
officinalis I-Medicinal food
extract O
, O
on O
corticosterone O
levels O
in O
serum O
in O
normal O
mice O
and O
monoamine O
turnover O
in O
hippocampus-amygdala O
homogenates O
in O
a O
mouse O
model O
of O
physical O
and O
psychological O
stress O
. O

To O
determine O
the O
minimum O
dose O
of O
VA O
for O
antianxiety O
effect O
, O
eight-week-old O
ICR O
mice O
were O
orally O
administered O
VA O
( O
0.2 O
, O
0.5 O
, O
and O
1.0 O
mg O
/ O
kg O
/ O
0.3 O
mL O
) O
once O
daily O
for O
3 O
weeks O
to O
probe O
for O
immobility O
time O
and O
serum O
corticosterone O
levels O
. O

At O
a O
VA O
dose O
of O
0.5 O
and O
1.0 O
mg O
/ O
kg O
, O
animals O
showed O
a O
decrease O
in O
the O
duration O
of O
immobility O
time O
and O
serum O
corticosterone O
levels O
. O

To O
confirm O
the O
antianxiety O
effect O
of O
VA O
, O
eight-week-old O
ICR O
mice O
received O
VA O
at O
a O
dose O
of O
0.5 O
mg O
/ O
kg O
, O
orally O
, O
once O
daily O
for O
3 O
weeks O
, O
before O
being O
subjected O
to O
physical O
or O
psychological O
stress O
for O
3 O
days O
, O
in O
a O
specially O
designed O
communication O
box O
, O
followed O
by O
estimation O
of O
levels O
of O
monoamines O
and O
their O
metabolites O
in O
the O
hippocampus-amygdala O
region O
. O

In O
conclusion O
, O
VA O
administration O
at O
0.5 O
mg O
/ O
kg O
can O
mitigate O
the O
physical O
and O
psychological O
stress O
response O
by O
decreasing O
the O
turnover O
of O
5 O
- O
HT O
to O
5 O
- O
hydroxyindoleacetic O
acid O
and O
NE O
to O
3 O
- O
methoxy O
- O
4 O
- O
hydroxyphenylethyleneglycol O
sulfate O
in O
the O
hippocampus O
and O
amygdala O
. O

Objective O
: O
A O
growing O
number O
of O
researchers O
have O
examined O
the O
use O
of O
over-the-counter O
( O
OTC O
) O
medications O
and O
herbal O
or O
dietary O
supplements O
among O
college O
students O
. O

There O
is O
concern O
about O
the O
efficacy O
and O
safety O
of O
these O
products O
, O
particularly O
because O
students O
appear O
to O
use O
them O
at O
a O
higher O
rate O
than O
does O
the O
general O
public O
. O

Participants O
and O
methods O
: O
The O
authors O
administered O
surveys O
to O
college O
students O
( O
N O
= O
201 B-#Participants
) O
to O
assess O
the O
frequency O
of O
use O
in O
the O
past O
week O
. O

Results O
: O
A O
substantial O
percentage O
reported O
using O
OTC O
medications O
( O
74.1% O
) O
, O
herbal O
or O
dietary O
supplements O
( O
70.6% O
) O
, O
or O
both O
concurrently O
( O
61.2% O
) O
. O

Dose O
frequency O
of O
OTC O
medications O
was O
the O
best O
predictor O
of O
self-reported O
emotional B-Symptom_WorkedFor
distress I-Symptom_WorkedFor
in O
the O
past O
week O
. O

Higher O
doses O
of O
products O
containing O
pseudoephedrine B-Other_ingredients
or O
valerian B-Medicinal food
were O
associated O
with O
self-reported O
anxiety B-Symptom_WorkedFor
. O

Conclusions O
: O
These O
data O
further O
reflect O
an O
increasing O
trend O
toward O
self-medication O
among O
college O
students O
. O

Investigators O
must O
conduct O
reliability O
and O
validity O
studies O
to O
evaluate O
the O
clinical O
utility O
of O
the O
measurement O
tool O
developed O
in O
this O
study O
. O

Introduction O
: O
Anxiety B-Symptom_WorkedFor
is O
one O
of O
the O
components O
of O
patient O
stress B-Symptom_TestedFor
in O
the O
dental O
office O
and O
is O
recognized O
as O
one O
of O
the O
main O
factors O
that O
negatively O
affect O
treatment O
. O

The O
control O
of O
anxiety B-Symptom_WorkedFor
can O
be O
performed O
through O
conscious O
sedation O
, O
for O
which O
benzodiazepine B-Other_ingredients
is O
the O
drug O
of O
choice O
in O
dental O
practice O
, O
however O
present O
side-effects O
. O

Objective O
: O
The O
objective O
of O
the O
following O
study O
is O
to O
evaluate O
the O
efficacy O
of O
Valeriana B-Medicinal food
officinalis I-Medicinal food
L I-Medicinal food
. O

( O
Valerian B-Medicinal food
) O
for O
control O
of O
anxiety B-Symptom_WorkedFor
during O
the O
third O
molar O
surgery O
. O

Materials O
and O
methods O
: O
A O
single O
oral O
dose O
of O
either O
Valerian B-Medicinal food
( O
100 B-Dosage
mg I-Dosage
) O
or O
placebo O
was O
randomly O
administered O
1 O
h O
before O
each O
surgical O
procedure O
to O
20 B-#Participants
volunteers O
between O
17 O
and O
31 O
years O
of O
age O
. O

Anxiety O
level O
was O
assessed O
by O
physiological O
parameters O
( O
blood O
pressure O
and O
heart O
rate O
[ O
HR O
] O
) O
and O
the O
observation O
of O
signs O
. O

Descriptive B-Metric
analysis I-Metric
, O
Chi-square B-Metric
test I-Metric
, O
Friedman B-Metric
test I-Metric
, O
Wilcoxon B-Metric
test I-Metric
and O
effect B-Metric
size I-Metric
test O
were O
performed O
( O
P O
< O
0.05 O
) O
. O

Results O
: O
According O
to O
the O
researcher's O
( O
80% O
) O
and O
surgeon's O
( O
75% O
) O
evaluations O
, O
the O
patients O
treated O
with O
Valerian B-Medicinal food
were O
calmer O
and O
more O
relaxed O
during O
surgery O
. O

Valerian O
had O
a O
greater O
effect O
on O
the O
maintenance O
of O
systolic O
blood B-Symptom_WorkedFor
pressure I-Symptom_WorkedFor
and O
HR O
after O
surgery O
. O

Conclusion O
: O
Valerian O
was O
more O
effective O
at O
controlling O
anxiety B-Symptom_WorkedFor
than O
a O
placebo O
when O
used O
for O
the O
conscious O
sedation O
of O
adult O
patients O
submitted O
to O
impacted O
lower O
third O
molar O
surgery O
. O

Anxiety B-Symptom_TestedFor
disorders O
are O
chronic O
and O
functionally O
disabling O
conditions O
with O
high O
psychological O
stress B-Symptom_TestedFor
, O
characterised O
by O
cognitive O
symptoms O
of O
excessive O
worry B-Symptom_TestedFor
and O
focus O
difficulties O
and O
physiological O
symptoms O
such O
as O
muscle B-Symptom_TestedFor
tension I-Symptom_TestedFor
and O
insomnia B-Symptom_TestedFor
. O

Gamma-aminobutyric O
acid O
( O
GABA O
) O
is O
an O
inhibitory O
neurotransmitter O
within O
the O
central O
nervous O
system O
and O
is O
a O
key O
target O
of O
pharmacotherapies O
in O
the O
treatment O
of O
anxiety B-Symptom_TestedFor
. O

Although O
current O
pharmaceutical O
treatments O
are O
often O
efficacious O
, O
they O
may O
cause O
undesirable O
side O
effects O
including O
cognitive O
decrements O
and O
withdrawal O
symptoms O
. O

Plant-based O
" O
phytomedicines O
" O
may O
provide O
novel O
treatment O
options O
, O
to O
act O
as O
an O
adjunctive O
or O
alternative O
to O
existing O
anxiolytic O
medications O
. O

As O
such O
, O
we O
conducted O
a O
systematic O
review O
to O
assess O
the O
current O
body O
of O
literature O
on O
anxiolytic O
phytomedicines O
and O
/ O
or O
phytoconstituents O
. O

An O
open-ended O
search O
to O
5 O
July O
2017 O
was O
conducted O
using O
MEDLINE O
( O
PubMed O
) O
, O
Scopus O
, O
and O
Cochrane O
library O
online O
databases O
and O
performed O
in O
a O
stepped O
format O
from O
preclinical O
to O
clinical O
investigations O
. O

Eligible O
studies O
must O
have O
had O
( O
a O
) O
in O
vitro O
evidence O
of O
GABA-modulating O
activity O
, O
( O
b O
) O
animal O
studies O
using O
anxiety O
models O
to O
test O
an O
anxiolytic O
effect O
, O
and O
( O
c O
) O
human O
clinical O
trials O
. O

Ten O
phytomedicines O
were O
identified O
as O
having O
preclinical O
investigations O
showing O
interaction O
with O
the O
GABA O
system O
, O
in O
addition O
to O
human O
clinical O
trials O
: O
kava B-Medicinal food
, O
valerian B-Medicinal food
, O
pennywort B-Medicinal food
, O
hops B-Medicinal food
, O
chamomile B-Medicinal food
, O
Ginkgo B-Medicinal food
biloba I-Medicinal food
, O
passionflower B-Medicinal food
, O
ashwagandha B-Medicinal food
, O
skullcap B-Medicinal food
, O
and O
lemon B-Medicinal food
balm I-Medicinal food
. O

Collectively O
, O
the O
literature O
reveals O
preclinical O
and O
clinical O
evidence O
for O
various O
phytomedicines O
modulating O
GABA-pathways O
, O
with O
comparative O
anxiolytic O
effect O
to O
the O
current O
array O
of O
pharmaceuticals O
, O
along O
with O
good O
safety O
and O
tolerability O
profiles O
. O

Background O
: O
Considering O
the O
negative O
effects O
of O
stress B-Symptom_WorkedFor
on O
health O
, O
there O
is O
a O
growing O
interest O
in O
stress-reducing B-Symptom_WorkedFor
interventions O
. O

The O
present O
study O
examines O
the O
effects O
of O
a O
fixed O
combination O
of O
valerian B-Medicinal food
, O
passion B-Medicinal food
flower I-Medicinal food
, O
lemon B-Medicinal food
balm I-Medicinal food
, O
and O
butterbur B-Medicinal food
extracts O
( O
Ze B-Drug/Scientific name
185 I-Drug/Scientific name
) O
on O
biological O
and O
affective O
responses O
to O
a O
standardized O
psychosocial O
stress B-Symptom_WorkedFor
paradigm O
. O

Purpose O
: O
The O
aim O
of O
the O
present O
study O
was O
to O
investigate O
the O
efficacy O
of O
Ze B-Drug/Scientific name
185 I-Drug/Scientific name
on O
cortisol O
and O
anxiety B-Symptom_WorkedFor
stress B-Symptom_WorkedFor
responses O
to O
acute O
psychosocial O
stress B-Symptom_WorkedFor
in O
healthy O
subjects O
. O

Study O
design O
: O
This O
study O
was O
a O
randomized O
, O
placebo-controlled O
, O
double O
blind O
study O
with O
3 O
parallel O
groups O
. O

Methods O
: O
72 B-#Participants
healthy O
male O
participants O
were O
randomized O
to O
3 O
groups O
( O
Ze B-Drug/Scientific name
185 I-Drug/Scientific name
, O
placebo O
or O
no O
treatment O
) O
during O
4 O
days O
prior O
to O
a O
standardized O
psychosocial O
stress B-Symptom_WorkedFor
paradigm O
. O

Principle O
outcomes O
were O
salivary O
cortisol O
and O
self-reported O
anxiety O
responses O
to O
stress O
assessed O
at O
the O
fourth O
day O
. O

Results O
: O
The O
stress O
paradigm O
induced O
significant O
and O
large O
cortisol O
and O
self-reported O
anxiety O
responses O
. O

Groups O
did O
not O
differ O
significantly O
in O
their O
salivary O
cortisol O
response O
to O
stress O
, O
but O
participants O
in O
the O
Ze B-Drug/Scientific name
185 I-Drug/Scientific name
condition O
showed O
significantly O
attenuated O
responses O
in O
self-reported O
anxiety O
in O
comparison O
to O
placebo O
( O
F O
( O
3 O
, O
41 O
) O
= O
3.33 O
, O
p O
= O
0.03 O
) O
and O
no O
treatment O
( O
F O
( O
3 O
, O
43 O
) O
= O
2.77 O
, O
p O
= O
0.05 O
) O
. O

Conclusion O
: O
The O
results O
show O
that O
Ze B-Drug/Scientific name
185 I-Drug/Scientific name
significantly O
attenuated O
the O
subjective O
emotional O
stress O
response O
during O
an O
acute O
stress O
situation O
, O
without O
affecting O
biological O
stress O
responses O
. O

Given O
that O
a O
circumscribed O
biological O
stress O
response O
is O
to O
be O
considered O
as O
an O
adaptive O
mechanism O
, O
Ze B-Drug/Scientific name
185 I-Drug/Scientific name
reduces O
self-reported O
anxiety O
response O
to O
stress O
without O
affecting O
assumingly O
adaptive O
biological O
stress O
responses O
. O

Objective O
: O
An O
examination O
of O
the O
relationship O
of O
plasma O
cobalamin B-Drug/Scientific name
( O
vitamin B-Medicinal food
B I-Medicinal food
( I-Medicinal food
12 I-Medicinal food
) O
) O
level O
to O
overall O
psychological B-Symptom_WorkedFor
distress I-Symptom_WorkedFor
, O
specific O
mood O
states O
, O
and O
major B-Symptom_WorkedFor
depressive I-Symptom_WorkedFor
disorder I-Symptom_WorkedFor
was O
conducted O
in O
159 B-#Participants
bereaved O
men O
( O
90 O
HIV B-participant_health
- I-participant_health
1 I-participant_health
( O
+ O
) O
and O
69 O
HIV B-participant_health
- I-participant_health
1 I-participant_health
( O
- O
) O
) O
. O

Methods O
: O
The O
relationship O
of O
a O
continuous O
measure O
of O
cobalamin B-Drug/Scientific name
level O
to O
psychological B-Symptom_WorkedFor
distress I-Symptom_WorkedFor
was O
examined O
, O
while O
controlling O
for O
HIV B-participant_health
- I-participant_health
1 I-participant_health
serostatus O
, O
life O
stressors O
, O
social O
support O
, O
and O
coping O
styles O
. O

Results O
: O
Of O
this O
sample O
, O
23.9% O
were O
either O
overtly O
or O
marginally O
cobalamin B-Drug/Scientific name
deficient O
; O
however O
, O
the O
deficiency O
rate O
was O
not O
significantly O
different O
by O
HIV O
- O
1 O
serostatus O
. O

Cobalamin B-Drug/Scientific name
level O
was O
inversely O
related O
to O
self-reported O
overall O
distress B-Symptom_WorkedFor
level O
and O
specifically O
to O
depression B-Symptom_WorkedFor
, O
anxiety B-Symptom_WorkedFor
, O
and O
confusion O
subscale O
scores O
, O
as O
well O
as O
to O
clinically O
rated O
depressed O
and O
anxious O
mood O
. O

Lower O
plasma O
cobalamin B-Drug/Scientific name
levels O
also O
were O
associated O
with O
the O
presence O
of O
symptoms O
consistent O
with O
major B-Symptom_WorkedFor
depressive I-Symptom_WorkedFor
disorder I-Symptom_WorkedFor
. O

Conclusion O
: O
These O
findings O
suggest O
that O
cobalamin O
level O
may O
be O
physiologically O
related O
to O
depressed O
and O
anxious O
mood O
level O
, O
as O
well O
as O
to O
syndromal B-Symptom_WorkedFor
depression I-Symptom_WorkedFor
. O

Acute O
, O
non-clinical O
insomnia B-Symptom_WorkedFor
is O
not O
uncommon O
. O

Sufferers O
commonly O
turn O
to O
short-term O
use O
of O
herbal O
supplements O
to O
alleviate O
the O
symptoms O
. O

This O
placebo-controlled O
, O
double-blind O
study O
investigated O
the O
efficacy O
of O
LZComplex3 B-Drug/Scientific name
( O
lactium B-Other_ingredients
™ O
, O
Zizyphus B-Other_ingredients
, O
Humulus B-Other_ingredients
lupulus I-Other_ingredients
, O
magnesium B-Other_ingredients
and O
vitamin B-Medicinal food
B6 I-Medicinal food
) O
, O
in O
otherwise O
healthy O
adults O
with O
mild O
insomnia B-Symptom_WorkedFor
. O

After O
a O
7 O
- O
day O
single-blind O
placebo O
run-in O
, O
eligible O
volunteers O
( O
n O
= O
171 B-#Participants
) O
were O
randomized O
( O
1 O
: O
1 O
) O
to O
receive O
daily O
treatment O
for O
2 B-Duration
weeks I-Duration
with O
LZComplex3 B-Drug/Scientific name
or O
placebo O
. O

Results O
revealed O
that O
sleep O
quality O
measured O
by O
change O
in O
Pittsburgh B-Metric
Sleep I-Metric
Quality I-Metric
Index I-Metric
( O
PSQI O
) O
score O
improved O
in O
both O
the O
LZComplex3 B-Drug/Scientific name
and O
placebo O
groups O
. O

There O
were O
no O
significant O
between O
group O
differences O
between O
baseline O
and O
endpoint O
on O
the O
primary O
outcome O
. O

The O
majority O
of O
secondary O
outcomes O
, O
which O
included O
daytime O
functioning O
and O
physical B-Symptom_WorkedFor
fatigue I-Symptom_WorkedFor
, O
mood B-Symptom_WorkedFor
and O
anxiety B-Symptom_WorkedFor
, O
cognitive B-Symptom_WorkedFor
performance I-Symptom_WorkedFor
, O
and O
stress B-Symptom_WorkedFor
reactivity O
, O
showed O
similar O
improvements O
in O
the O
LZComplex3 B-Drug/Scientific name
and O
placebo O
groups O
. O

A O
similar O
proportion O
of O
participants O
reported O
adverse O
events O
( O
AEs O
) O
in O
both O
groups O
, O
with O
two O
of O
four O
treatment-related O
AEs O
in O
the O
LZComplex3 B-Drug/Scientific name
group O
resulting O
in O
permanent O
discontinuation O
. O

It O
currently O
cannot O
be O
concluded O
that O
administration O
of O
LZComplex3 B-Drug/Scientific name
for O
2 B-Duration
weeks I-Duration
improves O
sleep B-Symptom_WorkedFor
quality I-Symptom_WorkedFor
, O
however O
, O
a O
marked O
placebo O
response O
( O
despite O
placebo O
run-in O
) O
and O
/ O
or O
short O
duration O
of O
treatment O
may O
have O
masked O
a O
potential O
beneficial O
effect O
on O
sleep B-Symptom_WorkedFor
quality I-Symptom_WorkedFor
. O

Introduction O
: O
Animal O
and O
clinical O
studies O
suggest O
complementary O
effects O
of O
magnesium B-Other_ingredients
and O
high-dose O
pyridoxine B-Drug/Scientific name
( O
vitamin B-Medicinal food
B6 I-Medicinal food
) O
on O
stress B-Symptom_WorkedFor
reduction O
. O

This O
is O
the O
first O
randomized O
trial O
evaluating O
the O
effects O
of O
combined O
magnesium B-Other_ingredients
and O
vitamin B-Medicinal food
B6 I-Medicinal food
supplementation O
on O
stress B-Symptom_WorkedFor
in O
a O
stressed O
population O
with O
low O
magnesemia O
using O
a O
validated O
measure O
of O
perceived O
stress O
. O

Methods O
: O
In O
this O
Phase O
IV O
, O
investigator-blinded O
trial O
( O
EudraCT O
: O
2015 O
- O
003749 O
- O
24 O
) O
, O
healthy O
adults O
with O
Depression B-Metric
Anxiety I-Metric
Stress I-Metric
Scales I-Metric
( O
DASS B-Metric
- I-Metric
42 I-Metric
) I-Metric
stress I-Metric
subscale I-Metric
score O
> O
18 O
and O
serum O
magnesium B-Other_ingredients
concentration O
0.45 B-Dosage
mmol I-Dosage
/ I-Dosage
L I-Dosage
- I-Dosage
0.85 I-Dosage
mmol I-Dosage
/ I-Dosage
L I-Dosage
, O
were O
randomized O
1 O
: O
1 O
to O
magnesium-vitamin B-Drug/Scientific name
B6 I-Drug/Scientific name
combination I-Drug/Scientific name
( O
Magne B-Drug/Scientific name
B6 I-Drug/Scientific name
[ I-Drug/Scientific name
Mg-vitamin I-Drug/Scientific name
B6 I-Drug/Scientific name
] O
; O
daily O
dose O
300 B-Dosage
mg I-Dosage
and I-Dosage
30 I-Dosage
mg I-Dosage
, O
respectively O
) O
or O
magnesium B-Other_ingredients
alone O
( O
Magnespasmyl O
[ O
Mg O
] O
; O
daily O
dose O
300 B-Dosage
mg I-Dosage
) O
. O

Outcomes O
included O
change O
in O
DASS B-Metric
- I-Metric
42 I-Metric
stress I-Metric
subscale I-Metric
score O
from O
baseline O
to O
Week O
8 O
( O
primary O
endpoint O
) O
and O
Week O
4 O
, O
and O
incidence O
of O
adverse O
events O
( O
AEs O
) O
. O

Results O
: O
In O
the O
modified O
intention-to-treat O
analysis O
( O
N O
= O
264 B-#Participants
subjects O
) O
, O
both O
treatment O
arms O
substantially O
reduced O
DASS B-Metric
- I-Metric
42 I-Metric
stress I-Metric
subscale I-Metric
score O
from O
baseline O
to O
Week O
8 O
( O
Mg-vitamin O
B6 O
, O
44.9% O
; O
Mg O
42.4% O
) O
; O
no O
statistical O
difference O
between O
arms O
was O
observed O
( O
p O
> O
0.05 O
) O
. O

An O
interaction O
( O
p O
= O
0.0097 O
) O
between O
baseline O
stress O
level O
and O
treatment O
warranted O
subgroup O
analysis O
( O
as O
per O
statistical O
plan O
) O
; O
adults O
with O
severe O
/ O
extremely O
severe O
stress B-Symptom_WorkedFor
( O
DASS B-Metric
- I-Metric
42 I-Metric
stress I-Metric
subscale I-Metric
score O
≥ O
25 O
; O
N O
= O
162 O
) O
had O
a O
24% O
greater O
improvement O
with O
Mg-vitamin B-Drug/Scientific name
B6 I-Drug/Scientific name
versus O
Mg B-Other_ingredients
at O
Week O
8 O
( O
3.16 O
points O
, O
95% O
CI O
0.50 O
to O
5.82 O
, O
p O
= O
0.0203 O
) O
. O

Consistent O
results O
were O
observed O
in O
the O
per O
protocol O
analysis O
and O
at O
Week O
4 O
. O

Overall O
, O
12.1% O
of O
Mg-vitamin B-Drug/Scientific name
B6 I-Drug/Scientific name
treated O
and O
17.4% O
of O
Mg-treated B-Other_ingredients
subjects O
experienced O
AEs O
potentially O
treatment O
related O
. O

Conclusions O
: O
These O
findings O
suggest O
oral O
Mg B-Other_ingredients
supplementation O
alleviated O
stress B-Symptom_WorkedFor
in O
healthy O
adults O
with O
low O
magnesemia O
and O
the O
addition O
of O
vitamin O
B6 O
to O
Mg O
was O
not O
superior O
to O
Mg O
supplementation O
alone O
. O

With O
regard O
to O
subjects O
with O
severe O
/ O
extremely O
severe O
stress B-Symptom_WorkedFor
, O
this O
study O
provides O
clinical O
support O
for O
greater O
benefit O
of O
Mg B-Other_ingredients
combined O
with O
vitamin B-Medicinal food
B6 I-Medicinal food
. O

nan O

When O
the O
5 B-Other_ingredients
- I-Other_ingredients
fluorouracil I-Other_ingredients
, O
leucovorin B-Medicinal food
, O
and O
oxaliplatin B-Other_ingredients
( O
FOLFOX B-Drug/Scientific name
) O
chemotherapy O
regimen O
is O
used O
to O
treat O
colorectal B-Symptom_TestedFor
cancer I-Symptom_TestedFor
( O
CRC B-Symptom_TestedFor
) O
, O
chemotherapy-induced O
peripheral O
neuropathy O
( O
CIPN O
) O
caused O
by O
oxaliplatin B-Other_ingredients
can O
substantially O
affect O
quality B-Metric
of I-Metric
life I-Metric
( O
QOL B-Metric
) O
in O
the O
CRC B-Symptom_TestedFor
patients O
. O

This O
study O
compared O
emotional O
distress O
and O
QOL B-Metric
during O
FOLFOX B-Drug/Scientific name
in O
CRC B-Symptom_TestedFor
patients O
with O
and O
without O
CIPN O
symptoms.This O
cross-sectional O
, O
descriptive O
, O
and O
comparative O
study O
recruited O
68 B-#Participants
CRC B-participant_health
patients O
receiving O
FOLFOX B-Drug/Scientific name
at O
a O
local O
teaching O
hospital O
and O
at O
a O
medical O
center O
in O
southern O
Taiwan O
. O

Self-reported O
structured O
questionnaires O
( O
oxaliplatin-associated O
neuropathy O
questionnaire O
, O
profile O
of O
mood O
states O
short O
form O
, O
and O
the O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
Quality O
of O
Life O
Questionnaire O
, O
Core O
30 O
, O
version O
3.0 O
) O
were O
used O
for O
1 O
- O
time O
data O
collection O
. O

The O
Chi-square B-Metric
test I-Metric
, O
Fisher B-Metric
exact I-Metric
test I-Metric
, O
and O
Mann-Whitney B-Metric
U I-Metric
test I-Metric
were O
used O
to O
analyze O
data O
, O
and O
a O
P-value O
< O
.05 O
was O
considered O
statistically O
significant.The O
CIPN O
group O
had O
45 O
( O
66.2% O
) O
patients O
, O
and O
the O
non-CIPN O
group O
had O
23 O
( O
33.8% O
) O
patients O
. O

The O
5 O
most O
common O
symptoms O
were O
coldness-related O
burning O
sensation O
or O
discomfort O
in O
the O
upper O
limbs O
, O
numbness O
in O
the O
upper O
limbs O
, O
tingling O
in O
the O
upper O
limbs O
, O
impairment O
of O
vision O
, O
and O
discomfort O
in O
the O
throat O
. O

The O
CIPN O
group O
had O
more O
females O
( O
P O
= O
.013 O
) O
, O
a O
more O
advanced O
stage O
of O
CRC B-Symptom_TestedFor
( O
P O
= O
.04 O
) O
and O
a O
higher O
chemotherapy O
dosage O
( O
P O
= O
.006 O
) O
. O

The O
2 O
groups O
did O
not O
significantly O
differ O
in O
anxiety O
( O
P O
= O
.065 O
) O
or O
depression O
( O
P O
= O
.135 O
) O
. O

Compared O
to O
the O
non-CIPN O
group O
, O
the O
CIPN O
group O
had O
significantly O
lower O
functioning O
( O
P O
= O
.001 O
) O
and O
global O
health O
status O
( O
P O
< O
.001 O
) O
and O
significantly O
more O
symptoms O
( O
P O
< O
.001 O
) O
. O
The O
CIPN O
group O
had O
significantly O
lower O
QOL B-Metric
compared O
to O
the O
non-CIPN O
group O
. O

However O
, O
the O
CIPN O
group O
did O
not O
have O
lower O
emotional O
distress O
compared O
to O
the O
non-CIPN O
group O
. O

The O
results O
of O
this O
study O
demonstrate O
the O
need O
for O
in-service O
courses O
specifically O
designed O
to O
train O
health O
professionals O
in O
assessing O
and O
managing O
CIPN O
symptoms O
to O
improve O
QOL B-Metric
in O
CRC B-Symptom_TestedFor
patients O
receiving O
FOLFOX B-Drug/Scientific name
. O

Background O
: O
Neurochemical O
and O
electrophysiological O
studies O
indicate O
that O
the O
locus O
coeruleus O
( O
LC O
) O
- O
norepinephrine O
system O
is O
activated O
by O
physiological O
and O
external O
stressors O
. O

This O
activation O
is O
mediated O
in O
part O
by O
corticotropin-releasing O
factor O
( O
CRF O
) O
, O
the O
hypothalamic O
neurohormone O
that O
initiates O
the O
endocrine O
response O
to O
stress O
. O

We O
have O
previously O
shown O
that O
the O
central O
nucleus O
of O
the O
amygdala O
( O
CNA O
) O
provides O
CRF O
afferents O
to O
noradrenergic O
processes O
in O
the O
peri-LC O
area O
that O
may O
serve O
to O
integrate O
emotional O
and O
cognitive O
responses O
to O
stress B-Symptom_TestedFor
. O

The O
bed O
nucleus O
of O
the O
stria O
terminalis O
( O
BNST O
) O
shares O
many O
anatomical O
and O
neurochemical O
characteristics O
with O
the O
CNA O
, O
including O
a O
high O
density O
of O
CRF-immunoreactive O
cells O
and O
fibers O
; O
however O
, O
recent O
studies O
have O
suggested O
that O
the O
CNA O
and O
the O
BNST O
may O
differentially O
regulate O
responses O
to O
conditioned O
and O
unconditioned O
fear O
, O
respectively O
, O
suggesting O
divergent O
neuroanatomical O
circuits O
underlying O
these O
processes O
. O

Methods O
: O
In O
the O
present O
study O
, O
neuroanatomical O
substrates O
subserving O
regulation O
of O
the O
LC O
by O
the O
BNST O
were O
examined O
. O

Anterograde O
tract-tracing O
was O
combined O
with O
immunoelectron O
microscopy O
to O
test O
the O
hypotheses O
that O
BNST O
efferents O
target O
noradrenergic O
neurons O
of O
the O
LC O
and O
that O
these O
efferents O
exhibit O
immunolabeling O
for O
CRF O
. O

Results O
: O
Ultrastructural O
analysis O
of O
sections O
that O
were O
dually O
labeled O
for O
the O
anterograde O
tracer O
biotinylated O
dextran O
amine O
( O
BDA O
) O
injected O
into O
the O
BNST O
and O
tyrosine O
hydroxylase O
( O
TH O
) O
- O
immunoreactivity O
demonstrated O
that O
BDA-labeled O
axon O
terminals O
formed O
synaptic O
specializations O
( O
primarily O
inhibitory O
) O
with O
TH-labeled O
dendrites O
and O
dendrites O
that O
lacked O
TH O
immunoreactivity O
. O

In O
contrast O
to O
CNA O
efferents O
that O
exhibited O
substantial O
immunolabeling O
for O
CRF O
, O
far O
fewer O
BDA-labeled O
terminals O
from O
the O
BNST O
in O
the O
rostrolateral O
peri-LC O
contained O
CRF O
. O

Conclusions O
: O
The O
present O
results O
indicate O
that O
the O
BNST O
may O
provide O
distinct O
neurochemical O
regulation O
of O
the O
peri-LC O
as O
compared O
to O
other O
limbic O
afferents O
such O
as O
the O
CNA O
. O

These O
data O
are O
interesting O
in O
light O
of O
behavioral O
studies O
showing O
that O
the O
CNA O
and O
BNST O
may O
be O
differentially O
involved O
in O
fear O
versus O
anxiety B-Symptom_TestedFor
, O
respectively O
. O

Metal O
ions O
are O
crucial O
for O
normal O
neurochemical O
signaling O
and O
perturbations O
in O
their O
homeostasis O
have O
been O
associated O
with O
neurodegenerative O
processes O
. O

Hypothesizing O
that O
in O
vivo O
modulation O
of O
key O
neurochemical O
processes O
including O
metal O
ion O
regulation O
( O
by O
transferrin O
receptor O
- O
1 O
: O
TfR O
- O
1 O
) O
in O
cells O
can O
improve O
disease O
outcome O
, O
we O
investigated O
the O
efficacy O
of O
a O
complex B-Drug/Scientific name
vitamin I-Drug/Scientific name
supplement I-Drug/Scientific name
( O
CVS B-Drug/Scientific name
) O
containing O
B-vitamins B-Drug/Scientific name
and O
ascorbic B-Drug/Scientific name
acid I-Drug/Scientific name
in O
preventing O
/ O
reversing O
behavioral O
decline O
and O
neuropathology O
in O
rats O
. O

Wistar O
rats O
( O
eight O
weeks-old O
) O
were O
assigned O
into O
five O
groups O
( O
n O
= O
8 O
) O
, O
including O
controls O
and O
those O
administered O
CVS O
( O
400 O
mg O
/ O
kg O
/ O
day O
) O
for O
two O
weeks O
before O
or O
after O
AlCl3 O
( O
100 O
mg O
/ O
kg O
) O
- O
induced O
neurotoxicity O
. O

Following O
behavioral O
assessments O
, O
prefrontal O
cortex O
( O
PFC O
) O
and O
hippocampus O
were O
prepared O
for O
biochemical O
analyses O
, O
histology O
and O
histochemistry O
. O

CVS B-Drug/Scientific name
significantly O
reversed O
reduction O
of O
exploratory O
/ O
working O
memory O
, O
frontal-dependent O
motor O
deficits O
, O
cognitive B-Symptom_WorkedFor
decline I-Symptom_WorkedFor
, O
memory B-Symptom_WorkedFor
dysfunction I-Symptom_WorkedFor
and O
anxiety B-Symptom_WorkedFor
. O

These O
correlated O
with O
CVS-dependent B-Drug/Scientific name
modulation O
of O
TfP O
- O
1 O
expression O
that O
were O
accompanied O
by O
significant O
reversal O
of O
neural O
oxidative O
stress O
in O
expressed O
superoxide O
dismutase O
, O
nitric O
oxide O
, O
catalase O
, O
glutathione O
peroxidase O
and O
malondialdehyde O
. O

Furthermore O
, O
CVS B-Drug/Scientific name
inhibited O
neural O
bioenergetics O
dysfunction O
, O
with O
increased O
labelling O
of O
glucokinase O
within O
PFC O
and O
hippocampus O
correlating O
with O
increased O
glucose O
- O
6 O
- O
phosphate O
dehydrogenase O
and O
decreased O
lactate O
dehydrogenase O
expressions O
. O

These O
relates O
to O
inhibition O
of O
over-expressed O
acetylcholinesterase O
and O
increased O
total O
protein O
synthesis O
. O

Histological O
and O
Nissl O
staining O
of O
thin O
sections O
corroborated O
roles O
of O
CVS B-Drug/Scientific name
in O
reversing O
AlCl3 O
- O
induced O
neuropathology O
. O

Summarily O
, O
we O
showed O
the O
role O
of O
CVS B-Drug/Scientific name
in O
normalizing O
important O
neurochemical O
molecules O
linking O
concurrent O
progression O
of O
oxidative O
stress O
, O
bioenergetics O
deficits O
, O
synaptic O
dysfunction O
and O
cellular O
hypertrophy O
during O
neurodegeneration O
. O

Introduction O
: O
Data O
on O
comparison O
of O
myo-inositol O
and O
metformin O
on O
mental O
health O
parameters O
and O
biomarkers O
of O
oxidative O
stress O
in O
subjects O
with O
polycystic B-participant_health
ovary I-participant_health
syndrome I-participant_health
( O
PCOS B-participant_health
) O
are O
scarce O
. O

This O
purpose O
of O
this O
study O
was O
to O
compare O
of O
myo-inositol B-Medicinal food
and O
metformin B-Other_ingredients
on O
mental O
health O
parameters O
and O
biomarkers O
of O
oxidative O
stress O
in O
subjects O
with O
PCOS B-participant_health
. O

Methods O
: O
This O
randomized O
controlled O
trial O
was O
conducted O
among O
60 B-#Participants
subjects O
diagnosed O
with O
PCOS B-participant_health
according O
to O
the O
Rotterdam O
criteria O
. O

Subjects O
were O
randomly O
assigned O
into O
two O
groups O
to O
intake O
either O
myo-inositol B-Medicinal food
( O
n O
= O
30 O
) O
or O
metformin B-Other_ingredients
( O
n O
= O
30 O
) O
for O
12 B-Duration
weeks I-Duration
. O

Parameters O
of O
mental O
health O
were O
recorded O
at O
baseline O
and O
after O
the O
12 B-Duration
- I-Duration
week I-Duration
intervention O
. O

Fasting O
blood O
samples O
were O
obtained O
at O
baseline O
and O
the O
end O
of O
the O
study O
to O
determine O
biomarkers O
of O
biomarkers O
of O
oxidative O
stress O
. O

Results O
: O
After O
the O
12 B-Duration
- I-Duration
week I-Duration
intervention O
, O
changes O
in O
beck B-Metric
depression I-Metric
inventory I-Metric
total O
score O
( O
- O
1.0 O
± O
1.7 O
vs O
. O
- O
0.3 O
± O
0.7 O
, O
p O
= O
0.03 O
) O
, O
general O
health O
questionnaire O
scores O
( O
- O
1.7 O
± O
2.9 O
vs O
. O
- O
0.5 O
± O
1.2 O
, O
p O
= O
0.02 O
) O
, O
depression B-Symptom_WorkedFor
anxiety B-Symptom_WorkedFor
and O
stress B-Symptom_WorkedFor
scale O
scores O
( O
- O
3.9 O
± O
6.4 O
vs O
. O
- O
0.9 O
± O
1.9 O
, O
p O
= O
0.01 O
) O
and O
plasma O
total O
antioxidant O
capacity O
( O
TAC O
) O
concentrations O
( O
+ O
106.1 O
± O
69.6 O
vs O
. O
+ O
2.1 O
± O
132.4 O
mmol O
/ O
L O
, O
p O
< O
0.001 O
) O
in O
the O
myo-inositol B-Medicinal food
group O
were O
significantly O
different O
from O
the O
changes O
in O
these O
indicators O
in O
the O
metformin B-Other_ingredients
group O
. O

Myo-inositol B-Medicinal food
supplementation O
for O
12 B-Duration
weeks I-Duration
among O
patients O
with O
PCOS B-participant_health
did O
not O
affect O
plasma O
glutathione O
and O
malondialdehyde O
levels O
. O

Conclusions O
: O
Overall O
, O
our O
data O
supported O
that O
myo-inositol O
supplementation O
for O
12 B-Duration
weeks I-Duration
among O
patients O
with O
PCOS B-participant_health
had O
favorable O
effects O
on O
parameters O
of O
mental O
health O
and O
plasma O
TAC O
levels O
. O

Background O
: O
Nutritional O
requirements O
need O
to O
be O
met O
in O
order O
to O
adapt O
to O
pre O
- O
and O
postnatal O
changes O
. O

Our O
aim O
was O
to O
systematically O
review O
the O
evidence O
of O
associations O
between O
nutritional O
biomarkers O
and O
psychological B-Symptom_TestedFor
distress I-Symptom_TestedFor
during O
pregnancy O
and O
in O
the O
first O
postnatal O
year O
. O

Methods O
: O
MEDLINE O
, O
EMBASE O
, O
PsycINFO O
, O
Scielo O
, O
LILACS O
, O
clinicaltrials.gov O
, O
International O
Clinical O
Trials O
Registry O
, O
Cochrane O
Library O
, O
Scopus O
and O
Web O
of O
Science O
databases O
were O
searched O
for O
articles O
from O
inception O
to O
4 O
/ O
15 O
/ O
2016 O
. O

Studies O
of O
maternal O
nutritional O
biomarkers O
in O
blood O
( O
fatty O
acids O
/ O
micronutrients O
/ O
amino O
acids O
) O
and O
associations O
with O
psychological B-Symptom_TestedFor
distress I-Symptom_TestedFor
( O
depression B-Symptom_TestedFor
/ O
anxiety B-Symptom_TestedFor
/ O
stress B-Symptom_TestedFor
) O
were O
included O
. O

Two O
independent O
reviewers O
extracted O
data O
based O
on O
study O
designs O
, O
participants O
, O
outcomes O
, O
exposures O
, O
and O
association O
measures O
. O

Results O
: O
Thirty-eight O
studies O
were O
included O
. O

A O
total O
of O
13 O
studies O
showed O
divergent O
or O
no O
associations O
between O
serum O
/ O
plasma O
/ O
erythrocyte O
fatty O
acid O
concentrations O
and O
depression B-Symptom_TestedFor
/ O
anxiety B-Symptom_TestedFor
during O
pregnancy O
and O
postpartum O
. O

Changes O
in O
serum O
cholesterol O
levels O
from O
pregnancy O
to O
postpartum O
showed O
a O
significant O
inverse O
correlation O
with O
depression B-Symptom_TestedFor
in O
one O
out O
of O
three O
studies O
. O

Five O
out O
of O
seven O
studies O
found O
an O
inverse O
association O
between O
serum O
vitamin B-Medicinal food
D I-Medicinal food
levels O
and O
pre B-Symptom_WorkedFor
- I-Symptom_WorkedFor
and I-Symptom_WorkedFor
postnatal I-Symptom_WorkedFor
depression I-Symptom_WorkedFor
. O

Plasma O
tryptophan O
levels O
were O
inversely O
correlated O
with O
postnatal O
depression O
scores O
in O
three O
out O
of O
four O
studies O
. O

We O
identified O
that O
one O
out O
of O
two O
studies O
presented O
no O
significant O
association O
between O
vitamin B-Medicinal food
B12 I-Medicinal food
/ O
folate B-Medicinal food
/ O
ferritin O
concentrations O
and O
depression B-Symptom_TestedFor
in I-Symptom_TestedFor
postpartum I-Symptom_TestedFor
. O

Limitations O
: O
There O
was O
higher O
variability O
between O
association O
measures O
, O
time O
and O
scales O
of O
depression B-Symptom_TestedFor
and O
anxiety B-Symptom_TestedFor
assessments O
. O

Conclusions O
: O
The O
majority O
of O
high-quality O
studies O
suggest O
that O
lower O
vitamin B-Medicinal food
D I-Medicinal food
levels O
may O
be O
associated O
with O
postpartum B-Symptom_WorkedFor
depression I-Symptom_WorkedFor
. O

However O
, O
further O
evidence O
is O
needed O
for O
guiding O
clinical O
practice O
on O
nutritional O
biomarkers O
. O

Depression B-Symptom_WorkedFor
, O
the O
most O
common O
type O
of O
mental O
illness O
, O
is O
the O
second O
leading O
cause O
of O
disability O
and O
is O
increasing O
among O
Americans O
. O

The O
effect O
of O
improved O
nutrition O
, O
particularly O
with O
dietary O
supplements O
, O
on O
depression B-Symptom_WorkedFor
may O
provide O
an O
alternative O
to O
standard O
medical O
treatment O
. O

Some O
studies O
have O
shown O
that O
certain O
nutrients O
( O
e.g O
. O
, O
inositol O
and O
S-adenosyl O
methionine O
) O
are O
effective O
at O
improving O
depressed O
mood O
, O
although O
the O
results O
are O
not O
unequivocal O
. O

The O
current O
study O
was O
a O
randomized O
, O
double-blind O
, O
placebo-controlled O
trial O
to O
evaluate O
the O
efficacy O
of O
a O
vitamin B-Medicinal food
B I-Medicinal food
complex O
nutritional O
supplement O
( O
Max B-Drug/Scientific name
Stress I-Drug/Scientific name
B I-Drug/Scientific name
) O
for O
improving O
depressive O
and O
anxiety O
symptoms O
according O
to O
the O
Beck B-Metric
Depression I-Metric
and I-Metric
Anxiety I-Metric
Inventories I-Metric
( O
BDI O
and O
BAI O
) O
in O
60 B-#Participants
adults O
diagnosed O
with O
major O
depression B-participant_health
or O
other O
forms O
of O
depressive B-participant_health
disorders I-participant_health
. O

Secondary O
outcomes O
included O
quality O
of O
life O
according O
to O
the O
SF O
- O
36 O
. O

Participants O
were O
assessed O
at O
baseline O
and O
30 O
- O
and O
60 O
- O
day O
followups O
. O

Max B-Drug/Scientific name
Stress I-Drug/Scientific name
B I-Drug/Scientific name
showed O
significant O
and O
more O
continuous O
improvements O
in O
depressive B-Symptom_WorkedFor
and O
anxiety B-Symptom_WorkedFor
symptoms O
, O
compared O
to O
placebo O
. O

Additionally O
, O
Max B-Drug/Scientific name
Stress I-Drug/Scientific name
B I-Drug/Scientific name
showed O
significant O
improvement O
on O
the O
mental O
health O
scale O
of O
the O
SF O
- O
36 O
compared O
to O
placebo O
. O

Thus O
, O
we O
showed O
modest O
utility O
of O
Max B-Drug/Scientific name
Stress I-Drug/Scientific name
B I-Drug/Scientific name
to O
improve O
mood O
symptoms O
and O
mental O
health O
quality O
of O
life O
in O
adults O
with O
depression B-Symptom_WorkedFor
. O

Thiamine B-Drug/Scientific name
( O
vitamin B-Medicinal food
B1 I-Medicinal food
) O
deficiency O
in O
the O
brain O
has O
been O
implicated O
in O
the O
development O
of O
dementia B-Symptom_WorkedFor
and O
symptoms O
of O
depression B-Symptom_WorkedFor
. O

Indirect O
evidence O
suggests O
that O
thiamine B-Drug/Scientific name
may O
contribute O
to O
these O
pathologies O
by O
controlling O
the O
activities O
of O
glycogen O
synthase O
kinase O
( O
GSK O
) O
- O
3β O
. O

While O
decreased O
GSK O
- O
3β O
activity O
appears O
to O
impair O
memory O
, O
increased O
GSK O
- O
3β O
activity O
is O
associated O
with O
the O
distressed O
/ O
depressed O
state O
. O

However O
, O
hitherto O
direct O
evidence O
for O
the O
effects O
of O
thiamine B-Drug/Scientific name
on O
GSK O
- O
3β O
function O
has O
not O
been O
reported O
. O

Here O
, O
we O
administered O
thiamine B-Drug/Scientific name
or O
, O
the O
more O
bioavailable O
precursor O
, O
benfotiamine B-Drug/Scientific name
at O
200mg O
/ O
kg O
/ O
day O
for O
2weeks O
to O
C57BL O
/ O
6J O
mice O
, O
to O
determine O
whether O
treatment O
might O
affect O
behaviours O
that O
are O
known O
to O
be O
sensitive O
to O
GSK O
- O
3β O
activity O
and O
whether O
such O
administration O
impacts O
on O
GSK O
- O
3β O
expression O
within O
the O
brain O
. O

The O
mice O
were O
tested O
in O
models O
of O
contextual O
conditioning O
and O
extinction O
, O
a O
5 O
- O
day O
rat O
exposure O
stress O
test O
, O
and O
a O
modified O
swim O
test O
with O
repeated O
testing O
. O

The O
tricyclic O
antidepressant O
imipramine O
( O
7.5mg O
/ O
kg O
/ O
day O
) O
, O
was O
administered O
as O
a O
positive O
control O
for O
the O
effects O
of O
thiamine O
or O
benfotiamine O
. O

As O
for O
imipramine O
, O
both O
compounds O
inhibited O
the O
upregulation O
of O
GSK O
- O
3β O
induced O
by O
predator O
stress O
or O
repeated O
swimming O
, O
and O
reduced O
floating O
scores O
and O
the O
predator O
stress-induced O
behavioural O
changes O
in O
anxiety O
and O
exploration O
. O

Coincident O
, O
thiamine B-Drug/Scientific name
and O
benfotiamine B-Drug/Scientific name
improved O
learning O
and O
extinction O
of O
contextual O
fear O
, O
and O
the O
acquisition O
of O
the O
step-down O
avoidance O
task O
. O

Our O
data O
indicate O
that O
thiamine B-Drug/Scientific name
and O
benfotiamine B-Drug/Scientific name
have O
antidepressant B-Symptom_WorkedFor
/ O
anti-stress B-Symptom_WorkedFor
effects O
in O
naïve O
animals O
that O
are O
associated O
with O
reduced O
GSK O
- O
3β O
expression O
and O
conditioning O
of O
adverse O
memories O
. O

Thus O
thiamine B-Drug/Scientific name
and O
benfotiamine B-Drug/Scientific name
may O
modulate O
GSK O
- O
3β O
functions O
in O
a O
manner O
that O
is O
dependent O
on O
whether O
the O
contextual O
conditioning O
is O
adaptive O
or O
maladaptive O
. O

Preclinical O
drug O
safety O
evaluation O
studies O
, O
typically O
conducted O
in O
two O
or O
more O
animal O
species O
, O
reveal O
and O
define O
dose-dependent O
toxicities O
and O
undesirable O
effects O
related O
to O
pharmacological O
mechanism O
of O
action O
. O

Idiosyncratic O
toxic O
responses O
are O
often O
not O
detected O
during O
this O
phase O
in O
development O
due O
to O
their O
relative O
rarity O
in O
incidence O
and O
differences O
in O
species O
sensitivity O
. O

This O
paper O
reviews O
and O
discusses O
the O
metabolic B-Symptom_TestedFor
idiosyncratic I-Symptom_TestedFor
toxicity I-Symptom_TestedFor
and O
species O
differences O
observed O
for O
the O
experimental O
non-benzodiazepine O
anxiolytic O
, O
panadiplon B-Other_ingredients
. O

This O
compound O
produced O
evidence O
of O
hepatic O
toxicity O
in O
Phase O
1 O
clinical O
trial O
volunteers O
that O
was O
not O
predicted O
by O
rat O
, O
dog O
or O
monkey O
preclinical O
studies O
. O

However O
, O
subsequent O
studies O
in O
Dutch-belted O
rabbits O
revealed O
a O
hepatic O
toxic O
syndrome O
consistent O
with O
a O
Reye's O
Syndrome-like O
idiosyncratic O
response O
. O

Investigations O
into O
the O
mechanism O
of O
toxicity O
using O
rabbits O
and O
cultured O
hepatocytes O
from O
several O
species O
, O
including O
human O
, O
provided O
a O
sketch O
of O
the O
complex O
pathway O
required O
to O
produce O
hepatic O
injury O
. O

This O
pathway O
includes O
drug O
metabolism O
to O
a O
carboxylic O
acid O
metabolite O
( O
cyclopropane O
carboxylic O
acid O
) O
, O
inhibition O
of O
mitochondrial O
fatty O
acid O
beta-oxidation O
, O
and O
effects O
on O
intermediary O
metabolism O
including O
depletion O
of O
glycogen O
and O
disruption O
of O
glucose O
homeostasis O
. O

We O
also O
provide O
evidence O
suggesting O
that O
the O
carboxylic O
acid O
metabolite O
decreases O
the O
availability O
of O
liver O
CoA O
and O
carnitine O
secondary O
to O
the O
formation O
of O
unusual O
acyl O
derivatives O
. O

Hepatic O
toxicity O
could O
be O
ameliorated O
by O
administration O
of O
carnitine O
, O
and O
to O
a O
lesser O
extent O
by O
pantothenate O
. O

These O
hepatocellular O
pathway O
defects O
, O
though O
not O
directly O
resulting O
in O
cell O
death O
, O
rendered O
hepatocytes O
sensitive O
to O
secondary O
stress O
, O
which O
subsequently O
produced O
apoptosis O
and O
hepatocellular O
necrosis O
. O

Not O
all O
rabbits O
showed O
evidence O
of O
hepatic O
toxicity O
, O
suggesting O
that O
individual O
or O
species O
differences O
in O
any O
step O
along O
this O
pathway O
may O
account O
for O
idiosyncratic O
responses O
. O

These O
differences O
may O
be O
roughly O
applied O
to O
other O
metabolic O
idiosyncratic O
hepatotoxic O
responses O
and O
include O
variations O
in O
drug O
metabolism O
, O
effects O
on O
mitochondrial O
function O
, O
nutritional O
status O
, O
and O
health O
or O
underlying O
disease O
. O

Objective O
: O
Previous O
research O
has O
demonstrated O
that O
a O
theoretical O
model O
including O
measures O
of O
life O
stressors O
, O
social O
support O
, O
and O
coping O
style O
significantly O
predicts O
psychological O
distress O
. O

This O
study O
tested O
plasma B-Drug/Scientific name
pyridoxine I-Drug/Scientific name
( O
vitamin B-Medicinal food
B6 I-Medicinal food
) O
deficiency O
status O
as O
a O
predictor O
of O
overall O
psychological B-Symptom_WorkedFor
distress I-Symptom_WorkedFor
and O
specific O
mood O
states O
in O
this O
model O
, O
controlling O
for O
HIV O
- O
1 O
serostatus O
. O

Method O
: O
Subjects O
included O
HIV B-participant_health
- I-participant_health
1 I-participant_health
+ I-participant_health
( O
N O
= O
76 B-#Participants
) O
and O
HIV B-participant_health
- I-participant_health
1 I-participant_health
- I-participant_health
( O
N O
= O
58 B-#Participants
) O
recently O
bereaved O
homosexual O
men O
. O

At O
baseline O
, O
subjects O
completed O
a O
battery O
of O
psychosocial O
questionnaires O
, O
together O
with O
a O
physical O
examination O
and O
venipuncture O
. O

The O
Profile B-Metric
of I-Metric
Mood I-Metric
States I-Metric
( O
POMS O
) O
provided O
measures O
of O
overall O
psychological B-Symptom_WorkedFor
distress I-Symptom_WorkedFor
as O
well O
as O
specific O
mood O
states O
. O

Pyridoxine B-Drug/Scientific name
deficiency O
status O
( O
a O
categorical O
measure O
of O
deficient O
vs O
. O
adequate O
status O
) O
was O
determined O
with O
a O
bioassay O
of O
erythrocyte O
aspartate O
aminotransferase O
activity O
. O

Results O
: O
Pyridoxine B-Drug/Scientific name
deficiency O
was O
a O
significant O
predictor O
of O
increased O
overall O
psychological B-Symptom_WorkedFor
distress I-Symptom_WorkedFor
in O
this O
model O
, O
controlling O
for O
life O
stressors O
, O
social O
support O
, O
coping O
style O
, O
and O
HIV O
- O
1 O
serostatus O
. O

In O
post O
hoc O
analyses O
of O
specific O
mood O
state O
effects O
, O
pyridoxine B-Drug/Scientific name
deficiency O
status O
was O
significantly O
associated O
with O
increases O
in O
depressed B-Symptom_WorkedFor
, O
fatigued B-Symptom_WorkedFor
, O
and O
confused O
mood O
levels O
, O
but O
not O
with O
those O
of O
anxiety B-Symptom_TestedFor
, O
anger B-Symptom_TestedFor
, O
or O
vigor B-Symptom_TestedFor
. O

Discussion O
: O
These O
findings O
suggest O
that O
adequate O
pyridoxine B-Drug/Scientific name
status O
may O
be O
necessary O
to O
avert O
psychological B-Symptom_WorkedFor
distress I-Symptom_WorkedFor
in O
the O
setting O
of O
bereavement O
. O

Inasmuch O
as O
pyridoxine B-Medicinal food
is O
a O
cofactor O
for O
5 O
- O
hydroxytryptophan O
decarboxylase O
- O
- O
an O
enzyme O
in O
the O
biosynthesis O
pathway O
of O
serotonin O
- O
- O
serotonin O
level O
in O
the O
brain O
is O
implicated O
as O
the O
mediating O
factor O
. O

Background O
: O
Women O
juggling O
multiple O
roles O
in O
our O
complex O
society O
are O
increasingly O
experiencing O
psychological B-Symptom_WorkedFor
stress I-Symptom_WorkedFor
. O

Dietary O
supplementation O
to O
manage O
stress B-Symptom_WorkedFor
is O
widespread O
despite O
limited O
supporting O
evidence O
. O

A O
systematic O
review O
of O
the O
available O
literature O
was O
undertaken O
to O
investigate O
the O
efficacy O
of O
specific O
dietary O
supplements O
in O
managing O
female O
stress B-Symptom_WorkedFor
and O
anxiety B-Symptom_WorkedFor
. O

Objectives O
: O
To O
identify O
the O
impact O
of O
essential B-Medicinal food
fatty I-Medicinal food
acids I-Medicinal food
( O
EFAs B-Drug/Scientific name
) O
, O
B B-Medicinal food
vitamins I-Medicinal food
, O
vitamin B-Medicinal food
C I-Medicinal food
, O
magnesium B-Medicinal food
and O
/ O
or O
zinc B-Medicinal food
, O
consumed O
as O
dietary O
supplements O
to O
the O
daily O
diet O
, O
on O
female O
stress B-Symptom_WorkedFor
and O
anxiety B-Symptom_WorkedFor
levels O
. O

Inclusion O
criteria O
types O
of O
participants O
: O
Women O
aged O
18 O
years O
and O
over O
, O
who O
had O
participated O
in O
a O
study O
where O
stress O
and O
/ O
or O
anxiety O
were O
assessed O
. O

Types O
of O
intervention O
( O
s O
) O
: O
Dietary O
supplementation O
with O
EFAs B-Drug/Scientific name
, O
B B-Medicinal food
vitamins I-Medicinal food
, O
vitamin B-Medicinal food
C I-Medicinal food
, O
magnesium B-Medicinal food
and O
/ O
or O
zinc B-Medicinal food
. O

Types O
of O
comparators O
: O
Supplements O
, O
either O
alone O
or O
combined O
, O
were O
compared O
with O
either O
no O
intervention O
or O
placebo O
. O

Types O
of O
studies O
: O
Randomized O
controlled O
and O
pseudo-randomized O
trials O
were O
included O
. O

Outcomes O
: O
Stress O
and O
anxiety O
were O
assessed O
using O
self-report O
or O
physiological O
outcome O
measures O
. O

Search O
strategy O
: O
Published O
and O
unpublished O
studies O
were O
sought O
via O
MEDLINE O
( O
via O
PubMed O
) O
, O
Embase O
, O
Scopus O
, O
CINAHL O
, O
PsycINFO O
, O
PsycARTICLES O
, O
MedNar O
, O
National O
Institute O
of O
Mental O
Health O
and O
the O
International O
Association O
for O
Women's O
Mental O
Health O
. O

Methodological O
quality O
: O
Methodological O
quality O
was O
evaluated O
using O
standardized O
critical O
appraisal O
instruments O
from O
the O
Joanna O
Briggs O
Institute O
. O

Data O
extraction O
: O
Data O
were O
extracted O
using O
the O
standardized O
data O
extraction O
instruments O
from O
the O
Joanna O
Briggs O
Institute O
. O

Data O
synthesis O
: O
Due O
to O
heterogeneity O
of O
the O
included O
studies O
, O
narrative O
synthesis O
was O
performed O
. O

Results O
: O
Fourteen O
studies O
were O
included O
in O
this O
review O
. O

Essential B-Medicinal food
fatty I-Medicinal food
acids I-Medicinal food
were O
effective O
in O
reducing O
perceived B-Symptom_WorkedFor
stress I-Symptom_WorkedFor
and O
salivary B-Symptom_WorkedFor
cortisol I-Symptom_WorkedFor
levels I-Symptom_WorkedFor
during O
pregnancy O
and O
anxiety B-Symptom_WorkedFor
in O
premenstrual O
women O
, O
and O
anxiety O
during O
menopause O
in O
the O
absence O
of O
depression O
, O
but O
were O
ineffective O
when O
depression O
was O
disregarded O
. O

Disregarding O
the O
hormonal O
phase O
, O
EFAs O
were O
ineffective O
in O
reducing O
stress O
or O
anxiety O
in O
four O
groups O
of O
women O
. O

Combined O
magnesium O
and O
vitamin B-Medicinal food
B6 I-Medicinal food
supplementation O
reduced O
premenstrual B-Symptom_WorkedFor
anxiety I-Symptom_WorkedFor
but O
had O
no O
effect O
when O
used O
in O
isolation O
and O
did O
not O
affect O
stress O
in O
women O
suffering O
from O
dysmenorrhea O
when O
combined O
or O
used O
in O
isolation O
. O

Older O
women O
experienced O
anxiety O
reduction O
using O
vitamin B-Medicinal food
B6 I-Medicinal food
, O
but O
not O
folate B-Medicinal food
or O
vitamin B-Medicinal food
B12 I-Medicinal food
. O

High-dose O
sustained-release O
vitamin B-Medicinal food
C I-Medicinal food
was O
effective O
in O
reducing O
anxiety B-Symptom_WorkedFor
and O
blood O
pressure O
in O
response O
to O
stress O
. O

Conclusion O
: O
The O
current O
review O
suggests O
that O
EFAs O
may O
be O
effective O
in O
reducing O
prenatal O
stress O
and O
salivary O
cortisol O
and O
may O
reduce O
anxiety O
during O
premenstrual O
syndrome O
and O
during O
menopause O
in O
the O
absence O
of O
depression O
. O

Magnesium B-Medicinal food
and O
vitamin B-Medicinal food
B6 I-Medicinal food
may O
be O
effective O
in O
combination O
in O
reducing O
premenstrual B-Symptom_WorkedFor
stress I-Symptom_WorkedFor
, O
and O
vitamin O
B6 O
alone O
may O
reduce O
anxiety O
effectively O
in O
older O
women O
. O

High-dose O
sustained-release O
vitamin B-Medicinal food
C I-Medicinal food
may O
reduce O
anxiety B-Symptom_WorkedFor
and O
mitigate O
increased O
blood B-Symptom_WorkedFor
pressure I-Symptom_WorkedFor
in O
response O
to O
stress O
. O

Implications O
for O
practice O
: O
Essential B-Medicinal food
fatty I-Medicinal food
acids I-Medicinal food
may O
be O
effective O
in O
reducing O
prenatal O
stress O
and O
salivary O
cortisol O
levels O
, O
and O
premenstrual O
or O
menopausal O
anxiety O
in O
the O
absence O
of O
depression O
. O

Combining O
magnesium B-Medicinal food
and O
vitamin B-Medicinal food
B6 I-Medicinal food
may O
reduce O
premenstrual B-Symptom_WorkedFor
anxiety I-Symptom_WorkedFor
and O
vitamin O
B6 O
may O
reduce O
anxiety B-Symptom_WorkedFor
in O
older O
women O
. O

High-dose O
sustained-release O
vitamin B-Medicinal food
C I-Medicinal food
may O
reduce O
anxiety B-Symptom_WorkedFor
and O
mitigate O
increased O
blood B-Symptom_WorkedFor
pressure I-Symptom_WorkedFor
in O
response O
to O
stress O
. O

Implications O
for O
research O
: O
Investigating O
supplementation O
in O
longer O
term O
studies O
is O
warranted O
and O
should O
include O
compliance O
testing O
, O
the O
use O
of O
inert O
substances O
as O
controls O
and O
reliable O
outcome O
measures O
. O

A O
48 O
- O
year-old O
male O
patient O
with O
underlying O
CPT O
II O
enzyme O
deficiency O
is O
described O
. O

Emotional B-Symptom_TestedFor
stress I-Symptom_TestedFor
appeared O
to O
precipitate O
recurrent O
myalgias O
, O
rhabdomyolysis O
and O
reversible O
renal O
impairment O
over O
a O
40 O
- O
year O
period O
. O

Our O
search O
of O
the O
English O
literature O
indicates O
this O
to O
be O
the O
first O
time O
that O
the O
emotional B-Symptom_TestedFor
stress I-Symptom_TestedFor
has O
been O
documented O
to O
precipitate O
the O
CPT O
II O
syndrome O
. O

Although O
the O
pathogenesis O
of O
this O
syndrome O
has O
yet O
to O
be O
established O
, O
existing O
knowledge O
is O
briefly O
reviewed O
and O
the O
likely O
metabolic O
and O
neuroendocrine O
mechanisms O
which O
link O
emotional B-Symptom_TestedFor
stress I-Symptom_TestedFor
to O
muscle O
metabolism O
are O
examined O
. O

These O
mechanisms O
influence O
the O
extent O
of O
lipolysis O
or O
glycolysis O
that O
occurs O
during O
the O
process O
of O
muscle O
ATP O
generation O
. O

It O
is O
suggested O
that O
neuroendocrine O
and O
other O
stress O
related O
changes O
which O
favour O
lipolysis O
over O
glycolysis O
adversely O
affect O
muscle O
energy O
metabolism O
in O
patients O
whose O
mitochondria O
are O
deficient O
in O
CPT O
II O
enzyme O
. O

Possible O
treatment O
strategies O
are O
those O
that O
favour O
glycolysis O
over O
fatty O
acid O
metabolism O
and O
include O
a O
variety O
of O
ways O
of O
modulating O
sympathetic O
and O
parasympathetic O
tone O
. O

The O
use O
of O
carbohydrate O
supplementation O
beta-blockers O
and O
anxiolytic B-Medicinal food
agents I-Medicinal food
is O
discussed O
. O

Oxidative O
and O
functional O
effects O
of O
alpha-lipoic B-Drug/Scientific name
acid I-Drug/Scientific name
( O
a-LA B-Drug/Scientific name
) O
were O
studied O
in O
the O
course O
of O
45 B-Duration
- I-Duration
day I-Duration
adaptation O
to O
high O
altitudes O
( O
3200 O
m O
in O
the O
Central O
Tien O
Shan O
, O
June O
- O
August O
) O
. O

Comparison O
of O
a-LA B-Drug/Scientific name
with O
mildronate O
stated O
similarity O
of O
their O
antioxidant O
and O
membrane O
effects O
on O
the O
third O
( O
stable O
) O
phase O
of O
adaptation O
( O
day O
45 O
) O
, O
as O
both O
substances O
demonstrated O
a O
distinct O
lyso-PL-limiting O
effect O
and O
did O
not O
change O
dramatically O
concentration O
of O
diene O
conjugates O
( O
primary O
products O
of O
lipid O
peroxidation O
) O
in O
brain O
tissue O
. O
a-LA B-Drug/Scientific name
surpassed O
mildronate O
in O
the O
rate O
of O
the O
compensating O
effect O
in O
respect O
of O
behavior O
disorders O
and O
anxiety B-Symptom_WorkedFor
in O
rats O
. O

Besides O
, O
the O
substances O
contributed O
equally O
to O
physical O
performance O
increment O
by O
the O
end O
of O
adaptation O
. O

The O
positive O
effect O
of O
a-LA B-Drug/Scientific name
on O
the O
functional O
characteristics O
was O
hand O
in O
hand O
with O
minimization O
of O
the O
consequences O
of O
oxidative B-Symptom_WorkedFor
stress I-Symptom_WorkedFor
. O

These O
experimental O
data O
imply O
that O
a-LA B-Drug/Scientific name
can O
be O
effective O
in O
controlling O
the O
long O
process O
of O
adaptation O
to O
high O
altitude O
conditions O
. O

